<SEC-DOCUMENT>0001193125-18-359219.txt : 20181227
<SEC-HEADER>0001193125-18-359219.hdr.sgml : 20181227
<ACCEPTANCE-DATETIME>20181227162546
ACCESSION NUMBER:		0001193125-18-359219
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		88
FILED AS OF DATE:		20181227
DATE AS OF CHANGE:		20181227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merus N.V.
		CENTRAL INDEX KEY:			0001651311
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-229044
		FILM NUMBER:		181254942

	BUSINESS ADDRESS:	
		STREET 1:		YALELAAN 62
		CITY:			3584 CM UTRECHT
		STATE:			P7
		ZIP:			3584 CM
		BUSINESS PHONE:		31 030 253 8800

	MAIL ADDRESS:	
		STREET 1:		YALELAAN 62
		CITY:			3584 CM UTRECHT
		STATE:			P7
		ZIP:			3584 CM

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merus B.V.
		DATE OF NAME CHANGE:	20150819
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>d569434df1.htm
<DESCRIPTION>F-1
<TEXT>
<HTML><HEAD>
<TITLE>F-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on December&nbsp;27, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>Form F-1
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of
Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name into English) </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>The Netherlands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other Jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Incorporation or Organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Yalelaan 62 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>3584 CM Utrecht </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The&nbsp;Netherlands </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+31
30 253 8800 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive
offices) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Merus US, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>One
Broadway </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Cambridge, Massachusetts 02142 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+1 781 760 0013 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service) </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies of
all communications, including communications sent to agent for service, should be sent to: </I></B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Peter&nbsp;N.&nbsp;Handrinos</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>200 Clarendon Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Boston,&nbsp;Massachusetts&nbsp;02116</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+1 617&nbsp;948&nbsp;6000</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Paul van der Bijl</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>NautaDutilh N.V.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Beethovenstraat 400</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>1082 PR
Amsterdam</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The Netherlands</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>+31 20 717 1000 </B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public</B>: From time to time after the effective date of this Registration Statement<B> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act
of 1933, check the following box.&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom" ALIGN="right">Emerging&nbsp;growth&nbsp;company&nbsp;&nbsp;&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each Class of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to Be</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registered(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering
Price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>per Share(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed<BR>Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;Price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration&nbsp;Fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Common shares, nominal value &#128;0.09 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">6,299,997</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$12.04</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$75,851,964</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$9,193</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416(a) of the Securities Act of 1933, as amended, this registration statement also covers
such additional shares as may hereafter be offered or issued to prevent dilution resulting from share splits, share dividends, recapitalizations or certain other capital adjustments. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman; " ALIGN="left">Calculated in accordance with Rule 457(c) under the Securities Act of 1933, as amended, based on the average
of the high and low prices reported for the registrant&#146;s common shares on December&nbsp;20, 2018. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>The registrant hereby amends
this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in
accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine</B>.<B> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this preliminary prospectus is not complete and may be changed. The
selling shareholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer
to buy these securities in any state or jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019
</B></FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g02u78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>6,299,997 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale from time to time in one or more offerings by the selling shareholders named herein of up to an
aggregate of 6,299,997 of our common shares, nominal value &#128;0.09&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The common shares registered hereby may be offered and sold by the
selling shareholders through one or more underwriters, broker-dealers or agents. If the common shares are sold through underwriters or broker-dealers, the selling shareholders will be responsible for underwriting discounts or commissions or
agent&#146;s commissions. The common shares may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See &#147;Plan of
Distribution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not selling any common shares under this prospectus, and we will not receive any of the proceeds from the offer and sale of
common shares by the selling shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus describes the general manner in which our common shares may be offered and sold by any selling
shareholder. When the selling shareholders sell common shares under this prospectus, we may, if necessary and required by law, provide a prospectus supplement that will contain specific information about the terms of that offering. Any prospectus
supplement may also add to, update, modify or replace information contained in this prospectus. We urge you to read carefully this prospectus, and any accompanying prospectus supplement before you make your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common shares are listed on The Nasdaq Global Market under the symbol &#147;MRUS.&#148; On December&nbsp;26, 2018, the last reported sale price of our
common shares on The Nasdaq Global Market was $13.40 per share.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common shares involves risks. See &#147;<A HREF="#toc569434_5">Risk Factors
</A>&#148; beginning on page&nbsp;12. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; under applicable Securities and Exchange Commission rules and are
eligible for reduced public company disclosure requirements. See &#147;Summary&#151;Implications of Being an Emerging Growth Company and a Foreign Private Issuer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed on the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_2">PRESENTATION OF FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_3">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_4">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_6">MARKET AND INDUSTRY DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_7">TRADEMARKS, SERVICE MARKS AND TRADENAMES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_10">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_11">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_12">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_14">SELECTED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_15">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
 OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_16">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_17">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_18">PRINCIPAL AND SELLING SHAREHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_19">RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_20">DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_21">MATERIAL TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_22">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_23">EXPENSES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_24">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_25">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_26">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_27">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc569434_28">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained in this prospectus, any prospectus supplement or in any free writing prospectus we may authorize to be
delivered or made available to you. We have not and the selling shareholders have not authorized anyone to provide you with different information. The selling shareholders are offering to sell, and seeking offers to buy, our common shares only in
jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of common shares. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For investors outside the United States: Neither we nor the selling shareholders have done anything that would permit this offering or possession or
distribution of this prospectus in any jurisdiction, other than the United States, where action for that purpose is required. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any
restrictions relating to, the offering of our common shares and the distribution of this prospectus outside the United States. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is a
part of a registration statement on Form F-1 that we filed with the Securities and Exchange Commission, or the SEC, using a &#147;shelf&#148; registration or continuous offering process. Under this shelf process, the selling shareholders may from
time to time sell the common shares covered by this prospectus. Additionally, under the shelf process, in certain circumstances, we may provide a prospectus supplement that will contain certain specific information about the terms of a particular
offering by one or more of the selling shareholders. We may also provide a prospectus supplement to add information to, or update or change information contained in this prospectus. You should read this prospectus before deciding to invest in our
common shares. You may obtain this information without charge by following the instructions under &#147;Where You Can Find More Information; Incorporation by Reference&#148; appearing elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the rules of the SEC, we are currently eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we are not required
to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_2"></A>PRESENTATION OF FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We report under International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or the IASB. None of the
financial statements presented or incorporated by reference in this prospectus were prepared in accordance with generally accepted accounting principles in the United States. We present our financial statements in euros and in accordance with IFRS
as issued by the IASB. We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that preceded them. All
references in this prospectus to &#147;$,&#148; &#147;US$,&#148; &#147;U.S.$,&#148; &#147;U.S. dollars,&#148; &#147;dollars&#148; and &#147;USD&#148; mean U.S. dollars and all references to &#147;&#128;&#148; mean euros, unless otherwise noted. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_3"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this
prospectus, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of
management for future operations and future results of anticipated products, are forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and
other federal securities laws. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as
&#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;contemplate,&#148; &#147;believe,&#148; &#147;estimate,&#148;
&#147;predict,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus are only predictions. We have based these forward-looking statements
largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this
prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections in this prospectus titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations&#148; and elsewhere in this prospectus. These forward-looking statements are subject to numerous risks, including, without limitation, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our operations as a clinical-stage company with a limited operating history and a history of operating losses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">uncertainty about the initiation, timing, progress and results of clinical trials of our bispecific antibody
candidates, including regarding when results of such trials will be made public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations related to payments and clinical development under our collaboration agreement with Incyte
Corporation, or Incyte; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical development for MCLA-128 as part of a combination therapy for metastatic breast cancer and in other
solid tumor cancers, MCLA-117 for the treatment of patients with acute myeloid leukemia, or AML, and MCLA-158 for the treatment of patients with solid tumors with an initial focus on metastatic colorectal cancer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">research and development for MCLA-145, which is being co-developed with Incyte, and for other bispecific antibody
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals for any of our bispecific antibody candidates;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish sales, marketing and distribution capabilities for any of our bispecific antibody
candidates for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain manufacturing arrangements for our bispecific antibody candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
bispecific antibody candidates and related technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to defend against any claims by third parties that we are infringing upon their intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenues, capital requirements and our need for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our bispecific antibody candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other risk factors discussed in this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains market data and industry forecasts that were obtained from industry publications. These data involve a number of assumptions and
limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information included in this
prospectus is generally reliable, such information is inherently imprecise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_4"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus. This summary may not contain all the information that may be important to you,
and we urge you to read this entire prospectus carefully, including the &#147;Risk Factors,&#148; &#147;Business&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; sections and our
audited financial statements, including the notes thereto, included in this prospectus, before deciding to invest in our common shares</I>.<I> </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Overview </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
immuno-oncology company developing innovative bispecific antibody therapeutics. Our pipeline of full-length human bispecific antibody candidates, which we refer to as Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, are generated
from our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, which is able to generate a diverse array of antibody-heavy chains against virtually any target, paired with a common light chain. Two heavy chains
paired with a common light chain can be combined to produce novel bispecific antibodies that bind a diverse array of targets and display differentiated biology. By binding to two different targets, Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can provide a variety of mechanisms of action. For example, Merus Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be designed to simultaneously block receptors that drive
tumor cell growth and survival and to mobilize the patient&#146;s immune response by engaging T-cells and/or activating various killer cells to eradicate tumors. In our pre-clinical studies, our bispecific antibody candidates were effective in
killing tumor cells, a result that we believe supports their potential efficacy in the treatment of cancer. In February 2015, we commenced a Phase 1/2 clinical trial of our most advanced bispecific antibody candidate, MCLA-128, for the treatment of
HER2-expressing solid tumors. In January 2018, we dosed the first patient in a Phase 2, open-label, multi-center international clinical trial to evaluate MCLA-128 in two metastatic breast cancer, or MBC, populations including HER2-positive MBC
patients and hormone receptor positive/HER2-low MBC patients. MCLA-128 is a full-length IgG bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity, or ADCC, targeting HER2 and HER3 receptors. MCLA-128 blocks the HER3
signaling pathway by employing a DOCK&nbsp;&amp; BLOCK<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mechanism of action. MCLA-128 is designed to dock onto a specific region of the HER2 receptor to orientate MCLA-128&#146;s HER3 binding
arm to block HER2:HER3 heterodimerization. Oncogenic signaling through the HER3 pathway, even in the presence of high heregulin concentrations, may thus be effectively blocked. The Phase 2 clinical trial is designed to observe the activity of this
HER2/HER3-targeted candidate in combination with current standards of care in areas of unmet need. We plan to provide an update on the Phase 2 clinical trial in the second half of 2019. Concurrently, our Phase 1/2 clinical trial evaluating single
agent activity for MCLA-128 in gastric cancer and non-small cell lung cancer, or NSCLC, is ongoing. We reported data from the gastric cancer patient cohort in the single-agent trial of MCLA-128 at the European Society for Medical Oncology Congress,
or ESMO, in October 2018. The data showed a clinical benefit rate of 24% (6 of 25 patients), with MCLA-128 being well tolerated with mainly grade 1/2 adverse events in patients treated with MCLA-128 across all indications explored to date, and
showing a low risk of immunogenicity. Promising single agent antitumor activity was seen in heavily pretreated gastric cancer/gastro-oesophageal junction, or GC/GEJ, cancer patients progressing on anti-HER2 therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, we commenced a Phase 1, single-arm, open-label, global clinical trial of our second bispecific antibody candidate, MCLA-117, for the treatment of
acute myeloid leukemia, or AML, and we announced the filing of the Investigational New Drug application, or IND, the United States for MCLA-117 in 2018 and the subsequent authorization to proceed with clinical studies by the U.S. Food and Drug
Administration, or the FDA. AML generally has a poor prognosis and limited progress has been made in disease outcomes despite a growing AML patient population. Clinical and pre-clinical studies suggest that treatment-resistant leukemic stem cells
are a potential cause of disease relapse. MCLA-117 binds to CD3, a cell-surface molecule present on all T-cells, and to CLEC12A, a cell surface molecule present on approximately 90 to 95% of AML tumor cells and stem cells in newly diagnosed and
relapsed patients. MCLA-117 is designed to recruit and activate T-cells to kill AML tumor </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cells and stem cells. In our pre-clinical studies, MCLA-117 killed tumor cells in blood samples of AML patients. We plan to seek orphan drug designation for MCLA-117 for the treatment of AML from
the FDA and the European Medicines Agency, or EMA. We are continuing our dose escalation of the Phase 1 clinical trial for MCLA-117. We plan to provide an update on our MCLA-117 program upon announcement of the maximum tolerated dose for MCLA-117
and anticipate data readouts for the Phase 1 clinical trial in the second half of 2019. We also intend to evaluate MCLA-117 for the treatment of myelodysplastic syndrome, or MDS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to MCLA-128 and MCLA-117, we are also developing MCLA-158, a bispecific antibody candidate that is designed to bind to cancer stem cells
expressing leucine-rich repeat-containing G protein-coupled receptor&nbsp;5, or Lgr5, and epidermal growth factor receptors, or EGFR, for the potential treatment of solid tumors with an initial focus on metastatic colorectal cancer, and the first
Clinical Trials Application, or CTA, to the EMA was approved to initiate a Phase 1 clinical trial in Europe in January 2018. We also filed an IND for MCLA-158 with the FDA in the first quarter of 2018, which received authorization to proceed from
the FDA in April 2018. In May 2018, we commenced a Phase 1, open-label, multicenter clinical trial of MCLA-158 and expect emerging data by the end of 2019. MCLA-158 is designed to kill cancer stem cells using two different mechanisms of action. The
first mechanism of action involves blocking growth and survival pathways in tumor stem cells. The second mechanism of action involves the recruitment and enhancement of immune effector cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we also have a pipeline of proprietary antibody candidates in preclinical development, including the bispecific antibody candidate MCLA-145,
which is being developed in collaboration with Incyte Corporation and is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. We expect to provide further information on this program upon acceptance of an IND for MCLA-145.
We also have several other antibody candidates in pre-clinical development that bind to other target combinations. Each of our antibody candidates in our preclinical and clinical pipeline are designed to bind to targets believed to be useful in the
treatment of cancer with an intention to establish efficacy and obtain information for submission to the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform employs an array of proprietary technologies and techniques to generate bispecific human antibodies. We utilize our patented
MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mouse harboring a common light chain in its germline that is capable of producing an array of antibodies with diverse heavy chains that are capable of binding virtually any antigen, the
information from which can then be used to generate bispecific antibody candidates. We employ our patented Spleen to Screen<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> technology to efficiently screen panels of common light chain
antibodies, designed to allow us to rapidly identify and generate Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> therapeutic candidates with differentiated modes of action. The Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology also includes use of proprietary host cells and patented dimerization technology for efficient bispecific antibody production. The Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format retains the IgG format of conventional mAbs, designed to preserve the format&#146;s key features, including stability, long half-life and low immunogenicity, when developing our bispecific
antibody candidates. We leverage industry-standard manufacturing processes and infrastructure to efficiently produce Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to become a leading
immuno-oncology company developing innovative bispecific antibodies to treat and potentially cure various types of cancer. Our business strategy comprises the following components: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B><B><I>Successfully develop our most advanced bispecific antibody candidate, MCLA-128, for the treatment of
solid tumors.</I></B><B></B>&nbsp;We are developing MCLA-128 for the treatment of patients with HER2-expressing and other solid tumors cancer. We commenced a Phase 1/2 clinical trial of MCLA-128 in Europe in February 2015. In the dose escalation
phase of the trial, the recommended dose of MCLA-128 was established. Preliminary efficacy data suggests consistent antitumor activity in heavily pretreated metastatic breast cancer patients progressing on HER2 therapies. In January 2018, we
commenced a combination Phase 2 clinical trial in the United States for <FONT STYLE="white-space:nowrap">MCLA-128</FONT> and we plan to provide an update on the Phase 2 clinical trial in the second half of 2019. Concurrently, our Phase 1/2 clinical
trial </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
evaluating single agent activity for MCLA-128 in gastric cancer and NSCLC is ongoing. We reported data from the gastric cancer patient cohort in the single-agent trial of MCLA-128 at ESMO in
October 2018. The data showed a clinical benefit rate of 24% (6 of 25 patients), with MCLA-128 being well tolerated with mainly grade 1/2 adverse events in patients treated with MCLA-128 across all indications explored to date and showing a low risk
of immunogenicity. Promising single-agent trial antitumor activity was seen in heavily pretreated GC/GEJ cancer patients progressing on anti-HER2 therapy. We believe that if MCLA-128 is successfully developed and obtains regulatory approval, it has
the potential to address disease-specific challenges that are not currently being met by existing therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Successfully develop our second most advanced bispecific antibody candidate, MCLA-117, for the treatment of
AML.</I></B>&nbsp;We are developing MCLA-117 for the treatment of patients with AML. We commenced a Phase 1 clinical trial of MCLA-117 in Europe in May 2016 for the treatment of patients with AML to assess its safety, tolerability and anti-tumor
activity and filed an IND in the United States in January 2018, for which we obtained authorization to proceed from the FDA in February 2018. We are continuing our dose escalation of the Phase 1 clinical trial for MCLA-117. We plan to provide an
update on our MCLA-117 program upon announcement of the maximum tolerated dose for MCLA-117 and anticipate data readouts for the Phase 1 clinical trial in the second half of 2019. If the results of this clinical trial are favorable, we plan to seek
orphan drug designation from the FDA and the EMA for MCLA-117 for the treatment of AML. We believe that if MCLA-117 is successfully developed and obtains regulatory approval, it has the potential to transform the treatment of AML. We also intend to
evaluate MCLA-117 for the treatment of MDS. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Successfully develop our third bispecific antibody candidate, MCLA-158, for the treatment of metastatic
colorectal cancer and other solid tumors.</I></B>&nbsp;We are developing MCLA-158 for the treatment of solid tumors with an initial focus on the treatment of metastatic colorectal cancer. MCLA-158 has received approval of a CTA in several European
countries for the potential treatment of metastatic colorectal cancer, including patients with the RAS-mutation, which represent a substantial unmet need. We also filed an IND for MCLA-158 with the FDA in the first quarter of 2018, for which we
received authorization to proceed from the FDA in April 2018. In May 2018, we commenced an open-label, multicenter, Phase 1 clinical trial of MCLA-158 and expect emerging data by the end of 2019. MCLA-158 is an ADCC-enhanced Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5, or Lgr5, and epidermal growth factor receptors, or EGFR. We believe that if MCLA-158
is successfully developed and obtains regulatory approval, it has the potential to address and transform the treatment of metastatic colorectal cancer and other solid tumors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerate the internal discovery and development of additional immunotherapeutic antibody
candidates</I></B><B>.</B><B><I></I></B>&nbsp;We believe we are well positioned to expand our pipeline of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of other forms of cancer. Our platform employs our
proprietary common light chain transgenic MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the production of diverse human heavy chains that can be paired to generate bispecific antibodies, coupled with our Spleen to Screen<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> technology that is designed to allow us to rapidly identify and generate Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> therapeutic candidates with differentiated modes of
action that have the potential to kill tumor cells with high potency. We are conducting pre-clinical studies of MCLA-145 in collaboration with Incyte and expect to provide further information on this program upon acceptance of an IND for MCLA-145.
We are also conducting pre-clinical studies in an array of proprietary preclinical candidates binding to other target combinations that are the subject of our internal programs. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I></I></B><B><I>Seek strategic collaborative relationships.</I></B>&nbsp;We intend to continue to seek
strategic collaborations to facilitate the capital-efficient development of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform and to identify potential target combinations in immuno-oncology and other
therapeutic areas. We have entered into </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
collaborations with Incyte, ONO Pharmaceutical Co., Ltd., and Simcere Pharmaceutical Group, to develop bispecific antibody candidates based on our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform and plan to work with other collaborators to validate and expand the use of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform and the
development of bispecific antibody candidates. We believe these collaborations could potentially provide significant funding to advance our bispecific antibody candidate pipeline while allowing us to benefit from the development expertise of our
collaborators. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use our technology platform to develop Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of various types of
cancer. The following table summarizes our bispecific antibody candidate pipeline: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g77h39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated as Merus B.V. under the laws of the Netherlands on June&nbsp;16, 2003. Our principal executive offices are located at Yalelaan 62, 3584
CM Utrecht, The Netherlands. Our telephone number at the Utrecht address is +31 30 253 8800. Our website address is www.merus.nl. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus.
We have included our website address in this prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Associated with Our Business
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making an investment decision. You should carefully consider all of
the information set forth in this prospectus and, in particular, should evaluate the specific factors set forth under the &#147;Risk Factors&#148; section of this prospectus in deciding whether to invest in our common shares. Among these important
risks are the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history, have incurred significant losses since our inception, expect to incur losses
for the foreseeable future and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need additional funding to complete the development of our bispecific antibody candidates and
commercialize our products, if approved, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform is an unproven novel
approach to the production of molecules for therapeutic intervention. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are early in our development efforts and our bispecific antibody candidates, including MCLA-128, MCLA-117 and
MCLA-158, may not be successful in clinical trials and, as a result, may never be approved as marketable therapeutics. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend heavily on the success of our bispecific antibody candidates, and we cannot give any assurance that any
of our bispecific antibody candidates will receive regulatory approval, which is necessary before they can be commercialized. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on our collaboration agreements with third parties, such as our agreement with Incyte Corporation, for
the development of certain of our bispecific antibody candidates, and if those third parties fail to perform or if those agreements are terminated, the development and commercialization of such bispecific antibody candidates would be delayed or
terminated. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter regulatory changes that delay or impede our development and commercialization efforts.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely, and expect to continue to rely, on third parties to conduct our clinical trials and to manufacture our
bispecific antibody candidates for pre-clinical and clinical testing, and those third parties may not perform satisfactorily, which could delay our product development activities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to adequately protect our technology, or to secure and maintain freedom to operate and/or issue
patents protecting our bispecific antibody candidates, others could preclude us from commercializing our technology and products and/or compete against us more directly, which would have a material adverse impact on our business, results of
operations, financial condition and prospects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face significant competition from other biotechnology and pharmaceutical companies and our operating results
will suffer if we fail to compete effectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our ability to compete may be adversely affected if we are unsuccessful in defending against claims that we are
infringing on our competitors&#146; intellectual property rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our future growth and ability to compete depends on retaining our key personnel and recruiting additional
qualified personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The rights of shareholders in companies subject to Dutch corporate law, like us, differ in material respects from
the rights of shareholders of corporations incorporated in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Implications of Being an Emerging
Growth Company and a Foreign Private Issuer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act, or
JOBS Act. As such, we are eligible, for up to five years, to take advantage of certain exemptions from various reporting requirements that are applicable to other publicly traded entities that are not emerging growth companies. These exemptions
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are not required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are not required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board, regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are not required to submit certain executive compensation matters to shareholder advisory votes, such as
&#147;say-on-pay,&#148; &#147;say-on-frequency&#148; and &#147;say-on-golden parachutes&#148;; and </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are not required to disclose certain executive compensation related items such as the correlation between
executive compensation and performance and comparisons of the chief executive officer&#146;s compensation to median employee compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the closing of the initial public offering
of our common shares or such earlier time that we no longer qualify as an emerging growth company. As a result, the information we provide to our shareholders may be different than you might receive from other public reporting companies in which you
hold equity interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition
period provided in Section&nbsp;13(a) of the Exchange Act, for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We have chosen to irrevocably opt out of this extended transition period and as a result, we comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required
for non-emerging growth companies. Under federal securities laws, our decision to opt out of the extended transition period is irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will
remain an emerging growth company until the earliest of: (i)&nbsp;the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion; (ii)&nbsp;the last day of the fiscal year following the fifth anniversary of the date of
the closing of the initial public offering of our common shares; (iii)&nbsp;the date that we become a &#147;large accelerated filer&#148; as defined in Rule&nbsp;12b-2 under the Exchange Act, which would occur if the aggregate market value of our
common shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter; or (iv)&nbsp;the date on which we have issued more than $1&nbsp;billion in non-convertible debt
securities during any three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We report under the Exchange Act as a non-U.S. company with foreign private issuer status. Even after we no
longer qualify as an emerging growth company, for as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of
a security registered under the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading
activities and liability for insiders who profit from trades made in a short period of time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing
unaudited financial and other specific information, or current reports on Form 8-K, upon the occurrence of specified significant events. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both foreign private issuers and emerging growth companies are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if
we no longer qualify as an emerging growth company, but remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures required of companies that are neither an emerging growth company nor a foreign
private issuer. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common shares offered by the selling shareholders </P></TD>
<TD>6,299,997 common shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common shares issued and outstanding </P></TD>
<TD>22,750,867 common shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>The selling shareholders will receive the proceeds from the sale of common shares in this offering. We will not receive any proceeds from the sale of the common shares but will pay the expenses (other than any underwriting discounts and
broker&#146;s commissions and similar expense) of this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Dividend policy </P></TD>
<TD>We have never paid or declared any cash dividends on our common shares, and we do not anticipate paying any cash dividends on our common shares in the foreseeable future. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our common shares. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Listing </P></TD>
<TD>Our common shares are listed on The Nasdaq Global Market under the symbol &#147;MRUS.&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of our common shares issued and
outstanding is based on 22,750,867 common shares outstanding as of October&nbsp;31, 2018 and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,621,256 common shares issuable upon the exercise of share options outstanding as of October&nbsp;31, 2018 at a
weighted average exercise price of &#128;14.63&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">109,412 common shares issuable upon the vesting of restricted share units outstanding as of October&nbsp;31,
2018; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">552,249 common shares reserved for future issuance under our 2016 Incentive Award Plan as described in
&#147;Management&#151;Long-Term Incentive Plan.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information contained in this prospectus assumes
no exercise of the outstanding options and no vesting of the restricted share units described above after October&nbsp;31, 2018. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read the following summary financial data together with our financial statements and the related notes thereto included elsewhere and incorporated
by reference in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus. We have derived the statement of profit or loss and comprehensive loss data
for the years ended December&nbsp;31, 2016 and 2017 and the statement of financial position data as of December&nbsp;31, 2017 from our audited financial statements incorporated by reference in this prospectus. We have derived the statement of profit
or loss and comprehensive loss data for the six months ended June&nbsp;30, 2017 and 2018 and the statement of financial position data as of June&nbsp;30, 2018 from our unaudited financial statements included elsewhere in this prospectus. Our
historical results are not necessarily indicative of the results that should be expected in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain our books and records in euros, and
we prepare our financial statements under International Financial Reporting Standards as issued by the International Accounting Standards Board. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six-month&nbsp;period&nbsp;ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B><br><B>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B><br><B>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B><br><B>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,821</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net finance income / (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Result before taxation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Result after taxation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences from the translation of foreign operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other comprehensive income for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic (and diluted) loss per share*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic (and diluted)*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,196,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,236,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,809,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,976,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the periods included in these financial statements, share options were excluded from the diluted loss per
share calculation as the Company was in a loss position in each period presented above. As a result, basic and diluted loss per share is equal. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Revenue for the periods noted has been restated due to the impact of the retrospective effects of the adoption
of IFRS 15, an accounting standard related to revenue recognition. Revenue for the year ended December&nbsp;31, 2017 has been restated to reflect additional revenue of &#128;8.3&nbsp;million, or &#128;0.43&nbsp;per share,
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
primarily related to the amortization of the up-front license payment received from Incyte. Revenue for the year ended December&nbsp;31, 2016 has been restated to reflect a reduction in revenue
of &#128;0.2&nbsp;million, or &#128;0.01&nbsp;per share, related to lower amortization of the up-front license payment received from ONO. Revenue for the six months ended June&nbsp;30, 2017 has been restated to reflect additional revenue of
&#128;3.8&nbsp;million, or &#128;0.20&nbsp;per share, related to the amortization of the up-front license payment received from Incyte. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of</B><br><B>June&nbsp;30,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(euros in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Financial Position Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">170,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider the risks and uncertainties described below and the other information in this prospectus before making an investment in our
common shares. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common shares could decline and you could lose all or part of
your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See &#147;Cautionary Statement Regarding Forward-Looking Statements.&#148; Our actual results could differ materially and adversely from
those anticipated in these forward-looking statements as a result of certain factors</I>.<I> </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and Industry </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may
never achieve or maintain profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage immuno-oncology company with a limited operating history. We have incurred net
losses of &#128;64.7&nbsp;million, &#128;47.4&nbsp;million, and &#128;23.3&nbsp;million for the years ended December&nbsp;31, 2017, 2016, and 2015, respectively, and &#128;13.0&nbsp;million and &#128;39.3&nbsp;million for the six months ended
June&nbsp;30, 2018 and 2017, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, we had an accumulated loss of &#128;167.2&nbsp;million. Our losses have resulted
principally from expenses incurred in research and development of our bispecific antibody candidates and from management and administrative costs and other expenses that we have incurred while building our business infrastructure. We expect to
continue to incur significant operating losses for the foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval and commercialization of our bispecific antibody candidates. We anticipate that our
expenses will increase substantially as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct our ongoing Phase 2 clinical trial of MCLA-128, our most advanced bispecific antibody candidate, for the
treatment of metastatic breast cancer in combination with other therapies and our ongoing, single agent, Phase 1/2 clinical trial for the treatment of gastric and non-small cell lung cancers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct our ongoing Phase 1 clinical trial of MCLA-117, our second most advanced bispecific antibody candidate,
for the treatment of acute myeloid leukemia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct our ongoing Phase 1 clinical trial of MCLA-158 for the treatment of solid tumors with an initial focus on
colorectal cancer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the research and development of our other bispecific antibody candidates, including completing
pre-clinical studies and commencing clinical trials for MCLA-145, which is being <FONT STYLE="white-space:nowrap">co-developed</FONT> with Incyte Corporation, or Incyte; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand the clinical programs to explore new potential combination therapies or indications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to enhance our technology platform, which generates our pipeline of product candidates, and discover and
develop additional antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for any antibody candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities
to commercialize any products for which we may obtain regulatory approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">secure, maintain and/or obtain freedom to operate for our technologies and products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add clinical, scientific, operational, financial and management information systems and personnel, including
personnel to support our product development and potential future commercialization efforts and to support our operation as a public company; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter any issues with any of the above, including but not limited to failed studies,
complex results, manufacturing challenges, safety issues or other regulatory challenges. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have financed our operations primarily
through (i)&nbsp;the initial public offering of our common shares, (ii)&nbsp;a placement of equity securities with Incyte Corporation, or Incyte, (iii)&nbsp;an upfront milestone payment received from Incyte under a collaboration and license
agreement, or the Collaboration Agreement and (iv)&nbsp;a private placement of common shares in February 2018. We have devoted a significant portion of our financial resources and efforts to developing our full-length human bispecific antibody
therapeutics, which we refer to as Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, our technology platform, identifying potential bispecific antibody candidates, conducting pre-clinical studies of a variety of candidates,
including MCLA-145 and conducting our clinical trials of MCLA-128, MCLA-117 and MCLA-158. We are in the early stages of development of our bispecific antibody candidates, and we have not completed development of any Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or any other drugs or biologics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we must succeed in developing and
eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing pre-clinical testing and clinical trials of our bispecific antibody candidates,
discovering and developing additional antibody candidates, obtaining regulatory approval for any bispecific antibody candidates that successfully complete clinical trials, establishing manufacturing and marketing capabilities and ultimately selling
any products for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to
achieve profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with pharmaceutical product and biological development, we are unable
to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration, or the FDA, or the European Medicines Agency, or EMA, or other
regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our bispecific antibody candidates, our expenses could increase and
commercial revenue could be further delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we do generate product royalties or product sales, we may never achieve or sustain profitability on
a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our common shares and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need additional funding in order to complete development of our bispecific antibody candidates and commercialize our products, if approved.
If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing clinical trials of MCLA-128, MCLA-117, and
MCLA-158 and continue to research, develop and conduct pre-clinical studies of MCLA-145 and our other antibody candidates. In addition, if we obtain regulatory approval for any of our bispecific antibody candidates, we expect to incur significant
commercialization expenses related to product manufacturing, marketing, sales and distribution. Furthermore, we continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial
additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future
commercialization efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we expect that our existing cash, cash equivalents and investments as of June&nbsp;30,
2018 and the proceeds received from the $15.0 million investment by Regeneron Pharmaceuticals in December 2018 will be sufficient to fund our operations into the second quarter of 2021. We have based this estimate on assumptions that may prove to be
wrong, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost, progress and results of our ongoing clinical trials of MCLA-128 and the Phase 1 clinical trials of
MCLA-117 and MCLA-158; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of our collaboration with Incyte to develop bispecific antibodies candidates, including research and
development and clinical trials for MCLA-145; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing clinical supplies of our bispecific antibody candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, progress, results and costs of pre-clinical development, laboratory testing and clinical trials for
our other antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing and outcome of regulatory review of any of our antibody candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and
distribution, for any of our antibody candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of securing, maintaining and/or obtaining freedom to operate for our technologies and
products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our bispecific antibody candidates for which we receive
marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in businesses, products and technologies, including our collaboration
with Incyte and any other licensing or collaboration arrangements for any of our bispecific antibody candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend
heavily on the success of our bispecific antibody candidates, and we cannot give any assurance that any of our bispecific antibody candidates will receive regulatory approval, which is necessary before they can be commercialized. If we, Incyte, or
any other strategic partners we may enter into collaboration agreements with for the development and commercialization of our bispecific antibody candidates, are unable to commercialize our bispecific antibody candidates, or experience significant
delays in doing so, our business, financial condition and results of operations will be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested a
significant portion of our efforts and financial resources in the development of bispecific antibody candidates using our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform. Our ability to generate royalty and
product revenues, which we do not expect will occur for at least the next several years, if ever, will depend heavily on the successful development and eventual commercialization of these bispecific antibody candidates, which may never occur. We
currently generate no revenues from sales of any products, and we may never be able to develop or commercialize a marketable product. Each of our bispecific antibody candidates will require additional clinical development, management of clinical,
pre-clinical and manufacturing activities, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, including commercial manufacturing supply, building of a commercial organization, substantial investment and significant
marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote any of our bispecific antibody candidates before we receive regulatory approval from the FDA, the EMA or comparable foreign regulatory
authorities, and we may never receive such regulatory approval for any of our bispecific antibody candidates. The success of our bispecific antibody candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for bispecific antibody candidates which we may license to others, such as to Incyte, the successful efforts of
those parties in completing clinical trials of, receipt of regulatory approval for and commercialization of such bispecific antibody candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for the bispecific antibody candidates to which we retain rights, completion of pre-clinical studies and clinical
trials of, receipt of marketing approvals for, establishment of commercial manufacturing supplies of and successful commercialization of such bispecific antibody candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for all of our bispecific antibody candidates, if and when approved, acceptance of our bispecific antibody
candidates by patients, the medical community and third-party payors, effectively competing with other therapies, a continued acceptable safety profile following approval and qualifying for, maintaining, enforcing and defending our intellectual
property rights and claims. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our collaborators, as applicable, do not achieve one or more of these factors in a timely manner
or at all, we could experience significant delays or an inability to successfully commercialize our bispecific antibody candidates, which would materially adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not previously submitted a Biologics License Application, or BLA, to the FDA, a Marketing Authorisation Application, or MAA, to the EMA, or similar
regulatory approval filings to comparable foreign authorities, for any bispecific antibody candidate, and we cannot be certain that any of our bispecific antibody candidates will be successful in clinical trials or receive regulatory approval.
Further, our bispecific antibody candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our bispecific antibody candidates, we may not be able to continue our
operations. Even if we successfully obtain regulatory approvals to market one or more of our bispecific antibody candidates, our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory
approval and have commercial rights. If the markets for patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to seek regulatory approval to commercialize our bispecific antibody candidates both in the United States and the EU, and potentially in additional
foreign countries. While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many other countries we must comply with the numerous and varying regulatory requirements of such countries regarding
safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our bispecific antibody candidates, and we cannot predict success in these jurisdictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform is an unproven, novel approach to the production of
molecules for therapeutic intervention. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not received regulatory approval for a therapeutic based on a full-length human bispecific IgG
approach. We cannot be certain that our approach will lead to the development of approvable or marketable products. In addition, our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> may have different effectiveness rates in
various indications and in different geographical areas. Finally, the FDA, the EMA or other regulatory agencies may lack experience in evaluating the safety and efficacy of products based on
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> therapeutics, which could result in a longer than expected regulatory review process, increase our expected development costs and delay or prevent commercialization of our
bispecific antibody candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform relies on third parties for
biological materials. Some biological materials have not always met our expectations or requirements, and any disruption in the supply of these biological materials could materially adversely affect our business. Although we have control processes
and screening procedures, biological materials are susceptible to damage and contamination and may contain active pathogens. Improper storage of these materials, by us or any third-party suppliers, may require us to destroy some of our biological
raw materials or product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics could harm
our development strategy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek to identify patient subsets within a disease category that may derive selective and meaningful benefit from
the bispecific antibody candidates we are developing. Through collaborations, we may develop </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companion diagnostics to help us to more accurately identify patients within a particular subset, both during our clinical trials and in connection with the commercialization of our bispecific
antibody candidates. Companion diagnostics are subject to regulation by the FDA, the EU legislative bodies, and comparable foreign regulatory authorities as companion diagnostic medical devices and typically require separate regulatory approval
prior to commercialization. If needed, we intend to develop companion diagnostics in collaboration with third parties and are dependent on the scientific insights and sustained cooperation and effort of any third-party collaborators in developing
and obtaining approval for companion diagnostics. We and our collaborators may encounter difficulties in developing and obtaining approval for any companion diagnostics, including issues relating to selectivity/specificity, analytical validation,
reproducibility or clinical validation. Any delay or failure by us or our collaborators to develop or obtain regulatory approval of companion diagnostics could delay or prevent approval of our bispecific antibody candidates. In addition, our
collaborators may encounter production difficulties that could constrain the supply of the companion diagnostics, and both they and we may have difficulties gaining acceptance of the use of the companion diagnostics in the clinical community. If
such companion diagnostics fail to gain market acceptance, it would have an adverse effect on our ability to derive revenues from sales of our products. In addition, the diagnostic company with whom we contract may decide to discontinue selling or
manufacturing the companion diagnostic that we anticipate using in connection with development and commercialization of our bispecific antibody candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able
to enter into arrangements with another diagnostic company to obtain supplies of an alternative companion diagnostic test for use in connection with the development and commercialization of our bispecific antibody candidates or do so on commercially
reasonable terms, which could adversely affect and/or delay the development or commercialization of our bispecific antibody candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our limited
operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our
inception in 2003, we have devoted a significant portion of our resources to developing MCLA-128, MCLA-117, MCLA-158 and our other antibody candidates, building our intellectual property portfolio, developing our clinical manufacturing supply chain,
planning our business, raising capital and providing general and administrative support for these operations. While we have ongoing clinical trials for MCLA-128, <FONT STYLE="white-space:nowrap">MCLA-117</FONT> and MCLA-158, we have not completed
any clinical trials for any bispecific antibody candidate. We have not yet demonstrated our ability to successfully complete any Phase 2 clinical trial or any Phase&nbsp;3 or other pivotal clinical trials, obtain regulatory approvals, manufacture a
commercial scale product or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to
continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Consequently, any predictions you make about our future success or viability may not be as accurate as
they could be if we had a longer operating history. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our holders, restrict our operations or
require us to relinquish rights to our technologies or bispecific antibody candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial
product revenues, we expect to finance our cash needs through equity or debt financings and upfront and milestone payments, if any, received under our collaboration with Incyte and any other future licenses or collaborations, together with our
existing cash and cash equivalents. In order to accomplish our business objectives and further develop our product pipeline, we will, however, need to seek additional funds. If we raise additional capital through the sale of equity or convertible
debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common shares. In addition, the possibility of such
issuance may cause the market price of our common shares to decline. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures, declaring </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividends, or acquiring, selling or licensing intellectual property rights, which could adversely impact our ability to conduct our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have
to relinquish valuable rights to our intellectual property, technologies, future revenue streams or bispecific antibody candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek funds through
arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and
commercialize our bispecific antibody candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to obtain funding on a timely basis, we may be
required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any of our bispecific antibody candidates, or be unable to expand our operations or otherwise capitalize on our
business opportunities, as desired, which could materially affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business may
become subject to economic, political, regulatory and other risks associated with international operations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a company based in the Netherlands,
our business is subject to risks associated with conducting business internationally. Many of our suppliers and collaborative and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by
a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability, in particular, in non-U.S. economies and
markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing regulatory requirements for drug approvals in non-U.S. countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing jurisdictions could present different issues for securing, maintaining and/or obtaining freedom to
operate in such jurisdictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially reduced protection for intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in compliance with non-U.S. laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in non-U.S. regulations and customs, tariffs and trade barriers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in non-U.S. currency exchange rates of the euro and currency controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in a specific country&#146;s or region&#146;s political or economic environment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or
non-U.S. governments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing reimbursement regimes and price controls in certain non-U.S. markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative consequences from changes in tax laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties associated with staffing and managing international operations, including differing labor relations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters
including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exchange rate fluctuations or abandonment of the euro currency may materially
affect our results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the international scope of our operations, fluctuations in exchange rates,
particularly between the euro and the U.S. dollar, may adversely affect us. Although we are based in the Netherlands, we source research and development, manufacturing, consulting and other services from several countries. Further, potential future
revenue may be derived from abroad, particularly from the United States. Additionally, our funding has mainly come from investors and collaborators mainly in the United States. As a result, our business and share price may be affected by
fluctuations in foreign exchange rates between the euro and these other currencies, which may also have a significant impact on our reported results of operations and cash flows from period to period. Currently, we do not have any exchange rate
hedging arrangements in place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the possible abandonment of the euro by one or more members of the EU could materially affect our business in
the future. Despite measures taken by the EU to provide funding to certain EU member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the euro
could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the re-introduction of individual currencies in one or more EU member states, or in more extreme circumstances, the dissolution of the EU. The
effects on our business of a potential dissolution of the EU, the exit of one or more EU member states from the EU or the abandonment of the euro as a currency, are impossible to predict with certainty, and any such events could have a material
adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks from improper conduct by our employees, agents, contractors,
or collaborators could adversely affect our reputation, business, prospects, operating results, and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot ensure that our
compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate,
including, without limitation, health care, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and patient privacy and other privacy laws and regulations. Such improper actions could subject us to
civil or criminal investigations, and monetary and injunctive penalties, and could adversely impact our ability to conduct business, operating results, and reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to a number of anti-corruption laws, including the Foreign Corrupt Practices Act, or FCPA, in the United States, the Bribery Act in the United
Kingdom and the anti-corruption provisions of the Dutch Criminal Code in the Netherlands. Our failure to comply with anti-corruption laws applicable to us could result in penalties, which could harm our reputation and harm our business, financial
condition, results of operations, cash flows or prospects. The FCPA generally prohibits companies and their intermediaries from making improper payments to foreign officials for the purpose of obtaining or keeping business and/or other benefits. The
FCPA also requires public companies to maintain accurate books and records and devise a system of sufficient internal accounting controls. We regularly review and update our policies and procedures and internal controls designed to provide
reasonable assurance that we, our employees, distributors and other intermediaries comply with the anti-corruption laws to which we are subject. However, there are inherent limitations to the effectiveness of any policies, procedures and internal
controls, including the possibility of human error and the circumvention or overriding of the policies, procedures and internal controls. There can be no assurance that such policies or procedures or internal controls will work effectively at all
times or protect us against liability under these or other laws for actions taken by our employees, distributors and other intermediaries with respect to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC and Department of Justice continue to view FCPA enforcement activities as a high priority. There is no certainty that all of our employees, agents,
contractors, or collaborators, or those of our affiliates, will comply </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against
us, our officers, or our employees, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could
materially damage our reputation, our brand, our international operations, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development and Clinical Testing of Our Bispecific Antibody Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>All of our bispecific antibody candidates are in pre-clinical or early-stage clinical development. Clinical drug development is a lengthy and expensive
process with uncertain timelines and uncertain outcomes. If clinical trials of our bispecific antibody candidates, particularly MCLA-128, MCLA-117 or MCLA-158, are prolonged or delayed, we or any collaborators may be unable to obtain required
regulatory approvals, and therefore be unable to commercialize our bispecific antibody candidates on a timely basis or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain the
requisite regulatory approvals to market and sell any of our bispecific antibody candidates, we or any collaborator for such candidates must demonstrate through extensive pre-clinical studies and clinical trials that our products are safe and
effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of pre-clinical studies and early-stage
clinical trials of our bispecific antibody candidates may not be predictive of the results of later-stage clinical trials. Bispecific antibody candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits
despite having progressed through pre-clinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety
profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have not completed
any clinical trials required for the approval of any of our bispecific antibody candidates. Although we are conducting ongoing clinical trials for MCLA-128, MCLA-117 and MCLA-158, and are conducting pre-clinical studies for other bispecific antibody
candidates, we may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be
delayed, suspended, or terminated for a variety of reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to reach agreement on acceptable terms with prospective contract research organizations, or
CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in establishing the appropriate dosage levels in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to recruit suitable patients to participate in a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the difficulty in certain countries in identifying the sub-populations that we are trying to treat in a
particular trial, which may delay enrollment and reduce the power of a clinical trial to detect statistically significant results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lower than anticipated retention rates of patients in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to have patients complete a trial or return for post-treatment follow-up; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding new clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safety or tolerability concerns could cause us or our collaborators or Health Authorities, as applicable, to
suspend or terminate a trial if we or our collaborators or Health Authorities, find that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to obtain regulatory approval to commence a trial; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to obtain institutional review board, or IRB, approval at each site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party research contractors failing to comply with regulatory requirements or meet their contractual
obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements, policies and guidelines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of bispecific antibody candidate for use in clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the quality or stability of a bispecific antibody candidate falling below acceptable standards;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the treatment landscape for our target indications that may make our bispecific antibody candidates no
longer relevant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third party actions claiming infringement by our bispecific antibody candidates in clinical trials outside of the
United States and obtaining injunctions interfering with our progress; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters
including earthquakes, typhoons, floods and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We could encounter delays if a clinical trial is suspended or terminated by us, by
the IRBs or Ethics Committees of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA, the Competent Authorities of the EEA Member States (the 28 EU
Member States plus Iceland, Liechtenstein and Norway) or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with
regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EEA Competent Authorities or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety
issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion
of, or termination of, any clinical trial of our bispecific antibody candidates, the commercial prospects of our bispecific antibody candidates will be harmed, and our ability to generate product revenues from any of these bispecific antibody
candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our bispecific antibody candidate development and approval process and jeopardize our ability to commence product sales and
generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our bispecific antibody candidates and
impair our ability to commercialize our bispecific antibody candidates and may harm our business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these occurrences may
harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval
of our bispecific antibody candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials must be conducted in accordance with the FDA, the EU and other applicable regulatory
authorities&#146; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and Ethics Committees or IRBs at the medical institutions where the clinical trials are conducted. In addition, clinical
trials must be conducted with supplies of our bispecific antibody candidates produced under current good manufacturing practice, or cGMP, requirements and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper
and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our
clinical trials in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a
significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. In addition, clinical trials that are conducted in countries outside the EU
and the United </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-EU and non-U.S. CROs, as well as expose
us to risks associated with clinical investigators who are unknown to the FDA or the EMA, and different standards of diagnosis, screening and medical care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our bispecific antibody candidates may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If
such side effects are identified during the development of our bispecific antibody candidates or following approval, if any, we may need to abandon our development of such bispecific antibody candidates, the commercial profile of any approved label
may be limited, or we may be subject to other significant negative consequences following marketing approval, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Undesirable side effects
that may be caused by our bispecific antibody candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the
EMA or other comparable foreign authorities. In February 2015, we commenced a Phase 1/2 clinical trial in Europe of our most advanced bispecific antibody candidate, <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> for the treatment of various solid
tumors. Additionally, in January 2018 we commenced a Phase&nbsp;2 clinical trial in Europe and the United States exploring MCLA-128, in combination with other agents, in patients with metastatic breast cancer. To date, patients treated with MCLA-128
have experienced adverse reactions that may be related to the treatment, including infusion-related reactions, diarrhea, vomiting, fatigue, skin rash, sore mouth and shortness of breath. In May 2016, we commenced a Phase 1 clinical trial in Europe
of our bispecific antibody MCLA-117. To date, patients treated with MCLA-117 have experienced adverse reactions that may be related to the treatment, most commonly infusion-related reactions. In May 2018 we commenced a Phase 1 clinical trial in
Europe of our bispecific antibody MCLA-158 in patients with solid tumors with an initial focus on colorectal cancer. To date, patients treated with MCLA-158 have experienced adverse reactions that may be related to the treatment, most commonly
infusion-related reactions. Results of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA, the EMA, EEA Competent
Authorities, or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our bispecific antibody candidates for any or all targeted indications. The drug-related side effects could affect patient
recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. Additionally, if any of our
bispecific antibody candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approvals of such products and require us to take our approved product off
the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or
field alerts to physicians and pharmacies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution
to patients, or that we implement a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the product outweigh its risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the dose or the way the product is administered, conduct additional clinical trials
or change the labeling of the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to limitations on how we may promote the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of the product may decrease significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to litigation or product liability claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected
product or could substantially increase commercialization costs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adverse events in the field of oncology could damage public perception of our bispecific antibody candidates and negatively affect our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The commercial success of our products will depend in part on public acceptance of the use of cancer immunotherapies. Adverse events in clinical
trials of our bispecific antibody candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of oncology that may occur in the future, could result in a
decrease in demand for any products that we may develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future adverse events in immuno-oncology or the biopharmaceutical industry could also result in
greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining regulatory approval for our bispecific
antibody candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on enrollment of patients in our clinical trials for our bispecific antibody candidates. If we are unable to enroll
patients in our clinical trials, our research and development efforts and business, financial condition and results of operations could be materially adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. For the MCLA-128 Phase 2 clinical
trial, we plan to enroll approximately 120 patients with metastatic breast cancer in the United States and Europe. In the Phase 1 clinical trial of MCLA-117, we plan to enroll approximately 50 adult patients with AML. In the Phase 1 clinical trial
of MCLA-158, we plan to enroll approximately 120 adult patients with colorectal cancer and possibly other solid tumors. These trials and other trials we conduct may be subject to delays as a result of patient enrollment taking longer than
anticipated or patient withdrawal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our clinical trials will likely compete with other clinical trials for antibody candidates that are in the same
therapeutic areas as our bispecific antibody candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being
conducted by one of our competitors. Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use,
which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patient enrollment depends on many
factors, including the size and nature of the patient population, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the availability of competing clinical trials, the availability
of new drugs approved for the indication the clinical trial is investigating, and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. These factors may
make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our bispecific antibody candidates will increase our costs, slow down our
bispecific antibody candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or
completion of clinical trials may also ultimately lead to the denial of regulatory approval of our bispecific antibody candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become exposed to costly and damaging liability claims, either when testing our bispecific
antibody candidates in the clinic or at the commercial stage; and our product liability insurance may not cover all damages from such claims. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. Currently, we have no products that have been approved for
commercial sale; however, the current and future use of bispecific antibody candidates by us and our corporate collaborators in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims
might be made by patients that use the product, healthcare providers, pharmaceutical companies, our corporate collaborators or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend
and could materially adversely affect the market for our bispecific antibody candidates or any prospects for commercialization of our bispecific antibody candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory
approval, may exhibit unforeseen side effects. If any of our bispecific antibody candidates were to cause adverse side effects during clinical trials or after approval of the bispecific antibody candidate, we may be exposed to substantial
liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our bispecific antibody candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we maintain adequate product liability insurance for our bispecific antibody candidates, it is possible that our liabilities could exceed our
insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our bispecific antibody candidates. However, we may not be able to maintain insurance coverage at a
reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured
liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of the events described
above occur, this could have a material adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval
processes of the FDA, the EMA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our bispecific antibody candidates, our business will be
substantially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The time required to obtain approval by the FDA, the EMA and comparable foreign authorities is unpredictable but typically
takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical
data necessary to gain approval may change during the course of a bispecific antibody candidate&#146;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any bispecific antibody candidate and it is
possible that none of our existing bispecific antibody candidates or any bispecific antibody candidates we may seek to develop in the future will ever obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our bispecific antibody candidates could fail to receive regulatory approval for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with the design or implementation of
our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA, the EMA or comparable foreign regulatory
authorities that a bispecific antibody candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA, the EMA or
comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a bispecific antibody candidate&#146;s clinical and other benefits outweigh
its safety risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, the EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from
pre-clinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our bispecific antibody candidates may not be sufficient to support
the submission of a BLA or other submission or to obtain regulatory approval in the United&nbsp;States, the EU or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, the EMA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or
facilities of third-party manufacturers with which we contract for clinical and commercial supplies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, the EMA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we
contemplate developing with collaborators; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA, the EMA or comparable foreign regulatory authorities may
significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This lengthy approval process as well as the
unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our bispecific antibody candidates, which would significantly harm our business, results of operations and prospects. The FDA,
the EMA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our bispecific antibody candidates. Even if we believe the data collected
from clinical trials of our bispecific antibody candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other regulatory authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, even if we were to obtain approval, regulatory authorities may approve any of our bispecific antibody candidates for fewer or more limited
indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a bispecific antibody candidate with a label that
does not include the labeling claims necessary or desirable for the successful commercialization of that bispecific antibody candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our bispecific antibody
candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if our bispecific antibody candidates obtain regulatory approval, we will be subject to ongoing obligations and continued
regulatory review, which may result in significant additional expense. Additionally, our bispecific antibody candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we
fail to comply with regulatory requirements or experience unanticipated problems with our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA, the EMA or a comparable foreign
regulatory authority approves any of our bispecific antibody candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to
extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we
conduct post-approval, all of which may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our bispecific antibody candidates may also be subject to
limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor
the safety and efficacy of the bispecific antibody candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there are changes in the application of legislation or regulatory policies, or if problems are discovered
with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include imposing fines on us, imposing
restrictions on the product or its manufacture and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical trials, change
our product labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory
requirements, which could materially adversely affect our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our
efforts to use and expand our technology platform to build a pipeline of antibody candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to use and expand
our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform to build a pipeline of antibody candidates and progress these antibody candidates through clinical development for the treatment of a variety of different
types of diseases. Although our research and development efforts to date have resulted in a pipeline of bispecific antibody candidates directed at various cancers, we may not be able to develop bispecific antibody candidates that are safe and
effective. Even if we are successful in continuing to build our pipeline, the potential antibody candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other
characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize antibody candidates, we will face
difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our share price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain marketing approval of any of our bispecific antibody candidates in a major pharmaceutical market such as the United States or the EU,
we may never obtain approval or commercialize our products in other major markets, which would limit our ability to realize their full market potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements of such countries or
territories regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in
any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays,
difficulties and costs for us and may require additional pre-clinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of
our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have
negative effects on the process for regulatory approval in other countries. We currently do not have any bispecific antibody candidates approved for sale in any jurisdiction, whether in the Netherlands, the United States or any other international
markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be
reduced and our ability to realize the full market potential of our products will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Due to our limited resources and access to capital, we
must, and have in the past decided to, prioritize development of certain bispecific antibody candidates over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenues. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have limited resources and access to capital to fund our operations, we must decide which antibody candidates to pursue and the amount of resources
to allocate to each. Our decisions concerning the allocation of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research, collaboration, management and financial resources toward particular compounds, bispecific antibody candidates or therapeutic areas may not lead to the development of viable commercial
products and may divert resources away from better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us
to miss valuable opportunities. If we make incorrect determinations regarding the market potential of our bispecific antibody candidates or misread trends in the biopharmaceutical industry, in particular for our lead bispecific antibody candidates,
our business, financial condition and results of operations could be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we are subject to environmental, health
and safety laws and regulations, we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations, including our research, development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and
regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of, and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells,
carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or
other sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and
historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses
in connection with future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed and our financial condition and results of operations may be materially adversely
affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaborators may engage in misconduct or
other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaborators may engage in
fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (i)&nbsp;the regulations of the FDA, the EMA and other regulatory
authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii)&nbsp;manufacturing standards; (iii)&nbsp;federal and state data privacy, security, fraud and abuse and other healthcare
laws and regulations in the United States and abroad; or (iv)&nbsp;laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are
subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion,
sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent
data in our pre-clinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with
such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a significant impact on our business and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in
Medicare, Medicaid and other U.S. federal healthcare programs, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely
affect our ability to operate our business and our results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our research and development activities could be affected or delayed as a
result of possible restrictions on animal testing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain laws and regulations require us to test our bispecific antibody candidates on animals
before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities
by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted,
delayed or become more expensive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval of Our Bispecific Antibody Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our bispecific antibody
candidates and may affect the prices we may set. The successful commercialization of our bispecific antibody candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage and
reimbursement levels and pricing policies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the EU, and other foreign jurisdictions, there have been, and we expect there
will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the
United States federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March&nbsp;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act, or collectively the ACA, was enacted, which substantially changes the way healthcare is financed by both governmental and private insurers. Among the provisions of the ACA, those of greatest importance to the pharmaceutical and
biotechnology industries include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an annual, non-deductible fee on any entity that manufactures or imports certain branded prescription drugs and
biologic agents, which is apportioned among these entities according to their market share in certain government healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale
discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new requirements to report certain financial arrangements with physicians and certain others, including reporting
&#147;transfers of value&#148; made or distributed to prescribers and other healthcare providers and reporting investment interests held by physicians and their immediate family members; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to
23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of a manufacturer&#146;s Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#146;s Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a Center for Medicare Innovation at the Centers for Medicare&nbsp;&amp; Medicaid Services, or
CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that the current presidential administration and U.S. Congress will likely continue to seek to modify, repeal, or otherwise invalidate all, or
certain provisions of, the ACA. However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of
2011 resulted in aggregate reductions of Medicare payments to providers of 2%&nbsp;per fiscal year. These reductions went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through
2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including
hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare
and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, payment
methodologies, including payment for companion diagnostics, may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS began bundling the Medicare payments for certain laboratory tests ordered while a patient
received services in a hospital outpatient setting and, beginning in 2018, CMS began paying for clinical laboratory services based on a weighted average of reported prices that private payors, Medicare Advantage plans, and Medicaid Managed Care
plans pay for laboratory services. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and
proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For
example, the 21st Century Cures Act, or Cures Act, changed the reimbursement methodology for infusion drugs and biologics furnished through durable medical equipment in an attempt to remedy over- and underpayment of certain products. We expect that
additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our
bispecific antibody candidates or additional pricing pressures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also become increasingly active in passing
legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of
operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their
prescription drug and other healthcare programs. This </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could reduce the ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our current or any future products.
In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery
of healthcare in the EU,&nbsp;including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health
service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU&nbsp;member states have
resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay
marketing approval of our bispecific antibody candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval. In international markets, reimbursement and
healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot
predict how the policies of changing political administrations could impact, impose significant burdens on, or otherwise materially delay, FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing statutes
through rulemaking, issuance of guidance, and review and approval of marketing applications.&nbsp;For example, certain policies of the current presidential administration may impact our business and industry. Namely, the current presidential
administration has taken several executive actions, including the issuance if a number of Executive Orders. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#146;s ability to
exercise its regulatory authority.&nbsp;If these executive actions impose constraints on FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, policies of the individual government agencies, including the FDA or similar regulatory authorities, may change and additional government regulations
may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, the Cures Act, among other things, which is intended to modernize the regulation of drugs and biologics and spur innovation, has not yet
been implemented and its ultimate implementation is unclear. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to
maintain regulatory compliance, our bispecific antibody candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to healthcare laws, regulation and enforcement; our failure to comply with these laws could harm our results of operations and
financial conditions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not currently have any products on the market, if we obtain FDA approval for any of our bispecific antibody
candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations,
including, without limitation, the U.S. federal Anti-Kickback Statute. Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may
impact, among other things, our proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and
distribute our products for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Finally, we may be
subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly
and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual
for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does
not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, which,
among other things, impose criminal and civil penalties, including through civil whistleblower or <I>qui tam</I> actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the U.S. federal
government, claims for payment or approval that are false or fraudulent , knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to
avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a
false or fraudulent claim for purposes of the False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal
and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making
any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute
or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH,
and its implementing regulations, and as amended again by the Final HIPAA Omnibus Rule, Modifications to the HIPAA Privacy, Security, Enforcement and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act; Other
Modifications to the HIPAA Rules, published in January 2013, which imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health
information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or
disclosure of individually identifiable health information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal Food, Drug and Cosmetic Act, or FDCA, which prohibits, among other things, the adulteration or
misbranding of drugs, biologics and medical devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA,
and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report annually to the CMS
information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the
physicians described above and their immediate family members; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to
our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing
and marketing information, and that requires the tracking and reporting of gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in
certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing
interactions with and payments to healthcare providers and data privacy and security requirements. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ensuring that our internal
operations and future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not
comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any
other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as
Medicare and Medicaid, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we
expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above
occur, it could adversely affect our ability to operate our business and our results of operations. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are
successful in defending against any such actions that may be brought against us, our business may be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face potential liability related
to the privacy of health information we obtain from clinical trials sponsored by us or our collaborators, from research institutions and our collaborators, and directly from individuals. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most health care providers, including research institutions from which we or our collaborators obtain patient health information, are subject to privacy and
security regulations promulgated under the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act. Any person may be prosecuted under HIPAA&#146;s
criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually identifiable health
information from a HIPAA-covered health care provider or research institution that has not satisfied HIPAA&#146;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally
identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient
assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information
protected by HIPAA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our clinical trial programs and research collaborations outside the U.S. may implicate international data protection laws, including,
in Europe, the General Data Protection Regulation, or the GDPR and local laws further implementing or supplementing the GDPR. The GDPR implements more stringent operational requirements for processors and controllers of personal data including
requirements for such companies to be able to ensure and be able to demonstrate compliance with the GDPR. If our privacy or data security measures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up
to 20&nbsp;million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher. In addition to statutory enforcement, a non-compliance can lead to compensation claims by affected individuals,
negative publicity and a potential loss of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to EU laws on personal data export, as we may transfer personal data from the EU
to other jurisdictions which are not considered by the European Commission to offer &#147;adequate&#148; protection of personal data. Such transfers need to be legitimized by a valid transfer mechanism under the GDPR. There is currently ongoing
litigation challenging two of the more commonly used transfer mechanisms, the EU model clauses and the U.S. Privacy Shield, and all adequacy decisions may be subject to review by the European Commission at any time. It is uncertain whether these
mechanisms will be invalidated by the EU courts or following review. Invalidation of any mechanism on which we rely could require operational changes and increased costs and may lead to governmental enforcement actions, litigation, fines and
penalties or adverse publicity that could have an adverse effect on our business. See &#147;Business&#151;Privacy and Data Protection Laws in Europe.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws
both inside and outside the United States. Claims that we have violated individuals&#146; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in
adverse publicity that could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or any collaborators fail to comply with applicable federal, state, or local regulatory
requirements, we could be subject to a range of regulatory actions that could affect our or any collaborators&#146; ability to seek to commercialize our clinical candidates. Any threatened or actual government enforcement action could also generate
adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to
Commercialization of Our Bispecific Antibody Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We operate in highly competitive and rapidly changing industries, which may result in
others discovering, developing or commercializing competing products before or more successfully than we do. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The biopharmaceutical and
pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a
cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and
biopharmaceutical companies, academic institutions, government agencies and other private and public research institutions in Europe, the United States and other jurisdictions. These organizations may have significantly greater resources than we do
and conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that compete with our bispecific antibody candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new technologies become available. If
we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any bispecific antibody candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may
become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our bispecific antibody candidates or our technology obsolete, less competitive or
uneconomical. Our competitors may, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have significantly greater financial, manufacturing, marketing, drug development, technical and human resources
than we do; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to
administer, or have fewer or less severe side effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain quicker regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish superior proprietary positions covering our products and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement more effective approaches to sales and marketing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">form more advantageous strategic alliances. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should any of these factors occur, our business, financial condition and results of operations could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, collaborators may decide to market and sell products that compete with the bispecific antibody candidates that we have agreed to license to them,
and any competition by our collaborators could also have a material adverse effect on our future business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to obtain orphan drug designation or obtain or maintain orphan drug
exclusivity for our products, our competitors may sell products to treat the same conditions and our revenue will be reduced. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan
Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the
United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the EU, the EMA&#146;s Committee for Orphan Medicinal Products, or COMP, grants orphan drug designation
to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Additionally, designation is
granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to
justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected
by the condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards
clinical trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may
not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the
manufacturer is unable to assure sufficient product quantity. In the EU, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological
product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to seek orphan drug designation from the FDA and the EMA for our assets in clinical development, including MCLA-128 or MCLA-117, where supported by
data in the appropriate indications that meet the criteria for orphan status. Even if we are able to obtain orphan designation in the United States and/or the EU, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive
marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the
manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect
the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA or the EMA can subsequently approve the same drug with the same active moiety
for the same condition if the FDA or the EMA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor
gives the drug any advantage in the regulatory review or approval process. In addition, while we intend to seek orphan drug designation, when appropriate, we may not receive such designation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of our bispecific antibody candidates will depend in part on the extent to which governmental authorities and health
insurers establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain adequate coverage and reimbursement for our bispecific antibody candidates, if approved, could limit our ability to market those products
and decrease our ability to generate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such
as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford products such as our bispecific antibody candidates, assuming approval. Our ability to achieve acceptable levels of
coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize and attract additional collaboration partners to invest in the
development of our bispecific antibody candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high.
We cannot be sure that coverage and reimbursement in the United States, the EU or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.
Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less
expensive therapy is available. It is possible that a third-party payor may consider our bispecific antibody candidate and other therapies as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved
efficacy or improved convenience of administration with our bispecific antibody candidate, pricing of existing drugs may limit the amount we will be able to charge for our bispecific antibody candidate. These payors may deny or revoke the
reimbursement status of a given drug product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not
available or is available only at limited levels, we may not be able to successfully commercialize our bispecific antibody candidates and may not be able to obtain a satisfactory financial return on products that we may develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors,
including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as
models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies
before they will reimburse health care providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our bispecific antibody candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage
and reimbursement for drug products exists among third-party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often
a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or
obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we
believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our bispecific antibody candidates. In many countries, the prices of medical
products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products, but monitor and control company profits. Additional foreign price controls or
other changes in pricing regulation could restrict the amount that we are able to charge for our bispecific antibody candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the
United States and may be insufficient to generate commercially reasonable revenue and profits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, increasing efforts by governmental and
third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide
adequate payment for our bispecific antibody candidates. We expect to experience pricing pressures in connection with the sale of any of our bispecific antibody candidates due to the trend toward managed healthcare, the increasing influence of
health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result,
increasingly high barriers are being erected to the entry of new products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our products may not gain market acceptance, in which case we may not be
able to generate product revenues, which will materially adversely affect our business, financial condition and results of operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if the
FDA, the EMA or any other regulatory authority approves the marketing of any bispecific antibody candidates that we develop on our own or with a collaborator, physicians, healthcare providers, patients or the medical community may not accept or use
them. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of any of our bispecific antibody candidates will depend on a
variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and clinical profile of competing products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to provide acceptable evidence of safety and efficacy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relative convenience and ease of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effectiveness; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient diagnostics and screening infrastructure in each market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of adequate coverage, reimbursement and adequate payment from health maintenance organizations and
other insurers, both public and private; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other potential advantages over alternative treatment methods. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our bispecific antibody candidates fail to gain market acceptance, this will have a material adverse
impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not to be large enough to allow us to generate significant revenues. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution capabilities on our
own or through collaborations, or if we fail to achieve adequate pricing and/or reimbursement we will not be successful in commercializing our bispecific antibody candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have no marketing, sales and distribution capabilities because all of our bispecific antibody candidates are still in clinical or pre-clinical
development. If any of our bispecific antibody candidates are approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our bispecific antibody
candidates, or to outsource this function to a third party. Either of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our bispecific antibody candidates. In addition, we may not be able
to hire a sales force that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact
the commercialization of our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our
product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third-party collaborators, which may not be successful and are
generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved
products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never commercialized a bispecific antibody candidate before and may lack the necessary expertise, personnel and resources to successfully
commercialize our products on our own or together with suitable collaborators. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never commercialized a bispecific antibody candidate, and
we currently have no sales force, marketing or distribution capabilities. To achieve commercial success for the bispecific antibody candidates, which we may license to others, we will rely on the assistance and guidance of those collaborators. For
bispecific antibody candidates for which we retain commercialization rights, we will have to develop our own sales, marketing and supply organization or outsource these activities to a third party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Factors that may affect our ability to commercialize our bispecific antibody candidates on our own include recruiting and retaining adequate numbers of
effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our bispecific antibody candidates and other unforeseen costs associated with creating an independent sales and marketing
organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our bispecific antibody candidates. We may not be able to build an effective sales and marketing organization. If we are
unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our bispecific antibody candidates, we may not generate revenues from them or be able to reach or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our bispecific antibody candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, signed into law on March&nbsp;23, 2010, includes a subtitle called the Biologics Price Competition and
Innovation Act of 2009, or BPCIA, which created an abbreviated approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be
submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the
reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own
pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate
impact, implementation, and meaning are subject to uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that any of our bispecific antibody candidates approved as a biological
product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise. Other aspects of the BPCIA, some of which may impact the BPCIA
exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic
substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jurisdictions in addition to the United States have established abbreviated pathways for regulatory approval of biological products that are biosimilar to
earlier approved reference products. For example, the EU has had an established regulatory pathway for biosimilars since 2005. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increased likelihood
of biosimilar competition has increased the risk of loss of innovators&#146; market exclusivity. Due to this risk, and uncertainties regarding patent protection, if our clinical candidates are approved for marketing, it is not possible to predict
the length of market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States
regulatory law that might reduce biological product regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues and we may not generate adequate or sufficient revenues from them or be
able to reach or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our pre-clinical studies and
clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our bispecific antibody candidates and our business
could be substantially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators
and third-party CROs, to conduct our pre-clinical studies and clinical trials and to monitor and manage data for our ongoing pre-clinical and clinical programs. We rely on these parties for execution of our pre-clinical studies and clinical trials,
and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our
reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with good clinical practice, or GCP, requirements, which are regulations and guidelines
enforced by the FDA, the Competent Authorities of the Member States of the EEA, and comparable foreign regulatory authorities for all of our products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of
trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA or comparable foreign regulatory
authorities may require us to perform additional clinical trials before approving our marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In
addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including
time, which they devote to our bispecific antibody candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our bispecific antibody candidates, or if their performance is
substandard, it may delay or compromise the prospects for approval and commercialization of any bispecific antibody candidates that we develop. In addition, the use of third-party service providers may require us to disclose our proprietary
information to these parties, which could increase the risk that this information will be misappropriated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our CROs have the right to terminate their
agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our
clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of our
relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or
meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical
trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our bispecific antibody candidates. As a result, our results of operations and the commercial prospects for our
bispecific antibody candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Switching or adding
additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired
clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we
will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The collaboration and license agreement, or the Collaboration Agreement, with Incyte Corporation, or Incyte, is important to our business. If suitable
bispecific antibody candidates are not identified for further development and commercialization activities under the Collaboration Agreement, or if we or Incyte fail to adequately perform under the Collaboration Agreement, or if we or Incyte
terminate the Collaboration Agreement, the development and commercialization of our bispecific antibody candidates would be delayed or terminated and our business would be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Collaboration Agreement may be terminated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in its entirety or on a program-by-program basis by Incyte for convenience; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in its entirety or on a program-by-program basis by either party due to a material breach of the Collaboration
Agreement, or any one or more programs under the Collaboration Agreement, as applicable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a program-by-program basis (but not in its entirety), by either party if the other party challenges the
terminating party&#146;s patents for such program, and such challenge is not withdrawn within 30 days. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Collaboration Agreement
is terminated with respect to one or more programs, all rights in the terminated programs revert to us, subject to payment to Incyte of a reverse royalty of between 0% and 4% on sales of future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products, depending on the stage of development as of the date of termination, if we elect to pursue development and commercialization of bispecific antibody products arising from the terminated
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Termination of the Collaboration Agreement could cause significant delays in our product candidate development and commercialization efforts,
which could prevent us from commercializing our bispecific antibody candidates without first expanding our internal capabilities or entering into another agreement with a third party. Any suitable alternative collaboration or license agreement would
take considerable time to negotiate and could also be on less favorable terms to us. In addition, under the Collaboration Agreement, Incyte agreed to conduct certain clinical development activities. If the Collaboration Agreement were to be
terminated, and whether or not we identify another suitable collaborator, we may need to seek additional financing to support the research and development of any terminated product candidates so that we may continue development activities, or we may
be forced to discontinue development of terminated product candidates, each of which could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
Collaboration Agreement, with the exception of MCLA-145 where we retain full US rights, we are dependent upon Incyte to successfully develop and commercialize bispecific antibody candidates that are identified for further development under the
Collaboration Agreement. With the exception of those programs where we retain certain co-development rights, we have limited ability to influence or control Incyte&#146;s development and commercialization activities or the resources it allocates to
development of bispecific antibody product candidates identified under the Collaboration Agreement. Our interests and Incyte&#146;s interests may differ or conflict from time to time, or we may disagree with Incyte&#146;s level of effort or resource
allocation. Incyte may internally prioritize programs under development within the collaboration differently than we would, or it may not allocate sufficient resources to effectively or optimally develop or commercialize bispecific antibody
candidates arising from such programs. If these events were to occur, our ability to receive revenue from the commercialization of products arising from such programs would be reduced, and our business would be adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to enter into new strategic relationships our business, financial condition, commercialization prospects and results of operations may be
materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product development programs and the potential commercialization of our bispecific antibody candidates will
require substantial additional cash to fund expenses. Therefore, for some of our bispecific antibody candidates, we may decide to enter into new collaborations with pharmaceutical or biopharmaceutical companies for the development and potential
commercialization of those bispecific antibody candidates. For instance, we have license and collaboration agreements with ONO, Incyte and Simcere Pharmaceutical Group which we have licensed the development and commercialization of certain of our
bispecific antibody candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to
negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations on acceptable
terms, or at all. If that were to occur, we may have to curtail the development of a particular bispecific antibody candidate, reduce or delay its development program or one or more of our other development programs, delay its potential
commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our bispecific antibody candidates to
market and generate product revenue. If we do&nbsp;enter into a new collaboration agreement, we could be subject to the following risks, each of which may materially harm our business, commercialization prospects and financial condition: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to control the amount and timing of resources that the collaboration partner devotes to the
product development program; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the collaboration partner may experience financial difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to relinquish important rights such as marketing, distribution and intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator could move forward with a competing product developed either independently or in collaboration
with third parties, including our competitors; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business combinations or significant changes in a collaborator&#146;s business strategy may adversely affect our
willingness to complete our obligations under any arrangement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently rely on third-party suppliers and other third parties
for production of our bispecific antibody candidates and our dependence on these third parties may impair the advancement of our research and development programs and the development of our bispecific antibody candidates. Moreover, we intend to rely
on third parties to produce commercial supplies of any approved bispecific antibody candidate and our commercialization of any of our bispecific antibody candidates could be stopped, delayed or made less profitable if those third parties fail to
obtain approval of the FDA or comparable regulatory authorities, fail to provide us with sufficient quantities of bispecific antibody product or fail to do so at acceptable quality levels or prices or fail to otherwise complete their duties in
compliance with their obligations to us or other parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on and expect to continue to rely on third-party contract manufacturing
organizations, or CMOs, for the supply of current good manufacturing practice-grade, or cGMP-grade, clinical trial materials and commercial quantities of our bispecific antibody candidates and products, if approved. Reliance on third-party providers
may expose us to more risk than if we were to manufacture bispecific antibody candidates ourselves. The facilities used by our contract manufacturers to manufacture our bispecific antibody candidates must be approved by the FDA pursuant to
inspections that will be conducted after we submit our BLA to the FDA. We have limited control over the manufacturing process of, and beyond contractual terms, we are completely dependent on our contract manufacturing partners for compliance with
cGMP for the manufacture of our bispecific antibody candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be
able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified
personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our bispecific antibody candidates or if it withdraws any such approval in the future, we may need to find alternative
manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our bispecific antibody candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws,
regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our bispecific antibody candidates or that obtained approvals could be revoked, which would adversely affect our business and reputation.
Furthermore, third-party providers may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement because of their own financial difficulties or business priorities,
at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate replacement or another acceptable solution in time, our clinical trials could be delayed or our commercial activities could be harmed. In addition, the
fact that we are dependent on our collaborators, our suppliers and other third parties for the manufacture, filling, storage and distribution of our bispecific antibody candidates means that we are subject to the risk that the products may have
manufacturing defects that we have limited ability to prevent or control. The sale of products containing such defects could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Growth in the costs and expenses of components or raw materials may also adversely influence our business, financial condition and results of operations.
Supply sources could be interrupted from time to time and, if interrupted, there is no guarantee that supplies could be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our
bispecific antibody candidates for our clinical trials. There are a limited number of suppliers for raw materials that we use to manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the
manufacture of the materials necessary to produce our bispecific antibody candidates for our clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw
materials by our manufacturers. Moreover, we currently do not have any agreements for the commercial production of these raw materials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a bispecific
antibody candidate to complete the clinical trial, any significant delay in the supply of a bispecific antibody candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer
could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our bispecific antibody candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has
been obtained for our bispecific antibody candidates, the commercial launch of our bispecific antibody candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our
bispecific antibody candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on our manufacturers and other subcontractors to comply with and respect the proprietary rights of others in
conducting their contractual obligations for us. If our manufacturers or other subcontractors fail to acquire the proper licenses or otherwise infringe third party proprietary rights in the course of completing their contractual obligations to us,
we may have to find alternative manufacturers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or market our bispecific antibody candidates, if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property and Information Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on patents and other intellectual property rights to protect our technology, including bispecific antibody candidates and our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, the enforcement, defense and maintenance of which may be challenging and costly. Failure to enforce or protect these rights adequately could harm our ability to compete and
impair our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights
for technology, including our bispecific antibody and antibody candidates, products and methods used to manufacture those antibody and antibody candidates, the methods for treating patients using those products, among other aspects of our technology
or on licensing-in such rights. Failure to protect or to obtain, maintain or extend adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market our products and bispecific antibody
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive and time-consuming, and we and our current or future licensors, licensees or collaborators may
not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors, licensees or collaborators will fail to identify patentable aspects
of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Further, the issuance, scope, validity, enforceability and commercial value of our and our current or future
licensors&#146;, licensees&#146; or collaborators&#146; patent rights are highly uncertain. Our and our licensors&#146; pending and future patent applications may not result in patents being issued which protect our technology or products, in whole
or in part, or which effectively prevent others from commercializing competitive technologies and products. The patent examination process may require us or our licensors, licensees or collaborators to narrow the scope of the claims of our or our
licensors&#146;, licensees&#146; or collaborators&#146; pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure you that all of the potentially relevant prior art relating to our
patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our
bispecific antibody candidates, third parties may initiate opposition, interference, re-examination, post-grant review, inter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
partes review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in
the patent claims being narrowed or invalidated. Our and our licensors&#146;, licensees&#146; or collaborators&#146; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until
a patent issues from such applications, and then only to the extent the issued claims cover the technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because patent applications are confidential
for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to our technology, including a bispecific antibody candidate. Furthermore, if
third parties have filed such patent applications on or before March&nbsp;15, 2013, an interference proceeding can be initiated by such third parties to determine who was the first to invent any of the subject matter covered by the patent claims of
our applications. If third parties have filed such applications after March&nbsp;15, 2013, a derivation proceeding can be initiated by such third parties to determine whether our invention was derived from theirs. Even where we have a valid and
enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering one or more of our products or the Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform could
be found invalid or unenforceable if challenged in court. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To protect our competitive position, we may from time to time need to resort to
litigation to enforce or defend any patents or other intellectual property rights owned by or licensed to us, or to determine or challenge the scope or validity of patents or other intellectual property rights of third parties. As enforcement of
intellectual property rights is difficult, unpredictable and expensive, we may fail in enforcing our rights&#151;in which case our competitors may be permitted to use our technology without being required to pay us any license fees. In addition,
litigation involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a claim-by-claim basis) or held unenforceable. Such an adverse court ruling could allow third parties to commercialize
our product candidates or methods, or our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, and then compete directly with us, without payment to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or methods, the defendant could counterclaim
that our patent is invalid and/or unenforceable. In patent litigation in the United States or in certain jurisdictions in Europe, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge
could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the
patent withheld relevant information from the U.S. Patent and Trademark Office, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable.
With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity
and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our technologies, products, methods or certain aspects of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
technology platform. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology
without infringing our patents or other intellectual property rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights of third parties could adversely affect our
ability to commercialize our bispecific antibody candidates, such that we could be required to litigate or obtain licenses from third parties in order to develop or market our bispecific antibody candidates. Such litigation or licenses could be
costly or not available on commercially reasonable terms. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our competitive position may suffer if patents issued to third parties or other
third-party intellectual property rights cover our methods or product candidates or elements thereof, our manufacture or uses relevant to our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development plans, our bispecific antibody candidates, or other attributes of our bispecific antibody candidates or our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
technology platform. In such cases, we may not be in a position to develop or commercialize products or bispecific antibody candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right
concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. In addition, we are aware of issued patents and pending patent applications held by third parties that may be
construed as covering some of our bispecific antibody candidates. We believe that if such patents or patent applications (if issued as currently pending) were asserted against us, we would have counterclaims and defenses against such claims,
including non-infringement, the affirmative defense of safe harbor designed to protect activity undertaken to obtain federal regulatory approval of a drug, including under 35 U.S.C. &#167; 271(e) and similar foreign statutes, patent invalidity
and/or unenforceability. However, if such counterclaims and defenses were not successful and such patents were successfully asserted against us such that they are found to be valid and enforceable, and infringed by our bispecific antibody
candidates, unless we obtain a license to such patents, which may not be available on commercially reasonable terms or at all, we could be prevented from continuing to develop or commercialize our products. We could also be required to pay
substantial damages. Similarly, the targets of our bispecific antibody candidates have also been the subject of research by many companies, which have filed patent applications or have patents related to such targets and their uses. There can be no
assurance any such patents will not be asserted against us or that we will not need to seek licenses from such third parties. We may not be able to secure such licenses on acceptable terms, if at all, and any such litigation would be costly and
time-consuming. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is also possible that we failed to identify relevant patents or applications. For example, U.S. applications filed before
November&nbsp;29, 2000 and certain U.S. applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States and elsewhere are published approximately
18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our products or platform technology could have been filed by
others without our knowledge. Furthermore, we operate in a highly competitive field, and given our limited resources, it is unreasonable to monitor all patent applications purporting to gain broad coverage in the areas in which we are active.
Additionally, pending patent applications which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our methods, product candidates or the use of our product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third party intellectual property right holders, including our competitors, may actively bring infringement claims against us. The granting of orphan
drug status in respect of any of our bispecific antibody candidates does not guarantee our freedom to operate and is separate from our risk of possible infringement of third parties&#146; intellectual property rights. We may not be able to
successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage or continue costly, unpredictable and time-consuming litigation and may
be prevented from or experience substantial delays in marketing our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail in any such dispute, in addition to being forced to pay damages,
we or our licensees may be temporarily or permanently prohibited from commercializing any of our bispecific antibody candidates that are held to be infringing. We might, if possible, also be forced to redesign bispecific antibody candidates so that
we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to
our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if the breadth or strength of protection provided by our or our licensors&#146; or collaboration partners&#146; patents and
patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future bispecific antibody candidates. Furthermore, because of the substantial amount of discovery required in
connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to compete may be adversely affected if we are unsuccessful in defending against any
claims by competitors or others that we are infringing upon their intellectual property rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The various markets in which we plan to operate
are subject to frequent and extensive litigation regarding patents and other intellectual property rights.&nbsp;In addition, many companies in intellectual property-dependent industries, including those producing therapeutics to treat and
potentially cure cancer, have employed intellectual property litigation as a means to gain an advantage over their competitors. As a result, we may be required to defend against claims of intellectual property infringement that may be asserted by
our competitors against us and, if the outcome of any such litigation is adverse to us, it may affect our ability to compete effectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our involvement
in litigation, and in any interferences, opposition proceedings or other intellectual property proceedings inside and outside of the United States may divert management from focusing on business operations, could cause us to spend significant
amounts of money and may have no guarantee of success. Any current and potential intellectual property litigation also could force us to do one or more of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stop selling, incorporating, manufacturing or using our products in the United States and/or other jurisdictions
that use the subject intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain from a third party asserting its intellectual property rights, a license to sell or use the relevant
technology, which license may not be available on reasonable terms, or at all, or may be non-exclusive thereby giving our competitors access to the same technologies licensed to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesign those products or processes that use any allegedly infringing or misappropriated technology, which may
result in significant cost or delay to us, or which redesign could be technically infeasible; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay damages, including the possibility of treble damages in a patent case if a court finds us to have willfully
infringed certain intellectual property rights. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are aware that significant number of patents and patent applications may exist
relating to aspects of therapeutic antibody technologies filed by, and issued to, third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you that we will ultimately prevail if
any of this third-party intellectual property is asserted against us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property litigation could cause us to spend substantial
resources and distract our personnel from their normal responsibilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings
relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of
hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, we could have a substantial adverse effect on the price of our common shares. Such litigation or
proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation
or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or
maintaining necessary rights to our bispecific antibody candidates through acquisitions and in-licenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have rights to the
intellectual property, including patent applications relating to our bispecific antibody candidates. Because our programs may require the use of proprietary rights held by third parties, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, our bispecific antibody candidates may require
specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property
rights from third parties that we identify as necessary for our bispecific antibody candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also
pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical
development and commercialization capabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, we sometimes collaborate with U.S. and non-U.S. academic institutions to accelerate our
pre-clinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the
collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other
parties, potentially blocking our ability to pursue our applicable bispecific antibody candidate or program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to
be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable
to successfully obtain a license to third-party intellectual property rights necessary for the development of a bispecific antibody candidate or program, we may have to abandon development of that bispecific antibody candidate or program and our
business and financial condition could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build
name recognition in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registered or unregistered trademarks or trade names
may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential
collaborators, partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be
adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout the world. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments and similar non-U.S. legislation for extending the term of patents covering each of our
bispecific antibody candidates, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance
fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if
patents covering our bispecific antibody candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar or generic medications. Given the amount of time
required for the development, testing and regulatory review of new bispecific antibody candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent
portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending upon the
timing, duration and conditions of FDA marketing approval of our bispecific antibody candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term
extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply
within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term
extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a
result, our revenue from applicable products could be reduced, possibly materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We enjoy only limited geographical protection with respect to
certain patents and may face difficulties in certain jurisdictions, which may diminish the value of intellectual property rights&nbsp;in those jurisdictions. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We generally file our first patent application (<I>i.e.</I>, priority filing) at the EPO. International applications under the Patent Cooperation Treaty, or
PCT, are usually filed within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in additional jurisdictions where we believe our bispecific antibody candidates may be marketed. We
have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant
proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others.&nbsp;It is also quite common
that depending on the country, the scope of patent protection may vary for the same bispecific antibody candidate and/or technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may use
our and our licensors&#146; or collaboration partners&#146; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and
our licensors or collaboration partners have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our bispecific antibody candidates, and our and our licensors&#146; or collaboration
partners&#146; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of some
jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If
we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we
may face additional competition from others in those jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some countries have compulsory licensing laws under which a patent owner may be
compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could
materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business and results of
operations may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations,
and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make compounds that are the same as or similar to our bispecific antibody candidates but
that are not covered by the claims of the patents that we own or have exclusively licensed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of third parties may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or any future strategic partners might not have been the first to conceive or reduce to
practice the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our licensors or any future strategic partners might not have been the first to file patent applications
covering certain of our inventions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may
be held invalid or unenforceable, as a result of legal challenges by our competitors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties performing manufacturing or testing for us using our products or technologies could use the
intellectual property of others without obtaining a proper license. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional technologies that are patentable. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our products.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining
and enforcing patents in the biopharmaceutical industry involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2011, the America Invents Act, or the AIA, was enacted in the United States, resulting in significant changes to the U.S. patent system. An
important change introduced by the AIA was a transition to a &#147;first-to-file&#148; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention, which
went into effect on March&nbsp;16, 2013. Therefore, a third party that now files a patent application in the USPTO before we do could be awarded a patent covering an invention of ours even if we created the invention before it was created by the
third party. While we are cognizant of the time from invention to filing of a patent application, circumstances could prevent us from promptly filing patent applications for our inventions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA were changes that limit where a patentee may file a patent infringement suit and providing opportunities
for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard
in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate
the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in
a district court action. The AIA and its continued implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, and the patent applications of our collaborators or licensors, and the enforcement
or defense of our issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing
patents could change in unpredictable ways that could weaken our ability to obtain new patents or to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforce our existing patents and patents that we might obtain in the future. Similarly, there is complexity and uncertainty related to European patent laws.&nbsp;For example, the European Patent
Convention was amended in April 2010&nbsp;to limit the time permitted for filing divisional applications. In addition, the EP patent system is relatively stringent in the type of amendments that are allowed during prosecution. These limitations and
requirements could adversely affect our ability to obtain new patents in the future that may be important for our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Confidentiality
agreements with employees and others may not adequately prevent disclosure of trade secrets and protect other proprietary information. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consider
proprietary trade secrets and/or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets and/or confidential know-how to protect our technology, especially where patent protection is believed to be
of limited value. However, trade secrets and/or confidential know-how are difficult to maintain as confidential. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To protect this type of information
against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements with us. However, current or former employees, consultants, contractors and
advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim
that a third party obtained illegally and is using trade secrets and/or confidential know-how is expensive, time consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. Furthermore,
if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.
Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to obtain or maintain trade secrets and/or confidential know-how trade protection could adversely affect our competitive position. Moreover, our
competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, our competitors could limit our use of our
trade secrets and/or confidential know-how. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under certain circumstances and to guarantee our freedom to operate, we may also decide to publish some
know-how to prevent others from obtaining patent rights covering such know-how. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims by third parties asserting that our
employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many
of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights,
non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims
that we or these employees have used or disclosed confidential information or intellectual property, including trade secrets or other proprietary information, of any such employee&#146;s former employer. Litigation may be necessary to defend against
these claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be
available on commercially reasonable terms or at all. Even if we successfully prosecute or defend against such claims, litigation could result in substantial costs and distract management. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural,
document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of
the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in
many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or
complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment
of fees and failure to properly legalize and submit formal documents. If we or our licensors or collaborators fail to maintain the patents and patent applications covering our bispecific antibody candidates, our competitors might be able to enter
the market, which would have an adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of social media could give rise to liability, breaches of data security, or
reputational harm. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and our employees use social media to communicate internally and externally. There is risk that the use of social media by
us or our employees to communicate about our products or business may give rise to liability, lead to the loss of trade secrets or other intellectual property, or result in public exposure of personal information of our employees, clinical trial
patients, customers, and others. Furthermore, negative posts or comments about us or our products in social media could seriously damage our reputation, brand image, and goodwill. Any of these events could have a material adverse effect on our
business, prospects, operating results, and financial condition and could adversely affect the price of our Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our computer systems, or
those used by our CROs or other contractors or consultants, may fail or suffer security breaches, which could adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our computer systems and data and those of our current or future CROs or other contractors and consultants are
vulnerable to compromise or damage from computer hacking, malicious software, fraudulent activity, employee misconduct, human error, telecommunication and electrical failures, natural disasters, or other cybersecurity attacks or accidents. Future
acquisitions could expose us to additional cybersecurity risks and vulnerabilities from any newly acquired information technology infrastructure. Cybersecurity attacks are constantly increasing in sophistication and are made by groups and
individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, &#147;hacktivists,&#148; nation states, and others. As a company with an increasingly global presence, our systems are
subject to frequent attacks. Due to the nature of some of these attacks, there is a risk that an attack may remain undetected for a period of time. While we continue to make investments to improve the protection of data and information technology,
there can be no assurance that our efforts will prevent service interruptions or security breaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any cybersecurity incident could adversely affect our
business, by leading to, for example, the loss of trade secrets or other intellectual property, demands for ransom or other forms of blackmail, or the unauthorized disclosure of personal or other sensitive information of our employees, clinical
trial patients, customers, and others. Although to our knowledge we have not experienced any material cybersecurity incident to date, if such an event were to occur, it could seriously harm our development programs and our business operations. We
could be subject to regulatory actions taken by governmental authorities, litigation under laws that protect the privacy of personal information, or other forms of legal proceedings, which could result in significant liabilities or penalties.
Further, a cybersecurity incident may disrupt our business or damage our reputation, which could have a material adverse effect on our business, prospects, operating results, share price and shareholder value, and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial condition.&nbsp;We could also incur substantial remediation costs, including the costs of investigating the incident, repairing or replacing damaged systems, restoring normal business
operations, implementing increased cybersecurity protections, and paying increased insurance premiums. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Employee Matters and Managing
Growth </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success depends upon the continued contributions of our key management, scientific and technical personnel, many of whom have been
instrumental for us and have substantial experience with our therapies and related technologies. These key management individuals include the members of our board of directors. For example, our founder and President &amp; Chief Executive Officer,
Ton Logtenberg, holds a Ph.D. in medical biology, was a professor in the Department of Immunology at Utrecht University and co-founded the Dutch biotechnology company, Crucell N.V. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The loss of key managers and senior scientists could delay our research and development activities. In addition, the competition for qualified personnel in
the biopharmaceutical and pharmaceutical field is intense, and our future success depends upon our ability to attract, retain and motivate highly-skilled scientific, technical and managerial employees. We face competition for personnel from other
companies, universities, public and private research institutions and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement business strategy, which could have a
material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we
may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to experience significant growth in the number of
our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational
and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated
growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business
development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our
Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common shares may be volatile and may fluctuate due to factors beyond our control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The share price of publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain
highly volatile in the future. The market price of our common shares may fluctuate significantly due to a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">positive or negative results of testing and clinical trials by us, strategic partners or competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in entering into strategic relationships with respect to development and/or commercialization of our
bispecific antibody candidates or entry into strategic relationships on terms that are not deemed to be favorable to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological innovations or commercial product introductions by us or competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in government regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments concerning proprietary rights, including patents and litigation matters; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">public concern relating to the commercial value or safety of any of our bispecific antibody candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financing or other corporate transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports or comments by securities or industry analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market conditions in the pharmaceutical industry or in the economy as a whole; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events and factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These and other market and industry factors may cause the market price and demand for our securities to fluctuate substantially, regardless of our actual
operating performance, which may limit or prevent investors from readily selling their common shares and may otherwise negatively affect the liquidity of our common shares. In addition, the stock market in general, and biopharmaceutical companies in
particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will continue to incur increased costs as a result of operating as a public company with limited liability (naamloze vennootschap), and our
management team will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company,
and particularly after we no longer qualify as an emerging growth company, we will continue to incur significant legal, accounting and other expenses related to our operation as a public company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall
Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Market, or Nasdaq, and other applicable securities rules and regulations impose various requirements on non-U.S. reporting public companies, including the
establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our Board of Directors and other personnel will need to continue to devote a substantial amount of time to these compliance initiatives.
Moreover, these rules and regulations have and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application
in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance
practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we are required to furnish a report by our management on
our internal control over financial reporting with our Annual Report on Form 20-F. While we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our
independent registered public accounting firm. To maintain compliance with Section&nbsp;404, we engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we
continue to dedicate internal resources and have engaged outside consultants and adopted a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as
appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be
able to maintain effective internal control over financial reporting as required by Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the
reliability of our financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified material weaknesses in our internal control over financial reporting that could, if
not remediated, result in material misstatements in our financial statements and cause shareholders to lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common shares.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public reporting company, we are subject to the rules and regulations established from time to time by the SEC and Nasdaq. These rules and
regulations require, among other things, that we have, and periodically evaluate, procedures with respect to our internal control over financial reporting. Reporting obligations as a public company are likely to continue to place a considerable
strain on our financial and management systems, processes and controls, as well as on our personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as a public company, we are required to
document and test our internal control over financial reporting pursuant to Section&nbsp;404 so that our management can certify as to the effectiveness of our internal control over financial reporting, which requires us to document and make
significant changes to our internal control over financial reporting. While we are an &#147;emerging growth company,&#148; our independent registered public accounting firm will not be required to test the effectiveness of our internal control over
financial reporting in connection with an auditor attestation pursuant to Section&nbsp;404. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In its review of our internal control over financial
reporting in connection with the annual audit for 2017, management has identified a material weakness associated with a lack of adequate cut-off procedures to ensure the timely recognition, measurement and classification of operating expenses and
recording of certain period-end accruals. Specifically, we did not design and maintain effective internal control over the assessment of the accounting for significant contractual arrangements related to our clinical research and manufacturing
agreements and the classification of operating expenses. In its review of our internal control over financial reporting in connection with the annual audit for the year ended December&nbsp;31, 2016, management identified the following material
weaknesses: insufficient accounting resources required to fulfill IFRS and SEC reporting requirements and the absence of comprehensive IFRS accounting policies and financial reporting procedures. As of December&nbsp;31, 2017, these material
weaknesses were not remediated. As a result of these material weaknesses, our management concluded that our internal control over financial reporting was not effective as of December&nbsp;31, 2017. Notwithstanding these material weaknesses, our
management, based on the substantial work performed, concluded that our consolidated financial statements for the periods covered by and included in this prospectus are fairly stated in all material respects in accordance with IFRS for each of the
periods presented in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in the &#147;Internal Control Over Financial Reporting&#148; section of this prospectus, we have taken
and plan to take additional steps intended to address the underlying causes of the material weakness. There can be no assurance that any measures we take will remediate the material weaknesses identified, nor can there be any assurance as to how
quickly we will be able to remediate these material weaknesses. In addition, we may encounter problems or delays in completing the implementation of these measures. If these material weaknesses are not remediated, or if other undetected material
weaknesses in our internal controls exist, it could result in material misstatements in our financial statements requiring us to restate previously issued financial statements. In addition, material weaknesses, and any resulting restatements, could
cause investors to lose confidence in our reported financial information, and could subject us to regulatory scrutiny and to litigation from shareholders, which could have a material adverse effect on our business and the price of our common shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, the correction of any such material weaknesses, including the ones noted above, could require additional remedial measures including
additional personnel, which could be costly and time-consuming. If we do not maintain adequate financial and management personnel, processes and controls, we may not be able to manage our business effectively or accurately report our financial
performance on a timely basis, which could cause a decline in our common share price and adversely affect our results of operations and financial condition. Failure to comply with the Sarbanes-Oxley Act of 2002 could potentially subject us to
sanctions or investigations by the SEC, Nasdaq or other regulatory authorities, which would require additional financial and management resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In preparing our financial statements, our management is required to apply accounting standards that
require significant interpretation. If our interpretation is incorrect or if regulatory or other authorities disagree with our interpretation, we may be required to restate or revise previously issued financial statements, which could have a
material adverse impact on our financial position and the perception of our company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of our financial statements in accordance
with IFRS as issued by the IASB requires our management to make significant interpretations of accounting standards. Certain of these standards require our management to make particularly subjective or complex judgments about matters that are
uncertain and such judgements can result in materially different amounts than would be recorded using a different interpretation of these standards. In addition, in implementing any new or revised accounting standards, our management must interpret
these standards. If our interpretation of any accounting standard is incorrect or if regulatory or other authorities disagree with our interpretation, we may need to revise or restate previously issued financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 11, 2018, we received a comment letter from the staff of the Division of Corporation Finance of the SEC, or the Staff, relating to our Annual
Report on Form 20-F for the fiscal year ended December 31, 2017 and our Report on Form 6-K furnished on August 10, 2018, which included our unaudited interim financial statements for the six months ended June 30, 2018. We responded to these comments
and received a second comment letter on November&nbsp;1, 2018 to which we responded on December 3, 2018. We received a third comment letter on December 20, 2018 and are in the process of responding to the Staff. The Staff requested information
regarding our recognition and measurement of revenue under our license and collaboration agreement and the related share subscription agreement with Incyte, or the Incyte Agreements. More specifically, the Staff requested information regarding our
accounting for the $80.0&nbsp;million purchase by Incyte of our common shares under the share subscription agreement and our valuation of such purchase, our analysis of the allocation of the transaction price, including the $120.0&nbsp;million
upfront payment under the license and collaboration agreement the timing of our accounting of the transaction, and our consideration of payments we may receive in connection with our collaboration with Incyte in light of our adoption of
&#147;IFRS&nbsp;15&#151;Revenue from Contracts with Customers,&#148; or IFRS 15, which became effective for annual and interim reporting periods beginning on or after January&nbsp;1, 2018. We have been discussing the comments with the Staff, and we
cannot predict when these comments will be resolved or the outcome. If the Staff ultimately disagrees with our accounting related to the Incyte Agreements, the impact to our previously issued financial statements for the year ended December&nbsp;31,
2017 and the subsequent interim periods could be material and we could be required to restate these financial statements, which could have a material adverse impact on our financial position. Such revision or restatement could also negatively affect
the perception of our company&#146;s financial operations, which could materially adversely impact our business and the trading price of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Members of our senior management, members of our board of directors, and certain shareholders affiliated with members of our board of directors may be
able to exercise significant control over us, and the interests of our other shareholders may conflict with the interests of our existing shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October 31, 2018, members of our senior management, our board of directors and shareholders affiliated with members of our board of directors, in the
aggregate, owned approximately 9% of our common shares. Depending on the level of attendance at our general meetings of shareholders, these shareholders may be in a position to determine the outcome of decisions taken at any such general meeting.
Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our general meetings of shareholders may control any shareholder resolution requiring a simple majority, including the appointment of board
members, certain decisions relating to our capital structure, the approval of certain significant corporate transactions and amendments to our articles of association. Among other consequences, this concentration of ownership may have the effect of
delaying or preventing a change in control and might therefore negatively affect the market price of our common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the event we
receive an offer from a third party to acquire us or prior to our soliciting an offer from, or negotiating terms with, any third party, with respect to a sale or license of two of our undisclosed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates in pre-clinical development, we must first notify one of our existing shareholders of such opportunity and negotiate in good faith with such shareholder the terms of a purchase
or license agreement for such product candidates. This obligation may have the effect of delaying or preventing a change in control of us that shareholders may consider favorable, including transactions in which shareholders might otherwise receive
a premium for your shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales, or the possibility of future sales, of a substantial number of our common shares could adversely affect
the price of the shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a registration rights agreement pursuant to which we agreed, under certain circumstances, to file a
registration statement to register the resale of the shares held by certain of our existing shareholders, as well as to cooperate in certain public offerings of such shares. In addition, we have registered and intend to continue to register all
common shares that we may issue under our equity compensation plans. Once registered, these common shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates who hold such shares. In
addition, in connection with entering into the Collaboration Agreement, we entered into a Share Subscription Agreement with Incyte, pursuant to which we issued and sold to Incyte 3,200,000 of our common shares. Incyte&#146;s ability to sell these
common shares is subject to certain limitations, including limitations on the volume of shares that may be sold during a given time period. However, future sales of a substantial number of our common shares, or the perception that such sales will
occur, could cause a decline in the market price of our common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions of our articles of association or Dutch corporate law might deter
acquisition bids for us that might be considered favorable and prevent or frustrate any attempt to replace or remove the then board of directors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions of our articles of association may make it more difficult for a third party to acquire control of us or effect a change in our board of directors.
These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the authorization of a class of preferred shares that may be issued to a friendly party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility to appoint our board members for staggered terms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a provision that our board members may only be removed by the general meeting of shareholders by a two-thirds
majority of votes cast representing more than 50% of our outstanding share capital (unless the removal was proposed by the board of directors); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that certain matters, including an amendment of our articles of association, may only be brought to
our shareholders for a vote upon a proposal by our board of directors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our anti-takeover provision may prevent a beneficial
change of control. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We adopted an anti-takeover measure pursuant to which our board of directors may, without shareholder approval, issue (or grant
the right to acquire) preferred shares. Pursuant to a call option agreement entered into with an independent special purpose foundation, we may issue an amount of preferred shares up to 100% of our issued capital held by third parties immediately
prior to the issuance of such preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preferred shares will be issued to the foundation for their nominal value, of which only 25% will be
due upon issuance. The voting rights of our shares are based on nominal value and as we expect our shares to continue to trade substantially in excess of nominal value, preferred shares issued at nominal value can obtain significant voting power for
a substantially reduced price and thus be used as a defensive measure. These preferred shares will have both a liquidation and dividend preference over our common shares and will accrue cash dividends at a fixed rate. Subject to the foundation
exercising its call option under the call option agreement, the board may issue these preferred shares to protect us from influences that do not serve our best interests and threaten to undermine our continuity, independence and identity. These
influences may include a third-party acquiring a significant percentage of our common shares, the announcement of a public offer for our common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares, other concentration of control over our common shares or any other form of pressure on us to alter our strategic policies. The foundation&#146;s articles of association provide that it
will act to serve the best interests of us, our associated business and all parties connected to us, by opposing any influences that conflict with these interests and threaten to undermine our continuity, independence and identity. This foundation
is structured to operate independently of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not expect to pay cash dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not paid any cash dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend
that any earnings will be reinvested in our business and that cash dividends will not be paid until we have an established revenue stream to support continuing cash dividends. Payment of any future dividends to shareholders will in addition
effectively be at the discretion of the general meeting, upon proposal of the board of directors, after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. In
addition, payment of future cash dividends may be made only if our shareholders&#146; equity exceeds the sum of our paid-in and called-up share capital plus the reserves required to be maintained by Dutch law or by our articles of association.
Accordingly, investors cannot rely on cash dividend income from our common shares and any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of our common shares outside the Netherlands may not be able to exercise preemptive rights. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of an increase in our share capital, holders of our common shares are generally entitled under Dutch law to full preemptive rights, unless these
rights are excluded either by a resolution of the general meeting of shareholders, or by a resolution of the board (if the board has been designated by the general meeting of shareholders for this purpose). Certain holders of our common shares
outside the Netherlands, in particular U.S. holders of our common shares, may not be able to exercise preemptive rights unless a registration statement under the Securities Act is declared effective with respect to our common shares issuable upon
exercise of such rights or an exemption from the registration requirements is available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The rights of our shareholders may be different from the
rights of shareholders in companies governed by the laws of U.S. jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a Dutch public company with limited liability (<I>naamloze
vennootschap</I>). Our corporate affairs are governed by our articles of association and by the laws governing companies incorporated in the Netherlands. The rights of shareholders and the responsibilities of members of our board may be different
from the rights and obligations of shareholders in companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our board is required by Dutch law to consider the interests of our company, its shareholders, its employees
and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to, the interests of our shareholders.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are not obligated to and do not comply with all the best practice provisions of the Dutch Corporate Governance Code. This may affect the rights
of our shareholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the Dutch Corporate Governance Code, or the DCGC. The DCGC contains both principles and best practice
provisions for board of directors, shareholders and general meetings of shareholders, financial reporting, auditors, disclosure, compliance and enforcement standards. The DCGC applies to all Dutch companies listed on a government-recognized stock
exchange, whether in the Netherlands or elsewhere, including Nasdaq. The principles and best practice provisions apply to our board (in relation to role and composition, conflicts of interest and independence requirements, board committees and
remuneration), shareholders and the general meeting of shareholders (for example, regarding anti-takeover protection and our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations to provide information to our shareholders) and financial reporting (such as external auditor and internal audit requirements). We do not comply with all the best practice provisions
of the DCGC. As a result, the rights of our shareholders may be affected and our shareholders may not have the same level of protection as a shareholder in another Dutch public company with limited liability (<I>naamloze vennootschap</I>) listed in
the Netherlands that fully complies with the DCGC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Claims of U.S. civil liabilities may not be enforceable against us. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the Netherlands. Most of our assets are located outside the United States. The United States and the Netherlands
currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. With respect to choice of court agreements in civil or commercial matters, we note
that the Hague Convention on Choice of Court Agreements entered into force for the Netherlands, but has not entered into force for the United States. Consequently, a final judgment for payment given by a court in the United&nbsp;States, whether or
not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the Netherlands. In order to obtain a judgment which is enforceable in the Netherlands, the party in whose favor a final and conclusive judgment
of the U.S. court has been rendered will be required to file its claim with a court of competent jurisdiction in the Netherlands. Such party may submit to the Dutch court the final judgment rendered by the U.S. court. If and to the extent that the
Dutch court finds that the jurisdiction of the U.S. court has been based on grounds which are internationally acceptable and that proper legal procedures have been observed, the court of the Netherlands will, in principle, give binding effect to the
judgment of the U.S. court, unless such judgment contravenes principles of public policy of the Netherlands or is irreconcilable with a judgement of a Dutch court or foreign court that is acknowledged in the Netherlands. Dutch courts may deny the
recognition and enforcement of punitive damages or other awards. Moreover, a Dutch court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or
damages. Enforcement and recognition of judgments of U.S. courts in the Netherlands are solely governed by the provisions of the Dutch Code of Civil Procedure (<I>Wetboek van Burgerlijke Rechtsvordering</I>). As a result of the above, it may not be
possible for investors to effect service of process within the United States upon us or members of our board or certain experts named herein who are residents of the Netherlands or countries other than the United States or to enforce any judgments
against the same obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a
foreign private issuer and, as a result, we will not be subject to U.S. proxy rules and will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer status.
Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i)&nbsp;the sections of the Exchange Act regulating
the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii)&nbsp;the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities
and liability for insiders who profit from trades made in a short period of time; and (iii)&nbsp;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified
information, or current reports on Form&nbsp;8-K, upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until 120 days after the end of each fiscal year,
while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form&nbsp;10-K within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair Disclosure, aimed
at preventing issuers from making selective disclosures of material information. As a result of the above, our shareholders may not have the same protections afforded to shareholders of companies that are not foreign private issuers. However, we are
subject to Dutch laws and regulations with regard to such matters and voluntarily furnish quarterly unaudited financial information to the SEC on Form 6-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer and as permitted by the listing requirements of Nasdaq, we rely on certain
home country governance practices rather than the corporate governance requirements of Nasdaq. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as a foreign private issuer. As a
result, in accordance with the listing requirements of Nasdaq, we rely on home country governance requirements and certain exemptions thereunder rather than relying on the corporate governance requirements of Nasdaq. In accordance with Dutch law and
generally accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c),
which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting stock. Although we must provide shareholders with an agenda and other relevant
documents for the general meeting of shareholders, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands, thus our practice will
vary from the requirement of Nasdaq Listing Rule&nbsp;5620(b). In addition, we have opted out of certain Dutch shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition of stock or
assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the requirements of Nasdaq Rule 5635,
which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. Accordingly, our shareholders may not have the same protections afforded to shareholders of companies that are subject
to these Nasdaq requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may lose our foreign private issuer status which would then require us to comply with the Exchange Act&#146;s
domestic reporting regime and cause us to incur significant legal, accounting and other expenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer and therefore we
are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. If we no longer qualify as a foreign private issuer as of end of the second quarter of a
fiscal year, we would be required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers as of the start of the following fiscal year. In order to maintain our current
status as a foreign private issuer, (a)&nbsp;a majority of our common shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i)&nbsp;a majority of our executive officers or directors may not be
United States citizens or residents, (ii)&nbsp;more than 50&nbsp;percent of our assets cannot be located in the United States and (iii)&nbsp;our business must be administered principally outside the United States. If we lost this status, we would be
required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our
corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer
may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly
time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance,
and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and we cannot be certain if the reduced reporting requirements applicable to &#147;emerging growth
companies&#148; will make our common shares less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the JOBS
Act. For as long as we continue to be an &#147;emerging growth company,&#148; we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies,&#148;
including not being required to comply with the auditor attestation requirements of Section&nbsp;404, exemptions from the requirements of holding a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an &#147;emerging growth company,&#148; we are not
required to report selected financial data for periods prior to the earliest audited financial statements presented in the registration statement for the initial public offering of our common shares. As a result, we only have to present selected
financial data for periods starting with the year ended December&nbsp;31, 2014. Public companies that are not emerging growth companies must present selected financial data for a five-year period. We may take advantage of these exemptions until we
are no longer an &#147;emerging growth company.&#148; We could be an &#147;emerging growth company&#148; for up to five years, although circumstances could cause us to lose that status earlier, including if the aggregate market value of our common
shares held by non-affiliates exceeds $700&nbsp;million as of the end of our second fiscal quarter, in which case we would no longer be an &#147;emerging growth company&#148; as of the fiscal year-end. We cannot predict if investors will find our
common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and the price of our common shares may be
more volatile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts publish inaccurate or unfavorable research about our business, the price of our common shares and
our trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common shares depends in part on the research and reports that securities or industry
analysts publish about us or our business. If one or more of the analysts who cover us downgrade our common shares or publish inaccurate or unfavorable research about our business, the price of our common shares would likely decline. If one or more
of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common shares could decrease, which might cause the price of our common shares and trading volume to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be classified as a passive foreign investment company for U.S. federal income tax purposes, which could result in adverse U.S. federal income tax
consequences to U.S. investors in the common shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the current and anticipated value of our assets, including goodwill, and the
composition of our income, assets and operations, we do not believe we were a &#147;passive foreign investment company,&#148; or PFIC, for our taxable year ended December&nbsp;31, 2017; however, we may be a PFIC for the current taxable year. A
non-U.S. company will be considered a PFIC for any taxable year if (i)&nbsp;at least 75% of its gross income is passive income, or (ii)&nbsp;at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a
taxable year) is attributable to assets that produce or are held for the production of passive income. The value of our assets generally is determined by reference to the market price of our common shares, which may fluctuate considerably. In
addition, the composition of our income and assets is affected by how, and how quickly, we spend the cash we raise. If we were to be treated as a PFIC for any taxable year during which a U.S. Holder (as defined in the section of this prospectus
entitled &#147;Material Tax Considerations&#148;) holds a common share, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder. See &#147;Certain Material Tax Considerations for U.S. Holders&#151;Passive Foreign
Investment Company Rules.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If a United States person is treated as owning at least 10% of our common shares, such holder may be subject to
adverse U.S. federal income tax consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a U.S. Holder is treated as owning (directly, indirectly or constructively) at least 10% of the
value or voting power of our common shares, such U.S. Holder may be treated as a &#147;United States shareholder&#148; with respect to each &#147;controlled foreign corporation&#148; in our group (if any). If our group includes one or more U.S.
subsidiaries, certain of our non-U.S. subsidiaries could be treated as controlled foreign corporations (regardless of whether we are treated as a controlled foreign corporation). A United States shareholder of a controlled foreign corporation may be
required to report annually and include in its U.S. taxable income its pro rata share of &#147;Subpart F income,&#148; &#147;global intangible low-taxed income&#148; and investments in U.S. property by controlled foreign corporations, regardless of
whether we make any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax deductions or foreign </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject you to significant monetary penalties
and may prevent the statute of limitations from starting with respect to your U.S. federal income tax return for the year for which reporting was due. We cannot provide any assurances that we will assist investors in determining whether any of our
non-U.S. subsidiaries is treated as a controlled foreign corporation or whether such investor is treated as a United States shareholder with respect to any of such controlled foreign corporations. Further, we cannot provide any assurances that we
will furnish to any United States shareholders information that may be necessary to comply with the aforementioned reporting and tax payment obligations. U.S. Holders should consult their tax advisors regarding the potential application of these
rules to their investment in our common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive tax reform legislation could adversely affect our business and financial condition.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. government has recently enacted comprehensive tax legislation that includes significant changes to the taxation of business entities,
referenced herein as the Tax Reform Act. These changes include, among others, a permanent reduction to the corporate income tax rate, limiting interest deductions and the use of net operating losses, adopting elements of a territorial tax system and
introducing certain anti-base erosion provisions. We continue to examine the impact this tax reform legislation may have on our business. The effect of the Tax Reform Act on our business, whether adverse or favorable, is uncertain, and may not
become evident for some period of time. U.S. Holders should consult their legal and tax advisors regarding any such legislation and the potential tax consequences of investing in our common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_6"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We obtained the industry, market and competitive position data in this prospectus from our own internal estimates and research as well as from industry and
general publications and research, surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believed to be reliable, although they do not guarantee the
accuracy or completeness of such information. While we are not aware of any misstatements regarding the market or industry data presented herein, our estimates involve risks and uncertainties and are subject to change based on various factors,
including those discussed under the heading &#147;Risk Factors,&#148; &#147;Cautionary Statement Regarding Forward-Looking Information&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
in this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_7"></A>TRADEMARKS, SERVICE MARKS AND TRADENAMES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have proprietary rights to trademarks used in this prospectus including Merus, Biclonics and MeMo, which are important to our business, many of which are
registered under applicable intellectual property laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Solely for convenience, the trademarks, service marks, logos and trade names referred to in this
prospectus are without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and &#153; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights
or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks,
service marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies&#146; trademarks, service marks, copyrights or trade names to imply a
relationship with, or endorsement or sponsorship of us by, any other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_10"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will not receive any of the proceeds from the sale of our common shares in this offering. The selling shareholders will receive all of the proceeds from
this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling shareholders will pay any underwriting discounts, selling commissions and share transfer taxes or any other expenses incurred
by the selling shareholders in connection with the sale of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration
and filing fees, fees and expenses of our counsel and our independent registered public accountants.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_11"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never paid or declared any cash dividends on our common shares, and we do not anticipate paying any cash dividends on our common shares in the
foreseeable future. We intend to retain all available funds and any future earnings to fund the development and expansion of our business. Under Dutch law, as a Dutch public company with limited liability (<I>naamloze vennootschap</I>), we may only
pay dividends to the extent that our shareholders&#146; equity (<I>eigen vermogen</I>) exceeds the sum of our paid-up and called-up share capital plus the reserves required to be maintained by Dutch law or our articles of association. Subject to
such restrictions, any future determination to pay dividends will be at the discretion of our general meeting upon the proposal of our board of directors. Any future approval will depend upon our board of directors&#146; review of a number of
factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_12"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below sets forth our cash and cash equivalents and capitalization as of June&nbsp;30, 2018 derived from our unaudited interim financial statements
included elsewhere in this prospectus: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors should read this table in conjunction with our audited financial statements incorporated by reference in
this prospectus, as well as &#147;Use of Proceeds,&#148; &#147;Selected Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(euro in&nbsp;thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of</B><br><B>June&nbsp;30,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">170,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings (including current portion)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued capital:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">92,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,631,822&nbsp;common shares issuable upon the exercise of share options outstanding as of June&nbsp;30, 2018 at
a weighted average exercise price of &#128;14.24&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">118,301 common shares issuable upon the vesting of restricted share units outstanding as of June&nbsp;30, 2018;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">638,490 common shares reserved for future issuance under our 2016 Incentive Award Plan as of June&nbsp;30, 2018.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_14"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read the following selected financial data together with our financial statements and the related notes thereto included elsewhere and incorporated
by reference in this prospectus and the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of this prospectus. We have derived the statement of profit or loss and comprehensive loss data
for the years ended December&nbsp;31, 2015, 2016 and 2017 and the statement of financial position data as of December&nbsp;31, 2016 and 2017 from our audited financial statements incorporated by reference in this prospectus. We have derived the
statement of profit or loss and comprehensive loss data for the six months ended June&nbsp;30, 2017 and 2018 and the statement of financial position data as of June&nbsp;30, 2018 from our unaudited financial statements included elsewhere in this
prospectus. Our historical results are not necessarily indicative of the results that should be expected in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain our books and records
in euros, and we prepare our financial statements under International Financial Reporting Standards as issued by the International Accounting Standards Board. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B><br><B>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B><br><B>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B><br><B>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014<BR>Restated***</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B><br><B>Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>(euros in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Profit or Loss and Comprehensive Loss Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">16,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,821</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(550</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,785</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,391</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net finance income / (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Result before taxation</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Result after taxation</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences from the translation of foreign operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other comprehensive income for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic (and diluted) loss per&nbsp;share*</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.96</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(5.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding, basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,196,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,236,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,871,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,829,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,809,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,976,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the periods included in these financial statements, share options were excluded from the diluted loss per
share calculation as we were in a loss position in each period presented above. As a result, basic and diluted loss per share is equal. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Revenue for the years ended December&nbsp;31, 2017, 2016 and 2015 and for the six months ended June&nbsp;30,
2017 have been restated due to the impact of the retrospective effects of the adoption of IFRS&nbsp;15, an accounting standard related to revenue recognition. Revenue for the year ended December&nbsp;31, 2017 has been restated to reflect additional
revenue of &#128;8.3&nbsp;million, or &#128;0.43&nbsp;per share, primarily related to the amortization of the up-front license payment received from Incyte. Revenue for the year ended December&nbsp;31, 2016 has been restated to reflect a reduction
in revenue of &#128;0.2&nbsp;million, or &#128;0.01&nbsp;per share, related to lower amortization of the up-front license payment received from ONO. Revenue for the year ended December&nbsp;31, 2015 has been restated to reflect a reduction in
revenue of &#128;0.1&nbsp;million, or &#128;0.01&nbsp;per share, related to lower amortization of the up-front license payment received from ONO. Revenue for the six months ended June&nbsp;30, 2017 has been restated to reflect additional revenue of
&#128;3.8&nbsp;million, or &#128;0.20&nbsp;per share, related to the amortization of the up-front license payment received from Incyte. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Revenue for the year ended December 31, 2014 has been restated for the impact of the retrospective effects of
the adoption of IFRS 15, which resulted in additional revenue of &#128;0.7 million, or &#128;0.23 per share, related to higher amortization of the up-front license payment received from ONO. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Financial Position Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">149,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">56,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">170,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">215,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(106,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(138,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total liabilities, accumulated loss and total equity have been restated for the impact of the retrospective
effects of the adoption of IFRS&nbsp;15, an accounting standard related to revenue recognition. The result of the restatement was a decrease to total liabilities and accumulated loss and an increase to total equity of &#128;8.7&nbsp;million,
&#128;0.4&nbsp;million, and &#128;4.2&nbsp;million as of December&nbsp;31, 2017,&nbsp;December&nbsp;31, 2016 and June&nbsp;30, 2017, respectively. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_15"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the information under
&#147;Selected Financial Data,&#148; our unaudited interim financial statements, including the notes thereto, included in this prospectus and our audited financial statements, including the notes thereto, incorporated by reference in this
prospectus. The following discussion is based on our financial information prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, which might differ in material respects
from generally accepted accounting principles in other jurisdictions. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in
these forward-looking statements as a result of many factors, including but not limited to those described under &#147;Risk Factors&#148; and elsewhere in this prospectus</I>.<I> </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage immuno-oncology company
developing innovative bispecific antibody therapeutics. Our pipeline of full-length human bispecific antibody candidates, which we refer to as Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, are generated from our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, which is able to generate a diverse array of antibody-heavy chains against virtually any target, paired with a common light chain. Two heavy chains paired with a common light
chain can be combined to produce novel bispecific antibodies that bind a diverse array of targets and display differentiated biology. By binding to two different targets, Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can
provide a variety of mechanisms of action. For example, Merus Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be designed to simultaneously block receptors that drive tumor cell growth and survival and to mobilize the
patient&#146;s immune response by engaging T-cells and/or activating various killer cells to eradicate tumors. In our pre-clinical studies, our bispecific antibody candidates were effective in killing tumor cells, a result that we believe supports
their potential efficacy in the treatment of cancer. In February 2015, we commenced a Phase 1/2 clinical trial of our most advanced bispecific antibody candidate, MCLA-128, for the treatment of HER2-expressing solid tumors. In January 2018, we dosed
the first patient in a Phase 2, open-label, multi-center international clinical trial to evaluate MCLA-128 in two metastatic breast cancer, or MBC, populations including HER2-positive MBC patients and hormone receptor positive/HER2-low MBC patients.
MCLA-128 is a full-length IgG bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity, or ADCC, targeting HER2 and HER3 receptors. MCLA-128 blocks the HER3 signaling pathway by employing a DOCK&nbsp;&amp; BLOCK<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mechanism of action. MCLA-128 is designed to dock onto a specific region of the HER2 receptor to orientate MCLA-128&#146;s HER3 binding arm to block HER2:HER3 heterodimerization. Oncogenic
signaling through the HER3 pathway, even in the presence of high heregulin concentrations, may thus be effectively blocked. The Phase 2 clinical trial is designed to observe the activity of this HER2/HER3-targeted candidate in combination with
current standards of care in areas of unmet need. We plan to provide an update on the Phase 2 clinical trial in the second half of 2019. Concurrently, our Phase 1/2 clinical trial evaluating single agent activity for MCLA-128 in gastric cancer and
non-small cell lung cancer, or NSCLC, is ongoing. We reported data from the gastric cancer patient cohort in the single-agent trial of MCLA-128 at the European Society for Medical Oncology Congress in October 2018. The data showed a clinical benefit
rate of 24% (6 of 25 patients), with MCLA-128 being well tolerated with mainly grade 1/2 adverse events in patients treated with MCLA-128 across all indications explored to date and showing a low risk of immunogenicity. Promising single agent
antitumor activity was seen in heavily pretreated gastric cancer/gastro-oesophageal junction cancer patients progressing on anti-HER2 therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May
2016, we commenced a Phase 1, single-arm, open-label, global clinical trial of our second bispecific antibody candidate, MCLA-117, for the treatment of acute myeloid leukemia, or AML, and we announced the filing of the IND in the United States for
MCLA-117 in 2018 and the subsequent authorization to proceed with clinical studies by the FDA. AML generally has a poor prognosis and limited progress has been made in disease outcomes despite a growing AML patient population. Clinical and
pre-clinical studies suggest that treatment-resistant leukemic stem cells are a potential cause of disease relapse. MCLA-117 binds to CD3, a cell-surface molecule present on all T-cells, and to CLEC12A, a cell surface molecule present on
approximately 90 to 95% of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
AML tumor cells and stem cells in newly diagnosed and relapsed patients. MCLA-117 is designed to recruit and activate T-cells to kill AML tumor cells and stem cells. In our pre-clinical studies,
MCLA-117 killed tumor cells in blood samples of AML patients. We plan to seek orphan drug designation for MCLA-117 for the treatment of AML from the FDA and the EMA. We are continuing our dose escalation of the Phase 1 clinical trial for MCLA-117.
We plan to provide an update on our MCLA-117 program upon announcement of the maximum tolerated dose for MCLA-117 and anticipate data readouts for the Phase 1 clinical trial in the second half of 2019. We also intend to evaluate MCLA-117 for the
treatment of myelodysplastic syndrome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to MCLA-128 and MCLA-117, we are also developing MCLA-158, a bispecific antibody candidate that is
designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5, or Lgr5, and epidermal growth factor receptors, or EGFR, for the potential treatment of solid tumors with an initial focus on metastatic
colorectal cancer, and the first Clinical Trials Application to the EMA was approved to initiate a Phase 1 clinical trial in Europe in January 2018. We also filed an IND for MCLA-158 with the FDA in the first quarter of 2018, which received
authorization to proceed from the FDA in April 2018. In May 2018, we commenced a Phase 1, open-label, multicenter clinical trial of MCLA-158 and expect emerging data by the end of 2019. MCLA-158 is designed to kill cancer stem cells using two
different mechanisms of action. The first mechanism of action involves blocking growth and survival pathways in tumor stem cells. The second mechanism of action involves the recruitment and enhancement of immune effector cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we also have a pipeline of proprietary antibody candidates in preclinical development, including the bispecific antibody candidate MCLA-145,
which is being developed in collaboration with Incyte Corporation and is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. We expect to provide further information on this program upon acceptance of an IND for MCLA-145.
We also have several other antibody candidates in pre-clinical development that bind to other target combinations. Each of our antibody candidates in our preclinical and clinical pipeline are designed to bind to targets believed to be useful in the
treatment of cancer with an intention to establish efficacy and obtain information for submission to the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception in June 2003, our
initial operations were focused on organizing and staffing our company, business planning, raising capital, and establishing our proprietary Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform technology, bispecific antibody
candidates, and our intellectual property portfolio. In more recent periods, we have devoted a significant portion of our financial resources and efforts to continued development of our
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, identifying potential bispecific antibody candidates and conducting pre-clinical studies and initiating and conducting our clinical trials of MCLA-128, MCLA-117
and MCLA-158. We do not currently have any approved products and have never generated any revenue from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have financed our operations
primarily through (i)&nbsp;the initial public offering of our common shares, (ii)&nbsp;a public placement of equity securities with Incyte Corporation, or Incyte, (iii)&nbsp;an upfront milestone payment received from Incyte under a collaboration and
license agreement, or the Collaboration Agreement and (iv)&nbsp;a private placement of common shares on February&nbsp;15, 2018. Commencing on May&nbsp;9, 2016, we raised net proceeds of &#128;51.1&nbsp;million from the IPO of our common shares,
received net proceeds of &#128;74.4&nbsp;million from placements of equity securities with Incyte and received aggregate net proceeds of &#128;112.0&nbsp;million from a license payment from Incyte in February of 2017. In February 2018, we issued and
sold an aggregate of 3,099,997 of our common shares to certain new and existing investors for aggregate gross proceeds of approximately $55.8&nbsp;million, at a purchase price of $18.00 per share. In December 2018, we issued and sold an aggregate of
600,000 shares to Regeneron Pharmaceuticals, Inc., or Regeneron, in connection with our settlement of certain litigation with Regeneron for aggregate gross proceeds of $15.0 million. See &#147;Business&#151;Legal Proceedings.&#148; As of
June&nbsp;30, 2018, we held cash and cash equivalents of &#128;170.3 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2016, we entered into a collaboration and license agreement, or
the Collaboration Agreement, with Incyte Corporation, or Incyte. Under the terms of the Collaboration Agreement, we and Incyte agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing our
proprietary bispecific technology platform. The collaboration encompasses up to 11 independent programs, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including two of our current preclinical immuno-oncology discovery programs. In January 2017, upon the Collaboration Agreement becoming effective, Incyte made an upfront non-refundable payment to
us of $120&nbsp;million. For more on the Collaboration Agreement, see &#147;Collaboration Agreements&#148; below. In connection with the Collaboration Agreement, we entered into a Share Subscription Agreement, pursuant to which, in January 2017, we
issued and sold to Incyte 3,200,000 common shares for an aggregate purchase price of $80.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2016, the general meeting of our
shareholders resolved to approve and effect a capital reorganization, based on a reverse share split. The effect of the reverse share split was a 1-for-1.8 reverse share split of the outstanding common and preferred shares held by our shareholders.
This reverse share split became effective on May&nbsp;6, 2016. All share, per-share and related information presented in the financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the
impact of the reverse share split. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, we completed the initial public offering of our common shares, or the IPO, and issued 6,139,926 common
shares, including 639,926 common shares issued upon the partial exercise of the underwriters of their option to purchase additional shares, for net proceeds to us, after deducting underwriting discounts and commissions and offering expenses, of
$53.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage company and have not generated any revenue from product sales. We expect to incur significant expenses and
operating losses for the foreseeable future as we advance our bispecific antibody candidates from discovery through pre-clinical development and into clinical trials, and seek regulatory approval and pursue commercialization of any approved
bispecific antibody candidate. In addition, if we obtain regulatory approval for any of our bispecific antibody candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and
distribution. We expect to incur expenses in connection with the in-license or acquisition of additional bispecific antibody candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate
that we will require additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity
or debt financings or other sources, which may include collaborations and business development opportunities with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital
as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we expect that our existing cash, cash equivalents and investments as of June&nbsp;30, 2018 and the proceeds received
from the $15.0&nbsp;million investment by Regeneron Pharmaceuticals in December 2018 will be sufficient to fund our operations into the second quarter of 2021. For this assessment we have taken into consideration our existing cash and cash
equivalents of &#128;170.3&nbsp;million, which include the $55.8&nbsp;million, or &#128;44.8&nbsp;million, in proceeds received from our private placement offering that closed in February 2018, and investments of &#128;53.7&nbsp;million as of
June&nbsp;30, 2018 as well as $15.0&nbsp;million, or &#128;13.1&nbsp;million, in proceeds from Regeneron Pharmaceuticals. See &#147;&#151;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our business
strategy, we intend to continue to seek strategic collaborations to facilitate the capital-efficient development of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform and to identify potential target
combinations in immuno-oncology and other therapeutic areas. We believe that these collaborations could potentially provide significant funding to advance our bispecific antibody candidate pipeline while allowing us to benefit from the development
expertise of our collaborators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incyte Corporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a collaboration and license agreement, or the Collaboration Agreement, with Incyte Corporation, or Incyte. Under the terms of the
Collaboration Agreement, we and Incyte have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing our proprietary bispecific technology platform. The collaboration encompasses up to 11
independent programs, including some of our current preclinical immuno-oncology discovery programs. For one of the current preclinical programs concerning <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> we retain the exclusive right to develop and
commercialize products and product candidates in the United States, while Incyte has the exclusive right to develop and commercialize products and product candidates arising from such program outside the United States. For MCLA-145, we and Incyte
will conduct and share equally the costs of mutually agreed global development activities and will be solely responsible for independent development activities in our respective territories. We have the option to co-fund development of products
arising from one specified program, and subject to certain conditions, to a second specified program, in each case exchange for a share of profits in the United States, as well as the right to participate in a specified proportion of detailing
activities in the United States for one of such programs. In addition, if MCLA-145 fails to complete IND-enabling toxicology studies successfully, we will be granted an additional option to co-fund development of a specified program other than
MCLA-145 in exchange for a share of profits in the United States. If we exercise our co-funding option for a program, we would be responsible for funding 35% of the associated future global development costs and, for certain of such programs, would
be responsible for reimbursing Incyte for certain development costs incurred prior to the option exercise. All products as to which we have exercised our option to co-fund development would be subject to joint development plans and overseen by a
joint development committee, with Incyte having final determination as to such plans in cases of dispute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For each program other than MCLA-145, where we
have not elected to co-fund development or where we do not have such a co-funding option, Incyte is solely responsible for all costs of global development and commercialization activities. We retain the rights to our technology platform as well as
clinical and pre-clinical candidates and future programs emerging from our platform that are outside the scope of the Collaboration Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January
2017, upon the Collaboration Agreement becoming effective, Incyte made an upfront non-refundable payment to us of $120&nbsp;million or &#128;112.0&nbsp;million for the rights granted under the Collaboration Agreement. For each program as to which we
do not have commercialization or co-development rights, we are eligible to receive up to $100&nbsp;million in future contingent development and regulatory milestones and up to $250&nbsp;million in commercialization milestones, as well as tiered
royalties ranging from 6% to 10% of global net sales. For each program as to which we have exercised our option to co-fund development, we are eligible to receive a 50% share of profits (or sustain 50% of any losses) in the United States and tiered
royalties ranging from 6% to 10% of net sales of products outside of the United States. If we opt to cease co-funding a program as to which we exercised our co-development option, then we will no longer receive a share of profits in the United
States but will be eligible to receive the same milestones from the co-funding termination date and the same tiered royalties described above with respect to non-co-developed programs and, depending on the stage at which we choose to cease
co-funding development costs, additional royalties ranging up to 4% of net sales in the United States. For MCLA-145, for which we retain all commercial rights in the United States, we and Incyte are each eligible to receive tiered royalties on net
sales in the other&#146;s territory at rates ranging from 6% to 10%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Collaboration Agreement will continue on a program-by-program basis until
neither party has any royalty payment obligations with respect to such program or, if earlier, the termination of the Collaboration Agreement or any program in accordance with the terms of the Collaboration Agreement. The Collaboration Agreement may
be terminated in its entirety, or on a program-by-program basis, by Incyte for convenience. The Collaboration Agreement may also be terminated by either party under certain other circumstances, including material breach, or on a program-by-program
basis for patent challenge of patents under the applicable program, in each case as set forth in the Collaboration Agreement. If the Collaboration Agreement is terminated in its entirety or with respect to one or more programs, all rights in the
terminated programs revert to us, subject to payment to Incyte </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of a reverse royalty of up to 4% on sales of future products, if we elect to pursue development and commercialization of products arising from the terminated programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Collaboration Agreement, we entered into a Share Subscription Agreement with Incyte, pursuant to which, in January 2017, we issued and
sold to Incyte 3,200,000 common shares for an aggregate purchase price of $80.0&nbsp;million or &#128;74.7 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ONO Pharmaceutical </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, we entered into a strategic research and license agreement with ONO Pharmaceutical Co., Ltd., or ONO, under which we granted ONO an exclusive,
worldwide, royalty-bearing license to research, test, make, use and market bispecific antibody candidates based on our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform with undisclosed targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ONO paid us a non-refundable upfront fee of &#128;1.0&nbsp;million. We are eligible to receive up to an aggregate of &#128;34.0&nbsp;million in milestone
payments upon achievement of specified research and clinical development milestones. To date, we have achieved three of the specified pre-clinical milestones under this research and license agreement and have received an aggregate of
&#128;2.8&nbsp;million in milestone payments. For products commercialized under this agreement, if any, we are also eligible to receive a mid-single digit royalty on net sales. For a designated period, which may include limited time periods
following termination of this agreement, in certain circumstances we and our affiliates are prohibited from researching, developing or commercializing bispecific antibodies against the undisclosed target combinations that are the subject of this
agreement. This research and license agreement will expire after all milestone payments have been received and all related patent rights have expired, unless terminated earlier. ONO also provides funding for our research and development activities
under an agreed-upon plan. ONO has the right to terminate this agreement at any time for any reason, with or without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for
uncured material breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2018, we entered into a second contract research and license agreement with ONO. Pursuant to an exclusive
option granted to ONO in a prior agreement executed in April 2014, ONO exercised its option to enter into the March 2018 agreement. We granted ONO an exclusive, worldwide, royalty-bearing license, with the right to sublicense, research, test, make,
use and market bispecific antibody candidates based on our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform against two undisclosed targets directed to a particular undisclosed target combination. ONO
identifies and selects the licensed bispecific antibodies for which it is responsible for conducting further non-clinical and clinical development activities for such licensed bispecific antibodies and pharmaceutical products containing such
antibodies, including manufacture and process development. ONO controls and has exclusive rights over the worldwide commercialization of any approved products, including worldwide supply, and is solely responsible for all costs and expenses related
to commercialization. ONO has agreed to fund our research and development activities and be responsible for the payment of all costs and expenses for its own research and development activities, which are set out in a mutually agreed upon research
plan. We retain all rights to use and commercialize any antibodies that are generated under the collaborative research program, excluding the up to five lead and/or selected antibodies against the targets ONO is pursuing, provided that the use and
commercialization is not with respect to the particular target combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ONO has agreed to pay an upfront non-refundable payment of &#128;700,000 for
the rights granted and we are also eligible to receive an aggregate of &#128;33.7&nbsp;million in milestone payments upon achievement of specified research and clinical development milestones. For products commercialized under the License Agreement,
if any, the Company is eligible to receive a mid-single digit royalty on net sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a designated period, which may include limited time periods
following termination of this agreement, in certain circumstances we are prohibited from researching, developing or commercializing bispecific antibodies against the undisclosed target combination that are the subject of this agreement. ONO also
provides funding for our research and development activities under an agreed-upon plan. This research and license agreement will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expire after all milestone payments have been received and all related patent rights have expired, unless terminated earlier. ONO has the right to terminate this agreement at any time for any
reason, with or without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for uncured material breach. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Simcere Pharmaceutical Group </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On, January&nbsp;8,
2018, we entered into an agreement with Simcere Pharmaceutical Group granting Simcere an exclusive license to develop and commercialize in China three bispecific antibodies utilizing our proprietary Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform in the area of immuno-oncology. We will retain all rights outside of China. Under the terms of the agreement, we have agreed to lead research and discovery activities while
Simcere has agreed to be responsible for the IND-enabling studies, clinical development, regulatory filings and commercialization of these product candidates in China. As a key strategic component of the collaboration, Simcere will be responsible
for IND enabling studies and manufacturing of clinical trial materials in China, which we intend to use to assist regulatory filing and early stage clinical development in the rest of the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We received an upfront, non-refundable payment of $2.75 million, or &#128;2.3&nbsp;million, relating to three separate research programs. We will be eligible
to receive milestone payments contingent upon Simcere achieving certain specified development and commercial goals. We will be eligible to receive tiered royalty payments on sales of any products resulting from the collaboration in China from
Simcere. Simcere will be eligible to receive tiered royalty payments on sales outside of China from us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, our revenue has consisted
principally of the amortization of up-front payments, milestones and cost reimbursements in support of our license and collaboration agreements and revenue from several government grants, primarily with respect to research and development activities
related to the use of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology in various indication areas. We have no products approved for sale. We do not expect to receive any revenue from any bispecific antibody
candidates that we develop, including MCLA-128, MCLA-117 and MCLA-158 and our pre-clinical bispecific antibody candidates, including MCLA-145, until we obtain regulatory approval and commercialize such products, or until we potentially enter into
collaborative agreements with third parties for the development and commercialization of such candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We enter into collaboration agreements which
are within the scope of IFRS 15, under which we license rights to certain of our product candidates and perform research and development services. The terms of these arrangements typically include payment of one or more of the following:
non-refundable, upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is recognized when our customer obtains control of the goods or services, in an amount that reflects the consideration that we determine to expect to
receive in exchange for those goods or services. To determine revenue recognition for arrangements that are within the scope of IFRS 15, We perform the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the
performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies the
performance obligation. We apply the five-step model to contracts only when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services we transfer to the customer. As part of the accounting
for these arrangements, we must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to
each performance obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently generate a portion of our revenue through collaboration and license agreements with strategic
collaborators for the development and commercialization of product candidates. The collaboration and license agreements are within the scope of IFRS 15. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adoption of IFRS 15 impacts the amortization of our up-front license payments. We previously recognized revenue from up-front license payments on a
straight-line basis over the contractual term or the period of continuing involvement which was previously estimated to be 21 years for the collaboration and license agreement we entered into with Incyte on December&nbsp;20, 2016, and 4.5&nbsp;years
for the research and license agreement the Company entered into with ONO on April&nbsp;8, 2014. In applying IFRS&nbsp;15, we evaluated the distinct performance obligations in each agreement. Specifically, for Incyte, the total period for which we
expect to provide access to our proprietary technology is currently estimated to be nine years, which is the research term initially agreed to in the Incyte collaboration and license agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We adopted the new standard effective January&nbsp;1, 2018, using the retrospective method, with the effect of initially applying this standard recognized at
the beginning of the earliest period presented. We had two open contracts on the adoption date and have assessed these contracts under the new revenue standard. In addition, we elected to apply the practical expedient to not apply this guidance to
contracts that were completed before the beginning of the earliest period presented, or January&nbsp;1, 2015, and the practical expedients for contract modifications (assessing the contracts in combination with any modifications before
January&nbsp;1, 2017). Under the practical expedient, we excluded certain option and exclusivity agreements that expired in 2015 and 2014, respectively. As a result of the adoption of IFRS&nbsp;15, our prior year financial statements have been
restated. We have accounted for the impact of adopting IFRS&nbsp;15 as a cumulative catch-up as a decrease of approximately &#128;8.7&nbsp;million to deferred revenue with an offset to accumulated deficit, effective January&nbsp;1, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Up-front License Payments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the license to our
intellectual property is determined to be distinct from the other performance obligations identified in the agreement, we recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer
and the customer is able to use and benefit from the license. If not distinct, the license is combined with other performance obligations in the contract. For licenses that are combined with other performance obligations, we assess the nature of the
combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purpose of recognizing revenue. We evaluate the
measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our research
and license agreements with our collaborators, we have received upfront license payments relating to the integrated packages of deliverables under the contracts. Each contract contains either one single performance obligation or multiple performance
obligations that the up-front consideration was allocated to. These upfront license payments are initially recorded in deferred revenue on the consolidated statements of financial position and are recognized as revenue on either: (i)&nbsp;a
straight-line basis over the period of the related performance obligation or the contractual term of the arrangement; or (ii)&nbsp;based on another appropriate depiction of the Company&#146;s performance over the period of the related performance
obligation or the contractual term, such as costs incurred relating to full-time equivalent research employees. The applicable period over which to recognize the upfront payment is a significant judgment, which is re-assessed at each reporting date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record revenue from our collaboration and license agreements with Incyte, ONO and Simcere. Under each agreement, we have received upfront license
payments, which are initially recorded in deferred revenue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration income, which is typically related to reimbursements from collaborators for our performance of research and development services under the
respective agreements, is recognized on the basis of labor hours </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
valued at a contractually agreed rate. Collaboration income includes reimbursements for related out-of-pocket expenses. Cost reimbursements to which we are entitled under agreements are
recognized as revenue in the same period as the cost for which they are intended to compensate. We act as the principal and therefore record these reimbursements as collaboration income. Under our agreements, Incyte and ONO reimburse us for these
external expenses and compensate us for time spent on the project by our employees. We recognize these reimbursements and compensation as collaboration income. In addition, we record collaboration income in the same quarter of the recorded cost they
are intended to compensate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under the agreements, we
perform the five steps listed above. As part of the accounting for the arrangement, we must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. We use key
assumptions to determine the stand-alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success. Finally, we capitalize the incremental costs of
obtaining a contract with a customer if we expect to recover those costs. Such incremental costs would not have been incurred if the contract with a customer had not been obtained. To date, we have not capitalized any incremental costs for obtaining
a contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our contracts often include development and regulatory milestone payments which are assessed under the most likely amount method and
constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within our control or the licensee&#146;s control, such as regulatory approvals, are not considered probable of being achieved until those
approvals are received. At each reporting date, we <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the probability of achievement of development milestones and any related constraint, and if necessary, adjusts the overall transaction price. Any
such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Government Grants
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government grants are recognized when there is reasonable assurance that the conditions underlying the grant have been met and that the grant will be
received. Government grants to cover research and development expenses incurred are recognized as revenue on a gross basis in the consolidated statement of profit or loss and comprehensive loss on a systematic basis over the periods in which we
recognize expenses for the related costs for which the grants are intended to compensate. In the case of grants related to assets, the received grant will be deducted from the carrying amount of the asset. For these grants, we have reporting
obligations at the end of the grant contract term. The unconditional receipt of the grant allowances is dependent on the final review of the reporting provided by us at the end of the contract term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development costs consist principally of the costs associated with our research and development activities, conducting preclinical studies and clinical trials and activities related to our regulatory filings. Our research and development expenses
consist of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">salaries for research and development staff and related expenses, including share-based compensation expenses;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with contract research organizations, or CROs, contract manufacturing
organizations, and consultants that conduct and support clinical trials and preclinical studies </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to develop product candidates, including raw materials and supplies, product testing, and facility related
expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with obtaining and maintaining patents and other intellectual property; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amortization and depreciation of tangible and intangible fixed assets used to develop our product candidates.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expense research and development costs when we incur them. We record costs for certain development activities, such as clinical
trials, based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information our vendors provide to us. We expense the manufacturing costs of our internally-developed
product candidates that are used in clinical trials as they are incurred, as research and development expense. We do not allocate employee-related costs, depreciation, rental and other indirect costs to specific research and development programs
because these costs are deployed across multiple programs under research and development and, as such, are separately classified as unallocated research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses are expected to increase as we advance the clinical development of <FONT STYLE="white-space:nowrap">MCLA-128,</FONT>
MCLA-117 and MCLA-158 and further advance the research and development of our pre-clinical bispecific antibody candidates and other earlier stage products. IND-enabling studies for MCLA-145, our most advanced drug candidate in our collaboration and
license agreement with Incyte Corporation, are ongoing. The successful development of our bispecific antibody candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will
be necessary to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our bispecific antibody candidates. This is due to numerous risks and uncertainties associated with developing drugs,
including the uncertainty of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, rate of progress and expense of our research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials and early-stage results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and timing of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to market, commercialize and achieve market acceptance for MCLA-128, MCLA-117, MCLA-158 and MCLA-145
or any other bispecific antibody candidate that we may develop in the future. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these variables with
respect to the development of any of our antibody candidates would significantly change the costs, timing and viability associated with the development of that antibody candidate. For example, if the FDA, the EMA or other regulatory authority were
to require us to conduct pre-clinical and clinical studies beyond those which we currently anticipate will be required for the completion of clinical development or if we experience significant delays in enrollment in any clinical trials, we could
be required to expend significant additional financial resources and time on the completion of our clinical development programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development activities are central to our business model. We expect research and development costs to increase significantly for the foreseeable future as our development programs progress, as we continue to support the clinical trials of our
bispecific antibody candidates as treatments for various cancers and as we move these candidates into additional clinical trials. There are numerous factors associated with the successful commercialization of any of our bispecific antibody
candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control
may impact our clinical development programs and plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management and Administration Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management and administration costs consist principally of salaries and related expenses for employees other than research and development staff, including
share-based compensation expenses. We expect that our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
management and administration costs will increase in the future as our business expands and we increase our headcount to support the expected growth in our operating activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expenses consist principally
of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">professional fees for auditing and tax services and consulting expenses not related to research and development
activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">professional fees for legal services, including litigation costs, not related to the protection and maintenance
of our intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of facilities, communication and office expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">board of director fees and corresponding share-based compensation expenses; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information technology services; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amortization and depreciation of tangible and intangible fixed assets not related to research and development
activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our other expenses will increase in the future as we expand our operating activities and we continue to incur
additional costs associated with operating as a public company. We expect other expenses to increase in future periods to support our research and development efforts, including the continuation of the clinical trials of our bispecific antibody
candidates as treatments for various cancers and the initiation of clinical trials for potential new antibody candidates. These cost increases will likely be due to increased headcount, increased share-based compensation expenses, expanded
infrastructure and increased costs for insurance. Public company-related expense increases will include costs of additional legal fees, accounting and audit fees, consulting fees, director and officer liability insurance premiums and costs related
to investor relations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Finance Income and Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finance income consists of interest earned on our cash and cash equivalents held on account, accretion of investment earnings and net foreign exchange gains on
our U.S. dollar denominated cash, cash equivalents and investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finance expenses consist of net foreign exchange losses on our U.S. dollar
denominated cash, cash equivalents and investments, interest and related expenses for the settlement of our forward contract for the Share Subscription Agreement with Incyte and interest accrued on our formerly outstanding indebtedness and financing
costs associated with our registration statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Six Months Ended June&nbsp;30, 2018 and 2017 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The below table summarizes our results of operations for the six months ended June&nbsp;30, 2018 and 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June 30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B><br><B>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">16,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,821</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,394</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-29</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,863</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(711</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net finance income / (expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-122</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-67</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-67</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total
revenue increased by &#128;6.3&nbsp;million to &#128;16.5&nbsp;million for the six months ended June&nbsp;30, 2018, from &#128;10.1&nbsp;million for the six months ended June&nbsp;30, 2017. The increase in total revenue was primarily attributable to
progress made with our license and collaboration agreements with Incyte, ONO and Simcere. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adoption of IFRS 15 impacts the amortization of our
up-front license payments. We previously recognized revenue from up-front license payments on a straight-line basis over the contractual term or the period of continuing involvement. In applying IFRS 15, we evaluated the distinct performance
obligations for our Incyte Agreements, or the total period for which we expect to provide access to our proprietary technology which is currently estimated to be nine years, and resulted in the recognition of additional revenue of
&#128;3.8&nbsp;million for up-front payment amortization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our components of revenue for the six months ended June&nbsp;30,
2018 and June&nbsp;30, 2017, respectively: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months ended</B><br><B>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Up-front payment amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9,087</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">6,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from contracts with customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from grants on research projects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(650</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-78</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">16,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">10,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Up-front payment amortization was &#128;9.1&nbsp;million and &#128;6.9&nbsp;million for the six months ended June&nbsp;30,
2018 and 2017, respectively. During the six months ended June&nbsp;30, 2018, up-front payment amortization included amounts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
related to our Incyte, ONO and Simcere Agreements. The increase in up-front payment amortization revenue related to &#128;1.0&nbsp;million for our Incyte Agreement, which did not begin until the
end of the first quarter of 2017 and &#128;1.1 and &#128;0.1&nbsp;million related to our 2018 ONO Agreement and Simcere Agreement, respectively, both of which began during the first quarter of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration income for the six months ended June&nbsp;30, 2018 was &#128;7.2&nbsp;million and consisted of cost reimbursements and research milestones
achieved in support of our research and license agreements with Incyte, ONO and Simcere. During the six months ended June&nbsp;30, 2018, we recognized &#128;4.3&nbsp;million and &#128;0.2&nbsp;million of cost reimbursements in support of our
research and license agreements with Incyte and ONO, respectively. We recognized an aggregate of &#128;2.5&nbsp;million and &#128;0.1&nbsp;million in research milestones under our ONO and Simcere agreements, respectively, for the six months ended
June&nbsp;30, 2018. During the six months ended June&nbsp;30, 2017, &#128;2.4&nbsp;million of cost reimbursements in support of our research and license agreements with Incyte and ONO, respectively. We did not recognize any research milestones
during 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2018, we recognized &#128;0.2&nbsp;million in grant income compared to &#128;0.8&nbsp;million in grant income for the six months
ended June&nbsp;30, 2017. On June&nbsp;12, 2017, the European Commission approved for reimbursement the final installment of the FP-7 grant for &#128;0.7 million. Revenue for this final installment was recorded in income from grants on research
projects during the six months ended June&nbsp;30, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months ended</B><br><B>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">22,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">15,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs increased &#128;7.4&nbsp;million, or 48%, to &#128;22.8&nbsp;million for the six months ended
June&nbsp;30, 2018, from &#128;15.4&nbsp;million for the six months ended June&nbsp;30, 2017. The increase was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;7.6&nbsp;million and &#128;2.2 increases in spending for our MCLA-128 and MCLA-145 programs in support of
our ongoing clinical trial, pre-clinical and discovery programs incurring higher costs associated with development, manufacturing and production design activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;3.7&nbsp;million decrease in expenses in connection with our pre-clinical and discovery programs in support
of ongoing development activities for MCLA-158 (&#128;3.0 million) and clinical activities for MCLA-117 (&#128;0.7 million); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increase of &#128;0.5&nbsp;million for conducting research and development, preclinical, manufacturing and
production design in connection with various pre-clinical and discovery programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;1.4&nbsp;million increase in employee salary and related benefits attributable to the hiring of more
development personnel during the six months ended June&nbsp;30, 2018, a decrease of &#128;0.1&nbsp;million of subsidies under the WBSO Act, offset, in part, by a &#128;0.5&nbsp;million decrease in share compensation expenses; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;0.1&nbsp;million decrease related to lower spending on intellectual property and license costs for legal
and professional services. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development expenses may vary substantially from period to period based on the timing of
our research and development activities, including due to timing of initiation of clinical trials and enrollment of patients in clinical trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management and Administration Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management and administrative costs consist of salaries and related expenses for employees in finance, legal, human resources and business development
functions. These costs include all salary, salary related expenses and share-based compensation expenses. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months ended</B><br><B>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-28.6</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management and administration costs decreased &#128;2.2&nbsp;million, or 28.6%, during the six months ended June&nbsp;30, 2018
as compared to the six months ended June&nbsp;30, 2017. The decrease was primarily attributable to lower share-based compensation expenses of &#128;3.0&nbsp;million offset, in part, by the expansion of our headcount in finance, legal and business
development functions to support the expansion of our operations and included increases in salary and related expenses of &#128;0.8&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expenses </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months ended</B><br><B>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expenses increased &#128;1.9&nbsp;million, or 45%, during the six months ended June&nbsp;30, 2018 as compared to the six
months ended June&nbsp;30, 2017. The increase was due to higher consulting, accounting and professional fees of &#128;1.1&nbsp;million in support of maintaining public company status, higher facilities expenses in support of higher headcount of
&#128;0.5&nbsp;million and board oversight costs of &#128;0.3 million.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months ended</B><br><B>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and similar income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net gain on foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">711</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss on foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-100</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Finance Income and Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finance income increased &#128;4.3&nbsp;million, or 711%, during the six months ended June&nbsp;30, 2018 as compared to the six months ended June&nbsp;30,
2017. This increase was due to gains on our U.S. dollar denominated cash, cash equivalents and investments of approximately of &#128;4.1&nbsp;million due to a strengthening U.S. dollar during 2018. As of June&nbsp;30, 2018, we held approximately
$92.6 million and $40.9 million in U.S. dollar denominated cash and cash equivalent accounts and investment accounts, respectively, subject to the fluctuation in foreign currency </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
between the euro and U.S. dollar. Interest income primarily results from interest earned on cash held on account and accretion of investment earnings. Our current year increase in cash
equivalents and investments was due primarily from the funds received as part of the private placement during the first quarter of 2018. We experienced increased losses on our U.S. dollar denominated cash, cash equivalents and investments of
approximately &#128;12.0&nbsp;million during the six months ended June&nbsp;30, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2016, we signed the Incyte Agreements whereas
these contracts were denominated in U.S. dollars. We determined that the subscription agreement to sell our own shares to which we became committed on December&nbsp;20, 2016, should be accounted for as a forward contract or a derivative financial
instrument which was recognized in the statement of financial position as of December&nbsp;31, 2016. Interest expense for the six months ended June&nbsp;30, 2017 includes an amount of &#128;10.7&nbsp;million related to the effective settlement of
the forward contract on January&nbsp;23, 2017, the date the shares were issued and the date through which the related expense was incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income
Tax Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income tax expenses were &#128;0.1&nbsp;million and &#128;0.1&nbsp;million for the six months ended June&nbsp;30, 2018 and 2017,
respectively. Income tax expense is attributable to our U.S. operating subsidiary which provides general management services and strategic advisory services to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Years Ended December&nbsp;31, 2017 and 2016 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The below table summarizes our results of operations for the years ended December&nbsp;31, 2017 and 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">19,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">773.1</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,701</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85.2</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,697</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221.7</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,395</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.9</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.6</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1164</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net finance income / (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(249</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,013</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss for the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total
revenue increased by &#128;19.4&nbsp;million, or 773%, to &#128;21.9&nbsp;million for the year ended December&nbsp;31, 2017, from &#128;2.5&nbsp;million for the year ended December&nbsp;31, 2016. The increase was primarily attributable to our
license and collaboration agreement with Incyte, or the Incyte Agreement, which became effective during the first quarter of 2017 and for which we recognized revenue throughout 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adoption of IFRS 15 impacted the amortization of our up-front license payments. We previously recognized revenue from up-front license payments on a
straight-line basis over the contractual term or the period of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continuing involvement. In applying IFRS 15, we evaluated the distinct performance obligations for our Incyte and ONO Agreements, or the total period for which we expect to provide access to our
proprietary technology. This evaluation resulted in a restatement to increase our revenue by &#128;8.3&nbsp;million primarily relating to up-front payments for our Incyte Agreements for the year ended December&nbsp;31, 2017 and a restatement to
decrease our revenue by &#128;0.2&nbsp;million relating to up-front payments for our ONO Agreement for the year ended December&nbsp;31, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table summarizes our components of revenue: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Up-front payment amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,550</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">422</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from grants on research projects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(192</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">21,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">773</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2017, up-front payment amortization increased &#128;14.9&nbsp;million and related
entirely to the amortization of up-front payment received under our Incyte Agreements. For the year ended December&nbsp;31, 2016, we recognized less than &#128;0.1&nbsp;million of amortization of the up-front payment related to our April 2014 ONO
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration income for the year ended December&nbsp;31, 2017 was &#128;5.8&nbsp;million and consisted of cost reimbursements in support of
our research and license agreements with Incyte and ONO. We did not recognize any research milestones during 2017. During 2016, we recognized one research milestone reached by our agreement with ONO which amounted to &#128;0.7 million. Additionally,
we received an amount of &#128;0.4&nbsp;million revenue from a new consultancy agreement that was signed with ONO on March&nbsp;7, 2016. During 2017, we had two active grants consisting of cash allowances for specific research and development
projects. For the years ended December&nbsp;31, 2017 and 2016, we recognized &#128;1.2&nbsp;million and &#128;1.4&nbsp;million in grant income, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">34,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">18,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">15,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs increased &#128;15.7&nbsp;million, or 85%, to &#128;34.1&nbsp;million for the year ended
December&nbsp;31, 2017, from &#128;18.4&nbsp;million for the year ended December&nbsp;31, 2016. The increase was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;9.1&nbsp;million increase in expenses in connection with our pre-clinical and discovery programs in support
of ongoing development activities for MCLA-158 (&#128;3.5 million) and MCLA-145 (&#128;3.2 million) and other expenses for conducting research and development, preclinical, manufacturing and production design in connection with various pre-clinical
and discovery programs (&#128;2.4);; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;2.0&nbsp;million increase in spending for our MCLA-128 and &#128;0.4&nbsp;million increase in spending for
MCLA-117 programs in support of our ongoing clinical trials expenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;2.6&nbsp;million increase in employee salary and related benefits and &#128;2.5&nbsp;million increase in
share compensation expenses, offset, in part, by the receipt of an additional &#128;1.8&nbsp;million in subsidies under </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the WBSO Act, all of which were attributable to the hiring of more development personnel during the year ended December&nbsp;31, 2017; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;0.7&nbsp;million increase related to higher spending on intellectual property and license costs for legal
and professional services. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development expenses may vary substantially from period to period based on the timing of
our research and development activities, including due to timing of initiation of clinical trials and enrollment of patients in clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management and Administration Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management
and administrative costs consist of salaries and related expenses for employees in finance, legal, human resources and business development functions. These costs include all salary, salary related expenses and share-based compensation expenses.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management and administration costs increased &#128;9.4&nbsp;million, or 222%, during the year ended December&nbsp;31, 2017 as
compared to the year ended December&nbsp;31, 2016. The increase was primarily attributable to an increase in employee headcount and compensation-related expenses of &#128;2.5&nbsp;million for non-research and development personnel and higher
share-based compensation expenses of &#128;6.9&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expenses increased &#128;1.7&nbsp;million, or 22%, during the year ended December&nbsp;31, 2017 as compared to the year
ended December&nbsp;31, 2016. The increase was due to higher consulting, accounting and professional fees of &#128;1.7&nbsp;million in support of maintaining public company status, higher facilities expenses in support of higher headcount of
&#128;0.4&nbsp;million which were offset in part, by lower litigation costs of &#128;0.4 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Finance Income (Expenses) </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and similar income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1164</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4655</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,235</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total finance income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,556</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finance expense increased &#128;9.7&nbsp;million during the year ended December&nbsp;31, 2017 as compared to
the year ended December&nbsp;31, 2016. This increase was due to an increase in foreign exchange expense of &#128;19.0&nbsp;million, offset, in part, by an &#128;8.5&nbsp;million decrease in interest expense and higher interest income of &#128;1.0
million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income primarily results from interest earned on cash held on account and accretion of investment earnings. Our current year increase
in cash, cash equivalents and investments was due primarily from the $200&nbsp;million of funds received as part of the Incyte Agreements during the first quarter of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We experienced increased losses on our U.S. dollar denominated cash, cash equivalents and investments of approximately &#128;19.1&nbsp;million during 2017. As
of December&nbsp;31, 2017, we held approximately $98.0 million and $49.4 million in U.S. dollar denominated cash and cash equivalent accounts and investment accounts, respectively, subject to the fluctuation in foreign currency between the euro and
U.S. dollar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2016, we signed the Incyte Agreements whereas these contracts were denominated in U.S.&nbsp;dollars. We determined that
the subscription agreement to sell our own shares to which we became committed on December&nbsp;20, 2016, should be accounted for as a forward contract or a derivative financial instrument which was recognized in the statement of financial position
as of December&nbsp;31, 2016. The interest expense and similar expenses for the year ended December&nbsp;31, 2017 include an amount of &#128;10.7&nbsp;million related to the effective settlement of the forward contract on January&nbsp;23, 2017, the
date the shares were issued and the date through which the related expense was incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2017, we expensed &#128;0.2&nbsp;million of prepaid share
issuance costs related to a potential future issuance of shares under our F-3 Registration Statement when the future issuance was no longer consider probable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Tax Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income tax expenses were
&#128;0.2&nbsp;million and zero for the years ended December&nbsp;31, 2017 and 2016, respectively. Current-year income tax expense was attributable to our U.S. operating subsidiary, which was established in February 2016 to provide general
management services and strategic advisory services to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of Years Ended December&nbsp;31, 2016 and 2015 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The below table summarizes our results of operations for the years ended December&nbsp;31, 2016 and 2015. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.8</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,243</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.9</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,258</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454.4</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4.4</TD>
<TD NOWRAP VALIGN="bottom">%)</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.6</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,974</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net finance income / (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,387</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,256</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,181</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total
revenue increased by &#128;0.6&nbsp;million, or 32%, to &#128;2.5&nbsp;million for the year ended December&nbsp;31, 2016, from &#128;1.9&nbsp;million for the year ended December&nbsp;31, 2015. The increase was primarily attributable to the
&#128;0.7&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increase in grant revenue, mainly related to additional research activities performed under the FP7 grant, a research grant provided by the European Union. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adoption of IFRS 15 also impacted the amortization of our up-front license payments. We previously recognized revenue from up-front license payments on a
straight-line basis over the contractual term or the period of continuing involvement. In applying IFRS 15, we evaluated the distinct performance obligations for our ONO Agreements, or the total period for which we expect to provide access to our
proprietary technology. This evaluation resulted in a restatement to decrease our revenue by &#128;0.2&nbsp;million and less than &#128;0.1&nbsp;million relating to up-front payment from our ONO Agreement for the years ended December&nbsp;31, 2016
and 2015, respectively, as a result of the change in the estimated period of performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our components of revenue: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Up-front payment amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">%)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from grants on research projects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2016 and 2015, up-front payment amortization related entirely to our ONO agreement,
which was fully amortized in the first quarter of 2016. Collaboration income for the year ended December&nbsp;31, 2016 was &#128;1.1&nbsp;million and consisted of one research milestone recognized with ONO which amounted to &#128;0.7&nbsp;million
and cost reimbursements in support of our research and license agreement with ONO. We recognized one research milestone during 2015 which amounted to &#128;1.0 million. During 2016 and 2015, we had three and two active grants, respectively,
consisting of cash allowances for specific research and development projects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">18,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">16,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs increased &#128;2.2&nbsp;million, or 14%, to &#128;18.4&nbsp;million for the year ended
December&nbsp;31, 2016, from &#128;16.2&nbsp;million for the year ended December&nbsp;31, 2015. The increase was primarily due to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;3.5&nbsp;million increase in expenses in connection with the expansion of various pre-clinical and
discovery programs during 2016; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;2.1&nbsp;million increase in expenses related to our MCLA-128 program, due to higher contract manufacturing
costs and costs associated with pre-clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;1.3&nbsp;million increase in employee salary and related benefits and &#128;0.3&nbsp;million increase in
share compensation expenses, offset, in part, by the receipt of an additional &#128;1.4&nbsp;million in subsidies under </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the WBSO Act, all of which were attributable to the hiring of more development personnel during the year ended December&nbsp;31, 2016; offset, in part by </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;3.8&nbsp;million decrease in expenses related to our MCLA-117 program. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management and Administration Costs </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">454</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management and administration costs increased &#128;3.5&nbsp;million, or 454%, during the year ended December&nbsp;31, 2016 as
compared to the year ended December&nbsp;31, 2015. The increase was primarily attributable to an increase in employee headcount and compensation-related expenses of &#128;1.5&nbsp;million for non-research and development personnel and higher
share-based compensation expenses of &#128;2.0 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Expenses </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">-4</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other expenses decreased &#128;0.4&nbsp;million, or 4%, during the year ended December&nbsp;31, 2016 as compared to the year
ended December&nbsp;31, 2015. The decrease was primarily attributable to a decrease of &#128;2.9&nbsp;million in lower litigation costs, offset by increases of &#128;1.9&nbsp;million for consulting, accounting and legal fees in support of our IPO
and maintaining public company status and &#128;0.6&nbsp;million in Board fees and related share-based compensation expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Finance Income
(Expenses) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#128;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and similar income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(195</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,040</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,764</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total finance income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,411</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,387</TD>
<TD NOWRAP VALIGN="bottom">%</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finance expense increased &#128;19.4&nbsp;million during the year ended December&nbsp;31, 2016 as compared to the year ended
December&nbsp;31, 2015. This increase was due to increases in interest expense of &#128;19.0&nbsp;million and foreign exchange losses of &#128;0.4 million. We experienced losses on our U.S. dollar denominated cash and cash equivalents of
approximately &#128;0.4&nbsp;million during 2016 on our U.S. dollar denominated cash and cash equivalent accounts subject to the fluctuation in foreign currency between the euro and U.S. dollar. The increase in cash during 2016 was primarily a
result of the receipt of net proceeds of approximately $53.3 million from our IPO during 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in interest expense of &#128;19.0&nbsp;million is primarily related to the accounting impact on
the financial derivative recognized under the Incyte Agreement. The subscription agreement to sell our own shares in which we became committed on December&nbsp;20, 2016, was accounted for as a forward contract or a derivative financial instrument.
The change in fair value of the derivative financial instrument of approximately &#128;19.2&nbsp;million was recognized as interest expense for the year ended December&nbsp;31, 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Funds
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception in 2003, we have devoted substantially all of our resources to developing our platform technology, bispecific antibody
candidates, building our intellectual property portfolio, developing our supply chain, business planning, raising capital and providing for general and administrative support for these operations. We do not currently have any approved products and
have never generated any revenue from product sales. We have principally financed our operations through (i)&nbsp;the initial public offering of our common shares, (ii)&nbsp;a public placement of equity securities with Incyte Corporation, or Incyte,
(iii)&nbsp;an upfront milestone payment received from Incyte under a collaboration and license agreement, or the Collaboration Agreement and (iv)&nbsp;a private placement of common shares on February&nbsp;15, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2016, we closed an initial public offering of 5,500,000 of our common shares and, on May&nbsp;26, 2016, of an additional 639,926 of our common
shares, at a price to the public of $10 per share. We received net proceeds, after deducting underwriting discounts and commissions and offering expenses, of $53.3&nbsp;million. On May&nbsp;19, 2016, our common shares were listed on the Nasdaq and
all of our preferred shares converted into common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2016, we entered into a collaboration and license agreement, or the Collaboration
Agreement, and a share subscription agreement, or the Share Subscription Agreement, with Incyte Corporation, or Incyte. In January 2017, we received an upfront payment of $120.0&nbsp;million (&#128;110.2&nbsp;million)&nbsp;from Incyte pursuant to
the Collaboration Agreement and $80.0&nbsp;million (&#128;74.7&nbsp;million)&nbsp;upon the issuance and sale by us of 3.2&nbsp;million common shares to Incyte pursuant to the Share Subscription Agreement, for total cash proceeds to us of
$200.0&nbsp;million (&#128;184.9&nbsp;million). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2018, we entered into a Purchase Agreement with the purchasers named therein (the
&#147;Investors&#148;). Pursuant to the Purchase Agreement, we agreed to sell an aggregate of 3,099,997 of our common shares, nominal value &#128;0.09&nbsp;per share, to the Investors for aggregate gross proceeds of approximately $55.8&nbsp;million,
at a purchase price equal to $18.00 per share. The closing of the private placement occurred on February&nbsp;15, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2018, we
issued and sold an aggregate of 600,000&nbsp;shares to Regeneron in connection with our settlement of certain litigation with Regeneron for aggregate gross proceeds of $15.0&nbsp;million. See &#147;Business &#151; Legal Proceedings.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, we had cash and cash equivalents of &#128;170.3&nbsp;million and investments of &#128;53.7 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no ongoing material financing commitments, such as lines of credit or guarantees that are expected to affect our liquidity over the next five years,
other than leases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table
below summarizes our cash flows for each of the periods presented. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(408</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash from in financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2017, we used &#128;37.4&nbsp;million of cash in operating activities, as compared to the use of
&#128;25.7&nbsp;million in cash during 2016, an increase in the use of cash of &#128;11.7&nbsp;million. This increase in net cash used in operating activities was the result of the increase in net loss adjusted for non-cash items of
&#128;10.4&nbsp;million and changes in working capital of &#128;1.2&nbsp;million. Our non-operating and non-cash charges during the year ended December&nbsp;31, 2017 primarily consisted of unrealized foreign exchange results of
&#128;15.8&nbsp;million, share option expenses of &#128;12.8&nbsp;million and the change in fair value of the derivative financial instrument of &#128;10.7&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2016, we used &#128;25.7&nbsp;million of cash in operating activities, as compared to the use of &#128;23.0&nbsp;million in cash during 2015, an
increase in the use of cash of &#128;2.7&nbsp;million. This increase in net cash used in operating activities was the result of the increase in net loss adjusted for non-cash items of &#128;1.9&nbsp;million and changes in working capital of
&#128;1.0&nbsp;million. Our non-cash charges during the year ended December&nbsp;31, 2016 primarily consisted of the change in change in the fair value of the derivative financial instrument of &#128;19.2&nbsp;million and share option expenses of
&#128;3.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for 2017 and 2016 was &#128;41.6&nbsp;million and &#128;0.4&nbsp;million, respectively. The
increase in net cash used in investing activities during 2017 related primarily to &#128;41.8&nbsp;million for purchases of investments, offset, in part, by higher interest received of &#128;0.8&nbsp;million. The increase in net cash used in
investing activities to &#128;0.4&nbsp;million for the year ended December&nbsp;31, 2016 from &#128;0.05&nbsp;million for the year ended December&nbsp;31, 2015 was primarily due to an increase in investments in laboratory and office equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities in 2017 was &#128;186.2&nbsp;million which was primarily due to receipt of &#128;186.7&nbsp;million from the Incyte
Agreements, offset, in part, by the full repayment of the loan from Rabobank of &#128;0.5&nbsp;million. Net cash provided by financing activities in 2016 was &#128;50.2&nbsp;million which was primarily related to proceeds from our IPO in May of
2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities in 2015 was &#128;54.4&nbsp;million and related to aggregate private placements resulting in gross cash
proceeds of &#128;46.5&nbsp;million and the receipt of an &#128;8.0&nbsp;million convertible bridge loan granted by several shareholders in June 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating and Capital Expenditure Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have not achieved profitability since our inception and, as of June&nbsp;30, 2018, we had an accumulated loss of &#128;167.2&nbsp;million. We expect to continue to incur significant operating losses for the foreseeable future as we continue our
research and development efforts and seek to obtain regulatory approval and commercialization of our bispecific antibody candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our
expenses to increase substantially in connection with our ongoing development activities related to MCLA-128, MCLA-117, MCLA-158 and our pre-clinical programs. In addition, we expect to continue to incur additional costs associated with operating as
a public company. We anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct the clinical trials for MCLA-128, our most advanced bispecific antibody candidate in Phase 2 for
metastatic breast cancer populations and Phase 1/2 in other solid tumors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct the Phase 1 clinical trial of MCLA-117, our second most advanced bispecific antibody candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conduct the Phase 1 clinical trial of MCLA-158, our third most advanced bispecific antibody candidate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue the research and development of our other bispecific antibody candidates in preclinical development,
including MCLA-145; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to enhance our technology platform, which generates our pipeline of Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and discover and develop additional antibody candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals for any bispecific antibody candidates that successfully completes clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potentially establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities
to commercialize any products for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, expand and protect our intellectual property portfolio, including litigation costs associated with
defending against alleged patent infringement claims or enforcing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add clinical, scientific, operational, financial and management information systems and personnel, including
personnel to support our product development and potential future commercialization efforts and to support our operation as a public company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter any issues any of the above, including but not limited to failed studies,
complex results, safety issues or other regulatory challenges. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we expect that our existing cash,
cash equivalents and investments as of June&nbsp;30, 2018 and the proceeds received from the $15.0&nbsp;million investment by Regeneron Pharmaceuticals in December 2018 will be sufficient to fund our operations into the second quarter of 2021. For
this assessment we have taken into consideration our existing cash and cash equivalents of &#128;170.3&nbsp;million, which include the $55.8&nbsp;million, or &#128;44.8&nbsp;million, in proceeds received from our private placement offering that
closed in February 2018, and investments of &#128;53.7&nbsp;million as of June&nbsp;30, 2018 as well as $15.0&nbsp;million, or &#128;13.1&nbsp;million, in proceeds from Regeneron Pharmaceuticals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, our working capital is sufficient for our present requirements. However, we have based this estimate on assumptions that may prove to be
wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development of <FONT STYLE="white-space:nowrap">MCLA-128,</FONT> MCLA-117, MCLA-158 and our
pre-clinical programs and because the extent to which we may enter into collaborations with third parties for development of these bispecific antibody candidates is unknown, we are unable to estimate the amounts of increased capital outlays and
operating expenses associated with completing the research and development of our bispecific antibody candidates. Our future capital requirements for MCLA-128, MCLA-117, MCLA-158 or our pre-clinical programs, including MCLA-145, will depend on many
factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress, timing and completion of pre-clinical testing and clinical trials for our current or any future
bispecific antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of potential new bispecific antibody candidates we identify and decide to develop;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in growing our organization to the size needed to allow for the research, development and
potential commercialization of our current or any future bispecific antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in filing patent applications and maintaining and enforcing patents or defending against
claims or infringements raised by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the time and costs involved in obtaining regulatory approval for our bispecific antibody candidates and any
delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of these bispecific antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any licensing or milestone fees we might have to pay during future development of our current or any future
bispecific antibody candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selling and marketing activities undertaken in connection with the anticipated commercialization of our current
or any future bispecific antibody candidates and costs involved in the creation of an effective sales and marketing organization; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future
sales of our bispecific antibody candidates, if approved. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Identifying potential bispecific antibody candidates and conducting pre-clinical testing and clinical trials
is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our bispecific antibody
candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain
substantial additional funds to achieve our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adequate additional funds may not be available to us on acceptable terms, or at all. To
the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your
rights as a shareholder. Additional debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute your ownership interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise
additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or bispecific antibody candidates or
grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development programs or any future
commercialization efforts or grant rights to develop and market bispecific antibody candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below
summarizes our contractual obligations at June&nbsp;30, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1-3&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3-5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts in the table reflect payments due for our office and laboratory facility in Utrecht, Netherlands.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have identified control deficiencies associated with a lack of adequate cut-off procedures to ensure the proper and timely recognition, measurement and
classification of operating expenses and certain period-end accruals. Specifically, we did not design and maintain effective internal control over the assessment of the accounting for significant contractual arrangements related to our clinical
research and manufacturing agreements and the classification of operating expenses. There is a reasonable possibility that these deficiencies could result in a material misstatement of our financial statements or in related disclosures in our annual
or interim consolidated financial statements that we would not be able to prevent or detect on a timely basis. Accordingly, we have determined that these control deficiencies constitute a material weakness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2016, we identified two material weaknesses related to insufficient accounting resources required to fulfill IFRS and SEC
reporting requirements and insufficient comprehensive IFRS accounting policies and financial reporting procedures. Due to the material weakness described above, we determined that these material weaknesses were not remediated as of December&nbsp;31,
2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have implemented and continue to implement various measures to address these internal control deficiencies. These measures are outlined below.
With the oversight of management and our Audit Committee, we have taken </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and plan to take steps intended to address the underlying causes of the material weaknesses identified, primarily through the redesign of specific processes and controls associated with review of
contractual agreements, including a quarterly identification and review of significant agreements with the management team to ensure that the relevant accounting implications are identified and considered. Additionally, we are in the process of
redesigning our controls over operating expenses, including the related balance sheet accounts. We are also continuing the hiring of additional financial resources, enhancing our IFRS accounting policies and procedures and developing review controls
related to our financial close and reporting processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we plan to complete this remediation process as quickly as possible, we cannot, at this
time, estimate when such remediation may occur, and our initiatives may not prove successful in remediating the material weakness. We may determine to enhance other existing controls and/or implement additional controls as the remediation process
progresses. It will take time to determine whether the additional controls we are implementing will be sufficient to accomplish their intended purpose. Accordingly, the material weaknesses may continue for a period of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee and management are closely monitoring the remediation process. Until the remediation efforts discussed in this section, including any
additional remediation efforts that our management identifies as necessary, are completed, tested and determined effective, we will not be able to conclude that the material weaknesses have been remediated. In addition, we may need to incur
incremental costs associated with this remediation, primarily due to the hiring and training of finance and accounting personnel and the implementation and validation of improved accounting and financial reporting procedures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unresolved Staff Comments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 11, 2018, we
received a comment letter from the staff of the Division of Corporation Finance of the SEC, or the Staff, relating to our Annual Report on Form 20-F for the fiscal year ended December 31, 2017 and our Report on Form 6-K filed on August 10, 2018,
which included our unaudited interim financial statements for the six months ended June 30, 2018. We responded to these comments and received a second comment letter on November&nbsp;1, 2018 to which we responded on December&nbsp;3, 2018. We
received a third comment letter on December&nbsp;20, 2018 and are in the process of responding to the Staff. The Staff requested information regarding our recognition and measurement of revenue under our license and collaboration agreement and the
related share subscription agreement with Incyte, or the Incyte Agreements. More specifically, the Staff requested information regarding our accounting for the $80.0&nbsp;million purchase by Incyte of our common shares under the share subscription
agreement and our valuation of such purchase, our analysis of the allocation of the transaction price, including the $120.0&nbsp;million upfront payment under the license and collaboration agreement, the timing of our accounting of the transaction,
and our consideration of payments we may receive in connection with our collaboration with Incyte in light of our adoption of IFRS&nbsp;15, which became effective for annual and interim reporting periods beginning on or after January&nbsp;1, 2018.
We believe that our interpretation of IFRS&nbsp;15 and our revenue recognition under the Incyte Agreements, as described in the notes to our financial statements that are included or incorporated into this prospectus and that are included in our
other filings with the SEC, is appropriate. As of the date of this prospectus, we are discussing the comments with the Staff, and we cannot predict when these comments will be resolved. If the Staff ultimately disagrees with our accounting related
to the Incyte Agreements, the impact to our previously issued financial statements for the year ended December&nbsp;31, 2017 and the subsequent interim periods could be material and we could be required to restate these financial statements. See
&#147;Risk Factors&#151;<I>In preparing our financial statements, our management is required to apply accounting policies that require significant interpretation. If such interpretations are incorrect or if regulatory or other authorities disagree
with such interpretations, we may be required to restate or revise previously issued financial statements, which could have an adverse impact on our financial position or the perception of our company in the market.&#148;</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the periods presented, we did not and do not currently have any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosure About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to market risk. Market risk is the risk that changes in market prices &#150; such as foreign exchange rates and interest rates &#150; will
affect the our income or the value of our holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return. Our market risk relates to
foreign exchange and to a lesser extent, interest rate risks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign currency risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign exchange risk arises from future commercial transactions and recognized assets and liabilities in foreign currencies. With respect to monetary assets
and liabilities denominated in foreign currencies, our primary currency exposure is impacted by monetary assets and liabilities denominated in U.S. Dollars. Changes in sensitivity rates reflect various changes in the economy year-over-year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a sensitivity analysis for a change in our primary currency exposure relating to monetary assets and liabilities denominated in
U.S. Dollars as of June&nbsp;30, 2018. The analysis shows the impact that a change in the exchange rate at that date would have on our total comprehensive loss: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Financial Statement Line Item Exposure</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effect&nbsp;on&nbsp;profit<BR>before&nbsp;tax&nbsp;if&nbsp;USD<BR>strengthens 5%<BR>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effect&nbsp;on&nbsp;profit<BR>before&nbsp;tax&nbsp;if&nbsp;USD<BR>weakens 5%</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,941</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,686</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables, other liabilities and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(579</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>115,645</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,782</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,782</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The closing exchange rates per the European Central Bank utilized above for converting U.S. dollars to Euros at June&nbsp;30,
2018 was &#128;0.8578&nbsp;per dollar. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exposure to interest rate risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interest rate profile of our interest-bearing financial instruments is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(euros&nbsp;in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fixed-rate instruments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Variable rate instruments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the limited impact of changes in interest rates on the Company no sensitivity data is provided. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operating and financial review is based on our financial statements, which we have prepared in accordance with IFRS as issued by the IASB. The preparation
of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the
reported revenues and expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions. There have been no material adjustments to prior period estimates for any of the periods included
in this prospectus, other than those amounts that have been restated as a result of the adoption of IFRS 15. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our significant accounting policies are more
fully described in the notes to our financial statements which are incorporated by reference in this prospectus. We believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our financial
condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is recognized when our customer obtains control of the goods or services we provide. Revenue is recognized in an amount that reflects the consideration
that we expect to receive in exchange for those goods or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain research and license agreements with Incyte, ONO and Simcere. In
connection with these arrangements, we received upfront license payments relating to the integrated package of deliverables under the contracts. Each contract contains either one single performance obligation or multiple performance obligations that
the up-front consideration was allocated to. These upfront license payments are initially recorded in deferred revenue on the consolidated statements of financial position and are recognized as revenue on either: (i)&nbsp;a straight-line basis over
the period of the related performance obligation or the contractual term of the arrangement; or (ii)&nbsp;based on another appropriate depiction of our performance over the period of the related performance obligation or the contractual term, such
as costs incurred relating to full-time equivalent research employees. The applicable period over which to recognize the upfront payment is a significant judgment, which is re-assessed at each reporting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration income, which is typically related to reimbursements from collaborators for our performance of research and development services under the
respective agreements, is recognized on the basis of labor hours valued at a contractually agreed rate. Collaboration income includes reimbursements for related out-of-pocket expenses. Cost reimbursements to which we are entitled under agreements
are recognized as revenues in the same quarter of the recorded cost they are intended to compensate. We act as the principal and therefore record these reimbursements as collaboration income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We receive certain government and regional grants, which support our research efforts in defined projects, and include contributions towards the cost of
research and development. When there is reasonable assurance that we will comply with the conditions attached to a received grant, and when there is reasonable assurance that the grant will be received, government grants are recognized as revenue on
a gross basis in the profit or loss account on a systematic basis over the periods in which the entity recognizes expenses for the related costs for which the grants are intended to compensate. In the case of grants related to assets, the received
grant will be deducted from the carrying amount of the asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incur research and development expenses related to our clinical and pre-clinical drug development programs. Development expenses are defined as expenses
incurred to achieve technical and commercial feasibility. Expenditure on research activities is recognized as an expense in the period in which it is incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Development is capitalized if, and only if, all of the following have been demonstrated: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the technical feasibility of completing the intangible asset so that it will be available for use or sale;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the intention to complete the intangible asset and use or sell it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to use or sell the intangible asset; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how the intangible asset will generate probable future economic benefits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of adequate technical, financial and other resources to complete the development and to use or
sell the intangible asset; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to measure reliably the expenditure. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above criteria for capitalization of development costs have not been met and therefore, all development expenditures relating to internally generated
intangible assets to date have been expensed when incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our financial statements, we are required to estimate our
accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf, estimating the level of service performed and the associated cost incurred for the service when we have not yet
been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each statement
of financial position date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant
estimates in our accrued research and development expenses are related to fees paid to CROs in connection with research and development activities for which we have not yet been invoiced. We base our expenses related to CROs on our estimates of the
services received and efforts expended pursuant to quotes and contracts with CROs that conduct research and development on our behalf. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial
terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a
prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of
services or the level of effort varies from our estimate, we adjust the accrual or prepayment expense accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not expect our
estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts
that are too high or too low in any particular period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain stock ownership programs that entitle key management personnel, staff and consultants providing similar services to purchase or receive our common
shares. Under these programs, holders of vested options are entitled to purchase our common shares at the exercise price determined at the date of grant while holders of vested restricted stock units (&#147;RSUs&#148;) are entitled to the right to
receive our common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The options granted under the share option programs vest in installments over a four-year period from the grant date.
Twenty-five percent of the options vest on the first anniversary of the vesting commencement date, and the remaining 75% of the options vest in 36 monthly installments for each full month of continuous service provided by the option holder
thereafter, such that 100% of the options shall become vested on the fourth anniversary of the vesting commencement date. The options granted are exercisable once vested. Options will lapse on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eighth anniversary of the date of grant for options granted under the Merus B.V. 2010 Employee Option Plan (the &#147;2010 Plan&#148;) and on the tenth anniversary of the date of grant for the
options granted under the 2016 Incentive Award Plan (the &#147;2016 Plan&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The option exercise price of each option is specified in the applicable
notice of grant and equals either the fair market value per common share as determined at the date of grant or another price determined by our board of directors when granting the options. Each option is exercisable at such times and subject to such
terms and conditions as specified in the applicable notice of grant. We may, in the event of a change of control of our company, decide to exchange, cancel and settle in cash and/or accelerate the vesting of the outstanding options or our board of
directors may consider other appropriate steps with respect to the outstanding options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The RSUs granted under the 2016 Plan vest in installments over a
four-year period from the grant date. Each RSU represents the right to receive one common share of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based compensation reflects the
compensation expense of our share option and RSU programs granted to employees or others providing similar services, which are measured at the grant date fair value of the options or RSU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation expense is spread over the vesting period in accordance with each separate vesting tranche of the award granted, taking into consideration
actual and expected forfeitures at each reporting date and at the respective vesting dates. The grant date fair value share-based compensation is recognized as an expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the IPO, we estimated the fair value of each share option grant using the Black-Scholes option-pricing model for members of our executive management
team, which includes our board of directors and other key personnel, or the Hull&nbsp;&amp; White option pricing model for other participants, including board members. Service and non-market performance conditions attached to the transactions were
not taken into account in measuring fair value. Following our IPO, we use the Hull&nbsp;&amp; White option pricing model for all participants. The share option expenses have been adjusted to reflect the use of the Hull&nbsp;&amp; White option
pricing model for all participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions we used to determine the fair value of share options granted are as follows, presented on a weighted
average basis: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="11" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended</B><br><B>June&nbsp;30, 2018</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Key<BR>Management</B><br><B>Personnel</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Personnel</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Key<BR>Management<BR>Personnel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Employees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Key<BR>Management<BR>Personnel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Employees</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Key<BR>Management<BR>Personnel</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Employees</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Expected volatility (weighted-<BR>average)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">95.05%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">94.88%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">95.30%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">97.15%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">94.85%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">94.85%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">95.1%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">94.6%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Expected life (weighted-<BR>average)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8-10&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10&nbsp;years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Risk-free interest rate (based on government bonds)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2.29%-2.51%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2.24%-2.62%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.84%-1.86%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.10%-1.87%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">0.16%-0.70%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0.16%&nbsp;0.70%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2.79%-2.94%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">2.84%-2.94%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These assumptions represented our best estimates, but the estimates involve inherent uncertainties and the application of our
judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The options outstanding at June&nbsp;30, 2018 and December&nbsp;31, 2017 had exercise prices in the range of &#128;1.93 to &#128;27.47&nbsp;per
share. On October&nbsp;5, 2015, we amended the exercise price of all options granted under the 2010 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Option Plan prior to January 2015 to be &#128;1.93&nbsp;per share to reflect the relative decrease in estimated fair value for each common share. As a result, we recognized an additional share
option expense that was immaterial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since we were a private company prior to the closing of the initial public offering of our common shares,
company-specific historical and implied volatility information is not available. Expected volatility was therefore estimated based on the observed daily share price returns of publicly traded peer companies over a historic period equal to the period
for which expected volatility was estimated. The group of comparable listed companies were publicly traded entities active in the business of developing antibody-based therapeutics, treatments and drugs and were selected taking into consideration
the availability of meaningful trading data history and market capitalization. We will continue to use this group for calculation of expected volatility data until sufficient historical market data is available for estimating the volatility of our
common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the options are not transferable, the participants will tend to exercise the options prior to the maturity date. Expected early
exercises have been incorporated in the option valuation by assuming that the participants will exercise the options if the share price increases to two times the exercise price at a future point in time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Valuation of Our Common Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the
initial public offering of our common shares, the fair value of our common shares was determined by our then management board and supervisory board, and took into account our most recently available valuation of common shares performed by an
independent valuation firm and our assessment of additional objective and subjective factors we believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our then management board and supervisory board considered numerous objective and subjective factors to determine their best estimate of the fair value of our
common shares as of each grant date, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our research and development programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">achievement of enterprise milestones, including entering into collaboration and licensing agreements, as well as
funding milestones; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contemporaneous third-party valuations of our common shares for our most recent share issuances;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our need for future financing to fund operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prices at which we sold our preferred shares and the rights and preferences of our preferred shares and our
preferred shares relative to our common shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a discrete liquidity event, such as a sale of our company or an initial public
offering given prevailing market conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market and economic conditions impacting our industry sector; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of an active public market for our common shares and our preferred shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the fair values of our common shares as of each grant date, three generally accepted approaches were considered: income approach, market
approach and cost approach. In addition, the guidance prescribed by the American Institute of Certified Public Accounts, or AICPA, <I>Audit and Accounting Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>
has been considered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The &#147;prior sale of company stock&#148; method, a form of the market approach, had been applied to estimate the total enterprise
value. The prior sale of company stock method considers any prior arm&#146;s length sales of our equity securities. Considerations factored into the analysis included: the type and amount of equity sold, the estimated volatility, the estimated time
to liquidity, the relationship of the parties involved, the risk-free rate, the timing compared to the common shares valuation date and the financial condition and our structure at the time of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale. As such, the value per share was benchmarked to the external transactions of our securities and external financing rounds. Throughout this period, a number of financing rounds were held,
which resulted in the issuance of preferred shares. The preferred shares were transacted with numerous existing and new investors, and therefore the pricing in these financing rounds was considered a strong indication of fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given that there were multiple classes of equity, the hybrid method was applied in order to allocate equity to the various equity classes. The hybrid method
is a hybrid between the probability-weighted expected return method, or PWERM, and the Option Pricing Method, or OPM, which estimates the probability weighted value across certain exit scenarios, but uses the OPM to estimate the remaining unknown
potential exit scenarios. As a part of this analysis, we estimated cumulative probabilities of 65% and 35% of an initial public offering and for a sale of our company, respectively, from September 2014 onwards. Prior to this date, we estimated
cumulative probabilities of 32.5% and 67.5% of an initial public offering and for a sale of our company, respectively. A discount for lack of marketability, or DLOM, was applied, corresponding to the time to exit under the various scenarios to
reflect the increased risk arising from the inability to readily sell the shares. When assessing the DLOM, the Black-Scholes option pricing model was used. Under this method, the cost of the put option, which can hedge the price change before the
privately held shares can be sold, was considered as the basis to determine the DLOM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the commencement of public trading of our common shares in May
2016 in connection with the initial public offering of our common shares, estimates by our board of directors are no longer necessary to determine the fair value of common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to income taxes in
the Netherlands and the United States. Significant judgment is required in determining the use of net operating loss carry-forwards and taxation of upfront and milestone payments for income tax purposes. There are many transactions and calculations
for which the ultimate tax determination is uncertain. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the current and deferred income tax assets and liabilities
in the period in which such determination is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Federal and state income taxes were paid in the United States because of our United States subsidiary;
however, no tax charge or income was recognized in our Dutch entity during the reporting periods since we are in a loss-making position and have a history of losses. As a result of the adoption of IFRS 15, tax losses carried forward have been
revised to reflect the impact of the retrospective effects of the adoption of IFRS 15. We have revised tax loss carry-forwards of &#128;140.5&nbsp;million, &#128;100.7&nbsp;million, and &#128;75.9&nbsp;million as of December&nbsp;31, 2017, 2016, and
2015, respectively. As a result of Dutch income tax law, tax loss carry-forwards incurred through December 31, 2018 are subject to a time limitation of nine years. All tax loss carry-forwards incurred after December 31, 2018 will be subject to a
time limitation of six years. In November 2018, the Dutch tax authorities confirmed that the $120.0 million upfront license fee received from Incyte can be fully recognized in 2017 for corporate income tax purposes, which will significantly reduce
our tax loss carryforwards. There will be no impact on our consolidated statements of financial position or consolidated statement of profit or loss and comprehensive loss as no deferred tax asset is recognized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax assets are recognized for tax losses and other temporary differences to the extent that the realization of the related tax benefit through
future taxable profits is probable. We recognize deferred tax assets arising from unused tax losses or tax credits only to the extent the relevant fiscal unity has sufficient taxable temporary differences or if there is convincing other evidence
that sufficient taxable profit will be available against which the unused tax losses or unused tax credits can be utilized by the fiscal unity. Our judgment is that sufficient convincing other evidence is not available and therefore, a deferred tax
asset is not recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to promote innovative technology development activities and investments in new technologies, a corporate income tax
incentive has been introduced in Dutch tax law called the &#147;Innovation Box.&#148; Based on the Innovations Box ruling, we would owe on the first 75% of qualifying profits under the Dutch jurisdiction effectively 5% (or 7% beginning in 2018) for
Dutch income taxes. The remaining profit would be taxed at the Dutch statutory tax rate of 25%. Taxable profits will only qualify for the Innovations Box once the tax losses </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
carried forward are completely utilized. The agreement with the tax authorities was originally signed for the tax years beginning in 2011 through 2015 and was subsequently extended through the
year 2019. Since we are loss-making, no Dutch income tax is recognized in profit or loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the adoption of IFRS 9 &#150; Financial Instruments (&#147;IFRS 9&#148;) on January&nbsp;1, 2018, investments are classified as held-to-maturity and
are initially measured at fair value. Subsequent to initial recognition, they are measured at amortized cost using the effective interest rate method. Investments are classified as held-to-maturity and carried at amortized cost as management has the
positive intent and ability to hold them until maturity. Interest income from these securities is included in finance income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS 9 replaces the
provisions of IAS 39 that relate to the recognition, classification and measurement of financial assets and financial liabilities, derecognition of financial instruments, impairment of financial assets and hedge accounting. IFRS 9 also significantly
amends other standards dealing with financial instruments such as IFRS 7 <I>Financial Instruments: Disclosures</I>. We assessed the classification and measurement of the financial instruments we held at the date of initial application of IFRS 9, or
January&nbsp;1, 2018, and have classified our financial instruments into the appropriate IFRS 9 categories. There were no changes to the carrying value of our financial instruments resulting from this reclassification and accordingly there was no
impact to our opening accumulated deficit at January&nbsp;1, 2018, as a result of the adoption of IFRS&nbsp;9. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of new standards, amendments to standards and interpretations are effective for annual periods beginning after January&nbsp;1, 2018, and have
not been applied in preparing these financial statements. The standard which may be relevant to us is set out below. We do not plan to adopt this standard early. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>IFRS 16 Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2016, the IASB issued
IFRS 16, Leases. The standard established the principles that lessees and lessors will apply to report useful information to users of financial statements about the amount, timing and uncertainty of cash flows arising from a lease. The standard is
effective for periods beginning on or after January&nbsp;1, 2019. Early adoption is permitted; however, we expect to adopt this standard in the first quarter of 2019. We are still evaluating the full impact this standard will have on our
consolidated financial statements and related disclosures, but expect to recognize substantially all of our leases in our statements of financial position by recording a right-to-use asset and a corresponding lease liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_16"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics. Our pipeline of full-length human bispecific antibody
candidates, which we refer to as Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, are generated from our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, which is able to generate a diverse
array of antibody-heavy chains against virtually any target, paired with a common light chain. Two heavy chains paired with a common light chain can be combined to produce novel bispecific antibodies that bind a diverse array of targets and display
differentiated biology. By binding to two different targets, Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can provide a variety of mechanisms of action. For example, Merus
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be designed to simultaneously block receptors that drive tumor cell growth and survival and to mobilize the patient&#146;s immune response by engaging T-cells and/or activating
various killer cells to eradicate tumors. In our pre-clinical studies, our bispecific antibody candidates were effective in killing tumor cells, a result that we believe supports their potential efficacy in the treatment of cancer. In February 2015,
we commenced a Phase 1/2 clinical trial of our most advanced bispecific antibody candidate, MCLA-128, for the treatment of HER2-expressing solid tumors. In January 2018, we dosed the first patient in a Phase 2, open-label, multi-center international
clinical trial to evaluate MCLA-128 in two metastatic breast cancer, or MBC, populations including HER2-positive MBC patients and hormone receptor positive/HER2-low MBC patients. MCLA-128 is a full-length IgG bispecific antibody with enhanced
antibody-dependent cell-mediated cytotoxicity, or ADCC, targeting HER2 and HER3 receptors. MCLA-128 blocks the HER3 signaling pathway by employing a DOCK&nbsp;&amp; BLOCK<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mechanism. MCLA-128
is designed to &#147;dock&#148; onto a specific region of the HER2 receptor to orientate MCLA-128&#146;s HER3 binding arm to &#147;block&#148; HER2:HER3 heterodimerization. Oncogenic signaling through the HER3 pathway, even in the presence of high
heregulin concentrations, may thus be effectively blocked. The Phase 2 clinical trial is designed to observe the activity of this HER2/HER3-targeted candidate in combination with current standards of care in areas of unmet need. The trial is ongoing
and is enrolling patients at sites in the United States and Europe. We plan to provide an update on the Phase 2 clinical trial in the second half of 2019. Concurrently, our Phase 1/2 clinical trial evaluating single agent activity for MCLA-128 in
gastric, cancer and non-small cell lung cancer or NSCLC is ongoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We reported data from the gastric cancer patient cohort in the single-agent trial of
MCLA-128 at the European Society for Medical Oncology Congress, or ESMO, in October 2018. The data showed a clinical benefit rate of 24% (6 of 25 patients), with MCLA-128 being well tolerated with mainly grade 1/2 adverse events in patients treated
with MCLA-128 across all indications explored to date, and showing a low risk of immunogenicity. Promising single agent antitumor activity was seen in heavily pretreated gastric/gastro-oesophageal junction, or GC/GEJ, cancer patients progressing on
anti-HER2 therapy. Notably, the unique mechanism of action of MCLA-128 was published in the May 2018 edition of the scientific journal <I>Cancer Cell</I> titled, &#147;Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently
Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.&#148; PB4188, the research candidate described in the paper, was identified after screening a panel of hundreds of bispecific antibodies binding to the HER2/HER3 target pair in relevant
functional assays. Using a structure function approach, we demonstrated that PB4188 employs a unique mechanism to inhibit the growth of tumors by docking to HER2 and blocking ligand interaction with HER3, thereby preventing stabilization of the
HER2:HER3 heterodimer and sustained signaling. The activity of PB4188 was unaffected by increasing concentrations of HRG, the ligand for HER3 which mirrors the autocrine or paracrine signaling environment of the tumor, in contrast to monoclonal
antibodies against the same targets, tested as single agents or in combination. These in vitro findings were verified in four independent and pathophysiologically relevant xenograft models, which showed dose dependency and correlation with relevant
pharmacodynamic factors. This unbiased functional screening led to the identification of development candidate MCLA-128. These results reinforce the potential of our functional screening process that allows for the discovery of unique biology driven
by the bispecific antibody format. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, we commenced a single-arm, open-label, global Phase 1 clinical trial of our second bispecific antibody
candidate, MCLA-117, for the treatment of acute myeloid leukemia, or AML, and we announced the filing of the Investigational New Drug application, or IND, in the United States for MCLA-117 in 2018 and the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">subsequent authorization to proceed with clinical studies by the U.S. Food and Drug Administration, or the FDA.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
AML generally has a poor prognosis and limited progress has been made in disease outcomes despite a growing AML patient population. Clinical and pre-clinical studies suggest that
treatment-resistant leukemic stem cells are a potential cause of disease relapse. MCLA-117 binds to CD3, a cell-surface molecule present on all T-cells, and to CLEC12A, a cell surface molecule present on approximately 90 to 95% of AML tumor cells
and stem cells in newly diagnosed and relapsed patients. MCLA-117 is designed to recruit and activate T-cells to kill AML tumor cells and stem cells. In our pre-clinical studies, MCLA-117 killed tumor cells in blood samples of AML patients. If the
results of this clinical trial are favorable, we plan to seek orphan drug designation for MCLA-117 for the treatment of AML from the FDA and the European Medicines Agency, or EMA. We are continuing our dose escalation of the Phase 1 clinical trial
for MCLA-117. We plan to provide an update on our MCLA-117 program upon announcement of the maximum tolerated dose for MCLA-117 and anticipate data readouts for the Phase 1 clinical trial in the second half of 2019. We also intend to evaluate
MCLA-117 for the treatment of myelodysplastic syndrome, or MDS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to MCLA-128 and MCLA-117, we are also developing MCLA-158, a bispecific
antibody candidate that is designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5, or Lgr5, and epidermal growth factor receptors, or EGFR, for the potential treatment of solid tumors with an
initial focus on metastatic colorectal cancer, and the first Clinical Trials Application, or CTA, to the EMA was approved to initiate a Phase 1 clinical trial in Europe in January 2018. We also filed an IND for MCLA-158 with the FDA in the first
quarter of 2018, which received authorization to proceed from the FDA in April 2018. In May 2018, we commenced an open-label, multicenter Phase 1 clinical trial of MCLA-158 and expect emerging data by the end of 2019. MCLA-158 is designed to kill
cancer stem cells using two different mechanisms of action. The first mechanism of action involves blocking growth and survival pathways in tumor stem cells. The second mechanism of action involves the recruitment and enhancement of immune effector
cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we also have a pipeline of proprietary antibody candidates in preclinical development, including the bispecific antibody candidate
MCLA-145, which is being developed in collaboration with Incyte Corporation and is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target. MCLA-145, the first drug candidate co-developed under our global research collaboration
with Incyte, continues to progress in IND-enabling studies and we expect to provide further information on this program upon IND acceptance. We have full rights to develop and commercialize MCLA-145 in the United States and Incyte is responsible for
its development and commercialization outside the U.S. We also have several other antibody candidates in pre-clinical development that bind to other target combinations. Each of our antibody candidates in our preclinical and clinical pipeline are
designed to bind to targets believed to be useful in the treatment of cancer with an intention to establish efficacy and obtain information for submission to the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform employs an array of proprietary technologies and techniques to
generate bispecific human antibodies. We utilize our patented MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mouse harboring a common light chain in its germline that is capable of producing an array of antibodies with diverse heavy
chains that are capable of binding virtually any antigen, the information from which can then be utilized to generate bispecific antibody candidates. We also employ our patented Spleen to
Screen<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> technology to efficiently screen panels of common light chain antibodies, designed to allow us to rapidly identify and generate
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> therapeutic candidates with differentiated modes of action. The Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology also includes use of proprietary host
cells and patented dimerization technology useful to produce bispecific antibodies efficiently. The Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format retains the IgG format of conventional mAbs and is designed to preserve
the format&#146;s key features, including stability, long half-life and low immunogenicity, when developing our bispecific antibody candidates. We leverage industry-standard manufacturing processes and infrastructure to efficiently produce Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to become a leading immuno-oncology company developing innovative bispecific antibodies to treat and potentially cure various types of cancer. Our
business strategy comprises the following components: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Successfully develop our most advanced bispecific antibody candidate, MCLA-128, for the treatment of solid
tumors</I></B><B>.</B>&nbsp;We are developing MCLA-128 for the treatment of patients with HER2-expressing and other solid tumors, including breast, gastric and non-small cell lung cancer. We commenced a Phase 1/2 clinical trial of MCLA-128 in Europe
in February 2015. In the dose escalation phase of the trial, the recommended dose of MCLA-128 was established. Preliminary efficacy data suggests consistent antitumor activity in heavily pretreated metastatic breast cancer patients progressing on
HER2 therapies. In January 2018, we commenced a combination Phase 2 clinical trial in the United States for MCLA-128 and we plan to provide an update on the Phase 2 clinical trial in the second half of 2019. Concurrently, our Phase 1/2 clinical
trial evaluating single agent activity for MCLA-128 in gastric cancer and NSCLC is ongoing. We reported data from the gastric cancer patient cohort in the single-agent trial of MCLA-128 at ESMO in October 2018. The data showed a clinical benefit
rate of 24% (6 of 25 patients.), with MCLA-128 being well tolerated with mainly grade 1/2 adverse events in patients treated with MCLA-128 across all indications explored to date and showing a low risk of immunogenicity. Promising single agent
antitumor activity was seen in heavily pretreated GC/GEJ cancer patients progressing on anti-HER2 therapy. We believe that if MCLA-128 is successfully developed and obtains regulatory approval, it has the potential to address disease-specific
challenges that are not currently being met by existing therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Successfully develop our second most advanced bispecific antibody candidate, MCLA-117, for the treatment of
AML</I></B><B>.</B><B><I></I></B>&nbsp;We are developing MCLA-117 for the treatment of patients with AML. We commenced a Phase 1 clinical trial of MCLA-117 in Europe in May 2016 for the treatment of patients with AML to assess its safety,
tolerability and anti-tumor activity and filed an IND in the United States in January 2018, for which we obtained authorization to proceed from the FDA in February 2018. We are continuing our dose escalation of the Phase 1 clinical trial for
MCLA-117. We plan to provide an update on our MCLA-117 program upon announcement of the maximum tolerated dose for MCLA-117 and anticipate data readouts for the Phase 1 clinical trial in the second half of 2019. If the results of this clinical trial
are favorable, we plan to seek orphan drug designation from the FDA and the EMA for MCLA-117 for the treatment of AML. We believe that if MCLA-117 is successfully developed and obtains regulatory approval, it has the potential to transform the
treatment of AML. We also intend to evaluate MCLA-117 for the treatment of MDS. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Successfully develop our third bispecific antibody candidate, MCLA-158, for the treatment of metastatic
colorectal cancer and other solid tumors</I></B><B>.</B>&nbsp;We are developing MCLA-158 for the treatment of solid tumors with an initial focus on the treatment of metastatic colorectal cancer. MCLA-158 has received approval of a CTA in several
European countries for the potential treatment of metastatic colorectal cancer, including patients with the RAS-mutation, which represent a substantial unmet need. We also filed an IND for MCLA-158 with the FDA in the first quarter of 2018, which
received authorization to proceed from the FDA in April 2018. In May 2018, we commenced an open-label, multicenter Phase 1 clinical trial of MCLA-158 and expect emerging data by the end of 2019. MCLA-158 is an ADCC-enhanced Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> designed to bind to cancer stem cells expressing leucine-rich repeat-containing G protein-coupled receptor 5, or Lgr5, and epidermal growth factor receptors, or EGFR. We believe that if MCLA-158
is successfully developed and obtains regulatory approval, it has the potential to address and transform the treatment of metastatic colorectal cancer and other solid tumors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerate the internal discovery and development of additional immunotherapeutic antibody
candidates</I></B><B>.</B><B><I></I></B>&nbsp;We believe we are well positioned to expand our pipeline of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of other forms of cancer. Our platform employs our
proprietary common light chain transgenic MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the production of diverse human heavy chains that can be paired to generate bispecific antibodies, coupled with our Spleen to Screen<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> technology that is designed to allow us to rapidly identify and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
generate Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> therapeutic candidates with differentiated modes of action that have the potential to kill tumor cells with high
potency. We are conducting pre-clinical studies of MCLA-145 in collaboration with Incyte and expect to provide further information on this program upon acceptance of an IND for MCLA-145. We are also conducting pre-clinical studies of an array of
proprietary candidates binding to other target combinations that are the subjects of our internal programs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Seek strategic collaborative relationships</I></B><B>.</B><B><I></I></B>&nbsp;We intend to continue to seek
strategic collaborations to facilitate the capital-efficient development of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform and to identify potential target combinations in immuno-oncology and other
therapeutic areas. We have entered into collaborations with Incyte, ONO Pharmaceutical Co., Ltd., and Simcere Pharmaceutical Group, to develop bispecific antibody candidates based on our
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform and plan to work with other collaborators to validate and expand the use of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform and
the development of bispecific antibody candidates. We believe these collaborations could potentially provide significant funding to advance our bispecific antibody candidate pipeline while allowing us to benefit from the development expertise of our
collaborators. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use our technology platform to develop Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for the treatment of various types of
cancer. The following table summarizes our bispecific antibody candidate pipeline: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g77h39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of Existing Immunotherapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite a number of advances in the past decade, a significant unmet need in cancer still exists. While targeted antibody therapeutics have been successful in
treating some cancers, the therapeutic effects of almost all such therapies are transient. Cancer cells are able to adapt to escape recognition and elimination by the immune system, thereby contributing to tumor growth and progression. Acquired
resistance to cancer therapies remains a significant clinical problem with patients frequently relapsing and the tumors metastasizing to other organs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immunotherapy is a new class of cancer treatment that works to harness the intrinsic powers of the immune system to fight tumor cells. There are a number of
immunotherapies that engage various aspects of the immune system, for example: (1)&nbsp;monoclonal antibodies with enhanced ADCC, (2)&nbsp;bispecific T-cell engaging molecules, (3)&nbsp;immunomodulatory monoclonal antibodies and (4)&nbsp;CAR-T and
TCR therapies. While these therapies vary in mechanism of action, they rely on specific components of the innate or adaptive immune system to kill tumor cells or counteract signals produced by cancer cells that suppress immune responses. The
potential of immunotherapeutic approaches is best demonstrated by the long durable remissions, exceeding 10 years, observed after checkpoint inhibitor treatment in a subset of patients with advanced melanoma. More recent evidence from clinical
trials suggests that a growing list of cancers will respond to checkpoint inhibitors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Monoclonal Antibodies with Enhanced ADCC.</I></B>&nbsp;Monoclonal antibodies bind to a single target
expressed by tumor cells and have been modified to more efficiently attract immune effector cells, such as NK cells and macrophages, to effectively kill tumor cells. Several mAbs with enhanced ADCC for the treatment of solid and leukemic tumors have
yielded promising results in clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By binding to a single target, mAbs with enhanced ADCC depend on the varying levels of expression of that
target on the tumor and normal tissues to leverage the advantage of enhanced tumor cell-killing while minimizing toxicity. Ideal targets for antibodies would be solely expressed by the diseased cell and not by normal cells. Unfortunately, many of
these targets are also expressed by healthy tissues. By binding to a single target, mAbs with enhanced ADCC potentially can induce autoimmune toxicity, so-called &#147;on-target, off-tumor&#148; toxicity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Bispecific T-Cell Engaging Molecules.&nbsp;</I></B>Bispecific T-cell engaging molecules enhance a patient&#146;s immune response to tumors by
re-targeting T-cells to tumor cells. These molecules have been developed for a variety of both hematological and solid tumors and are currently in clinical trials. We are aware of a bispecific T-cell engaging molecule therapeutic that has received
regulatory approval for the treatment of acute lymphoblastic leukemia as well as additional bispecific T-cell engaging molecules that are currently in clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most T-cell engaging molecules in development are currently based on antibody fragments connected by a flexible linker and, unlike Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, do not utilize the advantages of the full-length IgG format. These molecules may have shorter half-lives than conventional mAbs, which could require continuous infusion of the molecule or could
pose manufacturing and immunogenicity challenges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Immunomodulatory mAbs.&nbsp;</I></B>Immunotherapeutic strategies have been shown in clinical
trials to increase the ability of the immune system to recognize and eradicate tumor cells. Among these treatment strategies, immunomodulatory mAbs that enhance the function of T-cells have achieved noteworthy results for multiple types of cancers.
Immunomodulatory mAbs that bind to molecules involved in T-cell inhibition are called checkpoint inhibitors because they block normally negative regulators of T-cell immunity. These checkpoint inhibitors target molecules such as the cytotoxic
T-lymphocyte antigen 4, or CTLA-4, and PD-1. Additionally, immunomodulatory mAbs that bind to co-stimulatory molecules involved in T-cell activation, such as the tumor necrosis factor receptors OX40 and CD137, have shown tumor cell-killing activity
in pre-clinical animal models of cancer and are currently being evaluated in early-stage clinical trials. Combinations of immunomodulatory mAbs have been observed to enhance the anti-cancer response in pre-clinical studies and in clinical trials of
patients with various tumor types, but have also been observed to result in more pronounced toxicities. We believe that Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> have the potential to capture the benefits of combinations of
immunomodulatory mAbs, combined with more specific targeting to tumor-specific T-cells and tumor cells, thereby potentially diminishing the toxic side effects and providing a cost-effective two-in-one therapeutic for the treatment of cancer
patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>CAR-T and TCR Therapies.&nbsp;</I></B>T-cells recognize diseased cells by receptors engaging with antigens that are present on cancer
cells. CAR-T therapy entails genetically engineering T-cells to express synthetic chimeric antigen receptors, or CARs, that direct T-cells to antigens on the surface of cancer cells. The T-cell receptor, or TCR, modifies T-cells to express
high-affinity tumor specific TCRs that recognize intra-cellular antigens present on the surface of target cells. In clinical trials, CAR-T and TCR therapies have been observed to have anti-tumor activity in a narrow spectrum of hematologic cancers.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe a key limitation of CAR-T and TCR therapies is the need to retrieve non-compromised immune effector cells from a cancer patient, which
requires a complex and costly individualized process to develop the therapy. These challenges limit their potential and use in a variety of indications, including the treatment of solid tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To address patient populations not responding to single-antibody based drugs, there is an increased focus on synergistically combining immunotherapeutics in
the scientific community and from biopharmaceutical companies. Opportunities to create innovative antibody-based therapeutics lie in several technology advances, including bispecific antibodies that bind to multiple targets, Fc-optimization, which
enhances the body&#146;s immune system to mediate the killing of cancer cells, and antibody drug conjugates, or ADCs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Background on Antibodies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conventional antibody is a Y-shaped molecule that consists of two identical heavy chains and two identical light chains, as shown in the figure below.
These four chains pair to form two variable regions that bind to antigens, or targets, and a constant region, which includes a region known as the Fc, that binds to receptors present on effector cells in the immune system. In conventional mAbs, the
variable regions are identical and bind to the same targets. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g75u56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In bispecific antibodies, the variable regions can be modified to bind to two different targets. To achieve this in the
full-length IgG format, two different heavy chains and two identical light chains, also referred to as the common light chain, are combined. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In both
conventional mAbs and IgG bispecific antibodies, the Fc region can bind to Fc receptors present on effector cells. This binding results in the recruitment and activation of immune effector cells and amplifies the immune system&#146;s response to
antigens bound by the variable region of the antibody. This process is called ADCC. The Fc region can be modified to enhance ADCC so as to generate a more potent immune response against a particular target. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a pipeline of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> generated from our patented technology platform. Our platform enables
the rapid identification of immunotherapeutics with the potential to produce tumor cell-killing activity and/or to modulate the tumor microenvironment to promote more effective anti-tumor immune responses, and allows for the flexible and rapid
generation of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> against virtually any particular target pair. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By binding to two
different targets, Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be designed to block receptors that drive tumor cell growth and survival and to mobilize the patient&#146;s immune response by activating various killer cells
to eradicate tumors. We believe our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform allows us to approach cancer treatment through multiple modes of action: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Blocking combinations of growth factor receptors that drive tumor cell growth and relapse while simultaneously
recruiting immune effector cells through enhanced ADCC.&nbsp;Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> may be generated for various combinations of growth factor receptors that play a role in tumors with different molecular
profiles, while a modification in the Fc region of the Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> facilitates the enhanced recruitment of immune effector cells, such as NK cells and macrophages, to directly kill tumor cells
through ADCC. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I></I></B><B><I>Activating T-cells to kill tumor cells by binding to CD3 expressed on T-cells and a
tumor-associated target</I></B><B>.</B>&nbsp;CD3 is a cell-surface molecule present on all T-cells. We create Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that are designed to simultaneously bind to CD3 and a tumor-associated
target, which allows for T-cell recruitment and engagement to selectively kill tumor cells. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I></I></B><B><I>Blocking two checkpoint inhibitory pathways for more efficient T-cell
activation.&nbsp;</I></B>Cancer cells are able to block the tumor-killing function of T-cells through the expression of inhibitory molecules. Scientific research has shown that combinations of mAbs are more potent than single mAbs when used against
these inhibitory molecules to unblock and revive this mechanism of T-cells which kills tumor cell targets. Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be designed to prevent the blocking of T-cells by cancer cells while
retaining the advantages of specific targeting in the tumor environment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I></I></B><B><I>Achieving a DOCK &amp; BLOCK<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
mechanism of action to favorably impact hard-to-target receptors that may drive tumor growth or escape.</I></B> Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are designed to be capable of binding a tumor associated target
prevalent on cancer cells, which then permits the other arm of the Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> to be proximate to bind and block lesser expressed targets that have ligand or enzymatic functions that may tend
to drive tumor growth or escape. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I></I></B><B><I>Blocking a checkpoint inhibitory pathway while simultaneously providing a co-stimulatory
signal for more efficient activation of T-cells</I></B><B>.</B>&nbsp;In addition to being blocked by inhibitory molecules, tumor specific T-cells may simultaneously require an activation signal to engage in tumor cell-killing. Biclonics can be
designed to concurrently alleviate the blocking of T-cells and deliver the signals required to activate the killing potential of T-cells. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Simultaneously targeting a growth factor receptor expressed by tumor cells and an immunomodulatory molecule
involved in blocking tumor-specific T-cells.</I></B>&nbsp;Growth factor receptors like epidermal growth factor receptors, or EGFR, and HER2 are expressed on many tumors. Biclonics can be designed to target such growth factor receptors while
delivering an activation signal or de-blocking signal to T-cells. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our process to select lead Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for clinical development takes approximately 12 months and is illustrated below. We use our patented MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Spleen to Screen<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> human antibody generation and Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> production technologies to rapidly build large collections of Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> directed against particular target pairs. We then test these collections in cell-based functional assays to identify Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that have
differentiated modes of action. We select the most potent or efficacious Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and evaluate them in multiple <I>in vitro</I> and <I>in vivo</I> assays to identify lead candidates for
clinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Selection of Lead Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g46a06.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform includes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Human antibody generation.</I></B>&nbsp;Our platform for generating human antibodies is comprised of
transgenic mice, which we refer to as MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, which harbors a common light chain in its germline. The antibody sequence information obtained from MeMo<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be used to generate human antibodies and phage </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
display&nbsp;for the generation of panels of common light chain human mAbs. MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> harnesses the power of the <I>in vivo</I> immune system
to yield human antibodies with high potency, specificity, solubility and low immunogenicity. Using this technology, we produce large and diverse panels of high-affinity antibodies against a broad variety of targets. We believe this approach enhances
the discovery and development of high-quality human antibodies that, through the common light chain, generates sequences that are ready to be converted into the Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I></I></B><B><I>The full-length Immunoglobulin G format.&nbsp;</I></B>The Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format retains several of the favorable attributes of conventional human IgG mAbs, including their stability and predictability during manufacturing as well as their long half-life and low
immunogenicity during treatment of patients. Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> consist of two different heavy chains that need to stably form, or heterodimerize, inside a manufacturing cell line. Using our patented
technology, we insert amino acids with opposite charges in each of these heavy chains to efficiently drive this process. The use of a single, or common, light chain in our human Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
antibodies is designed to have the heavy chains pair with the correct, common light chain to form functional antigen binding regions. The combination of these approaches prevents the need for additional, more artificial techniques, such as the use
of linkers or chemical reactions, to force the pairing of different parts of the bispecific antibody. The resulting Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are bispecific heterodimeric IgG antibodies that closely mimic
IgG antibodies that are produced naturally by the immune system. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format also permits us to make modifications to the Fc region of the IgG antibody in order to enhance or limit effector functions associated with this part of the molecule. This
strategy has been successfully executed with conventional therapeutic mAbs. In order to enhance efficacy and promote immunotherapeutic activity, we can use genetically altered cell lines used in production to generate Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that are enhanced for ADCC, resulting in the improved ability to recruit NK cells and macrophages. This ADCC enhancement has been made to our most advanced bispecific antibody candidate,
MCLA-128, and another of our antibody candidates, MCLA-158. In order to improve safety and tolerability, we can modify our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> to prevent the excessive release of signaling proteins
called cytokines, which can overstimulate the immune system. This process is called Fc-silencing as it blocks the ability of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> to bind to certain protein receptors on cells, known
as Fc receptors, which are associated with cytokine release. We utilize Fc silencing in the design of our bispecific antibody candidate, MCLA-117. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I></I></B><B><I>High-throughput functional screening.&nbsp;</I></B>We employ our Spleen to Screen<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> technology to rapidly screen panels of target-specific common light chain antibodies. Subsequently, DNA constructs are generated and introduced into mammalian cells that encode panels of
target-specific human antibodies. The common light chain format and modified Fc region of the IgG antibody ensure the secretion of virtually pure Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;into the cell culture medium.
The medium of thousands of cell cultures is harvested and individually used in cell- and tissue-based functional assays to permit the identification of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> with differentiated modes of
action. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, the chart below shows the results of a pre-clinical study in which hundreds of different
Biclonics targeting HER2 and HER3 were functionally screened against tumor cell samples, with and without heregulin present. Of the antibody candidates depicted in the chart, 40 exhibited superior inhibition of cell growth compared to trastuzumab, a
drug commonly prescribed for the treatment of breast cancer, and were selected in the process leading to identification of MCLA-128. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g12d69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Benefits of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform provides the following benefits: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Rapid generation of human IgG antibodies having diversity at the heavy chain targeting an array of
antigens, that are ready to be paired to produce our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, bispecific antibodies.</I></B> Use of our patented MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Spleen to
Screen<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, heterodimerization and Fc modification technologies, permits us to rapidly generate a large amount of diverse bispecific antibodies capable of targeting an array of antigen combinations.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I></I></B><B><I>Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;are stable,
bispecific, full-length human IgG antibodies with no linkers or fusion proteins.&nbsp;</I></B>Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> retain the IgG format of antibodies that are produced naturally by the immune system.
Additionally, in contrast to many other bispecific antibody formats, Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> do not require linkers to force the correct pairing of heavy and light chains or exploit fusion proteins to add
functionality to the molecule. These qualities minimize time-consuming engineering efforts and allow us to create Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> with predictable behavior during pre-clinical development.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> preserve the stability, behavior and
adaptability of normal IgG antibodies.</I></B>&nbsp;Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;are based on the robust and commonly used IgG format to yield the favorable <I>in vivo</I>&nbsp;qualities associated with
conventional mAbs, such as stability, long half-life and low immunogenicity. As a result, our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> format provides attractive options for dosage schedules and methods of administration,
rendering them compatible with multiple modes of action for the efficient killing of tumor cells. Further, the IgG format allows us to apply previously established technologies to further optimize our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> for therapeutic use. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> can be reliably manufactured with high
yields.</I></B>&nbsp;Because our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> retain the IgG format of antibodies, our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are manufactured using the large-scale
industry-standard processes that are also used for the production of conventional mAbs, and the yields of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> we obtain are comparable to those of normal IgG antibodies. In stable cell
lines, we are able to obtain over </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
90% of bispecific antibody formation using these processes and the IgG-based purification process results in up to greater than 98% purity for our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform allows for
functional evaluation of Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;in the relevant therapeutic format leading to the discovery of therapeutic candidates with differentiated properties.</I></B>&nbsp;Our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform enables rapid functional screening of large collections of bispecific antibodies which allows us to identify lead candidates with multiple mechanisms of action that have the
potential to effectively kill tumor cells with high potency. This is an important step in the identification of lead bispecific antibody candidates with functionalities that compare favorably against other forms of immunotherapeutics, such as
conventional mAbs as well as their combinations. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Bispecific Antibody Candidate Portfolio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We commenced a Phase 2, open-label, multi-center, international clinical trial of our most advanced bispecific antibody candidate, MCLA-128 for the treatment
of patients with MBC in January 2018 and plan to provide an update in the second half of 2019. Concurrently, our Phase 1/2 study of MCLA-128 in gastric and non-small cell lung cancers is ongoing. Additionally, we commenced a Phase&nbsp;1,
single-arm, open-label clinical trial of our second bispecific antibody candidate, MCLA-117, for the treatment of patients with AML in May 2016, and announced the filing of an IND in the United States for MCLA-117 in January 2018, which subsequently
received authorization from the FDA. Dose escalation in the Phase 1 trial is ongoing. We plan to provide an update on our MCLA-117 program upon announcement of the maximum tolerated dose for MCLA-117 and anticipate data readouts for the Phase 1
clinical trial in the second half of 2019. In May 2018, we commenced a Phase&nbsp;1, open-label, multicenter clinical trial of MCLA-158, for the treatment of solid tumors with an initial focus on metastatic colorectal cancer, for which we have
received CTA approvals in several European countries. We filed an IND with FDA in the first quarter of 2018, which received authorization to proceed from the FDA in April 2018, and have expanded the trial to the United States. We expect emerging
data from this trial by the end of 2019. In addition, we have several other bispecific antibody candidates in pre-clinical development, including MCLA-145, which binds PD-L1 and an undisclosed target, on which we are collaborating with Incyte and on
which we expect to provide further information upon acceptance of an IND, among other preclinical candidates in various stages of development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MCLA-128 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MCLA-128 is an ADCC-enhanced Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that is designed to bind HER2 to effectively block the HER3 signaling pathway. HER3-mediated inherent and acquired resistance to HER2-targeted therapies has been implicated in various solid
tumors, including breast, gastric and non-small cell lung cancer tumor cells. The scientific rationale for targeting HER2, or human epidermal growth factor receptor 2, and HER3, or human epidermal growth factor receptor 3, is that HER2 is amplified
in many solid tumors and is associated with poor prognosis and the activation of HER3 causes cancer cells to be or to become resistant to treatment. On the surface of tumor cells, HER2 preferably pairs, or dimerizes, with HER3, and the resulting
pair drives malignant progression of HER2-expressing cancer cells. Heregulin, which is the ligand for HER3, causes cancer cells to grow and become resistant to treatment with HER2-targeted therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have designed MCLA-128 to overcome the inherent and acquired resistance of tumor cells using two different mechanisms. The first mechanism blocks growth
and survival pathways to stop tumor expansion, while preventing tumor cells from escaping through activation of the HER3/heregulin pathway. The second mechanism, enhanced ADCC, involves the recruitment and enhancement of immune effector cells, such
as NK cells and macrophages, to directly kill the tumor through a modification of the Fc region. This dual mechanism of action is illustrated in the graphic below. MCLA-128 blocks the HER3 signaling pathway by employing a DOCK&nbsp;&amp; BLOCK<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mechanism. MCLA-128 is designed to &#147;dock&#148; onto a specific region of the HER2 receptor to orientate MCLA-128&#146;s HER3 binding arm to &#147;block&#148; HER2:HER3 heterodimerization.
Oncogenic signaling through the HER3 pathway, even in the presence of high heregulin concentrations, may thus be effectively blocked. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MCLA-128 Mechanism of Action </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g50z56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pre-Clinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our pre-clinical studies of HER2-expressing tumor cell lines, we measured the impact of MCLA-128 on heregulin-driven growth and cellular changes,
characterized by a metastatic phenotype. In these studies, we observed that both growth and metastatic characteristics were poorly blocked by therapeutic mAbs targeting HER2 and HER3, while the application of MCLA-128 resulted in the inhibition of
heregulin induced changes in cultures of cancer cells. MCLA-128 also blocked activation of two key signaling pathways for the growth and survival of tumor cells more effectively than the combination of the currently approved therapeutic HER2 mAbs,
Herceptin (trastuzumab) and Perjeta (pertuzumab). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shown in the chart below, the administration of MCLA-128 reduced heregulin-driven tumor growth at
significantly lower concentrations than mAbs targeting HER2 or HER3 and the combination of Herceptin and Perjeta. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g38s90.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MCLA-128 also blocked phosphorylation and activation of key proteins in the signaling pathways for the cell
growth and survival of cancer cell lines, a result that was not observed with the combination of HER2 mAbs, Herceptin and Perjeta. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also studied the
ADCC activity of MCLA-128 in cell lines expressing different types of Fc receptors. As shown in the two charts below, because MCLA-128 is ADCC enhanced, it was able to bind and activate Fc receptors required for the recruitment of immune killer
cells regardless of the receptor affinity of the patient. Studies have estimated that more than 50% of the patient population carry Fc receptors that are of low affinity and are poorly activated by therapeutic antibodies such as Herceptin. We have
observed in our pre-clinical studies that MCLA-128 was also more potent than Herceptin in activating immune killer cells carrying low affinity Fc receptors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Fc Receptor Activation by MCLA-128 (Fc</U></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><B></B><B>R Subtype) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g08c57.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g13w29.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the pre-clinical studies, we also compared the ability of MCLA-128 to inhibit the <I>in vivo</I> growth
of cell lines such as JIMT-1, which is an aggressive breast cancer line resistant to HER2-targeted therapies. In these studies, we administered four doses of MCLA-128 at 2.5 mg/kg. The MCLA-128-treated mice experienced as high as a 58% reduction of
their tumor size during the 21-day treatment period, compared to a less than 11% reduction after administration of a combination of Herceptin and Perjeta. Regrowth of the tumor was observed after treatment was halted on day 21. This result is
illustrated in the chart below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g34o39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Analysis of tumors taken from mice at day 21 showed that HER3 signaling was effectively blocked when treated with MCLA-128
whereas no effect was observed with the combination of Herceptin and Perjeta. Pre-clinical studies have been conducted to evaluate whether tumor suppression can be sustained by continuing treatment over the 60-day observation period. The result was
that tumor suppression was not sustained. However, a higher percentage (60%)&nbsp;of mice treated with MCLA-128 survived beyond 60 days than mice receiving either the vehicle or the combination of Herceptin and Perjeta. This result is illustrated in
the chart below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g04t94.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Development of MCLA-128 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2015, we commenced an open-label Phase 1/2 clinical trial of MCLA-128 in Europe for the treatment of HER2-expressing solid tumors. The first part
of the trial, the dose escalation phase, is complete. In Part 1 of this trial, MCLA-128 was well-tolerated up to the highest tested dose of 900 mg and we observed a favorable safety profile and early positive data of efficacy. No dose limiting
toxicities were observed. The cumulative safety and available pharmacokinetic, or PK, data, along with the aid of a PK simulation study, were used to support a recommended dose for a Phase 2 clinical trial of 750 mg, administered over 120 minutes,
which we are using in Part 2 of this trial. The Part 2 is ongoing, and is designed to further study the safety, tolerability and clinical efficacy of MCLA-128 in patients with solid tumors that are relapsed or refractory to available standard
treatment or for whom no curative therapy is available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For this Phase 1/2 trial, we have implemented an exploratory biomarker investigation using tumor
tissue and blood samples from patients. The biomarkers we are evaluating include heregulin expression, HER2 and HER3 receptor expression and PI3K/AKT pathway activation status, which refers to an intracellular pathway regulating processes such as
cell survival, cell proliferation and cell growth. We believe this approach, in conjunction with genetic profiling, will allow for the validation of biomarker assays and will provide guidance for enrolling additional patients based on relevant
biomarkers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Adverse events observed have included infusion related reactions, which were mild or moderate in severity and well managed with premedication
or symptomatic medication. No severe GI events or symptomatic cardiac events have been reported. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase 2 portion of the study is ongoing and designed
to explore selected metastatic indications including breast, gastric and non-small cell lung cancers. In May 2017, we announced the results of our first-in-human Phase 1/2 study of MCLA-128 in solid tumors, including final Phase 1 data and promising
preliminary activity in patients with HER2-positive MBC from the Phase 2 portion of the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the ongoing study, a cohort of 11 HER2-positive
MBC patients has been treated with single agent MCLA-128 (9 patients at RP2D and two patients at 480 mg q3 weeks from part 1). These MBC patients were all heavily pretreated, having received a median of 6 prior lines of metastatic therapy, all
having 2-5 prior HER2 inhibitor therapies, and some of the patients with outright disease progression to the last line of therapy. One MBC patient achieved a confirmed partial response (&gt;8+ months) and 7 had stable disease (including 4 sustained
stabilizations lasting greater than 5 months). The clinical benefit rate (complete and partial responses plus stable disease lasting at least 12 weeks) among the cohort of MBC patients was 64% or 7 of 11 patients. We believe the antitumor activity
reported as single agent and extensive preclinical evidence support further development of MCLA-128 in combination in MBC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2018, we commenced
a Phase 2, open-label, multi-center international clinical trial to evaluate MCLA-128 in two MBC populations including HER2-positive MBC patients and hormone receptor positive/HER2-low MBC patients. The MCLA-128 Phase 2 clinical trial is ongoing and
expected to enroll approximately 120 patients in total across the United States and Europe. The first cohort, HER2-positive MBC patients who are progressing on anti-HER2 therapies including trastuzumab, pertuzumab and TDM-1, will receive MCLA-128 in
combination with trastuzumab and chemotherapy. The second cohort, MBC patients with confirmed hormone receptor positive status and HER2-low (immuno-histo-chemistry (IHC) HER2 1+ or 2+ and fluorescent in-situ hybridization (FISH) negative for HER2
amplification) who are progressing on hormone therapies and CDK4/6 inhibitors, will receive MCLA-128 in combination with endocrine therapy. The primary endpoint for both cohorts is the clinical benefit rate at 24 weeks. We plan to provide an update
on the Phase&nbsp;2 clinical trial in the second half of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We reported data from the gastric cancer patient cohort in the single-agent trial of
MCLA-128 at ESMO in October 2018. The data showed a clinical benefit rate of 24% (6 of 25 patients), with MCLA-128 being well tolerated with mainly grade 1/2 adverse events in patients treated with MCLA-128 across all indications explored to date.
Promising single agent antitumor activity, including one patient with a durable complete response of 5.8&nbsp;months, was seen in heavily pretreated GC/GEJ cancer patients progressing on one to three anti-HER2 therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MCLA-117 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MCLA-117 for AML </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MCLA-117 is a Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;that is designed to bind to CD3, a cell-surface molecule present on all T-cells, and to CLEC12A, a cell surface molecule present on AML tumor cells and stem cells. CLEC12A is not found on
normal blood stem cells nor on cells that give rise to red blood cells and platelets nor is it present on other non-hematopoietic cells in the body. This is in contrast to the expression patterns of CD123 and CD33, which are present on normal blood
stem cells, and in the case of CD33, also the cells that give rise to red blood cells and platelets. Both CD123 and CD33 are being explored by others as targets for AML therapy. We believe that the expression pattern of CLEC12A makes it an
attractive and differentiated molecule for targeted therapy in cancer patients. Moreover, CLEC12A is expressed on approximately 90 to 95% of newly diagnosed and relapsed cases of AML, and we believe that many patients with AML could potentially
benefit from treatment with MCLA-117. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By binding to CD3 and CLEC12A, MCLA-117 is designed to recruit and activate T-cells to kill CLEC12A-expressing AML
tumor cells and stem cells. AML tumor stem cells are thought to be resistant to current chemotherapeutic treatment regimens, and the inability to eliminate these cells with conventional therapies is thought to significantly contribute to disease
relapse in AML patients. We believe that elimination of this leukemic stem cell population by treatment with MCLA-117 may prevent recurrence of the tumor. The mechanism of action of MCLA-117 is illustrated in the graphic below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MCLA-117 Mechanism of Action </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g36t94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unlike some other bispecific antibody formats, the full-length IgG format of MCLA-117 and its associated longer half-life
is designed to keep it from having to be administered through continuous infusion using infusion pumps. In addition, through Fc-silencing, MCLA-117 is designed to avoid binding to Fc receptors present on macrophages and other blood cells that could
result in toxicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that MCLA-117 could be developed as induction therapy, as consolidation therapy to treat minimal residual disease and as
rescue therapy for patients with relapsed or refractory AML. We intend to explore its use both as a single agent and in combination with commonly used chemotherapy agents and other treatment regimens of AML. We expect the safety profile of MCLA-117
to be favorable based on the restricted expression of CLEC12A in human tissues which is anticipated to result in manageable neutropenia. We also expect infusion related reactions based on the observed level of cytokine release upon co-culture with
blood cells, which can be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
mitigated by gradual dose increments and by providing co-medication when required. As CLEC12A is not expressed on megakaryocyte and erythroid progenitor cells, we expect the application of
MCLA-117 would not result in a decrease of platelet counts or red blood cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our pre-clinical studies, MCLA-117 specifically targeted and killed AML
tumor cells mediated by a high affinity of the Biclonics for CLEC12A and a relatively low affinity for CD3. In these studies, MCLA-117 recruits T-cells to selectively kill tumor cells in blood samples of AML patients containing an unfavorable ratio
of T-cells to AML tumor cells. We observed that 1,000 ng/ml of MCLA-117 was sufficient to induce the elimination of tumor cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shown in the figure
below, treatment of an AML patient&#146;s blood samples with MCLA-117 resulted in the efficient killing of AML tumor cells in our pre-clinical studies. An unmanipulated primary blood sample containing both CLEC12A positive patient tumor cells and
T-cells was cultured for 10 days with either a dosage of 1,000 ng/ml of MCLA-117 or a dosage of a control Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> that does not bind to CLEC12A but retains CD3 binding activity. On day 10,
the percentage of AML tumor cells in the culture dish dosed with MCLA-117 had decreased from 93% to 1% while the proportion of T-cells had increased from 5% to 95%, indicating that CD3 positive T-cells had been effectively activated to proliferate,
engage and kill the AML tumor cells by MCLA-117. In contrast, the percentage of AML tumor cells in the culture dish dosed with a control Biclonics had slightly decreased from 93% to 81% while the proportion of T-cells had only increased from 5% to
16%, indicating that binding to CLEC12A by MCLA-117 was required to result in the efficient killing of AML tumor cells. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g75x33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We commenced a Phase 1, single-arm, open-label clinical trial in Europe of MCLA-117 in May 2016 for the treatment of
patients with AML to assess its safety, tolerability and anti-tumor activity. The first phase of the trial is designed as a dose escalation study, followed by a second safety dose expansion phase. The study is designed to enroll adult patients with
all AML subtypes. Patients with relapsed or refractory disease and newly diagnosed, untreated AML patients who are older than 65 years and are usually not eligible as candidates for intensive or conventional approved treatments would all be eligible
for enrollment in the trial. The trial is ongoing and we expect to enroll approximately 50 patients in this trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary endpoint of the Phase 1
trial is the assessment of the safety and tolerability of MCLA-117 in order to determine the maximum tolerated dose and frequency of administration. Secondary endpoints include pharmacokinetic measures, anti-tumor response and clinical benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January of 2018, we submitted an IND to the FDA for MCLA-117 for the potential treatment of AML, which was authorized to proceed by the FDA in February
2018, and have expanded the trial to the United States. We are continuing our dose escalation of the Phase 1 clinical trial for MCLA-117. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the results of the clinical trial are favorable, we plan to seek orphan drug designation from the FDA and
the EMA for MCLA-117 in the United States and in Europe, respectively, for the treatment of AML. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MCLA-117 for MDS </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also intend to evaluate MCLA-117 for the treatment of MDS. MDS is a disease that occurs when the blood-forming cells in the bone marrow lose the ability to
develop normally. Patients with MDS have lower numbers of one or more types of cells in the blood such as red blood cells and platelets and are at higher risk to develop AML. Similar to AML, we believe that the expression pattern of CLEC12A makes it
an attractive and differentiated molecule for targeted therapy in patients with MDS. CLEC12A is expressed in approximately 89% of patients with MDS, and we believe that many patients with MDS could potentially benefit from treatment with MCLA-117.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>MCLA-158 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MCLA-158 is an ADCC-enhanced
Biclonics that is designed to bind to Lgr5 and EGFR-expressing cancer stem cells for the treatment of solid tumors, including colorectal cancer. Cancer stem cells are a subpopulation of long-lived and chemo-resistant cells that contribute to the
growth and metastatic potential of a tumor. Cancer stem cells have the capacity to divide and give rise to new cancer stem cells via a process called self-renewal, the capacity to differentiate or change into the other cells that form the bulk of
the tumor and an ability to withstand chemotherapy and radiation exposure. We believe these features make cancer stem cells an attractive therapeutic target to overcome the inherent and acquired resistance of tumors to conventional therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2012, colorectal cancer was the third most common cancer worldwide. Patients with metastatic disease have a mean survival time of less than two&nbsp;years.
Approximately 90% of all colorectal cancers display mutational activation of the Wnt pathway. The Wnt pathway is critical for the maintenance of stem cells and has been linked to cancer. Lgr5 is an amplifying receptor of the Wnt pathway, is
over-expressed in approximately 70% of advanced colorectal cancers and is correlated with lymph node metastases. Lgr5 expression is higher in metastatic tumors and associated with tumor-initiating cells or cancer stem cells. Lgr5 positive cells are
highly mitotically active and are expected to be particularly dependent on growth and survival factors that activate EGFR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have designed MCLA-158 to
target cancer stem cells expressing Lgr5 and EGFR using two different mechanisms of action. The first mechanism of action blocks growth and survival pathways in cancer stem cells. The second mechanism of action, enhanced ADCC, involves the
recruitment and enhancement of immune effector cells to directly kill cancer stem cells that persist in solid tumors, such as colorectal cancer, and cause relapse and metastasis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our pre-clinical studies, we used our proprietary technology combined with high content imaging to identify MCLA-158 after screening hundreds
of&nbsp;bispecific antibodies for activity in more than 20 patient-derived colorectal cancer organoids. Organoids are cell cultures based on cancer cells from patients that mimic the physiology of tumor growth and depend on the presence of cancer
stem cells for their maintenance. In our pre-clinical studies, MCLA-158 was significantly more potent than an EGFR-targeting mAb, cetuximab, in inhibiting the growth of patient-derived colorectal cancer organoids. In our ex-vivo organoid studies,
MCLA-158 selectively blocked the ability of colorectal cancer organoids to regrow after serial passaging, suggesting that MCLA-158 has the potential to eliminate stem cells in vitro. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our pre-clinical studies MCLA-158 has been observed to be selectively more active in human tumor-derived organoids than in organoids derived from normal
human colon. The activity of MCLA-158 on the tumor organoid size was more than 100 times greater than on the normal colon organoids. In contrast, the activity of cetuximab was similar to the activity of MCLA-158 on normal colon organoids and 20 to
100 times less than the activity of MCLA-158 on tumor organoids. We observed this result on three additional normal colon organoids and four tumor organoids, three of which were derived from metastatic lesions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our pre-clinical studies to date and the expression pattern of Lgr5 and EGFR and their known roles
in tumor progression, we believe that MCLA-158 has the potential to improve the survival outcome of patients with metastatic colorectal cancer, non-small cell lung cancer, ovarian cancer and potentially other solid tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have received approval of CTAs in several European countries for MCLA-158 for the potential treatment of metastatic colorectal cancer, including patients
with the RAS-mutation, which represent a substantial unmet need. The first CTA was approved to initiate a Phase 1 clinical trial in Europe in January 2018. We filed an IND for MCLA-158 with the FDA in the first quarter of 2018, which received
authorization to proceed from the FDA in April 2018. In May 2018, we commenced an open-label, multicenter Phase 1 clinical trial of MCLA-158 in patients with solid tumors with an initial focus on metastatic colorectal cancer and expect emerging data
by the end of 2019. The Phase 1 trial consists of two parts: dose escalation and dose expansion. The dose escalation part is intended to determine the appropriate dose of MCLA-158. The dose expansion part is intended to evaluate the safety and
tolerability of the defined dose of MCLA-158 in patients with solid tumors. The trial is also designed to evaluate preliminary antitumor activity of single-agent MCLA-158. We expect to enroll approximately 120&nbsp;adult patients with colorectal
cancer and possibly other solid tumors in this trial. Recruitment in the trial is ongoing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Bispecific Antibody Candidates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MCLA-145 </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MCLA-145 is a Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;that is designed to bind to PD-L1 and a second immunomodulatory target. <FONT STYLE="white-space:nowrap">MCLA-145</FONT> is designed to enhance the activation of tumor specific tumor
infiltrating lymphocytes. MCLA-145, the first drug candidate co-developed under our global research and collaboration with Incyte Corporation, continues to progress in IND-enabling studies. We expect to provide further information on this program
upon acceptance of an IND for MCLA-145. We have full rights to develop and commercialize MCLA-145 in the United States and Incyte is responsible for its development and commercialization outside the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pre-Clinical Discovery Programs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to leverage
our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform to identify multiple additional antibody candidates and advance them to clinical development. Each of these antibody candidates are designed to bind to
targets believed to be useful in the treatment of cancer with an intention to establish efficacy and obtain information for submission to the FDA. Our current focus is on a number of immunotherapeutic targets and pathways that have demonstrated
promising tumor killing ability in early-stage clinical trials and scientific literature. Using our platform, we will continue to evaluate new targets and combinations to identify potential candidates with the highest immunotherapeutic potential and
select those candidates to be advanced into clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our business strategy, we intend to continue to seek research collaborations in order to derive further value from our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> platform and more fully exploit its potential. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incyte Corporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a collaboration and license agreement, or the Collaboration Agreement, with Incyte Corporation, or Incyte. Under the terms of the
Collaboration Agreement, we and Incyte have agreed to collaborate with respect to the research, discovery and development of bispecific antibodies utilizing our proprietary bispecific technology platform. The collaboration encompasses up to 11
independent programs, including some of our current preclinical immuno-oncology discovery programs. For one of the current preclinical programs, concerning MCLA-145, we retain the exclusive right to develop and commercialize products and product
candidates in the United States, while Incyte has the exclusive right to develop and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialize products and product candidates arising from such program outside the United States. For <FONT STYLE="white-space:nowrap">MCLA-145,</FONT> we and Incyte will conduct and share
equally the costs of mutually agreed global development activities and will be solely responsible for independent development activities in our respective territories. We have the option to co-fund development of products arising from one specified
program, and subject to certain conditions, to a second specified program, in each case exchange for a share of profits in the United States, as well as the right to participate in a specified proportion of detailing activities in the United States
for one of such programs. In addition, if MCLA-145 fails to complete IND-enabling toxicology studies successfully, we will be granted an additional option to co-fund development of a specified program other than MCLA-145 in exchange for a share of
profits in the United States. If we exercise our co-funding option for a program, we would be responsible for funding 35% of the associated future global development costs and, for certain of such programs, would be responsible for reimbursing
Incyte for certain development costs incurred prior to the option exercise. All products as to which we have exercised our option to co-fund development would be subject to joint development plans and overseen by a joint development committee, with
Incyte having final determination as to such plans in cases of dispute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For each program other than MCLA-145, where we have not elected to co-fund
development or where we do not have such a co-funding option, Incyte is solely responsible for all costs of global development and commercialization activities. We retain the rights to our bispecific technology platform as well as clinical and
pre-clinical candidates and future programs emerging from our platform that are outside the scope of the Collaboration Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2017, upon
the Collaboration Agreement becoming effective, Incyte made an upfront non-refundable payment to us of $120&nbsp;million for the rights granted under the Collaboration Agreement. For each program as to which we do not have commercialization or
co-development rights, we are eligible to receive up to $100&nbsp;million in future contingent development and regulatory milestones and up to $250&nbsp;million in commercialization milestones, as well as tiered royalties ranging from 6% to 10% of
global net sales. For each program as to which we have exercised our option to co-fund development, we are eligible to receive a 50% share of profits (or sustain 50% of any losses) in the United States and tiered royalties ranging from 6% to 10% of
net sales of products outside of the United States. If we opt to cease co-funding a program as to which we exercised our co-development option, then we will no longer receive a share of profits in the United States but will be eligible to receive
the same milestones from the co-funding termination date and the same tiered royalties described above with respect to non-co-developed programs and, depending on the stage at which we choose to cease co-funding development costs, additional
royalties ranging up to 4% of net sales in the United States. For MCLA-145, for which we retain all commercial rights in the United States, we and Incyte are each eligible to receive tiered royalties on net sales in the other&#146;s territory at
rates ranging from 6% to 10%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Collaboration Agreement will continue on a program-by-program basis until neither party has any royalty payment
obligations with respect to such program or, if earlier, the termination of the Collaboration Agreement or any program in accordance with the terms of the Collaboration Agreement. The Collaboration Agreement may be terminated in its entirety, or on
a program-by-program basis, by Incyte for convenience. The Collaboration Agreement may also be terminated by either party under certain other circumstances, including material breach, or on a program-by-program basis for patent challenge of patents
under the applicable program, in each case as set forth in the Collaboration Agreement. If the Collaboration Agreement is terminated in its entirety or with respect to one or more programs, all rights in the terminated programs revert to us, subject
to payment to Incyte of a reverse royalty of up to 4% on sales of future products, if we elect to pursue development and commercialization of products arising from the terminated programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Collaboration Agreement, we entered into a Share Subscription Agreement with Incyte, pursuant to which, in January 2017, we issued and
sold to Incyte 3,200,000 common shares for an aggregate purchase price of $80.0&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ONO Pharmaceutical </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, we entered into a strategic research and license agreement with ONO, under which we granted ONO an exclusive, worldwide, royalty-bearing license
to research, test, make, use and market a limited set of bispecific antibody candidates, if approved, based on our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, directed to two undisclosed targets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ONO paid us a non-refundable upfront fee of &#128;1.0&nbsp;million, and we are eligible to receive up to an aggregate of &#128;34.0&nbsp;million in milestone
payments upon achievement of specified research and clinical development milestones. To date, we have achieved three of the specified pre-clinical milestones under this research and license agreement and have received an aggregate of
&#128;1.8&nbsp;million in milestone payments. For products commercialized under this agreement, if any, we are also eligible to receive a mid-single digit royalty on net sales. For a designated period, which may include limited time periods
following termination of this agreement, in certain circumstances we and our affiliates are prohibited from researching, developing or commercializing bispecific antibodies against the undisclosed target combination that are the subject of this
agreement. ONO also provides funding for our research and development activities under an agreed-upon plan. This research and license agreement will expire after all milestone payments have been received and all related patent rights have expired,
unless terminated earlier. ONO has the right to terminate this agreement at any time for any reason, with or without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for
uncured material breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2018, we entered into a second contract research and license agreement with ONO. Pursuant to an exclusive
option granted to ONO in the prior agreement executed in April 2014, ONO exercised its option to enter into the March 2018 agreement. We granted ONO an exclusive, worldwide, royalty-bearing license, with the right to sublicense, research, test,
make, use and market bispecific antibody candidates based on our Biclonics<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B> technology platform against two undisclosed targets directed to a particular undisclosed target combination.
ONO identifies and selects the licensed bispecific antibodies for which it is responsible for conducting further non-clinical and clinical development activities for such licensed bispecific antibodies and pharmaceutical products containing such
antibodies, including manufacture and process development. ONO controls and has exclusive rights over the worldwide commercialization of any approved products, including worldwide supply, and is solely responsible for all costs and expenses related
to commercialization. ONO has agreed to fund our research and development activities and be responsible for the payment of all costs and expenses for its own research and development activities, which are set out in a mutually agreed upon research
plan. We retain all rights to use and commercialize any antibodies that are generated under the collaborative research program, excluding the up to five lead and/or selected antibodies against the targets ONO is pursuing, provided that the use and
commercialization is not with respect to the particular target combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ONO has agreed to pay an upfront non-refundable payment of &#128;700,000 for
the rights granted and we are also eligible to receive an aggregate of &#128;33.7&nbsp;million in milestone payments upon achievement of specified research and clinical development milestones. For products commercialized under the License Agreement,
if any, the Company is eligible to receive a mid-single digit royalty on net sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a designated period, which may include limited time periods
following termination of this agreement, in certain circumstances we are prohibited from researching, developing or commercializing bispecific antibodies against the undisclosed target combination that are the subject of this agreement. ONO also
provides funding for our research and development activities under an agreed-upon plan. This research and license agreement will expire after all milestone payments have been received and all related patent rights have expired, unless terminated
earlier. ONO has the right to terminate this agreement at any time for any reason, with or without cause. The licenses granted to ONO may convert to royalty-free, fully-paid, perpetual licenses if ONO terminates the agreement for uncured material
breach. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Simcere Pharmaceutical Group </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;8, 2018, we entered into an agreement with Simcere Pharmaceutical Group, or Simcere, granting Simcere an exclusive license to develop and
commercialize in China three bispecific antibodies utilizing our proprietary Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform in the area of immuno-oncology. We retain all rights outside of China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to lead research and discovery activities while Simcere has agreed to be responsible for the IND-enabling studies, clinical development,
regulatory filings and commercialization of these product candidates in China. We received an upfront payment, and are eligible to receive milestone payments contingent upon Simcere achieving certain specified development and commercial goals. We
are eligible to receive tiered royalty payments on sales of any products resulting from the collaboration in China from Simcere. Simcere is eligible to receive tiered royalty payments on sales outside of China from us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Biclonics<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform relies on third parties for biological materials. We rely on and expect to continue to rely on third-party contract manufacturing organizations, or CMOs, for the supply of
current good manufacturing practice-grade, or cGMP-grade, clinical trial materials and commercial quantities of our bispecific antibody candidates and products, if approved. We currently do not have any agreements for the commercial production of
bispecific product candidates, but we have contracted several biopharmaceutical CMOs for the clinical manufacturing of MCLA-128, MCLA-117, MCLA-158 and MCLA-145. We believe that the standardized
Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> manufacturing process can be transferred to additional CMOs and potential future co-development or co-commercialization collaborations or partnerships for the production of clinical
and commercial supplies of our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in the ordinary course of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sales and
Marketing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not yet defined our sales, marketing or product distribution strategy for MCLA-128, MCLA-117, MCLA-158 or any of our other
bispecific antibody candidates because our bispecific antibody candidates are still in pre-clinical or early-stage clinical development. Our commercial strategy may include the use of strategic partners, distributors, a contract sales force, or the
establishment of our own commercial and specialty sales force. We plan to further evaluate these alternatives as we approach approval for one of our bispecific antibody candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We compete directly with companies that
focus on immuno-oncology and companies dedicating their resources to cancer therapies. We also face competition from academic research institutions, governmental agencies and other various public and private research institutions. With the
proliferation of new drugs and therapies into oncology, we expect to face increasingly intense competition as new technologies become available. Any bispecific antibody candidates that we successfully develop and commercialize will compete with
existing therapies and new therapies that may become available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our competitors have significantly greater financial,
manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number
of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and
retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of all of our therapeutic bispecific antibody candidates,
if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from
government and other third-party payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products
that are safer, more effective, less expensive, more convenient or easier to administer, or have fewer or less severe effects than any products that we may develop. Our competitors also may obtain FDA, EMA or other regulatory approval for their
products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if our bispecific antibody candidates achieve marketing approval,
they may be priced at a significant premium over competitive products if any have been approved by then. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to currently marketed therapies,
there are also a number of products in late-stage clinical development to treat cancer, including other bispecific antibodies or similar molecules. Our closest competitors in this area include Affimed N.V., Zymeworks Inc., Genmab A/S, MacroGenics,
Inc., Merrimack Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc. and Xencor, Inc. The bispecific antibody candidates in development by competitors may provide efficacy, safety, dosing convenience and other benefits that are not provided by
currently marketed therapies. As a result, they may provide significant competition for any of our bispecific antibody candidates for which we obtain marketing approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We strive to protect and enhance
the proprietary technologies, inventions, and improvements that we believe are important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek
to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms
and bispecific antibody candidates that are important to the development and implementation of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December 12, 2018: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to our bispecific antibody candidate MCLA-128 consists of one PCT application, filed
on February&nbsp;27, 2015 which entered national phases in the United States, Europe and 17&nbsp;other foreign countries with an expected expiry not earlier than February&nbsp;27, 2035. Claims are directed to the MCLA-128 composition of matter and
methods of using MCLA-128 to treat subjects having or at risk of having an ErbB-2 and/or ErbB3 positive tumor. In addition, our portfolio includes four PCT patent application covering further methods of using MCLA-128, including in combination
therapies, to treat patients, three of which were filed on April&nbsp;3, 2018, and one filed on May&nbsp;17, 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to our bispecific antibody candidate MCLA-117 consists of a first PCT application,
filed on September&nbsp;27, 2013, which entered national phases in the United States, Europe and 14&nbsp;foreign countries with an expected expiry not earlier than September&nbsp;27, 2033. There is currently one pending US application, one issued EP
patent, 13 pending foreign applications, and four issued patents in several foreign jurisdictions. In addition, we filed a second PCT application related to MCLA-117 on July&nbsp;8, 2016, which has entered national phases in the United States,
Europe and 13 foreign countries with an expected expiry not earlier than July, 2036. There is currently one issued U.S. patent and one pending U.S. application, one issued and one pending EP applications, and 12 pending foreign applications. Claims
are related to the MCLA-117 composition of matter and methods of using MCLA-117 in the treatment or prevention of MDS, chronic myelogenous leukemia, or CML, or AML; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to our bispecific antibody candidate MCLA-158 consists of one PCT filed on
October&nbsp;21, 2016, which entered or will enter national phases in the United States, Europe and 14 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
other foreign countries with an expiry no earlier than October&nbsp;21, 2036. Claims are directed to the MCLA-158 composition of matter and methods of using MCLA-158 in the treatment or
prevention of various solid tumors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to our MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mouse consists
of three issued U.S. patents, eight pending U.S. applications, 12 issued foreign patents including one issued European patent that has been validated in many countries, and 11 pending foreign applications, all with an expected expiry not earlier
than June&nbsp;29, 2029. Claims are directed to a common light chain mouse and methods of producing antibodies by exposing the mouse to an antigen. For a discussion concerning opposition proceedings against this patent family see &#147;&#151;Legal
Proceedings&#148; and Note 11 to our Consolidated Financial Statements included in this prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to our Spleen to Screen<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>
technology consists of two issued U.S. patents, one pending U.S. application, one issued European Patent, and two issued foreign patents, with four foreign pending applications, all with an expected expiry not earlier than September&nbsp;16, 2035.
For a discussion concerning opposition proceedings against this patent family see &#147;&#151;Legal Proceedings&#148; and Note 11 to our Consolidated Financial Statements included in this prospectus. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our patent portfolio related to recombinant production of mixtures of antibodies, and includes claims directed to
host cells generating multi-specific antibodies consists of five issued U.S. patents, and four pending U.S. applications, two issued European patents, 15 issued foreign patents, and four pending foreign applications, all with an expected expiry not
earlier than July, 2022. For a discussion concerning opposition proceedings against this patent family see &#147;&#151;Legal Proceedings&#148; and Note 11 to our Consolidated Financial Statements included in this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to continue to expand our intellectual property estate by filing patent applications directed to dosage forms, methods of treatment and additional
compositions created or identified from our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform, improvements to our Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform and
ongoing development of our antibody candidates. Specifically, we seek patent protection in the United States and internationally for novel compositions of matter directed to aspects of the molecules, basic structures and processes for manufacturing
these molecules and the use of these molecules in a variety of therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our patent portfolio is intended to cover, but is not limited to, the
composition of matter of our bispecific antibody candidates, their methods of use, the Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> technology platform used to generate them, related technologies and/or other aspects of the
inventions that are important to our business, including our MeMo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> mouse, Spleen to Screen<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> technology, and recombinant host cells capable
of producing our antibody candidates. We also rely on trademarks, trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent
protection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our
proprietary positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success will depend on our ability to obtain and maintain patent and other proprietary protection for commercially important
technology, inventions and know-how related to our business, defend and enforce our patents, maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of our trade secrets and operate without infringing
the valid and enforceable patents and other proprietary rights of third parties. For important factors related to our proprietary technology, inventions, improvements, platforms and bispecific antibody candidates, please see the section entitled
&#147;Risk Factors&#151;Risks Related to Intellectual Property and Information Technology.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to extensive regulation. We expect our bispecific antibody candidates to be regulated as biologics. Biological products are subject to
regulation under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Public Health Service Act, or PHS Act, and other federal, state, local and foreign statutes and regulations. Both the FD&amp;C Act and the PHS Act and their corresponding regulations govern,
among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Biological Products Development Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
process required by the FDA before a biologic may be marketed in the United States generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, and pre-clinical
animal trials and applicable requirements for the humane use of laboratory animals and formulation studies in accordance with applicable regulations, including good laboratory practices, or GLPs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials according to the FDA&#146;s regulations,
commonly referred to as good clinical practice, or GCP, regulations and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product
for its intended use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity, and
potency from results of nonclinical testing and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological
product is produced to assess compliance with current Good Manufacturing Practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s identity, strength, quality and
purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval, or licensure, of the BLA. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before testing any biological bispecific antibody candidate in humans, the bispecific antibody candidate enters the pre-clinical testing stage. Pre-clinical
tests, also referred to as nonclinical trials, generally include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the bispecific antibody candidate. The
conduct of the pre-clinical tests must comply with federal regulations and requirements including GLPs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical trial sponsor must submit the
results of the pre-clinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some pre-clinical testing may continue even after
the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any
outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological bispecific antibody candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes
a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the
administration of the biological bispecific antibody candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control. Clinical trials are
conducted under protocols detailing, among other things, the objectives of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial
will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#146;s regulations
comprising the GCP requirements, including the requirement that all research subjects provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each
institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized
and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial
until completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1. The biological bispecific antibody candidate is initially introduced into healthy human subjects and
tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2. The biological bispecific antibody candidate is evaluated in a limited patient population to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an
expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are
used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and
clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected
adverse events, any findings from other trials, tests in laboratory animals or<I> in vitro</I> testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over
that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any
unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the information. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any
time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is
not being conducted in accordance with the IRB&#146;s requirements or if the biological bispecific antibody candidate has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of clinical
trials of FDA-regulated products, including biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of
investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the
results of these trials can be delayed until the new product or new indication being studied has been approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal trials and must also develop
additional information about the physical characteristics of the biological bispecific antibody candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the
risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of
consistently producing quality batches of the bispecific antibody candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally,
appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological bispecific antibody candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Review and Approval Processes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the
completion of clinical trials of a biological bispecific antibody candidate, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal
trials, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to
assess the safety and effectiveness of the biological bispecific antibody candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product
is safe and effective. A sponsor who is planning to submit a marketing application for a drug or biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit
an initial Pediatric Study Plan, or PSP, within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for
which orphan designation has been granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a user fee.
The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are
assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within 60 days following submission
of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of
submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is
accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable
purity profile, and whether the product is being manufactured in accordance with cGMP requirements to assure and preserve the product&#146;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological
products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application
should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also
will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological bispecific antibody candidate. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed
REMS; the FDA will not approve the BLA without a REMS, if required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will inspect the facilities at which the product is
manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more
clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the
submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret
data differently than the applicant interprets the same data. If the FDA decides not to approve the BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the BLA identified
by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant
might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise
be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product
distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase IV clinical trials, designed to further
assess a biological product&#146;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the performance goals agreed to by the FDA under the PDUFA is to review 90% of standard BLAs in 10 months from the filing date and 90% of priority BLAs
in six months from the filing date, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the
PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA
goal date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA
may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable
expectation that the cost of developing and marketing the drug for this type of disease or condition will be recovered from sales in the United States. Orphan product designation must be requested before submitting a BLA. After the FDA grants orphan
product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval
process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical
trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not
approve any other application to market the same drug for the same indication for a period of seven&nbsp;years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the
manufacturer with orphan exclusivity is unable to assure sufficient quantities of the approved orphan designated product. Competitors, however, may receive approval of different products for the indication for which the orphan product has
exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains
approval of the same biological product as defined by the FDA or if our bispecific antibody candidate is determined to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contained within the competitor&#146;s product for the same indication or disease. If a drug or biological product designated as an orphan product receives marketing approval for an indication
broader than what is designated, it may not be entitled to orphan product exclusivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new biological products that meet certain criteria.
Specifically, new biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition.
Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new biologic may request that the FDA designate the biologic as a Fast Track product at any time during the
clinical development of the product. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the
submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to
expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a
significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new biological product designated for
priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that
provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect
on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the
severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a biological product subject to accelerated approval perform adequate and
well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.
Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted in 2012, the FDA established a
Breakthrough Therapy Designation which is intended to expedite the development and review of products that treat serious or life-threatening diseases or conditions. A breakthrough therapy is defined as a drug that is intended, alone or in
combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more
clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the features of Fast Track designation, as well as more intensive FDA interaction and guidance. The
Breakthrough Therapy Designation is a distinct status from both accelerated approval and priority review, but these can also be granted to the same bispecific antibody candidate if the relevant criteria are met. The FDA must take certain actions,
such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. All requests for breakthrough therapy designation will be reviewed within 60 days of
receipt, and FDA will either grant or deny the request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fast Track designation, priority review, accelerated approval and breakthrough therapy designation do not
change the standards for approval but may expedite the development or approval process. Even if we receive one of these designations for our bispecific antibody candidates, the FDA may later decide that our bispecific antibody candidates no longer
meet the conditions for qualification. In addition, these designations may not provide us with a material commercial advantage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval
Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maintaining substantial compliance with applicable federal, state, and local statutes and regulations requires the expenditure of
substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to cGMP requirements. We will rely, and expect to continue to rely, on third parties for the
production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance
and maintenance of records and documentation. Other post-approval requirements applicable to biological products include record-keeping requirements, reporting of adverse effects, and reporting updated safety and efficacy information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also must comply with the FDA&#146;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on
promoting products for uses or in patient populations that are not described in the product&#146;s approved labeling (known as &#147;off-label use&#148;), industry-sponsored scientific and educational activities, and promotional activities involving
the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible
civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil
or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension
of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register
their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must continue to
expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of
changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Patent Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of the FDA approval of the use of our bispecific antibody candidates, some of our U.S. patents may be
eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five
years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval
date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application, except that the
review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved biological product is eligible for the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extension and the application for the extension must be submitted prior to the expiration of the patent and within a 60-day period from the date the product is first approved for commercial
marketing. The U.S. PTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for one of our currently owned patents to add patent
life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA; however, there can be no assurance that any such extension will be granted to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and Exclusivity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Biologics Price
Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has issued several guidance
documents outlining an approach to review and approve biosimilars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires that there be no clinically meaningful differences
between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or studies. Interchangeability requires that a product is biosimilar to
the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic
and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated
with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked
out by the FDA. For example, in January 2017 the FDA issued draft guidance outlining considerations for sponsors seeking to demonstrate interchangeability with a reference biologic. However, to date the FDA has not approved a BLA for an
interchangeable biological product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following
the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this
12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own pre-clinical data and data from adequate and
well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products
deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A biological
product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity
protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#147;Written Request&#148; for such a trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The BPCIA is complex and continues to be interpreted and implemented by the FDA. Certain aspects of the BPCIA, some of which may impact the BPCIA exclusivity
provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and meaning of the BPCIA remain subject to significant uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FDA Regulation of Companion Diagnostics </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect
that our bispecific antibody candidates may require use of an <I>in vitro</I> diagnostic to identify appropriate patient populations for our products. These diagnostics, often referred to as companion diagnostics,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are regulated as medical devices. In the United States, the FD&amp;C Act and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical
device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market
surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket
notification, also called 510(k) clearance, and premarket approval, or PMA approval. We expect that any companion diagnostic developed for our bispecific antibody candidates will utilize the PMA pathway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If use of a companion diagnostic is essential to safe and effective use of a drug or biologic product, then the FDA generally will require approval or
clearance of the diagnostic contemporaneously with the approval of the therapeutic product. On August&nbsp;6, 2014, the FDA issued a final guidance document addressing the development and approval process for &#147;<I>In Vitro</I> Companion
Diagnostic Devices.&#148; According to the guidance, for novel candidates such as our bispecific antibody candidates, a companion diagnostic device and its corresponding drug or biologic candidate should be approved or cleared contemporaneously by
the FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device,
unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device
under the FDA&#146;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be
studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on
the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. In July 2016, the FDA issued a draft guidance document intended to further assist sponsors of therapeutic products and sponsors of
<I>in vitro</I> companion diagnostic devices on issues related to co-development of these products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA generally requires companion diagnostics
intended to select the patients who will respond to cancer treatment to obtain approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic. The review of these <I>in vitro</I> companion diagnostics in conjunction with
the review of a cancer therapeutic involves coordination of review by the FDA&#146;s Center for Biologics Evaluation and Research and by the FDA&#146;s Center for Devices and Radiological Health. The PMA process, including the gathering of clinical
and pre-clinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#146;s
safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for certain devices must
generally include the results from extensive pre-clinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic,
the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. As part of the PMA review, the FDA will typically inspect the
manufacturer&#146;s facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an
approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to
secure final approval of the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include
post-approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter.
A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the
PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements,
conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination
based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and
indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#146;s manufacturing processes and those of its suppliers are required to
comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and
manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation Outside of the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical
trials and any commercial sales and distribution of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the
commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the
commencement of human clinical trials. In the European Union, for example, a CTA must be submitted to each country&#146;s national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is
approved in accordance with a country&#146;s requirements, clinical trial development may proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The requirements and process governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their
origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain regulatory approval of an investigational biological product under European Union regulatory systems, we
must submit a marketing authorization application. The application used to file the BLA in the United States is similar to that required in the European Union, with the exception of, among other things, country-specific document requirements. The
European Union also provides opportunities for market exclusivity. For example, in the European Union, upon receiving marketing authorization, new chemical entities generally receive eight years of data exclusivity and an additional two years of
market exclusivity. If granted, data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a generic application. During the additional two-year period of market exclusivity, a generic
marketing authorization can be submitted, and the innovator&#146;s data may be referenced, but no generic product can be marketed until the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expiration of the market exclusivity. However, there is no guarantee that a product will be considered by the European Union&#146;s regulatory authorities to be a new chemical entity, and
products may not qualify for data exclusivity. Products receiving orphan designation in the European Union can receive ten years of market exclusivity; during this period, no marketing authorization application may be accepted and no marketing
authorization may be granted for a similar medicinal product for the same indication. An orphan product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies. No extension to any supplementary
protection certificate can be granted on the basis of pediatric studies for orphan indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The criteria for designating an &#147;orphan medicinal
product&#148; in the European Union are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as orphan if (1)&nbsp;it is intended for the diagnosis, prevention or
treatment of a life-threatening or chronically debilitating condition; (2)&nbsp;either (a)&nbsp;such condition affects no more than five in 10,000 persons in the European Union when the application is made, or (b)&nbsp;the product, without the
benefits derived from orphan status, would not generate sufficient return in the European Union to justify investment; and (3)&nbsp;there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing
in the European Union, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as
reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan drug designation must be submitted before the
application for marketing authorization. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing
authorization is submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria
for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar product for the same indication at any time if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the second applicant can establish that its product, although similar, is safer, more effective or otherwise
clinically superior; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicant consents to a second orphan medicinal product application; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicant cannot supply enough orphan medicinal product. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of
clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have
their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other
things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to FDA
restrictions on marketing of pharmaceutical and biological products, other U.S. federal and state healthcare regulatory laws restrict business practices in the biopharmaceutical industry, which include, but are not limited to, state and federal
anti-kickback, false claims, data privacy and security, and physician payment and drug pricing transparency laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute
prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covertly, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any item or service reimbursable, in whole or in part, under
Medicare, Medicaid or other federal healthcare programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical
manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and
safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not meet the requirements of a statutory or regulatory
exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the
arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving
remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the intent standard under the
Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA
codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. The majority of states also have
anti-kickback laws, which establish similar prohibitions and in some cases may apply to items or services reimbursed by any third-party payor, including commercial insurers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal false claims and civil monetary penalties laws, including the civil False Claims Act, prohibit any person or entity from, among other things,
knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false
or fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim includes &#147;any request or demand&#148; for money or
property presented to the U.S. government. Actions under the civil False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the civil False Claims Act can
result in very significant monetary penalties and treble damages. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation
that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#146; marketing of products for unapproved (<I>e.g.</I>, off-label) uses. In
addition, the civil monetary penalties statute imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that
was not provided as claimed or is false or fraudulent. Many states also have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless
of the payor. Given the significant size of actual and potential settlements, it is expected that the government authorities will continue to devote substantial resources to investigating healthcare providers&#146; and manufacturers&#146; compliance
with applicable fraud and abuse laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal
criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or
stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or
fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, the ACA broadened the reach of certain criminal healthcare fraud statutes created under
HIPAA by amending the intent requirement such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare providers.
The ACA imposed, among other things, new annual reporting requirements through the Physician Payments Sunshine Act for covered manufacturers for certain payments and &#147;transfers of value&#148; provided to physicians and teaching hospitals, as
well as ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests
may result in civil monetary penalties of up to an aggregate of $150,000 per year and up to an aggregate of $1&nbsp;million per year for &#147;knowing failures.&#148; Covered manufacturers must submit reports by the 90th&nbsp;day of each subsequent
calendar year. In addition, certain states require implementation of compliance programs and compliance with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
government, impose restrictions on marketing practices, and/or tracking and reporting of pricing and marketing information as well as gifts, compensation and other remuneration or items of value provided to physicians and other healthcare
professionals and entities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also be subject to data privacy and security regulation by both the federal government and the states in which we
conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, including the Final HIPAA Omnibus Rule published on January&nbsp;25, 2013,
impose specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates. Among other things, HITECH made HIPAA&#146;s security standards
directly applicable to &#147;business associates,&#148; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf
of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for
damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#146;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in
certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties,
including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion
from participation in federal and state healthcare programs and individual imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that any of our bispecific antibody candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and
regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or other transfers of value
to healthcare professionals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Privacy and Data Protection Laws in Europe </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to European laws relating to our and our suppliers&#146;, partners&#146; and subcontractors&#146; (where they act as processors) collection,
control, processing and other use of personal data (i.e., any data relating to an identifiable living individual, whether that individual can be identified directly or indirectly). We are subject to the supervision of local data protection
authorities in those jurisdictions where we are established, and where we process personal data in the context of the activities of that establishment (e.g., undertaking clinical trials). We and our suppliers, partners and subcontractors process
personal data including in relation to our employees, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees of customers, clinical trial patients, healthcare professionals and employees of suppliers including health and medical information. The data privacy regime in the EU includes the
General Data Protection Regulation, or GDPR, and national laws and regulations implementing or supplementing it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The GDPR requires that personal data is
only collected for specified, explicit and legal purposes as set out in the GDPR or local laws, and the data may then only be processed in a manner compatible with those purposes. The personal data collected and processed must be adequate, relevant
and not excessive in relation to the purposes for which it is collected and processed, it must be held securely, not transferred outside of the European Economic Area, or EEA (unless certain steps are taken to ensure an adequate level of
protection), and must not be retained for longer than necessary for the purposes for which it was collected. In addition, the GDPR requires companies processing personal data to take certain organizational steps to ensure that they have adequate
records, policies, security, training and governance frameworks in place to ensure, and to be able to demonstrate, protection. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal
basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, requires the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale,
introduces mandatory data breach notification throughout the EU and imposes additional obligations on us when we are contracting with service providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, to the extent a company processes, controls or otherwise uses &#147;special category&#148; personal data (including patients&#146; health or
medical information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances and the manner in which a company is legally permitted to process that data. Finally, the GDPR provides a broad right
for EU member states to create supplemental national laws which may result in divergence across Europe making it harder to maintain a consistent operating model or standard operating procedures. Such laws, for example, may relate to the processing
of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to EU laws on personal data export, as we may transfer personal data from the EU to other jurisdictions which are not considered by the
European Commission to offer &#147;adequate&#148; protection of personal data. Such transfers need to be legitimized by a valid transfer mechanism under the GDPR. There is currently ongoing litigation challenging two of the more commonly used
transfer mechanisms, the EU model clauses and the U.S. Privacy Shield, and all adequacy decisions may be subject to review by the European Commission at any time. It is uncertain whether these mechanisms will be invalidated by the EU courts or
following review. Invalidation of any mechanism on which we rely could require operational changes, including finding alternative bases for the compliant transfer of personal data from the EEA to the United States, and increased costs and may lead
to governmental enforcement actions, litigation, fines and penalties or adverse publicity that could have an adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are
costs and administrative burdens associated with compliance with the GDPR and the resultant changes in the EU and EEA member states&#146; national laws. Any failure or perceived failure to comply with global privacy laws carries with it the risk of
significant penalties and sanctions of up to &#128;20&nbsp;million or 4% of global turnover. These laws or new interpretations, enactments or supplementary forms of these laws, could create liability for us, could impose additional operational
requirements on our business, could affect the manner in which we use and transmit patient information and could increase our cost of doing business. Claims of violations of privacy rights or contractual breaches, even if we are not found liable,
could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Coverage and Reimbursement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological products for which we obtain regulatory
approval. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to
cover a significant portion of the cost of our products. Sales of any products for which we receive regulatory approval for commercial sale will therefore depend, in part, on the availability of coverage and adequate reimbursement from third-party
payors. Third-party payors include government authorities, managed care plans, private health insurers and other organizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the
process for determining whether a third-party payor will provide coverage for a pharmaceutical or biological product typically is separate from the process for setting the price of such product or for establishing the reimbursement rate that the
payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular
indication. A decision by a third-party payor not to cover our bispecific antibody candidates could reduce physician utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial
condition. Moreover, a third-party payor&#146;s decision to provide coverage for a pharmaceutical or biological product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to
enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for new products can differ significantly from payor to payor. One third-party
payor&#146;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the
coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, governments influence the price of products through their pricing and reimbursement rules and control of national health care systems
that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed to by the government. To obtain
reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to
fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription products, has become very intense. As a result, increasingly high barriers are being
erected to the entry of new products. In addition, in some countries, cross border imports from low-priced markets exert a commercial pressure on pricing within a country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of pharmaceutical or biological products
have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of pharmaceutical or biological products,
medical devices and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA
approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Healthcare Reform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to
control costs by limiting coverage and the amount of reimbursement for particular medical products. For example, in March 2010, the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under
the Medicaid Drug Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid
Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers&#146;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outpatient drugs coverage under Medicare Part D; subjected drug manufacturers to new annual fees based on pharmaceutical companies&#146; share of sales to federal healthcare programs; and created
a new Patient Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The current presidential administration and U.S. Congress will
likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. However, the ultimate content, timing or effect of any healthcare reform legislation on the U.S. healthcare industry is unclear. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare
funding, more rigorous coverage criteria and lower reimbursement, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other
government-funded programs may result in a similar reduction in payments from private payors. Moreover, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which
have resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government
program reimbursement methodologies for pharmaceutical and biological products. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from
other countries and bulk purchasing. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, on August&nbsp;2, 2011, the Budget Control Act of 2011 was enacted, which, among other things, included aggregate reductions of Medicare
payments to providers of 2%&nbsp;per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute will stay in effect through 2027 unless additional Congressional action is taken. On
January&nbsp;2, 2013, the American Taxpayer Relief Act was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the
statute of limitations period for the government to recover overpayments to providers from three to five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that additional state and
federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once
approved or additional pricing pressures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October 31, 2018, we had 96 employees, 48 of whom hold M.D. or Ph.D. degrees. Seventy-four of our employees work in research and development and 22 work
in management and administrative areas. All of our employees are located in the Netherlands except for 18 employees located in the United States. None of our employees is subject to a collective bargaining agreement or represented by a trade or
labor union. We are in the process of establishing a works council for our employees, which we expect will go into effect on January 1, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We lease approximately 12,320 square meters
of office and laboratory space in Utrecht, the Netherlands. This facility serves as our corporate headquarters and central laboratory facility. The leases for this space expire on October&nbsp;31, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2014, Regeneron Pharmaceuticals, Inc., or Regeneron, filed a complaint in the United States District Court for the Southern District of New
York alleging that we were infringing one or more claims in Regeneron&#146;s U.S. Patent No.&nbsp;8,502,018, entitled &#147;Methods of Modifying Eukaryotic Cells&#148;, or the &#145;018 patent. In 2015, the trial court entered judgments finding that
we do not infringe the claims of the &#145;018 patent, that the patent is invalid, and that the patent was procured through inequitable conduct and is unenforceable. On July&nbsp;27, 2017 the U.S. Court of Appeals for the Federal Circuit affirmed
the trial court&#146;s conclusion that Regeneron engaged in inequitable conduct before the United States Patent and Trademark Office while prosecuting the &#145;018 patent and affirmed that the &#145;018 patent is unenforceable. On December&nbsp;26,
2017, the Federal Circuit denied Regeneron&#146;s petition for rehearing and rehearing en banc seeking a review of that decision and on October&nbsp;1, 2018, the Supreme Court of the United States denied Regeneron&#146;s petition for certiorari,
rendering the case finally resolved in our favor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 26, 2018, the trial court granted our motion for attorneys&#146; fees, expert fees, and costs
associated with our defense of the above litigation, and ordered the parties to address the amount of the award. We provided a detailed explanation of our attorneys&#146; fees, expert fees, and costs of such award, which Regeneron responded to
seeking a reduction of the amount. The matter was fully briefed as of May 18, 2018, and the court issued an Order on June 25, 2018, which published on July 10, 2018, granting our motion for $8,332,453.46 in attorneys&#146; fees, $465,390.34 in
expert fees, and $1,717,100.69 in litigation expenses and costs, along with pre- and post-judgment interest. Regeneron appealed the decision awarding attorneys&#146; fees to us to the Federal Circuit, filing its opening brief on November 7, 2018.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 11, 2014, Regeneron served a writ in the Netherlands alleging that we were infringing one or more claims in their European patent EP 1 360 287
B1. We had opposed that patent in June 2014. On September 17, 2014, Regeneron&#146;s patent EP 1 360 287 B1 was revoked in its entirety by the European Opposition Division of the European Patent Office, or the EPO. In Europe, an appeal hearing
occurred in October and November 2015 at the Technical Board of Appeal for the EPO at which time the patent was reinstated to Regeneron with amended claims. On October 2, 2017, we filed an appeal with the Technical Board of Appeal for the EPO to
address whether the patent having claims amended during the course of opposition complies with Art. 84 EPC, Art. 123(2) EPC and Rule 80 EPC. On May 25, 2018, at Regeneron&#146;s request, a hearing before the Technical Board of Appeals for the EPO
was scheduled for September 13, 2018, to address whether the description of EP 1 360 287 B1 patent having claims amended during the course of opposition complies with Art. 84 EPC, Art. 123(2) EPC and Rule 80 EPC. The Technical Board of Appeals
provided preliminary views on the matter on August 23, 2018, after which our appeal filed on October 2, 2017 was withdrawn on September 5, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regeneron also previously raised opposition proceedings against certain of our patents in jurisdictions including Europe, Japan and Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2018, we signed a global settlement and cross-license agreement with Regeneron, where the parties have agreed to end all pending
litigation and opposition proceedings pertaining to certain of our and Regeneron&#146;s respective antibody generation technologies. Regeneron also purchased 600,000 of our common shares at a price of $25 per share for total aggregate proceeds to us
of $15&nbsp;million. Under the terms of the settlement, Regeneron has agreed to withdraw its appeal of the decision awarding attorneys&#146; fees to us as a result of the U.S. District Court litigation described above, and we have agreed to dismiss
our fee award. In addition, Regeneron has agreed to dismiss its stayed case in the Netherlands asserting the EP&nbsp;1&nbsp;360&nbsp;287 B1 patent, and both parties have agreed to withdraw all pending oppositions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2018, Regeneron and an unnamed third party filed notices of opposition against our EP 2604625 patent entitled &#147;Generation of Binding
Molecules,&#148; in the EPO. The notices asserted, as applicable, added subject matter, lack of novelty, lack of inventive step, and insufficiency. Regeneron will no longer be pursuing this opposition pursuant to the December&nbsp;20, 2018
settlement. On August&nbsp;20, 2018, we timely responded to these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
submissions, with proceedings to be ongoing. As this opposition proceeding continues, we cannot assure you that we will ultimately prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in various other claims and legal proceedings relating to claims arising out of our operations. We are not currently a
party to any other material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_17"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Senior Management and Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table presents information about our senior management and board of directors, including their ages as of the date of this prospectus: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Position</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Senior Management</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lex Bakker, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Development Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Crowley</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John de Kruif</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Technology Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Hui Liu, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ton Logtenberg, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President &amp; Chief Executive Officer and President of Merus US, Inc.</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Peter B. Silverman</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General Counsel, and Chief Intellectual Property Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">L. Andres Sirulnik, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mark Throsby, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B></B><B><I>Board of Directors</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Ton Logtenberg, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President &amp; Chief Executive Officer (Executive Director)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Russell G. Greig, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Board (Non-Executive Director)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Mark Iwicki</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member (Non-Executive Director)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Len Kanavy</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member (Non-Executive Director)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John de Koning, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member (Non-Executive Director)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Anand Mehra, M.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member (Non-Executive Director)</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Gregory Perry</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member (Non-Executive Director)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the current business addresses for our board of directors is c/o Merus N.V., Yalelaan&nbsp;62,
3584 CM Utrecht, the Netherlands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the members of our board of directors or senior management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Senior Management </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Alexander (&#147;Lex&#148;)
Berthold Hendrik Bakker, Ph.D</I></B><B>.</B> has served as our Chief Development Officer since October 2010. His responsibilities include strategic scientific leadership, management of preclinical and clinical development and manufacturing,
business development support, external collaboration and partnership management. Prior to joining Merus, Dr.&nbsp;Bakker directed preclinical and clinical development at Crucell N.V., a biotechnology company. Mr.&nbsp;Bakker holds a Ph.D in Tumor
Immunology from the University of Nijmegen and was a postdoctoral fellow at the DNAX Research Institute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>John Crowley</I></B> has served as our
Chief Financial Officer since November 2016. His responsibilities include accounting, financial planning and analysis, tax, treasury and investor relations. From September 2013 to November 2016, he served as Corporate Senior Vice President,
Corporate Controller and Chief Accounting Officer of Charles River Laboratories, Inc., a pre-clinical and clinical service provider for the pharmaceutical industry. Prior to Charles River Laboratories, he was the Vice President, Corporate Controller
and Chief Accounting Officer of Ironwood Pharmaceuticals, Inc. from March 2012 to September 2013, and held senior corporate finance positions at Vertex Pharmaceuticals, Inc. from April 2010 to March 2012, and Sunovian Pharmaceuticals, Inc. from
April 2008 to April 2010. Mr.&nbsp;Crowley holds B.S. degrees in both economics and accountancy from Babson College and is a Certified Public Accountant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>John de Kruif, Ph.D.</I></B> has served as our Chief Technology Officer since January 2013 and
previously served as our Chief Scientific Officer from April 2007 to January 2013. His responsibilities include management of antibody discovery, antibody engineering, external collaborations, partnerships management and operational activities.
Before joining Merus, from October 2000 to October 2006, he served as a director of antibody discovery for Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology. Dr.&nbsp;de Kruif holds a PhD in Antibody
Engineering from Utrecht University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hui Liu, Ph.D.</I></B> has served as our Chief Business Officer since December 2015, since September 2018. His
responsibilities include all aspects of business development, including in- and out- licensing, acquisitions and alliance management, and expansion of Merus in the United States. Prior to joining Merus, Dr.&nbsp;Liu served as Vice President and
Global Head, Business Development&nbsp;&amp; Licensing, Oncology at Novartis AG, a pharmaceutical company, from 2013 to 2015, and as Vice President and Global Head, Business Development&nbsp;&amp; Licensing, Vaccines&nbsp;&amp; Diagnostics, from
2009 to 2012. Prior to Novartis, Dr.&nbsp;Liu held various management positions at Pfizer, Inc., a pharmaceutical company, from 2004 to 2009 and at Pfizer, Inc. and its predecessor company Warner-Lambert from 1997 to 2001. From 2001 to 2004,
Dr.&nbsp;Liu was an investment banker at Goldman Sachs and Citigroup. Dr.&nbsp;Liu holds a Ph.D. in molecular biology and an M.B.A. in finance from the University of Michigan and a B.S. in biology from Peking University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ton Logtenberg, Ph.D.</I></B> has served as our President &amp; Chief Executive Officer and an executive board member since co-founding our company in
June 2003. Dr. Logtenberg also serves as President of our subsidiary, Merus US, Inc. Prior to joining Merus, Dr.&nbsp;Logtenberg co-founded Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology, and served
as its executive vice president and chief scientific officer from July 2000 until November 2003. Dr.&nbsp;Logtenberg has served as a member of the board of directors of the Jenner Foundation since 2008 and a member of the board of directors of
Utrecht Science Park since November 2014. Dr.&nbsp;Logtenberg holds a Ph.D. in medical biology from Utrecht University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Peter B. Silverman,
J.D.</I></B> has served as our General Counsel since February 2018 and our Chief Intellectual Property Officer since February 2017. His responsibilities include management of the company&#146;s legal strategy and overseeing all aspects of the
company&#146;s legal operations. Prior to joining Merus, Mr.&nbsp;Silverman was a Partner at Kirkland&nbsp;&amp; Ellis LLP, where he represented numerous life sciences companies concerning an array of legal matters.&nbsp;Mr.&nbsp;Silverman also
served as judicial law clerk to U.S. District Court Judge Anne E. Thompson of the District of New Jersey.&nbsp;He holds a J.D. from Fordham University School of Law. He is admitted to practice law in New York. Mr.&nbsp;Silverman also holds a B.A. in
biology from the University of Rochester. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Andres Sirulnik, M.D., Ph.D.</I></B> has served as our Chief Medical Officer since October 2016. His
responsibilities include clinical strategy and development. Prior to joining Merus, Dr.&nbsp;Sirulnik was at Novartis Pharmaceuticals from 2008 to 2016, most recently serving as Vice President &#150; Senior Global Clinical Program Head and Research
Physician in Oncology Clinical Development. From 2003 to 2008, Dr.&nbsp;Sirulnik was an attending physician in the leukemia program at Dana Farber Cancer Institute and Instructor in Medicine at Harvard Medical School where he focused his research
and clinical work in rare hematologic malignancies. Dr.&nbsp;Sirulnik received his medical degree from the University of Buenos Aires, Argentina, and his Ph.D. in medicine and molecular biology at the University of Cambridge, England. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mark Throsby, Ph.D.</I></B> has served as our Chief Scientific Officer since January 2013 and previously served as our Chief Operating Officer from
October 2008 to January 2013. His responsibilities include strategic scientific leadership, management of discovery, pre-clinical research and translational research, business development support, external collaborations and partnerships management.
Before joining Merus, from October 2000 to October 2008, he served as a senior scientist and then as director of antibody discovery for Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology. Dr.&nbsp;Throsby
holds a Ph.D. in neuro-immunology from Monash University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ton Logtenberg, Ph.D.</I></B> has served as an executive director of our company since founding our company in June 2003. See &#147;&#151;Senior
Management.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Russell G. Greig</I></B>, <B><I>Ph.D. </I></B>has served as the Chairman of our board of directors and been a non-executive
member of our board of directors since July 2018. Dr.&nbsp;Greig worked at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline&#146;s corporate venture group. Prior to joining SR One, he served as President of
GlaxoSmithKline&#146;s Pharmaceuticals International from 2003 to 2008 as well as on the GlaxoSmithKline corporate executive team. Currently, Dr.&nbsp;Greig serves as Chairman of: AM&nbsp;Pharma and MedEye Solutions in the Netherlands, eTheRNA in
Belgium and Sanifit in Spain. He was previously Chairman of Ablynx in Belgium (acquired by Sanofi, France), Isconova in Sweden (acquired by Novavax, United States), Novagali in France (acquired by Santen, Japan), Syntaxin in the United Kingdom
(acquired by Ipsen, France) and Bionor in Norway, as well as board member of TiGenix in Belgium (acquired by Takeda, Japan), Oryzon in Spain and Onxeo Pharma (previously BioAlliance Pharma) in France, and a venture partner at Kurma Life Sciences
(Paris, France). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mark Iwicki </I></B>has been a non-executive member of our board of directors since June 2015. From June 2015 until July 2018,
Mr.&nbsp;Iwicki served as the Chairman of our board of directors. Mr.&nbsp;Iwicki is the chief executive officer and chairman of the board of directors of Kala Pharmaceuticals, Inc. and serves as a member of the boards of directors of Aimmune
Therapeutics, Inc., Nimbus Therapeutics, Oxeia Biopharmaceuticals and Akero Therapeutics, Inc. In addition, Mr.&nbsp;Iwicki has served on the board of the Wellesley Youth Hockey Association. Mr.&nbsp;Iwicki served as president and chief executive
officer and a member of the board of directors of Civitas Therapeutics, Inc. from January 2014 until its acquisition by Acorda Therapeutics, Inc. in October 2014. From December 2012 to January 2014, Mr.&nbsp;Iwicki served as president and chief
executive officer and director at Blend Therapeutics, Inc. From 2007 to June 2012, Mr.&nbsp;Iwicki was president and chief executive officer and director of Sunovion Pharmaceuticals, Inc., formerly Sepracor, Inc. Mr.&nbsp;Iwicki holds an M.B.A. from
Loyola University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Len Kanavy</I></B> has been a non-executive member of our board of directors since July 2018. Mr.&nbsp;Kanavy most recently
served as Senior Vice President, Commercial Business Operations at Genentech where he was responsible for strategic decisions of the U.S. commercial business including product launches, valuation of business development opportunities, clinical
development plan options and pricing. He was a Board Member of the Genentech Access to Care Foundation. Prior to joining Genentech, Mr.&nbsp;Kanavy was Vice President, Commercial Operations at Novartis Pharmaceuticals, where he led teams in business
analytics, strategy, and product launches. He currently serves on the board of privately held KMK Consulting. Mr.&nbsp;Kanavy holds a B.S. in Business Administration and an MBA with a specialization in Finance from the University of Scranton. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>John de Koning, Ph.D.</I></B> was nominated to serve on our board of directors by Co&ouml;peratief LSP&nbsp;IV&nbsp;U.A., one of our shareholders, and
has been a non-executive member of our board of directors since&nbsp;January&nbsp;2010. Dr.&nbsp;De&nbsp;Koning has been a partner at LSP (Life Sciences Partners) since January 2006. Dr.&nbsp;De Koning currently serves on the boards of the private
companies GTX medical, eTheRNA and Aelin Therapeutics. Previously, he served on the supervisory boards of BMEYE (acquired by Edwards Lifesciences), Prosensa (acquired by BioMarin) and Skyline Diagnostics, and as a non-executive director on the
boards of argenx, Pronota (acquired by MyCartis) and Innovative Biosensors Inc. Dr.&nbsp;De Koning holds an M.Sc. in medical biology from Utrecht University and a Ph.D. in oncology from the Erasmus University Rotterdam. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anand Mehra, M.D.</I></B> was nominated to serve on our board of directors by Sofinnova Venture Partners IX, L.P., one of our shareholders, and has been
a non-executive member of our board of directors since August 2015. Dr.&nbsp;Mehra has been with Sofinnova Ventures since 2007, most recently holding the position of a general partner where he focuses on working with entrepreneurs to build drug
development companies. He has led the firm&#146;s investments in Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals, Inc., Aclaris Therapeutics, Inc., and Prothena Corporation PLC. He currently serves as a member of the boards of
directors of Spark </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Therapeutics, Inc., Aclaris Therapeutics, Inc. and Marinus Pharmaceuticals Inc. as well as on the boards of several private companies. Dr.&nbsp;Mehra holds his M.D. from Columbia
University&#146;s College of Physicians and Surgeons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gregory D. Perry</I></B> has been a non-executive member of our board of directors since May
2016 and Vice Chairman of our board of directors since August 2018. Mr. Perry is the Chief Financial Officer at Finch Therapeutics Group and serves as a member of the Board of Directors of Kala Pharmaceuticals. Mr.&nbsp;Perry served as Chief
Financial and Administrative Officer of Novelion Therapeutics Inc. or Novelion, a public company, from November 2016 to December 2017. Prior to this, Mr.&nbsp;Perry was Chief Financial Officer of Aegerion Pharmaceuticals Inc, a public company, from
July 2015 until its merger with Novelion in November 2016. Prior to that, he served as Chief Financial and Business Officer of Eleven Biotherapeutics, Inc., a public company, from January 2014 to June 2015. Before joining Eleven Biotherapeutics,
Mr.&nbsp;Perry served as the Interim Chief Financial Officer of InVivo Therapeutics, a public company, from September 2013 to December 2013, and prior to that he served as the Senior Vice President and Chief Financial Officer of ImmunoGen, Inc., a
public company, from 2009 until he was promoted in 2011 to Executive Vice President and Chief Financial Officer, a role he held until 2013. Before that, he was the Chief Financial Officer of Elixir Pharmaceuticals. Mr.&nbsp;Perry previously was
Senior Vice President and Chief Financial Officer of Transkaryotic Therapies. He has also held various financial leadership roles within PerkinElmer Inc., Domantis Ltd., Honeywell and General Electric. Since February 2018, Mr.&nbsp;Perry has served
on the Board of Directors of Kala Pharmaceuticals, including as Chair of its Audit Committee. From December 2011 to February 2016, Mr.&nbsp;Perry served on the Board of Directors of Ocata Therapeutics (a public biotechnology company), including as
Chair of its Audit Committee and a member of its Compensation Committee, until it was acquired by Astellas Pharma Inc. Mr.&nbsp;Perry received a B.A. in Economics and Political Science from Amherst College. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Governance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Composition
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors is comprised of seven members. Each board member is elected for a term of up to four years. A non-executive board member
may be re-appointed for up to two subsequent terms. Board members must retire periodically in accordance with a rotation plan. Our board members do not have a retirement age requirement under our articles of association. Our board members are
elected, or re-appointed as the case may be, by our general meeting of shareholders in accordance with our articles of association to serve until their successors are duly elected and qualified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expiration of the current terms of the members of our Board of Directors and the period each member has served in that term are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Current<BR>Term&nbsp;Began</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Current<BR>Term&nbsp;Expires</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Iwicki</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell G. Greig</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Len Kanavy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Koning, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anand Mehra, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Perry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">* Ton Logtenberg does not have a fixed expiration date for his current term of office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or understanding between us and any of the members of our board of directors providing for benefits upon termination of their
service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Committees of the Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has established an Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee, which operate pursuant to
written charters adopted by our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Audit Committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee, which consists of Gregory Perry, Anand Mehra and John de Koning, assists our board of directors in overseeing our accounting and financial
reporting processes and the audits of our financial statements. Mr.&nbsp;Perry serves as Chairman of the committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee&#146;s
responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending the appointment of the independent auditor to the general meeting of shareholders;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of
preparing or issuing an audit report or performing other audit services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pre-approving the audit services and non-audit services to be provided by our independent auditor before the
auditor is engaged to render such services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the independent auditor&#146;s qualifications, performance and independence, and presenting its
conclusions to the board on at least an annual basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with the board and the independent auditor our financial statements and our financial
reporting process; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approving or ratifying any related person transaction (as defined in our related person transaction policy) in
accordance with our related person transaction policy. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audit committee meets as often as one or more members of the audit committee
deem necessary, but in any event, meets at least four times per year. The audit committee meets at least once per year with our independent accountant, without our management being present. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation
committee, which consists of Mark Iwicki, Len Kanavy and Gregory Perry, assists our board of directors in determining management compensation. Mr.&nbsp;Iwicki serves as Chairman of the committee. The compensation committee prepares a proposal for
the board concerning the compensation of each member of our management to be proposed for adoption by the general meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
compensation committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, reviewing and proposing policies relevant to management compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating each member of management&#146;s performance in light of such policies and reporting to the board;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analyzing the possible outcomes of the variable remuneration components and how they may affect the remuneration
of management; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending any equity long-term incentive component of each member of management&#146;s compensation in line
with the remuneration policy and reviewing our management compensation and benefits policies generally; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing risks arising from our compensation policies and practices. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Nomination and Corporate Governance Committee </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nomination and corporate governance committee, which consists of Russell Greig, Mark Iwicki and John de Koning, assists our board of directors in
identifying individuals qualified to become members of our board and part of our management consistent with criteria established by our board and in developing our corporate governance principles. Mr.&nbsp;Greig serves as Chairman of the nomination
and corporate governance committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nomination and corporate governance committee&#146;s responsibilities include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">drawing up selection criteria and appointment procedures for board members and management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and evaluating the size and composition of our board and management and making a proposal for a
composition profile of the board at least annually; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending nominees for election to our board and its corresponding committees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessing the functioning of individual members of the board and management and reporting the results of such
assessment to the board; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to the board our rules governing the board, reviewing and reassessing the adequacy of
such rules governing the board and recommending any proposed changes to the board. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer. As a result, in
accordance with the rules of the Nasdaq Stock Market LLC, we comply with Dutch governance requirements and certain exemptions thereunder rather than complying with Nasdaq corporate governance standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the Nasdaq listing rules with which we do not comply: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nasdaq Listing Rule 5620(c): In accordance with Dutch law and generally accepted business practices, our articles
of association do not provide quorum requirements generally applicable to general meetings of shareholders in the United States. To this extent, our practice varies from the requirement of Nasdaq Listing Rule 5620(c), which requires an issuer to
provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nasdaq Listing Rule 5620(b): Although we must provide shareholders with an agenda and other relevant documents
for the general meeting of shareholders, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands, thus our practice varies from the
requirement of Nasdaq Listing Rule&nbsp;5620(b). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nasdaq Listing Rule 5605(d) and (e): As permitted by the listing requirements of Nasdaq, we have also opted out
of the requirements of Nasdaq Listing Rule 5605(d), which requires an issuer to have a compensation committee that consists entirely of independent directors, and Nasdaq Listing Rule&nbsp;5605(e), which requires an issuer to have independent
director oversight of director nominations. Although we have chosen not to comply with Nasdaq Rule 5605(d) regarding the independence of our compensation committee, all of the current members of our compensation committee meet the heightened
independence requirements under this rule. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nasdaq Listing Rule 5635: We have opted out of shareholder approval requirements for the issuance of securities
in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this
extent, our practice varies from the requirements of Nasdaq Listing Rule 5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Code of Business Conduct and Ethics </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Business Conduct and Ethics, or the Code of Conduct, that is applicable to all of our employees, management, including our principal
executive officer, principal financial officer and principal accounting officer, board of directors, consultants, and others temporarily assigned to perform work or services for us. The Code of Conduct is available on our website at
<I>www.merus.nl</I>. Our board of directors is responsible for administering the Code of Conduct. The board of directors is allowed to amend, alter or terminate the Code of Conduct. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Senior Management Remuneration
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the approximate remuneration paid during our 2017 fiscal year to our senior management. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name and Principal Position</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Awards(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lex B.H. Bakker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">266,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">85,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">206,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">35,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">593,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President, Chief Development Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Crowley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">320,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">120,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">874,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Kruif</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">237,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">76,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">152,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">37,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">504,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Senior Vice President, Chief Technology Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hui Liu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">305,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">114,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,504,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Business Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">432,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">337,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,675,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">51,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5,497,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President &amp; Chief Executive Officer and President of Merus US</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter B. Silverman(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">238,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">86,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">437,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">761,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, General Counsel and Chief IP Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">L. Andres Sirulnik</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">389,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">147,756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,144,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,681,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Throsby</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">305,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">114,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,270,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">35,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,726,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Scientific Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount shown reflects bonuses awarded for achievement of performance goals in our 2017 fiscal year.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount shown represents the grant date fair value of option awards and restricted stock units, or RSUs, granted
in 2017. Option awards are measured using the Hull&nbsp;&amp; White option pricing model. For a description of the assumptions used in valuing these awards, see note 14 to our financial statements incorporated by reference in this prospectus.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount shown represents pension, retirement or other similar contributions made by us. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Silverman&#146;s salary was prorated to reflect the start of his employment with the Company on
February&nbsp;15, 2017. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Below is a brief description of the compensation plans and arrangements in which our senior management
participate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Base Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We pay our senior management a base salary to compensate them for the satisfactory performance of services rendered to our company. Base salary is intended to
provide a fixed component of compensation reflecting the senior management&#146;s level of responsibility and performance. Our senior management&#146;s base salaries for 2017 are set forth in the table above entitled &#147;Senior Management
Remuneration.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Short-Term Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
maintain a short-term incentive plan pursuant to which we may grant our employees, including our senior management, incentive cash bonuses based upon corporate and/or individual performance. We generally pay annual cash bonuses based upon the
achievement of set financial targets, non-financial and personal goals and company milestones for the period. Achievement of the targets is measured following year-end and the actual bonus amounts paid to our senior management, including our
executive officers, are determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The corporate objectives set for 2017 pursuant to our short-term incentive plan accounted
for 75% of the senior management&#146;s bonus opportunity and were generally related to clinical developments, intellectual property, business developments and funding initiatives. Individual objectives are established annually for each member of
the senior management and, in 2017, accounted for 25% of the senior management&#146;s bonus opportunity. The actual bonus amounts paid to our senior management for 2017 are set forth in the table above entitled &#147;Senior Management
Remuneration&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Long-Term Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
maintain the 2016 Plan under which we may grant cash and equity-based incentive awards to eligible service providers, including our board members, in order to attract, retain and motivate the persons who make important contributions to our company.
The plan administrator has the authority to take all actions and make all determinations under the 2016 Plan, to interpret the 2016 Plan and award agreements and to adopt, amend and repeal rules for the administration of the 2016 Plan as it deems
advisable. The plan administrator also has the authority to determine which eligible service providers receive awards, grant awards and set the terms and conditions of all awards under the 2016 Plan, including any vesting and vesting acceleration
provisions, subject to the conditions and limitations in the 2016 Plan. The 2016 Plan provides for the grant of stock options, stock appreciation rights, restricted stock, dividend equivalents, restricted stock units, and other stock or cash based
awards. In connection with any spin-off, change in control, or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2016 Plan to prevent the dilution or enlargement of intended
benefits, facilitate the transaction or event or give effect to the change in applicable laws or accounting principles. The plan administrator may generally amend or terminate the 2016 Plan at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the options that we granted to our senior management in 2017 under the 2016
Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Subject to<BR>Option<BR>(#)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price&nbsp;Per<BR>Share&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted</B><br><B>Share<BR>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lex Bakker, CDO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/30/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Crowley, CFO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Kruif, CTO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/30/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hui Liu, CBO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/30/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, CEO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">377,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/30/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Silverman, GC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/14/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">L. Andres Sirulnik, CMO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Throsby, CSO</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/30/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The options and RSUs vest as to 25% of the shares on the first anniversary of the grant date and as to the
remaining 75% of the shares in equal monthly installments for the 36 calendar months thereafter. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pension Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We offer some of our senior management the opportunity to participate in a post-retirement plan in order to provide competitive post-retirement benefits. For
2017, we contributed a total of &#128;&nbsp;0.1 million&nbsp;to provide pension, retirement or similar benefits to our senior management. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment
Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lex B.H. Bakker, Chief Development Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2010, we entered into an employment agreement with Mr.&nbsp;Bakker pursuant to which he serves as our Chief Development Officer. The agreement is for an
unspecified term and may be terminated at the end of a calendar month by either Mr.&nbsp;Bakker or the company, subject to the applicable statutory notice periods. Pursuant to the employment agreement, Mr.&nbsp;Bakker is entitled to a base salary,
an annual vacation allowance of 8% of his gross salary, participation in a pension scheme, reimbursement for certain commuting expenses and, in the event if his disability, certain continued payments of his base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement contains restrictive covenants which restrict Mr.&nbsp;Bakker&#146;s ability to compete with the company for a period of 12 months following
termination. Mr.&nbsp;Bakker is subject to a penalty of &#128;10,000 for each violation of this covenant and an additional fine of &#128;1,000 for each day the violation continues. Mr.&nbsp;Bakker is also prohibited from performing work for another
employer or client during the course of his employment with us and is subject to a per violation fine of &#128;5,000 and per day fine of &#128;1,000 for as long as the violation continues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement also contains covenants regarding Mr.&nbsp;Bakker&#146;s protection of our confidential information for a period of 5 years following his
termination, violation of which subjects him to penalties of &#128;50,000 for each violation and &#128;1,000 for each day the violation continues, and regarding ownership of our intellectual property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>John Crowley, Chief Financial Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
October&nbsp;5, 2016, we and our wholly-owned subsidiary Merus US, Inc., which we refer to as Merus US, entered into an employment agreement with John Crowley. Pursuant to the employment agreement, Mr.&nbsp;Crowley serves as Executive Vice President
and Chief Financial Officer of us and Merus US. The employment agreement provides for an initial annual base salary of $362,500 and the opportunity to earn an annual cash incentive award based on performance with a target value equal to 35% of
Mr.&nbsp;Crowley&#146;s annual base salary. If Mr.&nbsp;Crowley&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employment is terminated by Merus US without cause or due to Mr.&nbsp;Crowley&#146;s resignation for good reason, then subject to his executing a general release of claims and continuing
compliance with the Company&#146;s proprietary information agreement, Mr.&nbsp;Crowley will be entitled to receive (i)&nbsp;base salary continuation payments for 6 months and (ii)&nbsp;potential accelerated vesting of any portion of his initial
option award that is unvested as of the date of his termination. If Mr.&nbsp;Crowley&#146;s employment is terminated without cause or due to Mr.&nbsp;Crowley&#146;s resignation for good reason within 12 months following a change in control of us,
then subject to his executing a general release of claims and continuing compliance with the proprietary information agreement, Mr.&nbsp;Crowley will be entitled to receive (i)&nbsp;a lump sum payment equal to six months of his base salary and 50%
of his target annual bonus; (ii)&nbsp;direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to nine months, and (iii)&nbsp;accelerated vesting of any portion of his unvested equity awards,
except that performance-based equity awards will only vest subject to the attainment of the applicable performance goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>John de Kruif, Chief
Technology Officer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2007, we entered into an employment agreement with Dr.&nbsp;de Kruif for an unspecified term, which agreement may be
terminated at the end of a calendar month by either Dr.&nbsp;de Kruif or the company subject to the applicable statutory notice periods. Pursuant to the employment agreement, Dr.&nbsp;de Kruif is entitled to a base salary, an annual vacation
allowance equal to 8% of his gross salary, participation in a pension scheme and, in the event if his disability, certain continued payments of his base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement contains restrictive covenants which restrict Dr.&nbsp;de Kruif&#146;s ability to compete with us for a period of 12 months following
termination. Dr.&nbsp;de Kruif is subject to a penalty of &#128;10,000 for each violation of this covenant and an additional fine of &#128;1,000 for each day the violation continues. Dr.&nbsp;de Kruif is also prohibited from performing work for
another employer or client during the course of his employment with us and is subject to a per violation fine of &#128;5,000 and per day fine of &#128;1,000 for as long as the violation continues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement also contains covenants regarding Dr.&nbsp;de Kruif&#146;s protection of our confidential information for a period of five years following
termination of his employment, violation of which subjects him to penalties of &#128;50,000 for each violation and &#128;1,000 for each day the violation continues. Dr.&nbsp;de Kruif has also entered into a separate agreement with us regarding
ownership of our intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hui Liu, Chief Business Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;1, 2015, we and Merus US entered into an employment agreement with Hui Liu, which was amended and restated on March&nbsp;2, 2016, pursuant to
which Mr.&nbsp;Liu serves as Executive Vice President and Chief Business Officer of us and Merus US. The employment agreement provides for an initial annual base salary of $335,000 and the opportunity to earn an annual cash incentive award based on
performance with a target value equal to 35% of Mr.&nbsp;Liu&#146;s annual base salary. If Mr.&nbsp;Liu&#146;s employment is terminated by Merus US without cause or due to Mr.&nbsp;Liu&#146;s resignation for good reason, then subject to his
executing a general release of claims and continuing compliance with the Company&#146;s proprietary information agreement, Mr.&nbsp;Liu will be entitled to receive (i)&nbsp;base salary continuation payments for 6 months and (ii)&nbsp;potential
accelerated vesting of any portion of his initial option award that is unvested as of the date of his termination. If Mr.&nbsp;Liu&#146;s employment is terminated without cause or due to Mr.&nbsp;Liu&#146;s resignation for good reason within 12
months following a change in control of us, then subject to his executing a general release of claims and continuing compliance with the proprietary information agreement, Mr.&nbsp;Liu will be entitled to receive (i)&nbsp;a lump sum payment equal to
six months of his base salary and 50% of his target annual bonus; (ii)&nbsp;direct payment of or reimbursement for continued medical, dental or vision coverage pursuant to COBRA for up to nine months, and (iii)&nbsp;accelerated vesting of any
portion of his initial option award that is unvested as of his date of termination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ton Logtenberg, President &amp; Chief Executive Officer and
Executive Director and President of Merus US </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into an employment agreement, as amended from time to time, with Ton Logtenberg
pursuant to which Dr.&nbsp;Logtenberg serves as our President &amp; Chief Executive Officer. The agreement is for an unspecified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
term and may be terminated by either Dr.&nbsp;Logtenberg or the company subject to the applicable statutory notice periods; provided that, the agreement will automatically terminate without
notice at the end of the month in which Dr.&nbsp;Logtenberg reaches the age at which he is entitled to pension under Dutch law. Pursuant to the employment agreement, Dr.&nbsp;Logtenberg is entitled to an annual base salary of no less than $463,000
USD, effective January&nbsp;1, 2017, and may earn an annual cash incentive award based on performance with a target value equal to 50% of his annual base salary. Dr.&nbsp;Logtenberg is also entitled to certain other benefits, including health and
disability benefits, reimbursement for commuting expenses and participation in the company&#146;s pension plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Dr.&nbsp;Logtenberg&#146;s employment
is terminated by the company without cause or due to Dr.&nbsp;Logtenberg&#146;s resignation for good reason, then subject to his executing a general release of claims and continued compliance with the company&#146;s proprietary information
agreement, Dr.&nbsp;Logtenberg will be entitled to receive (i)&nbsp;base salary continuation payments for 6 months and (ii)&nbsp;potential accelerated vesting of any portion of his option awards that are unvested as of the date of his termination.
If Dr.&nbsp;Logtenberg&#146;s employment is terminated without cause or due to Dr.&nbsp;Logtenberg&#146;s resignation for good reason within 12 months following a change in control, then subject to his executing a general release of claims and
continued compliance with the proprietary information agreement, Dr.&nbsp;Logtenberg will be entitled to receive (i)&nbsp;a lump sum payment equal to six months of his base salary and 50% of his target annual bonus and (ii)&nbsp;accelerated vesting
of any portion of his unvested equity awards, except that performance based equity awards will only vest subject to the attainment of the applicable performance goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement contains restrictive covenants which restrict Dr.&nbsp;Logtenberg&#146;s ability to compete with us for a period of 24 months following his
termination of employment or solicit our employees for a period of 12&nbsp;months following termination. In the event Dr.&nbsp;Logtenberg violates these restrictive covenants, he will be subject to a penalty of &#128;25,000 for each violation and an
additional penalty of &#128;1,000 for each day the violation continues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement also contains covenants regarding protection of our confidential
information, violation of which subjects Dr.&nbsp;Logtenberg to the same penalties as described above, and ownership of intellectual property. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Peter B. Silverman, General Counsel and Chief Intellectual Property Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective February, 2017, we and Merus US entered into an employment agreement with Peter B. Silverman.&nbsp;The employment agreement provides for an initial
annual base salary of $315,000 and the opportunity to earn an annual cash incentive award based on performance with a target value equal to 30% of Mr.&nbsp;Silverman&#146;s annual base salary. If Mr.&nbsp;Silverman&#146;s employment is terminated by
Merus US without cause or due to Mr.&nbsp;Silverman&#146;s resignation for good reason, then subject to his executing a general release of claims and continuing compliance with our proprietary information agreement, Mr.&nbsp;Silverman will be
entitled to receive (i)&nbsp;an amount in cash equal to the sum of 0.5 times his annual base salary and (ii)&nbsp;a pro-rata portion of his target annual bonus for the calendar year in which the date of termination occurs, which shall be paid in the
form of salary continuation in regular installments over the six-month period following his termination in accordance with the Company&#146;s customary payroll practices.&nbsp;On February&nbsp;21, 2018, Mr.&nbsp;Silverman was appointed Executive
Vice President and General Counsel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>L. Andres Sirulnik, Chief Medical Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;1, 2016, we and Merus US entered into an employment agreement with L. Andres Sirulnik. Pursuant to the employment agreement, Mr.&nbsp;Sirulnik
serves as Executive Vice President and Chief Medical Officer of us and Merus US. The employment agreement provides for an initial annual base salary of $390,000 and the opportunity to earn an annual cash incentive award based on performance with a
target value equal to 40% of Mr.&nbsp;Sirulnik&#146;s annual base salary. In addition, the Company agreed to pay Mr.&nbsp;Sirulnik an amount equal to $50,000, within thirty (30)&nbsp;days following each of November&nbsp;8, 2017 and November&nbsp;8,
2018, subject to Mr.&nbsp;Sirulnik&#146;s continued employment with the Company through each such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mark Throsby, Chief Science Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2008, we entered into an employment agreement with Mr.&nbsp;Throsby for an unspecified term, which agreement may be terminated at the end of a calendar
month by either Mr.&nbsp;Throsby or the company subject to the applicable statutory notice periods. Pursuant to the employment agreement, Mr.&nbsp;Throsby is entitled to a base salary, an annual vacation allowance equal to 8% of his gross salary,
participation in a pension scheme and, in the event if his disability, certain continued payments of his base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement contains restrictive
covenants which restrict Mr.&nbsp;Throsby&#146;s ability to compete with the company for a period of 12 months following termination. Mr.&nbsp;Throsby is subject to a penalty of &#128;10,000 for each violation of this covenant and an additional fine
of &#128;1,000 for each day the violation continues. Mr.&nbsp;Throsby is also prohibited from performing work for another employer or client during the course of his employment with us and is subject to a per violation fine of &#128;5,000 and per
day fine of &#128;1,000 for as long as the violation continues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement also contains covenants regarding Mr.&nbsp;Throsby&#146;s protection of our
confidential information for a period of 5 years following his termination, violation of which subjects him to penalties of &#128;50,000 for each violation and &#128;1,000 for each day the violation continues. Mr.&nbsp;Throsby has also entered into
a separate agreement with us regarding ownership of our intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the remuneration paid during our 2017 fiscal year to members of our board of directors. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;earned<BR>or paid in<BR>Cash</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in euros)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">822,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,675,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5,497,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Iwicki</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">59,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">120,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">180,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wolfgang Berthold, Ph.D.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">41,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">90,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">132,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lionel Carnot(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">35,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">61,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">97,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Koning, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">38,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">113,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">152,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anand Mehra, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">42,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">83,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">126,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack B. Nielsen(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Perry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">47,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">103,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">151,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Logtenberg did not receive any additional compensation for his service on our board during 2017.
Amounts paid to Dr.&nbsp;Logtenberg for his service as an executive officer are set forth above in the section &#147;Senior Management Remuneration&#148; above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount shown represents the grant date fair value of option awards granted in 2017 measured using the
Hull&nbsp;&amp; White option pricing model. For a description of the assumptions used in valuing these awards, see note 14 to our financial statements incorporated by reference in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Berthold resigned from our board of directors on June&nbsp;28, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Carnot resigned from our board of directors on July&nbsp;20, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Nielsen resigned from our board of directors on May&nbsp;24, 2017 and did not receive any compensation
for his service on our board during 2017. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Remuneration of Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Dutch law does not require that we establish a remuneration program for our members of our board of directors, we have established a Non-Executive
Director Compensation Program. Under this program, remuneration for the members of our board of directors consists of cash and initial and annual equity awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Each board member is entitled to receive an annual retainer of $35,000. The chairman of the board is entitled to an additional annual retainer of $50,000 and the chairman of the audit committee,
compensation committee and nomination and corporate governance committee are each entitled to an additional annual retainer of $15,000, $13,000 and $13,000, respectively. A board member serving as a member of a committee other than the chairman is
entitled to receive an additional annual retainer of $7,500 for service on the audit committee, $5,000 for service on the compensation committee, and $3,750 for service on the nomination and corporate governance committee. Retainers under the
program are payable in arrears in four equal quarterly installments within 15&nbsp;days following the end of each calendar quarter, provided, that the amount of each payment will be prorated for any portion of a quarter that a board member is not
serving on our board. The remuneration program further provides for an automatic increase of the annual retainers on the first day of each calendar year by an amount equal to 3% of the value of such annual retainer in effect as of the immediately
preceding calendar year. The board of directors may appoint observers to the board of directors, pending their formal appointment as a board member, in which case, unless the board of directors decides otherwise, the date service as an observer
commences shall be considered the effective date of commencing service as a board member for purposes of the remuneration program for the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each board member who is initially appointed to our board is eligible to receive an option to purchase the number of common shares of our company having an
aggregate grant date fair value of $200,000 on the date of grant. Unless otherwise determined by the board of directors, options to purchase common shares granted to an observer while serving, or upon commencing service, as an observer shall be
considered an initial award described in the previous sentence. In addition, if a board member has served on the board (as a non-executive director or as an observer) for at least six months and continues to serve as a board member following any
annual general meeting of shareholders held following his or her initial appointment as a board member, such board member is eligible to receive, on the date of each such annual meeting or as soon as practical thereafter, an option to purchase the
number of common shares of our company having an aggregate grant date fair value of $100,000 on the date of grant. Options granted to our board members under the program have an exercise price equal to the fair market value of our common shares on
the date of grant and expire not later than ten years after the date of grant. The options granted as initial awards vest as to 33% of the shares subject to the award on the first anniversary of the date of grant and in 24 substantially equal
monthly installments thereafter. The options granted annually to board members vest in 12 substantially equal monthly installments following the date of grant. In each case, vesting is subject to continued service as a board member or an observer
through each such vesting date. In addition, all unvested options vest in full upon the occurrence of a change in control. The grant date fair value of each initial award and annual award is, subject to approval by our board of directors, increased
on the first day of each calendar year by an amount equal to 3% of the grant date fair value in effect as of the immediately preceding calendar year, provided, that in no event shall the number of shares awarded pursuant to an initial award exceed
17,000 common shares and an annual award exceed 8,500 common shares, in each case, subject to adjustment as provided in the 2016 Plan. Our board of directors approved such 3% increase on September 18, 2018, with effect from 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each board member is entitled to be reimbursed for reasonable travel and other expenses incurred in connection with attending meetings of the board and any
committee of the board on which he or she serves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Board of Directors 2017 Fiscal Year Equity Awards </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year 2017, members of our board of directors were granted options to purchase common shares under the 2016 Plan as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Subject to<BR>Option<BR>(#)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price&nbsp;Per<BR>Share ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">377,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/30/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Iwicki</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wolfgang Berthold, Ph.D.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lionel Carnot(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Koning, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anand Mehra, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jack B. Nielsen(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Perry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/24/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The options vest as to 33% of the shares subject to each award on the first anniversary of the date of grant
and in 24 substantially equal monthly installments thereafter, subject to accelerated vesting upon the occurrence of a change in control event, except that for Dr. Logtenberg, the options vest as to 25% of the shares on the first anniversary of the
grant date and as to the remaining 75% of the shares in equal monthly installments for the 36 calendar months thereafter. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr. Berthold resigned from our board of directors on June 28, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr. Carnot resigned from our board of directors on July 20, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Nielsen resigned from our board of directors on May&nbsp;24, 2017. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_18"></A>PRINCIPAL AND SELLING SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information relating to the beneficial ownership of our common shares as of October&nbsp;31, 2018, unless otherwise indicated
in the footnotes to the table, by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person known to us who beneficially owns 5% or more of our outstanding common shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each member of our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each member of our senior management; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the selling shareholders </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of common shares beneficially owned by each entity, person, director or member of senior management is determined in accordance with the rules of
the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the entity or individual has sole or shared voting power or investment
power as well as any shares that the entity or individual has the right to acquire within 60 days following October 31, 2018 through the exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable
community property laws, the persons named in the table have sole voting and investment power with respect to all common shares held by that person, as applicable. Common shares that a person has the right to acquire within 60 days following October
31, 2018 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person. The percentage of shares
beneficially owned before the offering is computed on the basis of 22,750,867 common shares as of October 31, 2018. The percentage of shares beneficially owned after the offering assumes the sale by the selling shareholders of all common shares
registered pursuant to this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling shareholders named below may offer or sell from time to time pursuant to this prospectus up to an
aggregate of 6,299,997 common shares. Because the selling shareholders may sell, transfer or otherwise dispose of all, some or none of the common shares covered by this prospectus, we cannot determine the number of such shares that will be sold,
transferred or otherwise disposed of by the selling shareholders, or the amount or percentage of common shares that will be held by the selling shareholders upon termination of any particular offering or sale. See &#147;Plan of Distribution.&#148;
For the purposes of the table below, we assume that each selling shareholder will sell all of its common shares covered by this prospectus. When we refer to the selling shareholders in this prospectus, we mean the entities listed in the table below,
as well as their pledgees, donees, assignees, transferees and successors in interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated below, the address for each beneficial owner listed is c/o Merus N.V., at
Yalelaan 62, 3584 CM Utrecht, The Netherlands. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;Prior&nbsp;to<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Being<BR>Offered</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially<BR>Owned&nbsp;After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Name of beneficial owner</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% or greater shareholders and selling shareholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BVF(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,514,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,124,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,390,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Incyte Corporation(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bay City Capital Co&ouml;peratief U.A.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sofinnova Venture Partners IX, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,961,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,738,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cooperatief LSP IV UA(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,225,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,225,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Johnson&nbsp;&amp; Johnson&#151;JJDC, Inc.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,195,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,195,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aquilo Capital Management, LLC(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,352,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Management Group LLP(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,181,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Brothers Life Sciences L.P.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,160,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LSP Life Sciences Fund N.V.(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Senior management and Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ton Logtenberg, Ph.D.(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">683,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">683,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Crowley(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hui Liu(13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,753</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">L. Andres Sirulink(14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Throsby, Ph.D.(15)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lex B.H. Bakker, Ph.D.(16)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter B. Silverman(17)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Kruif(18)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Russell G. Greig, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Iwicki(19)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Len Kanavy(20)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,098 </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John de Koning, Ph.D.(21)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anand Mehra(4)(22)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,983,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">222,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Perry(23)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates beneficial ownership of less than 1% of the total outstanding common shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;2,179,666&nbsp;shares held directly by Biotechnology Value Fund, L.P. (&#147;BVF&#148;),
(b)&nbsp;1,659,586&nbsp;shares held directly by Biotechnology Value Fund II, L.P. (&#147;BVF2&#148;), (c)&nbsp;315,275&nbsp;shares held by Biotechnology Value Trading Fund OS LP (&#147;Trading Fund OS&#148;) (d)&nbsp;100,751 shares held directly by
Investment 10, L.L.C. (&#147;Investment&nbsp;10&#148;), and (e)&nbsp;259,635 shares held directly by MSI BVF SPV LLC (&#147;MSI&#148;). BVF Partners OS Ltd. (&#147;Partners OS&#148;), as the general partner of Trading Fund OS, may be deemed to
beneficially own the shares held by Trading Fund OS. BVF Partners L.P. (&#147;Partners&#148;), as the general partner of BVF and BVF2, the investment manager of Trading Fund OS, Investment&nbsp;10, and MSI and the sole member of Partners OS, may be
deemed to beneficially own the shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, Investment&nbsp;10, and MSI. BVF Inc., as the general partner of Partners, may be deemed to beneficially own the shares beneficially owned by
Partners Investment&nbsp;10, and MSI. Mark N. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the shares beneficially owned by BVF Inc. The beneficial ownership information presented is as of December&nbsp;19, 2018
and is based on a Schedule 13G/A filed with the SEC on June&nbsp;19, 2018 and information known to us. The address for each of these entities is 44 Montgomery Street, 40th Floor, San Francisco, CA 94104. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 3,200,000 common shares held directly by Incyte Corporation (&#147;Incyte&#148;).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 2,062,025 common shares held directly by Bay City Capital Fund V, L.P. (&#147;Fund V&#148;),
(b) 39,295 common shares held by Bay City Capital Fund V Co-Investment Fund, L.P. (&#147;Fund <FONT STYLE="white-space:nowrap">V-SBS&#148;)</FONT> are the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
two sole investors of COOP. Bay City Capital Management V LLC (&#147;BCCM V&#148;) is the general partner of Fund V and Fund V-SBS, and (c) 12,254 common shares held directly by Bay City Capital
LLC (&#147;BCC&#148;). BCC is the adviser and manager of BCCM V. BCCM V and BCC represent Fund V and Fund V-SBS, respectively. Thus, BCCM V and BCC share voting and investment power over the shares held by each of Fund V and Fund V-SBS. Lionel
Carnot is a member of BCCM V and is employed as a managing director of BCC together with Fred Craves, Carl Goldfischer, Dayton Misfeldt and Rob Hopfner. As such, each of these individuals may be deemed to share voting and investment power over these
entities, and they disclaim beneficial ownership of all shares except to the extent of any pecuniary interest therein. Beneficial ownership information is based on a Schedule 13D filed with the SEC on November 28, 2018. The mailing address for BCC,
Fund V, Fund V-SBS and BCCM V is De Boelelaan 7, 1083 HJ Amsterdam, Netherlands. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,961,039 common shares held directly by Sofinnova Venture Partners IX, L.P. (&#147;Sofinnova
VP&#148;). Sofinnova Management IX, L.L.C. (&#147;Sofinnova Management&#148;) is the general partner of Sofinnova VP and Anand Mehra, Michael Powell and James Healy are the managing members of Sofinnova Management. Sofinnova Management, Anand Mehra
(a member of our board), Michael Powell and James Healy may be deemed to have shared voting and dispositive power over the shares owned by Sofinnova VP. Such entities and individuals disclaim beneficial ownership over all shares except to the extent
of any pecuniary interest therein. Beneficial ownership information is based on information known to us and a Schedule 13D filed with the SEC on September&nbsp;27, 2017. The address for Sofinnova VP and Sofinnova Management is 3000 Sand Hill Road,
Building 4, Suite 250, Menlo Park, California 94025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,225,661 common shares held directly by Co&ouml;peratief LSP IV U.A. (&#147;LSP&#148;). LSP IV
Management BV (&#147;LSP Management&#148;) is the sole director of LSP. The managing directors of LSP Management are Martijn Kleijwegt, Rene Kuijten and Joachim Rothe. As such, LSP Management, Martijn Kleijwegt, Rene Kuijten and Joachim Rothe may be
deemed to beneficially own and share voting power over these shares. LSP Management, Martijn Kleijwegt, Rene Kuijten and Joachim Rothe disclaim beneficial ownership of the shares. John de Koning, a member of our board, is employed as a partner at
LSP. Mr.&nbsp;de Koning has no beneficial ownership of these shares, but he has a pecuniary interest in these shares pursuant to his employment at LSP. Beneficial ownership information is based on a Schedule 13D/A filed with the SEC on June&nbsp;3,
2016. LSP&#146;s mailing address is c/o LSP, Johannes Vermeerplein 9, 1071 DV Amsterdam, Netherlands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 1,195,943 common shares held directly by Johnson&nbsp;&amp; Johnson Innovation&#151;JJDC, Inc.
(&#147;JJDC&#148;). JJDC is a wholly-owned subsidiary of Johnson&nbsp;&amp; Johnson (&#147;J&amp;J&#148;). JJDC and J&amp;J have shared voting and dispositive power over the shares and J&amp;J may be deemed to indirectly beneficially own the shares.
Beneficial ownership information is based on a Schedule 13G filed with the SEC on January&nbsp;18, 2017. The address of JJDC is One Johnson&nbsp;&amp; Johnson Plaza, New Brunswick, NJ 08933. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;1,075,913 common shares held directly by Aquilo Capital, L.P. (&#147;Aquilo&#148;) and
(b)&nbsp;276,271 common shares held directly by Aquilo Capital II, L.P. (&#147;Aquilo II&#148;). Aquilo Capital Management LLC (&#147;Aquilo Management&#148;) is the general partner of Aquilo and Aquilo II and Marc Schneidman is the managing member
of Aquilo Management. Aquilo Management and Mr.&nbsp;Schneidman may be deemed to be beneficial owners of the shares held by Aquilo and Aquilo II, and Aquilo and Aquilo II may be deemed to beneficially own the shares held by the other entity. The
beneficial ownership information presented is as of December 18, 2018 and is based on a Schedule 13F-HR filed with the SEC on November 14, 2018 and information known to us. The address for Aquilo and Aquilo II is One Letterman Drive, Suite D4900,
San Francisco, California, 94129. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares are held directly by Wellington Management Group LLP. Wellington Investment Advisors Holdings LLP
which controls directly, or indirectly through Willington Management Global Holdings, Ltd., (&#147;Wellington Investment Advisers&#148;). Wellington Investment Advisors Holdings LLP is owned by Willington Group Holdings LLP, Wellington Group
Holdings LLP is owned by Wellington management Group LLP. Beneficial ownership information is based on a Schedule 13G filed with the SEC on February&nbsp;8, 2018. The address for each of these entities is c/o Wellington Management Company LLP,
280&nbsp;Congress Street, Boston, MA 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;1,054,257 common shares held directly by Baker Brothers Life Sciences, L.P. (&#147;Life
Sciences&#148;) and (b)&nbsp;105,757 common shares held directly by 667, L.P. (&#147;667&#148;, and together with Life </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Sciences, the &#147;Baker Funds&#148;). Baker Bros. Advisors LP (&#147;Advisors&#148;) is the Investment Adviser for the Baker Funds and has sole voting and investment power with respect to the
shares held by the Baker Funds. Baker Bros. Advisors (GP) LLC is the sole general partner of Advisors. Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker as principals of the Baker Bros. Advisors (GP) LLC, and Advisors disclaim
beneficial ownership of all shares. Beneficial ownership information is based on a Schedule 13G filed with the SEC on February&nbsp;14, 2017. The address for each of these entities is 667 Madison Avenue, 21st Floor, New York, NY 10065.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">LSP Advisory B.V. (&#147;LSP Advisory&#148;) is the sole director of LSP Life Sciences Fund N.V.
(&#147;LSP&#148;). The directors of LSP Advisory are Mark Wegter and Geraldine O&#146;Keeffe. As such, LSP Advisory, Mark Wegter and Geraldine O&#146;Keeffe may be deemed to beneficially own and share voting power over the shares held by LSP. LSP
Advisory, Mark Wegter and Geraldine O&#146;Keeffe disclaim beneficial ownership of the shares. LSP&#146;s mailing address is Johannes Vermeerplein 9, 1071 DV Amsterdam, Netherlands. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;160,814 common shares held by BioPhrase, B.V. (&#147;BioPhrase&#148;),
Dr.&nbsp;Logtenberg&#146;s personal holding company, (b)&nbsp;126,235 common shares held by Dr.&nbsp;Logtenberg, (c)&nbsp;391,058 options to purchase common shares held by Dr.&nbsp;Logtenberg, including options that vest within 60 days following
October&nbsp;31, 2018 and (d)&nbsp;5,156 restricted stock units (&#147;RSUs&#148;) held by Dr.&nbsp;Logtenberg, including RSUs that vest within 60&nbsp;days following October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60 days following
October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;12,221 common shares, (b)&nbsp;114,368 options to purchase common shares including options
that vest within 60&nbsp;days following October&nbsp;31, 2018 and (c)&nbsp;1,164 restricted stock units (&#147;RSUs&#148;), including RSUs that vest within 60&nbsp;days following October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60 days following
October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;10,358 common shares, (b)&nbsp;129,432 options to purchase common shares including options
that vest within 60&nbsp;days following October&nbsp;31, 2018 and (c)&nbsp;1,416 restricted stock units (&#147;RSUs&#148;), including RSUs that vest within 60&nbsp;days following October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;8,794 common shares, (b)&nbsp;33,977 options to purchase common shares including options
that vest within 60&nbsp;days following October&nbsp;31, 2018 and (c) 216 restricted stock units (&#147;RSUs&#148;), including RSUs that vest within 60&nbsp;days following October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60 days following
October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;1,653 common shares, (b)&nbsp;27,501 options to purchase common shares including options
that vest within 60&nbsp;days following October&nbsp;31, 2018 and (c)&nbsp;158 restricted stock units (&#147;RSUs&#148;), including RSUs that vest within 60&nbsp;days following October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60 days following
October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60 days following
October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60 days following
October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(22)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a)&nbsp;1,961,039 shares held by Sofinnova Venture Partners IX LP prior to this offering and
(b)&nbsp;22,353 options to purchase common shares, including options that vest within 60 days following October&nbsp;31, 2018. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(23)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase common shares, including options that vest within 60 days following
October&nbsp;31, 2018. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To our knowledge, there has been no significant change in the percentage ownership held by the major
shareholders listed above since January&nbsp;1, 2015, except as discussed elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_19"></A>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of material related party transactions with any members of our board of directors, senior management and the holders of more
than 5% of our common shares since January&nbsp;1, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2018, we entered into a Securities Purchase Agreement, or the Purchase Agreement, with certain new and existing investors, whom we refer
to in this prospectus as the &#147;selling shareholders.&#148; Pursuant to the Purchase Agreement, on February&nbsp;15, 2018, we issued and sold 3,099,997 of our common shares to the selling shareholders in a private placement, or the Private
Placement, at a price per share of $18.00 for total aggregate gross proceeds to us of $55.8 million. On February&nbsp;13, 2018, we entered into a Registration Rights Agreement with the investors in the Private Placement, pursuant to which we agreed
to register the resale of the common shares sold to the selling shareholders in the Private Placement. Sofinnova Venture Partners IX, L.P. purchased 222,222 common shares in the Private Placement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incyte Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2016, we entered into a
License and Collaboration Agreement, or the Collaboration Agreement, with Incyte Corporation, or Incyte. See &#147;Business&#151;Collaboration Agreements&#151;Incyte Corporation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Collaboration Agreement, we entered into a Share Subscription Agreement, or the Subscription Agreement, pursuant to which, in January
2017, Incyte purchased 3,200,000 common shares, or the Shares, at a purchase price per share of $25.00 for total aggregate proceeds to us of $80.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Subscription Agreement, for a specified period that may terminate earlier upon the occurrence of certain events related to the acquisition of
the Company or the termination of the Collaboration Agreement, or the Standstill Period, Incyte has agreed, subject to certain exceptions, that it will not, directly or indirectly, increase its percentage ownership of our voting securities, make or
solicit proxies or seek to influence the voting of our securities, seek to influence or control our management, make a proposal or offer to acquire our company or its assets, or seek to effect a change of control of our company or other similar
extraordinary transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Incyte agreed that for a period ending on the earlier of 18 months after the closing date of the Subscription Agreement or
the end of the Standstill Period, or the Lock-Up Period, it would not, subject to certain exceptions, sell or otherwise transfer or agree to transfer the Shares. The Lock-Up Period ended in July 2018. In addition, if the Standstill Period has not
been terminated early, for a period of three years after the end of the Lock-Up Period, Incyte will be restricted from selling or otherwise transferring more than one-third of the Shares during any 12-month period or ten percent of the Shares during
any three-month period, unless we consent otherwise. Incyte has further agreed that during the Standstill Period, it will vote all of the voting securities that it holds in accordance with the recommendation of a majority of our board of directors.
However, Incyte may vote its securities at its own discretion for certain extraordinary matters, including a change in control of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also
agreed to customary resale registration rights with respect to the Shares, however, any such resales will be subject to the Lock-Up Period and volume limitations on sale and transfer of the Shares described above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a
registration rights agreement, or the Registration Rights Agreement, with certain of our shareholders, pursuant to which such shareholders are entitled to the following rights with respect to the registration of their common shares for public resale
under the Securities Act. The registration of common shares as a result of the following rights being exercised would enable their holders to trade these shares without restriction under the Securities Act when the applicable registration statement
is declared effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the holders of, at least, 30% of the registrable securities then outstanding request that we effect a registration with respect to all or part of their
registrable securities, we may be required to register all or part of the registrable securities then outstanding. We are obligated to effect at most two registrations in response to these demand registration rights. If the holders requesting
registration intend to distribute their shares by means of an underwriting, the managing underwriter of such offering has the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we propose to register
any of our common shares under the Securities Act, subject to certain exceptions, the holders of registrable securities are entitled to notice of the registration and to include their registrable securities in the registration. If our proposed
registration involves an underwriting, the managing underwriter of such offering has the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Form S-3 Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the holders of our
registrable securities then outstanding request that we effect a registration of some or all of their registrable securities and we are entitled under the Securities Act to register our common shares on a registration statement on Form F-3, we are
obligated to effect such registration. We are not obligated to effect a registration pursuant to these F-3 registration rights if (i)&nbsp;the expected aggregate net proceeds from the sale of the registrable securities for which registration is
requested is equal to or less than $1.0&nbsp;million or (ii)&nbsp;if, within a given 12-month period, we have already effected two registrations on Form F-3 for the holders of registrable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinarily, other than underwriting discounts
and commissions, we are required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and
disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling security holders and blue sky fees and expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration
rights terminate upon the earlier of May&nbsp;24, 2020, or, with respect to the registration rights of an individual holder, when the holder can sell all of such holder&#146;s registrable securities in a three-month period without restriction under
Rule 144 under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For a description of our agreements with our executive officers, see &#147;Management&#151;Compensation.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into
agreements with members of our board of directors and our executive officers to indemnify them against expenses and liabilities to the fullest extent permitted by law. These agreements provide, subject to certain exceptions, for indemnification for
related expenses including, among other expenses, attorneys&#146; fees, judgments, penalties, fines and settlement amounts incurred by any of these individuals in any action or proceeding. In addition to such indemnification, we provide our board of
directors and executive officers with directors&#146; and officers&#146; liability insurance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_20"></A>DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our articles of
association and relevant provisions of Dutch law. Because the following is only a summary, it does not contain all of the information that may be important to you. The summary includes certain references to and descriptions of material provisions of
our articles of association and Dutch law in effect as of the date of this prospectus. The summary below does not purport to be complete and is qualified in its entirety by reference to applicable Dutch law and our articles of association, which is
incorporated by reference as an exhibit to the registration statement of which this prospectus is a part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated on June&nbsp;16, 2003 as a private company with limited liability (<I>besloten vennootschap met beperkte aansprakelijkheid</I>) under
Dutch law. In connection with the initial public offering of our common shares, we converted into a Dutch public company with limited liability (<I>naamloze vennootschap</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registered with the Dutch Trade Register (<I>handelsregister</I>) under number 30189136. Our corporate seat is in Utrecht, the Netherlands, and our
registered office is Yalelaan 62, 3584 CM Utrecht, the Netherlands. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October 31, 2018, our issued
share capital was &#128;2.0&nbsp;million, comprised of 22,750,867 common shares, nominal value &#128;0.09&nbsp;per share. As of October 31, 2018, our authorized share capital comprised 45,000,000 common shares and 45,000,000 preferred shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2016, we entered
into a call option agreement with an independent foundation (<I>stichting</I>) under Dutch law called Stichting Continu&iuml;teit Merus, or the Protective Foundation, pursuant to which the Protective Foundation would be allowed to acquire preferred
shares up to 100% of our issued capital held by third parties immediately prior to the issuance of such preferred shares without approval by our general meeting of shareholders or our board of directors. As of October 31, 2018, there were no
preferred shares outstanding, and we have no present plans to issue any preferred shares other than pursuant to an exercise by the Protective Foundation of its rights under the call option agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>History of Share Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2015, our
issued share capital has changed as provided below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;26, 2015, we issued 492,514 Class&nbsp;B preferred shares to certain investors for
aggregate consideration of &#128;5.0&nbsp;million in cash. In connection with this issuance of Class&nbsp;B preferred shares, we also issued an additional 844,834 of our Class&nbsp;B preferred shares pursuant to anti-dilution provisions included in
the subscription agreement for the Class&nbsp;B preferred shares. These additional shares were issued for no cash consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;21, 2015,
we issued 4,149,884 Class&nbsp;C preferred shares to certain investors in exchange for aggregate consideration of approximately &#128;49.7&nbsp;million, which included the conversion of our existing &#128;8.0&nbsp;million convertible bridge loan and
interest thereon into Class&nbsp;C preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2016, we issued 12,107 common shares upon the exercise of options by the former
Chairman of our board of directors (through the STAK) for aggregate consideration of &#128;23,317 in cash. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;6, 2016, we effected a 1-for-1.80 reverse share split of our common shares and all classes of
our preferred shares issued at that time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;19, 2016, in connection with the listing of our common shares on The Nasdaq Global Market, or
Nasdaq, we effected a conversion of all issued and outstanding preferred shares into 8,627,712 common shares, and we issued a total of 1,312,718 common shares to holders of our preferred shares in satisfaction of accrued and unpaid dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;24, 2016, we issued 5,500,000 common shares upon the closing of the initial public offering of our common shares, or IPO, at a price per share of
$10.00. On May&nbsp;26, 2016, we issued 639,926 common shares upon the exercise in part of the underwriters&#146; option to purchase additional shares. We received aggregate net proceeds of $53.3&nbsp;million, after deducting underwriting discounts
and commissions and offering expenses payable by us, from our IPO and the exercise of the underwriters&#146; option to purchase additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
January&nbsp;23, 2017, we issued 3,200,000 common shares to Incyte Corporation at price per share of $25.00, for an aggregate purchase price of $80.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2017, we issued 96,816 common shares upon the exercise of options by directors, officers, and employees for aggregate consideration of
&#128;189,574 in cash and granted 214,096 restricted share units, or RSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2017, we issued 8,846 common shares upon the exercise of options
by directors, officers, and employees for aggregate consideration of &#128;18,865 in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2017, we issued 783 common shares upon the exercise of
options by employees for aggregate consideration of &#128;1,511 in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2017, we issued 4,424 common shares upon the exercise of options by
employees for aggregate consideration of &#128;16,858 in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2017, we issued 7,331 common shares upon the vesting of RSUs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2017, we issued 5,556 common shares upon the exercise of options by an employee for aggregate consideration of &#128;10,723 in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2017, we issued 20,241 common shares upon the exercise of options by an employee for aggregate consideration of &#128;69,088 in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2018, we issued 6,876 common shares upon the exercise of options by employees for aggregate consideration of &#128;13,271 in cash and we issued
48,639 common shares upon the vesting of RSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2018, we issued 27,165 common shares upon the exercise of options by employees for aggregate
consideration of &#128;52,428 in cash and we issued 4,055 common shares upon the vesting of RSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;15, 2018, we issued 3,099,997 common
shares to certain new and existing investors at price per share of $18.00, for an aggregate purchase price of $55.8 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2018, we issued
4,055 common shares upon the vesting of RSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2018, we issued 4,055 common shares upon the vesting of RSUs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2018, we issued 4,055 common shares upon the vesting of RSUs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2018, we issued 4,055 common shares upon the vesting of RSUs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2018, we issued 47,279 common shares upon the exercise of options by employees for aggregate
consideration of &#128;583,111 in cash and we issued 4,055 common shares upon the vesting of RSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2018, we issued 1,750 common shares upon the
exercise of options by employees for aggregate consideration of &#128;23,865 in cash and we issued 4,055 common shares upon the vesting of RSUs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
September 2018, we issued 40,564 common shares upon the exercise of options by employees for aggregate consideration of &#128;97,598 in cash and we issued 4,055 common shares upon the vesting of RSUs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2018, we issued 12,254 common shares upon the exercise of options by employees for aggregate consideration of &#128;106,179 in cash and we issued
4,055 common shares upon the vesting of RSUs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have established equity incentive plans pursuant to which we have issued options to purchase common shares and RSUs to employees and directors. As of
October 31, 2018, there were options and RSUs outstanding to purchase 2,730,668 common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below summarizes our share options as of October 31, 2018 that we have granted to our directors
and our employees pursuant to our equity incentive plans. Share options granted under the Merus B.V. 2010 Employee Option Plan, or the 2010 Plan, have a term of eight years from grant date and share options granted under the 2016 Plan have a term of
ten years from grant date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="8" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Share Options Granted Under the</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Merus B.V. 2010 Employee Option Plan</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Share&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price&nbsp;Per<BR>Share&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;1, 2009 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;1, 2009 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;4, 2010 (officers and employees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;17, 2010 (officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;15, 2010 (director and employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;1, 2011 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;9, 2011 (director)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;3, 2011 (employees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;4, 2011 (director)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;4, 2012 (officers and employees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;18, 2012 (directors)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;17, 2013 (employees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;17, 2014 (officers and employees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;17, 2014 (directors)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;16, 2015 (officers and employees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;4, 2015 (directors)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">5.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August&nbsp;21, 2015 (directors)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,632</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;30, 2015 (officers and employees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">432,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;16, 2015 (officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;21, 2016 (directors)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="8" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Share Options Granted Under the</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. 2016 Incentive Award Plan, as amended</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Share&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price&nbsp;Per<BR>Share&nbsp;Option</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;18, 2016 (directors)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">8.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;29, 2016 (officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">219,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;1, 2016 (officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;1, 2017 (officers)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;17, 2017 (employees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;15, 2017 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;13, 2017 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;27, 2017 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;13, 2017 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;24, 2017 (directors)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;29, 2017 (employees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July&nbsp;1, 2017 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October&nbsp;4, 2017 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">November&nbsp;9, 2017 (employees)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February&nbsp;21, 2018 (employees and officers)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">442,568</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April&nbsp;4, 2018 (officer)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 25, 2018 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&nbsp;28, 2018 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 4, 2018 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 20, 2018 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 1, 2018 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 19, 2018 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">October 24, 2018 (employee)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Restricted Share Units Granted Under the
</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. 2016 Incentive Award Plan, as amended</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Share<BR>Subject&nbsp;to&nbsp;Vesting</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;1, 2017 (officers)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">214,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Articles of Association </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below is a summary of relevant information concerning our share capital and material provisions of our articles of association and applicable Dutch
law. This summary does not constitute legal advice regarding those matters and should not be regarded as such. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Articles of Association
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting of shareholders can only resolve to amend the articles of association at the proposal of the board of directors. A resolution
by the general meeting of shareholders to amend the articles of association requires a simple majority of the votes cast. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Company&#146;s
Shareholders&#146; Register </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We must keep our shareholders&#146; register accurate and up-to-date. The board of directors keeps our
shareholders&#146; register and records names and addresses of all holders of registered shares, showing the date on which the shares were acquired, the date of the acknowledgement of the transfer by or notification of the transfer to us as well as
the amount paid on each share. The register also includes the names and addresses of those with a right to use and enjoyment in common shares belonging to another person (<I>vruchtgebruik</I>) or a pledge in respect of registered
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares, as well as any other particulars which must be recorded in our shareholders&#146; register pursuant to Dutch law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Objectives </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate objectives
are: (1)&nbsp;to develop products and services in the area of biotechnology, (2)&nbsp;to finance group companies or other parties, (3)&nbsp;to borrow, to lend to raise funds, including the issue of bonds, promissory notes or other financial
instruments or evidence of indebtedness as well as to enter into agreements in connection with the aforementioned, (4)&nbsp;to supply advice and to render services to group companies and other parties, (5)&nbsp;to render guarantees, to bind us, to
provide security, to warrant performance in any other way and to assume liability, whether jointly and severally or otherwise, in respect of obligations of group companies or other parties, (6)&nbsp;to incorporate, to participate in any way
whatsoever in, to manage, to supervise and to hold any other interest in other entities, companies, partnerships and businesses, (7)&nbsp;to obtain, alienate, encumber, manage and exploit registered property and items of property in general,
(8)&nbsp;to trade in currencies, securities and items of property in general, (9)&nbsp;to develop and trade in patent, trademarks, licenses, know-how and other intellectual property rights, and (10)&nbsp;to perform any and all activity of an
industrial, financial or commercial nature and to do anything which in the broadest sense is connected with or may be conducive to the above-mentioned objects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limitation on Liability and Indemnification Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Dutch law, directors may be held liable by us or by third parties for damages in the event of improper or negligent performance of their duties,
including as a result of infringement of our articles of association or of certain provisions of the Dutch Civil Code. In certain circumstances, they may also incur additional specific civil and criminal liabilities. Directors and certain other
officers are insured under an insurance policy taken out by us against damages resulting from their conduct when acting in the capacities as such directors or officers. In addition, our articles of association provide for indemnification of our
current and former directors (and such other of our current or former officer or employee as designated by our board of directors), including reimbursement for reasonable legal fees and damages or fines based on acts or failures to act in their
duties. No indemnification shall be given to an indemnified officer (1)&nbsp;if a competent court or arbitral tribunal has established, without possibility for appeal, that the acts or omissions of such indemnified officer that led to the financial
losses, damages, expenses, suit, claim, action or legal proceedings resulted from either an improper performance of his or her duties as an officer of the company or an unlawful or illegal act, (2)&nbsp;to the extent that his or her financial
losses, damages and expenses are covered by insurance and the insurer has settled, or has provided reimbursement for, these financial losses, damages and expenses (or has irrevocably undertaken to do so) and (3)&nbsp;in relation to proceedings
brought by such indemnified officer against us, except for proceedings brought to enforce indemnification to which he or she is entitled pursuant to our articles of association or an agreement between such indemnified officer and us which has been
approved by our board of directors. Furthermore, indemnification under our articles of association will generally not be available in instances of willful misconduct (<I>opzet</I>), intentionally reckless (<I>bewust roekeloos</I>) or seriously
culpable (<I>ernstig verwijtbaar</I>) conduct unless Dutch law provides otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholders&#146; Meetings and Consents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>General Meeting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General meetings of shareholders are held
in Utrecht, Amsterdam, Rotterdam, The Hague or in the municipality of Haarlemmermeer (Schiphol Airport), all of which are in the Netherlands. The annual general meeting of shareholders must be held within six months of the end of each financial
year. Additional extraordinary general meetings of shareholders may also be held, whenever considered appropriate by the board of directors. An additional extraordinary general meeting of shareholders must also be held within three months after our
board of directors has considered it to be likely that our shareholders&#146; equity has decreased to an amount equal to or lower than half of our paid up and called up capital, in order to discuss the measures to be taken if so required. If our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors has failed to ensure the annual general meeting of shareholders or the mandatory extraordinary general meeting of shareholders is held, each shareholder or others with meeting
rights under Dutch law may be authorized by the competent Dutch court in preliminary relief proceedings to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Dutch law, one or more
shareholders or others with meeting rights under Dutch law, who jointly represent at least one-tenth of the issued capital may request us to convene a general meeting, setting out in detail the matters to be discussed. If our board of directors has
not taken the steps necessary to ensure that such meeting can be held within six weeks after the request, the requesting party/parties may, on their application, be authorized by the competent Dutch court in preliminary relief proceedings to convene
a general meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General meetings of shareholders can be convened by a notice to be published in a Dutch daily newspaper with national
circulation, which shall include an agenda stating the items to be voted and/or discussed and any other particulars required under Dutch law. The agenda shall include such items as have been included therein by the board of directors. The agenda
shall also include such items requested by one or more shareholders or others with meeting rights under Dutch law, representing at least 3% of the issued share capital. Requests must be made in writing and received by us at least 60 days before the
day of the meeting. No resolutions shall be adopted on items other than those which have been included in the agenda, unless by a unanimous vote of all shareholders and others with voting rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the Dutch Corporate Governance Code, or DCGC, shareholders are expected to exercise the right of requesting the convening of a general
meeting of shareholders or of putting an item on the agenda only after consulting the board of directors in that respect. If one or more shareholders intend to request that an item be put on the agenda that may result in a change in our strategy
(e.g., the removal of directors), the board of directors should be given the opportunity to invoke a reasonable response time of up to 180 days after the board of directors is informed of the intentions of the shareholder(s). The board of directors
should use this period for further deliberation, constructive consultation (in any event with the shareholder(s) who have made the request) and the exploration of alternatives. At the end of the response period, the board of directors should report
its actions to the general meeting of shareholders. The response time may be invoked only once for any given general meeting of shareholders and may not be invoked for an agenda item in respect of which the response period has been invoked
previously or for a general meeting of shareholders if a shareholder holds at least 75% of our issued share capital as a consequence of a successful public offer (irrespective of whether the offer was friendly or hostile). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting is presided over by the chairman of the board of directors. If no chairman has been elected or if he or she is not present at the meeting,
the general meeting shall be presided over by the chief executive officer. If no chief executive officer has been elected or if he or she is not present at the meeting, the general meeting shall be presided over by another director present at the
meeting. If no director is present at the meeting, the general meeting shall be presided over by any other person appointed by the general meeting. In each case, the person who should chair the general meeting pursuant to the rules described above
may appoint another person to chair the general meeting instead. Directors may always attend a general meeting of shareholders. In these meetings, they have an advisory vote. The chairman of the meeting may decide at his or her discretion to admit
other persons to the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All shareholders and others with meeting rights under Dutch law are authorized to attend the general meeting of
shareholders, to address the meeting and, in so far as they have such right, to vote. For this purpose, those who have voting rights and/or meeting rights under Dutch law on the record date for a general meeting of shareholders (i.e., the 28th day
prior to the meeting) and are recorded as such in a register designated by the board of directors shall be considered to have those rights, irrespective of whoever is entitled to the shares at the time of the general meeting of shareholders. The
board of directors is free to determine, when convening a general meeting of shareholders, whether to apply a record date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Quorum and Voting Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each common share and each preferred share carries the right to cast one vote at the general meeting of shareholders. This right can be exercised in person or
by proxy. No vote may be cast at a general meeting of shareholders in respect of a share belonging to us or any of our subsidiaries or in respect of a share for which we or any of our subsidiaries holds the depository receipts. Persons with a right
to the use and enjoyment of our shares held by another person and pledgees of shares belonging to us or our subsidiaries are not precluded from exercising their voting rights if the right to use and enjoyment or pledge was created before the
relevant share belonged to us or one of our subsidiaries. We and our subsidiaries may not vote shares in respect of which we or any of our subsidiaries hold(s) a right of use and enjoyment or a pledge. Shares which cannot be voted pursuant to these
rules will not be taken into account for the purpose of determining the number of votes cast, or the amount of the share capital that is represented, at a general meeting of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with Dutch law and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable to
general meetings of shareholders. Quorum requirements will only apply pursuant to Dutch law in case of a limited number of situations. Decisions of the general meeting of shareholders are taken by a simple majority of votes cast, except where Dutch
law or our articles of association provide for a qualified majority or unanimity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Election of Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our articles of association,
the directors are appointed by the general meeting of shareholders upon nomination by our board of directors. However, the general meeting of shareholders may at all times overrule the binding nomination by a resolution adopted by at least a
two-thirds majority of the votes cast, provided such majority represents more than half of the issued share capital. If the general meeting of shareholders overrules the binding nomination, the board of directors shall make a new nomination. If the
nomination comprises one candidate for a vacancy, a resolution concerning the nomination shall result in the appointment of the candidate, unless the nomination is overruled. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At a general meeting of shareholders, a resolution to appoint a director can only be passed in respect of candidates whose names are stated for that purpose
in the agenda of that general meeting of shareholders or in the explanatory notes thereto. Upon the appointment of a person as a director, the general meeting of shareholders shall determine whether that person is appointed as executive director or
as non-executive director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Duties and Liabilities of Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Dutch law, the board of directors as a collective is responsible for our management, strategy, policy and operations. The executive directors manage our
day-to-day business and operations and implement our strategy. The non-executive directors focus on the supervision on the policy and functioning of the performance of the duties of all directors and our general state of affairs. Each director has a
statutory duty to act in the corporate interest of the company and its business. Under Dutch law, the corporate interest extends to the interests of all corporate stakeholders, such as shareholders, creditors, employees, customers and suppliers. The
duty to act in the corporate interest of the company also applies in the event of a proposed sale or break-up of the company, provided that the circumstances generally dictate how such duty is to be applied and how the respective interests of
various groups of stakeholders should be weighed. Any resolution of the board of directors regarding a material change in our identity or character requires approval of the general meeting of shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and Other Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amount
Available for Distribution </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a Dutch public company with limited liability (<I>naamloze vennootschap</I>), we may only make distributions to the
extent that our shareholders&#146; equity exceeds the sum of the paid-in and called-up share capital plus the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reserves as required to be maintained by Dutch law. Under our articles of association, a dividend is first paid out of the profit, if available for distribution, with respect to any preferred
shares. After that, the board of directors shall determine which part of the remaining profit shall be added to our reserves. After reservation by the board of directors of any profit, the remaining profit will be at the disposal of the general
meeting of shareholders for distribution on our common shares. However, a distribution to the holders of common shares can only be resolved upon by the general meeting upon a proposal of the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may only make a distribution of dividends after the adoption of our annual accounts demonstrating that such distribution is legally permitted. The board of
directors is permitted, subject to certain requirements, to declare interim dividends (or other interim distributions) without the approval of the general meeting of shareholders. The general meeting of shareholders, subject to certain requirements
and a proposal to that effect made by the board of directors, may decide to make distributions from our distributable reserves. The board of directors, however, may resolve to charge amounts to be paid up on shares against our reserves, irrespective
of whether those shares are issued to existing shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends and other distributions shall be payable on such date and, if it concerns a
distribution in cash, in such currency as determined by the board of directors. If it concerns a distribution in the form of assets, the board of directors shall determine the value attributed to such distribution for purposes of recording the
distribution in our accounts with due observance of applicable law (including the applicable accounting principles). Claims to dividends and other distributions not paid within five years from the date that such dividends or distributions became
payable, will lapse and any such amounts will be considered to have been forfeited to us (<I>verjaring</I>). For the purpose of calculating the amount or allocation of any distribution, shares held by us in our own capital shall not be taken into
account. No distribution shall be made to us in respect of shares held by us in our own capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not anticipate paying any cash dividends for the
foreseeable future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Squeeze out Procedures </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under
Dutch law, a shareholder who, alone or together with one or more group companies, for his/their own account contribute(s) at least 95% of our issued share capital may initiate proceedings against our minority shareholders jointly for the transfer of
their shares to the claimant. The proceedings are held before the Enterprise Chamber of the Amsterdam court of Appeal, or Enterprise Chamber. The Enterprise Chamber may grant the claim for squeeze out in relation to all minority shareholders and
will determine the price to be paid for the shares, if necessary after appointment of one or three experts who will offer an opinion to the Enterprise Chamber on the value to be paid for the shares of the minority shareholders. Once the order to
transfer becomes final before the Enterprise Chamber, the shareholder acquiring the shares shall give written notice of the date and place of payment and the price to the holders of the shares to be acquired whose addresses are known to such
shareholder. Unless the addresses of all of them are known to the acquiring shareholder, such shareholder is required to publish the same in a Dutch daily newspaper with a national circulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Protective measures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Dutch law, various
protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. Our governance arrangements include several provisions that may have the effect of making a takeover of our company more difficult or less
attractive. In this respect, our general meeting of shareholders has granted the right to the Protective Foundation to acquire preferred shares pursuant to a call option agreement entered into on May&nbsp;6, 2016, or the call option agreement. This
call option is continuous in nature and can be exercised repeatedly on multiple occasions. If the Protective Foundation exercises the call option pursuant to the call option agreement, an amount of preferred shares up to 100% of our issued capital
held by third parties immediately prior to the issuance of such preferred shares will be issued to the Protective Foundation. These preferred shares will be issued to the Protective Foundation under the obligation to pay up to 25% of their nominal
value upon issuance. In order for the Protective Foundation to finance the issue price in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relation to the preferred shares, the Protective Foundation intends to enter into a finance arrangement with a bank. As an alternative to securing financing with a bank, subject to applicable
restrictions under Dutch law, the call option agreement provides that the Protective Foundation may request us (1)&nbsp;to provide, or cause our subsidiaries to provide, sufficient funding to the Protective Foundation to enable it to satisfy the
payment obligation (or part thereof) in cash and/or (2)&nbsp;to charge an amount equal to the payment obligation (or part thereof) against our profits and/or reserves in satisfaction of such payment obligation. The Protective Foundation&#146;s
articles of association provide that it will promote and protect the best interests of us, our associated business and our stakeholders and opposing influences that conflict with these interests and threaten our strategy, continuity, independence
and/or identity. These influences may include a third party acquiring a significant percentage of our common shares, the announcement of an unsolicited public offer for our common shares, other concentration of control over our common shares or any
other form of undue pressure on us to alter our strategic policies. The Protective Foundation is structured to operate independently of us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As indicated
above, if the Protective Foundation would exercise its call option, the preferred shares to be issued pursuant thereto shall be issued against the obligation to pay up to 25% of their nominal value. The voting rights of our shares are based on
nominal value and, as we expect our common shares to trade substantially in excess of nominal value, preferred shares issued at 25% of their nominal value can carry significant voting power for a substantially reduced price compared to the price of
our common shares and thus can be used as a defensive measure. These preferred shares will have both a liquidation and dividend preference over our common shares and will accrue cash dividends at a pre-determined rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Protective Foundation would be expected to require us to cancel its preferred shares once the perceived threat to the company and its stakeholders has
been removed or sufficiently mitigated or neutralized. However, subject to the same limitations described above, the Protective Foundation would continue to have the right to exercise the call option in the future in response to a new threat to the
interests of us, our business and our stakeholders from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our articles of association contain certain provisions which might
have the effect of delaying or preventing a change in control or otherwise discouraging a potential acquirer from attempting to obtain control of us. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements that certain shareholder matters, including the amendment of our articles of association may only be
voted on by the general meeting of shareholders at the proposal of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a provision that our directors may only be removed by the general meeting of shareholders by a two-thirds
majority of votes cast, provided such majority represents more than half of our issued share capital if such removal is not proposed by our board of directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our directors being appointed on the basis of a binding nomination by our board of directors, which can only be
overruled by the general meeting of shareholders by a resolution adopted by at least a two-thirds majority of the votes cast, provided such majority represents more than half of the issued share capital (in which case the board of directors shall
make a new nomination). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, we may implement staggered terms of up to four years for our directors, as a result of which only
approximately one-fourth of our directors will be subject to election in any one year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of Dutch Corporate Law and Our Articles of
Association and U.S. Corporate Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following comparison between Dutch corporation law, which applies to us, and Delaware corporation law, the law
under which many publicly listed corporations in the United States are incorporated, discusses additional matters not otherwise described in this prospectus. Although we believe this summary is materially accurate, the summary is subject to Dutch
law, including Book 2 of the Dutch Civil Code, and Delaware corporation law, including the Delaware General Corporation Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Governance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Duties of Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands</I>.&nbsp;We have
a one-tier board structure consisting of one or more executive directors and one or more non-executive directors. Under Dutch law, the board of directors as a collective is responsible for the management and the strategy, policy and operations of
the company. See &#147;&#151;Board of Directors&#151;Duties and Liabilities of Directors.&#148;<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>.&nbsp;The board of directors bears
the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. Delaware
courts have decided that the directors of a Delaware corporation are required to exercise informed business judgment in the performance of their duties. Informed business judgment means that the directors have informed themselves of all material
information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In
addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to
the stockholders. <I> </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Terms </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
Netherlands.</I> The DCGC provides the following best practice recommendations on the terms for directors&#146; service: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Executive directors should be appointed for a maximum period of four years, without limiting the number of
consecutive terms executive directors may serve. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Non-executive directors should be appointed for two consecutive periods of no more than four years. Thereafter,
non-executive directors may be reappointed for a maximum of two consecutive periods of no more than two years, provided that any reappointment after an eight-year term of office should be disclosed and explained in the company&#146;s annual board
report. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive director currently has an employment agreement with us for an indefinite period of time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting of shareholders shall at all times be entitled to suspend or remove a director. Under our articles of association, the general meeting of
shareholders may only adopt a resolution to suspend or remove such director by at least a two-thirds majority of the votes cast, provided such majority represents more than half of the issued share capital, unless the resolution is passed at the
proposal of the board of directors, in which case a simple majority of the votes cast is sufficient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware.</I> The Delaware General Corporation
Law generally provides for a one-year term for directors, but permits directorships to be divided into up to three classes with up to three-year terms, with the years for each class expiring in different years, if permitted by the certificate of
incorporation, an initial bylaw or a bylaw adopted by the stockholders. A director elected to serve a term on a &#147;classified&#148; board may not be removed by stockholders without cause. There is no limit in the number of terms a director may
serve. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Director Vacancies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
Netherlands.</I>&nbsp;Under Dutch law, directors are appointed and reappointed by the general meeting of shareholders. Under our articles of association, directors are appointed by the general meeting of shareholders upon the binding nomination by
our board of directors. However, the general meeting of shareholders may at all times overrule the binding nomination by a resolution adopted by at least a two-thirds majority of the votes cast, provided such majority represents more than half of
the issued share capital. If the general meeting of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholders overrules the binding nomination, the board of directors shall make a new nomination. If the nomination comprises one candidate for a vacancy, a resolution concerning the nomination
shall result in the appointment of the candidate, unless the nomination is overruled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our articles of association, a resolution of the general
meeting of shareholders to appoint a director can only be passed in respect of candidates whose names are stated for that purpose in the agenda of that general meeting of shareholders or in the explanatory notes thereto. Upon the appointment of a
person as a director, the general meeting of shareholders shall determine whether that person is appointed as executive director or as non-executive director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>.&nbsp;The Delaware General Corporation Law provides that vacancies and newly created directorships may be filled by a majority of the
directors then in office (even though less than a quorum) unless (i)&nbsp;otherwise provided in the certificate of incorporation or bylaws of the corporation or (ii)&nbsp;the certificate of incorporation directs that a particular class of stock is
to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy. <I> </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conflict-of-Interest Transactions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
Netherlands</I>.&nbsp;Under Dutch law and our articles of association, our directors shall not take part in any discussion or decision-making that involves a subject or transaction in relation to which he or she has a conflict of interest with us.
Our articles of association provide that if as a result thereof no resolution of the board of directors can be adopted, the resolution can nonetheless be adopted by the board of directors as if none of the directors had a conflict of interest. In
that case, each director is entitled to participate in the discussion and decision-making process and to cast a vote.<I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DCGC provides the
following best practice recommendations in relation to conflicts of interests: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a director should report any potential conflict of interest in a transaction that is of material significance to
the company and/or to such director to the other directors without delay, providing all relevant information in relation to the conflict; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the board of directors should then decide, outside the presence of the director concerned, whether there is a
conflict of interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transactions in which there is a conflict of interest with a director should be agreed on arms&#146; length
terms; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a decision to enter into such a transaction in which there is a conflict of interest with a director that is of
material significance to the company and/or to such director shall require the approval of the board of directors, and such transactions should be disclosed in the company&#146;s annual board report. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>.&nbsp;The Delaware General Corporation Law generally permits transactions involving a Delaware corporation and an interested director of that
corporation if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the material facts as to the director&#146;s relationship or interest are disclosed and a majority of
disinterested directors consent; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the material facts are disclosed as to the director&#146;s relationship or interest and a majority of shares
entitled to vote thereon consent; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transaction is fair to the corporation at the time it is authorized by the board of directors, a committee of
the board of directors or the stockholders. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Proxy Voting by Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;An absent director may issue a proxy for a specific board meeting but only to another director in writing (including in electronic
form). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware.</I>&nbsp;A director of a Delaware corporation may not issue a proxy representing the
director&#146;s voting rights as a director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholder Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;In accordance
with Dutch law and our articles of association, each issued common share confers the right to cast one vote at the general meeting of shareholders. No vote may be cast at a general meeting of shareholders in respect of a share belonging to us or any
of our subsidiaries or in respect of a share for which we or any of our subsidiaries holds the depository receipts. Persons with a right to the use and enjoyment of our shares held by another person and pledgees of shares belonging to us or our
subsidiaries are not precluded from exercising their voting rights if the right to use and enjoyment or pledge was created before the relevant share belonged to us or one of our subsidiaries. We and our subsidiaries may not vote shares in respect of
which we or any of our subsidiaries hold(s) a right of use and enjoyment or a pledge. Shares which cannot be voted pursuant to these rules will not be taken into account for the purpose of determining the number of votes cast, or the amount of the
share capital that is represented, at a general meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For each general meeting of shareholders, the board of directors may apply a
record date in order to establish which shareholders are entitled to attend and vote at the general meeting of shareholders. The record date and the manner in which shareholders can register and exercise their rights will be set out in the notice of
the meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware.</I>&nbsp;Under the Delaware General Corporation Law, each stockholder is entitled to one vote per share of stock, unless the
certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of directors of the corporation, or at elections held under specified circumstances. Either the
certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event will a quorum consist of less than one third of
the shares entitled to vote at a meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders as of the record date for the meeting are entitled to vote at the meeting, and the board of
directors may fix a record date that is no more than 60 nor less than 10&nbsp;days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day on which notice is given,
or if notice is waived then the record date is the close of business on the day next preceding the day on which the meeting is held. The determination of the stockholders of record entitled to notice or to vote at a meeting of stockholders shall
apply to any adjournment of the meeting, but the board of directors may fix a new record date for the adjourned meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholder Proposals
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;Pursuant to our articles of association, extraordinary general meetings of shareholders will be held whenever required
under Dutch law or whenever our board of directors deems such to be appropriate or necessary. Pursuant to Dutch law, one or more shareholders or others with meeting rights under Dutch law representing at least one-tenth of the issued share capital
may request us to convene a general meeting, setting out in detail the matters to be discussed. If our board of directors has not taken the steps necessary to ensure that such meeting can be held within six weeks after the request, the requesting
party/parties may, on their application, be authorized by the competent Dutch court in preliminary relief proceedings to convene a general meeting of shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, under our articles of association, the agenda for a general meeting of shareholders shall include such items requested by one or more shareholders, and
others with meeting rights under Dutch law, representing at least 3% of the issued share capital. Requests must be made in writing and received by us at least 60 days before the day of the meeting. In accordance with the DCGC, shareholders are
expected to exercise the right of requesting the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
convening of a general meeting of shareholders or of putting an item on the agenda only after consulting the board of directors in that respect. If one or more shareholders intend to request that
an item be put on the agenda that may result in a change in our strategy (e.g., the removal of directors), the board of directors should be given the opportunity to invoke a reasonable response time of up to 180 days after the board of directors is
informed of the intentions of the shareholder(s). The board of directors should use this period for further deliberation, constructive consultation (in any event with the shareholder(s) who have made the request) and the exploration of alternatives.
At the end of the response period, the board of directors should report its actions to the general meeting of shareholders. The response time may be invoked only once for any given general meeting of shareholders and may not be invoked for an agenda
item in respect of which the response period has been invoked previously or for a general meeting of shareholders if a shareholder holds at least 75% of our issued share capital as a consequence of a successful public offer (irrespective of whether
the offer was friendly or hostile). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware.</I>&nbsp;Delaware law does not specifically grant stockholders the right to bring business before an
annual or special meeting. However, if a Delaware corporation is subject to the SEC&#146;s proxy rules, a stockholder who owns at least $2,000 in market value, or 1% of the corporation&#146;s securities entitled to vote, may propose a matter for a
vote at an annual or special meeting in accordance with those rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Action by Written Consent </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;Our articles of association do not allow shareholders&#146; resolutions to be adopted in writing without holding a meeting of
shareholders. However, holders of preferred shares may pass resolutions in writing instead of at a meeting by a unanimous vote of all shareholders concerned. These votes may be cast electronically. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware.</I>&nbsp;Although permitted by Delaware law, publicly listed companies do not typically permit stockholders of a corporation to take action by
written consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appraisal Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
Netherlands.</I>&nbsp;The concept of appraisal rights is not known as such under Dutch law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, pursuant to Dutch law a shareholder who, alone or
together with one or more group companies, for his/their own account contribute(s) at least 95% of our issued share capital may initiate proceedings against our minority shareholders jointly for the transfer of their shares to the claimant. See
&#147;&#151;Shareholder Vote on Certain Reorganizations&#151;The Netherlands.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, Dutch law provides that, to the extent that the
acquiring company in a cross-border merger is organized under the laws of another Member State of the European Economic Area, a shareholder of a Dutch disappearing company who has voted against the cross-border merger may file a claim with the Dutch
company for compensation. Such compensation is to be determined by one or more independent experts. The shares of such shareholder that are subject to such claim will cease to exist as of the moment of entry into effect of the cross-border merger.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>.<I>&nbsp;</I>The Delaware General Corporation Law provides for stockholder appraisal rights, or the right to demand payment in cash of
the judicially determined fair value of the stockholder&#146;s shares, in connection with certain mergers and consolidations.<I></I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Shareholder Suits
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;In the event a third party is liable to a Dutch company, only the company itself can bring a civil action against that
party. The individual shareholders do not have the right to bring an action on behalf of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company. If individual shareholders bring an action for damages against such a third party in their name, a court will under normal circumstances dismiss such a claim. Only in the event that the
cause for the liability of a third party to the company also constitutes a tortious act directly against a shareholder could that shareholder have an individual right of action against such third party in its own name. The Dutch Civil Code provides
for the possibility to initiate actions collectively. A foundation or an association whose objective is to protect the rights of a group of persons having similar interests can institute a collective action. The collective action itself cannot
result in an order for payment of monetary damages but may only result in a declaratory judgment (verklaring voor recht). In order to obtain compensation for damages, the foundation or association and the defendant may reach&#151;often on the basis
of such declaratory judgment&#151;a settlement. A Dutch court may declare the settlement agreement binding upon all the injured parties with an opt-out choice for an individual injured party. An individual injured party may also itself institute a
civil claim for damages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware.</I>&nbsp;Under the Delaware General Corporation Law, a stockholder may bring a derivative action on behalf of the
corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated stockholders where the requirements for maintaining a class action under Delaware law have
been met. A person may institute and maintain such a suit only if that person was a stockholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a stockholder at
the time of the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim
before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Repurchase of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;Under Dutch law, a limited liability company may not subscribe for newly issued shares in its own capital. A limited liability
company may, however, subject to certain restrictions of Dutch law and its articles of association, acquire shares in its own capital. We may acquire fully paid shares in our own capital at any time for no valuable consideration. Furthermore,
subject to certain provisions of Dutch law and our articles of association, we may repurchase fully paid shares in our own capital for valuable consideration to the extent that (i) such repurchase would not cause our shareholders&#146; equity to
fall below an amount equal to the sum of the paid-up and called-up part of the issued share capital and the reserves we are required to maintain pursuant to applicable law and (ii) we would not as a result of such repurchase hold more than 50% of
our own issued share capital, including shares held by our subsidiaries and shares in respect of which a pledge has been created in our favor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than
shares acquired for no valuable consideration, common shares may only be acquired following a resolution of our board of directors, acting pursuant to an authorization for the repurchase of shares granted by the general meeting of shareholders. An
authorization by the general meeting of shareholders for the repurchase of shares can be granted for a maximum period of 18 months. Such authorization must specify the number and class of shares that may be acquired, the manner in which these shares
may be acquired and the price range within which the shares may be acquired. At our annual general meeting of shareholders held on July&nbsp;20, 2018, our board of directors was authorized, for a period of 18 months following the date of such
meeting, to cause the repurchase of shares (or depository receipts for shares) by us of up to 10% of our issued share capital (determined as at the close of business on the date of that meeting), for a price per share not exceeding 110% of the
average closing price of our common shares on Nasdaq for the five trading days prior to the date the acquisition is agreed upon by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No authorization
of the general meeting of shareholders is required if common shares are acquired by us with the intention of transferring such common shares to our employees (including employees of our group companies) under an applicable employee share purchase
plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>.&nbsp;Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares unless the capital of the
corporation is impaired or the purchase or redemption would cause an impairment of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital any of its preferred shares or, if no preferred shares are outstanding, any of its own shares if
such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Protective Measures </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
Netherlands.</I>&nbsp;Under Dutch law, various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. Our governance arrangements include several provisions that may have the effect of making a
takeover of our company more difficult or less attractive, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the authorization of a class of preferred shares that can be issued to the Protective Foundation upon the
exercise by the Protective Foundation of its call option, in such a manner as to dilute the voting interest of any potential acquirer or activist; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possibility to appoint our board members for staggered terms, as a result of which only approximately
one-fourth of our directors may be subject to election in any one year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a provision that our directors may only be removed by the general meeting of shareholders by a two-thirds
majority of votes cast, provided such majority represents more than half of our issued share capital, if such removal is not proposed by our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our directors being appointed on the basis of a binding nomination by our board of directors, which can only be
overruled by the general meeting of shareholders by a resolution adopted by at least a two-thirds majority of the votes cast, provided such majority represents more than half of the issued share capital (in which case the board of directors shall
make a new nomination); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requirements that certain shareholder matters, including an amendment of our articles of association, may only be
voted on by the general meeting of shareholders at the proposal of our board of directors. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware.</I>&nbsp;In addition to other
aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from actions
following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the
Delaware General Corporation Law prohibits &#147;business combinations,&#148; including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder that
beneficially owns 15% or more of a corporation&#146;s voting stock, within three years after the person becomes an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transaction that will cause the person to become an interested stockholder is approved by the board of
directors of the target prior to the transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the completion of the transaction in which the person becomes an interested stockholder, the interested
stockholder holds at least 85% of the voting stock of the corporation not including shares owned by persons who are directors and officers of interested stockholders and shares owned by specified employee benefit plans; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after the person becomes an interested stockholder, the business combination is approved by the board of
directors of the corporation and holders of at least 66.67% of the outstanding voting stock, excluding shares held by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Delaware corporation may elect not to be governed by Section&nbsp;203 by a provision contained in the original certificate of incorporation of the
corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board of directors of the
corporation. Such an amendment is not effective until twelve months following its adoption. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inspection of Books and Records </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;The board of directors should provide the general meeting of shareholders with all information requested by the general meeting of
shareholders, unless this would be contrary to an overriding interest of ours. If the board of directors invokes an overriding interest, it must give its reasons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware.</I>&nbsp;Under the Delaware General Corporation Law, any stockholder may inspect for any proper purpose certain of the corporation&#146;s books
and records during the corporation&#146;s usual hours of business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;The general meeting of shareholders shall at all times be entitled to suspend or remove a director. Under our articles of
association, the general meeting of shareholders may only adopt a resolution to suspend or remove such a director by at least a two-thirds majority of the votes cast, provided such majority represents more than half of the issued share capital,
unless the resolution is passed at the proposal of the board of directors, in which latter case a simple majority of the votes cast is sufficient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware.</I>&nbsp;Under the Delaware General Corporation Law, any director or the entire board of directors may be removed, with or without cause, by the
holders of a majority of the shares then entitled to vote at an election of directors, except (i)&nbsp;unless the certificate of incorporation provides otherwise, in the case of a corporation whose board is classified, stockholders may effect such
removal only for cause, or (ii)&nbsp;in the case of a corporation having cumulative voting, if less than the entire board is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect
him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preemptive Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The
Netherlands.</I>&nbsp;Under Dutch law and our articles of association, in the event of an issuance of common shares, each holder of common shares will have a pro rata preemptive right in proportion to the aggregate nominal value of the common shares
held by such holder (with the exception of common shares to be issued to our employees or employees of our group companies, common shares issued against a contribution other than in cash, or common shares issued to a party exercising a previously
acquired right to subscribe for such common shares). Under our articles of association, the preemptive rights in respect of newly issued common shares may be restricted or excluded by a resolution of the general meeting of shareholders at the
proposal of the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors may restrict or exclude the preemptive rights in respect of newly issued common shares if it
has been designated as the authorized body to do so by the general meeting of shareholders. Such designation can be granted for a period not exceeding five years. A resolution of the general meeting of shareholders to restrict or exclude the
preemptive rights or to designate the board of directors as the authorized body to do so requires a two-thirds majority of the votes cast, if less than one&nbsp;half of our issued share capital is represented at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our annual general meeting of shareholders held on July&nbsp;20, 2018, our board of directors was authorized for a period of five years from the date of
such meeting to limit or exclude preemptive rights in connection with the issue of common shares or the granting of rights to subscribe for common shares pursuant to the use of the authorization also granted at such annual general meeting of
shareholders to the board of directors to issue common shares and grant rights to subscribe for common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our articles of association, no
preemptive rights apply in respect of preferred shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>.&nbsp;Under the Delaware General Corporation Law, stockholders have no preemptive rights to
subscribe for additional issues of stock or to any security convertible into such stock unless, and to the extent that, such rights are expressly provided for in the certificate of incorporation.<I> </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;Dutch law
provides that dividends may be distributed after adoption of the annual accounts by the general meeting of shareholders from which it appears that such dividend distribution is allowed. Moreover, dividends, interim dividends (or other interim
distributions) and distributions from distributable reserves may only be made to the extent that shareholders&#146; equity exceeds the amount of the paid-up and called-up part of the issued share capital and the reserves that must be maintained
under Dutch law or the company&#146;s articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our articles of association, a dividend is first paid out of the profit, if
available for distribution, with respect to any preferred shares. After that, the board of directors shall determine which part of the remaining profit shall be added to our reserves. After reservation by the board of directors of any profit, the
remaining profit will be at the disposal of the general meeting of shareholders for distribution on our common shares. However, a distribution to the holders of common shares can only be resolved upon by the general meeting at the proposal of the
board of directors. We may only make a distribution of dividends after the adoption of our annual accounts demonstrating that such distribution is legally permitted. The board of directors is permitted, subject to certain requirements, to declare
interim dividends (or other interim distributions) without the approval of the general meeting of shareholders. The general meeting of shareholders, subject to certain requirements and a proposal to that effect made by the board of directors, may
decide to make distributions from our distributable reserves. The board of directors, however, may resolve to charge amounts to be paid up on shares against our reserves, irrespective of whether those shares are issued to existing shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends and other distributions shall be payable on such date and, if it concerns a distribution in cash, in such currency as determined by the board of
directors. If it concerns a distribution in the form of assets, the board of directors shall determine the value attributed to such distribution for purposes of recording the distribution in our accounts with due observance of applicable law
(including the applicable accounting principles). Claims to dividends and other distribution not paid within five years from the date that such dividends or distributions became payable, will lapse and any such amounts will be considered to have
been forfeited to us (<I>verjaring</I>).For the purpose of calculating the amount or allocation of any distribution, shares held by us in our own capital shall not be taken into account. No distribution shall be made to us in respect of shares held
by us in our own capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware. </I>Under the Delaware General Corporation Law, a Delaware corporation may pay dividends out of its surplus (the
excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year (provided that the amount of the capital of the corporation is not less
than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). In determining the amount of surplus of a Delaware corporation, the assets of the
corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors, without regard to their historical book value. Dividends may be paid in the form of common
shares, property or cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shareholder Vote on Certain Reorganizations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;Under Dutch law, the general meeting of shareholders must approve resolutions of the board of directors relating to a material
change in the identity or the character of the company or the business of the company, which includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a transfer of the business or virtually the entire business to a third party; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the entry into or termination of a long-term cooperation of the company or a subsidiary with another legal entity
or company or as a fully liable partner in a limited partnership or general partnership, if such cooperation or termination is of far-reaching significance for the company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acquisition or divestment by the company or a subsidiary of a participating interest in the capital of a
company having a value of at least one-third of the amount of the company&#146;s assets according to its statement of financial position and explanatory notes or, if the company prepares a consolidated statement of financial position, according to
its consolidated statement of financial position and explanatory notes in the last adopted annual accounts of the company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Dutch
law, a shareholder who, alone or together with one or more group companies, for his/their own account contribute(s) at least 95% of a company&#146;s issued share capital may initiate proceedings against the company&#146;s minority shareholders
jointly for the transfer of their shares to the claimant. The proceedings are held before the Enterprise Chamber, which may grant the claim for squeeze out in relation to all minority shareholders and will determine the price to be paid for the
shares, if necessary after appointment of one or three experts who will offer an opinion to the Enterprise Chamber on the value to be paid for the shares of the minority shareholders. Once the order to transfer becomes final before the Enterprise
Chamber, the shareholder acquiring the shares shall give written notice of the date and place of payment and the price to the holders of the shares to be acquired whose addresses are known to such shareholder. Unless the addresses of all of them are
known to the acquiring shareholder, such shareholder is required to publish the same in a Dutch daily newspaper with a national circulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware</I>.&nbsp;Under the Delaware General Corporation Law, the vote of a majority of the outstanding shares of capital stock entitled to vote thereon
generally is necessary to approve a merger or consolidation or the sale of all or substantially all of the assets of a corporation. The Delaware General Corporation Law permits a corporation to include in its certificate of incorporation a provision
requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Delaware General Corporation Law, no vote of the stockholders of a surviving corporation to a merger is needed, however, unless required by the
certificate of incorporation, if (i)&nbsp;the agreement of merger does not amend in any respect the certificate of incorporation of the surviving corporation, (ii)&nbsp;the shares of stock of the surviving corporation are not changed in the merger
and (iii)&nbsp;the number of shares of common stock of the surviving corporation into which any other shares, securities or obligations to be issued in the merger may be converted does not exceed 20% of the surviving corporation&#146;s common stock
outstanding immediately prior to the effective date of the merger. In addition, stockholders may not be entitled to vote in certain mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of such
corporation, but the stockholders will be entitled to appraisal rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Remuneration of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Netherlands.</I>&nbsp;Under Dutch law, we must adopt a remuneration policy for our directors. Such remuneration policy, and changes thereto, shall be
adopted by the general meeting of shareholders at the proposal of the board of directors. The board of directors determines the remuneration of the directors in accordance with the remuneration policy. Our executive directors may not participate in
the discussions or decision-making regarding the remuneration of executive directors. A proposal by the board of directors with respect to remuneration schemes in the form of shares or rights to shares is submitted by the board of directors to the
general meeting for its approval. This proposal must set out at least the maximum number of shares or rights to shares to be granted to the directors and the criteria for granting or amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our shareholders approved our Supervisory Board Member Compensation Program at a general meeting on May&nbsp;6, 2016. Our shareholders have approved certain
amendments to such program, and the program has been renamed the Non-Executive Director Compensation Program. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware.</I>&nbsp;Under the Delaware General Corporation Law, the stockholders do not generally have the
right to approve the compensation policy for directors or the senior management of the corporation, although certain aspects of executive compensation may be subject to stockholder vote due to the provisions of U.S. federal securities and tax law,
as well as exchange requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dutch Corporate Governance Code </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DCGC contains both principles and best practice provisions for boards of directors, shareholders and general meetings of shareholders, financial reporting,
auditors, disclosure, compliance and enforcement standards. A copy of the DCGC can be found on <I>www.mccg.nl</I>. As a listed Dutch company incorporated under Dutch law, we are subject to the DCGC and are required to disclose in our annual report,
filed in the Netherlands, whether we comply with the provisions of the DCGC. If we do not comply with the provisions of the DCGC (for example, because of a conflicting Nasdaq requirement or otherwise), we must list the reasons for any deviation from
the DCGC in our annual report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We acknowledge the importance of good corporate governance. However, at this stage, we do not comply with all the
provisions of the DCGC, to a large extent because such provisions conflict with or are inconsistent with the corporate governance rules of Nasdaq and U.S. securities laws that apply to us, or because such provisions do not reflect best practices of
global companies listed on Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discussions below summarize the most important differences between our governance structure and the principles and
best practices of the DCGC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk management and internal audit function (best practice provisions 1.2.2, 1.3.1 and 1.3.2)</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not established an internal audit department. Our board of directors is of the opinion that adequate alternative measures have
been taken in the form of the company&#146;s risk management and control systems and that it is presently not necessary to establish an internal audit function.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Independence of non-executive directors (best practice provision 2.1.7)</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, certain of our non-executive directors are not independent within the meaning of the DCGC. These non-executive directors are representatives of
(and/or employed by) some of our shareholders. Although we have the intention to increase the number of independent non-executive directors over time, it is our view that given the nature of our business and the practice in our industry and
considering our shareholder structure, it is justified that some of our non-executive directors are independent. We may need to deviate from the DCGC&#146;s independence definition for non-executive directors either because such provisions conflict
with or are inconsistent with the corporate governance rules of Nasdaq and U.S. securities laws that apply to us, or because such provisions do not reflect best practices of global companies listed on Nasdaq. We may need to further deviate from the
DCGC&#146;s independence definition for non-executive directors when looking for the most suitable candidates. For example, a future non-executive director candidate may have particular knowledge of, or experience in our industry, but may not meet
the definition of independence in the DCGC. As such background is very important to the efficacy of our board of directors, our board of directors may decide to nominate candidates for appointment who do not fully comply with the independence
criteria under the DCGC. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>&#149;</I></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I></I><I>Remuneration (best practice provisions 3.1.2, 3.2.3, 3.3.2 and 3.3.3) </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The options granted under the 2010 Plan vest in instalments over a four-year period from the grant date. Twenty-five percent of the options vest on the first
anniversary of the vesting commencement date, and the remaining 75% of the options vest in 36 monthly instalments for each full month of continuous service provided by the option holder thereafter, such that 100% of the options shall become vested
on the fourth anniversary of the vesting commencement date. The options granted are exercisable once vested. Options will lapse on the eighth anniversary of the date of grant. The options granted under the 2016 Plan will be subject to vesting in
accordance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the applicable award agreement and will be exercisable upon vesting. The term of options granted under the 2016 Plan may not be longer than ten years. We do not intend to comply with all of
the requirements under best practice provisions 3.1.2, 3.2.3, 3.3.2 and 3.3.3 of the DCGC as we believe it is in the best interest of the company to attract and retain highly skilled management board members on conditions based on market practice,
as we believe these are. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with market practice in the United States, the primary trading jurisdiction of our common shares, and in order to
further support our ability to attract and retain the right highly qualified candidates for a position on our board of directors, options awarded to our directors as part of their remuneration are subject to time-based vesting. The 2016 Plan under
which shares may be granted (including to the executive directors) provides for the retention of shares for the time period specified in the applicable award agreement. We believe that shares held by the members of our board of directors should be
retained for a certain period; however, such period may be shorter than five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with market practice in the United States, our
non-executive directors receive rights to acquire common shares in our capital as part of their remuneration and may also receive other equity-based remuneration. We believe that such remuneration structure is appropriate due to our listing on
Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under circumstances, the severance payment to which our President &amp; Chief Executive Officer might become entitled could exceed the maximum
recommended by the DCGC. This deviation from the DCGC is justified as it is consistent with market practice in the United States. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Majority requirements for dismissal and setting-aside binding nominations (best practice
provision&nbsp;4.3.3)</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors are appointed by our general meeting of shareholders upon the binding nomination by our board
of directors. Our general meeting of shareholders may only overrule the binding nomination by a resolution passed by a two-thirds majority of votes cast, provided such majority represents more than half of our issued share capital. In addition,
except if proposed by our board of directors, our directors may be suspended or dismissed by our general meeting of shareholders at any time by a resolution passed by a two-thirds majority of votes cast, provided such majority represents more than
half of the Company&#146;s issued share capital. The possibility to convene a new general meeting of shareholders as referred to in Section&nbsp;2:120(3) of the Dutch Civil Code in respect of these matters has been excluded in our articles of
association. We believe that these provisions support the continuity of the company and its business and that those provisions, therefore, are in the best interests of our shareholders and our other stakeholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common shares are listed on The Nasdaq
Global Market under the symbol &#147;MRUS.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. transfer agent and registrar for our common shares is American Stock Transfer&nbsp;&amp; Trust Company, LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_21"></A>CERTAIN MATERIAL TAX CONSIDERATIONS FOR U.S. HOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the certain material U.S. federal income tax considerations for the U.S. Holders described below of owning and disposing of
common shares. It is not a comprehensive description of all tax considerations that may be relevant to a particular person&#146;s decision to acquire securities. This discussion applies only to a U.S. Holder that holds common shares as a capital
asset for tax purposes (generally, property held for investment). In addition, it does not describe all of the tax consequences that may be relevant in light of a U.S. Holder&#146;s particular circumstances, including state and local tax
consequences, estate tax consequences, alternative minimum tax consequences, the potential application of the provisions of the Code known as the Medicare contribution tax, and tax consequences applicable to U.S. Holders subject to special rules,
such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or traders in securities who use a mark-to-market method of tax accounting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding common shares as part of a hedging transaction, &#147;straddle,&#148; wash sale, conversion
transaction or integrated transaction or persons entering into a constructive sale with respect to the common shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose &#147;functional currency&#148; for U.S. federal income tax purposes is not the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax exempt entities, including &#147;individual retirement accounts&#148; and &#147;Roth IRAs&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">S corporations or entities classified as partnerships for U.S. federal income tax purposes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies or real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired our common shares pursuant to the exercise of an employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to the
common shares being taken into account in an applicable financial statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own or are deemed to own ten percent or more of our shares by vote or value; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding common shares in connection with a trade or business conducted outside the United States.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an entity that is classified as a partnership for U.S. federal income tax purposes holds common shares, the U.S. federal income tax
treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding common shares and partners in such partnerships are encouraged to consult their tax advisers as to the particular
U.S. federal income tax consequences of holding and disposing of common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discussion is based on the Code, administrative pronouncements,
judicial decisions, final, temporary and proposed Treasury Regulations, and the income tax treaty between the Netherlands and the United States (the &#147;Treaty&#148;) all as of the date hereof, changes to any of which may affect the tax
consequences described herein&#151;possibly with retroactive effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;U.S. Holder&#148; is a holder who, for U.S. federal income tax purposes, is
a beneficial owner of common shares who is eligible for the benefits of the Treaty and is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a citizen or individual resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the
United States, any state therein or the District of Columbia; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Holders are encouraged to consult their tax advisers concerning the U.S. federal, state, local and
foreign tax consequences of owning and disposing of common shares in their particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;Passive Foreign Investment Company Rules,&#148; distributions paid on common shares, other than certain <I>pro
rata</I> distributions of common shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not calculate our
earnings and profits under U.S. federal income tax principles, we expect that distributions generally will be reported to U.S. Holders as dividends. Subject to applicable limitations, dividends paid to certain non-corporate U.S. Holders may be
taxable at preferential rates applicable to &#147;qualified dividend income.&#148; The amount of a dividend will include any amounts withheld by us in respect of Dutch income taxes. The amount of the dividend will be treated as foreign-source
dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Dividends will be included in a U.S. Holder&#146;s income on the date of the U.S. Holder&#146;s
receipt of the dividend. The amount of any dividend income paid in foreign currency will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the
payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder
may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. Such gain or loss would generally be treated as U.S.-source ordinary income or loss. The amount of any distribution of property other
than cash (and other than certain pro rata distributions of common shares or rights to acquire common shares) will be the fair market value of such property on the date of distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#146;s particular circumstances, Dutch income taxes withheld from
dividends on common shares at a rate not exceeding the rate provided by the Treaty will be creditable against the U.S. Holder&#146;s U.S. federal income tax liability. The rules governing foreign tax credits are complex and U.S. Holders should
consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any Dutch income tax, in
computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Taxable Disposition of Common Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;Passive Foreign Investment Company Rules,&#148; gain or loss realized on the sale or other taxable disposition of
common shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the common shares for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder&#146;s tax
basis in the common shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be <FONT STYLE="white-space:nowrap">U.S.-source</FONT> gain or loss for foreign tax
credit purposes. The deductibility of capital losses is subject to limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the current and anticipated value of our assets, including goodwill, and the composition of our income, assets and operations, we do not believe we
were a PFIC for our taxable year ended December&nbsp;31, 2017; however, we may be a PFIC for the current taxable year. A non-U.S. corporation will be classified as a PFIC for any taxable year in which, after applying certain look-through rules,
either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least 75% of its gross income is passive income; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least 50% of its gross assets (determined on the basis of a quarterly average) is attributable to assets that
produce passive income or are held for the production of passive income. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will be treated as owning our proportionate share of the
assets and earning our proportionate share of the income of any other corporation in which we own, directly or indirectly, 25% or more (by value) of the equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A separate determination must be made after the close of each taxable year as to whether we are a PFIC for that year. As a result, our PFIC status may change.
In particular, the total value of our assets for purposes of the asset test generally will be calculated using the market price of our common shares, which may fluctuate considerably. Fluctuations in the market price of our common shares may result
in our being a PFIC for any taxable year. In addition, the composition of our income and assets is affected by how, and how quickly, we spend the cash we raise in any offering. Depending on our retention of cash and cash equivalents, and on the
market price of our common shares, we may be a PFIC for the current taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are classified as a PFIC in any year with respect to which a U.S.
Holder owns the common shares, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns the common shares, regardless of whether we continue to meet the tests described above
unless (1)&nbsp;we cease to be a PFIC and (2)&nbsp;the U.S. Holder has made a &#147;deemed sale&#148; election under the PFIC rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC for
any taxable year, holders of our common shares will be subject to special tax rules with respect to any &#147;excess distribution&#148; that they receive and any gain they realize from a sale or other disposition (including a pledge) of common
shares. Distributions holder of our common shares receive in a taxable year that are greater than 125% of the average annual distributions they received during the shorter of the three preceding taxable years or their holding period for the common
shares will be treated as an excess distribution. Under these special tax rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the excess distribution or gain will be allocated ratably over their holding period for the common shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which
we became a PFIC, will be treated as ordinary income; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to each other year will be subject to the highest tax rate in effect for that year and the
interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
tax liability for amounts allocated to years prior to the year of disposition or &#147;excess distribution&#148; cannot be offset by any net operating losses for such years, and gains (but not losses) realized on the sale of the common shares cannot
be treated as capital, even if holders of our common shares hold the common shares as capital assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain elections may be available that would
result in alternative treatments (such as mark-to-market treatment of the common shares). The adverse consequences of owning stock in a PFIC could be mitigated if a U.S. Holder makes a valid &#147;qualified electing fund&#148; election, or QEF
election, which, among other things, would require a U.S. Holder to include currently in income its pro rata share of the PFIC&#146;s net capital gain and ordinary earnings, based on earnings and profits as determined for U.S. federal income tax
purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise provided by the U.S. Treasury, each U.S. shareholder of a PFIC is required to file an annual report containing such
information as the U.S. Treasury may require. A U.S. Holder&#146;s failure to file the annual report will cause the statute of limitations for such U.S. Holder&#146;s U.S. federal income tax return to remain open with regard to the items required to
be included in such report until three years after the U.S. Holder files the annual report, and, unless such failure is due to reasonable cause and not willful neglect, the statute of limitations for the U.S. Holder&#146;s entire U.S. federal income
tax return will remain open during such period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are or become a PFIC, holders of our common shares should consult their tax advisors regarding any
reporting requirements that may apply to them. U.S. Holders are urged to consult their tax advisors regarding the application of the PFIC rules to the ownership and disposition of the common shares and the potential availability of a mark-to-market
or QEF election. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject
to information reporting, and may be subject to backup withholding, unless (i)&nbsp;the U.S. Holder is a corporation or other exempt recipient or (ii)&nbsp;in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification
number and certifies that it is not subject to backup withholding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. The amount of any backup withholding from
a payment to a U.S. Holder will be allowed as a credit against the holder&#146;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information with Respect to Foreign Financial Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders who are individuals (and, under proposed regulations, certain entities) may be required to report information relating to the common
shares, subject to certain exceptions (including an exception for common shares held in accounts maintained by certain U.S. financial institutions). U.S. Holders should consult their tax advisers regarding their reporting obligations with respect to
their ownership and disposition of the common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_22"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the common shares issued to the&nbsp;selling shareholders&nbsp;to permit the resale of these shares by the holders of the common shares
from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the&nbsp;selling shareholders&nbsp;of the common shares. We will bear all fees and expenses incident to our obligation to register the
common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;selling shareholders&nbsp;and any of their transferees, donees, pledgees or other successors in interest may, from time to time,
sell all or a portion of the common shares beneficially owned by the&nbsp;selling shareholders&nbsp;and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the common shares are sold through
underwriters or broker-dealers, the&nbsp;selling shareholders&nbsp;will be responsible for underwriting discounts or commissions or agent&#146;s commissions. The common shares may be sold on any national securities exchange or quotation service on
which the common shares may be listed or quoted at the time of sale, in the&nbsp;over-the-counter&nbsp;market or in transactions otherwise than on these exchanges or systems or in the&nbsp;over-the-counter&nbsp;market and in one or more transactions
at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions.
The&nbsp;selling shareholders&nbsp;may use any one or more of the following methods when selling shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the effective date of the registration statement of which this
prospectus is a part; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions through broker-dealers that agree with the&nbsp;selling shareholder&nbsp;to sell a specified
number of such shares at a stipulated price per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through the writing or settlement of options or other hedging transactions, whether such options are listed on an
options exchange or otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through one or more underwritten offerings on a firm commitment or best efforts basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a combination of any such methods of sale;&nbsp;and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A&nbsp;selling shareholder&nbsp;also may resell all or a portion of the shares in open market transactions in reliance upon Rule&nbsp;144 under the Securities
Act, as permitted by that rule, or Section&nbsp;4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that the&nbsp;selling shareholder&nbsp;meets the criteria and conforms to the requirements of those
provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the&nbsp;selling shareholders&nbsp;may arrange for other broker-dealers to participate in sales. If
the&nbsp;selling shareholders&nbsp;effect such transactions by selling common shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or
commissions from the&nbsp;selling shareholders&nbsp;or commissions from purchasers of the common shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts to be negotiated, but, except as set
forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess of a customary brokerage commission in compliance with FINRA Rule&nbsp;2121 (and any successor); and in the case of a principal transaction a markup
or markdown in compliance with FINRA&nbsp;2121. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with sales of common shares or otherwise, the&nbsp;selling shareholders&nbsp;may enter into
hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common shares in the course of hedging in positions they assume. The&nbsp;selling shareholders&nbsp;may also sell common shares
short and if such short sale shall take place after the date that the registration statement of which this prospectus is a part is declared effective by the SEC, the&nbsp;selling shareholders&nbsp;may deliver common shares covered by this prospectus
to close out short positions and to return borrowed shares in connection with such short sales. The&nbsp;selling shareholders&nbsp;may also loan or pledge common shares to broker-dealers that in turn may sell such shares, to the extent permitted by
applicable law. The&nbsp;selling shareholders&nbsp;may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such
broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
Notwithstanding the foregoing, the&nbsp;selling shareholders&nbsp;have been advised that the&nbsp;selling shareholders&nbsp;may not use shares registered on the registration statement of which this prospectus forms a part to cover short sales of our
common shares made prior to the date the registration statement, of which this prospectus forms a part, has been declared effective by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;selling shareholders&nbsp;may, from time to time, pledge or grant a security interest in some or all of the common shares owned by the&nbsp;selling
shareholders&nbsp;and, if the&nbsp;selling shareholders&nbsp;default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the common shares from time to time pursuant to this prospectus or any amendment
to this prospectus under Rule&nbsp;424(b)(3) or other applicable provision of the Securities Act, amending, if necessary, the list of selling shareholders to include the pledgee, transferee or other successors in interest as a&nbsp;selling
shareholder&nbsp;under this prospectus. The&nbsp;selling shareholders&nbsp;also may transfer and donate the common shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling
beneficial owners for purposes of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;selling shareholders&nbsp;and any broker-dealer or agents participating in the distribution
of the common shares may be deemed to be &#147;underwriters&#148; within the meaning of Section&nbsp;2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any discounts or concessions allowed to, any such
broker-dealer or agent and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. If the&nbsp;selling shareholders&nbsp;are deemed to be an &#147;underwriter&#148;
within the meaning of Section&nbsp;2(11) of the Securities Act, they will be subject to the applicable prospectus delivery requirements of the Securities Act and may be subject to certain statutory liabilities of, including but not limited to,
Sections&nbsp;11, 12 and 17 of the Securities Act and&nbsp;Rule&nbsp;10b-5&nbsp;under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;selling shareholders&nbsp;have informed
us that they are not registered broker-dealers and do not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the common shares. Upon our being notified in writing by the&nbsp;selling
shareholders&nbsp;that any material arrangement has been entered into with a broker-dealer for the sale of common shares through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker-dealer, a
supplement to this prospectus will be filed, if required, pursuant to Rule&nbsp;424(b) under the Securities Act, disclosing: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the&nbsp;selling shareholder&nbsp;and of the participating broker-dealer(s), </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares involved, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which such the shares were sold, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by
reference in this prospectus,&nbsp;and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other facts material to the transaction. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In no event shall any broker-dealer receive fees, commissions and markups, which, in the aggregate, would
exceed eight percent (8%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the securities laws of some states, the common shares may be sold in such states only through registered or licensed
brokers or dealers. In addition, in some states the common shares may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the&nbsp;selling shareholders&nbsp;will sell any or all of the common shares registered pursuant to the registration statement,
of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;selling shareholders&nbsp;and any other person participating in such distribution will be subject to
applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, Regulation&nbsp;M of the Exchange Act, which may limit the timing of purchases and sales of any of the common shares by
the&nbsp;selling shareholders and any other participating person. Regulation&nbsp;M may also restrict the ability of any person engaged in the distribution of the common shares to engage in market-making activities with respect to the common shares.
All of the foregoing may affect the marketability of the common shares and the ability of any person or entity to engage in market-making activities with respect to the common shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay all expenses of the registration of the common shares, including, without limitation, SEC filing fees and expenses of compliance with state
securities or &#147;blue sky&#148; laws;&nbsp;<I>provided,&nbsp;however</I>, that the&nbsp;selling shareholders&nbsp;will pay all underwriting discounts and selling commissions, if any. We will indemnify the&nbsp;selling shareholders&nbsp;against
certain liabilities, including some liabilities under the Securities Act or the&nbsp;selling shareholders&nbsp;will be entitled to contribution. We may be indemnified by the&nbsp;selling shareholders&nbsp;against civil liabilities, including
liabilities under the Securities Act, that may arise from any written information furnished to us by the&nbsp;selling shareholders&nbsp;specifically for use in this prospectus or we may be entitled to contribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required, this prospectus may be amended and/or supplemented from time to time to describe a specific plan of distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_23"></A>EXPENSES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is an estimate of the expenses (all of which are to be paid by us) that we may incur in connection with the common shares being registered
hereby, other than the SEC registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">304,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_24"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the common shares held by the selling shareholders will be passed upon for us by NautaDutilh N.V. with its address at
Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_25"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Merus N.V. as of December&nbsp;31, 2017 and 2016, and for each of the years in the three-year period
ended December&nbsp;31, 2017, included in the Report on Form&nbsp;6-K filed by the Company on December&nbsp;27, 2018 have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG Accountants N.V.,
independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. The audit report refers to the adoption of International Financial Reporting Standard 15
<I>Revenue from Contracts with Customers</I>. The registered offices of KPMG Accountants N.V. are located at Laan van Langerhuize 1, 1186 DS Amstelveen, the Netherlands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_26"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporated under the laws of the Netherlands. A majority of our assets are located outside the United&nbsp;States. As a result, it may not be
possible for investors to effect service of process within the United&nbsp;States upon such persons or to enforce against them or us in U.S. courts, including judgments predicated upon the civil liability provisions of the federal securities laws of
the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States and the Netherlands currently do not have a treaty providing for the reciprocal recognition and enforcement of
judgments, other than arbitration awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be
recognized or enforceable in the Netherlands. In order to obtain a judgment which is enforceable in the Netherlands, the party in whose favor a final and conclusive judgment of the U.S. court has been rendered will be required to file its claim with
a court of competent jurisdiction in the Netherlands. Under current practice, the courts of the Netherlands may be expected to render a judgment in accordance with the judgment of the relevant foreign court, provided that such judgment (i)&nbsp;is a
final judgment and has been rendered by a court which has established its jurisdiction over the Dutch company on the basis of internationally accepted grounds of jurisdiction, (ii)&nbsp;has not been rendered in violation of elementary principles of
fair trial, (iii)&nbsp;is not contrary to the public policy of the Netherlands and (iv)&nbsp;is not incompatible with (a)&nbsp;a prior judgment of a Netherlands court rendered in a dispute between the same parties, or (b)&nbsp;a prior judgment of a
foreign court rendered in a dispute between the same parties, concerning the same subject matter and based on the same cause of action, provided that such prior judgment is capable of being recognized in the Netherlands. Dutch courts may deny the
recognition and enforcement of punitive damages or other awards. Moreover, a Dutch court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or
damages. Enforcement and recognition of judgments of U.S. courts in the Netherlands are solely governed by the provisions of the Dutch Civil Procedure Code. If no leave to enforce is granted, claimants must litigate the claim again before a
competent Dutch court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite any generally recognized choice of law clause for a jurisdiction other than the Netherlands contained in an agreement, a
court in the Netherlands (a)&nbsp;may apply overriding mandatory provisions of (i)&nbsp;Netherlands law and (ii)&nbsp;the law of the country where the obligations arising out of such agreement have to be or have been performed, in so far as those
overriding mandatory provisions render the performance of such agreement unlawful, (b)&nbsp;may refuse application of a provision of the chosen law if application thereof is manifestly incompatible with the public policy (<I>ordre public</I>) of the
Netherlands or the European Union, (c)&nbsp;may, in relation to the manner of performance of such agreement and the steps to be taken in the event of defective performance, have regard to the law of the country where performance of such agreement
takes place and (d)&nbsp;will ignore the choice of law clause to the extent it relates to (i)&nbsp;an act of unfair competition or an act restricting free competition, (ii)&nbsp;infringement of an intellectual property right, or (iii)&nbsp;the
proprietary aspects of a transfer of title or the granting of security and other proprietary rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_27"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the
SEC a registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under the Securities Act with respect to the common shares offered by this prospectus. This prospectus is a part of the registration statement and does not contain all
of the information set forth in the registration statement and its exhibits and schedules, portions of which have been omitted as permitted by the rules and regulations of the SEC. For further information about us and our common shares, you should
refer to the registration statement and its exhibits and schedules. Statements contained in this prospectus about the contents of any contract or any other document filed as an exhibit are not complete and in each instance we refer you to the copy
of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference. The agreements and other documents filed as exhibits to this registration statement are not
intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties
made by the registrant in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the periodic reporting and other informational requirements of the Exchange Act. Under the Exchange Act, we file annual reports and
other information with the SEC. As a foreign private issuer, we are exempt from, among other things, the rules under the Exchange Act prescribing the filing of proxy statements and quarterly and current reports. The SEC maintains an Internet site
that contains reports, proxy and information statements, and other information regarding issuers, such as we, that file electronically with the SEC at <I>http://www.sec.gov</I>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by Reference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC&#146;s rules allow us
to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is
deemed to be part of this prospectus. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this
prospectus modifies or replaces that statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus incorporates by reference the documents set forth below that have previously been filed
with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on Form 20-F for the year ended December 31, 2017, filed with the SEC on April&nbsp;30, 2018.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Report on Form 6-K furnished with the SEC on December 27, 2018. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to, but not filed
with, the SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those documents unless such exhibits are specifically incorporated by reference in this prospectus, will be provided at no cost to each
person, including any beneficial owner, who receives a copy of this prospectus on the written or oral request of that person made to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Merus N.V. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yalelaan 62 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3584 CM Utrecht </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The Netherlands
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">+31 30 253 8800 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The documents incorporated
by reference in this prospectus and certain other information filed by us with the SEC are also available on our website at <I>www.merus.nl</I>. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc569434_28"></A>Index to Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Unaudited Condensed Consolidated Financial Statements for the Three- and Six-month Periods Ended June 30, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintemp569434_1">Unaudited Condensed Consolidated Statement of Financial Position as of June
 30, 2018 and December 31, 2017 Restated</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintemp569434_2">Unaudited Condensed Consolidated Statement of Profit or Loss and Comprehensive
 Loss for the Three- and Six-month Periods Ended June 30, 2018 and 2017 Restated</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintemp569434_3">Unaudited Condensed Consolidated Statement of Changes in Equity for the Six-month
Period Ended June&nbsp;30, 2018 and 2017 Restated</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintemp569434_4">Unaudited Condensed Consolidated Statement of Cash Flows for the Six-month
 Period Ended June 30, 2018 and 2017 Restated</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintemp569434_5">Notes to the Unaudited Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintemp569434_1"></A>Unaudited Condensed Consolidated Statement of Financial Position </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(after appropriation of result for the period) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2017<br>Restated*</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,876</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>381</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,650</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,074</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,477</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>170,327</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>212,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>231,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issued and <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>258,061</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(167,226</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>92,872</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>105,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,433</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes and social security liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,972</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,860</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>33,365</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>139,083</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total equity and liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>231,955</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note&nbsp;3 for details regarding the restatement as a result of a change in accounting policy.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The footnotes are an integral part of these condensed consolidated interim financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintemp569434_2"></A>Unaudited Condensed Consolidated Statement of Profit or Loss
and Comprehensive Loss </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Three-month&nbsp;period&nbsp;ended</FONT></B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Six-month&nbsp;period&nbsp;ended</FONT></B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017&nbsp;Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017&nbsp;Restated**</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(euros in thousands, except per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,420</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,821</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,492</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,491</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,459</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,189</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,831</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net finance income / (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,542</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Result before taxation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,506</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,494</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,887</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Result after taxation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,601</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences from the translation of foreign operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other comprehensive income for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic (and diluted) loss per share*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic (and diluted)*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,628,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,392,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,809,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,976,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the periods included in these financial statements, share options were excluded from the diluted loss per
share calculation as the Company was in a loss position in each period presented above. As a result, basic and diluted loss per share is equal. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note&nbsp;3 for details regarding the restatement as a result of a change in accounting policy.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The footnotes are an integral part of these condensed consolidated interim financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintemp569434_3"></A>Unaudited Condensed Consolidated Statement of Changes in
Equity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>share<BR>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2017, as previously reported</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,295</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of adoption of accounting standard</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>390</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restated balance at January&nbsp;1, 2017*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,448</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>139,878</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(106,905</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34,421</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restated result after taxation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,324</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restated total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,306</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(39,306</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transactions with owners of the Company:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares (net)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity settled shared-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total contributions by owners</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>298</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,663</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,880</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>81,841</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restated balance at June&nbsp;30, 2017*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,746</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>213,541</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(138,331</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2017, as previously reported</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>47,887</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of adoption of accounting standard</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,705</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Restated balance at January&nbsp;1, 2018*</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,749</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>213,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(158,775</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>56,592</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,026</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,005</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,005</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transactions with owners of the Company:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of shares (net)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,731</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity settled shared-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,554</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total contributions by owners</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>288</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,443</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,554</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>49,285</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June&nbsp;30, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>258,061</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(167,226</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>92,872</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 3 for details regarding the restatement as a result of a change in accounting policy.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The footnotes are an integral part of these condensed consolidated interim financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintemp569434_4"></A>Unaudited Condensed Consolidated Statement of Cash Flows
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Six-month&nbsp;period&nbsp;ended&nbsp;June&nbsp;30,</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017 Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,026</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments for:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in fair value derivative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized foreign exchange results</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,648</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>218</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payment expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,554</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net finance (income) expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(531</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(593</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12,433</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,866</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in working capital:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes and social security assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(959</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,946</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(38</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,307</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,233</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,796</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes and social security liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(143</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash used in operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,829</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(302</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(15,132</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,576</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flow from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(29,560</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from investment maturities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of intellectual property</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisition of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(624</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>602</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,751</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flow from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuing shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,731</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from stock option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from collaboration and license agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of borrowings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(486</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,731</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,848</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,801</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,856</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents as at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149,678</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents as at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>170,327</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes in accrued capital expenditures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>271</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Note 3 for details regarding the restatement as a result of a change in accounting policy.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The footnotes are an integral part of these condensed consolidated interim financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintemp569434_5"></A>Notes to the Unaudited Condensed Consolidated Financial
Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merus N.V. is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, headquartered in Utrecht, the Netherlands. Merus
US, Inc. is a wholly-owned subsidiary of Merus N.V. located in Boston, Massachusetts, United States. These condensed consolidated interim financial statements as at and for the three- and <FONT STYLE="white-space:nowrap">six-month</FONT> periods
ended June&nbsp;30, 2018, comprise Merus N.V. and Merus US, Inc. (collectively, the &#147;Company&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13, 2018, the Company entered
into a Securities Purchase Agreement (the &#147;Purchase Agreement&#148;) with the purchasers named therein (the &#147;Investors&#148;). Pursuant to the Purchase Agreement, the Company agreed to sell an aggregate of 3,099,997 of its common shares,
nominal value &#128;0.09 per share (the &#147;Common Shares&#148;), to the Investors for aggregate gross proceeds of approximately $55.8&nbsp;million, at a purchase price equal to $18.00 per share (the &#147;Private Placement&#148;). The Purchase
Agreement contained customary representations and warranties from the Company and the Investors and customary closing conditions. On February&nbsp;15, 2018, the Company completed the sale under the Private Placement and received aggregate gross
proceeds of approximately $55.8&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nature of Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as its bispecific antibody candidates advance
through discovery, preclinical development and clinical trials, and as it seeks regulatory approval and pursues commercialization of any approved bispecific antibody candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, the Company may need additional financing to support its continuing operations. Until the Company can generate significant revenue from product
sales, if ever, the Company expects to finance its operations through public equity, debt financings, or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to the Company on
acceptable terms, or at all. The Company&#146;s inability to raise capital as and when needed would have a negative impact on its financial condition and ability to pursue its business strategy. The Company will need to generate significant revenues
to achieve profitability and may never do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the Company&#146;s current operating plan, it expects its existing cash balances and investments
to last through the end of 2020. For this assessment, the Company has taken into consideration its existing cash and cash equivalents of &#128;170.3&nbsp;million, which include the $55.8&nbsp;million, or &#128;44.8&nbsp;million, in proceeds received
from the Private Placement offering that closed in February 2018, and investments of &#128;53.7&nbsp;million as of June&nbsp;30, 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Significant accounting policies</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There have been no significant changes to the Company&#146;s accounting policies that were previously disclosed in its&nbsp;Annual&nbsp;Report on Form <FONT
STYLE="white-space:nowrap">20-F</FONT> for its fiscal year ended December&nbsp;31, 2017,&nbsp;or in the methodology used in formulating these significant judgments and estimates that affect the application of these policies, except for the adoption
of new accounting standards as disclosed more fully in Note 3. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These unaudited interim condensed consolidated financial statements (the &#147;interim financial statements&#148;) have been prepared in accordance with
International Accounting Standard 34 &#147;Interim Financial Reporting&#148; as issued by the International Accounting Standards Board (&#147;IASB&#148;). Certain information and disclosures normally included in financial statements prepared in
accordance with International Financial Reporting Standards </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(&#147;IFRS&#148;) have been condensed or omitted. Accordingly, these interim financial statements should be read in conjunction with the Company&#146;s annual financial statements for the year
ended December&nbsp;31, 2017. In the opinion of management, all adjustments (consisting of a normal recurring nature) considered necessary for a fair presentation have been included in the interim financial statements. All intercompany transactions
and balances are eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to
exercise its judgment in the process of applying the Company&#146;s accounting policies. The areas involving a higher degree of judgment or complexity or areas where assumptions and estimates are significant to these interim financial statements are
disclosed in Note 4. The results of operations for the three- and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018, are not necessarily indicative of operations to be expected for the full fiscal year ending
December&nbsp;31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign Currency Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Items recorded in each of the Company&#146;s entities are measured using the currency of the primary economic environment in which the entity operates (the
&#147;functional currency&#148;). The interim financial statements are presented in euros, which is Merus N.V.&#146;s functional currency. The functional currency of Merus US, Inc. is the U.S. dollar.&nbsp;All amounts are rounded to the nearest
thousand euros, except where otherwise indicated. Foreign currency gains and losses are reported on a net basis as either finance income or finance expense depending on whether foreign currency movements are in a net gain or net loss position. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Seasonality </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial results have
varied substantially, and are expected to continue to vary, from period to period. The Company believes that its ordinary activities are not linked to any particular seasonal factors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Segment Reporting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates in one reportable
segment, which comprises the discovery and development of innovative bispecific therapeutics. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash and Cash Equivalents </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of presentation in the statement of cash flows as well as the statement of financial position, cash and cash equivalents include deposits held
with financial institutions with original maturities of less than three months. Cash and cash equivalents include &#128;34.3&nbsp;million of short-term investments with a three-month or less maturity, callable on demand. The carrying values of
short-term investments approximate fair value due to their short-term maturities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into collaboration agreements which are within the scope of IFRS 15&#151;Revenue from Contracts with Customers (&#147;IFRS 15&#148;), under
which the Company licenses rights to certain of the Company&#146;s product candidates and performs research and development services. The terms of these arrangements typically include payment of one or more of the following: <FONT
STYLE="white-space:nowrap">non-refundable,</FONT> upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS 15 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers.
Under IFRS 15, the Company recognizes revenue when its customer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtains control of the goods or services, in an amount that reflects the consideration that the Company determines it expects to receive in exchange for those goods or services. To determine
revenue recognition for arrangements that the Company determines are within the scope of IFRS 15, the Company performs the following five steps: (i)&nbsp;identify the contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the
contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize revenue when (or as) the entity satisfies the performance obligation. The Company
applies the five-step model to contracts only when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements,
the Company must make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance
obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company currently generates a portion of its revenue through collaboration and license agreements with strategic collaborators for the
development and commercialization of product candidates. The collaboration and license agreements are within the scope of IFRS 15. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT
STYLE="white-space:nowrap">Up-front</FONT> License Payments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the license to the Company&#146;s intellectual property is determined to be distinct
from the other performance obligations identified in the agreement, the Company recognizes revenues from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license when the
license is transferred to the customer and the customer is able to use and benefit from the license. If not distinct, the license is combined with other performance obligations in the contract. For licenses that are combined with other performance
obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress
for purpose of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Company&#146;s research and license agreements with its collaborators, the Company has received upfront license payments relating to the
integrated packages of deliverables under the contracts. Each contract contains either one single performance obligation or multiple performance obligations that the <FONT STYLE="white-space:nowrap">up-front</FONT> consideration was allocated to.
These upfront license payments are initially recorded in deferred revenue on the consolidated statements of financial position and are recognized as revenue on either: (i)&nbsp;a straight-line basis over the period of the related performance
obligation or the contractual term of the arrangement; or (ii)&nbsp;based on another appropriate depiction of the Company&#146;s performance over the period of the related performance obligation or the contractual term, such as costs incurred
relating to full-time equivalent research employees. The applicable period over which to recognize the upfront payment is a significant judgment, which is <FONT STYLE="white-space:nowrap">re-assessed</FONT> at each reporting date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration income, which is
typically related to reimbursements from collaborators for the Company&#146;s performance of research and development services under the respective agreements, is recognized on the basis of labor hours valued at a contractually agreed rate.
Collaboration income includes reimbursements for related <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses. Cost reimbursements to which the Company is entitled under agreements are recognized as
revenue in the same period as the cost for which they are intended to compensate. The Company acts as the principal and therefore records these reimbursements as collaboration income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreements, the Company performs the five
steps listed above. As part of the accounting for the arrangement, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key
assumptions to determine the stand-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
alone selling price, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company capitalizes the incremental costs of obtaining a contract with a customer if it expects to recover those costs. Such incremental costs would not
have been incurred if the contract with a customer had not been obtained. To date, the Company has not capitalized any incremental costs for obtaining a contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s contracts often include development and regulatory milestone payments which are assessed under the most likely amount method and
constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#146;s control or the licensee&#146;s control, such as regulatory approvals, are not considered probable of being
achieved until those approvals are received. At each reporting date, the Company <FONT STYLE="white-space:nowrap">re-evaluates</FONT> the probability of achievement of development milestones and any related constraint, and if necessary, adjusts the
overall transaction price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would affect collaboration revenues in the period of adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For agreements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant
item to which the royalties relate, the Company recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or
partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting from any of the Company&#146;s collaboration agreements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Government Grants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company receives certain
government and regional grants, which support its research efforts in defined projects, and include contributions towards the cost of research and development. When there is reasonable assurance that the Company will comply with the conditions
attached to a received grant, and when there is reasonable assurance that the grant will be received, government grants are recognized as revenue on a gross basis in the consolidated statement of profit or loss and comprehensive loss on a systematic
basis over the periods in which the Company recognizes expenses for the related costs for which the grants are intended to compensate. In the case of grants related to assets, the received grant will be deducted from the carrying amount of the
asset. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>Reclassifications</I><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
amounts were reclassified in the prior period condensed consolidated interim financial statements to conform to the current period presentation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recently Issued International Financial Reporting Standards </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, the accounting policies adopted in the preparation of these interim financial statements are consistent with those applied in
the preparation of the Company&#146;s annual financial statements for the year ended December&nbsp;31, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Standards implemented since
December&nbsp;31, 2017 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue from Contracts with Customers&#151;IFRS 15 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the IASB issued IFRS 15, which supersedes existing revenue recognition guidance. Prior to the adoption of IFRS 15, revenue was recognized to the
extent that it was probable that the economic benefits would flow to the Company and the revenue could be reliably measured. The new standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer
of promised goods or services to customers. To achieve that core principle, an entity must identify the contract(s) with a customer, identify the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the
entity satisfies the performance obligation. IFRS 15 is effective for annual and interim reporting periods beginning on or after January&nbsp;1, 2018 and should be applied retrospectively to each prior reporting period presented or retrospectively
with the cumulative effect of initially applying this update recognized at the date of initial application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adoption of IFRS 15 impacts the
amortization of the Company&#146;s <FONT STYLE="white-space:nowrap">up-front</FONT> license payments. The Company previously recognized revenue from <FONT STYLE="white-space:nowrap">up-front</FONT> license payments on a straight-line basis over the
contractual term or the period of continuing involvement which was previously estimated to be 21 years for the collaboration and license agreement the Company entered into with Incyte Corporation (&#147;Incyte&#148;) on December&nbsp;20, 2016 (the
&#147;Incyte collaboration and license agreement&#148;), and 4.5 years for the research and license agreement the Company entered into with ONO Pharmaceutical Co., Ltd. (&#147;ONO&#148;) on April&nbsp;8, 2014 (the &#147;ONO research and license
agreement&#148;). In applying IFRS 15, the Company has evaluated the distinct performance obligations in each agreement. Specifically, for Incyte, the total period for which the Company expects to provide access to its proprietary technology is
currently estimated to be nine years, which is the research term initially agreed to in the Incyte collaboration and license agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
adopted the new standard effective January&nbsp;1, 2018, using the retrospective method, with the effect of initially applying this standard recognized at the beginning of the earliest period presented. The Company had two open contracts on the
adoption date and has assessed these contracts under the new revenue standard. In addition, the Company elected to apply the practical expedient to not apply this guidance to contracts that were completed before the beginning of the earliest period
presented, or January&nbsp;1, 2016, and the practical expedients for contract modifications (assessing the contracts in combination with any modifications before January&nbsp;1, 2017). Under the practical expedient, the Company excluded certain
option and exclusivity agreements that expired in 2015 and 2014, respectively. As a result of the adoption of IFRS 15, prior year financial statements have been restated. The Company has accounted for the impact of adopting IFRS 15 as a cumulative <FONT
STYLE="white-space:nowrap">catch-up</FONT> as a decrease of approximately &#128;8.7&nbsp;million to deferred revenue with an offset to accumulated deficit, effective January&nbsp;1, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following financial statement line items have been shown to reflect the adjustments recognized for each individual line item in the Company&#146;s
respective consolidated statements for the period noted: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Condensed Consolidated Statement of Profit or Loss and Comprehensive Loss </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30, 2017<BR>(As originally<BR>presented)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15</B><br><B>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months<BR>ended<BR>June&nbsp;30, 2017<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">(euros in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,162</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,952</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic (and diluted) loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended<BR>June&nbsp;30, 2017<BR>(As originally<BR>presented)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS&nbsp;15</B><br><B>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;months&nbsp;ended<BR>June&nbsp;30, 2017<BR>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">(euros in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total comprehensive loss for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,114</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic (and diluted) loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.07</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Condensed Consolidated Statement of Financial Position </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2017</B><br><B>As originally<BR>presented</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS 15<BR>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2017</B><br><B>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">(euros in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(167,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,705</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,644</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,939</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Condensed Consolidated Statement of Cash Flows </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2017</B><br><B>As originally<BR>presented</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IFRS 15<BR>Adoption</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2017</B><br><B>Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center">(euros in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Result after taxation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,808</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in working capital:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,808</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,899</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Instruments&#151;IFRS 9 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IFRS <FONT STYLE="white-space:nowrap">9-</FONT> Financial Instruments (&#147;IFRS 9&#148;) replaces the provisions of IAS 39 that relate to the recognition,
classification and measurement of financial assets and financial liabilities, derecognition of financial instruments, impairment of financial assets and hedge accounting. IFRS 9 also significantly amends other standards dealing with financial
instruments such as IFRS 7 <I>Financial Instruments: Disclosures</I>. The Company assessed the classification and measurement of the financial instruments it held at the date of initial application of IFRS 9, or January&nbsp;1, 2018, and has
classified its financial instruments into the appropriate IFRS 9 categories. There were no changes to the carrying value of the Company&#146;s financial instruments resulting from this reclassification and accordingly there was no impact to the
Company&#146;s opening accumulated deficit at January&nbsp;1, 2018, as a result of the adoption of IFRS&nbsp;9. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Standard issued but not yet effective
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The IASB has issued a new standard on leases that will require lessees to recognize most leases on their balance sheets as lease liabilities with a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">corresponding&nbsp;right-of-use&nbsp;asset.</FONT></FONT> The IASB has set an effective date to apply the new standard for periods beginning on or after January&nbsp;1, 2019. The Company is
assessing all effective agreements to determine whether there are embedded leases included under the definition in IFRS 16. Early adoption is permitted; however, the Company expects to adopt this standard in the first quarter of 2019. The Company is
evaluating the impact that this guidance will have on the Company&#146;s financial statements, including related disclosures, and expects the new standard to impact its internal controls, systems, and processes. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Use of Estimates, Judgments and Assumptions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the application of the Company&#146;s accounting policies, management is required to make judgments, estimates and assumptions that affect the reported
amounts of assets, liabilities, income and expenses that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results
may differ from these estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
prospectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the critical judgments and assumptions that management has made in the process of applying the Company&#146;s accounting
policies and that have the most significant effect on the amounts recognized in the interim financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity settled share-based payments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share options granted to employees, consultants and directors are measured at the grant date fair value of the equity instruments granted. The grant date fair
value is determined through the use of an option-pricing model considering the following variables: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise price of the option; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the expected life of the option; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the current value of the underlying shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the expected volatility of the share price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the dividends expected on the shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the risk-free interest rate for the life of the option. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated fair value of each share option granted was determined utilizing the Hull&nbsp;&amp; White option pricing model, which considers the terms and
conditions attached to the grants made and is reflective of expected exercise behavior. Because the Company&#146;s shares have been publicly traded for a relatively short amount of time, the expected volatility was set by also giving weight to the
historic share price volatility of a set of peer companies. The continuous yield on U.S. Treasury Bills with a term to maturity comparable to the expected life of the options, as published by the U.S. Department of Treasury, was applied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The result of the share option valuations and the related compensation expense that is recognized for the respective vesting periods during which services are
received are dependent on the model and input parameters used. Even though management considers the fair values reasonable and defensible based on the methodologies applied and the information available, others might derive a different fair value
for the Company&#146;s share options. These assumptions and estimates are further discussed in Note 9 to the financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capitalization of
development costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The criteria for capitalization of development costs have been considered by management and determined not to have been met in the
second quarter of 2018. Therefore, all development expenditures relating to internally generated intangible assets in 2018 were expensed as incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2018, deferred tax
assets have not been recognized in respect of tax losses as the Company has no history of generating taxable profits. Therefore, at the balance sheet date, there is no convincing evidence that sufficient taxable profit will be available against
which the tax losses can be utilized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merus US, Inc., which is incorporated in the United States in the State of Delaware, is subject to statutory U.S.
Federal corporate income taxes and state income taxes for Massachusetts. Current year income tax expense was attributable entirely to Merus US, Inc. which provides general management services and strategic advisory services to the Company. Corporate
income tax expenses were &#128;0.1&nbsp;million for the three- and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018, as compared to &#128;0.1&nbsp;million for the three- and
<FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deferred revenue </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Company&#146;s research, collaboration and license agreements with ONO, Incyte, and Jiangsu Simcere Pharmaceutical Co. Ltd.
(&#147;Simcere&#148;), the Company has received <FONT STYLE="white-space:nowrap">upfront&nbsp;non-refundable&nbsp;payments</FONT> for certain rights granted under the respective agreements. The applicable period over which to recognize these upfront
payments requires significant judgment and was impacted by the adoption of IFRS 15 (See Note 3 and Note 8). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue related to ONO upfront payments is deferred and amortized based on a measure of progress in
delivering research services under the contract. Revenue related to Incyte and Simcere upfront payments is deferred and amortized on a straight-line basis over the estimated research term (See Note 3 and Note 8). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and development expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expenses represent costs that primarily include: (i)&nbsp;payroll and related costs (including share-based payment expenses) associated with research and development personnel; (ii)&nbsp;costs related to clinical trials and preclinical
testing of the Company&#146;s technologies under development; (iii)&nbsp;costs to develop product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses; (iv)&nbsp;expenses for research
services provided by universities and contract laboratories; and (v)&nbsp;other research and development expenses. Research and development expenses are recognized in the consolidated statement of profit or loss and comprehensive loss as incurred
when these expenditures relate to the Company&#146;s research and development services and have no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into
various research and development contracts with research institutions and other companies. These agreements are generally cancelable. The Company records accruals for estimated ongoing research costs. When evaluating the adequacy of the accrued
liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any
reporting period. Actual results could differ from the Company&#146;s estimates. The Company&#146;s historical accrual estimates have not been materially different from the actual costs. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Investments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2018, the Company adopted IFRS 9 and classifies and accounts for its investments at amortized cost. The Company&#146;s investments as of
December&nbsp;31, 2017, were classified and accounted for as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">held-to-maturity</FONT></FONT> under IAS 39. The initial adoption of IFRS 9 had no impact on previously reported amounts
(See Note 3). IFRS 9 replaces the &#145;incurred loss&#146; model in IAS 39 with an &#145;expected credit loss&#146; (&#147;ECL&#148;) model. The new impairment model applies to financial assets measured at amortized cost, contract assets and debt
investments at fair value through other comprehensive loss, but not to investments in equity instruments.<B> </B>Under IFRS&nbsp;9, credit losses are recognized earlier than under IAS 39. Under IFRS 9, loss allowances are measured on either <FONT
STYLE="white-space:nowrap">12-month</FONT> ECLs which result from possible default events within the 12 months after the reporting date or lifetime ECLs which result from all possible default events over the expected life of a financial instrument.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial assets recorded at amortized cost consist of cash and cash equivalents, investments and trade and other receivables. These
financial assets are considered to have a low credit risk and, as such, there was no impact to the Company&#146;s opening accumulated deficit as a result of the change in impairment methodology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s investments include investments in commercial paper, securities issued by several public corporations and the United States Treasury.
Current investments include investments with a maturity date of greater than three months at the date of settlement. Investments with a maturity of 12 months or more from the original investment date are classified
<FONT STYLE="white-space:nowrap">as&nbsp;non-current.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investments as of June&nbsp;30, 2018, and December&nbsp;31, 2017, consist of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance as per</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commercial paper</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate fixed income bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Agency bond</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate fixed income bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2018, the Company purchased
investments totaling &#128;29.6&nbsp;million, which are held and denominated in U.S. dollars, and received proceeds of &#128;18.9&nbsp;million relating to investment maturities. As a result of the fluctuation in foreign currency between the euro and
U.S. dollar, the Company recorded foreign currency exchange gains of approximately &#128;3.1&nbsp;million and &#128;1.9&nbsp;million as a component of finance income / (expense) for the three- and <FONT STYLE="white-space:nowrap">six-month</FONT>
periods ended June&nbsp;30, 2018, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Trade and Other Receivables </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade and other receivables are short-term and due within 1 year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance as per</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unbilled receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VAT receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid pension costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest bank</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade and unbilled receivables relate primarily to invoicing for cost reimbursements relating to the Incyte collaboration and
license agreement and the ONO research and license agreement. VAT receivable relates to value added tax receivable from the Dutch tax authorities based on the tax application for the second quarter of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses reflected above in the form of prepaid expenses and prepaid pension costs consist of expenses that were paid during the reporting period but
are related to activities taking place in subsequent periods. The increase in prepaid expenses at June&nbsp;30, 2018 relate primarily to advanced payments made to contract research and contract manufacturing organizations in support of the
Company&#146;s upcoming clinical trial activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Liabilities and Accruals </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All amounts are short-term and payable within 1 year. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance per</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued auditor&#146;s fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IP &#150; Legal fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonuses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Subsidy advance received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research and development costs relate to accrued expenses for costs of certain development activities, such as clinical
trials, and are recorded based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations, and information provided the Company by vendors on their actual costs incurred. The
increase in research and development costs accrued expenses reflect the timing of enrollment in and support of the Company&#146;s clinical trials, manufacturing of drug candidates used for clinical
<FONT STYLE="white-space:nowrap">purposes,&nbsp;pre-clinical&nbsp;research</FONT> efforts to support the Company&#146;s internal research programs and the Incyte collaboration and license agreements and other collaboration agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The bonuses relate to the employee bonuses for the financial year 2018, which will be paid out in February 2019. The decrease in bonuses accrual compared to
December&nbsp;31, 2017, related to the annual payment of the 2017 bonuses in the first quarter of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The subsidy advances received relate to active
grants where the Company has received cash in excess of allowances which is required to be repaid or recognized as grant income when the relevant reimbursable costs are incurred as services are performed. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Deferred Revenue </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred revenue as of June&nbsp;30, 2018, and December&nbsp;31, 2017, consist of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance per</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2017&nbsp;Restated*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue &#150; current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See Note 3 for details regarding the restatement as a result of a change in accounting policy.</I>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the total deferred revenue balance at June&nbsp;30, 2018, &#128;120.6&nbsp;million related to the Incyte collaboration and license
agreement and a share subscription agreement entered into by the Company with Incyte on December&nbsp;20, 2016 (together, the &#147;Incyte Agreements&#148;), &#128;2.0 million&nbsp;related to the collaboration and license agreement entered into by
the Company with Simcere on January&nbsp;8, 2018 (the &#147;Simcere collaboration and license agreement&#148;), and &#128;0.1&nbsp;million related to the ONO research and license agreement. The total deferred revenue balance at December&nbsp;31,
2017, related solely to the Incyte Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Incyte collaboration and license agreement, Incyte agreed to pay the Company a <FONT
STYLE="white-space:nowrap">$120&nbsp;million&nbsp;non-refundable&nbsp;upfront</FONT> payment, and under the share subscription agreement, Incyte agreed to purchase 3.2&nbsp;million Common Shares at a price per share of $25.00, for an aggregate
purchase price of $80&nbsp;million. In January 2017, the Company completed the sale of its Common Shares under the share subscription agreement and received the $80&nbsp;million aggregate purchase price. In February 2017, the Company received the
$120&nbsp;million <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the contract for the share subscription agreement was
denominated in U.S. dollars, the Company determined that the forward contract to sell its own shares at a future date to which the Company became committed on December&nbsp;20, 2016, represented a derivative financial instrument. The fair values of
the derivative, or &#128;31.4&nbsp;million, and the <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment, or &#128;112.0&nbsp;million, were recorded as deferred revenue. The Company identified a single performance obligation,
providing access to its proprietary technology, relating to the Incyte Agreements and allocated all of the consideration received to this obligation. Both the upfront license payment and the derivative financial asset are being amortized as revenue
over time by measuring the progress toward the complete satisfaction of a performance obligation or specifically, the total period for which the Company expects to provide access to its proprietary technology under the Incyte Agreements, which is
currently estimated to be nine years in total, of which approximately 7.5 years remain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Simcere collaboration and license agreement, the
Company agreed to grant Simcere an exclusive license to develop and commercialize in China three bispecific antibodies utilizing the Company&#146;s Biclonics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;technology platform in the
area of immuno-oncology. The Company will retain all rights outside of China. As part of the agreement, the Company has agreed to lead research and discovery activities while Simcere has agreed to be responsible for the Investigational New Drug
enabling studies, clinical development, regulatory filings and commercialization of these product candidates in China. The Company received an upfront, <FONT STYLE="white-space:nowrap">non-refundable</FONT> payment of $2.75&nbsp;million, or
&#128;2.3&nbsp;million, relating to three separate research programs. Each research program was determined to be a separate performance obligation and consideration was allocated to each separate obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will amortize the upfront payment to revenue over time based on the estimated duration of each research program. As of June&nbsp;30, 2018, the
first research program had commenced. For the three- and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018, the Company recognized revenue of &#128;0.3&nbsp;million relating to this program for both amortization of
upfront payments and the achievements of milestones. The remaining two research programs had not commenced as of June&nbsp;30,&nbsp;2018. Accordingly, no revenue has been recognized related to the remaining two research programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;14, 2018, the Company entered into a second contract research and license agreement with ONO (the &#147;second ONO research and license
agreement&#148;). Pursuant to an exclusive option granted to ONO in the ONO research and license agreement, ONO exercised its option to enter into the second ONO research and license agreement. The Company granted ONO an exclusive, worldwide,
royalty-bearing license, with the right to sublicense, research, test, make, use and market bispecific antibody candidates based on the Company&#146;s Biclonics<B><SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP></B><B><SUP
STYLE="font-size:85%; vertical-align:top"> </SUP></B>technology platform against two undisclosed targets directed to a particular undisclosed target combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, ONO identifies and selects the licensed bispecific antibodies for which it is responsible for conducting <FONT
STYLE="white-space:nowrap">further&nbsp;non-clinical&nbsp;and</FONT> clinical development activities for such licensed bispecific antibodies and pharmaceutical products containing such antibodies, including manufacture and process development.
Additionally, ONO controls and has exclusive rights over the worldwide commercialization of any approved products, including worldwide supply, and is solely responsible for all costs and expenses related to commercialization. ONO has also agreed to
fund the Company&#146;s research and development activities and be responsible for the payment of all costs and expenses for its own research and development activities, which are set out in a mutually agreed upon research plan. The Company retains
all rights to use and commercialize any antibodies that are generated under the collaborative research program, excluding the up to five lead and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
selected antibodies against the targets ONO is pursuing, provided that the use and commercialization is not with respect to the particular target combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ONO agreed to pay the Company an <FONT STYLE="white-space:nowrap">upfront&nbsp;non-refundable&nbsp;payment</FONT> of &#128;0.7&nbsp;million,
&#128;0.3&nbsp;million intended to compensate the Company for research services already completed upon entering into the agreement, and &#128;0.2&nbsp;million to be paid to the Company over time for full time equivalent funding. The Company
identified a single performance obligation of providing research services to ONO and recognized as revenue approximately &#128;0.1&nbsp;million and &#128;1.1&nbsp;million during the three and six months ended June&nbsp;30, 2018, respectively. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shareholders&#146; Equity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placement of Common Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;13,
2018, the Company entered into the Purchase Agreement. Pursuant to the Purchase Agreement, the Company agreed to sell an aggregate of 3,099,997 of its Common Shares to the Investors for aggregate gross proceeds of approximately $55.8&nbsp;million,
at a purchase price equal to $18.00 per share. The Purchase Agreement contains customary representations and warranties from the Company and the Investors and customary closing conditions. On February&nbsp;15, 2018, the Company completed the sale
under the Private Placement and received gross proceeds of approximately $55.8&nbsp;million, or &#128;44.8&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Subscription Agreement
with Incyte </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the Incyte collaboration and license agreement discussed above under Note 8, the Company entered into a share subscription
agreement with Incyte on December&nbsp;20, 2016. On January&nbsp;23, 2017, under the terms of the share subscription agreement, the Company issued 3,200,000 of its Common Shares to Incyte at the agreed price per share of $25.00, for an aggregate
purchase price of $80.0&nbsp;million or &#128;74.7&nbsp;million. During the six months ended June&nbsp;30, 2017, the Company received proceeds, net of issuance costs, of &#128;74.4&nbsp;million. A &#128;1.1&nbsp;million discount on the subscription
share price, combined with a &#128;0.4&nbsp;million foreign currency translation accompanying the issuance of these shares, increased share capital by &#128;0.3&nbsp;million and share premium by &#128;73.4&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issued and <FONT STYLE="white-space:nowrap">paid-in</FONT> share capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All issued shares have been fully paid in cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Common
shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2018, 34,041 options were exercised at a weighted
average exercise price of &#128;1.93 per share. As a result, 34,041 Common Shares were issued, share capital increased by &#128;3,064 and share premium increased by &#128;62,635. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended&nbsp;June 30, 2017, 110,869 options were exercised with a weighted average exercise
price of &#128;2.05&nbsp;per share. As a result, 110,869 Common Shares were issued, share capital increased by &#128;9,978 and share premium increased by &#128;216,830. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At June&nbsp;30, 2018, a total of 22,632,800 Common Shares were issued and paid up. At June&nbsp;30, 2017, a total of 19,396,720 Common Shares were issued and
paid up. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Premium Reserve </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The share
premium reserve relates to amounts contributed by shareholders at the issue of shares in excess of the nominal value of the shares issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All share
premium can be considered as free share premium as referred to in the Netherlands Income Tax Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-based Payment Arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based payment expenses included in personnel expenses were &#128;4.6&nbsp;million and &#128;7.9&nbsp;million in the
<FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018, and June&nbsp;30, 2017, respectively. For details on the related share-based payment expenses recognized as employee benefit expenses, see Note 12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2016, the Company established the 2016 Incentive Award Plan (the &#147;2016 Plan&#148;). Options granted under the 2016 Plan are exercisable once
vested. The options granted under the 2016 Plan vest in installments over a four-year period from the grant date. Twenty-five percent of the options vest on the first anniversary of the vesting commencement date, and the remaining 75% of the options
vest in 36 monthly installments for each full month of continuous service provided by the option holder thereafter, such that 100% of the options shall become vested on the fourth anniversary of the vesting commencement date. Options will lapse on
the tenth anniversary of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Restricted Stock Units (&#147;RSUs&#148;) granted under the 2016 Plan also vest in installments over a
four-year period from the grant date. Each RSU represents the right to receive one Common Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As stated in the 2016 Plan, the Company has established
the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Compensation Program whereas <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors are entitled to cash compensation as well as equity compensation. The equity compensation
consists of an initial option grant as well as annual awards. The initial awards granted under the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Compensation Program vest in installments over a three-year period. Thirty-three
percent of the options vest on the first anniversary of the vesting commencement date, and the remaining 67% of the options in 24 substantially equal monthly installments thereafter, such that the award shall be fully vested on the third anniversary
of the vesting commencement date. Each subsequent award shall vest and become exercisable in 12 substantially equal monthly installments following the vesting commencement date, such that the subsequent award shall be fully vested on the first
anniversary of the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based payment expenses are recognized for each subsequent award that a
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director is entitled to over their remaining term. Since subsequent awards are not subject to shareholder approval, the grant date is established and expenses are based on grant date fair value.
The grant date fair value is not updated in each future reporting period and therefore the estimated fair value is not revised and expense recognized is based on the actual grant date fair value of the awards granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2018, the Company granted options to purchase 469,068 Common Shares with a grant date fair value of
&#128;4.4&nbsp;million to employees under the 2016 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the &#147;evergreen&#148; provisions of the 2016 Plan, the number of Common Shares
authorized for issuance under the plan automatically increased by 777,194 Common Shares to 1,090,368 Common Shares effective January&nbsp;1, 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Measurement of fair values of the equity-settled share-based payment arrangements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the employee share options has been measured using a binomial option pricing model, including members of the Board of Directors. Service and <FONT
STYLE="white-space:nowrap">non-market</FONT> performance conditions attached to the transactions were not taken into account in measuring fair value. Key management personnel include the Company&#146;s executive management and the Board of
Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The inputs used in the measurement of the fair values and the related fair values at the grant dates were as
follows for the options granted during the <FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Key&nbsp;Management<BR>Personnel<BR>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other&nbsp;Personnel<BR>(&#128;)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value at grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">9.34-9.45</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">9.30-10.37</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share price at grant date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">14.57-14.87</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">14.57-18.24</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">14.57-14.87</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">14.57-18.24</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility (weighted-average)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>95.1%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94.6%</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contractual life</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>10 years</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>0%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>0%</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate (based on government bonds)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2.79%-2.94%</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B><FONT STYLE="white-space:nowrap">2.84%-2.94%</FONT></B></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reconciliation of outstanding share options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of share options and the weighted average exercise prices of share options granted were as follows for the
<FONT STYLE="white-space:nowrap">six-month</FONT> period ended June&nbsp;30, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;average<BR>exercise price<BR>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13.99</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,213,985</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the <FONT STYLE="white-space:nowrap">six-month</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19.67</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(12,044</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired during the <FONT STYLE="white-space:nowrap">six-month</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.02</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the <FONT STYLE="white-space:nowrap">six-month</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.93</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,041</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the <FONT STYLE="white-space:nowrap">six-month</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.68</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>469,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14.24</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,631,822</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12.18</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,105,059</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The options outstanding at June&nbsp;30, 2018, had an exercise price in the range of &#128;1.93 to &#128;27.47 and a
weighted-average remaining contractual life of 8.2 years. The weighted-average share price at the date of exercise for share options exercised during the six months ended June&nbsp;30, 2018 was &#128;17.12. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were 2,631,822 outstanding share options at June&nbsp;30, 2018, with a weighted average exercise price of &#128;14.24. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of options outstanding as of June&nbsp;30, 2018, was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Group of employees entitled</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Key management personnel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,153,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">478,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,631,822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2018, the Company did not grant any new RSUs. The number of RSUs
outstanding is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;average<BR>grant price<BR>(&#128;)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>RSU&#146;s</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.03</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>194,546</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the <FONT STYLE="white-space:nowrap">six-month</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested during the <FONT STYLE="white-space:nowrap">six-month</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.03</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(76,245</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the <FONT STYLE="white-space:nowrap">six-month</FONT> period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.03</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>118,301</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Revenue </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue is recognized at the amount to which the Company expects to be entitled for the transfer of promised goods or services to customers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disaggregation of Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
revenues are generated entirely in the Netherlands. In the following table, revenue is disaggregated by primary source of revenue as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Three months ended</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">Six months ended</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June&nbsp;30,<BR>2017&nbsp;Restated*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">June 30<BR>2017&nbsp;Restated*</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Upfront payment amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,250</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,087</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,195</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from contracts with customers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,282</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income from grants on research projects</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>182</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,543</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,464</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B></B><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B></B>10,121<B></B></TD>
<TD NOWRAP VALIGN="bottom"><B></B><B></B>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><I>*</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>See Note 3 for details regarding the restatement as a result of a change in accounting policy.
</I></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three- and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018, the Company recognized
amortization of &#128;4.0&nbsp;million and &#128;7.9&nbsp;million on upfront payments related to the Incyte collaboration and license agreement, respectively, amortization of &#128;0.2&nbsp;million and &#128;1.1&nbsp;million on upfront payments
related to the ONO research and license agreement, respectively, and &#128;0.1&nbsp;million and &#128;0.1&nbsp;million on upfront payments related to the Simcere collaboration and license agreement, respectively. For the three- and <FONT
STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2017, the Company recognized &#128;4.0&nbsp;million and &#128;6.9&nbsp;million of amortization of the upfront payment related to the Incyte collaboration and license agreement,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaboration income for the three and six months ended June&nbsp;30, 2018, was &#128;2.2&nbsp;million and &#128;7.2&nbsp;million,
respectively, and consisted of cost reimbursements and research milestones achieved in support of the Company&#146;s research and license agreements with Incyte, ONO and Simcere. During the three and six months ended June&nbsp;30, 2018, the Company
recognized &#128;2.0&nbsp;million and &#128;4.3&nbsp;million of cost reimbursements in support of the Company&#146;s research and license agreements with Incyte, respectively, and &#128;0.1&nbsp;million and &#128;0.2&nbsp;million of cost
reimbursements in support of the Company&#146;s research and license agreements with ONO, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized an aggregate of
&#128;2.5&nbsp;million in research milestones under its ONO agreements for the six months ended June&nbsp;30, 2018 and &#128;0.1&nbsp;million in research milestones under its Simcere agreements for the three and six months ended June&nbsp;30, 2018.
During the three and six months ended June&nbsp;30, 2017, the Company recognized &#128;1.5&nbsp;million and &#128;2.4&nbsp;million of cost reimbursements in support of the Company&#146;s research and license agreements with Incyte and ONO,
respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has been awarded grants consisting of cash allowances for specific research and development
projects. The unconditional receipt of the grant allowances is dependent on the final review of the reporting provided by the Company at the end of the contract term. For the three and six months ended June&nbsp;30, 2018, the Company recognized
&#128;0.1&nbsp;million and &#128;0.2&nbsp;million in grant income, respectively, compared to &#128;0.8&nbsp;million in grant income for the three and six months ended June&nbsp;30, 2017. On June&nbsp;12, 2017, the European Commission approved for
reimbursement the final installment of the <FONT STYLE="white-space:nowrap">FP-7</FONT> grant for &#128;0.7&nbsp;million. Revenue for this final installment was recorded in income from grants on research projects during the three and six months
ended June&nbsp;30, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contract Balances </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A trade receivable is recorded when the Company satisfies a performance obligation by transferring a promised good or service and has earned the unconditional
right to consideration from its customer. Trade receivables relate to invoicing for cost reimbursements and research milestones achieved in support of the Company&#146;s research and license agreements with Incyte, ONO and Simcere. Payment terms
relating to these receivables are 30 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A contract asset is recorded when the Company satisfies a performance obligation by transferring a promised
good or service and has earned the right to consideration from its customer. These assets represent a conditional right to consideration. Contract assets relate to unbilled amounts for cost reimbursements and research milestones achieved in support
of the Company&#146;s research and license agreements with Incyte and ONO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A contract liability is recorded when consideration is received, or such
consideration is unconditionally due, from a customer prior to transferring goods or services under the terms of the contract. Contract liabilities are recognized as revenue as control of the products or services is transferred to the customer and
all revenue recognition criteria have been met. Contract liabilities relate to upfront payments received related to the Incyte Agreements, ONO research and license agreement, and the Simcere research and license agreement (See Note 8). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents changes in the Company&#146;s trade receivables, contract assets and contract liabilities during the six months ended
June&nbsp;30, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance&nbsp;at&nbsp;December&nbsp;31,<BR>2017 Restated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deductions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Balance&nbsp;at&nbsp;June&nbsp;30,<BR>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade&nbsp;&amp; other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total trade&nbsp;&amp; other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,628</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unbilled receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contract assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total contract liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the adoption of IFRS 15, total deferred revenue was reduced by &#128;8.7&nbsp;million as of December&nbsp;31,
2017. See Note 3 for details regarding the restatement as a result of a change in accounting policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deductions from deferred revenue are comprised of revenue recognized that was included in deferred revenue
at the beginning of the period totaling &#128;7.9&nbsp;million and revenue recognized that was not included in deferred revenue at the beginning of the period totaling &#128;1.3&nbsp;million for the six months ended June&nbsp;30, 2018. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Total Operating Expenses </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs are comprised of allocated employee costs, the costs of materials and laboratory consumables, intellectual property and license
costs and allocated other costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A breakdown of total operating expenses is presented as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Three-month&nbsp;period&nbsp;ended</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Six-month&nbsp;period&nbsp;ended</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">2017</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(euros&nbsp;in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manufacturing costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,858</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IP and license costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>492</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>844</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related R&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,107</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,808</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,344</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,311</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total research and development costs</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,523</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>22,821</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administration costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,639</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,491</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>849</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,745</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,134</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total other expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,297</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,983</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,459</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34,295</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development costs were &#128;12.5&nbsp;million and &#128;22.8&nbsp;million for the three and six months ended
June&nbsp;30, 2018, respectively, as compared to &#128;8.4&nbsp;million and &#128;15.4&nbsp;million for the three- and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2017, respectively. The increase in research and
development costs is primarily attributable to the increase in manufacturing costs, higher research and development headcount and related costs, as well as additional spending in support of the Company&#146;s clinical development programs for <FONT
STYLE="white-space:nowrap">MCLA-128,</FONT> <FONT STYLE="white-space:nowrap">MCLA-117,</FONT> <FONT STYLE="white-space:nowrap">MCLA-158</FONT> and <FONT STYLE="white-space:nowrap">MCLA-145.The</FONT> significant increase in manufacturing costs and
other research and development costs during 2018 relate primarily to the expansion of the Company&#146;s Phase 1 and Phase 1/2 clinical programs. Specifically, the Company incurred higher costs relating to outsourced contract manufacturing for
process development and drug delivery in support of the Company&#146;s <FONT STYLE="white-space:nowrap">MCLA-128</FONT> and <FONT STYLE="white-space:nowrap">MCLA-158</FONT> clinical development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A breakdown of other research and development costs is presented as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Three-month&nbsp;period&nbsp;ended</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Six-month&nbsp;period&nbsp;ended</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>June&nbsp;30,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>2017<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>2017<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discovery and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,078</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,698</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,763</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clinical costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,850</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,416</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,300</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total other research and development costs</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,344</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,311</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other research and development costs consist mainly of laboratory supplies and depreciation expense related to research and
development activities, which cannot be specifically allocated to a research project. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Litigation costs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2014, Regeneron Pharmaceuticals, Inc. (&#147;Regeneron&#148;) filed a complaint in the United States District Court for the Southern District
of New York (the &#147;Court&#148;), alleging that the Company was infringing on one or more claims in Regeneron&#146;s U.S. Patent No.&nbsp;8,502,018, entitled &#147;Methods of Modifying Eukaryotic Cells&#148; (the &#147;018 Patent&#148;). On
July&nbsp;3, 2014, the Company filed a response to the complaint, denying Regeneron&#146;s allegations of infringement and raising affirmative defenses, and filed counterclaims seeking, among other things, a declaratory judgment that the Company did
not infringe the patent and that the patent was invalid. The Company subsequently filed amended counterclaims during the period from August to December 2014, seeking a declaratory judgment of unenforceability of the patent due to Regeneron&#146;s
commission of inequitable conduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;21, 2014, the Court found that there was clear and convincing evidence that a claim term present in
each of the patent claims was indefinite and granted the Company&#146;s proposed claim constructions. On February&nbsp;24, 2015, the Court entered partial judgment in the proceeding, on the grounds that the Company did not infringe each of the
patent claims, and that each of the patent claims were invalid due to indefiniteness. On November&nbsp;2, 2015, the Court found Regeneron had withheld material information from the United States Patent and Trademark Office during prosecution of the
patent, and Regeneron had engaged in inequitable conduct and affirmative egregious misconduct in connection with the prosecution of the patent. On December&nbsp;18, 2015, Regeneron filed an appeal of the Court&#146;s decision. On July&nbsp;27, 2017,
the U.S. Court of Appeals for the Federal Circuit affirmed the trial court&#146;s conclusion that Regeneron had engaged in inequitable conduct before the United States Patent and Trademark Office and affirmed that the &#145;018 patent is
unenforceable. Regeneron petitioned for a panel rehearing and rehearing en banc of this decision by the Federal Circuit on September&nbsp;12, 2017, which the Company responded to and opposed on November&nbsp;2, 2017. On December&nbsp;26, 2017, the
full Federal Circuit denied Regeneron&#146;s request to rehear the matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The case returned to the District Court to adjudicate the Company&#146;s
motion requesting that Regeneron pay the Company&#146;s attorneys&#146; fees and costs incurred as a result of Regeneron filing suit. On March&nbsp;26, 2018, the trial court granted the Company&#146;s motion for attorneys&#146; fees, expert fees,
and costs and ordered the parties to address the amount of award. The Company provided a detailed explanation of its attorneys&#146; fees, expert fees, and costs of such award, which Regeneron responded to seeking a reduction of the amount. The
matter was fully briefed as of May&nbsp;18, 2018, and the Court issued an Order on June&nbsp;25, 2018, which published on July&nbsp;10, 2018, granting the Company&#146;s motion for $8,332,453.46 in attorneys&#146; fees, $465,390.34 in expert fees,
and $1,717,100.69 in litigation expenses and costs, along with interest. Regeneron has appealed the decision awarding attorneys&#146; fees to the Company to the Federal Circuit. On May&nbsp;25, 2018, Regeneron filed a petition for writ of certiorari
seeking review by the Supreme Court of the United States of the decision affirmed by the Federal Circuit. The Company&#146;s brief in opposition was filed on August&nbsp;8, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;11, 2014, Regeneron served a writ in the Netherlands alleging that the Company was infringing one or more claims of the European patent EP 1 360
287 B1. The Company opposed the patent in June 2014. On September&nbsp;17, 2014, Regeneron&#146;s patent EP 1 360 287 B1 was revoked in its entirety by the European Opposition Division of the European Patent Office (the &#147;EPO&#148;). In Europe,
an appeal hearing occurred in October and November 2015 at the Technical Board of Appeal for the EPO at which time the patent was reinstated to Regeneron with amended claims. On May&nbsp;25, 2018, at Regeneron&#146;s request, a hearing before the
Technical Board of Appeals for the EPO was scheduled for September&nbsp;13, 2018, to address whether the description of EP 1 360 287 B1 patent having claims amended during the course of opposition complies with Art. 84 EPC, Art. 123(2) EPC and Rule
80 EPC. The Company believes that its current business operations do not infringe the patent reinstated to Regeneron with amended claims because it believes it has not used the technology or methods claimed under the amended claims.&nbsp;The Dutch
litigation procedure is stayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The costs incurred in the above litigation and opposition were &#128;0.6&nbsp;million and &#128;0.8&nbsp;million for the
three- and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018, respectively, as compared to &#128;0.1&nbsp;million and &#128;0.4&nbsp;million for the three- and <FONT STYLE="white-space:nowrap">six-month</FONT>
periods ended June&nbsp;30, 2017, respectively, and are included in the statement of profit or loss and comprehensive loss for the period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;15, 2014, Regeneron filed a notice of opposition against the Company&#146;s EP 2314629 patent
(the &#147;EP &#146;629 patent&#148;), entitled &#147;Recombinant Production of Mixtures of Antibodies,&#148; in the EPO. The notice asserted, as applicable, added subject matter, lack of novelty, lack of inventive step, and insufficiency. The
Company responded on February&nbsp;24, 2015. Following an oral hearing before the Opposition Division of the EPO on June&nbsp;22, 2016, the Opposition Division upheld the EP &#146;629 Patent with amendments. Both Regeneron and the Company filed a
notice of appeal followed by grounds of appeal on December&nbsp;1 and 4, 2017, respectively, with further proceedings to follow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;11, 2014,
Regeneron filed a notice of opposition against the Company&#146;s EP 2147594 (the &#147;EP &#146;594 patent&#148;), entitled &#147;Antibody Producing <FONT STYLE="white-space:nowrap">Non-Human</FONT> Mammals,&#148; in the EPO. The notice asserted,
as applicable, lack of novelty, lack of inventive step, and insufficiency. The Company&#146;s response to the oppositions was filed on April&nbsp;2, 2015. Following an oral hearing before the Opposition Division of the EPO on October&nbsp;28, 2016,
the Opposition Division upheld the EP &#146;594 Patent without amendments. Regeneron filed grounds of appeal on July&nbsp;19, 2017, and the Company responded on November&nbsp;30, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2018, Regeneron and an unnamed third party filed notices of opposition against the Company&#146;s EP 2604625 patent (the &#147;EP &#145;625
patent&#148;), entitled &#147;Generation of Binding Molecules,&#148; in the EPO. The notices asserted, as applicable, added subject matter, lack of novelty, lack of inventive step, and insufficiency. The Company intends to timely respond to these
submissions with proceedings to be ongoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As each of these proceedings continues, the Company is not able to predict the outcome of, or estimate a
possible gain or a range of possible loss, if any, related to the above actions. Based on the current facts and circumstances, no provision has been recognized under IAS 37 related to contingent liabilities. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Employee Benefits </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of the employee benefits are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Three-month&nbsp;period&nbsp;ended</FONT><BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Six-month&nbsp;period&nbsp;ended</FONT><BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>2017<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>2017<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and wages</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WBSO subsidy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(733</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,900</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Social security premiums</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Health insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pension costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share award expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other personnel expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total employee benefits expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based payment expenses (see Note 9) were recognized as employee benefit expenses as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Three-month&nbsp;period&nbsp;ended</FONT><BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Six-month&nbsp;period&nbsp;ended</FONT><BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>2017<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>2017<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Management and administrative costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsidies earned under the WBSO relating to eligible research and development costs are deferred and
recognized in the Company&#146;s income statement as a reduction to labor costs over the period labor costs are expected to be incurred. The Company has received and recognized subsidies of &#128;0.7&nbsp;million and &#128;1.9&nbsp;million for the
three- and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018, respectively, as compared to &#128;1.0&nbsp;million and &#128;2.0&nbsp;million for the three- and <FONT STYLE="white-space:nowrap">six-month</FONT>
periods ended June&nbsp;30, 2017, respectively. The decrease in subsidies is primarily attributable to the decrease in eligible payroll tax withholdings during the same period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s headcount at&nbsp;June&nbsp;30, 2018 was approximately 85&nbsp;full-time equivalents and consisted of 70 employees in the Netherlands
and&nbsp;15 employees in the United States. A total of 18&nbsp;employees who are devoted to activities other than research and development and overall management of the Company were included under management and administration costs for the three-
and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s headcount at June&nbsp;30, 2017 was
approximately 64 full-time equivalents and consisted of 55 employees in the Netherlands and&nbsp;nine employees in the United States. A total of 13&nbsp;employees who were devoted to activities other than research and development and overall
management of the Company were included under management and administration costs for the three- and <FONT STYLE="white-space:nowrap">six-month</FONT> periods ended June&nbsp;30, 2017. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Finance Income and Expense </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Three-month&nbsp;period&nbsp;ended</FONT><BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Six-month&nbsp;period&nbsp;ended</FONT><BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>&nbsp;&nbsp;&nbsp;&nbsp;2017<B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B>&nbsp;&nbsp;&nbsp;&nbsp;2017<B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income and similar income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>494</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>834</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net gain on foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,917</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,411</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,945</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,667</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss on foreign exchange</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,962</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,696</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interest income primarily results from interest earned on cash held on account and accretion of investment earnings. The
Company&#146;s current year increase in cash, cash equivalents and investments was due primarily to the $55.8&nbsp;million of funds received as part of the Private Placement during the first quarter of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company experienced gains on its U.S. dollar denominated cash, cash equivalents and investments of approximately &#128;6.9 million and &#128;4.1 million
for the three and six months ended June 30, 2018, respectively, as compared to losses of &#128;12.0 million for the three and six months ended June 30, 2017. The Company presents foreign currency gains and losses on a net basis as either finance
income or finance expense depending on whether foreign currency movements are in a net gain or net loss position. The Company experienced foreign exchange losses on its U.S. dollar denominated cash, cash equivalents and investments of approximately
&#128;2.8 million during the three months ended March 31, 2018, which are reclassified to net gain on foreign exchange for the six months ended June 30, 2018. As of June 30, 2018, the Company held approximately $40.9 million and $92.6 million in
U.S. dollar denominated cash and cash equivalent accounts and investment accounts, respectively, subject to the fluctuation in foreign currency between the euro and U.S. dollar. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2016, the Company entered into the Incyte Agreements. As these contracts are denominated in U.S. dollars, the Company determined that the
subscription agreement to sell its own shares to which the Company became committed on December&nbsp;20, 2016, should be accounted for as a forward contract or a derivative financial instrument. Interest expense for the three and six months ended
June&nbsp;30, 2017, related entirely to the effective settlement of the forward contract on January&nbsp;23, 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Operating Leases </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases its corporate headquarters under an agreement term of five years which expires in the fourth quarter of 2021. If the lease is not terminated
by Merus N.V. it will be automatically renewed for a period of two years. The agreed rental price is &#128;0.4&nbsp;million per year. On May&nbsp;1, 2018, the Company leased additional space to expand its corporate headquarters under a separate
agreement. Under the terms of the new agreement, the term began on May&nbsp;1, 2018, and expires in the fourth quarter of 2021. The agreed upon rental price is &#128;0.5&nbsp;million per year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For leases that contain fixed increases in the minimum annual lease payment during the original term of the lease, the Company recognizes rental expense on a
straight-line basis over the lease term and records the difference between rent expense and the amount currently payable as deferred rent as a component of other liabilities and accruals. For the three and six months ended June&nbsp;30, 2018, the
Company recognized &#128;0.3&nbsp;million and &#128;0.5&nbsp;million, respectively, compared to &#128;0.2&nbsp;million and &#128;0.3&nbsp;million for the three and six months ended June&nbsp;30, 2017, respectively, for rent and service charges
related to the office space. In addition, the Company has provided a deposit of &#128;0.1&nbsp;million included in other assets as of June&nbsp;30, 2018, and December&nbsp;31, 2017. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events through August&nbsp;10, 2018, the date of issuance of the unaudited consolidated financial statements for the three
months ended June&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for the items described in Note 11 under litigation, there were no additional events requiring disclosure in the
notes to these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>6,299,997 Shares </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Merus N.V. </B></P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Shares </B></P> <P STYLE="font-size:90pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g569434g02u78.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:90pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:160pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART&nbsp;II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>6. Indemnification of Directors and Officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current and former directors and such other current or former officer or employee of the Company or its group companies as designated by the board of
directors have the benefit of the following indemnification provisions in our articles of association: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indemnified officers shall be indemnified and held
harmless for (in each case to the extent this relates to his or her position or former position with us, and in each case to the fullest extent permitted by applicable law): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any financial losses or damages incurred by such indemnified officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any expense reasonably paid or incurred by such indemnified officer in connection with any threatened, pending
or completed suit, claim, action or legal proceedings, whether civil, criminal, administrative or investigative and whether formal or informal, in which he or she becomes involved. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There shall be no entitlement to indemnification as referred to above: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if a competent court or arbitral tribunal has established, without possibility for appeal, that the acts or
omissions of such indemnified officer that led to the financial losses, damages, suit, claim, action or legal proceedings as described above results from either an improper performance of his or her duties as an officer of the Company or an unlawful
or illegal act; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that his or her financial losses, damages and expenses are covered by an insurance and the
insurer has settled, or has provided reimbursement for, these financial losses, damages and expenses (or has irrevocably undertaken to do so); or </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;in relation to proceedings brought by such indemnified officer against us, except for proceedings brought to enforce indemnification
to which he or she is entitled pursuant to our articles of association or an agreement between such indemnified officer and us that has been approved by our board of directors </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors. These indemnification agreements may require us, among other things, to indemnify
our directors for judgments, settlements, fines, and some expenses, including attorneys&#146; fees, incurred by a director in any action or proceeding arising out of his or her service as a director, or any of our subsidiaries or any other company
or enterprise to which the person provides services at our request. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>7. Recent sales of unregistered securities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class C Investment Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;21,
2015, the registrant issued 4,149,884 Class&nbsp;C preferred shares to certain investors in exchange for an aggregate consideration of &#128;49.7&nbsp;million, which includes the conversion of the registrant&#146;s existing &#128;8.0&nbsp;million
convertible bridge loan and interest thereon into Class C preferred shares. The foregoing issuance was made outside of the United States pursuant to Regulation S or to U.S. entities pursuant to Section&nbsp;4(a)(2) of the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share Issuances </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2016, we issued
12,107 common shares to Stichting Administratiekantoor Merus (or &#147;STAK&#148;) upon the exercise of options to purchase depositary receipts by the former Chairman of our Board for aggregate consideration of &#128;23,317 in cash. Such issuance
was made outside of the United States pursuant to Regulation S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;23, 2017, we issued 3,200,000 common shares to Incyte Corporation for aggregate gross
proceeds of $80.0 million. Such issuance was made pursuant to Section&nbsp;4(a)(2) of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;15, 2018, we issued 3,099,997
common shares to certain new and existing investors for aggregate gross proceeds of $55.8 million. Such issuance was made pursuant to Section&nbsp;4(a)(2) of the Securities Act. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>8. Exhibits. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"></P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Incorporated by Reference</B><br><B>to Filings Indicated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Form</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>File No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Filing&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex11.htm">Articles of Association (English&nbsp;Translation) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of NautaDutilh, counsel of the Registrant</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex41.htm">Merus N.V. 2010 Employee Option Plan, as amended </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex42.htm">Merus N.V. 2016 Incentive Award Plan and forms of award agreements thereunder, as amended</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d569434dex103.htm">Non-Executive Director Compensation Program</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516582683/d29248dex104.htm">Form of Board of Directors Indemnification Agreement </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>F-1/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">333-207490</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5/9/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312515346981/d29248dex105.htm">Employment Contract between the Registrant and Ton Logtenberg, dated January 21, 2010.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>F-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">333-207490</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10/19/15</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516758036/d268849dex101.htm">Employment Agreement, dated October 5, 2016, by and among Merus US, Inc., the Registrant and John&nbsp;J. Crowley </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>6-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">11/3/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex47.htm">Employment Agreement, dated December 16, 2015, by and among Merus US, Inc., the Registrant and Hui Liu, as amended on March 2,
2016</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex48.htm">Employment Agreement, dated November&nbsp;1, 2016, by and among Merus US, Inc., the Registrant and L. Andres Sirulnik</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex49.htm">English language translation of Employment Agreement, dated as of July 19, 2008, by and between the Registrant and Mark Throsby, as amended on
March 10, 2010</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex410.htm">English language translation of Employment Agreement, dated as of August 5, 2010, by and between the Registrant and Alexander
Bakker</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.10</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex411.htm">English language translation of Employment Agreement, dated as of April 2, 2007, by and between the Registrant and John de Kruif, as amended
 on March 10, 2010</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.11</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12#</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex412.htm">Employment Agreement, dated as of December 24, 2016, by and between the Registrant and Peter Silverman, as amended February 1,
2017</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516582683/d29248dex1012.htm">English language translation of Lease Agreement, dated April 22, 2016, by and between the Registrant and Stichting Incubator
Utrecht.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>F-1/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">333-207490</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5/9/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex4151.htm">English language translation of Amendment to Lease Agreement, dated as of November 1, 2016 by and between the Registrant and Stichting Incubator
 Utrecht</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.15.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518245788/d592967dex993.htm">English language translation of Lease Agreement, dated as of May 1, 2018, by and between the Registrant and Stichting Incubator
Utrecht</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>6-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">8/10/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312517148152/d355766dex412.htm">Collaboration and License Agreement, dated December&nbsp;20, 2016, by and between the Registrant and Incyte Corporation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/28/17</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312517148152/d355766dex413.htm">Share Subscription Agreement, dated December&nbsp;20, 2016, by and between the Registrant and Incyte Corporation </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.13</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/28/17</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312515346981/d29248dex109.htm">Contract Research and License Agreement and Addendum between the Registrant and ONO Pharmaceutical Co., Ltd., dated April 8, 2014.</A></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>F-1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">333-207490</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">10/19/15</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518143856/d502406dex419.htm">Contract Research and License Agreement by and between the Registrant and Ono Pharmaceuticals Co., Ltd., dated March 14, 2018</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>20-F</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.19</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/30/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518047493/d539820dex991.htm">Securities Purchase Agreement, dated February 13, 2018, by an among the registrant and the Investors identified on Exhibit A attached thereto
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>6-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">99.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2/16/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312518047493/d539820dex992.htm">Registration Rights Agreement, dated February 13, 2018, by and among the registrant and the Investors identified on Exhibit A attached thereto
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>6-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-37773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">99.2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2/16/18</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516606452/d326237dex41.htm">Registration Rights Agreement, dated May 24, 2016, by and among the Registrant and the shareholders party thereto</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>6-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">001-377773</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">5/27/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1651311/000119312516535709/d29248dex211.htm">List of Subsidiaries</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP>F-1/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">333-207490</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">21.1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">4/8/16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d569434dex231.htm">Consent of KPMG Accountants N.V.</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of NautaDutilh, counsel to the Registration (included in Exhibit 5.1)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">**</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#ii569434_1">Powers of attorney (included on signature page to the registration statement)</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Calculation Linkbase Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Label Linkbase Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Presentation Linkbase Document.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed by amendment. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates management contract or compensatory plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment granted as to portions of the exhibit. Confidential materials omitted and filed
separately with the Securities and Exchange Commission. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>9. Undertakings. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The undersigned hereby undertakes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities
offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the
Commission pursuant to Rule&nbsp;424(b) if, in the aggregate, the changes in volume and price represent no more than 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table in
the effective registration statement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of distribution not
previously disclosed in the registration statement or any material change to such information in the registration statement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective
amendment any of the securities being registered which remain unsold at the termination of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) To file a post-effective
amendment to the registration statement to include any financial statements required by Item 8.A. of Form <FONT STYLE="white-space:nowrap">20-F</FONT> at the start of any delayed offering or throughout a continuous offering. Financial statements and
information otherwise required by Section&nbsp;10(a)(3) of the Securities Act of 1933 need not be furnished, provided, that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to
this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date
the filed prospectus was deemed part of and included in the registration statement; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as
part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be
deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the
prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the
registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or
prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time
of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such
effective date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(6) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in
the initial distribution of securities: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant undertakes that in a primary offering of securities of the undersigned
registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the
undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the
undersigned registrant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The portion of any other free writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Any other communications that
is an offer in the offering made by the undersigned registrant to the purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Insofar as indemnification for liabilities arising
under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and
Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer, or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being
registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as
expressed in the Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The undersigned registrant hereby undertakes that:
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration
statement as of the time it was declared effective. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) For the purpose of determining any liability under the Securities Act of 1933, each
post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ii569434_1"></A>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form F-1 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Utrecht, the Netherlands on December 27, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MERUS N.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ton Logtenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Ton Logtenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: &nbsp;&nbsp;President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ton
Logtenberg and John Crowley and each of them, individually, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead in any and all
capacities, in connection with this registration statement, including to sign in the name and on behalf of the undersigned, this registration statement and any and all amendments thereto, including post-effective amendments and registrations filed
pursuant to Rule 462 under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto such attorneys-in-fact
and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming
all that said attorneys-in-fact and agents, or his substitute, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the
Securities Act of 1933, as amended, this registration statement has been signed by the following persons on December 27, 2018 in the capacities indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="51%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Ton Logtenberg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ton Logtenberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President and Chief Executive Officer and Executive Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Executive Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;John Crowley</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">John Crowley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Principal Financial Officer and Principal</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Accounting Officer)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Russell G. Greig</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Russell G. Greig</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Board of Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Mark Iwicki</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Mark Iwicki</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Non-Executive Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Len Kanavy</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Len Kanavy</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Non-Executive Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;John de Koning</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">John de Koning</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Non-Executive Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Anand Mehra</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Anand Mehra</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Non-Executive Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/&nbsp;&nbsp;&nbsp;&nbsp;Gregory Perry</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Gregory Perry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Non-Executive Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE OF AUTHORIZED UNITED STATES REPRESENTATIVE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Securities Act, the undersigned, the duly authorized representative in the United States of MERUS N.V. has signed this registration statement
in the City of Utrecht, the Netherlands on December&nbsp;27, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Authorized U.S. Representative</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Merus US, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ton Logtenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Ton Logtenberg</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: &nbsp;&nbsp;President</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>d569434dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>M<SMALL>ERUS</SMALL> N.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>ON</SMALL><FONT STYLE="white-space:nowrap">-E</FONT><SMALL>XECUTIVE</SMALL> D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL>
P<SMALL>ROGRAM</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">non-executive</FONT> directors (the &#147;<B><I><FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Directors</I></B>&#148; and each, a &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</I></B>&#148;) of Merus N.V. (the &#147;<B><I>Company</I></B>&#148;) shall receive cash
and equity compensation as set forth in this <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director Compensation Program (this &#147;<B><I>Program</I></B>&#148;). The compensation described in this Program shall be paid or be made, as
applicable, automatically and without further action of the Board of Directors (the &#147;<B><I>Board</I></B>&#148;) or the general meeting of shareholders (the &#147;<B><I>General Meeting</I></B>&#148;) of the Company, to each <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Director who is entitled to receive such cash or equity compensation, unless such <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director declines the receipt of such cash or equity compensation
by written notice to the Company. This Program shall remain in effect until it is revised or rescinded by further action taken by the Board at the recommendation of the Compensation Committee. This Program may be amended, modified or terminated at
any time by action taken by the Board at the recommendation of the Compensation Committee. Except as otherwise provided in this Program with respect to Observers (as defined below), the terms and conditions of this Program shall supersede any prior
cash and/or equity compensation arrangements for service as a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director (or as a supervisory director) between the Company and any of its <FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Time spent in office and service as a supervisory director of the Company prior to the amendment to the articles of
association of the Company on May&nbsp;29, 2017 shall, for purposes of this Program, be considered to be time spent in office and service as <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.&nbsp;&nbsp;&nbsp;&nbsp;C<SMALL>ASH</SMALL> C<SMALL>OMPENSATION</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;<U>Annual Retainers</U>. Each <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director shall receive an annual
retainer of $35,000 for service on the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">B. &nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Annual Retainers</U>. In addition, each <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Director shall receive the following annual retainers: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.
&nbsp;&nbsp;&nbsp;&nbsp;<I>Chairperson of the Board</I>. A <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director serving as Chairperson of the Board shall receive an additional annual retainer of $50,000 for such service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2. &nbsp;&nbsp;&nbsp;&nbsp;<I>Audit Committee</I>. A <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director serving as Chairperson of
the Audit Committee shall receive an additional annual retainer of $15,000 for such service. A <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director serving as a member other than the Chairperson of the Audit Committee shall receive an
additional annual retainer of $7,500 for such service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3. &nbsp;&nbsp;&nbsp;&nbsp;<I>Compensation Committee</I>. A <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $13,000 for such service. A <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director
serving as a member other than the Chairperson of the Compensation Committee shall receive an additional annual retainer of $5,000 for such service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4. &nbsp;&nbsp;&nbsp;&nbsp;<I>Nomination and Corporate Governance Committee</I>. A <FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Director serving as Chairperson of the Nomination and Corporate Governance </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Committee shall receive an additional annual retainer of $13,000 for such service. A <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director serving as a member other than the Chairperson
of the Nomination and Corporate Governance Committee shall receive an additional annual retainer of $3,750 for such service. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp; <U>Payment of Retainers</U>. The annual retainers described in Sections I(A) and I(B) shall be earned on a
quarterly basis based on a calendar quarter and shall be paid in cash by the Company in arrears not later than the fifteenth day following the end of each calendar quarter. In the event a <FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Director does not serve as a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director, or in the applicable positions described in Section I(B), for an entire calendar quarter, the retainer paid to such
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director shall be prorated for the portion of such calendar quarter actually served as a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director, or in such position, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">D.&nbsp;&nbsp;&nbsp;&nbsp; <U>Annual Increase</U>. Each annual retainer described in Sections I(A) and I(B) shall, without further action
taken by the Board or the General Meeting, automatically increase on the first day of each calendar year by an amount equal to 3% of the value of such annual retainer in effect as of the immediately preceding calendar year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">E. &nbsp;&nbsp;&nbsp;&nbsp;<U>Observers</U>. Unless the Board decides otherwise, the date service as an observer on the Board (an
&#147;<B><I>Observer</I></B>&#148;) commences pursuant to, and as from the effective date of, a written services agreement entered into between such Observer and the Company shall be considered the effective date of commencing service as a <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Director for purposes of Section I. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.&nbsp;&nbsp;&nbsp;&nbsp;E<SMALL>QUITY</SMALL>
C<SMALL>OMPENSATION</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors shall be eligible to be granted the equity
awards described below. The awards described below shall be granted under and shall be subject to the terms and provisions of the Company&#146;s 2016 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the
Company (the &#147;<B><I>Equity Plan</I></B>&#148;), shall be granted by the Board, and subject to such award or other agreements as approved by the Board. Subject to Section II(G), all applicable terms of the Equity Plan apply to this Program as if
fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan and the applicable award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;<U>Initial Awards</U>. Each <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director who is initially
appointed to the Board shall be eligible to receive an option to purchase the number of common shares of the Company having an aggregate Grant Date Fair Value (as defined below) of $200,000, with any partial shares that result being rounded down to
the nearest whole share. The awards described in this Section II(A) shall be referred to as &#147;<B><I>Initial Awards</I></B>.&#148; No <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director shall be granted more than one Initial Award.
&#147;<B><I>Grant Date Fair Value</I></B>&#148; shall mean the value of the option as of the date of grant, which value shall be determined using a Black-Scholes option pricing model and the valuation assumptions used by the Company in accounting
for options as of such date; provided, that the fair market value of the common shares of the Company used in such calculation shall be based on the average trading price of the common shares of the Company over the preceding thirty day period.
Unless otherwise determined by the Board, </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
options to purchase common shares granted to an Observer while serving, or upon commencing service, as an Observer shall be considered an Initial Award under this Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">B. &nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent Awards</U>. A <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director who (i)&nbsp;has been
serving as a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director or Observer for at least six months and (ii)&nbsp;will continue to serve as a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director immediately following any annual
General Meeting held following his or her initial appointment as a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director, is eligible to be granted, at the occasion of or as soon as practically possible following each such annual General
Meeting an option to purchase the number of common shares of the Company having an aggregate Grant Date Fair Value of $100,000, with any partial shares that result being rounded down to the nearest whole share. The awards described in this Section
II(B) shall be referred to as &#147;<B><I>Subsequent Awards</I></B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">C. &nbsp;&nbsp;&nbsp;&nbsp;<U>Acceptance</U>. For the
avoidance of doubt, any grant of Initial Awards and Subsequent Awards under this Program will require a written or electronic notice of acceptance of the relevant <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director, in the absence of
which such <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director will be deemed to have waived its rights to such a grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">D.
&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms of Awards Granted to <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.
<I>&nbsp;&nbsp;&nbsp;&nbsp;Exercise Price</I>. The per share exercise price of each option granted to a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director shall equal the Fair Market Value (as defined in the Equity Plan) of a common
share of the Company on the date the option is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2. <I>&nbsp;&nbsp;&nbsp;&nbsp;Vesting</I>. Each Initial Award shall vest and
become exercisable as to 33% of the shares subject to such Initial Award on the first anniversary of the date of grant and in 24 substantially equal monthly installments thereafter, such that the Initial Award shall be fully vested on the third
anniversary of the date of grant, subject to the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director continuing in service as a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director (or an Observer) through each such vesting
date. Each Subsequent Award shall vest and become exercisable in 12 substantially equal monthly installments following the date of grant, such that the Subsequent Award shall be fully vested on the first anniversary of the date of grant, subject to
the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director continuing in service on the Board as a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director (or an Observer) through each such vesting date. Unless the Board decides
otherwise, any portion of an Initial Award or Subsequent Award which is unvested or unexercisable at the time of a <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director&#146;s termination of service on the Board shall be immediately
forfeited upon such termination of service and shall not thereafter become vested and exercisable. All Initial Awards and Subsequent Awards shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity
Plan), to the extent outstanding at such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<I>Term</I>. The maximum term of each Initial Award and each
Subsequent Award granted hereunder shall be ten (10)&nbsp;years from the date the option is granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">E. &nbsp;&nbsp;&nbsp;&nbsp;<U>Annual
Increase; Award Limit</U>. The Grant Date Fair Value of each Initial Award and Subsequent Award described in this Program shall, subject to approval by the Board, increase on the first day of each calendar year by an amount equal to 3% of the Grant
Date Fair Value applicable to Initial Awards and Subsequent Awards in effect as of the immediately preceding calendar year; provided, that, in no event shall the number of shares awarded pursuant </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to (i)&nbsp;an Initial Award exceed 17,000 common shares of the Company and (ii)&nbsp;a Subsequent Award exceed 8,500 common shares of the Company, in each case, subject to adjustment as provided
in the Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">F. &nbsp;&nbsp;&nbsp;&nbsp;<U>Tax deductions</U>. To the extent required to comply with applicable tax laws, the
Company shall be allowed to make necessary deductions on any compensation payable under this Program, including (without limitation) for purposes of any payroll tax or income tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">G. &nbsp;&nbsp;&nbsp;&nbsp;<U>Prevailing terms</U>. In the event of any inconsistency between the terms of the Equity Plan and this Program,
the terms of this Program shall prevail. Notwithstanding anything in this Program to the contrary, the terms of an Initial Award granted to an Observer shall be subject to the terms of the award agreement pursuant to which such Initial Award is
granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d569434dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Merus N.V.: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our report dated April&nbsp;30, 2018, except as to Note 4 which is as of December&nbsp;27, 2018, with respect to the consolidated
statements of financial position of Merus N.V. as of December&nbsp;31, 2017 and 2016, and the related consolidated statements of profit or loss and comprehensive loss, changes in equity, and cash flows for each of the years in the three-year period
ended December&nbsp;31, 2017, and the related notes (collectively, the &#147;consolidated financial statements&#148;), incorporated herein by reference to the Form <FONT STYLE="white-space:nowrap">6-K</FONT> of Merus N.V. dated December&nbsp;27,
2018, and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus. Our report refers to the adoption of International Financial Reporting Standard 15 Revenue from Contracts with Customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG Accountants N.V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amstelveen, the Netherlands </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;27, 2018 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>mrus-20180630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS Xcelerate Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2018-12-20T14:39:20Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full" xmlns:mrus="http://www.merus.nl/20180630" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mrus-20180630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <ifrs-full:ParValuePerShare contextRef="eol_PE977595--18F-1-0004_STD_0_20180213_0" unitRef="iso4217_EUR_per_shares" decimals="INF" id="id_13905947_8EBCF6B0-2BD7-4161-9BDA-68DA288E35FA_1001_1">0.09</ifrs-full:ParValuePerShare>
  <ifrs-full:NumberOfSharesIssued contextRef="eol_PE977595--18F-1-0004_STD_0_20180213_0_3421584x3421771" unitRef="shares" decimals="INF" id="id_13905947_5A681492-32CD-4871-B176-68E19A5E7824_2002_0">3099997</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:CashAndCashEquivalents contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1002_38">215788000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7004_11">76956000</ifrs-full:Equity>
  <ifrs-full:NumberOfSharesIssuedAndFullyPaid contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0" unitRef="shares" decimals="INF" id="id_13905947_4E93FDBD-180F-4429-A427-2560BF3D82FC_1001_2">110869</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0" unitRef="Employees" decimals="INF" id="id_13905947_A0D3A659-C144-45DF-BBAB-AB0673FA252C_1001_0">64</ifrs-full:NumberOfEmployees>
  <mrus:IncreaseDecreaseInSharePremium contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0" unitRef="iso4217_EUR" decimals="0" id="id_13905947_4E93FDBD-180F-4429-A427-2560BF3D82FC_1001_4">216830</mrus:IncreaseDecreaseInSharePremium>
  <mrus:CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0" unitRef="iso4217_USD" decimals="-5" id="id_13905947_C3AD34F7-86D1-4ED8-87F1-0474F4AFADFC_1003_1">92600000</mrus:CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency>
  <mrus:IncreaseDecreaseInSharePremium contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F11CC06B-697A-4F9B-882C-914F72F2CD3B_2003_7">73400000</mrus:IncreaseDecreaseInSharePremium>
  <ifrs-full:NumberOfSharesIssuedAndFullyPaid contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0_3417439x3422519" unitRef="shares" decimals="INF" id="id_13905947_836AEA41-9B48-411F-90B3-BB366E2FE014_1002_0">19396720</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7001_11">1746000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7002_11">213541000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7003_11">-138331000</ifrs-full:Equity>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0_3420782x3421581" unitRef="Employees" decimals="INF" id="id_13905947_A0D3A659-C144-45DF-BBAB-AB0673FA252C_2001_1">55</ifrs-full:NumberOfEmployees>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0_3420782x3424474" unitRef="Employees" decimals="INF" id="id_13905947_A0D3A659-C144-45DF-BBAB-AB0673FA252C_3001_2">9</ifrs-full:NumberOfEmployees>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--18F-1-0004_STD_0_20170630_0_3475752x3514214" unitRef="Employees" decimals="INF" id="id_13905947_A0D3A659-C144-45DF-BBAB-AB0673FA252C_4001_3">13</ifrs-full:NumberOfEmployees>
  <ifrs-full:CashAndCashEquivalents contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_DB1474F3-15C8-43E3-8DCF-5AB41E4E04B5_1001_0">170327000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:Assets contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_11">231955000</ifrs-full:Assets>
  <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_23">10860000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_24">33365000</ifrs-full:CurrentLiabilities>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_1_2">122690000</ifrs-full:DeferredIncome>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_1_0">16972000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_1_1">105718000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:ContractLiabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_4E3648C1-9E0F-4B1F-8972-3B460AAE5B96_3003_4">122690000</ifrs-full:ContractLiabilities>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_1_4">37077000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentTradeReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_1_0">2069000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:ContractAssets contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_1629FCB0-433E-4D77-BA8B-CAE88CECCBE6_3003_4">446000</ifrs-full:ContractAssets>
  <ifrs-full:CurrentAssets contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_10">212881000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_21">100000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
  <ifrs-full:CurrentValueAddedTaxReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_1_2">622000</ifrs-full:CurrentValueAddedTaxReceivables>
  <ifrs-full:EquityAndLiabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_26">231955000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_16">92872000</ifrs-full:Equity>
  <ifrs-full:HeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_DB1474F3-15C8-43E3-8DCF-5AB41E4E04B5_1001_1">53727000</ifrs-full:HeldtomaturityInvestments>
  <ifrs-full:IssuedCapital contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_13">2037000</ifrs-full:IssuedCapital>
  <ifrs-full:NoncurrentAssets contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_5">19074000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_CD790B21-C922-41A3-B279-F2F96C8E0911_1001_2">2631822</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfSharesIssuedAndFullyPaid contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_15D662B1-8197-4CEB-9788-3A915726F2CC_1001_2">34041</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
  <ifrs-full:OtherNoncurrentAssets contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_4">167000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_2">381000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:Liabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_25">139083000</ifrs-full:Liabilities>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="Employees" decimals="INF" id="id_13905947_2EC4EC12-4F3A-4311-BBB0-940CDFD57153_1001_0">85</ifrs-full:NumberOfEmployees>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_96A0CC06-52C6-4929-A57B-1AABC49D7D22_1001_4">118301</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_ED0FD632-D8DF-4B72-A191-8F0B75EB192A_1001_6">1105059</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NoncurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_1_6">16650000</ifrs-full:NoncurrentHeldtomaturityInvestments>
  <ifrs-full:OtherCurrentReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_1_6">66000</ifrs-full:OtherCurrentReceivables>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_15">-167226000</ifrs-full:RetainedEarnings>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_1_7">5477000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_683ABA53-ADBF-4156-A1AD-9E218C68EFC9_3003_4">2069000</ifrs-full:TradeAndOtherReceivables>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_1">1876000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_40A61122-D215-4006-A058-1B70C336F299_1001_1">34300000</ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents>
  <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_20">5433000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="2" id="id_13905947_C22DB5BC-7272-4839-99C3-9F91D51D8900_1001_4">20.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:SharePremium contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_14">258061000</ifrs-full:SharePremium>
  <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_1_7">10860000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="INF" id="id_13905947_EEE9AAE7-A783-44B1-8796-7E219287C056_1001_1">14.24</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <mrus:OtherAccruals contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_1_6">465000</mrus:OtherAccruals>
  <mrus:SecurityDeposits contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_17AFD412-2624-4690-A45D-BAE695726BE9_1001_1">100000</mrus:SecurityDeposits>
  <mrus:CurrentPrepaidPensionCosts contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_1_4">359000</mrus:CurrentPrepaidPensionCosts>
  <mrus:CurrentInterestBank contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_1_5">275000</mrus:CurrentInterestBank>
  <mrus:CurrentPrepaidGeneralExpenses contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_1_3">1640000</mrus:CurrentPrepaidGeneralExpenses>
  <mrus:IncreaseDecreaseInSharePremium contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="0" id="id_13905947_15D662B1-8197-4CEB-9788-3A915726F2CC_1001_4">62635</mrus:IncreaseDecreaseInSharePremium>
  <mrus:AccruedPersonnel contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_1_1">315000</mrus:AccruedPersonnel>
  <mrus:AccruedResearchAndDevelopmentStudies contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_1_2">8777000</mrus:AccruedResearchAndDevelopmentStudies>
  <mrus:AccruedIntellectualPropertyLegalFee contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_1_3">128000</mrus:AccruedIntellectualPropertyLegalFee>
  <mrus:Bonuses contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_1_4">940000</mrus:Bonuses>
  <mrus:SubsidyAdvanceReceived contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_1_5">145000</mrus:SubsidyAdvanceReceived>
  <mrus:AccruedAuditorsFee contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_1_0">90000</mrus:AccruedAuditorsFee>
  <mrus:CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_USD" decimals="-5" id="id_13905947_C3AD34F7-86D1-4ED8-87F1-0474F4AFADFC_1001_1">40900000</mrus:CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency>
  <mrus:CurrentUnbilledReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_1_1">446000</mrus:CurrentUnbilledReceivables>
  <mrus:WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_F7727428-03FD-452B-8FC8-0A134F40E4B5_1001_5">14.24</mrus:WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement>
  <mrus:WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_F7727428-03FD-452B-8FC8-0A134F40E4B5_1001_3">1.93</mrus:WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement>
  <mrus:WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_F7727428-03FD-452B-8FC8-0A134F40E4B5_1001_6">12.18</mrus:WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416740x3421023" unitRef="shares" decimals="INF" id="id_13905947_CD790B21-C922-41A3-B279-F2F96C8E0911_2001_0">2153810</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfSharesIssued contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416740x3486468" unitRef="shares" decimals="-5" id="id_13905947_DA2F4DFB-E45C-4AAB-A02E-92BD478BACF0_2001_1">3200000</ifrs-full:NumberOfSharesIssued>
  <mrus:NonRefundableUpfrontPaymentsReceivable contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416740x3486468" unitRef="iso4217_USD" decimals="-6" id="id_13905947_DA2F4DFB-E45C-4AAB-A02E-92BD478BACF0_2001_0">120000000</mrus:NonRefundableUpfrontPaymentsReceivable>
  <mrus:FairValueOfDerivatives contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416740x3486468_3423034x3508994" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_FFA023FB-BB67-45FC-A962-1305EB3861AF_3001_0">31400000</mrus:FairValueOfDerivatives>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416740x3514206" unitRef="shares" decimals="INF" id="id_13905947_CD790B21-C922-41A3-B279-F2F96C8E0911_3001_1">478012</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:ContractLiabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_4E3648C1-9E0F-4B1F-8972-3B460AAE5B96_3002_4">122690000</ifrs-full:ContractLiabilities>
  <ifrs-full:TradeAndOtherReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_683ABA53-ADBF-4156-A1AD-9E218C68EFC9_3002_4">2069000</ifrs-full:TradeAndOtherReceivables>
  <ifrs-full:ContractAssets contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417430x3496068" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_1629FCB0-433E-4D77-BA8B-CAE88CECCBE6_3002_4">446000</ifrs-full:ContractAssets>
  <ifrs-full:NumberOfSharesIssuedAndFullyPaid contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417439x3422519" unitRef="shares" decimals="INF" id="id_13905947_836AEA41-9B48-411F-90B3-BB366E2FE014_1001_0">22632800</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15001_22">2037000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15002_22">258061000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15003_22">-167226000</ifrs-full:Equity>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3420782x3421581" unitRef="Employees" decimals="INF" id="id_13905947_2EC4EC12-4F3A-4311-BBB0-940CDFD57153_2001_1">70</ifrs-full:NumberOfEmployees>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3420782x3424474" unitRef="Employees" decimals="INF" id="id_13905947_2EC4EC12-4F3A-4311-BBB0-940CDFD57153_3001_2">15</ifrs-full:NumberOfEmployees>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3422662x3416700" unitRef="iso4217_EUR" decimals="INF" id="id_13905947_AAA22312-FB64-4984-974F-9DFFACFA77D4_1001_1">27.47</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3422662x3423353" unitRef="iso4217_EUR" decimals="INF" id="id_13905947_AAA22312-FB64-4984-974F-9DFFACFA77D4_2001_0">1.93</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F719A1EF-A867-4BBA-896C-1087838992D2_1001_0">120600000</ifrs-full:DeferredIncome>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3423078x3496111" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F719A1EF-A867-4BBA-896C-1087838992D2_2001_1">2000000</ifrs-full:DeferredIncome>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F719A1EF-A867-4BBA-896C-1087838992D2_3001_2">100000</ifrs-full:DeferredIncome>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3424453x3479596" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_1001_0">17715000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3424453x3514284" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2001_2">15289000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:NoncurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3424453x3514284" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2001_5">16650000</ifrs-full:NoncurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3424453x3530660" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_3001_3">1499000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3424453x3535979" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_4001_1">2574000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:NumberOfEmployees contextRef="eol_PE977595--18F-1-0004_STD_0_20180630_0_3475752x3514214" unitRef="Employees" decimals="INF" id="id_13905947_2EC4EC12-4F3A-4311-BBB0-940CDFD57153_4001_3">18</ifrs-full:NumberOfEmployees>
  <ifrs-full:CashAndCashEquivalents contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2002_37">56917000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1004_3">34421000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1001_3">1448000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3421013_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_3001_1">1448000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1002_3">139878000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3422849_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_3002_1">139878000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1003_3">-106905000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3422911_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_2003_2">390000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3422911_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_3003_1">-107295000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_2004_2">390000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20161231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_3004_1">34031000</ifrs-full:Equity>
  <ifrs-full:ParValuePerShare contextRef="eol_PE977595--18F-1-0004_STD_0_20170123_0_3416740x3486468" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_13905947_F11CC06B-697A-4F9B-882C-914F72F2CD3B_2001_1">25.00</ifrs-full:ParValuePerShare>
  <ifrs-full:NumberOfSharesIssued contextRef="eol_PE977595--18F-1-0004_STD_0_20170123_0_3416740x3486468" unitRef="shares" decimals="INF" id="id_13905947_F11CC06B-697A-4F9B-882C-914F72F2CD3B_2001_0">3200000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:CashAndCashEquivalents contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_9">149678000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:Assets contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_11">196803000</ifrs-full:Assets>
  <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_23">8627000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_24">27660000</ifrs-full:CurrentLiabilities>
  <ifrs-full:DeferredIncome contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_2_2">128486000</ifrs-full:DeferredIncome>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_2_0">15935000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_2_1">112551000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:ContractLiabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_4E3648C1-9E0F-4B1F-8972-3B460AAE5B96_1003_1">128486000</ifrs-full:ContractLiabilities>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2_4">34043000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentTradeReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_0">1594000</ifrs-full:CurrentTradeReceivables>
  <ifrs-full:ContractAssets contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_1629FCB0-433E-4D77-BA8B-CAE88CECCBE6_1003_1">710000</ifrs-full:ContractAssets>
  <ifrs-full:CurrentAssets contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_10">188134000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_21">243000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
  <ifrs-full:CurrentValueAddedTaxReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_2">582000</ifrs-full:CurrentValueAddedTaxReceivables>
  <ifrs-full:EquityAndLiabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_26">196803000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_16">56592000</ifrs-full:Equity>
  <ifrs-full:HeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2_7">41103000</ifrs-full:HeldtomaturityInvestments>
  <ifrs-full:IssuedCapital contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_13">1749000</ifrs-full:IssuedCapital>
  <ifrs-full:NoncurrentAssets contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_5">8669000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_13905947_ED0FD632-D8DF-4B72-A191-8F0B75EB192A_2001_0">2213985</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:OtherNoncurrentAssets contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_4">129000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_2">312000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:Liabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_25">140211000</ifrs-full:Liabilities>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="shares" decimals="INF" id="id_13905947_96A0CC06-52C6-4929-A57B-1AABC49D7D22_2001_0">194546</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:NoncurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2_6">7060000</ifrs-full:NoncurrentHeldtomaturityInvestments>
  <ifrs-full:OtherCurrentReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_6">92000</ifrs-full:OtherCurrentReceivables>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_F44ECD9F-49B1-4C74-9CA4-5F150EBB902F_3_0">-158775000</ifrs-full:RetainedEarnings>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_7">4413000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_683ABA53-ADBF-4156-A1AD-9E218C68EFC9_1003_1">1594000</ifrs-full:TradeAndOtherReceivables>
  <ifrs-full:PropertyPlantAndEquipment contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_1">1168000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_20">2855000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="2" id="id_13905947_C22DB5BC-7272-4839-99C3-9F91D51D8900_2001_0">20.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:SharePremium contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_14">213618000</ifrs-full:SharePremium>
  <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_2_7">8627000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <mrus:OtherAccruals contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_2_6">535000</mrus:OtherAccruals>
  <mrus:SecurityDeposits contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_17AFD412-2624-4690-A45D-BAE695726BE9_5_1">100000</mrus:SecurityDeposits>
  <mrus:CurrentPrepaidPensionCosts contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_4">838000</mrus:CurrentPrepaidPensionCosts>
  <mrus:CurrentInterestBank contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_5">170000</mrus:CurrentInterestBank>
  <mrus:CurrentPrepaidGeneralExpenses contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_3">427000</mrus:CurrentPrepaidGeneralExpenses>
  <mrus:AccruedPersonnel contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_2_1">446000</mrus:AccruedPersonnel>
  <mrus:AccruedResearchAndDevelopmentStudies contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_2_2">5272000</mrus:AccruedResearchAndDevelopmentStudies>
  <mrus:AccruedIntellectualPropertyLegalFee contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_2_3">509000</mrus:AccruedIntellectualPropertyLegalFee>
  <mrus:Bonuses contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_2_4">1545000</mrus:Bonuses>
  <mrus:SubsidyAdvanceReceived contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_2_5">224000</mrus:SubsidyAdvanceReceived>
  <mrus:AccruedAuditorsFee contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C104C8B9-FAFE-4967-A44E-BDB8ABF870AE_2_0">96000</mrus:AccruedAuditorsFee>
  <mrus:CurrentUnbilledReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_1">710000</mrus:CurrentUnbilledReceivables>
  <mrus:WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_F7727428-03FD-452B-8FC8-0A134F40E4B5_2001_0">13.99</mrus:WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:ContractLiabilities contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_4E3648C1-9E0F-4B1F-8972-3B460AAE5B96_1002_1">128486000</ifrs-full:ContractLiabilities>
  <ifrs-full:TradeAndOtherReceivables contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_683ABA53-ADBF-4156-A1AD-9E218C68EFC9_1002_1">1594000</ifrs-full:TradeAndOtherReceivables>
  <ifrs-full:ContractAssets contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417430x3496068" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_1629FCB0-433E-4D77-BA8B-CAE88CECCBE6_1002_1">710000</ifrs-full:ContractAssets>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9001_14">1749000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3421013_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_11001_12">1749000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9002_14">213618000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3422849_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_11002_12">213618000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9003_14">-158775000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3422911_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_10003_13">8705000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3422911_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_11003_12">-167480000</ifrs-full:Equity>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_F44ECD9F-49B1-4C74-9CA4-5F150EBB902F_2_2">8939000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_F44ECD9F-49B1-4C74-9CA4-5F150EBB902F_2_1">-17644000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_10004_13">8705000</ifrs-full:Equity>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_F44ECD9F-49B1-4C74-9CA4-5F150EBB902F_2_0">8705000</ifrs-full:RetainedEarnings>
  <ifrs-full:DeferredIncomeClassifiedAsCurrent contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_F44ECD9F-49B1-4C74-9CA4-5F150EBB902F_1_2">6996000</ifrs-full:DeferredIncomeClassifiedAsCurrent>
  <ifrs-full:DeferredIncomeClassifiedAsNoncurrent contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_F44ECD9F-49B1-4C74-9CA4-5F150EBB902F_1_1">130195000</ifrs-full:DeferredIncomeClassifiedAsNoncurrent>
  <ifrs-full:Equity contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_11004_12">47887000</ifrs-full:Equity>
  <ifrs-full:RetainedEarnings contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_F44ECD9F-49B1-4C74-9CA4-5F150EBB902F_1_0">-167480000</ifrs-full:RetainedEarnings>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424453x3479596" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_1002_0">15527000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424453x3514284" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2002_2">7886000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:NoncurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424453x3514284" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2002_5">7060000</ifrs-full:NoncurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424453x3530660" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_3002_3">1453000</ifrs-full:CurrentHeldtomaturityInvestments>
  <ifrs-full:CurrentHeldtomaturityInvestments contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424453x3535979" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_4002_1">9177000</ifrs-full:CurrentHeldtomaturityInvestments>
  <mrus:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424457x3514207" unitRef="shares" decimals="0" id="id_13905947_D555CEA8-9732-4371-B576-29EAB2CB298A_1001_0">777194</mrus:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <mrus:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE977595--18F-1-0004_STD_0_20180101_0_3424457x3514207" unitRef="shares" decimals="0" id="id_13905947_D555CEA8-9732-4371-B576-29EAB2CB298A_1002_0">1090368</mrus:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <mrus:OperatingLeaseTermOfLeaseAgreement contextRef="eol_PE977595--18F-1-0004_STD_1_20161101_0" id="id_13905947_180AFCAB-8D44-4456-B976-A2EB90CA331A_3_1">P5Y</mrus:OperatingLeaseTermOfLeaseAgreement>
  <mrus:UpfrontPayment contextRef="eol_PE977595--18F-1-0004_STD_1_20170228_0" unitRef="iso4217_USD" decimals="-6" id="id_13905947_DA2F4DFB-E45C-4AAB-A02E-92BD478BACF0_2_5">120000000</mrus:UpfrontPayment>
  <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued contextRef="eol_PE977595--18F-1-0004_STD_1_20180213_0" unitRef="shares" decimals="0" id="id_13905947_8EBCF6B0-2BD7-4161-9BDA-68DA288E35FA_1_0">3099997</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_1_20180213_0" unitRef="iso4217_USD" decimals="-5" id="id_13905947_8EBCF6B0-2BD7-4161-9BDA-68DA288E35FA_1_2">55800000</ifrs-full:ProceedsFromIssuingShares>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_1_20180213_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_13905947_8EBCF6B0-2BD7-4161-9BDA-68DA288E35FA_1_3">18.00</mrus:SharePurchasedPricePerShare>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_1_20180213_0_3421584x3421771" unitRef="iso4217_USD" decimals="-5" id="id_13905947_5A681492-32CD-4871-B176-68E19A5E7824_1001_3">55800000</ifrs-full:ProceedsFromIssuingShares>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_1_20180213_0_3421584x3421771" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_13905947_5A681492-32CD-4871-B176-68E19A5E7824_1001_2">18.00</mrus:SharePurchasedPricePerShare>
  <mrus:ProceedsFromIssuanceOfPrivatePlacementUnits contextRef="eol_PE977595--18F-1-0004_STD_1_20180215_0_3421584x3421771_3422662x3416700" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_5A681492-32CD-4871-B176-68E19A5E7824_1004_1">44800000</mrus:ProceedsFromIssuanceOfPrivatePlacementUnits>
  <mrus:ProceedsFromIssuanceOfPrivatePlacementUnits contextRef="eol_PE977595--18F-1-0004_STD_1_20180215_0_3421584x3421771_3422662x3423353" unitRef="iso4217_USD" decimals="-5" id="id_13905947_5A681492-32CD-4871-B176-68E19A5E7824_1003_1">55800000</mrus:ProceedsFromIssuanceOfPrivatePlacementUnits>
  <ifrs-full:RentalExpense contextRef="eol_PE977595--18F-1-0004_STD_1_20180501_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_180AFCAB-8D44-4456-B976-A2EB90CA331A_2_0">500000</ifrs-full:RentalExpense>
  <mrus:EstimatedContractualTerm contextRef="eol_PE977595--18F-1-0004_STD_1_20140408_0_3423078x3513897" id="id_13905947_09ABC44B-6866-46CA-8CFA-C240DCB34CA9_3002_1">P4Y6M</mrus:EstimatedContractualTerm>
  <mrus:ReimbursementOfGrant contextRef="eol_PE977595--18F-1-0004_STD_1_20170612_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_D77DC940-FCD4-40E7-A6FB-3187867382D8_5_1">700000</mrus:ReimbursementOfGrant>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_1_20170123_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F11CC06B-697A-4F9B-882C-914F72F2CD3B_1002_2">74700000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_1_20170123_0_3416740x3486468" unitRef="iso4217_USD" decimals="-5" id="id_13905947_F11CC06B-697A-4F9B-882C-914F72F2CD3B_1001_2">80000000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_3">-10667000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_3_2">-6899000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_13">1673000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_3">-2.07</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_27">-29000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInOperations contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_17">-15559000</ifrs-full:CashFlowsFromUsedInOperations>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_11">-1946000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_7">593000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_4">12357000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_34">186332000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_20">-15576000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_5">147000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_6">7880000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_8">-8866000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_2">-39306000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:FinanceCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_5">22696000</ifrs-full:FinanceCosts>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_4_5">7880000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_36">-11856000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:FinanceIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_2">610000</ifrs-full:FinanceIncome>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_5">7694000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_19">12000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8004_9">7880000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:FinanceIncomeCost contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_8">-22086000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_35">170727000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_C3AD34F7-86D1-4ED8-87F1-0474F4AFADFC_4_0">-12000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_10">118000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:InterestExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_3">10667000</ifrs-full:InterestExpense>
  <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_26">496000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromExerciseOfOptions contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_30">227000</ifrs-full:ProceedsFromExerciseOfOptions>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_18">5000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8004_8">73961000</ifrs-full:IssueOfEquity>
  <ifrs-full:OperatingExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_9">27241000</ifrs-full:OperatingExpense>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_14">18000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherShorttermEmployeeBenefits contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_4_6">264000</ifrs-full:OtherShorttermEmployeeBenefits>
  <ifrs-full:ProfitLossBeforeTax contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_9">-39206000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_1">-17120000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="shares" decimals="INF" id="id_13905947_4E93FDBD-180F-4429-A427-2560BF3D82FC_1_0">110869</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_29">74431000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:NetForeignExchangeLoss contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_4">12029000</ifrs-full:NetForeignExchangeLoss>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_13">18000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherExpenseByNature contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_8">4120000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_25">525000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_4">15427000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_4_4">10121000</ifrs-full:Revenue>
  <ifrs-full:SocialSecurityContributions contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_4_2">293000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_3_0">-39324000</ifrs-full:ProfitLoss>
  <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_32">486000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_4_7">10998000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:WagesAndSalaries contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_4_0">4182000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="2" id="id_13905947_4E93FDBD-180F-4429-A427-2560BF3D82FC_1_1">2.05</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageShares contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="shares" decimals="0" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_17">18976446</ifrs-full:WeightedAverageShares>
  <mrus:IncreaseDecreaseInCapital contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="0" id="id_13905947_4E93FDBD-180F-4429-A427-2560BF3D82FC_1_3">9978</mrus:IncreaseDecreaseInCapital>
  <mrus:ProceedsFromCollaborationAgreement contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_31">111993000</mrus:ProceedsFromCollaborationAgreement>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8004_10">81841000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <mrus:AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_10">2024000</mrus:AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets>
  <mrus:ClinicalCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_4_1">2002000</mrus:ClinicalCosts>
  <mrus:OtherResearchAndDevelopmentExpenseOther contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_4_2">1467000</mrus:OtherResearchAndDevelopmentExpenseOther>
  <mrus:DiscoveryAndPreclinicalCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_4_0">2076000</mrus:DiscoveryAndPreclinicalCosts>
  <mrus:LitigationAndOppositionExpenses contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_20062C73-94B2-4C97-B3DF-1D70D3CFD778_4_0">400000</mrus:LitigationAndOppositionExpenses>
  <mrus:AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_14">1784000</mrus:AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals>
  <mrus:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_16">719000</mrus:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities>
  <mrus:ChangesInRestrictedCash contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_33">167000</mrus:ChangesInRestrictedCash>
  <mrus:SubsidiesIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_DAB346F9-6A94-4CCF-A34E-B5A8F8E36BFA_4_0">2000000</mrus:SubsidiesIncome>
  <mrus:GrantIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_D77DC940-FCD4-40E7-A6FB-3187867382D8_4_0">800000</mrus:GrantIncome>
  <mrus:PensionCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_4_4">322000</mrus:PensionCosts>
  <mrus:HealthInsurance contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_4_3">62000</mrus:HealthInsurance>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_4_3">7880000</mrus:StockAwardExpense>
  <mrus:WBSOSubsidy contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_4_1">2005000</mrus:WBSOSubsidy>
  <mrus:OtherOperatingExpenses contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_7">3726000</mrus:OtherOperatingExpenses>
  <mrus:LitigationCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_6">394000</mrus:LitigationCosts>
  <mrus:ManufacturingCost contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_0">5611000</mrus:ManufacturingCost>
  <mrus:PersonnelRelatedResearchAndDevelopmentExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_2">3303000</mrus:PersonnelRelatedResearchAndDevelopmentExpense>
  <mrus:OtherResearchAndDevelopmentExpenses contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_3">5545000</mrus:OtherResearchAndDevelopmentExpenses>
  <mrus:RentAndServiceChargesExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_17AFD412-2624-4690-A45D-BAE695726BE9_4_0">300000</mrus:RentAndServiceChargesExpense>
  <mrus:InterestAndRelatedIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_0">610000</mrus:InterestAndRelatedIncome>
  <mrus:ShareBasedPaymentExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_84110F43-59B6-48C0-9F29-6D218231CB48_2_0">7900000</mrus:ShareBasedPaymentExpense>
  <mrus:IPAndLicenseCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_1">968000</mrus:IPAndLicenseCosts>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F11CC06B-697A-4F9B-882C-914F72F2CD3B_1003_5">400000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <mrus:IncreaseDecreaseInCapital contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F11CC06B-697A-4F9B-882C-914F72F2CD3B_1003_6">300000</mrus:IncreaseDecreaseInCapital>
  <mrus:ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F11CC06B-697A-4F9B-882C-914F72F2CD3B_1003_4">1100000</mrus:ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements>
  <mrus:NetProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3486468" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F11CC06B-697A-4F9B-882C-914F72F2CD3B_1003_3">74400000</mrus:NetProceedsFromIssuingShares>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3496102" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_1004_2">9289000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3509602" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_2004_3">832000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3514218" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_3004_1">2391000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3514219" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_4004_0">6898000</ifrs-full:Revenue>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8001_8">298000</ifrs-full:IssueOfEquity>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8001_10">298000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8002_8">73663000</ifrs-full:IssueOfEquity>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8002_10">73663000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8003_6">-39306000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8003_9">7880000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8003_5">18000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8003_4">-39324000</ifrs-full:ProfitLoss>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_8003_10">7880000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3420782x3424474" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_815F699E-A355-43D5-837D-421B2FDF1D79_1004_0">100000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_2_2">-3808000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3420637" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_2_3">0.20</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_2_2">3808000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_2_1">3808000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_2_0">3808000</ifrs-full:Revenue>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_2_0">3808000</ifrs-full:ProfitLoss>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_1_2">-3091000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3422609" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_1_3">-2.27</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_1_2">-43114000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_1_1">-20928000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_1_0">6313000</ifrs-full:Revenue>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_1_0">-43132000</ifrs-full:ProfitLoss>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_A3D51094-34FC-4E71-8335-DC012B6F147B_1004_0">6900000</mrus:UpfrontPaymentAmortization>
  <mrus:MilestoneRevenuesAndCostsReimbursements contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_6D8B0FA7-C876-416E-A118-676AE983F4F0_3004_3">2400000</mrus:MilestoneRevenuesAndCostsReimbursements>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3475752x3481637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_1004_0">1798000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3475752x3491841" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_2004_2">300000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20170630_0_3475752x3514214" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_3004_1">5782000</mrus:StockAwardExpense>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_15">-5796000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncome>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_13">2307000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_16">-0.60</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_27">-10751000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInOperations contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_17">-14829000</ifrs-full:CashFlowsFromUsedInOperations>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_11">-959000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_7">531000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_4">-3648000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <dei:AmendmentFlag contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_4849A84C-1483-40D9-9E28-8AA24D90A6CF_1_1">false</dei:AmendmentFlag>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_34">44731000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_20">-15132000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_12">-38000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_5">218000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_6">4554000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_8">-12433000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_15">-13005000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_5114F73C-5959-4859-A905-4C9BE9973322_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company operates in one reportable segment, which comprises the
 discovery and development of innovative bispecific
 therapeutics.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_B16A8FBF-F8FF-4F60-A75F-40D66F9A6B32_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Foreign Currency Transactions&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Items recorded in each of the Company&amp;#x2019;s entities are measured
 using the currency of the primary economic environment in which the
 entity operates (the &amp;#x201C;functional currency&amp;#x201D;). The
 interim financial statements are presented in euros, which is Merus
 N.V.&amp;#x2019;s functional currency. The functional currency of Merus
 US, Inc. is the U.S. dollar.&amp;#xA0;All amounts are rounded to the
 nearest thousand euros, except where otherwise indicated. Foreign
 currency gains and losses are reported on a net basis as either
 finance income or finance expense depending on whether foreign
 currency movements are in a net gain or net loss position.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_63F4480A-F527-4BB7-9775-86D1E01970B5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company enters into collaboration agreements which are within
 the scope of IFRS 15&amp;#x2014;Revenue from Contracts with Customers
 (&amp;#x201C;IFRS 15&amp;#x201D;), under which the Company licenses rights to
 certain of the Company&amp;#x2019;s product candidates and performs
 research and development services. The terms of these arrangements
 typically include payment of one or more of the following:
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable,&lt;/font&gt; upfront
 fees; reimbursement of research and development costs; development,
 regulatory, and commercial milestone payments; and royalties on net
 sales of licensed products.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 IFRS 15 requires an entity to recognize the amount of revenue to
 which it expects to be entitled for the transfer of promised goods
 or services to customers. Under IFRS 15, the Company recognizes
 revenue when its customer obtains control of the goods or services,
 in an amount that reflects the consideration that the Company
 determines it expects to receive in exchange for those goods or
 services. To determine revenue recognition for arrangements that
 the Company determines are within the scope of IFRS 15, the Company
 performs the following five steps: (i)&amp;#xA0;identify the
 contract(s) with a customer; (ii)&amp;#xA0;identify the performance
 obligations in the contract; (iii)&amp;#xA0;determine the transaction
 price; (iv)&amp;#xA0;allocate the transaction price to the performance
 obligations in the contract; and (v)&amp;#xA0;recognize revenue when
 (or as) the entity satisfies the performance obligation. The
 Company applies the five-step model to contracts only when it is
 probable that it will collect the consideration to which it is
 entitled in exchange for the goods or services it transfers to the
 customer. As part of the accounting for these arrangements, the
 Company must make significant judgments, including identifying
 performance obligations in the contract, estimating the amount of
 variable consideration to include in the transaction price and
 allocating the transaction price to each performance
 obligation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company currently generates a portion of its revenue through
 collaboration and license agreements with strategic collaborators
 for the development and commercialization of product candidates.
 The collaboration and license agreements are within the scope of
 IFRS 15.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Up-front&lt;/font&gt; License
 Payments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 If the license to the Company&amp;#x2019;s intellectual property is
 determined to be distinct from the other performance obligations
 identified in the agreement, the Company recognizes revenues from
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable,&lt;/font&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;up-front&lt;/font&gt; fees allocated to
 the license when the license is transferred to the customer and the
 customer is able to use and benefit from the license. If not
 distinct, the license is combined with other performance
 obligations in the contract. For licenses that are combined with
 other performance obligations, the Company assesses the nature of
 the combined performance obligation to determine whether the
 combined performance obligation is satisfied over time or at a
 point in time and, if over time, the appropriate method of
 measuring progress for purpose of recognizing revenue. The Company
 evaluates the measure of progress each reporting period and, if
 necessary, adjusts the measure of performance and related revenue
 recognition.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Pursuant to the Company&amp;#x2019;s research and license agreements
 with its collaborators, the Company has received upfront license
 payments relating to the integrated packages of deliverables under
 the contracts. Each contract contains either one single performance
 obligation or multiple performance obligations that the
 &lt;font style="WHITE-SPACE: nowrap"&gt;up-front&lt;/font&gt; consideration was
 allocated to. These upfront license payments are initially recorded
 in deferred revenue on the consolidated statements of financial
 position and are recognized as revenue on either: (i)&amp;#xA0;a
 straight-line basis over the period of the related performance
 obligation or the contractual term of the arrangement; or
 (ii)&amp;#xA0;based on another appropriate depiction of the
 Company&amp;#x2019;s performance over the period of the related
 performance obligation or the contractual term, such as costs
 incurred relating to full-time equivalent research employees. The
 applicable period over which to recognize the upfront payment is a
 significant judgment, which is &lt;font style="WHITE-SPACE: nowrap"&gt;re-assessed&lt;/font&gt; at each reporting
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Collaboration Income&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Collaboration income, which is typically related to reimbursements
 from collaborators for the Company&amp;#x2019;s performance of research
 and development services under the respective agreements, is
 recognized on the basis of labor hours valued at a contractually
 agreed rate. Collaboration income includes reimbursements for
 related &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;out-of-pocket&lt;/font&gt;&lt;/font&gt; expenses. Cost
 reimbursements to which the Company is entitled under agreements
 are recognized as revenue in the same period as the cost for which
 they are intended to compensate. The Company acts as the principal
 and therefore records these reimbursements as collaboration
 income.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In determining the appropriate amount of revenue to be recognized
 as the Company fulfills its obligations under the agreements, the
 Company performs the five steps listed above. As part of the
 accounting for the arrangement, the Company must develop
 assumptions that require judgment to determine the stand-alone
 selling price for each performance obligation identified in the
 contract. The Company uses key assumptions to determine the
 stand-alone selling price, which may include market conditions,
 reimbursement rates for personnel costs, development timelines and
 probabilities of regulatory success.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company capitalizes the incremental costs of obtaining a
 contract with a customer if it expects to recover those costs. Such
 incremental costs would not have been incurred if the contract with
 a customer had not been obtained. To date, the Company has not
 capitalized any incremental costs for obtaining a contract.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s contracts often include development and
 regulatory milestone payments which are assessed under the most
 likely amount method and constrained if it is probable that a
 significant revenue reversal would occur. Milestone payments that
 are not within the Company&amp;#x2019;s control or the licensee&amp;#x2019;s
 control, such as regulatory approvals, are not considered probable
 of being achieved until those approvals are received. At each
 reporting date, the Company &lt;font style="WHITE-SPACE: nowrap"&gt;re-evaluates&lt;/font&gt; the probability of
 achievement of development milestones and any related constraint,
 and if necessary, adjusts the overall transaction price. Any such
 adjustments are recorded on a cumulative &lt;font style="WHITE-SPACE: nowrap"&gt;catch-up&lt;/font&gt; basis, which would affect
 collaboration revenues in the period of adjustment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For agreements that include sales-based royalties, including
 milestone payments based on the level of sales, and the license is
 deemed to be the predominant item to which the royalties relate,
 the Company recognizes revenue at the later of (i)&amp;#xA0;when the
 related sales occur, or (ii)&amp;#xA0;when the performance obligation
 to which some or all of the royalty has been allocated has been
 satisfied (or partially satisfied). To date, the Company has not
 recognized any consideration related to sales-based royalty revenue
 resulting from any of the Company&amp;#x2019;s collaboration
 agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Government Grants&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company receives certain government and regional grants, which
 support its research efforts in defined projects, and include
 contributions towards the cost of research and development. When
 there is reasonable assurance that the Company will comply with the
 conditions attached to a received grant, and when there is
 reasonable assurance that the grant will be received, government
 grants are recognized as revenue on a gross basis in the
 consolidated statement of profit or loss and comprehensive loss on
 a systematic basis over the periods in which the Company recognizes
 expenses for the related costs for which the grants are intended to
 compensate. In the case of grants related to assets, the received
 grant will be deducted from the carrying amount of the asset.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
  <ifrs-full:DisclosureOfDeferredIncomeExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_E8C2A07A-3431-4ADE-B935-88CEF48CCA50_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Deferred Revenue&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Deferred revenue as of June&amp;#xA0;30, 2018, and December&amp;#xA0;31,
 2017, consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Balance per&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&amp;#xA0;Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue &amp;#x2013; current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,972&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,718&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;112,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="2%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;i&gt;See Note 3 for details regarding the restatement as
 a result of a change in accounting policy.&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Of the total deferred revenue balance at June&amp;#xA0;30, 2018,
 &amp;#x20AC;120.6&amp;#xA0;million related to the Incyte collaboration and
 license agreement and a share subscription agreement entered into
 by the Company with Incyte on December&amp;#xA0;20, 2016 (together, the
 &amp;#x201C;Incyte Agreements&amp;#x201D;), &amp;#x20AC;2.0 million&amp;#xA0;related
 to the collaboration and license agreement entered into by the
 Company with Simcere on January&amp;#xA0;8, 2018 (the &amp;#x201C;Simcere
 collaboration and license agreement&amp;#x201D;), and
 &amp;#x20AC;0.1&amp;#xA0;million related to the ONO research and license
 agreement. The total deferred revenue balance at December&amp;#xA0;31,
 2017, related solely to the Incyte Agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Under the Incyte collaboration and license agreement, Incyte agreed
 to pay the Company a &lt;font style="WHITE-SPACE: nowrap"&gt;$120&amp;#xA0;million&amp;#xA0;non-refundable&amp;#xA0;upfront&lt;/font&gt;
 payment, and under the share subscription agreement, Incyte agreed
 to purchase 3.2&amp;#xA0;million Common Shares at a price per share of
 $25.00, for an aggregate purchase price of $80&amp;#xA0;million. In
 January 2017, the Company completed the sale of its Common Shares
 under the share subscription agreement and received the
 $80&amp;#xA0;million aggregate purchase price. In February 2017, the
 Company received the $120&amp;#xA0;million &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt; upfront payment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As the contract for the share subscription agreement was
 denominated in U.S. dollars, the Company determined that the
 forward contract to sell its own shares at a future date to which
 the Company became committed on December&amp;#xA0;20, 2016, represented
 a derivative financial instrument. The fair values of the
 derivative, or &amp;#x20AC;31.4&amp;#xA0;million, and the &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt; upfront payment, or
 &amp;#x20AC;112.0&amp;#xA0;million, were recorded as deferred revenue. The
 Company identified a single performance obligation, providing
 access to its proprietary technology, relating to the Incyte
 Agreements and allocated all of the consideration received to this
 obligation. Both the upfront license payment and the derivative
 financial asset are being amortized as revenue over time by
 measuring the progress toward the complete satisfaction of a
 performance obligation or specifically, the total period for which
 the Company expects to provide access to its proprietary technology
 under the Incyte Agreements, which is currently estimated to be
 nine years in total, of which approximately 7.5 years remain.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Under the Simcere collaboration and license agreement, the Company
 agreed to grant Simcere an exclusive license to develop and
 commercialize in China three bispecific antibodies utilizing the
 Company&amp;#x2019;s Biclonics&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;technology
 platform in the area of immuno-oncology. The Company will retain
 all rights outside of China. As part of the agreement, the Company
 has agreed to lead research and discovery activities while Simcere
 has agreed to be responsible for the Investigational New Drug
 enabling studies, clinical development, regulatory filings and
 commercialization of these product candidates in China. The Company
 received an upfront, &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt; payment of
 $2.75&amp;#xA0;million, or &amp;#x20AC;2.3&amp;#xA0;million, relating to three
 separate research programs. Each research program was determined to
 be a separate performance obligation and consideration was
 allocated to each separate obligation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company will amortize the upfront payment to revenue over time
 based on the estimated duration of each research program. As of
 June&amp;#xA0;30, 2018, the first research program had commenced. For
 the three- and &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;
 periods ended June&amp;#xA0;30, 2018, the Company recognized revenue of
 &amp;#x20AC;0.3&amp;#xA0;million relating to this program for both
 amortization of upfront payments and the achievements of
 milestones. The remaining two research programs had not commenced
 as of June&amp;#xA0;30,&amp;#xA0;2018. Accordingly, no revenue has been
 recognized related to the remaining two research programs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On March&amp;#xA0;14, 2018, the Company entered into a second contract
 research and license agreement with ONO (the &amp;#x201C;second ONO
 research and license agreement&amp;#x201D;). Pursuant to an exclusive
 option granted to ONO in the ONO research and license agreement,
 ONO exercised its option to enter into the second ONO research and
 license agreement. The Company granted ONO an exclusive, worldwide,
 royalty-bearing license, with the right to sublicense, research,
 test, make, use and market bispecific antibody candidates based on
 the Company&amp;#x2019;s Biclonics&lt;b&gt;&lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/b&gt; technology
 platform against two undisclosed targets directed to a particular
 undisclosed target combination.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Under the terms of the agreement, ONO identifies and selects the
 licensed bispecific antibodies for which it is responsible for
 conducting &lt;font style="WHITE-SPACE: nowrap"&gt;further&amp;#xA0;non-clinical&amp;#xA0;and&lt;/font&gt;
 clinical development activities for such licensed bispecific
 antibodies and pharmaceutical products containing such antibodies,
 including manufacture and process development. Additionally, ONO
 controls and has exclusive rights over the worldwide
 commercialization of any approved products, including worldwide
 supply, and is solely responsible for all costs and expenses
 related to commercialization. ONO has also agreed to fund the
 Company&amp;#x2019;s research and development activities and be
 responsible for the payment of all costs and expenses for its own
 research and development activities, which are set out in a
 mutually agreed upon research plan. The Company retains all rights
 to use and commercialize any antibodies that are generated under
 the collaborative research program, excluding the up to five lead
 and/or selected antibodies against the targets ONO is pursuing,
 provided that the use and commercialization is not with respect to
 the particular target combination.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 ONO agreed to pay the Company an &lt;font style="WHITE-SPACE: nowrap"&gt;upfront&amp;#xA0;non-refundable&amp;#xA0;payment&lt;/font&gt;
 of &amp;#x20AC;0.7&amp;#xA0;million, &amp;#x20AC;0.3&amp;#xA0;million intended to
 compensate the Company for research services already completed upon
 entering into the agreement, and &amp;#x20AC;0.2&amp;#xA0;million to be paid
 to the Company over time for full time equivalent funding. The
 Company identified a single performance obligation of providing
 research services to ONO and recognized as revenue approximately
 &amp;#x20AC;0.1&amp;#xA0;million and &amp;#x20AC;1.1&amp;#xA0;million during the
 three and six months ended June&amp;#xA0;30, 2018, respectively.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfDeferredIncomeExplanatory>
  <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_F5AC03EF-4F62-46FE-9190-C0831B659296_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Employee Benefits&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Details of the employee benefits are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;

 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Salaries and wages&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,876&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,451&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,505&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,182&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 WBSO subsidy&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(733&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(953&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,900&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Social security premiums&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;198&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;293&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Health insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Pension costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;181&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;390&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Share award expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,109&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,554&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other personnel expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;433&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;264&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total employee benefits expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,619&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Share-based payment expenses (see Note 9) were recognized as
 employee benefit expenses as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;

 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;714&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;673&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,525&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Management and administrative costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,343&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,852&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;177&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,109&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,554&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Subsidies earned under the WBSO relating to eligible research and
 development costs are deferred and recognized in the
 Company&amp;#x2019;s income statement as a reduction to labor costs over
 the period labor costs are expected to be incurred. The Company has
 received and recognized subsidies of &amp;#x20AC;0.7&amp;#xA0;million and
 &amp;#x20AC;1.9&amp;#xA0;million for the three-
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;periods ended June&amp;#xA0;30,
 2018, respectively, as compared to &amp;#x20AC;1.0&amp;#xA0;million and
 &amp;#x20AC;2.0&amp;#xA0;million for the three-
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2017, respectively. The decrease in subsidies
 is primarily attributable to the decrease in eligible payroll tax
 withholdings during the same period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company&amp;#x2019;s headcount at&amp;#xA0;June&amp;#xA0;30, 2018 was
 approximately 85&amp;#xA0;full-time equivalents and consisted of 70
 employees in the Netherlands and&amp;#xA0;15 employees in the United
 States. A total of 18&amp;#xA0;employees who are devoted to activities
 other than research and development and overall management of the
 Company were included under management and administration costs for
 the three- and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company&amp;#x2019;s headcount at June&amp;#xA0;30, 2017 was
 approximately 64 full-time equivalents and consisted of 55
 employees in the Netherlands and&amp;#xA0;nine employees in the United
 States. A total of 13&amp;#xA0;employees who were devoted to activities
 other than research and development and overall management of the
 Company were included under management and administration costs for
 the three- and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2017.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
  <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_D67E04D5-135E-4216-8CBB-A5FADCBCB1C0_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr style="page-break-inside:avoid"&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;" align="left"&gt;&lt;b&gt;General information&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Merus N.V. is a clinical-stage immuno-oncology company developing
 innovative bispecific antibody therapeutics, headquartered in
 Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned
 subsidiary of Merus N.V. located in Boston, Massachusetts, United
 States. These condensed consolidated interim financial statements
 as at and for the three- and &lt;font style="white-space:nowrap"&gt;six-month&lt;/font&gt; periods ended June&amp;#xA0;30,
 2018, comprise Merus N.V. and Merus US, Inc. (collectively, the
 &amp;#x201C;Company&amp;#x201D;).&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 On February&amp;#xA0;13, 2018, the Company entered into a Securities
 Purchase Agreement (the &amp;#x201C;Purchase Agreement&amp;#x201D;) with the
 purchasers named therein (the &amp;#x201C;Investors&amp;#x201D;). Pursuant to
 the Purchase Agreement, the Company agreed to sell an aggregate of
 3,099,997 of its common shares, nominal value &amp;#x20AC;0.09 per share
 (the &amp;#x201C;Common Shares&amp;#x201D;), to the Investors for aggregate
 gross proceeds of approximately $55.8&amp;#xA0;million, at a purchase
 price equal to $18.00 per share (the &amp;#x201C;Private
 Placement&amp;#x201D;). The Purchase Agreement contained customary
 representations and warranties from the Company and the Investors
 and customary closing conditions. On February&amp;#xA0;15, 2018, the
 Company completed the sale under the Private Placement and received
 aggregate gross proceeds of approximately $55.8&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;Nature of Business&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company expects to continue to incur significant expenses and
 operating losses for the foreseeable future as its bispecific
 antibody candidates advance through discovery, preclinical
 development and clinical trials, and as it seeks regulatory
 approval and pursues commercialization of any approved bispecific
 antibody candidate.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 As a result, the Company may need additional financing to support
 its continuing operations. Until the Company can generate
 significant revenue from product sales, if ever, the Company
 expects to finance its operations through public equity, debt
 financings, or other sources, which may include collaborations with
 third parties. Adequate additional financing may not be available
 to the Company on acceptable terms, or at all. The Company&amp;#x2019;s
 inability to raise capital as and when needed would have a negative
 impact on its financial condition and ability to pursue its
 business strategy. The Company will need to generate significant
 revenues to achieve profitability and may never do so.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Based on the Company&amp;#x2019;s current operating plan, it expects its
 existing cash balances and investments to last through the end of
 2020. For this assessment, the Company has taken into consideration
 its existing cash and cash equivalents of
 &amp;#x20AC;170.3&amp;#xA0;million, which include the $55.8&amp;#xA0;million, or
 &amp;#x20AC;44.8&amp;#xA0;million, in proceeds received from the Private
 Placement offering that closed in February 2018, and investments of
 &amp;#x20AC;53.7&amp;#xA0;million as of June&amp;#xA0;30, 2018.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
  <ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_F0CC4E1B-CF0B-4B60-AD12-7171802AB30A_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Investments&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On January&amp;#xA0;1, 2018, the Company adopted IFRS 9 and classifies
 and accounts for its investments at amortized cost. The
 Company&amp;#x2019;s investments as of December&amp;#xA0;31, 2017, were
 classified and accounted for as &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;held-to-maturity&lt;/font&gt;&lt;/font&gt; under IAS 39.
 The initial adoption of IFRS 9 had no impact on previously reported
 amounts (See Note 3). IFRS 9 replaces the &amp;#x2018;incurred
 loss&amp;#x2019; model in IAS 39 with an &amp;#x2018;expected credit
 loss&amp;#x2019; (&amp;#x201C;ECL&amp;#x201D;) model. The new impairment model
 applies to financial assets measured at amortized cost, contract
 assets and debt investments at fair value through other
 comprehensive loss, but not to investments in equity instruments.
 Under IFRS&amp;#xA0;9, credit losses are recognized earlier than under
 IAS 39. Under IFRS 9, loss allowances are measured on either
 &lt;font style="WHITE-SPACE: nowrap"&gt;12-month&lt;/font&gt; ECLs which result
 from possible default events within the 12 months after the
 reporting date or lifetime ECLs which result from all possible
 default events over the expected life of a financial
 instrument.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s financial assets recorded at amortized cost
 consist of cash and cash equivalents, investments and trade and
 other receivables. These financial assets are considered to have a
 low credit risk and, as such, there was no impact to the
 Company&amp;#x2019;s opening accumulated deficit as a result of the
 change in impairment methodology.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s investments include investments in commercial
 paper, securities issued by several public corporations and the
 United States Treasury. Current investments include investments
 with a maturity date of greater than three months at the date of
 settlement. Investments with a maturity of 12 months or more from
 the original investment date are classified &lt;font style="WHITE-SPACE: nowrap"&gt;as&amp;#xA0;non-current.&lt;/font&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Investments as of June&amp;#xA0;30, 2018, and December&amp;#xA0;31, 2017,
 consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Balance as per&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,715&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,527&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. Treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,177&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate fixed income bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,289&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Agency bond&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,499&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,453&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Investments, current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37,077&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,043&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate fixed income bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,060&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-current&lt;/font&gt;
 investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,060&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53,727&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;
 period ended June&amp;#xA0;30, 2018, the Company purchased investments
 totaling &amp;#x20AC;29.6&amp;#xA0;million, which are held and denominated
 in U.S. dollars, and received proceeds of &amp;#x20AC;18.9&amp;#xA0;million
 relating to investment maturities. As a result of the fluctuation
 in foreign currency between the euro and U.S. dollar, the Company
 recorded foreign currency exchange gains of approximately
 &amp;#x20AC;3.1&amp;#xA0;million and &amp;#x20AC;1.9&amp;#xA0;million as a component
 of finance income / (expense) for the three- and &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; periods ended June&amp;#xA0;30,
 2018, respectively.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory>
  <ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_7FAC4FF3-EE1B-43DE-A320-8E6F7D22D752_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Other Liabilities and Accruals&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 All amounts are short-term and payable within 1 year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Balance per&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued auditor&amp;#x2019;s fee&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 R&amp;amp;D costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,777&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,272&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IP &amp;#x2013; Legal fee&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;509&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Bonuses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;940&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Subsidy advance received&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;465&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;535&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,627&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The research and development costs relate to accrued expenses for
 costs of certain development activities, such as clinical trials,
 and are recorded based on an evaluation of the progress to
 completion of specific tasks using data such as patient enrollment,
 clinical site activations, and information provided the Company by
 vendors on their actual costs incurred. The increase in research
 and development costs accrued expenses reflect the timing of
 enrollment in and support of the Company&amp;#x2019;s clinical trials,
 manufacturing of drug candidates used for clinical &lt;font style="WHITE-SPACE: nowrap"&gt;purposes,&amp;#xA0;pre-clinical&amp;#xA0;research&lt;/font&gt;
 efforts to support the Company&amp;#x2019;s internal research programs
 and the Incyte collaboration and license agreements and other
 collaboration agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The bonuses relate to the employee bonuses for the financial year
 2018, which will be paid out in February 2019. The decrease in
 bonuses accrual compared to December&amp;#xA0;31, 2017, related to the
 annual payment of the 2017 bonuses in the first quarter of
 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The subsidy advances received relate to active grants where the
 Company has received cash in excess of allowances which is required
 to be repaid or recognized as grant income when the relevant
 reimbursable costs are incurred as services are performed.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory>
  <ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_1206A5A0-1E1F-41FA-A81F-5F2850D87140_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Recently Issued International Financial Reporting
 Standards&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Except as otherwise indicated, the accounting policies adopted in
 the preparation of these interim financial statements are
 consistent with those applied in the preparation of the
 Company&amp;#x2019;s annual financial statements for the year ended
 December&amp;#xA0;31, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Standards implemented since December&amp;#xA0;31, 2017&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenue from Contracts with Customers&amp;#x2014;IFRS
 15&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In May 2014, the IASB issued IFRS 15, which supersedes existing
 revenue recognition guidance. Prior to the adoption of IFRS 15,
 revenue was recognized to the extent that it was probable that the
 economic benefits would flow to the Company and the revenue could
 be reliably measured. The new standard requires an entity to
 recognize the amount of revenue to which it expects to be entitled
 for the transfer of promised goods or services to customers. To
 achieve that core principle, an entity must identify the
 contract(s) with a customer, identify the performance obligations
 in the contract, determine the transaction price, allocate the
 transaction price to the performance obligations in the contract,
 and recognize revenue when (or as) the entity satisfies the
 performance obligation. IFRS 15 is effective for annual and interim
 reporting periods beginning on or after January&amp;#xA0;1, 2018 and
 should be applied retrospectively to each prior reporting period
 presented or retrospectively with the cumulative effect of
 initially applying this update recognized at the date of initial
 application.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The adoption of IFRS 15 impacts the amortization of the
 Company&amp;#x2019;s &lt;font style="WHITE-SPACE: nowrap"&gt;up-front&lt;/font&gt;
 license payments. The Company previously recognized revenue from
 &lt;font style="WHITE-SPACE: nowrap"&gt;up-front&lt;/font&gt; license payments
 on a straight-line basis over the contractual term or the period of
 continuing involvement which was previously estimated to be 21
 years for the collaboration and license agreement the Company
 entered into with Incyte Corporation (&amp;#x201C;Incyte&amp;#x201D;) on
 December&amp;#xA0;20, 2016 (the &amp;#x201C;Incyte collaboration and license
 agreement&amp;#x201D;), and 4.5 years for the research and license
 agreement the Company entered into with ONO Pharmaceutical Co.,
 Ltd. (&amp;#x201C;ONO&amp;#x201D;) on April&amp;#xA0;8, 2014 (the &amp;#x201C;ONO
 research and license agreement&amp;#x201D;). In applying IFRS 15, the
 Company has evaluated the distinct performance obligations in each
 agreement. Specifically, for Incyte, the total period for which the
 Company expects to provide access to its proprietary technology is
 currently estimated to be nine years, which is the research term
 initially agreed to in the Incyte collaboration and license
 agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company adopted the new standard effective January&amp;#xA0;1,
 2018, using the retrospective method, with the effect of initially
 applying this standard recognized at the beginning of the earliest
 period presented. The Company had two open contracts on the
 adoption date and has assessed these contracts under the new
 revenue standard. In addition, the Company elected to apply the
 practical expedient to not apply this guidance to contracts that
 were completed before the beginning of the earliest period
 presented, or January&amp;#xA0;1, 2016, and the practical expedients
 for contract modifications (assessing the contracts in combination
 with any modifications before January&amp;#xA0;1, 2017). Under the
 practical expedient, the Company excluded certain option and
 exclusivity agreements that expired in 2015 and 2014, respectively.
 As a result of the adoption of IFRS 15, prior year financial
 statements have been restated. The Company has accounted for the
 impact of adopting IFRS 15 as a cumulative &lt;font style="WHITE-SPACE: nowrap"&gt;catch-up&lt;/font&gt; as a decrease of
 approximately &amp;#x20AC;8.7&amp;#xA0;million to deferred revenue with an
 offset to accumulated deficit, effective January&amp;#xA0;1, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following financial statement line items have been shown to
 reflect the adjustments recognized for each individual line item in
 the Company&amp;#x2019;s respective consolidated statements for the
 period noted:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Condensed Consolidated Statement of Profit or Loss and
 Comprehensive Loss&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&lt;br /&gt;
 ended&lt;br /&gt;
 June&amp;#xA0;30, 2017&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS&amp;#xA0;15&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&lt;br /&gt;
 ended&lt;br /&gt;
 June&amp;#xA0;30, 2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;(euros in
 thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,237&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Operating result&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total comprehensive loss for the period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(21,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic (and diluted) loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30, 2017&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS&amp;#xA0;15&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30, 2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;(euros in
 thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Operating result&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(20,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total comprehensive loss for the period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(39,306&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic (and diluted) loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Condensed Consolidated Statement of Financial Position&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2017&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;As originally&lt;br /&gt;
 presented&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2017&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;(euros in
 thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(167,480&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,705&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(158,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue, &lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;130,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,644&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;112,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,996&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,939&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Condensed Consolidated Statement of Cash Flows&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2017&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;As originally&lt;br /&gt;
 presented&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2017&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;(euros in
 thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Result after taxation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,132&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(39,324&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Changes in working capital:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,091&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,899&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Financial Instruments&amp;#x2014;IFRS 9&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 IFRS &lt;font style="WHITE-SPACE: nowrap"&gt;9-&lt;/font&gt; Financial
 Instruments (&amp;#x201C;IFRS 9&amp;#x201D;) replaces the provisions of IAS
 39 that relate to the recognition, classification and measurement
 of financial assets and financial liabilities, derecognition of
 financial instruments, impairment of financial assets and hedge
 accounting. IFRS 9 also significantly amends other standards
 dealing with financial instruments such as IFRS 7 &lt;i&gt;Financial
 Instruments: Disclosures&lt;/i&gt;. The Company assessed the
 classification and measurement of the financial instruments it held
 at the date of initial application of IFRS 9, or January&amp;#xA0;1,
 2018, and has classified its financial instruments into the
 appropriate IFRS 9 categories. There were no changes to the
 carrying value of the Company&amp;#x2019;s financial instruments
 resulting from this reclassification and accordingly there was no
 impact to the Company&amp;#x2019;s opening accumulated deficit at
 January&amp;#xA0;1, 2018, as a result of the adoption of
 IFRS&amp;#xA0;9.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Standard issued but not yet effective&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The IASB has issued a new standard on leases that will require
 lessees to recognize most leases on their balance sheets as lease
 liabilities with a &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;corresponding&amp;#xA0;right-of-use&amp;#xA0;asset.&lt;/font&gt;&lt;/font&gt;
 The IASB has set an effective date to apply the new standard for
 periods beginning on or after January&amp;#xA0;1, 2019. The Company is
 assessing all effective agreements to determine whether there are
 embedded leases included under the definition in IFRS 16. Early
 adoption is permitted; however, the Company expects to adopt this
 standard in the first quarter of 2019. The Company is evaluating
 the impact that this guidance will have on the Company&amp;#x2019;s
 financial statements, including related disclosures, and expects
 the new standard to impact its internal controls, systems, and
 processes.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory>
  <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_FBA8E943-8990-4CDD-9BBA-00DA3FF2D201_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The inputs used in the measurement of the fair values and the
 related fair values at the grant dates were as follows for the
 options granted during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period ended June&amp;#xA0;30,
 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Key&amp;#xA0;Management&lt;br /&gt;
 Personnel&lt;br /&gt;
 (&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;All&amp;#xA0;Other&amp;#xA0;Personnel&lt;br /&gt;
 (&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value at grant date&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;9.34-9.45&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;9.30-10.37&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Share price at grant date&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;14.57-14.87&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;14.57-18.24&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;14.57-14.87&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;14.57-18.24&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility (weighted-average)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;95.1%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;94.6%&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contractual life&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;10 years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;10 years&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;0%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;0%&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate (based on government bonds)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2.79%-2.94%&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2.84%-2.94%&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
  <ifrs-full:DisclosureOfInterestIncomeExpenseExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_5136D7CE-DB79-44F6-A22B-E5FCE8748B95_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Finance Income and Expense&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;

 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2018&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2017&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2018&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2017&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finance income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest income and similar income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;494&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;420&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;834&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net gain on foreign exchange&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,917&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,111&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,411&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;420&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,945&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss on foreign exchange&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(22,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Interest income primarily results from interest earned on cash held
 on account and accretion of investment earnings. The
 Company&amp;#x2019;s current year increase in cash, cash equivalents and
 investments was due primarily to the $55.8&amp;#xA0;million of funds
 received as part of the Private Placement during the first quarter
 of 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company experienced gains on its U.S. dollar denominated cash,
 cash equivalents and investments of approximately &amp;#x20AC;6.9
 million and &amp;#x20AC;4.1 million for the three and six months ended
 June 30, 2018, respectively, as compared to losses of &amp;#x20AC;12.0
 million for the three and six months ended June 30, 2017. The
 Company presents foreign currency gains and losses on a net basis
 as either finance income or finance expense depending on whether
 foreign currency movements are in a net gain or net loss position.
 The Company experienced foreign exchange losses on its U.S. dollar
 denominated cash, cash equivalents and investments of approximately
 &amp;#x20AC;2.8 million during the three months ended March 31, 2018,
 which are reclassified to net gain on foreign exchange for the six
 months ended June 30, 2018. As of June 30, 2018, the Company held
 approximately $40.9 million and $92.6 million in U.S. dollar
 denominated cash and cash equivalent accounts and investment
 accounts, respectively, subject to the fluctuation in foreign
 currency between the euro and U.S. dollar.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On December&amp;#xA0;20, 2016, the Company entered into the Incyte
 Agreements. As these contracts are denominated in U.S. dollars, the
 Company determined that the subscription agreement to sell its own
 shares to which the Company became committed on December&amp;#xA0;20,
 2016, should be accounted for as a forward contract or a derivative
 financial instrument. Interest expense for the three and six months
 ended June&amp;#xA0;30, 2017, related entirely to the effective
 settlement of the forward contract on January&amp;#xA0;23, 2017.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfInterestIncomeExpenseExplanatory>
  <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_5F5D3639-9BC0-41B1-9224-DD3118AA1C25_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company has evaluated subsequent events through August&amp;#xA0;10,
 2018, the date of issuance of the unaudited consolidated financial
 statements for the three months ended June&amp;#xA0;30, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Except for the items described in Note 11 under litigation, there
 were no additional events requiring disclosure in the notes to
 these financial statements.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
  <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_98E8E2B9-83DF-49E0-9673-5C8E48B3BC9E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The number of share options and the weighted average exercise
 prices of share options granted were as follows for the
 &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period ended
 June&amp;#xA0;30, 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;average&lt;br /&gt;
 exercise price&lt;br /&gt;
 (&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number of&lt;br /&gt;
 options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;13.99&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,213,985&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;19.67&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(12,044&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expired during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.02&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(5,146&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1.93&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(34,041&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.68&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;469,068&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.24&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,631,822&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercisable at June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;12.18&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,105,059&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
  <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_DE8C8697-7FFD-49A0-860B-E65E510AC27C_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Use of Estimates, Judgments and Assumptions&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In the application of the Company&amp;#x2019;s accounting policies,
 management is required to make judgments, estimates and assumptions
 that affect the reported amounts of assets, liabilities, income and
 expenses that are not readily apparent from other sources. The
 estimates and associated assumptions are based on historical
 experience and other factors that are considered to be relevant.
 Actual results may differ from these estimates.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Estimates and underlying assumptions are reviewed on an ongoing
 basis. Revisions to accounting estimates are recognized
 prospectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following are the critical judgments and assumptions that
 management has made in the process of applying the Company&amp;#x2019;s
 accounting policies and that have the most significant effect on
 the amounts recognized in the interim financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Equity settled share-based payments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Share options granted to employees, consultants and directors are
 measured at the grant date fair value of the equity instruments
 granted. The grant date fair value is determined through the use of
 an option-pricing model considering the following variables:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(a)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the exercise price of the option;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(b)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the expected life of the option;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(c)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the current value of the underlying shares;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(d)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the expected volatility of the share price;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(e)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the dividends expected on the shares; and&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="4%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(f)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;the risk-free interest rate for the life of the
 option.&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The estimated fair value of each share option granted was
 determined utilizing the Hull&amp;#xA0;&amp;amp; White option pricing
 model, which considers the terms and conditions attached to the
 grants made and is reflective of expected exercise behavior.
 Because the Company&amp;#x2019;s shares have been publicly traded for a
 relatively short amount of time, the expected volatility was set by
 also giving weight to the historic share price volatility of a set
 of peer companies. The continuous yield on U.S. Treasury Bills with
 a term to maturity comparable to the expected life of the options,
 as published by the U.S. Department of Treasury, was applied.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The result of the share option valuations and the related
 compensation expense that is recognized for the respective vesting
 periods during which services are received are dependent on the
 model and input parameters used. Even though management considers
 the fair values reasonable and defensible based on the
 methodologies applied and the information available, others might
 derive a different fair value for the Company&amp;#x2019;s share
 options. These assumptions and estimates are further discussed in
 Note 9 to the financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Capitalization of development costs&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The criteria for capitalization of development costs have been
 considered by management and determined not to have been met in the
 second quarter of 2018. Therefore, all development expenditures
 relating to internally generated intangible assets in 2018 were
 expensed as incurred.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Income taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 As of June&amp;#xA0;30, 2018, deferred tax assets have not been
 recognized in respect of tax losses as the Company has no history
 of generating taxable profits. Therefore, at the balance sheet
 date, there is no convincing evidence that sufficient taxable
 profit will be available against which the tax losses can be
 utilized.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Merus US, Inc., which is incorporated in the United States in the
 State of Delaware, is subject to statutory U.S. Federal corporate
 income taxes and state income taxes for Massachusetts. Current year
 income tax expense was attributable entirely to Merus US, Inc.
 which provides general management services and strategic advisory
 services to the Company. Corporate income tax expenses were
 &amp;#x20AC;0.1&amp;#xA0;million for the three- and &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; periods ended June&amp;#xA0;30,
 2018, as compared to &amp;#x20AC;0.1&amp;#xA0;million for the three- and
 &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; periods ended
 June&amp;#xA0;30, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Deferred revenue&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Pursuant to the Company&amp;#x2019;s research, collaboration and license
 agreements with ONO, Incyte, and Jiangsu Simcere Pharmaceutical Co.
 Ltd. (&amp;#x201C;Simcere&amp;#x201D;), the Company has received &lt;font style="WHITE-SPACE: nowrap"&gt;upfront&amp;#xA0;non-refundable&amp;#xA0;payments&lt;/font&gt;
 for certain rights granted under the respective agreements. The
 applicable period over which to recognize these upfront payments
 requires significant judgment and was impacted by the adoption of
 IFRS 15 (See Note 3 and Note 8).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Revenue related to ONO upfront payments is deferred and amortized
 based on a measure of progress in delivering research services
 under the contract. Revenue related to Incyte and Simcere upfront
 payments is deferred and amortized on a straight-line basis over
 the estimated research term (See Note 3 and Note 8).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Research and development expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Research and development expenses represent costs that primarily
 include: (i)&amp;#xA0;payroll and related costs (including share-based
 payment expenses) associated with research and development
 personnel; (ii)&amp;#xA0;costs related to clinical trials and
 preclinical testing of the Company&amp;#x2019;s technologies under
 development; (iii)&amp;#xA0;costs to develop product candidates,
 including raw materials and supplies, product testing,
 depreciation, and facility related expenses; (iv)&amp;#xA0;expenses for
 research services provided by universities and contract
 laboratories; and (v)&amp;#xA0;other research and development expenses.
 Research and development expenses are recognized in the
 consolidated statement of profit or loss and comprehensive loss as
 incurred when these expenditures relate to the Company&amp;#x2019;s
 research and development services and have no alternative future
 uses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company has entered into various research and development
 contracts with research institutions and other companies. These
 agreements are generally cancelable. The Company records accruals
 for estimated ongoing research costs. When evaluating the adequacy
 of the accrued liabilities, the Company analyzes progress of the
 studies, including the phase or completion of events, invoices
 received and contracted costs. Significant judgments and estimates
 may be made in determining the accrued balances at the end of any
 reporting period. Actual results could differ from the
 Company&amp;#x2019;s estimates. The Company&amp;#x2019;s historical accrual
 estimates have not been materially different from the actual
 costs.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
  <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_ED9BD0FC-05E7-44BD-9C3C-BA1B492DC7E7_1_0">&lt;div&gt;
 &lt;p&gt;&lt;br class="Apple-interchange-newline" /&gt;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;

 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2018&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2017&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2018&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2017&lt;b&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finance income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest income and similar income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;494&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;420&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;834&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net gain on foreign exchange&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,917&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,111&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,411&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;420&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,945&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;610&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Finance costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,667&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss on foreign exchange&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,962&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(22,696&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
  <ifrs-full:DisclosureOfRevenueExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_78F811D8-AF16-44E4-95BA-080642CAD49D_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Revenue&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Revenue is recognized at the amount to which the Company expects to
 be entitled for the transfer of promised goods or services to
 customers.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s revenues are generated entirely in the
 Netherlands. In the following table, revenue is disaggregated by
 primary source of revenue as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="54%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;Three months
 ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;Six months
 ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2017&amp;#xA0;Restated*&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;June 30&lt;br /&gt;
 2017&amp;#xA0;Restated*&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Upfront payment amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,250&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,973&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;9,087&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,898&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Collaboration income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,179&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,195&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue from contracts with customers&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,429&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,444&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;16,282&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,289&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Income from grants on research projects&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;114&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;793&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;182&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;832&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,543&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,237&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;16,464&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&lt;i&gt;*&lt;/i&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;i&gt;See Note 3 for details regarding the restatement as
 a result of a change in accounting policy.&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For the three- and &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; periods ended June&amp;#xA0;30,
 2018, the Company recognized amortization of
 &amp;#x20AC;4.0&amp;#xA0;million and &amp;#x20AC;7.9&amp;#xA0;million on upfront
 payments related to the Incyte collaboration and license agreement,
 respectively, amortization of &amp;#x20AC;0.2&amp;#xA0;million and
 &amp;#x20AC;1.1&amp;#xA0;million on upfront payments related to the ONO
 research and license agreement, respectively, and
 &amp;#x20AC;0.1&amp;#xA0;million and &amp;#x20AC;0.1&amp;#xA0;million on upfront
 payments related to the Simcere collaboration and license
 agreement, respectively. For the three- and &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; periods ended June&amp;#xA0;30,
 2017, the Company recognized &amp;#x20AC;4.0&amp;#xA0;million and
 &amp;#x20AC;6.9&amp;#xA0;million of amortization of the upfront payment
 related to the Incyte collaboration and license agreement,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Collaboration income for the three and six months ended
 June&amp;#xA0;30, 2018, was &amp;#x20AC;2.2&amp;#xA0;million and
 &amp;#x20AC;7.2&amp;#xA0;million, respectively, and consisted of cost
 reimbursements and research milestones achieved in support of the
 Company&amp;#x2019;s research and license agreements with Incyte, ONO
 and Simcere. During the three and six months ended June&amp;#xA0;30,
 2018, the Company recognized &amp;#x20AC;2.0&amp;#xA0;million and
 &amp;#x20AC;4.3&amp;#xA0;million of cost reimbursements in support of the
 Company&amp;#x2019;s research and license agreements with Incyte,
 respectively, and &amp;#x20AC;0.1&amp;#xA0;million and
 &amp;#x20AC;0.2&amp;#xA0;million of cost reimbursements in support of the
 Company&amp;#x2019;s research and license agreements with ONO,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company recognized an aggregate of &amp;#x20AC;2.5&amp;#xA0;million in
 research milestones under its ONO agreements for the six months
 ended June&amp;#xA0;30, 2018 and &amp;#x20AC;0.1&amp;#xA0;million in research
 milestones under its Simcere agreements for the three and six
 months ended June&amp;#xA0;30, 2018. During the three and six months
 ended June&amp;#xA0;30, 2017, the Company recognized
 &amp;#x20AC;1.5&amp;#xA0;million and &amp;#x20AC;2.4&amp;#xA0;million of cost
 reimbursements in support of the Company&amp;#x2019;s research and
 license agreements with Incyte and ONO, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The Company has been awarded grants consisting of cash allowances
 for specific research and development projects. The unconditional
 receipt of the grant allowances is dependent on the final review of
 the reporting provided by the Company at the end of the contract
 term. For the three and six months ended June&amp;#xA0;30, 2018, the
 Company recognized &amp;#x20AC;0.1&amp;#xA0;million and
 &amp;#x20AC;0.2&amp;#xA0;million in grant income, respectively, compared to
 &amp;#x20AC;0.8&amp;#xA0;million in grant income for the three and six
 months ended June&amp;#xA0;30, 2017. On June&amp;#xA0;12, 2017, the
 European Commission approved for reimbursement the final
 installment of the &lt;font style="WHITE-SPACE: nowrap"&gt;FP-7&lt;/font&gt;
 grant for &amp;#x20AC;0.7&amp;#xA0;million. Revenue for this final
 installment was recorded in income from grants on research projects
 during the three and six months ended June&amp;#xA0;30, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Contract Balances&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 A trade receivable is recorded when the Company satisfies a
 performance obligation by transferring a promised good or service
 and has earned the unconditional right to consideration from its
 customer. Trade receivables relate to invoicing for cost
 reimbursements and research milestones achieved in support of the
 Company&amp;#x2019;s research and license agreements with Incyte, ONO
 and Simcere. Payment terms relating to these receivables are 30
 days.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 A contract asset is recorded when the Company satisfies a
 performance obligation by transferring a promised good or service
 and has earned the right to consideration from its customer. These
 assets represent a conditional right to consideration. Contract
 assets relate to unbilled amounts for cost reimbursements and
 research milestones achieved in support of the Company&amp;#x2019;s
 research and license agreements with Incyte and ONO.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 A contract liability is recorded when consideration is received, or
 such consideration is unconditionally due, from a customer prior to
 transferring goods or services under the terms of the contract.
 Contract liabilities are recognized as revenue as control of the
 products or services is transferred to the customer and all revenue
 recognition criteria have been met. Contract liabilities relate to
 upfront payments received related to the Incyte Agreements, ONO
 research and license agreement, and the Simcere research and
 license agreement (See Note 8).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table presents changes in the Company&amp;#x2019;s trade
 receivables, contract assets and contract liabilities during the
 six months ended June&amp;#xA0;30, 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="38%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Balance&amp;#xA0;at&amp;#xA0;December&amp;#xA0;31,&lt;br /&gt;
 2017 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Additions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Deductions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Balance&amp;#xA0;at&amp;#xA0;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade&amp;#xA0;&amp;amp; other receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total trade&amp;#xA0;&amp;amp; other receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;693&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(957&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;693&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(957&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As a result of the adoption of IFRS 15, total deferred revenue was
 reduced by &amp;#x20AC;8.7&amp;#xA0;million as of December&amp;#xA0;31, 2017.
 See Note 3 for details regarding the restatement as a result of a
 change in accounting policy.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Deductions from deferred revenue are comprised of revenue
 recognized that was included in deferred revenue at the beginning
 of the period totaling &amp;#x20AC;7.9&amp;#xA0;million and revenue
 recognized that was not included in deferred revenue at the
 beginning of the period totaling &amp;#x20AC;1.3&amp;#xA0;million for the
 six months ended June&amp;#xA0;30, 2018.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
  <dei:DocumentPeriodEndDate contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_4849A84C-1483-40D9-9E28-8AA24D90A6CF_1_2">2018-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityEmergingGrowthCompany contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_79805C7A-9AD4-4FD2-A1A8-CE46B284FE52_1_4">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_79805C7A-9AD4-4FD2-A1A8-CE46B284FE52_1_5">false</dei:EntityExTransitionPeriod>
  <ifrs-full:FinanceCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_3_5">1000</ifrs-full:FinanceCosts>
  <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_1DFE429D-C531-4DB7-9FAF-7145552C3E6B_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Shareholders&amp;#x2019; Equity&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Private Placement of Common Shares&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On February&amp;#xA0;13, 2018, the Company entered into the Purchase
 Agreement. Pursuant to the Purchase Agreement, the Company agreed
 to sell an aggregate of 3,099,997 of its Common Shares to the
 Investors for aggregate gross proceeds of approximately
 $55.8&amp;#xA0;million, at a purchase price equal to $18.00 per share.
 The Purchase Agreement contains customary representations and
 warranties from the Company and the Investors and customary closing
 conditions. On February&amp;#xA0;15, 2018, the Company completed the
 sale under the Private Placement and received gross proceeds of
 approximately $55.8&amp;#xA0;million, or &amp;#x20AC;44.8&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Share Subscription Agreement with Incyte&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Concurrent with the Incyte collaboration and license agreement
 discussed above under Note 8, the Company entered into a share
 subscription agreement with Incyte on December&amp;#xA0;20, 2016. On
 January&amp;#xA0;23, 2017, under the terms of the share subscription
 agreement, the Company issued 3,200,000 of its Common Shares to
 Incyte at the agreed price per share of $25.00, for an aggregate
 purchase price of $80.0&amp;#xA0;million or &amp;#x20AC;74.7&amp;#xA0;million.
 During the six months ended June&amp;#xA0;30, 2017, the Company
 received proceeds, net of issuance costs, of
 &amp;#x20AC;74.4&amp;#xA0;million. A &amp;#x20AC;1.1&amp;#xA0;million discount on the
 subscription share price, combined with a &amp;#x20AC;0.4&amp;#xA0;million
 foreign currency translation accompanying the issuance of these
 shares, increased share capital by &amp;#x20AC;0.3&amp;#xA0;million and
 share premium by &amp;#x20AC;73.4&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Issued and &lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt;
 share capital&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 All issued shares have been fully paid in cash.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Common shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 For the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period
 ended June&amp;#xA0;30, 2018, 34,041 options were exercised at a
 weighted average exercise price of &amp;#x20AC;1.93 per share. As a
 result, 34,041 Common Shares were issued, share capital increased
 by &amp;#x20AC;3,064 and share premium increased by &amp;#x20AC;62,635.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period
 ended&amp;#xA0;June 30, 2017, 110,869 options were exercised with a
 weighted average exercise price of &amp;#x20AC;2.05&amp;#xA0;per share. As a
 result, 110,869 Common Shares were issued, share capital increased
 by &amp;#x20AC;9,978 and share premium increased by &amp;#x20AC;216,830.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 At June&amp;#xA0;30, 2018, a total of 22,632,800 Common Shares were
 issued and paid up. At June&amp;#xA0;30, 2017, a total of 19,396,720
 Common Shares were issued and paid up.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Share Premium Reserve&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The share premium reserve relates to amounts contributed by
 shareholders at the issue of shares in excess of the nominal value
 of the shares issued.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 All share premium can be considered as free share premium as
 referred to in the Netherlands Income Tax Act.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;&lt;i&gt;Share-based Payment Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Share-based payment expenses included in personnel expenses were
 &amp;#x20AC;4.6&amp;#xA0;million and &amp;#x20AC;7.9&amp;#xA0;million in the
 &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; periods ended
 June&amp;#xA0;30, 2018, and June&amp;#xA0;30, 2017, respectively. For
 details on the related share-based payment expenses recognized as
 employee benefit expenses, see Note 12.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In June 2016, the Company established the 2016 Incentive Award Plan
 (the &amp;#x201C;2016 Plan&amp;#x201D;). Options granted under the 2016 Plan
 are exercisable once vested. The options granted under the 2016
 Plan vest in installments over a four-year period from the grant
 date. Twenty-five percent of the options vest on the first
 anniversary of the vesting commencement date, and the remaining 75%
 of the options vest in 36 monthly installments for each full month
 of continuous service provided by the option holder thereafter,
 such that 100% of the options shall become vested on the fourth
 anniversary of the vesting commencement date. Options will lapse on
 the tenth anniversary of the date of grant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Restricted Stock Units (&amp;#x201C;RSUs&amp;#x201D;) granted under the
 2016 Plan also vest in installments over a four-year period from
 the grant date. Each RSU represents the right to receive one Common
 Share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As stated in the 2016 Plan, the Company has established the
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-Executive&lt;/font&gt; Director
 Compensation Program whereas &lt;font style="WHITE-SPACE: nowrap"&gt;Non-Executive&lt;/font&gt; Directors are entitled
 to cash compensation as well as equity compensation. The equity
 compensation consists of an initial option grant as well as annual
 awards. The initial awards granted under the &lt;font style="WHITE-SPACE: nowrap"&gt;Non-Executive&lt;/font&gt; Director Compensation
 Program vest in installments over a three-year period. Thirty-three
 percent of the options vest on the first anniversary of the vesting
 commencement date, and the remaining 67% of the options in 24
 substantially equal monthly installments thereafter, such that the
 award shall be fully vested on the third anniversary of the vesting
 commencement date. Each subsequent award shall vest and become
 exercisable in 12 substantially equal monthly installments
 following the vesting commencement date, such that the subsequent
 award shall be fully vested on the first anniversary of the date of
 grant.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Share-based payment expenses are recognized for each subsequent
 award that a &lt;font style="WHITE-SPACE: nowrap"&gt;Non-Executive&lt;/font&gt;
 Director is entitled to over their remaining term. Since subsequent
 awards are not subject to shareholder approval, the grant date is
 established and expenses are based on grant date fair value. The
 grant date fair value is not updated in each future reporting
 period and therefore the estimated fair value is not revised and
 expense recognized is based on the actual grant date fair value of
 the awards granted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During the six months ended June&amp;#xA0;30, 2018, the Company granted
 options to purchase 469,068 Common Shares with a grant date fair
 value of &amp;#x20AC;4.4&amp;#xA0;million to employees under the 2016
 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Pursuant to the &amp;#x201C;evergreen&amp;#x201D; provisions of the 2016
 Plan, the number of Common Shares authorized for issuance under the
 plan automatically increased by 777,194 Common Shares to 1,090,368
 Common Shares effective January&amp;#xA0;1, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Measurement of fair values of the equity-settled share-based
 payment arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The fair value of the employee share options has been measured
 using a binomial option pricing model, including members of the
 Board of Directors. Service and &lt;font style="WHITE-SPACE: nowrap"&gt;non-market&lt;/font&gt; performance conditions
 attached to the transactions were not taken into account in
 measuring fair value. Key management personnel include the
 Company&amp;#x2019;s executive management and the Board of
 Directors.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The inputs used in the measurement of the fair values and the
 related fair values at the grant dates were as follows for the
 options granted during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period ended June&amp;#xA0;30,
 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="55%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Key&amp;#xA0;Management&lt;br /&gt;
 Personnel&lt;br /&gt;
 (&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;All&amp;#xA0;Other&amp;#xA0;Personnel&lt;br /&gt;
 (&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Fair value at grant date&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;9.34-9.45&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;9.30-10.37&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Share price at grant date&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;14.57-14.87&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;14.57-18.24&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercise price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;14.57-14.87&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;14.57-18.24&lt;/font&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility (weighted-average)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;95.1%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;94.6%&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contractual life&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;10 years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;10 years&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;0%&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;0%&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate (based on government bonds)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2.79%-2.94%&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;2.84%-2.94%&lt;/font&gt;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;&lt;i&gt;Reconciliation of outstanding share options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The number of share options and the weighted average exercise
 prices of share options granted were as follows for the
 &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period ended
 June&amp;#xA0;30, 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;average&lt;br /&gt;
 exercise price&lt;br /&gt;
 (&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number of&lt;br /&gt;
 options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;13.99&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,213,985&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;19.67&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(12,044&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expired during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.02&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(5,146&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1.93&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(34,041&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.68&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;469,068&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;14.24&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,631,822&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercisable at June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;12.18&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,105,059&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The options outstanding at June&amp;#xA0;30, 2018, had an exercise
 price in the range of &amp;#x20AC;1.93 to &amp;#x20AC;27.47 and a
 weighted-average remaining contractual life of 8.2 years. The
 weighted-average share price at the date of exercise for share
 options exercised during the six months ended June&amp;#xA0;30, 2018
 was &amp;#x20AC;17.12.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 There were 2,631,822 outstanding share options at June&amp;#xA0;30,
 2018, with a weighted average exercise price of &amp;#x20AC;14.24.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The number of options outstanding as of June&amp;#xA0;30, 2018, was as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;Group of employees entitled&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Key management personnel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,153,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 All other employees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;478,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,631,822&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 During the six months ended June&amp;#xA0;30, 2018, the Company did not
 grant any new RSUs. The number of RSUs outstanding is summarized as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;average&lt;br /&gt;
 grant price&lt;br /&gt;
 (&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;br /&gt;
 RSU&amp;#x2019;s&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;194,546&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(76,245&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;118,301&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
  <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_B2D403EC-F24D-4480-BA82-11AAD97D9CE1_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Significant accounting policies&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 There have been no significant changes to the Company&amp;#x2019;s
 accounting policies that were previously disclosed in
 its&amp;#xA0;Annual&amp;#xA0;Report on Form &lt;font style="WHITE-SPACE: nowrap"&gt;20-F&lt;/font&gt; for its fiscal year ended
 December&amp;#xA0;31, 2017,&amp;#xA0;or in the methodology used in
 formulating these significant judgments and estimates that affect
 the application of these policies, except for the adoption of new
 accounting standards as disclosed more fully in Note 3.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 These unaudited interim condensed consolidated financial statements
 (the &amp;#x201C;interim financial statements&amp;#x201D;) have been prepared
 in accordance with International Accounting Standard 34
 &amp;#x201C;Interim Financial Reporting&amp;#x201D; as issued by the
 International Accounting Standards Board (&amp;#x201C;IASB&amp;#x201D;).
 Certain information and disclosures normally included in financial
 statements prepared in accordance with International Financial
 Reporting Standards (&amp;#x201C;IFRS&amp;#x201D;) have been condensed or
 omitted. Accordingly, these interim financial statements should be
 read in conjunction with the Company&amp;#x2019;s annual financial
 statements for the year ended December&amp;#xA0;31, 2017. In the
 opinion of management, all adjustments (consisting of a normal
 recurring nature) considered necessary for a fair presentation have
 been included in the interim financial statements. All intercompany
 transactions and balances are eliminated in consolidation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The preparation of financial statements in conformity with IFRS
 requires the use of certain critical accounting estimates. It also
 requires management to exercise its judgment in the process of
 applying the Company&amp;#x2019;s accounting policies. The areas
 involving a higher degree of judgment or complexity or areas where
 assumptions and estimates are significant to these interim
 financial statements are disclosed in Note 4. The results of
 operations for the three- and &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; periods ended June&amp;#xA0;30,
 2018, are not necessarily indicative of operations to be expected
 for the full fiscal year ending December&amp;#xA0;31, 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Foreign Currency Transactions&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Items recorded in each of the Company&amp;#x2019;s entities are measured
 using the currency of the primary economic environment in which the
 entity operates (the &amp;#x201C;functional currency&amp;#x201D;). The
 interim financial statements are presented in euros, which is Merus
 N.V.&amp;#x2019;s functional currency. The functional currency of Merus
 US, Inc. is the U.S. dollar.&amp;#xA0;All amounts are rounded to the
 nearest thousand euros, except where otherwise indicated. Foreign
 currency gains and losses are reported on a net basis as either
 finance income or finance expense depending on whether foreign
 currency movements are in a net gain or net loss position.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Seasonality&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s financial results have varied substantially,
 and are expected to continue to vary, from period to period. The
 Company believes that its ordinary activities are not linked to any
 particular seasonal factors.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company operates in one reportable segment, which comprises the
 discovery and development of innovative bispecific
 therapeutics.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 For the purpose of presentation in the statement of cash flows as
 well as the statement of financial position, cash and cash
 equivalents include deposits held with financial institutions with
 original maturities of less than three months. Cash and cash
 equivalents include &amp;#x20AC;34.3&amp;#xA0;million of short-term
 investments with a three-month or less maturity, callable on
 demand. The carrying values of short-term investments approximate
 fair value due to their short-term maturities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company enters into collaboration agreements which are within
 the scope of IFRS 15&amp;#x2014;Revenue from Contracts with Customers
 (&amp;#x201C;IFRS 15&amp;#x201D;), under which the Company licenses rights to
 certain of the Company&amp;#x2019;s product candidates and performs
 research and development services. The terms of these arrangements
 typically include payment of one or more of the following:
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable,&lt;/font&gt; upfront
 fees; reimbursement of research and development costs; development,
 regulatory, and commercial milestone payments; and royalties on net
 sales of licensed products.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 IFRS 15 requires an entity to recognize the amount of revenue to
 which it expects to be entitled for the transfer of promised goods
 or services to customers. Under IFRS 15, the Company recognizes
 revenue when its customer obtains control of the goods or services,
 in an amount that reflects the consideration that the Company
 determines it expects to receive in exchange for those goods or
 services. To determine revenue recognition for arrangements that
 the Company determines are within the scope of IFRS 15, the Company
 performs the following five steps: (i)&amp;#xA0;identify the
 contract(s) with a customer; (ii)&amp;#xA0;identify the performance
 obligations in the contract; (iii)&amp;#xA0;determine the transaction
 price; (iv)&amp;#xA0;allocate the transaction price to the performance
 obligations in the contract; and (v)&amp;#xA0;recognize revenue when
 (or as) the entity satisfies the performance obligation. The
 Company applies the five-step model to contracts only when it is
 probable that it will collect the consideration to which it is
 entitled in exchange for the goods or services it transfers to the
 customer. As part of the accounting for these arrangements, the
 Company must make significant judgments, including identifying
 performance obligations in the contract, estimating the amount of
 variable consideration to include in the transaction price and
 allocating the transaction price to each performance
 obligation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company currently generates a portion of its revenue through
 collaboration and license agreements with strategic collaborators
 for the development and commercialization of product candidates.
 The collaboration and license agreements are within the scope of
 IFRS 15.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Up-front&lt;/font&gt; License
 Payments&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 If the license to the Company&amp;#x2019;s intellectual property is
 determined to be distinct from the other performance obligations
 identified in the agreement, the Company recognizes revenues from
 &lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable,&lt;/font&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;up-front&lt;/font&gt; fees allocated to
 the license when the license is transferred to the customer and the
 customer is able to use and benefit from the license. If not
 distinct, the license is combined with other performance
 obligations in the contract. For licenses that are combined with
 other performance obligations, the Company assesses the nature of
 the combined performance obligation to determine whether the
 combined performance obligation is satisfied over time or at a
 point in time and, if over time, the appropriate method of
 measuring progress for purpose of recognizing revenue. The Company
 evaluates the measure of progress each reporting period and, if
 necessary, adjusts the measure of performance and related revenue
 recognition.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Pursuant to the Company&amp;#x2019;s research and license agreements
 with its collaborators, the Company has received upfront license
 payments relating to the integrated packages of deliverables under
 the contracts. Each contract contains either one single performance
 obligation or multiple performance obligations that the
 &lt;font style="WHITE-SPACE: nowrap"&gt;up-front&lt;/font&gt; consideration was
 allocated to. These upfront license payments are initially recorded
 in deferred revenue on the consolidated statements of financial
 position and are recognized as revenue on either: (i)&amp;#xA0;a
 straight-line basis over the period of the related performance
 obligation or the contractual term of the arrangement; or
 (ii)&amp;#xA0;based on another appropriate depiction of the
 Company&amp;#x2019;s performance over the period of the related
 performance obligation or the contractual term, such as costs
 incurred relating to full-time equivalent research employees. The
 applicable period over which to recognize the upfront payment is a
 significant judgment, which is &lt;font style="WHITE-SPACE: nowrap"&gt;re-assessed&lt;/font&gt; at each reporting
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Collaboration Income&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Collaboration income, which is typically related to reimbursements
 from collaborators for the Company&amp;#x2019;s performance of research
 and development services under the respective agreements, is
 recognized on the basis of labor hours valued at a contractually
 agreed rate. Collaboration income includes reimbursements for
 related &lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;out-of-pocket&lt;/font&gt;&lt;/font&gt; expenses. Cost
 reimbursements to which the Company is entitled under agreements
 are recognized as revenue in the same period as the cost for which
 they are intended to compensate. The Company acts as the principal
 and therefore records these reimbursements as collaboration
 income.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In determining the appropriate amount of revenue to be recognized
 as the Company fulfills its obligations under the agreements, the
 Company performs the five steps listed above. As part of the
 accounting for the arrangement, the Company must develop
 assumptions that require judgment to determine the stand-alone
 selling price for each performance obligation identified in the
 contract. The Company uses key assumptions to determine the
 stand-alone selling price, which may include market conditions,
 reimbursement rates for personnel costs, development timelines and
 probabilities of regulatory success.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company capitalizes the incremental costs of obtaining a
 contract with a customer if it expects to recover those costs. Such
 incremental costs would not have been incurred if the contract with
 a customer had not been obtained. To date, the Company has not
 capitalized any incremental costs for obtaining a contract.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s contracts often include development and
 regulatory milestone payments which are assessed under the most
 likely amount method and constrained if it is probable that a
 significant revenue reversal would occur. Milestone payments that
 are not within the Company&amp;#x2019;s control or the licensee&amp;#x2019;s
 control, such as regulatory approvals, are not considered probable
 of being achieved until those approvals are received. At each
 reporting date, the Company &lt;font style="WHITE-SPACE: nowrap"&gt;re-evaluates&lt;/font&gt; the probability of
 achievement of development milestones and any related constraint,
 and if necessary, adjusts the overall transaction price. Any such
 adjustments are recorded on a cumulative &lt;font style="WHITE-SPACE: nowrap"&gt;catch-up&lt;/font&gt; basis, which would affect
 collaboration revenues in the period of adjustment.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For agreements that include sales-based royalties, including
 milestone payments based on the level of sales, and the license is
 deemed to be the predominant item to which the royalties relate,
 the Company recognizes revenue at the later of (i)&amp;#xA0;when the
 related sales occur, or (ii)&amp;#xA0;when the performance obligation
 to which some or all of the royalty has been allocated has been
 satisfied (or partially satisfied). To date, the Company has not
 recognized any consideration related to sales-based royalty revenue
 resulting from any of the Company&amp;#x2019;s collaboration
 agreements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Government Grants&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company receives certain government and regional grants, which
 support its research efforts in defined projects, and include
 contributions towards the cost of research and development. When
 there is reasonable assurance that the Company will comply with the
 conditions attached to a received grant, and when there is
 reasonable assurance that the grant will be received, government
 grants are recognized as revenue on a gross basis in the
 consolidated statement of profit or loss and comprehensive loss on
 a systematic basis over the periods in which the Company recognizes
 expenses for the related costs for which the grants are intended to
 compensate. In the case of grants related to assets, the received
 grant will be deducted from the carrying amount of the asset.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Reclassifications&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Certain amounts were reclassified in the prior period condensed
 consolidated interim financial statements to conform to the current
 period presentation.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_3_5">4554000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_8EA4A8FC-99D9-4A40-A8F9-BD3597C2C0D4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The number of options outstanding as of June&amp;#xA0;30, 2018, was as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;Group of employees entitled&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Key management personnel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,153,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 All other employees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;478,012&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,631,822&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory>
  <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_0724BBDE-1C3A-49AE-A1E2-4F2562C7434D_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Trade and Other Receivables&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Trade and other receivables are short-term and due within 1
 year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Balance as per&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 VAT receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;622&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,640&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid pension costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;359&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest bank&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;275&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;66&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,413&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Trade and unbilled receivables relate primarily to invoicing for
 cost reimbursements relating to the Incyte collaboration and
 license agreement and the ONO research and license agreement. VAT
 receivable relates to value added tax receivable from the Dutch tax
 authorities based on the tax application for the second quarter of
 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Prepaid expenses reflected above in the form of prepaid expenses
 and prepaid pension costs consist of expenses that were paid during
 the reporting period but are related to activities taking place in
 subsequent periods. The increase in prepaid expenses at
 June&amp;#xA0;30, 2018 relate primarily to advanced payments made to
 contract research and contract manufacturing organizations in
 support of the Company&amp;#x2019;s upcoming clinical trial
 activities.&lt;/p&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_36">1801000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <dei:EntityRegistrantName contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_79805C7A-9AD4-4FD2-A1A8-CE46B284FE52_1_1">Merus N.V.</dei:EntityRegistrantName>
  <ifrs-full:FinanceIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_3_2">4945000</ifrs-full:FinanceIncome>
  <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_009330E4-78A1-45E8-9082-B58ACE21FFCC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table presents changes in the Company&amp;#x2019;s trade
 receivables, contract assets and contract liabilities during the
 six months ended June&amp;#xA0;30, 2018:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="38%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Balance&amp;#xA0;at&amp;#xA0;December&amp;#xA0;31,&lt;br /&gt;
 2017 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Additions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Deductions&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Balance&amp;#xA0;at&amp;#xA0;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade&amp;#xA0;&amp;amp; other receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total trade&amp;#xA0;&amp;amp; other receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11,628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;693&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(957&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;693&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(957&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total contract liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
  <dei:DocumentType contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_4849A84C-1483-40D9-9E28-8AA24D90A6CF_1_0">F-1</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_79805C7A-9AD4-4FD2-A1A8-CE46B284FE52_1_2">0001651311</dei:EntityCentralIndexKey>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_3_5">5491000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_19">302000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17004_20">4554000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:FinanceIncomeCost contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_8">4944000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_35">18848000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_C3AD34F7-86D1-4ED8-87F1-0474F4AFADFC_2_0">4100000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_10">139000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:InterestExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_3_3">1000</ifrs-full:InterestExpense>
  <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_26">602000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_96A0CC06-52C6-4929-A57B-1AABC49D7D22_1_2">76245</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_96A0CC06-52C6-4929-A57B-1AABC49D7D22_1_1">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_ED0FD632-D8DF-4B72-A191-8F0B75EB192A_1_2">5146</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_ED0FD632-D8DF-4B72-A191-8F0B75EB192A_1_1">12044</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_18">1000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17004_19">44731000</ifrs-full:IssueOfEquity>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_ED0FD632-D8DF-4B72-A191-8F0B75EB192A_1_4">469068</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:OperatingExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_3_9">34295000</ifrs-full:OperatingExpense>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_14">21000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherShorttermEmployeeBenefits contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_3_6">433000</ifrs-full:OtherShorttermEmployeeBenefits>
  <ifrs-full:ProfitLossBeforeTax contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_9">-12887000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_5">-17831000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_15D662B1-8197-4CEB-9788-3A915726F2CC_1_0">34041</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_29">44731000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:NetForeignExchangeGain contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_3_1">4111000</ifrs-full:NetForeignExchangeGain>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="shares" decimals="INF" id="id_13905947_66A56972-35F5-4FB1-9608-DF9D79E0567B_1_0">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_13">21000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherExpenseByNature contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_3_8">5983000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_53D8332C-1F89-41BB-9CBC-609CE7960C95_2_0">29560000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_25">624000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_3_4">22821000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_3_4">16464000</ifrs-full:Revenue>
  <ifrs-full:SocialSecurityContributions contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_3_2">449000</ifrs-full:SocialSecurityContributions>
  <dei:TradingSymbol contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_79805C7A-9AD4-4FD2-A1A8-CE46B284FE52_1_0">MRUS</dei:TradingSymbol>
  <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_53D8332C-1F89-41BB-9CBC-609CE7960C95_2_1">18931000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <ifrs-full:ProfessionalFeesExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_USD" decimals="2" id="id_13905947_6C15909B-03CD-40FB-896F-D7AB9DA76AD7_1_1">465390.34</ifrs-full:ProfessionalFeesExpense>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_11">-13026000</ifrs-full:ProfitLoss>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_24">100000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:RentalExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_180AFCAB-8D44-4456-B976-A2EB90CA331A_1_0">400000</ifrs-full:RentalExpense>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_3_7">9619000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:WagesAndSalaries contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_3_0">5505000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="0" id="id_13905947_C22DB5BC-7272-4839-99C3-9F91D51D8900_1_1">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="2" id="id_13905947_15D662B1-8197-4CEB-9788-3A915726F2CC_1_1">1.93</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageShares contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="shares" decimals="0" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_17">21809950</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="0" id="id_13905947_C22DB5BC-7272-4839-99C3-9F91D51D8900_1_3">0</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="2" id="id_13905947_C22DB5BC-7272-4839-99C3-9F91D51D8900_1_2">20.03</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <mrus:SharePrice1 contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="INF" id="id_13905947_AAA22312-FB64-4984-974F-9DFFACFA77D4_1_3">0</mrus:SharePrice1>
  <mrus:IncreaseDecreaseInCapital contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="0" id="id_13905947_15D662B1-8197-4CEB-9788-3A915726F2CC_1_3">3064</mrus:IncreaseDecreaseInCapital>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17004_21">49285000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <mrus:AttorneysFees contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_USD" decimals="2" id="id_13905947_6C15909B-03CD-40FB-896F-D7AB9DA76AD7_1_0">8332453.46</mrus:AttorneysFees>
  <mrus:RevenueRecognizedIncludedInDeferredRevenue contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_88E77354-6603-4F7F-9854-A79677767FE9_1_0">7900000</mrus:RevenueRecognizedIncludedInDeferredRevenue>
  <mrus:RevenueRecognizedNotIncludedInDeferredRevenue contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_88E77354-6603-4F7F-9854-A79677767FE9_1_1">1300000</mrus:RevenueRecognizedNotIncludedInDeferredRevenue>
  <mrus:AdditionsToTradeAndOtherReceivables contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_683ABA53-ADBF-4156-A1AD-9E218C68EFC9_4003_2">12103000</mrus:AdditionsToTradeAndOtherReceivables>
  <mrus:DeductionsInTradeAndOtherReceivables contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_683ABA53-ADBF-4156-A1AD-9E218C68EFC9_4003_3">11628000</mrus:DeductionsInTradeAndOtherReceivables>
  <mrus:DeductionsInContractAssets contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_1629FCB0-433E-4D77-BA8B-CAE88CECCBE6_4003_3">957000</mrus:DeductionsInContractAssets>
  <mrus:AdditionsInContractLiabilities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_4E3648C1-9E0F-4B1F-8972-3B460AAE5B96_4003_2">3430000</mrus:AdditionsInContractLiabilities>
  <mrus:DeductionsInContractLiabilities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_4E3648C1-9E0F-4B1F-8972-3B460AAE5B96_4003_3">9226000</mrus:DeductionsInContractLiabilities>
  <mrus:AdditionsInContractAssets contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_1629FCB0-433E-4D77-BA8B-CAE88CECCBE6_4003_2">693000</mrus:AdditionsInContractAssets>
  <mrus:ClinicalCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_3_1">4248000</mrus:ClinicalCosts>
  <mrus:OtherResearchAndDevelopmentExpenseOther contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_3_2">2300000</mrus:OtherResearchAndDevelopmentExpenseOther>
  <mrus:DiscoveryAndPreclinicalCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_3_0">1763000</mrus:DiscoveryAndPreclinicalCosts>
  <mrus:LitigationAndOppositionExpenses contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_20062C73-94B2-4C97-B3DF-1D70D3CFD778_2_0">800000</mrus:LitigationAndOppositionExpenses>
  <mrus:AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_14">2233000</mrus:AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals>
  <mrus:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_16">-143000</mrus:AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities>
  <mrus:SubsidiesIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_DAB346F9-6A94-4CCF-A34E-B5A8F8E36BFA_2_0">1900000</mrus:SubsidiesIncome>
  <mrus:GrantIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_D77DC940-FCD4-40E7-A6FB-3187867382D8_2_0">200000</mrus:GrantIncome>
  <mrus:PensionCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_3_4">390000</mrus:PensionCosts>
  <mrus:HealthInsurance contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_3_3">188000</mrus:HealthInsurance>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_3_3">4554000</mrus:StockAwardExpense>
  <mrus:WBSOSubsidy contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_3_1">1900000</mrus:WBSOSubsidy>
  <mrus:OtherOperatingExpenses contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_3_7">5134000</mrus:OtherOperatingExpenses>
  <mrus:LitigationCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_3_6">849000</mrus:LitigationCosts>
  <mrus:ManufacturingCost contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_3_0">9858000</mrus:ManufacturingCost>
  <mrus:PersonnelRelatedResearchAndDevelopmentExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_3_2">3808000</mrus:PersonnelRelatedResearchAndDevelopmentExpense>
  <mrus:OtherResearchAndDevelopmentExpenses contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_3_3">8311000</mrus:OtherResearchAndDevelopmentExpenses>
  <mrus:RentAndServiceChargesExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_17AFD412-2624-4690-A45D-BAE695726BE9_2_0">500000</mrus:RentAndServiceChargesExpense>
  <mrus:InterestAndRelatedIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_3_0">834000</mrus:InterestAndRelatedIncome>
  <mrus:ChangesInAccruedCapitalExpenditures contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1_39">271000</mrus:ChangesInAccruedCapitalExpenditures>
  <mrus:ShareBasedPaymentExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_84110F43-59B6-48C0-9F29-6D218231CB48_1_0">4600000</mrus:ShareBasedPaymentExpense>
  <mrus:LitigationExpenses contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_USD" decimals="2" id="id_13905947_6C15909B-03CD-40FB-896F-D7AB9DA76AD7_1_2">1717100.69</mrus:LitigationExpenses>
  <mrus:TermsOfPaymentOfTradeReceivables contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_CD973F62-7E39-4709-A081-813FE44F1700_1_0">30 days</mrus:TermsOfPaymentOfTradeReceivables>
  <mrus:NumberOfReportableSegments1 contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="Segment" decimals="INF" id="id_13905947_5ACC7D48-C643-4751-97E5-182F17E4F76D_1_0">1</mrus:NumberOfReportableSegments1>
  <mrus:SharebasedCompensationWeightedAverageRemainingContractualLife contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_AAA22312-FB64-4984-974F-9DFFACFA77D4_1_2">P8Y2M12D</mrus:SharebasedCompensationWeightedAverageRemainingContractualLife>
  <mrus:LeasesExpirationPeriod contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_180AFCAB-8D44-4456-B976-A2EB90CA331A_1_3">Fourth quarter of 2021</mrus:LeasesExpirationPeriod>
  <mrus:CashAndCashEquivalentsMaximumMaturityPeriod contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_40A61122-D215-4006-A058-1B70C336F299_1_0">P3M</mrus:CashAndCashEquivalentsMaximumMaturityPeriod>
  <mrus:OperatingLeaseTermOfLeaseAgreement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_180AFCAB-8D44-4456-B976-A2EB90CA331A_1_2">P2Y</mrus:OperatingLeaseTermOfLeaseAgreement>
  <mrus:DisclosureOfHeldToMaturityInvestmentExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_C6DBE1DB-9962-4A8D-B416-CB72698B6F2B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Investments as of June&amp;#xA0;30, 2018, and December&amp;#xA0;31, 2017,
 consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Balance as per&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,715&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,527&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S. Treasury securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,574&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,177&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate fixed income bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,289&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,886&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Agency bond&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,499&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,453&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Investments, current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37,077&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,043&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate fixed income bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,060&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;font style="WHITE-SPACE: nowrap"&gt;Non-current&lt;/font&gt;
 investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,060&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53,727&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfHeldToMaturityInvestmentExplanatory>
  <mrus:DisclosureOfOperatingExpensesExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_DC0F7F7B-AD51-45DB-9CB3-9F3CA416FB8E_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="left"&gt;&lt;b&gt;Total Operating Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Research and development costs are comprised of allocated employee
 costs, the costs of materials and laboratory consumables,
 intellectual property and license costs and allocated other
 costs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 A breakdown of total operating expenses is presented as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;(euros&amp;#xA0;in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Manufacturing costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,580&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,236&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;9,858&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,611&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IP and license costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;492&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;844&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;968&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel related R&amp;amp;D&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,107&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,771&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,808&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,303&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other research and development costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,344&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;8,311&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Total research and development costs&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;12,523&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,420&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;22,821&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Management and administration costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,639&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,491&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,694&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Litigation costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;552&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;849&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;394&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,745&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,173&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,134&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,726&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Total other expenses&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,297&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,277&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,983&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total operating expenses&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,459&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,189&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;34,295&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,241&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Research and development costs were &amp;#x20AC;12.5&amp;#xA0;million and
 &amp;#x20AC;22.8&amp;#xA0;million for the three and six months ended
 June&amp;#xA0;30, 2018, respectively, as compared to
 &amp;#x20AC;8.4&amp;#xA0;million and &amp;#x20AC;15.4&amp;#xA0;million for the three-
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2017, respectively. The increase in research
 and development costs is primarily attributable to the increase in
 manufacturing costs, higher research and development headcount and
 related costs, as well as additional spending in support of the
 Company&amp;#x2019;s clinical development programs
 for&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-128,&lt;/font&gt;&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-117,&lt;/font&gt;&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-158&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-145.The&lt;/font&gt;&amp;#xA0;significant
 increase in manufacturing costs and other research and development
 costs during 2018 relate primarily to the expansion of the
 Company&amp;#x2019;s Phase 1 and Phase 1/2 clinical programs.
 Specifically, the Company incurred higher costs relating to
 outsourced contract manufacturing for process development and drug
 delivery in support of the
 Company&amp;#x2019;s&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-128&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;MCLA-158&lt;/font&gt;&amp;#xA0;clinical
 development programs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 A breakdown of other research and development costs is presented as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(euros in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Discovery and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;pre-clinical&lt;/font&gt;&amp;#xA0;costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,078&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,698&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,763&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,076&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Clinical costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,850&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,292&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,248&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,002&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other research and development costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,416&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;820&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,300&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,467&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Total other research and development costs&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,344&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;8,311&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Other research and development costs consist mainly of laboratory
 supplies and depreciation expense related to research and
 development activities, which cannot be specifically allocated to a
 research project.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Litigation costs&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On March&amp;#xA0;11, 2014, Regeneron Pharmaceuticals, Inc.
 (&amp;#x201C;Regeneron&amp;#x201D;) filed a complaint in the United States
 District Court for the Southern District of New York (the
 &amp;#x201C;Court&amp;#x201D;), alleging that the Company was infringing on
 one or more claims in Regeneron&amp;#x2019;s U.S. Patent
 No.&amp;#xA0;8,502,018, entitled &amp;#x201C;Methods of Modifying Eukaryotic
 Cells&amp;#x201D; (the &amp;#x201C;018 Patent&amp;#x201D;). On July&amp;#xA0;3, 2014,
 the Company filed a response to the complaint, denying
 Regeneron&amp;#x2019;s allegations of infringement and raising
 affirmative defenses, and filed counterclaims seeking, among other
 things, a declaratory judgment that the Company did not infringe
 the patent and that the patent was invalid. The Company
 subsequently filed amended counterclaims during the period from
 August to December 2014, seeking a declaratory judgment of
 unenforceability of the patent due to Regeneron&amp;#x2019;s commission
 of inequitable conduct.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On November&amp;#xA0;21, 2014, the Court found that there was clear and
 convincing evidence that a claim term present in each of the patent
 claims was indefinite and granted the Company&amp;#x2019;s proposed
 claim constructions. On February&amp;#xA0;24, 2015, the Court entered
 partial judgment in the proceeding, on the grounds that the Company
 did not infringe each of the patent claims, and that each of the
 patent claims were invalid due to indefiniteness. On
 November&amp;#xA0;2, 2015, the Court found Regeneron had withheld
 material information from the United States Patent and Trademark
 Office during prosecution of the patent, and Regeneron had engaged
 in inequitable conduct and affirmative egregious misconduct in
 connection with the prosecution of the patent. On December&amp;#xA0;18,
 2015, Regeneron filed an appeal of the Court&amp;#x2019;s decision. On
 July&amp;#xA0;27, 2017, the U.S. Court of Appeals for the Federal
 Circuit affirmed the trial court&amp;#x2019;s conclusion that Regeneron
 had engaged in inequitable conduct before the United States Patent
 and Trademark Office and affirmed that the &amp;#x2018;018 patent is
 unenforceable. Regeneron petitioned for a panel rehearing and
 rehearing en banc of this decision by the Federal Circuit on
 September&amp;#xA0;12, 2017, which the Company responded to and opposed
 on November&amp;#xA0;2, 2017. On December&amp;#xA0;26, 2017, the full
 Federal Circuit denied Regeneron&amp;#x2019;s request to rehear the
 matter.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The case returned to the District Court to adjudicate the
 Company&amp;#x2019;s motion requesting that Regeneron pay the
 Company&amp;#x2019;s attorneys&amp;#x2019; fees and costs incurred as a
 result of Regeneron filing suit. On March&amp;#xA0;26, 2018, the trial
 court granted the Company&amp;#x2019;s motion for attorneys&amp;#x2019; fees,
 expert fees, and costs and ordered the parties to address the
 amount of award. The Company provided a detailed explanation of its
 attorneys&amp;#x2019; fees, expert fees, and costs of such award, which
 Regeneron responded to seeking a reduction of the amount. The
 matter was fully briefed as of May&amp;#xA0;18, 2018, and the Court
 issued an Order on June&amp;#xA0;25, 2018, which published on
 July&amp;#xA0;10, 2018, granting the Company&amp;#x2019;s motion for
 $8,332,453.46 in attorneys&amp;#x2019; fees, $465,390.34 in expert fees,
 and $1,717,100.69 in litigation expenses and costs, along with
 interest. Regeneron has appealed the decision awarding
 attorneys&amp;#x2019; fees to the Company to the Federal Circuit. On
 May&amp;#xA0;25, 2018, Regeneron filed a petition for writ of
 certiorari seeking review by the Supreme Court of the United States
 of the decision affirmed by the Federal Circuit. The
 Company&amp;#x2019;s brief in opposition was filed on August&amp;#xA0;8,
 2018.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On March&amp;#xA0;11, 2014, Regeneron served a writ in the Netherlands
 alleging that the Company was infringing one or more claims of the
 European patent EP 1 360 287 B1. The Company opposed the patent in
 June 2014. On September&amp;#xA0;17, 2014, Regeneron&amp;#x2019;s patent EP
 1 360 287 B1 was revoked in its entirety by the European Opposition
 Division of the European Patent Office (the &amp;#x201C;EPO&amp;#x201D;). In
 Europe, an appeal hearing occurred in October and November 2015 at
 the Technical Board of Appeal for the EPO at which time the patent
 was reinstated to Regeneron with amended claims. On May&amp;#xA0;25,
 2018, at Regeneron&amp;#x2019;s request, a hearing before the Technical
 Board of Appeals for the EPO was scheduled for September&amp;#xA0;13,
 2018, to address whether the description of EP 1 360 287 B1 patent
 having claims amended during the course of opposition complies with
 Art. 84 EPC, Art. 123(2) EPC and Rule 80 EPC. The Company believes
 that its current business operations do not infringe the patent
 reinstated to Regeneron with amended claims because it believes it
 has not used the technology or methods claimed under the amended
 claims.&amp;#xA0;The Dutch litigation procedure is stayed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The costs incurred in the above litigation and opposition were
 &amp;#x20AC;0.6&amp;#xA0;million and &amp;#x20AC;0.8&amp;#xA0;million for the three-
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2018, respectively, as compared to
 &amp;#x20AC;0.1&amp;#xA0;million and &amp;#x20AC;0.4&amp;#xA0;million for the three-
 and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt;&amp;#xA0;periods
 ended June&amp;#xA0;30, 2017, respectively, and are included in the
 statement of profit or loss and comprehensive loss for the
 period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On July&amp;#xA0;15, 2014, Regeneron filed a notice of opposition
 against the Company&amp;#x2019;s EP 2314629 patent (the &amp;#x201C;EP
 &amp;#x2019;629 patent&amp;#x201D;), entitled &amp;#x201C;Recombinant Production
 of Mixtures of Antibodies,&amp;#x201D; in the EPO. The notice asserted,
 as applicable, added subject matter, lack of novelty, lack of
 inventive step, and insufficiency. The Company responded on
 February&amp;#xA0;24, 2015. Following an oral hearing before the
 Opposition Division of the EPO on June&amp;#xA0;22, 2016, the
 Opposition Division upheld the EP &amp;#x2019;629 Patent with
 amendments. Both Regeneron and the Company filed a notice of appeal
 followed by grounds of appeal on December&amp;#xA0;1 and 4, 2017,
 respectively, with further proceedings to follow.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On August&amp;#xA0;11, 2014, Regeneron filed a notice of opposition
 against the Company&amp;#x2019;s EP 2147594 (the &amp;#x201C;EP &amp;#x2019;594
 patent&amp;#x201D;), entitled &amp;#x201C;Antibody
 Producing&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Non-Human&lt;/font&gt;&amp;#xA0;Mammals,&amp;#x201D;
 in the EPO. The notice asserted, as applicable, lack of novelty,
 lack of inventive step, and insufficiency. The Company&amp;#x2019;s
 response to the oppositions was filed on April&amp;#xA0;2, 2015.
 Following an oral hearing before the Opposition Division of the EPO
 on October&amp;#xA0;28, 2016, the Opposition Division upheld the EP
 &amp;#x2019;594 Patent without amendments. Regeneron filed grounds of
 appeal on July&amp;#xA0;19, 2017, and the Company responded on
 November&amp;#xA0;30, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On April&amp;#xA0;5, 2018, Regeneron and an unnamed third party filed
 notices of opposition against the Company&amp;#x2019;s EP 2604625 patent
 (the &amp;#x201C;EP &amp;#x2018;625 patent&amp;#x201D;), entitled
 &amp;#x201C;Generation of Binding Molecules,&amp;#x201D; in the EPO. The
 notices asserted, as applicable, added subject matter, lack of
 novelty, lack of inventive step, and insufficiency. The Company
 intends to timely respond to these submissions with proceedings to
 be ongoing.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As each of these proceedings continues, the Company is not able to
 predict the outcome of, or estimate a possible gain or a range of
 possible loss, if any, related to the above actions. Based on the
 current facts and circumstances, no provision has been recognized
 under IAS 37 related to contingent liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</mrus:DisclosureOfOperatingExpensesExplanatory>
  <mrus:DisclosureOfOperatingLeaseExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_0BBA5C39-6574-43D3-AD73-BFA2C821E039_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr style="page-break-inside:avoid"&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;" align="left"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company leases its corporate headquarters under an agreement
 term of five years which expires in the fourth quarter of 2021. If
 the lease is not terminated by Merus N.V. it will be automatically
 renewed for a period of two years. The agreed rental price is
 &amp;#x20AC;0.4&amp;#xA0;million per year. On May&amp;#xA0;1, 2018, the Company
 leased additional space to expand its corporate headquarters under
 a separate agreement. Under the terms of the new agreement, the
 term began on May&amp;#xA0;1, 2018, and expires in the fourth quarter
 of 2021. The agreed upon rental price is &amp;#x20AC;0.5&amp;#xA0;million
 per year.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 For leases that contain fixed increases in the minimum annual lease
 payment during the original term of the lease, the Company
 recognizes rental expense on a straight-line basis over the lease
 term and records the difference between rent expense and the amount
 currently payable as deferred rent as a component of other
 liabilities and accruals. For the three and six months ended
 June&amp;#xA0;30, 2018, the Company recognized &amp;#x20AC;0.3&amp;#xA0;million
 and &amp;#x20AC;0.5&amp;#xA0;million, respectively, compared to
 &amp;#x20AC;0.2&amp;#xA0;million and &amp;#x20AC;0.3&amp;#xA0;million for the three
 and six months ended June&amp;#xA0;30, 2017, respectively, for rent and
 service charges related to the office space. In addition, the
 Company has provided a deposit of &amp;#x20AC;0.1&amp;#xA0;million included
 in other assets as of June&amp;#xA0;30, 2018, and December&amp;#xA0;31,
 2017.&lt;/p&gt;
 &lt;/div&gt;</mrus:DisclosureOfOperatingLeaseExplanatory>
  <mrus:DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_211F5BEE-0620-4E87-ADB4-3A9C8151725A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Reclassifications&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Certain amounts were reclassified in the prior period condensed
 consolidated interim financial statements to conform to the current
 period presentation.&lt;/p&gt;
 &lt;/div&gt;</mrus:DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory>
  <mrus:DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_1C728290-9EAC-453A-ADC0-0644F51A7F66_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Share-based payment expenses (see Note 9) were recognized as
 employee benefit expenses as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;

 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;714&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;673&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,525&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Management and administrative costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,343&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,376&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,852&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,782&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;205&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;177&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,109&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,554&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</mrus:DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory>
  <mrus:DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_414F385E-8592-4B90-8448-8EE371F3BBA7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 These unaudited interim condensed consolidated financial statements
 (the &amp;#x201C;interim financial statements&amp;#x201D;) have been prepared
 in accordance with International Accounting Standard 34
 &amp;#x201C;Interim Financial Reporting&amp;#x201D; as issued by the
 International Accounting Standards Board (&amp;#x201C;IASB&amp;#x201D;).
 Certain information and disclosures normally included in financial
 statements prepared in accordance with International Financial
 Reporting Standards (&amp;#x201C;IFRS&amp;#x201D;) have been condensed or
 omitted. Accordingly, these interim financial statements should be
 read in conjunction with the Company&amp;#x2019;s annual financial
 statements for the year ended December&amp;#xA0;31, 2017. In the
 opinion of management, all adjustments (consisting of a normal
 recurring nature) considered necessary for a fair presentation have
 been included in the interim financial statements. All intercompany
 transactions and balances are eliminated in consolidation.&lt;/p&gt;
 &lt;/div&gt;</mrus:DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory>
  <mrus:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_207F9AE1-E243-4547-97F9-B7D3DED3E5FF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 For the purpose of presentation in the statement of cash flows as
 well as the statement of financial position, cash and cash
 equivalents include deposits held with financial institutions with
 original maturities of less than three months. Cash and cash
 equivalents include &amp;#x20AC;34.3&amp;#xA0;million of short-term
 investments with a three-month or less maturity, callable on
 demand. The carrying values of short-term investments approximate
 fair value due to their short-term maturities.&lt;/p&gt;
 &lt;/div&gt;</mrus:DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory>
  <mrus:DisclosureOfTradeAndOtherCurrentReceivableExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_838C6C5C-9416-444B-A243-9EEF5084B766_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Trade and other receivables are short-term and due within 1
 year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Balance as per&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Trade receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,069&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,594&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unbilled receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;710&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 VAT receivable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;622&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,640&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid pension costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;359&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest bank&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;275&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other receivables&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;66&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,477&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,413&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfTradeAndOtherCurrentReceivableExplanatory>
  <mrus:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_ED7B63CF-C6A4-4B0E-8B6D-30DEB974D064_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Details of the employee benefits are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;

 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;br /&gt;
 June&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Salaries and wages&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,876&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,451&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,505&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,182&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 WBSO subsidy&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(733&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(953&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,900&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Social security premiums&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;198&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;449&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;293&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Health insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Pension costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;181&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;390&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;322&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Share award expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,109&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,254&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,554&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,880&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other personnel expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;433&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;264&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total employee benefits expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,931&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,263&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,619&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory>
  <mrus:DisclosureOfInformationAboutRevenueExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_505BE823-ECC4-4522-825A-3B1E5804C73C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s revenues are generated entirely in the
 Netherlands. In the following table, revenue is disaggregated by
 primary source of revenue as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="54%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;Three months
 ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;Six months
 ended&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;June&amp;#xA0;30,&lt;br /&gt;
 2017&amp;#xA0;Restated*&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;June 30&lt;br /&gt;
 2017&amp;#xA0;Restated*&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Upfront payment amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,250&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,973&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;9,087&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,898&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Collaboration income&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,179&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;7,195&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue from contracts with customers&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,429&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,444&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;16,282&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,289&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Income from grants on research projects&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;114&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;793&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;182&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;832&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;6,543&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,237&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;16,464&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&lt;i&gt;*&lt;/i&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;i&gt;See Note 3 for details regarding the restatement as
 a result of a change in accounting policy.&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfInformationAboutRevenueExplanatory>
  <mrus:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_200BA99E-2AA2-46A9-A8A6-2FACFC88BBCF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 During the six months ended June&amp;#xA0;30, 2018, the Company did not
 grant any new RSUs. The number of RSUs outstanding is summarized as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;average&lt;br /&gt;
 grant price&lt;br /&gt;
 (&amp;#x20AC;)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;br /&gt;
 RSU&amp;#x2019;s&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at January&amp;#xA0;1, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;194,546&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Forfeited during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;(76,245&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;)&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted during the &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at June&amp;#xA0;30, 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;20.03&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;118,301&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory>
  <mrus:DisclosureOfDeferredRevenueExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_04CCC279-A947-4A09-BF51-9BAF13BB40FF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Deferred revenue as of June&amp;#xA0;30, 2018, and December&amp;#xA0;31,
 2017, consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="68%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Balance per&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&amp;#xA0;Restated*&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue &amp;#x2013; current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,972&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,718&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;112,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122,690&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="2%" align="left"&gt;*&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"&gt;&lt;i&gt;See Note 3 for details regarding the restatement as
 a result of a change in accounting policy.&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDeferredRevenueExplanatory>
  <mrus:DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_5AC46393-3E87-42C3-9440-B9BDA22A18DC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The preparation of financial statements in conformity with IFRS
 requires the use of certain critical accounting estimates. It also
 requires management to exercise its judgment in the process of
 applying the Company&amp;#x2019;s accounting policies. The areas
 involving a higher degree of judgment or complexity or areas where
 assumptions and estimates are significant to these interim
 financial statements are disclosed in Note 4. The results of
 operations for the three- and &lt;font style="WHITE-SPACE: nowrap"&gt;six-month&lt;/font&gt; periods ended June&amp;#xA0;30,
 2018, are not necessarily indicative of operations to be expected
 for the full fiscal year ending December&amp;#xA0;31, 2018.&lt;/p&gt;
 &lt;/div&gt;</mrus:DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory>
  <mrus:DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_8BAA0B25-3CAA-406C-A77A-B71C15FAC560_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 A breakdown of other research and development costs is presented as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(euros in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Discovery and &lt;font style="WHITE-SPACE: nowrap"&gt;pre-clinical&lt;/font&gt;
 costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,078&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,698&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,763&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,076&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Clinical costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,850&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,292&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,248&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,002&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other research and development costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;1,416&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;820&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,300&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,467&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Total other research and development costs&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,344&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;8,311&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory>
  <mrus:DescriptionOfAccountingPolicyForSeasonality contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_E8D80067-DF26-445A-BDD4-B64AFB612663_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Seasonality&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s financial results have varied substantially,
 and are expected to continue to vary, from period to period. The
 Company believes that its ordinary activities are not linked to any
 particular seasonal factors.&lt;/p&gt;
 &lt;/div&gt;</mrus:DescriptionOfAccountingPolicyForSeasonality>
  <mrus:DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_1F7B76FD-D889-490B-B149-32ABCF5A00A0_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following financial statement line items have been shown to
 reflect the adjustments recognized for each individual line item in
 the Company&amp;#x2019;s respective consolidated statements for the
 period noted:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Condensed Consolidated Statement of Profit or Loss and
 Comprehensive Loss&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&lt;br /&gt;
 ended&lt;br /&gt;
 June&amp;#xA0;30, 2017&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS&amp;#xA0;15&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Three&amp;#xA0;months&lt;br /&gt;
 ended&lt;br /&gt;
 June&amp;#xA0;30, 2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;(euros in
 thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,027&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,237&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Operating result&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,162&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total comprehensive loss for the period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(21,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19,588&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic (and diluted) loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.01&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30, 2017&lt;br /&gt;
 (As originally&lt;br /&gt;
 presented)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS&amp;#xA0;15&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Six&amp;#xA0;months&amp;#xA0;ended&lt;br /&gt;
 June&amp;#xA0;30, 2017&lt;br /&gt;
 Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;(euros in
 thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,313&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,121&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Operating result&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(20,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total comprehensive loss for the period&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(39,306&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Basic (and diluted) loss per share&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.20&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Condensed Consolidated Statement of Financial Position&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="58%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2017&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;As originally&lt;br /&gt;
 presented&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;2017&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;(euros in
 thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accumulated loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(167,480&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,705&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(158,775&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue, &lt;font style="WHITE-SPACE: nowrap"&gt;non-current&lt;/font&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;130,195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,644&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;112,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,996&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,939&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,935&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Condensed Consolidated Statement of Cash Flows&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2017&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;As originally&lt;br /&gt;
 presented&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;IFRS 15&lt;br /&gt;
 Adoption&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&amp;#xA0;2017&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Restated&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;(euros in
 thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Result after taxation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,132&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(39,324&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Changes in working capital:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred revenue&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,091&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,899&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory>
  <mrus:DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_22052A0E-0766-45F1-BCDF-EE4AE1549AD3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 All amounts are short-term and payable within 1 year.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Balance per&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;br /&gt;
 2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(euros in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued auditor&amp;#x2019;s fee&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;90&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;315&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 R&amp;amp;D costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,777&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,272&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IP &amp;#x2013; Legal fee&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;128&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;509&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Bonuses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;940&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Subsidy advance received&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other accruals&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;465&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;535&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,627&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock>
  <mrus:DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" id="id_13905947_1F164F6F-506D-4BCD-ACF0-A8D473C3BF41_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 A breakdown of total operating expenses is presented as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="62%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Three-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;Six-month&amp;#xA0;period&amp;#xA0;ended&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;June&amp;#xA0;30,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;2017&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;
 &lt;b&gt;(euros&amp;#xA0;in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Manufacturing costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,580&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,236&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;9,858&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,611&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IP and license costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;492&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;844&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;968&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Personnel related R&amp;amp;D&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,107&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,771&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,808&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,303&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other research and development costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;4,344&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,810&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;8,311&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,545&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Total research and development costs&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;12,523&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,420&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;22,821&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,427&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Management and administration costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,639&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,491&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,694&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Litigation costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;552&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;104&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;849&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;394&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other operating expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;2,745&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,173&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,134&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,726&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;i&gt;Total other expenses&lt;/i&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;3,297&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,277&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;5,983&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,120&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Total operating expenses&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;18,459&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,189&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;34,295&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,241&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mrus:DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory>
  <mrus:WeightedAverageExercisePricePerShareOptionsExpired contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_F7727428-03FD-452B-8FC8-0A134F40E4B5_1_2">14.02</mrus:WeightedAverageExercisePricePerShareOptionsExpired>
  <mrus:WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_F7727428-03FD-452B-8FC8-0A134F40E4B5_1_1">19.67</mrus:WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement>
  <mrus:WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_F7727428-03FD-452B-8FC8-0A134F40E4B5_1_4">14.68</mrus:WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement>
  <mrus:IPAndLicenseCosts contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_3_1">844000</mrus:IPAndLicenseCosts>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023" unitRef="pure" decimals="3" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_3_3">0.951</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023" unitRef="pure" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_3_5">0.00</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <mrus:ContractualLifeOfShareAwards contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_3_4">P10Y</mrus:ContractualLifeOfShareAwards>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023_3422662x3416700" unitRef="pure" decimals="4" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_1_6">0.0279</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_1_2">14.57</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_1_1">14.57</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_1_0">9.34</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023_3422662x3423353" unitRef="pure" decimals="4" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_2_6">0.0294</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_2_2">14.87</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_2_1">14.87</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_2_0">9.45</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3486468" unitRef="iso4217_USD" decimals="-6" id="id_13905947_DA2F4DFB-E45C-4AAB-A02E-92BD478BACF0_1001_3">80000000</ifrs-full:ProceedsFromIssuingShares>
  <mrus:RemainingPeriodOfDeferredRevenueAmortization contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3486468" id="id_13905947_FFA023FB-BB67-45FC-A962-1305EB3861AF_1001_2">P7Y6M</mrus:RemainingPeriodOfDeferredRevenueAmortization>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3486468" unitRef="iso4217_USD_per_shares" decimals="2" id="id_13905947_DA2F4DFB-E45C-4AAB-A02E-92BD478BACF0_1001_2">25.00</mrus:SharePurchasedPricePerShare>
  <mrus:UpfrontPayment contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3486468_3423034x3508994" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_FFA023FB-BB67-45FC-A962-1305EB3861AF_2001_1">112000000</mrus:UpfrontPayment>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3496102" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_1003_2">16282000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3509602" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_2003_3">182000</ifrs-full:Revenue>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206" unitRef="pure" decimals="3" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_6_3">0.946</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206" unitRef="pure" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_6_5">0.00</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
  <mrus:ContractualLifeOfShareAwards contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_6_4">P10Y</mrus:ContractualLifeOfShareAwards>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206_3422662x3416700" unitRef="pure" decimals="4" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_4_6">0.0284</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_4_2">14.57</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_4_1">14.57</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206_3422662x3416700" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_4_0">9.30</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206_3422662x3423353" unitRef="pure" decimals="4" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_5_6">0.0294</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <mrus:EmployeeOptionExercisedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_5_2">18.24</mrus:EmployeeOptionExercisedPricePerShare>
  <mrus:SharePurchasedPricePerShare contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_5_1">18.24</mrus:SharePurchasedPricePerShare>
  <mrus:FairValueAssumptionsGrantDateSharePrice contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206_3422662x3423353" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_0F9A420E-20A4-4E0E-8BB3-698C3C597D04_5_0">10.37</mrus:FairValueAssumptionsGrantDateSharePrice>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514218" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_3003_1">7195000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514219" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_4003_0">9087000</ifrs-full:Revenue>
  <mrus:AdditionsInContractLiabilities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_4E3648C1-9E0F-4B1F-8972-3B460AAE5B96_4002_2">3430000</mrus:AdditionsInContractLiabilities>
  <mrus:DeductionsInContractLiabilities contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416963x3508994" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_4E3648C1-9E0F-4B1F-8972-3B460AAE5B96_4002_3">9226000</mrus:DeductionsInContractLiabilities>
  <mrus:AdditionsToTradeAndOtherReceivables contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_683ABA53-ADBF-4156-A1AD-9E218C68EFC9_4002_2">12103000</mrus:AdditionsToTradeAndOtherReceivables>
  <mrus:DeductionsInTradeAndOtherReceivables contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417430x3424016" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_683ABA53-ADBF-4156-A1AD-9E218C68EFC9_4002_3">11628000</mrus:DeductionsInTradeAndOtherReceivables>
  <mrus:DeductionsInContractAssets contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417430x3496068" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_1629FCB0-433E-4D77-BA8B-CAE88CECCBE6_4002_3">957000</mrus:DeductionsInContractAssets>
  <mrus:AdditionsInContractAssets contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417430x3496068" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_1629FCB0-433E-4D77-BA8B-CAE88CECCBE6_4002_2">693000</mrus:AdditionsInContractAssets>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417439x3478997" unitRef="iso4217_USD" decimals="-5" id="id_13905947_A48A1291-2A59-4883-9AD9-2C62ED534CD9_1001_0">55800000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17001_19">288000</ifrs-full:IssueOfEquity>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3421013" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17001_21">288000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IssueOfEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17002_19">44443000</ifrs-full:IssueOfEquity>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3422849" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17002_21">44443000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17003_17">-13005000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17003_20">4554000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17003_16">21000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17003_15">-13026000</ifrs-full:ProfitLoss>
  <mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3422911" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_17003_21">4554000</mrus:IncreaseThroughContributionsByAndDistributionsToOwnersEquity>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3420782x3424474" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_815F699E-A355-43D5-837D-421B2FDF1D79_1002_0">100000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <mrus:IncreaseDecreaseInDeferredRevenue1 contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3421584x3508886" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_C27E3A45-67B2-49CE-8443-3FEF57FF72AA_1001_0">8700000</mrus:IncreaseDecreaseInDeferredRevenue1>
  <mrus:RevenueRecognized contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3422158x3496110" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_C66B6A18-BDAD-41C0-902E-671FE1BDE989_1002_0">300000</mrus:RevenueRecognized>
  <mrus:UpfrontPayment contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423034x3508994_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F7DC5FE2-F781-4217-8C2F-7F3E2D278FAB_1002_0">700000</mrus:UpfrontPayment>
  <mrus:MilestoneRevenuesAndCostsReimbursements contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_602BFC1C-1423-4DFB-9FAD-2934E1B6AEF9_2002_1">4300000</mrus:MilestoneRevenuesAndCostsReimbursements>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_A3D51094-34FC-4E71-8335-DC012B6F147B_1002_0">7900000</mrus:UpfrontPaymentAmortization>
  <mrus:EstimatedContractualTerm contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3486516" id="id_13905947_09ABC44B-6866-46CA-8CFA-C240DCB34CA9_1001_0">P21Y</mrus:EstimatedContractualTerm>
  <mrus:EstimatedContractualTerm contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3496065" id="id_13905947_09ABC44B-6866-46CA-8CFA-C240DCB34CA9_2001_2">P9Y</mrus:EstimatedContractualTerm>
  <mrus:UpfrontPayment contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3496111" unitRef="iso4217_EUR" decimals="-4" id="id_13905947_CA6CC775-0FDB-47E8-89B4-485D09D5C276_1001_0">2300000</mrus:UpfrontPayment>
  <mrus:UpfrontPayment contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3496111" unitRef="iso4217_USD" decimals="-4" id="id_13905947_CA6CC775-0FDB-47E8-89B4-485D09D5C276_1002_0">2750000</mrus:UpfrontPayment>
  <mrus:MilestoneRevenues contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3496111" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_6D8B0FA7-C876-416E-A118-676AE983F4F0_2002_1">100000</mrus:MilestoneRevenues>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3496111" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_A3D51094-34FC-4E71-8335-DC012B6F147B_2002_2">100000</mrus:UpfrontPaymentAmortization>
  <mrus:MilestoneRevenues contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_6D8B0FA7-C876-416E-A118-676AE983F4F0_3002_0">2500000</mrus:MilestoneRevenues>
  <mrus:MilestoneRevenuesAndCostsReimbursements contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_602BFC1C-1423-4DFB-9FAD-2934E1B6AEF9_3002_2">200000</mrus:MilestoneRevenuesAndCostsReimbursements>
  <mrus:RevenueRemainingPerformanceObligations contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F7DC5FE2-F781-4217-8C2F-7F3E2D278FAB_2002_1">1100000</mrus:RevenueRemainingPerformanceObligations>
  <mrus:AmountPaidForFullTimeEquivalentFunding contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F7DC5FE2-F781-4217-8C2F-7F3E2D278FAB_2002_2">200000</mrus:AmountPaidForFullTimeEquivalentFunding>
  <mrus:AmountPaidToCompensateForResearchServices contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F7DC5FE2-F781-4217-8C2F-7F3E2D278FAB_2002_3">300000</mrus:AmountPaidToCompensateForResearchServices>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_A3D51094-34FC-4E71-8335-DC012B6F147B_3002_1">1100000</mrus:UpfrontPaymentAmortization>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" unitRef="shares" decimals="INF" id="id_13905947_48916B42-ABDA-4963-8944-4541B8092E01_1001_0">469068</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <mrus:ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_48916B42-ABDA-4963-8944-4541B8092E01_1001_1">4400000</mrus:ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <mrus:PeriodOfRemainingOptionsVestingPeriod contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" id="id_13905947_13A4BF82-7DDF-4FD7-A0BF-CB32B95014FA_1001_4">36 monthly installments</mrus:PeriodOfRemainingOptionsVestingPeriod>
  <mrus:DescriptionOfOptionLapse contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" id="id_13905947_13A4BF82-7DDF-4FD7-A0BF-CB32B95014FA_1001_6">Options will lapse on the tenth anniversary of the date of grant.</mrus:DescriptionOfOptionLapse>
  <mrus:DescriptionOfOptionsGranted contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" id="id_13905947_13A4BF82-7DDF-4FD7-A0BF-CB32B95014FA_1001_0">Options granted under the 2016 Plan are exercisable once vested.</mrus:DescriptionOfOptionsGranted>
  <mrus:NumberOfCommonShareEntitledToReceive contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" unitRef="shares" decimals="INF" id="id_13905947_EDE8C7AB-221E-4FF1-882C-4916C9C2D88F_1001_1">1</mrus:NumberOfCommonShareEntitledToReceive>
  <mrus:SharebasedCompensationAwardVestingPeriod contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" id="id_13905947_13A4BF82-7DDF-4FD7-A0BF-CB32B95014FA_1001_1">P4Y</mrus:SharebasedCompensationAwardVestingPeriod>
  <mrus:NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" id="id_13905947_EDE8C7AB-221E-4FF1-882C-4916C9C2D88F_1001_0">P4Y</mrus:NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod>
  <mrus:PercentageOfRemainingVestingOptions contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" unitRef="pure" decimals="2" id="id_13905947_13A4BF82-7DDF-4FD7-A0BF-CB32B95014FA_1001_3">0.75</mrus:PercentageOfRemainingVestingOptions>
  <mrus:PercentageOfInitialVestingOptions contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" unitRef="pure" decimals="2" id="id_13905947_13A4BF82-7DDF-4FD7-A0BF-CB32B95014FA_1001_2">0.25</mrus:PercentageOfInitialVestingOptions>
  <mrus:PercentageOfVestingOptions contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207" unitRef="pure" decimals="INF" id="id_13905947_13A4BF82-7DDF-4FD7-A0BF-CB32B95014FA_1001_5">1.00</mrus:PercentageOfVestingOptions>
  <mrus:PeriodOfVestingInstallmentsOfInitialVestingAwards contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514208" id="id_13905947_6F6BE207-005F-4D30-953A-B62F8B440730_1001_0">Three-year period</mrus:PeriodOfVestingInstallmentsOfInitialVestingAwards>
  <mrus:PeriodOfRemainingOptionsVestingPeriod contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514208" id="id_13905947_6F6BE207-005F-4D30-953A-B62F8B440730_1001_3">24 substantially equal monthly installments</mrus:PeriodOfRemainingOptionsVestingPeriod>
  <mrus:DescriptionOfGrantAward contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514208" id="id_13905947_6F6BE207-005F-4D30-953A-B62F8B440730_1001_5">Following the vesting commencement  date, such that the subsequent award shall be fully vested on the first  anniversary of the date of grant.</mrus:DescriptionOfGrantAward>
  <mrus:PeriodOfAwardsWillBeVestedAndExercised contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514208" id="id_13905947_6F6BE207-005F-4D30-953A-B62F8B440730_1001_4">12  substantially equal monthly installments</mrus:PeriodOfAwardsWillBeVestedAndExercised>
  <mrus:PercentageOfRemainingVestingOptions contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514208" unitRef="pure" decimals="2" id="id_13905947_6F6BE207-005F-4D30-953A-B62F8B440730_1001_2">0.67</mrus:PercentageOfRemainingVestingOptions>
  <mrus:PercentageOfInitialVestingOptions contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514208" unitRef="pure" decimals="2" id="id_13905947_6F6BE207-005F-4D30-953A-B62F8B440730_1001_1">0.33</mrus:PercentageOfInitialVestingOptions>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3475752x3481637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_1003_0">1525000</mrus:StockAwardExpense>
  <ifrs-full:NetForeignExchangeGain contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3475752x3486700" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_53D8332C-1F89-41BB-9CBC-609CE7960C95_1002_2">1900000</ifrs-full:NetForeignExchangeGain>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3475752x3491841" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_2003_2">177000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_181_20180630_0_3475752x3514214" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_3003_1">2852000</mrus:StockAwardExpense>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_28_20180228_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_DB1474F3-15C8-43E3-8DCF-5AB41E4E04B5_2_2">44800000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_28_20180228_0" unitRef="iso4217_USD" decimals="-5" id="id_13905947_DB1474F3-15C8-43E3-8DCF-5AB41E4E04B5_3_2">55800000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="eol_PE977595--18F-1-0004_STD_31_20170131_0" unitRef="iso4217_USD" decimals="-6" id="id_13905947_DA2F4DFB-E45C-4AAB-A02E-92BD478BACF0_3_4">80000000</ifrs-full:ProceedsFromIssuingShares>
  <mrus:IncreaseDecreaseInDeferredRevenue1 contextRef="eol_PE977595--18F-1-0004_STD_365_20171231_0_3421584x3508886" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_604587A5-4214-44D8-B517-36E5AA40A63F_1001_0">8700000</mrus:IncreaseDecreaseInDeferredRevenue1>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="eol_PE977595--18F-1-0004_STD_90_20180331_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_C3AD34F7-86D1-4ED8-87F1-0474F4AFADFC_5_0">-2800000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_3">-1.01</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_2">-19588000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:FinanceCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_2_5">11962000</ifrs-full:FinanceCosts>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_2_5">3254000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:FinanceIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_2_2">420000</ifrs-full:FinanceIncome>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_5">3492000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:FinanceIncomeCost contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_8">-11542000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_C3AD34F7-86D1-4ED8-87F1-0474F4AFADFC_3_0">-12000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_10">107000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:OperatingExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_9">14189000</ifrs-full:OperatingExpense>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_14">13000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherShorttermEmployeeBenefits contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_2_6">148000</ifrs-full:OtherShorttermEmployeeBenefits>
  <ifrs-full:ProfitLossBeforeTax contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_9">-19494000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_1">-7952000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:NetForeignExchangeLoss contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_2_4">11962000</ifrs-full:NetForeignExchangeLoss>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_13">13000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherExpenseByNature contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_8">2277000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_4">8420000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_2_4">6237000</ifrs-full:Revenue>
  <ifrs-full:SocialSecurityContributions contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_2_2">146000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_11">-19601000</ifrs-full:ProfitLoss>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_2_7">5263000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:WagesAndSalaries contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_2_0">2451000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WeightedAverageShares contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="shares" decimals="0" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_17">19392495</ifrs-full:WeightedAverageShares>
  <mrus:ClinicalCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_2_1">1292000</mrus:ClinicalCosts>
  <mrus:OtherResearchAndDevelopmentExpenseOther contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_2_2">820000</mrus:OtherResearchAndDevelopmentExpenseOther>
  <mrus:DiscoveryAndPreclinicalCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_2_0">1698000</mrus:DiscoveryAndPreclinicalCosts>
  <mrus:LitigationAndOppositionExpenses contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_20062C73-94B2-4C97-B3DF-1D70D3CFD778_3_0">100000</mrus:LitigationAndOppositionExpenses>
  <mrus:SubsidiesIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_DAB346F9-6A94-4CCF-A34E-B5A8F8E36BFA_3_0">1000000</mrus:SubsidiesIncome>
  <mrus:GrantIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_D77DC940-FCD4-40E7-A6FB-3187867382D8_3_0">800000</mrus:GrantIncome>
  <mrus:PensionCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_2_4">181000</mrus:PensionCosts>
  <mrus:HealthInsurance contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_2_3">36000</mrus:HealthInsurance>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_2_3">3254000</mrus:StockAwardExpense>
  <mrus:WBSOSubsidy contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_2_1">953000</mrus:WBSOSubsidy>
  <mrus:OtherOperatingExpenses contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_7">2173000</mrus:OtherOperatingExpenses>
  <mrus:LitigationCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_6">104000</mrus:LitigationCosts>
  <mrus:ManufacturingCost contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_0">2236000</mrus:ManufacturingCost>
  <mrus:PersonnelRelatedResearchAndDevelopmentExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_2">1771000</mrus:PersonnelRelatedResearchAndDevelopmentExpense>
  <mrus:OtherResearchAndDevelopmentExpenses contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_3">3810000</mrus:OtherResearchAndDevelopmentExpenses>
  <mrus:RentAndServiceChargesExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_17AFD412-2624-4690-A45D-BAE695726BE9_3_0">200000</mrus:RentAndServiceChargesExpense>
  <mrus:InterestAndRelatedIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_2_0">420000</mrus:InterestAndRelatedIncome>
  <mrus:IPAndLicenseCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_1">603000</mrus:IPAndLicenseCosts>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3416740x3496102" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_1002_2">5444000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3416740x3509602" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_2002_3">793000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3416740x3514218" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_3002_1">1471000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3416740x3514219" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_4002_0">3973000</ifrs-full:Revenue>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3420782x3424474" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_815F699E-A355-43D5-837D-421B2FDF1D79_1003_0">100000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3422913x3420637" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_2_3">0.11</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_2_2">2210000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_2_1">2210000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3422913x3420637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_2_0">2210000</ifrs-full:Revenue>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3422913x3422609" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_1_3">-1.12</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_1_2">-21798000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_1_1">-10162000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3422913x3422609" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_1_0">4027000</ifrs-full:Revenue>
  <mrus:MilestoneRevenuesAndCostsReimbursements contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_6D8B0FA7-C876-416E-A118-676AE983F4F0_1003_2">1500000</mrus:MilestoneRevenuesAndCostsReimbursements>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_A3D51094-34FC-4E71-8335-DC012B6F147B_1003_0">4000000</mrus:UpfrontPaymentAmortization>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3475752x3481637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_1002_0">673000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3475752x3491841" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_2002_2">205000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20170630_0_3475752x3514214" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_3002_1">2376000</mrus:StockAwardExpense>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR_per_shares" decimals="2" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_16">-0.20</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:ComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_15">-4557000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:FinanceCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_1_5">1000</ifrs-full:FinanceCosts>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_1_5">2109000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:FinanceIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_1_2">7411000</ifrs-full:FinanceIncome>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_1_5">2639000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:FinanceIncomeCost contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_8">7410000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_C3AD34F7-86D1-4ED8-87F1-0474F4AFADFC_1_0">6900000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_10">87000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:InterestExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_1_3">1000</ifrs-full:InterestExpense>
  <ifrs-full:OperatingExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_1_9">18459000</ifrs-full:OperatingExpense>
  <ifrs-full:OtherComprehensiveIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_14">36000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherShorttermEmployeeBenefits contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_1_6">224000</ifrs-full:OtherShorttermEmployeeBenefits>
  <ifrs-full:ProfitLossBeforeTax contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_9">-4506000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_5">-11916000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:NetForeignExchangeGain contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_1_1">6917000</ifrs-full:NetForeignExchangeGain>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_13">36000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
  <ifrs-full:OtherExpenseByNature contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_1_8">3297000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_1_4">12523000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_1_4">6543000</ifrs-full:Revenue>
  <ifrs-full:SocialSecurityContributions contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_1_2">198000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:ProfitLoss contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_11">-4593000</ifrs-full:ProfitLoss>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_1_7">4931000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:WagesAndSalaries contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_1_0">2876000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WeightedAverageShares contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="shares" decimals="0" id="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_17">22628611</ifrs-full:WeightedAverageShares>
  <mrus:ClinicalCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_1_1">1850000</mrus:ClinicalCosts>
  <mrus:OtherResearchAndDevelopmentExpenseOther contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_1_2">1416000</mrus:OtherResearchAndDevelopmentExpenseOther>
  <mrus:DiscoveryAndPreclinicalCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_2BA6E1A5-6ABA-47C9-AEC3-905678CFF467_1_0">1078000</mrus:DiscoveryAndPreclinicalCosts>
  <mrus:LitigationAndOppositionExpenses contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_20062C73-94B2-4C97-B3DF-1D70D3CFD778_1_0">600000</mrus:LitigationAndOppositionExpenses>
  <mrus:SubsidiesIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_DAB346F9-6A94-4CCF-A34E-B5A8F8E36BFA_1_0">700000</mrus:SubsidiesIncome>
  <mrus:GrantIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_D77DC940-FCD4-40E7-A6FB-3187867382D8_1_0">100000</mrus:GrantIncome>
  <mrus:PensionCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_1_4">188000</mrus:PensionCosts>
  <mrus:HealthInsurance contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_1_3">69000</mrus:HealthInsurance>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_1_3">2109000</mrus:StockAwardExpense>
  <mrus:WBSOSubsidy contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_9B0FC870-BE87-403A-84E7-46A58F46DE09_1_1">733000</mrus:WBSOSubsidy>
  <mrus:OtherOperatingExpenses contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_1_7">2745000</mrus:OtherOperatingExpenses>
  <mrus:LitigationCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_1_6">552000</mrus:LitigationCosts>
  <mrus:ManufacturingCost contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_1_0">5580000</mrus:ManufacturingCost>
  <mrus:PersonnelRelatedResearchAndDevelopmentExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_1_2">2107000</mrus:PersonnelRelatedResearchAndDevelopmentExpense>
  <mrus:OtherResearchAndDevelopmentExpenses contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_1_3">4344000</mrus:OtherResearchAndDevelopmentExpenses>
  <mrus:RentAndServiceChargesExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_17AFD412-2624-4690-A45D-BAE695726BE9_1_0">300000</mrus:RentAndServiceChargesExpense>
  <mrus:InterestAndRelatedIncome contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_1_0">494000</mrus:InterestAndRelatedIncome>
  <mrus:IPAndLicenseCosts contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_1_1">492000</mrus:IPAndLicenseCosts>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3416740x3496102" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_1001_2">6429000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3416740x3509602" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_2001_3">114000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3416740x3514218" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_3001_1">2179000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3416740x3514219" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_4001_0">4250000</ifrs-full:Revenue>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3420782x3424474" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_815F699E-A355-43D5-837D-421B2FDF1D79_1001_0">100000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <mrus:RevenueRecognized contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3422158x3496110" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_C66B6A18-BDAD-41C0-902E-671FE1BDE989_1001_0">300000</mrus:RevenueRecognized>
  <mrus:MilestoneRevenuesAndCostsReimbursements contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_602BFC1C-1423-4DFB-9FAD-2934E1B6AEF9_2001_1">2000000</mrus:MilestoneRevenuesAndCostsReimbursements>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3423078x3486516" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_A3D51094-34FC-4E71-8335-DC012B6F147B_1001_0">4000000</mrus:UpfrontPaymentAmortization>
  <mrus:MilestoneRevenues contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3423078x3496111" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_6D8B0FA7-C876-416E-A118-676AE983F4F0_2001_1">100000</mrus:MilestoneRevenues>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3423078x3496111" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_A3D51094-34FC-4E71-8335-DC012B6F147B_2001_2">100000</mrus:UpfrontPaymentAmortization>
  <mrus:MilestoneRevenuesAndCostsReimbursements contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_602BFC1C-1423-4DFB-9FAD-2934E1B6AEF9_3001_2">100000</mrus:MilestoneRevenuesAndCostsReimbursements>
  <mrus:RevenueRemainingPerformanceObligations contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_F7DC5FE2-F781-4217-8C2F-7F3E2D278FAB_2001_1">100000</mrus:RevenueRemainingPerformanceObligations>
  <mrus:UpfrontPaymentAmortization contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3423078x3513897" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_A3D51094-34FC-4E71-8335-DC012B6F147B_3001_1">200000</mrus:UpfrontPaymentAmortization>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3475752x3481637" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_1001_0">714000</mrus:StockAwardExpense>
  <ifrs-full:NetForeignExchangeGain contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3475752x3486700" unitRef="iso4217_EUR" decimals="-5" id="id_13905947_53D8332C-1F89-41BB-9CBC-609CE7960C95_1001_2">3100000</ifrs-full:NetForeignExchangeGain>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3475752x3491841" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_2001_2">52000</mrus:StockAwardExpense>
  <mrus:StockAwardExpense contextRef="eol_PE977595--18F-1-0004_STD_91_20180630_0_3475752x3514214" unitRef="iso4217_EUR" decimals="-3" id="id_13905947_E3BC4796-D315-482C-83E1-48D0FC7119A2_3001_1">1343000</mrus:StockAwardExpense>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3475752x3491841">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:OtherExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3475752x3486700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:NetFinanceIncomeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3475752x3481637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3423078x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3423078x3496111">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3423078x3486516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteCollaborationAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3422158x3496110">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3416740x3514219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:UpfrontPaymentAmortizationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3416740x3514218">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:CollaborationIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3416740x3509602">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0_3416740x3496102">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:RevenueFromContractsWithCustomersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20180630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2018-04-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3475752x3491841">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:OtherExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3475752x3481637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3423078x3486516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteCollaborationAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3416740x3514219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:UpfrontPaymentAmortizationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3416740x3514218">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:CollaborationIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3416740x3509602">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0_3416740x3496102">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:RevenueFromContractsWithCustomersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_91_20170630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_90_20180331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_365_20171231_0_3421584x3508886">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">mrus:IFRS15RevenueFromContractsWithCustomersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_31_20170131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_28_20180228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3475752x3491841">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:OtherExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3475752x3486700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:NetFinanceIncomeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3475752x3481637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514208">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">mrus:NonexecutiveCompensationProgramMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3424457x3514207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">mrus:TwoThousandSixteenOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3496111">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3496065">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteProprietaryTechnologyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423078x3486516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteCollaborationAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3423034x3508994_3423078x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3422158x3496110">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrus:UpfrontAndMilestonePaymentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3421584x3508886">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">mrus:IFRS15RevenueFromContractsWithCustomersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417439x3478997">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">mrus:PrivatePlacementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417430x3496068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3417430x3424016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416963x3508994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:UpfrontPaymentAmortizationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514218">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:CollaborationIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3514206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3509602">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3496102">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:RevenueFromContractsWithCustomersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3486468_3423034x3508994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0_3416740x3421023">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20180630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3475752x3491841">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:OtherExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3475752x3481637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ResearchAndDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3423078x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3423078x3486516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteCollaborationAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3514219">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:UpfrontPaymentAmortizationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3514218">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:CollaborationIncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3509602">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncomeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3496102">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:RevenueFromContractsWithCustomersMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_181_20170630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_1_20170123_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-23</startDate>
      <endDate>2017-01-23</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_1_20170612_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2017-06-12</startDate>
      <endDate>2017-06-12</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_1_20140408_0_3423078x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-04-08</startDate>
      <endDate>2014-04-08</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_1_20180501_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2018-05-01</startDate>
      <endDate>2018-05-01</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_1_20180215_0_3421584x3421771_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-02-15</startDate>
      <endDate>2018-02-15</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_1_20180215_0_3421584x3421771_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-02-15</startDate>
      <endDate>2018-02-15</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_1_20180213_0_3421584x3421771">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2018-02-13</startDate>
      <endDate>2018-02-13</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_1_20180213_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2018-02-13</startDate>
      <endDate>2018-02-13</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_1_20170228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2017-02-28</startDate>
      <endDate>2017-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_1_20161101_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <startDate>2016-11-01</startDate>
      <endDate>2016-11-01</endDate>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180101_0_3424457x3514207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">mrus:TwoThousandSixteenOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-01-01</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424457x3514207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">mrus:TwoThousandSixteenOptionPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424453x3535979">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:USTreasurySecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424453x3530660">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:AgencyBondMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424453x3514284">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:CorporateFixedIncomeBondsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3424453x3479596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:CommercialPaper1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3422911_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3422911_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3422849_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3421013_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417430x3496068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3417430x3424016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0_3416963x3508994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20171231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20170123_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-01-23</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20161231_0_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20161231_0_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3422911_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3422911_3422913x3420637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:IncreaseDecreaseDueToApplicationOfIFRS15Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3422849_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3421013_3422913x3422609">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:PreviouslyStatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20161231_0_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3424453x3535979">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:USTreasurySecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3424453x3530660">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:AgencyBondMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3424453x3514284">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:CorporateFixedIncomeBondsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3424453x3479596">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfFinancialAssetsAxis">mrus:CommercialPaper1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3423078x3513897">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:OnoResearchAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3423078x3496111">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:SimcereCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3423078x3486516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">mrus:IncyteCollaborationAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3422662x3423353">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3422662x3416700">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3420782x3421581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417439x3422519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417430x3496068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">mrus:UnbilledReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3417430x3424016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:TradeReceivablesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416963x3508994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416740x3514206">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:AllOtherEmployeesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416740x3486468_3423034x3508994">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">mrus:DeferredRevenueMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0_3416740x3421023">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <instant>2018-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20170630_0_3475752x3514214">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="mrus:IncomeStatementLineItemLocationAxis">mrus:ManagementAndAdministrationCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20170630_0_3420782x3424474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20170630_0_3420782x3421581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20170630_0_3417632x3422911">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20170630_0_3417632x3422849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20170630_0_3417632x3421013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20170630_0_3417439x3422519">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20170630_0_3416740x3486468">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">mrus:IncyteCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20170630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180213_0_3421584x3421771">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
      <segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:PotentialOrdinaryShareTransactionsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2018-02-13</instant>
    </period>
  </context>
  <context id="eol_PE977595--18F-1-0004_STD_0_20180213_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001651311</identifier>
    </entity>
    <period>
      <instant>2018-02-13</instant>
    </period>
  </context>
  <unit id="iso4217_EUR_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:EUR</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_EUR">
    <measure>iso4217:EUR</measure>
  </unit>
  <unit id="Employees">
    <measure>mrus:Employees</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Segment">
    <measure>mrus:Segment</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_16" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_16" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_17" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_10" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_10" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_11" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_13" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_14" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_17" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_8" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_8" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_9" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_16" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_16" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_17" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_10" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_10" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_13" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_14" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_17" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_8" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_8" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_9" xlink:label="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_4" xlink:label="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_5" xlink:label="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_8" xlink:label="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_8" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_9" xlink:label="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_4" xlink:label="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_5" xlink:label="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_8" xlink:label="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_8" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_9" xlink:label="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_3_0" xlink:label="id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_3_0" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_3_2" xlink:label="id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_3_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_2_0" xlink:label="id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_2_0" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_2_1" xlink:label="id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_2_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2_4" xlink:label="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2_6" xlink:label="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2_6" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_2_2" xlink:label="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_2_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_2_5" xlink:label="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_2_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_2" xlink:label="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_5" xlink:label="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_1" xlink:label="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_2" xlink:label="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_3" xlink:label="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_7" xlink:label="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_16" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_16" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_1" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_10" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_10" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_11" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_13" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_14" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_16" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_16" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_2" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_20" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_20" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_21" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_21" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_23" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_23" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_24" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_24" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_25" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_25" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_26" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_26" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_4" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_5" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_9" xlink:label="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_9" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_2_4" xlink:label="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_4_4" xlink:label="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_4_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1002_38" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1002_38" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_10" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_10" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_11" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_13" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_13" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_14" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_16" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_16" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_17" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_17" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_18" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_18" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_19" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_19" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_20" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_20" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_25" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_25" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_26" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_26" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_27" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_27" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_29" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_29" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_3" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_30" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_30" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_31" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_31" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_32" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_32" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_33" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_33" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_34" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_34" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_35" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_35" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_36" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_36" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_4" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_5" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_5" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_6" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_6" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_7" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_8" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_8" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2002_37" xlink:label="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2002_37" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_1" xlink:label="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_1" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_2" xlink:label="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_2" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_3" xlink:label="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1001_3" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1001_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1002_3" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1002_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1003_3" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1003_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1004_3" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1004_3" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15001_22" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15001_22" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15002_22" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15002_22" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15003_22" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15003_22" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7001_11" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7001_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7002_11" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7002_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7003_11" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7003_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7004_11" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7004_11" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9001_14" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9001_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9002_14" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9002_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9003_14" xlink:label="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9003_14" xlink:type="locator"/>
    <xbrll:loc xlink:href="#id_13905947_F44ECD9F-49B1-4C74-9CA4-5F150EBB902F_3_0" xlink:label="id_13905947_F44ECD9F-49B1-4C74-9CA4-5F150EBB902F_3_0" xlink:type="locator"/>
    <xbrll:footnote xlink:label="footnote_1006604597" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</xbrll:footnote>
    <xbrll:footnote xlink:label="footnote_1006604602" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For the periods included in these financial statements, share options were excluded from the diluted loss per share calculation as the Company was in a loss position in each period presented above. As a result, basic and diluted loss per share is equal.</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_16" xlink:to="footnote_1006604602" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_1_17" xlink:to="footnote_1006604602" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_10" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_11" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_13" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_14" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_17" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_17" xlink:to="footnote_1006604602" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_8" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_2_9" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_16" xlink:to="footnote_1006604602" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_3_17" xlink:to="footnote_1006604602" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_10" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_13" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_14" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_17" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_17" xlink:to="footnote_1006604602" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_8" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_24373E72-36AB-4A87-A9EB-ABC9A1827B41_4_9" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_4" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_5" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_8" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_2_9" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_4" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_5" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_8" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_293D191D-24BF-4A7B-A5D9-AA6C03626F61_4_9" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_3_0" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_5CFCCB2F-6F32-43AA-AE4B-60CBE49A49D8_3_2" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_2_0" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_5FBD760A-F75C-4CA7-B15F-4166D7FF1180_2_1" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2_4" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_69189D93-4872-4E7B-BE5E-8CDE1589BB6C_2_6" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_2_2" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_2_5" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_2" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_7FD7BA5D-B650-4B4C-8FC3-B63E1F7C08FD_4_5" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_1" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_2" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_3" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_8E2C34AC-EE19-4755-851E-D350FBDB6619_3_3" xlink:to="footnote_1006604602" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_8EBF7A55-03C7-4935-8ECB-0FFF44AB178B_2_7" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_1_16" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_1" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_10" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_11" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_13" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_14" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_16" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_2" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_20" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_21" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_23" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_24" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_25" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_26" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_4" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_5" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_9633A0E5-9CC6-4260-A113-9BF667FCC506_2_9" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_2_4" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_A3DFC678-BCEE-468D-92CC-3B9055E02797_4_4" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_1002_38" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_10" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_11" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_13" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_14" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_16" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_17" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_18" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_19" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_20" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_25" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_26" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_27" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_29" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_3" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_30" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_31" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_32" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_33" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_34" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_35" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_36" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_4" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_5" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_6" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_7" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2_8" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C0D2E5B9-B5EC-4342-8C85-858B48D823B4_2002_37" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_1" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_2" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_3" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_C456B3BD-DC5C-4DC9-9FFF-52B20AB5D4A3_3_3" xlink:to="footnote_1006604602" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1001_3" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1002_3" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1003_3" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_1004_3" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15001_22" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15002_22" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_15003_22" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7001_11" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7002_11" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7003_11" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_7004_11" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9001_14" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9002_14" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_CFB3D20F-8D3E-45D1-A0FD-8BF0F6DD1BD2_9003_14" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="id_13905947_F44ECD9F-49B1-4C74-9CA4-5F150EBB902F_3_0" xlink:to="footnote_1006604597" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
  </xbrll:footnoteLink>
</xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mrus-20180630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Schema - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2018-12-20T14:39:20Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:srt-types="http://fasb.org/srt-types/2018-01-31"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:mrus="http://www.merus.nl/20180630"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  targetNamespace="http://www.merus.nl/20180630"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000" id="ias_1_2018-03-16_role-210000">
        <link:definition>103 - Statement - Unaudited Condensed Consolidated Statement of Financial Position</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000" id="ias_1_2018-03-16_role-320000">
        <link:definition>104 - Statement - Unaudited Condensed Consolidated Statement of Profit or Loss and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000" id="ias_1_2018-03-16_role-610000">
        <link:definition>105 - Statement - Unaudited Condensed Consolidated Statement of Changes in Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000" id="ias_7_2018-03-16_role-520000">
        <link:definition>106 - Statement - Unaudited Condensed Consolidated Statement of Cash flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
        <link:definition>107 - Disclosure - General information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
        <link:definition>108 - Disclosure - Significant accounting policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
        <link:definition>109 - Disclosure - Recently Issued International Financial Reporting Standards</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory">
        <link:definition>110 - Disclosure - Use of Estimates, Judgments and Assumptions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
        <link:definition>111 - Disclosure - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory">
        <link:definition>112 - Disclosure - Trade and Other Receivables</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
        <link:definition>113 - Disclosure - Other Liabilities and Accruals</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory">
        <link:definition>114 - Disclosure - Deferred Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory">
        <link:definition>115 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatory">
        <link:definition>116 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory">
        <link:definition>117 - Disclosure - Total Operating Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory">
        <link:definition>118 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory">
        <link:definition>119 - Disclosure - Finance Income and Expense</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory">
        <link:definition>120 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory" id="Role_NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory">
        <link:definition>121 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies" id="Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies">
        <link:definition>122 - Disclosure - Significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables">
        <link:definition>123 - Disclosure - Recently Issued International Financial Reporting Standards (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables">
        <link:definition>124 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables">
        <link:definition>125 - Disclosure - Trade and Other Receivables (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables">
        <link:definition>126 - Disclosure - Other Liabilities and Accruals (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables">
        <link:definition>127 - Disclosure - Deferred Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables">
        <link:definition>128 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables">
        <link:definition>129 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables">
        <link:definition>130 - Disclosure - Total Operating Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables">
        <link:definition>131 - Disclosure - Employee Benefits (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables" id="Role_NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables">
        <link:definition>132 - Disclosure - Finance Income and Expense (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation" id="DisclosureGeneralInformationAdditionalInformation">
        <link:definition>133 - Disclosure - General Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>134 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation" id="DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation">
        <link:definition>135 - Disclosure - Recently Issued International Financial Reporting Standards - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss" id="DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss">
        <link:definition>136 - Disclosure - Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Profit or Loss and Comprehensive Loss (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions" id="DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions">
        <link:definition>137 - Disclosure - Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Financial Positions (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows" id="DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>138 - Disclosure - Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Cash Flows (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation" id="DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation">
        <link:definition>139 - Disclosure - Use of Estimates, Judgments and Assumptions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments" id="DisclosureInvestmentsSummaryOfInvestments">
        <link:definition>140 - Disclosure - Investments - Summary of Investments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation" id="DisclosureInvestmentsAdditionalInformation">
        <link:definition>141 - Disclosure - Investments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year" id="DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year">
        <link:definition>142 - Disclosure - Trade and Other Receivables - Summary of Trade and Other Receivables Due Within 1 Year (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year" id="DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year">
        <link:definition>143 - Disclosure - Other Liabilities ans Accruals - Summary of Short-term and Payable Within 1 Year (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue" id="DisclosureDeferredRevenueSummaryOfDeferredRevenue">
        <link:definition>144 - Disclosure - Deferred Revenue - Summary of Deferred Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation" id="DisclosureDeferredRevenueAdditionalInformation">
        <link:definition>145 - Disclosure - Deferred Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation" id="DisclosureShareholdersEquityAdditionalInformation">
        <link:definition>146 - Disclosure - Shareholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates" id="DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates">
        <link:definition>147 - Disclosure - Shareholders' Equity - Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions" id="DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions">
        <link:definition>148 - Disclosure - Shareholders' Equity - Summary of Reconciliation of Outstanding Share Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding" id="DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding">
        <link:definition>149 - Disclosure - Shareholders' Equity - Summary of Number of Share Options Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs" id="DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs">
        <link:definition>150 - Disclosure - Shareholders' Equity - Summary of Reconciliation of RSU's (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue" id="DisclosureRevenueSummaryOfRevenue">
        <link:definition>151 - Disclosure - Revenue - Summary of Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation" id="DisclosureRevenueAdditionalInformation">
        <link:definition>152 - Disclosure - Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory" id="DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory">
        <link:definition>153 - Disclosure - Revenue - Disclosure Of Changes In Trade Receivables Contract Assets And Contract Liabilities Explanatory (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses" id="DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses">
        <link:definition>154 - Disclosure - Total Operating Expenses - Summary of Total Operating Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation" id="DisclosureTotalOperatingExpensesAdditionalInformation">
        <link:definition>155 - Disclosure - Total Operating Expenses - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts" id="DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts">
        <link:definition>156 - Disclosure - Total Operating Expenses - Breakdown of Other Research and Development Costs (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits" id="DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits">
        <link:definition>157 - Disclosure - Employee Benefits - Disclosure of Detailed Information About Employee Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses" id="DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses">
        <link:definition>158 - Disclosure - Employee Benefits - Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation" id="DisclosureEmployeeBenefitsAdditionalInformation">
        <link:definition>159 - Disclosure - Employee Benefits - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense" id="DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense">
        <link:definition>160 - Disclosure - Finance Income and Expense - Summary of Finance Income and Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseAdditionalInformation" id="DisclosureFinanceIncomeAndExpenseAdditionalInformation">
        <link:definition>161 - Disclosure - Finance Income and Expense - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.merus.nl/taxonomy/role/DisclosureOperatingLeaseAdditionalInformation" id="DisclosureOperatingLeaseAdditionalInformation">
        <link:definition>162 - Disclosure - Operating Lease - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="mrus-20180630_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="mrus-20180630_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="mrus-20180630_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="mrus-20180630_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/srt-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <import namespace="http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="https://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <element name="AccruedAuditorsFee" id="mrus_AccruedAuditorsFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedIntellectualPropertyLegalFee" id="mrus_AccruedIntellectualPropertyLegalFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedPersonnel" id="mrus_AccruedPersonnel" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AccruedResearchAndDevelopmentStudies" id="mrus_AccruedResearchAndDevelopmentStudies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionsInContractAssets" id="mrus_AdditionsInContractAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionsInContractLiabilities" id="mrus_AdditionsInContractLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionsToTradeAndOtherReceivables" id="mrus_AdditionsToTradeAndOtherReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" id="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" id="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets" id="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AgencyBondMember" id="mrus_AgencyBondMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AllOtherEmployeesMember" id="mrus_AllOtherEmployeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmountPaidForFullTimeEquivalentFunding" id="mrus_AmountPaidForFullTimeEquivalentFunding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmountPaidToCompensateForResearchServices" id="mrus_AmountPaidToCompensateForResearchServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AttorneysFees" id="mrus_AttorneysFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="Bonuses" id="mrus_Bonuses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency" id="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CashAndCashEquivalentsMaximumMaturityPeriod" id="mrus_CashAndCashEquivalentsMaximumMaturityPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangeInWorkingCapitalAbstract" id="mrus_ChangeInWorkingCapitalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangesInAccruedCapitalExpenditures" id="mrus_ChangesInAccruedCapitalExpenditures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" id="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ChangesInRestrictedCash" id="mrus_ChangesInRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalCosts" id="mrus_ClinicalCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationIncomeMember" id="mrus_CollaborationIncomeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommercialPaper1Member" id="mrus_CommercialPaper1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContractualLifeOfShareAwards" id="mrus_ContractualLifeOfShareAwards" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CorporateFixedIncomeBondsMember" id="mrus_CorporateFixedIncomeBondsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CurrentInterestBank" id="mrus_CurrentInterestBank" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CurrentPrepaidGeneralExpenses" id="mrus_CurrentPrepaidGeneralExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CurrentPrepaidPensionCosts" id="mrus_CurrentPrepaidPensionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CurrentUnbilledReceivables" id="mrus_CurrentUnbilledReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeductionsInContractAssets" id="mrus_DeductionsInContractAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeductionsInContractLiabilities" id="mrus_DeductionsInContractLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeductionsInTradeAndOtherReceivables" id="mrus_DeductionsInTradeAndOtherReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredRevenueMember" id="mrus_DeferredRevenueMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory" id="mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" id="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory" id="mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfAccountingPolicyForSeasonality" id="mrus_DescriptionOfAccountingPolicyForSeasonality" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory" id="mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfGrantAward" id="mrus_DescriptionOfGrantAward" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfOptionLapse" id="mrus_DescriptionOfOptionLapse" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DescriptionOfOptionsGranted" id="mrus_DescriptionOfOptionsGranted" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfAccrualsAndOtherPayablesAbstract" id="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" id="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" id="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" id="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" id="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" id="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfDeferredIncomeAbstract" id="mrus_DisclosureOfDeferredIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDeferredIncomeLineItems" id="mrus_DisclosureOfDeferredIncomeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDeferredIncomeTable" id="mrus_DisclosureOfDeferredIncomeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureOfDeferredRevenueExplanatory" id="mrus_DisclosureOfDeferredRevenueExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" id="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" id="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" id="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" id="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfEmployeeBenefitsAbstract" id="mrus_DisclosureOfEmployeeBenefitsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfEmployeeBenefitsLineItems" id="mrus_DisclosureOfEmployeeBenefitsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfEmployeeBenefitsTable" id="mrus_DisclosureOfEmployeeBenefitsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="DisclosureoffinancialinformationAbstract" id="mrus_DisclosureoffinancialinformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfGeneralInformationAbstract" id="mrus_DisclosureOfGeneralInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfHeldToMaturityInvestmentExplanatory" id="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfInformationAboutRevenueExplanatory" id="mrus_DisclosureOfInformationAboutRevenueExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" id="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOperatingExpensesAbstract" id="mrus_DisclosureOfOperatingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOperatingExpensesExplanatory" id="mrus_DisclosureOfOperatingExpensesExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOperatingLeaseAbstract" id="mrus_DisclosureOfOperatingLeaseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfOperatingLeaseExplanatory" id="mrus_DisclosureOfOperatingLeaseExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfRecentlyIssuedIfrsAbstract" id="mrus_DisclosureOfRecentlyIssuedIfrsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfShareOfEquityInvestmentLineItems" id="mrus_DisclosureOfShareOfEquityInvestmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfSignificantAccountingPoliciesAbstract" id="mrus_DisclosureOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DisclosureOfTradeAndOtherCurrentReceivableExplanatory" id="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DiscoveryAndPreclinicalCosts" id="mrus_DiscoveryAndPreclinicalCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentandEntityInformationAbstract" id="mrus_DocumentandEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeOptionExercisedPricePerShare" id="mrus_EmployeeOptionExercisedPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EstimatedContractualTerm" id="mrus_EstimatedContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueAssumptionsGrantDateSharePrice" id="mrus_FairValueAssumptionsGrantDateSharePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfDerivatives" id="mrus_FairValueOfDerivatives" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FinanceIncomeExpenseLineItems" id="mrus_FinanceIncomeExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FinanceIncomeExpenseTable" id="mrus_FinanceIncomeExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="GrantIncome" id="mrus_GrantIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="HealthInsurance" id="mrus_HealthInsurance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IFRS15RevenueFromContractsWithCustomersMember" id="mrus_IFRS15RevenueFromContractsWithCustomersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeMember" id="mrus_IncomeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeStatementLineItemLocationAxis" id="mrus_IncomeStatementLineItemLocationAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
  <element name="IncomeStatementLineItemLocationMember" id="mrus_IncomeStatementLineItemLocationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInCapital" id="mrus_IncreaseDecreaseInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInDeferredRevenue1" id="mrus_IncreaseDecreaseInDeferredRevenue1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInSharePremium" id="mrus_IncreaseDecreaseInSharePremium" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseThroughContributionsByAndDistributionsToOwnersEquity" id="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncyteCollaborationAgreementMember" id="mrus_IncyteCollaborationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncyteCorporationMember" id="mrus_IncyteCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncyteProprietaryTechnologyMember" id="mrus_IncyteProprietaryTechnologyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InterestAndRelatedIncome" id="mrus_InterestAndRelatedIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IPAndLicenseCosts" id="mrus_IPAndLicenseCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeasesExpirationPeriod" id="mrus_LeasesExpirationPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LitigationAndOppositionExpenses" id="mrus_LitigationAndOppositionExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LitigationCosts" id="mrus_LitigationCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LitigationExpenses" id="mrus_LitigationExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ManagementAndAdministrationCostsMember" id="mrus_ManagementAndAdministrationCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ManufacturingCost" id="mrus_ManufacturingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneRevenues" id="mrus_MilestoneRevenues" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneRevenuesAndCostsReimbursements" id="mrus_MilestoneRevenuesAndCostsReimbursements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetFinanceIncomeExpenseMember" id="mrus_NetFinanceIncomeExpenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetProceedsFromIssuingShares" id="mrus_NetProceedsFromIssuingShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonCurrentAssetsFinanceLiabilitiesAbstract" id="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonexecutiveCompensationProgramMember" id="mrus_NonexecutiveCompensationProgramMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonRefundableUpfrontPaymentsReceivable" id="mrus_NonRefundableUpfrontPaymentsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfCommonShareEntitledToReceive" id="mrus_NumberOfCommonShareEntitledToReceive" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" id="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfReportableSegments1" id="mrus_NumberOfReportableSegments1" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OnoResearchAndLicenseAgreementMember" id="mrus_OnoResearchAndLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingExpensesFromRailroadAndRelatedBusinessAbstract" id="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLeaseTermOfLeaseAgreement" id="mrus_OperatingLeaseTermOfLeaseAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherAccruals" id="mrus_OtherAccruals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherExpensesMember" id="mrus_OtherExpensesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherOperatingExpenses" id="mrus_OtherOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherResearchAndDevelopmentExpenseOther" id="mrus_OtherResearchAndDevelopmentExpenseOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OtherResearchAndDevelopmentExpenses" id="mrus_OtherResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PensionCosts" id="mrus_PensionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfInitialVestingOptions" id="mrus_PercentageOfInitialVestingOptions" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfRemainingVestingOptions" id="mrus_PercentageOfRemainingVestingOptions" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfVestingOptions" id="mrus_PercentageOfVestingOptions" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOfAwardsWillBeVestedAndExercised" id="mrus_PeriodOfAwardsWillBeVestedAndExercised" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOfRemainingOptionsVestingPeriod" id="mrus_PeriodOfRemainingOptionsVestingPeriod" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodOfVestingInstallmentsOfInitialVestingAwards" id="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PersonnelRelatedResearchAndDevelopmentExpense" id="mrus_PersonnelRelatedResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrivatePlacementsMember" id="mrus_PrivatePlacementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromCollaborationAgreement" id="mrus_ProceedsFromCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceOfPrivatePlacementUnits" id="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ReimbursementOfGrant" id="mrus_ReimbursementOfGrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RemainingPeriodOfDeferredRevenueAmortization" id="mrus_RemainingPeriodOfDeferredRevenueAmortization" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RentalExpensesOnRealEstateAbstract" id="mrus_RentalExpensesOnRealEstateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RentAndServiceChargesExpense" id="mrus_RentAndServiceChargesExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndDevelopmentCostsMember" id="mrus_ResearchAndDevelopmentCostsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueFromContractsWithCustomersMember" id="mrus_RevenueFromContractsWithCustomersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueLineItems" id="mrus_RevenueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognized" id="mrus_RevenueRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognizedIncludedInDeferredRevenue" id="mrus_RevenueRecognizedIncludedInDeferredRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognizedNotIncludedInDeferredRevenue" id="mrus_RevenueRecognizedNotIncludedInDeferredRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRemainingPerformanceObligations" id="mrus_RevenueRemainingPerformanceObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueTable" id="mrus_RevenueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="SecurityDeposits" id="mrus_SecurityDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" id="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharebasedCompensationAwardVestingPeriod" id="mrus_SharebasedCompensationAwardVestingPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" id="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharebasedCompensationWeightedAverageRemainingContractualLife" id="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedPaymentExpense" id="mrus_ShareBasedPaymentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharePrice1" id="mrus_SharePrice1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SharePurchasedPricePerShare" id="mrus_SharePurchasedPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SimcereCollaborationAndLicenseAgreementMember" id="mrus_SimcereCollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockAwardExpense" id="mrus_StockAwardExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SubsidiesIncome" id="mrus_SubsidiesIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SubsidyAdvanceReceived" id="mrus_SubsidyAdvanceReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TermsOfPaymentOfTradeReceivables" id="mrus_TermsOfPaymentOfTradeReceivables" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TextBlockAbstract" id="mrus_TextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TransactionsWithOwnersAbstract" id="mrus_TransactionsWithOwnersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandSixteenOptionPlanMember" id="mrus_TwoThousandSixteenOptionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UnbilledReceivablesMember" id="mrus_UnbilledReceivablesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontAndMilestonePaymentsMember" id="mrus_UpfrontAndMilestonePaymentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontPayment" id="mrus_UpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontPaymentAmortization" id="mrus_UpfrontPaymentAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontPaymentAmortizationMember" id="mrus_UpfrontPaymentAmortizationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="USTreasurySecuritiesMember" id="mrus_USTreasurySecuritiesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WBSOSubsidy" id="mrus_WBSOSubsidy" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" id="mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" id="mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement" id="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement" id="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement" id="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WeightedAverageExercisePricePerShareOptionsExpired" id="mrus_WeightedAverageExercisePricePerShareOptionsExpired" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>mrus-20180630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Calculation Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2018-12-20T14:39:20Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DocumentandEntityInformation" roleURI="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_1_2018-03-16_role-210000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_1_2018-03-16_role-320000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_1_2018-03-16_role-610000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_7_2018-03-16_role-520000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureGeneralInformationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureInvestmentsSummaryOfInvestments" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureInvestmentsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureDeferredRevenueSummaryOfDeferredRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureDeferredRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquityAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRevenueSummaryOfRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTotalOperatingExpensesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureEmployeeBenefitsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureFinanceIncomeAndExpenseAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureOperatingLeaseAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOperatingLeaseAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_SharePremium" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncome" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceCosts" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OtherExpenseByNature" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncomeCost" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_Revenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_OperatingExpense" order="1.0500" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:to="ifrs-full_IssueOfEquity" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="1.0900" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangesInRestrictedCash" xlink:label="mrus_ChangesInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ProceedsFromCollaborationAgreement" xlink:label="mrus_ProceedsFromCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="1.2600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="mrus_ProceedsFromCollaborationAgreement" order="1.2700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="1.2800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="mrus_ChangesInRestrictedCash" order="1.2900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.1900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="1.2100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1.2200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="1.1600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_ProfitLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="1.2400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="1.3000" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_HeldtomaturityInvestments" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_HeldtomaturityInvestments" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentInterestBank" xlink:label="mrus_CurrentInterestBank"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentPrepaidGeneralExpenses" xlink:label="mrus_CurrentPrepaidGeneralExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentPrepaidPensionCosts" xlink:label="mrus_CurrentPrepaidPensionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentUnbilledReceivables" xlink:label="mrus_CurrentUnbilledReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_CurrentTradeReceivables" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="mrus_CurrentUnbilledReceivables" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="mrus_CurrentPrepaidGeneralExpenses" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="mrus_CurrentPrepaidPensionCosts" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="mrus_CurrentInterestBank" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables" order="1.0700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedAuditorsFee" xlink:label="mrus_AccruedAuditorsFee"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedIntellectualPropertyLegalFee" xlink:label="mrus_AccruedIntellectualPropertyLegalFee"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedPersonnel" xlink:label="mrus_AccruedPersonnel"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedResearchAndDevelopmentStudies" xlink:label="mrus_AccruedResearchAndDevelopmentStudies"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_Bonuses" xlink:label="mrus_Bonuses"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherAccruals" xlink:label="mrus_OtherAccruals"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SubsidyAdvanceReceived" xlink:label="mrus_SubsidyAdvanceReceived"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="mrus_AccruedAuditorsFee" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="mrus_AccruedPersonnel" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="mrus_AccruedResearchAndDevelopmentStudies" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="mrus_AccruedIntellectualPropertyLegalFee" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="mrus_Bonuses" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="mrus_SubsidyAdvanceReceived" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="mrus_OtherAccruals" order="1.0700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncome" xlink:label="ifrs-full_DeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_DeferredIncome" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_DeferredIncome" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IPAndLicenseCosts" xlink:label="mrus_IPAndLicenseCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_LitigationCosts" xlink:label="mrus_LitigationCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ManufacturingCost" xlink:label="mrus_ManufacturingCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherOperatingExpenses" xlink:label="mrus_OtherOperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherResearchAndDevelopmentExpenses" xlink:label="mrus_OtherResearchAndDevelopmentExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PersonnelRelatedResearchAndDevelopmentExpense" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="mrus_LitigationCosts" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="mrus_OtherOperatingExpenses" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="mrus_ManufacturingCost" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="mrus_IPAndLicenseCosts" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="mrus_PersonnelRelatedResearchAndDevelopmentExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="mrus_OtherResearchAndDevelopmentExpenses" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ClinicalCosts" xlink:label="mrus_ClinicalCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DiscoveryAndPreclinicalCosts" xlink:label="mrus_DiscoveryAndPreclinicalCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherResearchAndDevelopmentExpenseOther" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherResearchAndDevelopmentExpenses" xlink:label="mrus_OtherResearchAndDevelopmentExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_OtherResearchAndDevelopmentExpenses" xlink:to="mrus_DiscoveryAndPreclinicalCosts" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_OtherResearchAndDevelopmentExpenses" xlink:to="mrus_ClinicalCosts" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="mrus_OtherResearchAndDevelopmentExpenses" xlink:to="mrus_OtherResearchAndDevelopmentExpenseOther" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_HealthInsurance" xlink:label="mrus_HealthInsurance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PensionCosts" xlink:label="mrus_PensionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WBSOSubsidy" xlink:label="mrus_WBSOSubsidy"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_WagesAndSalaries" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="mrus_WBSOSubsidy" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_SocialSecurityContributions" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="mrus_HealthInsurance" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="mrus_PensionCosts" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits" order="1.0700" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_InterestAndRelatedIncome" xlink:label="mrus_InterestAndRelatedIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_InterestExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_NetForeignExchangeLoss" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="mrus_InterestAndRelatedIncome" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_NetForeignExchangeGain" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOperatingLeaseAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>mrus-20180630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Definition Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2018-12-20T14:39:20Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DocumentandEntityInformation" roleURI="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_1_2018-03-16_role-210000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_1_2018-03-16_role-320000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_1_2018-03-16_role-610000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_7_2018-03-16_role-520000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureGeneralInformationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureInvestmentsSummaryOfInvestments" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureInvestmentsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureDeferredRevenueSummaryOfDeferredRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureDeferredRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquityAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRevenueSummaryOfRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTotalOperatingExpensesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureEmployeeBenefitsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureFinanceIncomeAndExpenseAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureOperatingLeaseAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOperatingLeaseAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TransactionsWithOwnersAbstract" xlink:label="mrus_TransactionsWithOwnersAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="mrus_TransactionsWithOwnersAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_IssueOfEquity" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" order="1.1300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_EstimatedContractualTerm" xlink:label="mrus_EstimatedContractualTerm"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IFRS15RevenueFromContractsWithCustomersMember" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInDeferredRevenue1" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteProprietaryTechnologyMember" xlink:label="mrus_IncyteProprietaryTechnologyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="mrus_EstimatedContractualTerm" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="mrus_IncreaseDecreaseInDeferredRevenue1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_IFRS15RevenueFromContractsWithCustomersMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteProprietaryTechnologyMember" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_Revenue" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementTable" xlink:label="srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_RetainedEarnings" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangeInWorkingCapitalAbstract" xlink:label="mrus_ChangeInWorkingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="mrus_ChangeInWorkingCapitalAbstract" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AgencyBondMember" xlink:label="mrus_AgencyBondMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CommercialPaper1Member" xlink:label="mrus_CommercialPaper1Member"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CorporateFixedIncomeBondsMember" xlink:label="mrus_CorporateFixedIncomeBondsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="ifrs-full_FinancialAssetsTypeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="ifrs-full_FinancialAssetsTypeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="invest_InvestmentLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="invest_InvestmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfFinancialAssetsAxis" xlink:label="ifrs-full_TypesOfFinancialAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_USTreasurySecuritiesMember" xlink:label="mrus_USTreasurySecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_CommercialPaper1Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_USTreasurySecuritiesMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_CorporateFixedIncomeBondsMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_AgencyBondMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="invest_InvestmentLineItems" xlink:to="invest_InvestmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="invest_InvestmentTable" xlink:to="ifrs-full_TypesOfFinancialAssetsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsTypeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsTypeMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="invest_InvestmentLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="invest_InvestmentTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NetFinanceIncomeExpenseMember" xlink:label="mrus_NetFinanceIncomeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_NetFinanceIncomeExpenseMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="invest_InvestmentLineItems" xlink:to="invest_InvestmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_NetForeignExchangeGain" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="invest_InvestmentTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AmountPaidForFullTimeEquivalentFunding" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AmountPaidToCompensateForResearchServices" xlink:label="mrus_AmountPaidToCompensateForResearchServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncome" xlink:label="ifrs-full_DeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeferredRevenueMember" xlink:label="mrus_DeferredRevenueMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredIncomeLineItems" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredIncomeTable" xlink:label="mrus_DisclosureOfDeferredIncomeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FairValueOfDerivatives" xlink:label="mrus_FairValueOfDerivatives"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RemainingPeriodOfDeferredRevenueAmortization" xlink:label="mrus_RemainingPeriodOfDeferredRevenueAmortization"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRecognized" xlink:label="mrus_RevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRemainingPerformanceObligations" xlink:label="mrus_RevenueRemainingPerformanceObligations"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontAndMilestonePaymentsMember" xlink:label="mrus_UpfrontAndMilestonePaymentsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontPayment" xlink:label="mrus_UpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_DisclosureOfDeferredIncomeTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_DeferredIncome" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_UpfrontPayment" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_FairValueOfDerivatives" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_RemainingPeriodOfDeferredRevenueAmortization" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_RevenueRecognized" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_RevenueRemainingPerformanceObligations" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_AmountPaidForFullTimeEquivalentFunding" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_AmountPaidToCompensateForResearchServices" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="srt_ProductOrServiceAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCorporationMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_UpfrontAndMilestonePaymentsMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="mrus_DeferredRevenueMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.1800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfGrantAward" xlink:label="mrus_DescriptionOfGrantAward"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfOptionLapse" xlink:label="mrus_DescriptionOfOptionLapse"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfOptionsGranted" xlink:label="mrus_DescriptionOfOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInCapital" xlink:label="mrus_IncreaseDecreaseInCapital"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInSharePremium" xlink:label="mrus_IncreaseDecreaseInSharePremium"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NetProceedsFromIssuingShares" xlink:label="mrus_NetProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NonexecutiveCompensationProgramMember" xlink:label="mrus_NonexecutiveCompensationProgramMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NumberOfCommonShareEntitledToReceive" xlink:label="mrus_NumberOfCommonShareEntitledToReceive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PercentageOfInitialVestingOptions" xlink:label="mrus_PercentageOfInitialVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PercentageOfRemainingVestingOptions" xlink:label="mrus_PercentageOfRemainingVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PercentageOfVestingOptions" xlink:label="mrus_PercentageOfVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PeriodOfAwardsWillBeVestedAndExercised" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PeriodOfRemainingOptionsVestingPeriod" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PotentialOrdinaryShareTransactionsMember" xlink:label="ifrs-full_PotentialOrdinaryShareTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ProceedsFromIssuanceOfPrivatePlacementUnits" xlink:label="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharebasedCompensationAwardVestingPeriod" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ShareBasedPaymentExpense" xlink:label="mrus_ShareBasedPaymentExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePrice1" xlink:label="mrus_SharePrice1"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TwoThousandSixteenOptionPlanMember" xlink:label="mrus_TwoThousandSixteenOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NetProceedsFromIssuingShares" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_IncreaseDecreaseInCapital" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_IncreaseDecreaseInSharePremium" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ShareBasedPaymentExpense" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfOptionsGranted" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharebasedCompensationAwardVestingPeriod" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfInitialVestingOptions" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfRemainingVestingOptions" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfRemainingOptionsVestingPeriod" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfVestingOptions" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfOptionLapse" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NumberOfCommonShareEntitledToReceive" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfAwardsWillBeVestedAndExercised" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfGrantAward" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharePrice1" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCorporationMember" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_PotentialOrdinaryShareTransactionsMember" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="mrus_NonexecutiveCompensationProgramMember" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="mrus_TwoThousandSixteenOptionPlanMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AllOtherEmployeesMember" xlink:label="mrus_AllOtherEmployeesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ContractualLifeOfShareAwards" xlink:label="mrus_ContractualLifeOfShareAwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_EmployeeOptionExercisedPricePerShare" xlink:label="mrus_EmployeeOptionExercisedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FairValueAssumptionsGrantDateSharePrice" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_FairValueAssumptionsGrantDateSharePrice" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_EmployeeOptionExercisedPricePerShare" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ContractualLifeOfShareAwards" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AllOtherEmployeesMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AllOtherEmployeesMember" xlink:label="mrus_AllOtherEmployeesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AllOtherEmployeesMember" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CollaborationIncomeMember" xlink:label="mrus_CollaborationIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeMember" xlink:label="mrus_IncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueFromContractsWithCustomersMember" xlink:label="mrus_RevenueFromContractsWithCustomersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueLineItems" xlink:label="mrus_RevenueLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueTable" xlink:label="mrus_RevenueTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontPaymentAmortizationMember" xlink:label="mrus_UpfrontPaymentAmortizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_UpfrontPaymentAmortizationMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_CollaborationIncomeMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_RevenueFromContractsWithCustomersMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncomeMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_RevenueTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="ifrs-full_Revenue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CollaborationIncomeMember" xlink:label="mrus_CollaborationIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_GrantIncome" xlink:label="mrus_GrantIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IFRS15RevenueFromContractsWithCustomersMember" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInDeferredRevenue1" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_MilestoneRevenues" xlink:label="mrus_MilestoneRevenues"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_MilestoneRevenuesAndCostsReimbursements" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ReimbursementOfGrant" xlink:label="mrus_ReimbursementOfGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueLineItems" xlink:label="mrus_RevenueLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRecognizedIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRecognizedNotIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueTable" xlink:label="mrus_RevenueTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TermsOfPaymentOfTradeReceivables" xlink:label="mrus_TermsOfPaymentOfTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontPaymentAmortization" xlink:label="mrus_UpfrontPaymentAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_CollaborationIncomeMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_GrantIncome" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_ReimbursementOfGrant" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_TermsOfPaymentOfTradeReceivables" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_IncreaseDecreaseInDeferredRevenue1" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_RevenueRecognizedIncludedInDeferredRevenue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_RevenueRecognizedNotIncludedInDeferredRevenue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_IFRS15RevenueFromContractsWithCustomersMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_RevenueTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_UpfrontPaymentAmortization" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="ifrs-full_Revenue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_MilestoneRevenuesAndCostsReimbursements" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_MilestoneRevenues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember" order="1.1500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdditionsInContractAssets" xlink:label="mrus_AdditionsInContractAssets"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdditionsInContractLiabilities" xlink:label="mrus_AdditionsInContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdditionsToTradeAndOtherReceivables" xlink:label="mrus_AdditionsToTradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ifrs-full_ContractAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeductionsInContractAssets" xlink:label="mrus_DeductionsInContractAssets"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeductionsInContractLiabilities" xlink:label="mrus_DeductionsInContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeductionsInTradeAndOtherReceivables" xlink:label="mrus_DeductionsInTradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeferredRevenueMember" xlink:label="mrus_DeferredRevenueMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="ifrs-full_TradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UnbilledReceivablesMember" xlink:label="mrus_UnbilledReceivablesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_TradeReceivablesMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="mrus_UnbilledReceivablesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherReceivables" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsToTradeAndOtherReceivables" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInTradeAndOtherReceivables" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractAssets" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsInContractAssets" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInContractAssets" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractLiabilities" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsInContractLiabilities" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInContractLiabilities" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="mrus_DeferredRevenueMember" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfEmployeeBenefitsTable" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ManagementAndAdministrationCostsMember" xlink:label="mrus_ManagementAndAdministrationCostsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherExpensesMember" xlink:label="mrus_OtherExpensesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ResearchAndDevelopmentCostsMember" xlink:label="mrus_ResearchAndDevelopmentCostsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_StockAwardExpense" xlink:label="mrus_StockAwardExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:to="mrus_DisclosureOfEmployeeBenefitsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:to="mrus_StockAwardExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ResearchAndDevelopmentCostsMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ManagementAndAdministrationCostsMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_OtherExpensesMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfEmployeeBenefitsTable" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ManagementAndAdministrationCostsMember" xlink:label="mrus_ManagementAndAdministrationCostsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_NL" xlink:label="country_NL"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SubsidiesIncome" xlink:label="mrus_SubsidiesIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:to="mrus_DisclosureOfEmployeeBenefitsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:to="mrus_SubsidiesIncome" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:to="ifrs-full_NumberOfEmployees" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_NL" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ManagementAndAdministrationCostsMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency" xlink:label="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FinanceIncomeExpenseLineItems" xlink:label="mrus_FinanceIncomeExpenseLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FinanceIncomeExpenseTable" xlink:label="mrus_FinanceIncomeExpenseTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PrivatePlacementsMember" xlink:label="mrus_PrivatePlacementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_PrivatePlacementsMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mrus_FinanceIncomeExpenseLineItems" xlink:to="mrus_FinanceIncomeExpenseTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_FinanceIncomeExpenseLineItems" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_FinanceIncomeExpenseLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mrus_FinanceIncomeExpenseLineItems" xlink:to="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mrus_FinanceIncomeExpenseTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOperatingLeaseAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>mrus-20180630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Labels Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2018-12-20T14:39:20Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedAuditorsFee" xlink:label="mrus_AccruedAuditorsFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AccruedAuditorsFee_lbl" xml:lang="en-US" id="id_13905947_3463404_3_1">accrued auditors fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AccruedAuditorsFee_lbl" xml:lang="en-US" id="id_13905947_3463404_1_1">accrued auditors fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AccruedAuditorsFee_lbl" xml:lang="en-US" id="id_13905947_3463404_2_1">Accrued auditor's fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccruedAuditorsFee" xlink:to="mrus_AccruedAuditorsFee_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedIntellectualPropertyLegalFee" xlink:label="mrus_AccruedIntellectualPropertyLegalFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AccruedIntellectualPropertyLegalFee_lbl" xml:lang="en-US" id="id_13905947_3463218_3_1">Accrued intellectual property legal fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AccruedIntellectualPropertyLegalFee_lbl" xml:lang="en-US" id="id_13905947_3463218_1_1">Accrued intellectual property legal fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AccruedIntellectualPropertyLegalFee_lbl" xml:lang="en-US" id="id_13905947_3463218_2_1">IP - Legal fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccruedIntellectualPropertyLegalFee" xlink:to="mrus_AccruedIntellectualPropertyLegalFee_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedPersonnel" xlink:label="mrus_AccruedPersonnel"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AccruedPersonnel_lbl" xml:lang="en-US" id="id_13905947_3463216_3_1">Accrued personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AccruedPersonnel_lbl" xml:lang="en-US" id="id_13905947_3463216_1_1">Accrued personnel</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AccruedPersonnel_lbl" xml:lang="en-US" id="id_13905947_3463216_2_1">Personnel</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccruedPersonnel" xlink:to="mrus_AccruedPersonnel_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedResearchAndDevelopmentStudies" xlink:label="mrus_AccruedResearchAndDevelopmentStudies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AccruedResearchAndDevelopmentStudies_lbl" xml:lang="en-US" id="id_13905947_3463217_3_1">Accrued research and development studies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AccruedResearchAndDevelopmentStudies_lbl" xml:lang="en-US" id="id_13905947_3463217_1_1">Accrued research and development studies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AccruedResearchAndDevelopmentStudies_lbl" xml:lang="en-US" id="id_13905947_3463217_2_1">R&amp;D costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AccruedResearchAndDevelopmentStudies" xlink:to="mrus_AccruedResearchAndDevelopmentStudies_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdditionsInContractAssets" xlink:label="mrus_AdditionsInContractAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdditionsInContractAssets_lbl" xml:lang="en-US" id="id_13905947_3448902_3_1">Additions in contract assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdditionsInContractAssets_lbl" xml:lang="en-US" id="id_13905947_3448902_1_1">Additions in contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdditionsInContractAssets_lbl" xml:lang="en-US" id="id_13905947_3448902_2_1">Contract assets, additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdditionsInContractAssets" xlink:to="mrus_AdditionsInContractAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdditionsInContractLiabilities" xlink:label="mrus_AdditionsInContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdditionsInContractLiabilities_lbl" xml:lang="en-US" id="id_13905947_3448900_3_1">Additions in contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdditionsInContractLiabilities_lbl" xml:lang="en-US" id="id_13905947_3448900_1_1">Additions in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdditionsInContractLiabilities_lbl" xml:lang="en-US" id="id_13905947_3448900_2_1">Contract liabilities, additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdditionsInContractLiabilities" xlink:to="mrus_AdditionsInContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdditionsToTradeAndOtherReceivables" xlink:label="mrus_AdditionsToTradeAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdditionsToTradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3448895_3_1">Additions to trade and other receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdditionsToTradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3448895_1_1">Additions to trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdditionsToTradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3448895_2_1">Trade and other receivables, additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdditionsToTradeAndOtherReceivables" xlink:to="mrus_AdditionsToTradeAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" id="id_13905947_3417003_1_1">Adjustments for decrease (increase) in other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" id="id_13905947_3417003_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3416776_1_1">Adjustments for decrease (increase) in trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3416776_2_1">Trade and other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" id="id_13905947_3417004_1_1">Adjustments for depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" id="id_13905947_3417004_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" id="id_13905947_3416779_1_1">Adjustments for finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" id="id_13905947_3416779_14_1">Net finance (income) expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US" id="id_13905947_3416563_1_1">Adjustments for gains (losses) on change in fair value of derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US" id="id_13905947_3416563_14_1">Changes in fair value derivative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl" xml:lang="en-US" id="id_13905947_3416567_1_1">Adjustments for increase (decrease) in deferred income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl" xml:lang="en-US" id="id_13905947_3416567_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals_lbl" xml:lang="en-US" id="id_13905947_3449780_3_1">Adjustments for increase (decrease) in other liabilities and accurals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals_lbl" xml:lang="en-US" id="id_13905947_3449780_1_1">Adjustments for increase (decrease) in other liabilities and accurals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals_lbl" xml:lang="en-US" id="id_13905947_3449780_2_1">Other liabilities and accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_lbl" xml:lang="en-US" id="id_13905947_3449781_3_1">Adjustments for increase (decrease) in Tax and social security liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_lbl" xml:lang="en-US" id="id_13905947_3449781_1_1">Adjustments for increase (decrease) in Tax and social security liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_lbl" xml:lang="en-US" id="id_13905947_3449781_2_1">Taxes and social security liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets_lbl" xml:lang="en-US" id="id_13905947_3448889_3_1">Adjustments for ( increase) decrease in Taxes and social security assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets_lbl" xml:lang="en-US" id="id_13905947_3448889_1_1">Adjustments for increase (decrease) in Taxes and social security assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets_lbl" xml:lang="en-US" id="id_13905947_3448889_14_1">Taxes and social security assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" id="id_13905947_3416571_1_1">Adjustments for increase (decrease) in trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" id="id_13905947_3416571_2_1">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" id="id_13905947_3417013_1_1">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" id="id_13905947_3417013_2_1">Adjustments for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" id="id_13905947_3417014_1_1">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" id="id_13905947_3417014_2_1">Share-based payment expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US" id="id_13905947_3416786_1_1">Adjustments for unrealised foreign exchange losses (gains)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US" id="id_13905947_3416786_2_1">Unrealized foreign exchange results</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AgencyBondMember" xlink:label="mrus_AgencyBondMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AgencyBondMember_lbl" xml:lang="en-US" id="id_13905947_3530660_3_1">Agency bond.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AgencyBondMember_lbl" xml:lang="en-US" id="id_13905947_3530660_1_1">Agency bond [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AgencyBondMember_lbl" xml:lang="en-US" id="id_13905947_3530660_2_1">Agency bond [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AgencyBondMember" xlink:to="mrus_AgencyBondMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AllOtherEmployeesMember" xlink:label="mrus_AllOtherEmployeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AllOtherEmployeesMember_lbl" xml:lang="en-US" id="id_13905947_3514206_3_1">All other employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AllOtherEmployeesMember_lbl" xml:lang="en-US" id="id_13905947_3514206_1_1">All other employees [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AllOtherEmployeesMember_lbl" xml:lang="en-US" id="id_13905947_3514206_2_1">All other employees [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AllOtherEmployeesMember" xlink:to="mrus_AllOtherEmployeesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_13905947_3416806_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_13905947_3416806_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AmountPaidForFullTimeEquivalentFunding" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding_lbl" xml:lang="en-US" id="id_13905947_3448891_3_1">Amount paid for full time equivalent funding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding_lbl" xml:lang="en-US" id="id_13905947_3448891_1_1">Amount Paid For Full Time Equivalent Funding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding_lbl" xml:lang="en-US" id="id_13905947_3448891_2_1">Paid for full time equivalent funding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AmountPaidForFullTimeEquivalentFunding" xlink:to="mrus_AmountPaidForFullTimeEquivalentFunding_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AmountPaidToCompensateForResearchServices" xlink:label="mrus_AmountPaidToCompensateForResearchServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AmountPaidToCompensateForResearchServices_lbl" xml:lang="en-US" id="id_13905947_3448892_3_1">Amount paid to compensate for research services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AmountPaidToCompensateForResearchServices_lbl" xml:lang="en-US" id="id_13905947_3448892_1_1">Amount Paid To Compensate For Research Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AmountPaidToCompensateForResearchServices_lbl" xml:lang="en-US" id="id_13905947_3448892_2_1">Compensate for research service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AmountPaidToCompensateForResearchServices" xlink:to="mrus_AmountPaidToCompensateForResearchServices_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" id="id_13905947_3417056_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" id="id_13905947_3417056_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AttorneysFees" xlink:label="mrus_AttorneysFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_AttorneysFees_lbl" xml:lang="en-US" id="id_13905947_3448861_3_1">Attorneys fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_AttorneysFees_lbl" xml:lang="en-US" id="id_13905947_3448861_1_1">Attorneys Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_AttorneysFees_lbl" xml:lang="en-US" id="id_13905947_3448861_2_1">Attorneys' fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_AttorneysFees" xlink:to="mrus_AttorneysFees_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xml:lang="en-US" id="id_13905947_3416664_1_1">Basic and diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xml:lang="en-US" id="id_13905947_3416664_2_1">Basic (and diluted) loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_Bonuses" xlink:label="mrus_Bonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_Bonuses_lbl" xml:lang="en-US" id="id_13905947_3463219_3_1">Bonuses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_Bonuses_lbl" xml:lang="en-US" id="id_13905947_3463219_1_1">Bonuses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_Bonuses_lbl" xml:lang="en-US" id="id_13905947_3463219_2_1">Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_Bonuses" xlink:to="mrus_Bonuses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" id="id_13905947_3416700_1_1">Bottom of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" id="id_13905947_3416700_2_1">Bottom of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency" xlink:label="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency_lbl" xml:lang="en-US" id="id_13905947_3464188_3_1">Cash and cash equivalent accounts and investment in foreign currency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency_lbl" xml:lang="en-US" id="id_13905947_3464188_1_1">Cash and cash equivalent accounts and investment in foreign currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency_lbl" xml:lang="en-US" id="id_13905947_3464188_2_1">Foreign currency denominated cash and cash equivalent accounts and investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency" xlink:to="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" id="id_13905947_3416724_1_1">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" id="id_13905947_3416724_4_1">Cash and cash equivalents as at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" id="id_13905947_3416724_5_1">Cash and cash equivalents as at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" id="id_13905947_3416724_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CashAndCashEquivalentsMaximumMaturityPeriod" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod_lbl" xml:lang="en-US" id="id_13905947_3472572_3_1">Cash And Cash Equivalents Maximum Maturity Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod_lbl" xml:lang="en-US" id="id_13905947_3472572_1_1">Cash And Cash Equivalents Maximum Maturity Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod_lbl" xml:lang="en-US" id="id_13905947_3472572_2_1">Cash and cash equivalents, maximum original maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CashAndCashEquivalentsMaximumMaturityPeriod" xlink:to="mrus_CashAndCashEquivalentsMaximumMaturityPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_13905947_3416913_1_1">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_13905947_3416913_6_1">Net cash from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3416914_1_1">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3416914_2_1">Cash flow from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3416731_1_1">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3416731_6_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3416732_1_1">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3416732_2_1">Cash flow from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_13905947_3416918_1_1">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_13905947_3416918_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3417363_1_1">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3417363_2_1">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US" id="id_13905947_3416734_1_1">Cash flows from (used in) operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US" id="id_13905947_3416734_6_1">Cash used in operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xml:lang="en-US" id="id_13905947_3417139_1_1">Cash flows from (used in) operations before changes in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xml:lang="en-US" id="id_13905947_3417139_6_1">Cash flows from (used in) operations before changes in working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" id="id_13905947_3416740_1_1">Categories of related parties [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" id="id_13905947_3416740_2_1">Categories of related parties [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangeInWorkingCapitalAbstract" xlink:label="mrus_ChangeInWorkingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ChangeInWorkingCapitalAbstract_lbl" xml:lang="en-US" id="id_13905947_3431003_3_1">Change in working capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ChangeInWorkingCapitalAbstract_lbl" xml:lang="en-US" id="id_13905947_3431003_1_1">Change in Working Capital [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ChangeInWorkingCapitalAbstract_lbl" xml:lang="en-US" id="id_13905947_3431003_2_1">Changes in working capital:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="mrus_ChangeInWorkingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangesInAccruedCapitalExpenditures" xlink:label="mrus_ChangesInAccruedCapitalExpenditures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ChangesInAccruedCapitalExpenditures_lbl" xml:lang="en-US" id="id_13905947_3464218_3_1">Changes in accrued capital expenditures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ChangesInAccruedCapitalExpenditures_lbl" xml:lang="en-US" id="id_13905947_3464218_1_1">Changes in accrued capital expenditures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ChangesInAccruedCapitalExpenditures_lbl" xml:lang="en-US" id="id_13905947_3464218_2_1">Changes in accrued capital expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ChangesInAccruedCapitalExpenditures" xlink:to="mrus_ChangesInAccruedCapitalExpenditures_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements_lbl" xml:lang="en-US" id="id_13905947_3449816_3_1">Changes in fair value of financial assets and liabilities and exchange movements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements_lbl" xml:lang="en-US" id="id_13905947_3449816_1_1">Changes in fair value of financial assets and liabilities and exchange movements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements_lbl" xml:lang="en-US" id="id_13905947_3449816_2_1">Change in fair value asset and discount on share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" xlink:to="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangesInRestrictedCash" xlink:label="mrus_ChangesInRestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ChangesInRestrictedCash_lbl" xml:lang="en-US" id="id_13905947_3449782_3_1">Changes in restricted cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ChangesInRestrictedCash_lbl" xml:lang="en-US" id="id_13905947_3449782_1_1">Changes in Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ChangesInRestrictedCash_lbl" xml:lang="en-US" id="id_13905947_3449782_2_1">Increase in restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ChangesInRestrictedCash" xlink:to="mrus_ChangesInRestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US" id="id_13905947_3417430_1_1">Classes of assets [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US" id="id_13905947_3417430_2_1">Classes of assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" id="id_13905947_3417431_1_1">Assets [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" id="id_13905947_3417431_2_1">Assets [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xml:lang="en-US" id="id_13905947_3416963_1_1">Classes of liabilities [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xml:lang="en-US" id="id_13905947_3416963_2_1">Classes of liabilities [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" id="id_13905947_3417439_1_1">Classes of share capital [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" id="id_13905947_3417439_2_1">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" id="id_13905947_3417180_1_1">Share capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" id="id_13905947_3417180_2_1">Share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ClinicalCosts" xlink:label="mrus_ClinicalCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ClinicalCosts_lbl" xml:lang="en-US" id="id_13905947_3449704_3_1">Clinical costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ClinicalCosts_lbl" xml:lang="en-US" id="id_13905947_3449704_1_1">Clinical costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ClinicalCosts_lbl" xml:lang="en-US" id="id_13905947_3449704_2_1">Clinical costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ClinicalCosts" xlink:to="mrus_ClinicalCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CollaborationIncomeMember" xlink:label="mrus_CollaborationIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CollaborationIncomeMember_lbl" xml:lang="en-US" id="id_13905947_3514218_3_1">Collaboration income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CollaborationIncomeMember_lbl" xml:lang="en-US" id="id_13905947_3514218_1_1">Collaboration income [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CollaborationIncomeMember_lbl" xml:lang="en-US" id="id_13905947_3514218_2_1">Collaboration income [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CollaborationIncomeMember" xlink:to="mrus_CollaborationIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CommercialPaper1Member" xlink:label="mrus_CommercialPaper1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CommercialPaper1Member_lbl" xml:lang="en-US" id="id_13905947_3479596_3_1">Commercial paper 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CommercialPaper1Member_lbl" xml:lang="en-US" id="id_13905947_3479596_1_1">Commercial Paper 1 [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CommercialPaper1Member_lbl" xml:lang="en-US" id="id_13905947_3479596_2_1">Commercial paper [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CommercialPaper1Member" xlink:to="mrus_CommercialPaper1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" id="id_13905947_3417632_1_1">Components of equity [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" id="id_13905947_3417632_2_1">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" id="id_13905947_3417449_1_1">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" id="id_13905947_3417449_2_1">Total comprehensive loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" id="id_13905947_3417449_6_1">Total comprehensive loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_13905947_3417454_1_1">Condensed Balance Sheet Statements, Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_13905947_3417454_2_1">Condensed Balance Sheet Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementTable" xlink:label="srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US" id="id_13905947_3417851_1_1">Condensed Balance Sheet Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US" id="id_13905947_3417851_2_1">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_13905947_3417455_1_1">Condensed Cash Flow Statements, Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_13905947_3417455_2_1">Condensed Cash Flow Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedCashFlowStatementTable_lbl" xml:lang="en-US" id="id_13905947_3417456_1_1">Condensed Cash Flow Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedCashFlowStatementTable_lbl" xml:lang="en-US" id="id_13905947_3417456_2_1">Condensed Cash Flow Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_13905947_3417640_1_1">Condensed Income Statements, Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xml:lang="en-US" id="id_13905947_3417640_2_1">Condensed Income Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementTable_lbl" xml:lang="en-US" id="id_13905947_3417457_1_1">Condensed Income Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CondensedIncomeStatementTable_lbl" xml:lang="en-US" id="id_13905947_3417457_2_1">Condensed Income Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ifrs-full_ContractAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContractAssets_lbl" xml:lang="en-US" id="id_13905947_3418083_1_1">Contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_ContractAssets_lbl" xml:lang="en-US" id="id_13905947_3418083_4_1">Contract assets, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_ContractAssets_lbl" xml:lang="en-US" id="id_13905947_3418083_5_1">Contract assets, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractAssets" xlink:to="ifrs-full_ContractAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" id="id_13905947_3417870_1_1">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" id="id_13905947_3417870_4_1">Contract liabilities, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" id="id_13905947_3417870_5_1">Contract liabilities, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ContractualLifeOfShareAwards" xlink:label="mrus_ContractualLifeOfShareAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ContractualLifeOfShareAwards_lbl" xml:lang="en-US" id="id_13905947_3471984_3_1">Contractual life of share awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ContractualLifeOfShareAwards_lbl" xml:lang="en-US" id="id_13905947_3471984_1_1">Contractual Life of Share Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ContractualLifeOfShareAwards_lbl" xml:lang="en-US" id="id_13905947_3471984_2_1">Contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ContractualLifeOfShareAwards" xlink:to="mrus_ContractualLifeOfShareAwards_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CorporateFixedIncomeBondsMember" xlink:label="mrus_CorporateFixedIncomeBondsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CorporateFixedIncomeBondsMember_lbl" xml:lang="en-US" id="id_13905947_3514284_3_1">Corporate fixed income bonds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CorporateFixedIncomeBondsMember_lbl" xml:lang="en-US" id="id_13905947_3514284_1_1">Corporate fixed income bonds [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CorporateFixedIncomeBondsMember_lbl" xml:lang="en-US" id="id_13905947_3514284_2_1">Corporate fixed income bonds [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CorporateFixedIncomeBondsMember" xlink:to="mrus_CorporateFixedIncomeBondsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" id="id_13905947_3417497_1_1">Current accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" id="id_13905947_3417497_2_1">Other liabilities and accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" id="id_13905947_3418106_1_1">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" id="id_13905947_3418106_6_1">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" id="id_13905947_3417498_1_1">Current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" id="id_13905947_3417498_2_1">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_13905947_3417907_1_1">Current held-to-maturity investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_13905947_3417907_2_1">Current investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_13905947_3417907_12_1">Investments, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentHeldtomaturityInvestments" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentInterestBank" xlink:label="mrus_CurrentInterestBank"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CurrentInterestBank_lbl" xml:lang="en-US" id="id_13905947_3449792_3_1">Current interest bank.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CurrentInterestBank_lbl" xml:lang="en-US" id="id_13905947_3449792_1_1">Current interest bank</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CurrentInterestBank_lbl" xml:lang="en-US" id="id_13905947_3449792_2_1">Interest bank</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CurrentInterestBank" xlink:to="mrus_CurrentInterestBank_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" id="id_13905947_3417514_1_1">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" id="id_13905947_3417514_6_1">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3417909_1_1">Current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3417909_2_1">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" id="id_13905947_3418120_1_1">Current payables on social security and taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" id="id_13905947_3418120_2_1">Taxes and social security liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentPrepaidGeneralExpenses" xlink:label="mrus_CurrentPrepaidGeneralExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CurrentPrepaidGeneralExpenses_lbl" xml:lang="en-US" id="id_13905947_3449796_3_1">Current prepaid general expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CurrentPrepaidGeneralExpenses_lbl" xml:lang="en-US" id="id_13905947_3449796_1_1">Current prepaid general expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CurrentPrepaidGeneralExpenses_lbl" xml:lang="en-US" id="id_13905947_3449796_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CurrentPrepaidGeneralExpenses" xlink:to="mrus_CurrentPrepaidGeneralExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentPrepaidPensionCosts" xlink:label="mrus_CurrentPrepaidPensionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CurrentPrepaidPensionCosts_lbl" xml:lang="en-US" id="id_13905947_3449790_3_1">Current prepaid pension costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CurrentPrepaidPensionCosts_lbl" xml:lang="en-US" id="id_13905947_3449790_1_1">Current prepaid pension costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CurrentPrepaidPensionCosts_lbl" xml:lang="en-US" id="id_13905947_3449790_2_1">Prepaid pension costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CurrentPrepaidPensionCosts" xlink:to="mrus_CurrentPrepaidPensionCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" id="id_13905947_3417919_1_1">Current trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" id="id_13905947_3417919_2_1">Trade receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentUnbilledReceivables" xlink:label="mrus_CurrentUnbilledReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_CurrentUnbilledReceivables_lbl" xml:lang="en-US" id="id_13905947_3464205_3_1">Current unbilled Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_CurrentUnbilledReceivables_lbl" xml:lang="en-US" id="id_13905947_3464205_1_1">Current unbilled Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_CurrentUnbilledReceivables_lbl" xml:lang="en-US" id="id_13905947_3464205_2_1">Unbilled receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_CurrentUnbilledReceivables" xlink:to="mrus_CurrentUnbilledReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables_lbl" xml:lang="en-US" id="id_13905947_3418132_1_1">Current value added tax receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables_lbl" xml:lang="en-US" id="id_13905947_3418132_2_1">VAT receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeductionsInContractAssets" xlink:label="mrus_DeductionsInContractAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DeductionsInContractAssets_lbl" xml:lang="en-US" id="id_13905947_3448899_3_1">Deductions in contract assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DeductionsInContractAssets_lbl" xml:lang="en-US" id="id_13905947_3448899_1_1">Deductions in contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_DeductionsInContractAssets_lbl" xml:lang="en-US" id="id_13905947_3448899_14_1">Contract assets, deductions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeductionsInContractAssets" xlink:to="mrus_DeductionsInContractAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeductionsInContractLiabilities" xlink:label="mrus_DeductionsInContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DeductionsInContractLiabilities_lbl" xml:lang="en-US" id="id_13905947_3448901_3_1">Deductions in contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DeductionsInContractLiabilities_lbl" xml:lang="en-US" id="id_13905947_3448901_1_1">Deductions in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_DeductionsInContractLiabilities_lbl" xml:lang="en-US" id="id_13905947_3448901_14_1">Contract liabilities, deductions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeductionsInContractLiabilities" xlink:to="mrus_DeductionsInContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeductionsInTradeAndOtherReceivables" xlink:label="mrus_DeductionsInTradeAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DeductionsInTradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3448896_3_1">Deductions in trade and other receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DeductionsInTradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3448896_1_1">Deductions in trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_DeductionsInTradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3448896_14_1">Trade and other receivables, deductions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeductionsInTradeAndOtherReceivables" xlink:to="mrus_DeductionsInTradeAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncome" xlink:label="ifrs-full_DeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredIncome_lbl" xml:lang="en-US" id="id_13905947_3417554_1_1">Deferred income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredIncome_lbl" xml:lang="en-US" id="id_13905947_3417554_2_1">Total deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_DeferredIncome_lbl" xml:lang="en-US" id="id_13905947_3417554_6_1">Total deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredIncome" xlink:to="ifrs-full_DeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US" id="id_13905947_3417757_1_1">Deferred income classified as current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US" id="id_13905947_3417757_2_1">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US" id="id_13905947_3417757_12_1">Deferred revenue - current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent_lbl" xml:lang="en-US" id="id_13905947_3417758_1_1">Deferred income classified as non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent_lbl" xml:lang="en-US" id="id_13905947_3417758_2_1">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent_lbl" xml:lang="en-US" id="id_13905947_3417758_12_1">Deferred revenue, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeferredRevenueMember" xlink:label="mrus_DeferredRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DeferredRevenueMember_lbl" xml:lang="en-US" id="id_13905947_3508994_3_1">Deferred revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DeferredRevenueMember_lbl" xml:lang="en-US" id="id_13905947_3508994_1_1">Deferred revenue [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DeferredRevenueMember_lbl" xml:lang="en-US" id="id_13905947_3508994_2_1">Deferred revenue [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DeferredRevenueMember" xlink:to="mrus_DeferredRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory_lbl" xml:lang="en-US" id="id_13905947_3517350_3_1">The description of entity's accounting policy on basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory_lbl" xml:lang="en-US" id="id_13905947_3517350_1_1">Description Of Accounting Policy For Basis Of Presentation [Text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory_lbl" xml:lang="en-US" id="id_13905947_3517350_2_1">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory" xlink:to="mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3518096_3_1">The description of the entity's accounting policy for cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3518096_1_1">Description of accounting policy for cash and cash equivalents explanatory [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3518096_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:to="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US" id="id_13905947_3417953_1_1">Description of accounting policy for foreign currency translation [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US" id="id_13905947_3417953_2_1">Foreign Currency Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory_lbl" xml:lang="en-US" id="id_13905947_3516271_3_1">Description of accounting policy for reclassification of prior years information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory_lbl" xml:lang="en-US" id="id_13905947_3516271_1_1">Description of accounting policy for reclassification of prior years information [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory_lbl" xml:lang="en-US" id="id_13905947_3516271_2_1">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory" xlink:to="mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US" id="id_13905947_3417965_1_1">Description of accounting policy for recognition of revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US" id="id_13905947_3417965_2_1">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfAccountingPolicyForSeasonality" xlink:label="mrus_DescriptionOfAccountingPolicyForSeasonality"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfAccountingPolicyForSeasonality_lbl" xml:lang="en-US" id="id_13905947_3521462_3_1">Description of accounting policy for seasonality</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfAccountingPolicyForSeasonality_lbl" xml:lang="en-US" id="id_13905947_3521462_1_1">Description of accounting policy for seasonality</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfAccountingPolicyForSeasonality_lbl" xml:lang="en-US" id="id_13905947_3521462_2_1">Seasonality</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfAccountingPolicyForSeasonality" xlink:to="mrus_DescriptionOfAccountingPolicyForSeasonality_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US" id="id_13905947_3417593_1_1">Description of accounting policy for segment reporting [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US" id="id_13905947_3417593_2_1">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3520956_3_1">The description of the entity's accounting policy for use of judgements and estimates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3520956_1_1">Description of accounting policy for use of judgements and estimates [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3520956_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory" xlink:to="mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US" id="id_13905947_3418231_1_1">Expected volatility, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US" id="id_13905947_3418231_2_1">Expected volatility (weighted-average)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfGrantAward" xlink:label="mrus_DescriptionOfGrantAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfGrantAward_lbl" xml:lang="en-US" id="id_13905947_3470882_3_1">Description of grant award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfGrantAward_lbl" xml:lang="en-US" id="id_13905947_3470882_1_1">Description of grant award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfGrantAward_lbl" xml:lang="en-US" id="id_13905947_3470882_2_1">Description of grant award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfGrantAward" xlink:to="mrus_DescriptionOfGrantAward_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfOptionLapse" xlink:label="mrus_DescriptionOfOptionLapse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfOptionLapse_lbl" xml:lang="en-US" id="id_13905947_3470861_3_1">Description of option lapse.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfOptionLapse_lbl" xml:lang="en-US" id="id_13905947_3470861_1_1">Description of option lapse</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfOptionLapse_lbl" xml:lang="en-US" id="id_13905947_3470861_2_1">Description of option lapse</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfOptionLapse" xlink:to="mrus_DescriptionOfOptionLapse_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfOptionsGranted" xlink:label="mrus_DescriptionOfOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DescriptionOfOptionsGranted_lbl" xml:lang="en-US" id="id_13905947_3470862_3_1">Description of options granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DescriptionOfOptionsGranted_lbl" xml:lang="en-US" id="id_13905947_3470862_1_1">Description of options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DescriptionOfOptionsGranted_lbl" xml:lang="en-US" id="id_13905947_3470862_2_1">Description of options vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DescriptionOfOptionsGranted" xlink:to="mrus_DescriptionOfOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US" id="id_13905947_3418349_1_1">Risk free interest rate, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US" id="id_13905947_3418349_2_1">Risk-free interest rate (based on government bonds)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419022_1_1">Disclosure of accounting judgements and estimates [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419022_2_1">Use of Estimates, Judgments and Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:label="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract_lbl" xml:lang="en-US" id="id_13905947_3429262_3_1">Disclosure of accruals and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract_lbl" xml:lang="en-US" id="id_13905947_3429262_1_1">Disclosure of accruals and other payables [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract_lbl" xml:lang="en-US" id="id_13905947_3429262_2_1">Disclosure of accruals and other payables [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" xlink:label="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock_lbl" xml:lang="en-US" id="id_13905947_3522345_3_1">Disclosure of accruals other liabilities explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock_lbl" xml:lang="en-US" id="id_13905947_3522345_1_1">Disclosure of accruals other liabilities explanatory [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock_lbl" xml:lang="en-US" id="id_13905947_3522345_2_1">Summary of Short-term and Payable Within 1 Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" xlink:to="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418585_1_1">Disclosure of accrued expenses and other liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418585_2_1">Other Liabilities and Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" xlink:label="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3521685_3_1">Disclosure of adoption of new international financial information regulations amendments and interpretations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3521685_1_1">Disclosure of adoption of new international financial information regulations amendments and interpretations explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3521685_2_1">Condensed Consolidated Statements of Financial Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" xlink:to="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl" xml:lang="en-US" id="id_13905947_3418392_1_1">Disclosure of changes in accounting estimates [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl" xml:lang="en-US" id="id_13905947_3418392_2_1">Disclosure of changes in accounting estimates [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl" xml:lang="en-US" id="id_13905947_3418811_1_1">Disclosure of changes in accounting estimates [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl" xml:lang="en-US" id="id_13905947_3418811_2_1">Disclosure of changes in accounting estimates [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418607_1_1">Disclosure of changes in accounting policies, accounting estimates and errors [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418607_2_1">Recently Issued International Financial Reporting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3431956_3_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3431956_1_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3431956_2_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_13905947_3431957_3_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_13905947_3431957_1_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems_lbl" xml:lang="en-US" id="id_13905947_3431957_2_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable_lbl" xml:lang="en-US" id="id_13905947_3473222_3_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable_lbl" xml:lang="en-US" id="id_13905947_3473222_1_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable_lbl" xml:lang="en-US" id="id_13905947_3473222_2_1">Disclosure of changes in trade receivables, contract assets and contract liabilities [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredIncomeAbstract" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract_lbl" xml:lang="en-US" id="id_13905947_3426261_3_1">Disclosure of deferred income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract_lbl" xml:lang="en-US" id="id_13905947_3426261_1_1">Disclosure of deferred income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract_lbl" xml:lang="en-US" id="id_13905947_3426261_2_1">Disclosure of deferred income [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDeferredIncomeAbstract" xlink:to="mrus_DisclosureOfDeferredIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfDeferredIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418404_1_1">Disclosure of deferred income [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418404_2_1">Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDeferredIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfDeferredIncomeExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredIncomeLineItems" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems_lbl" xml:lang="en-US" id="id_13905947_3426262_3_1">Disclosure of deferred income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems_lbl" xml:lang="en-US" id="id_13905947_3426262_1_1">Disclosure of deferred income [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems_lbl" xml:lang="en-US" id="id_13905947_3426262_2_1">Disclosure of deferred income [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_DisclosureOfDeferredIncomeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredIncomeTable" xlink:label="mrus_DisclosureOfDeferredIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDeferredIncomeTable_lbl" xml:lang="en-US" id="id_13905947_3474543_3_1">Disclosure of deferred income [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDeferredIncomeTable_lbl" xml:lang="en-US" id="id_13905947_3474543_1_1">Disclosure of deferred income [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDeferredIncomeTable_lbl" xml:lang="en-US" id="id_13905947_3474543_2_1">Disclosure of deferred income [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="mrus_DisclosureOfDeferredIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredRevenueExplanatory" xlink:label="mrus_DisclosureOfDeferredRevenueExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDeferredRevenueExplanatory_lbl" xml:lang="en-US" id="id_13905947_3520728_3_1">The disclosure of deferred revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDeferredRevenueExplanatory_lbl" xml:lang="en-US" id="id_13905947_3520728_1_1">Disclosure of deferred revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDeferredRevenueExplanatory_lbl" xml:lang="en-US" id="id_13905947_3520728_2_1">Summary of Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDeferredRevenueExplanatory" xlink:to="mrus_DisclosureOfDeferredRevenueExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3519231_3_1">The disclosure of detailed information about employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3519231_1_1">Disclosure of detailed information about employee benefits [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3519231_2_1">Disclosure of Detailed Information About Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" xlink:to="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3516801_3_1">Share based payment arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3516801_1_1">Disclosure of Detailed Information about Share Based Payment Arrangements Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3516801_2_1">Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xlink:to="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" id="id_13905947_3521052_3_1">Disclosure of detailed information of research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" id="id_13905947_3521052_1_1">Disclosure of detailed information of research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" id="id_13905947_3521052_2_1">Breakdown of Other Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" xlink:to="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3522346_3_1">Disclosure of detailed information related to operating expenses explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3522346_1_1">Disclosure of detailed information related to operating expenses explanatory [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3522346_2_1">Summary of Total Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" xlink:to="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfEmployeeBenefitsAbstract" xlink:label="mrus_DisclosureOfEmployeeBenefitsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfEmployeeBenefitsAbstract_lbl" xml:lang="en-US" id="id_13905947_3430319_3_1">Disclosure of employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfEmployeeBenefitsAbstract_lbl" xml:lang="en-US" id="id_13905947_3430319_1_1">Disclosure of employee benefits [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfEmployeeBenefitsAbstract_lbl" xml:lang="en-US" id="id_13905947_3430319_2_1">Disclosure of employee benefits [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfEmployeeBenefitsAbstract" xlink:to="mrus_DisclosureOfEmployeeBenefitsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418423_1_1">Disclosure of employee benefits [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418423_2_1">Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems_lbl" xml:lang="en-US" id="id_13905947_3429102_3_1">Line items represent concepts included in a table. Disclosure of employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems_lbl" xml:lang="en-US" id="id_13905947_3429102_1_1">Disclosure of employee benefits [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems_lbl" xml:lang="en-US" id="id_13905947_3429102_2_1">Disclosure of employee benefits [line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:to="mrus_DisclosureOfEmployeeBenefitsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfEmployeeBenefitsTable" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable_lbl" xml:lang="en-US" id="id_13905947_3474064_3_1">Schedule disclosing of employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable_lbl" xml:lang="en-US" id="id_13905947_3474064_1_1">Disclosure of employee benefits [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable_lbl" xml:lang="en-US" id="id_13905947_3474064_2_1">Disclosure of employee benefits [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_DisclosureOfEmployeeBenefitsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418842_1_1">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418842_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419075_1_1">Disclosure of finance income (cost) [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419075_2_1">Summary of Finance Income and Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureoffinancialinformationAbstract" xlink:label="mrus_DisclosureoffinancialinformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureoffinancialinformationAbstract_lbl" xml:lang="en-US" id="id_13905947_3431928_3_1">Disclosure of financial information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureoffinancialinformationAbstract_lbl" xml:lang="en-US" id="id_13905947_3431928_1_1">DisclosureOfFinancialInformation [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureoffinancialinformationAbstract_lbl" xml:lang="en-US" id="id_13905947_3431928_2_1">DisclosureOfFinancialInformation [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureoffinancialinformationAbstract" xlink:to="mrus_DisclosureoffinancialinformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418445_1_1">Disclosure of general information about financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418445_2_1">General information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfGeneralInformationAbstract" xlink:label="mrus_DisclosureOfGeneralInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfGeneralInformationAbstract_lbl" xml:lang="en-US" id="id_13905947_3426958_3_1">Disclosure of general information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfGeneralInformationAbstract_lbl" xml:lang="en-US" id="id_13905947_3426958_1_1">Disclosure of general information [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfGeneralInformationAbstract_lbl" xml:lang="en-US" id="id_13905947_3426958_2_1">Disclosure of general information [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfGeneralInformationAbstract" xlink:to="mrus_DisclosureOfGeneralInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfHeldToMaturityInvestmentExplanatory" xlink:label="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory_lbl" xml:lang="en-US" id="id_13905947_3515435_3_1">Disclosure of held to maturity investment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory_lbl" xml:lang="en-US" id="id_13905947_3515435_1_1">Disclosure of Held to Maturity Investment [Text Bock]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory_lbl" xml:lang="en-US" id="id_13905947_3515435_2_1">Summary of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory" xlink:to="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418679_1_1">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418679_2_1">Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfInformationAboutRevenueExplanatory" xlink:label="mrus_DisclosureOfInformationAboutRevenueExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfInformationAboutRevenueExplanatory_lbl" xml:lang="en-US" id="id_13905947_3519386_3_1">The disclosure of information about revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfInformationAboutRevenueExplanatory_lbl" xml:lang="en-US" id="id_13905947_3519386_1_1">Disclosure of detailed information about revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfInformationAboutRevenueExplanatory_lbl" xml:lang="en-US" id="id_13905947_3519386_2_1">Summary of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfInformationAboutRevenueExplanatory" xlink:to="mrus_DisclosureOfInformationAboutRevenueExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418717_1_1">Disclosure of interest income (expense) [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418717_2_1">Finance Income and Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418476_1_1">Disclosure of investments other than investments accounted for using equity method [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418476_2_1">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:to="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418918_1_1">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3418918_2_1">Summary of Reconciliation of Outstanding Share Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" xlink:label="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3520275_3_1">The disclosure of the number and weighted average exercise prices of share other than options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3520275_1_1">Disclosure of number and weighted average exercise prices of share other than options [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3520275_2_1">Summary of Reconciliation of RSU's</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" xlink:to="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfOperatingExpensesAbstract" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_13905947_3431344_3_1">Disclosure Of Operating Expenses [abstract].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_13905947_3431344_1_1">Disclosure Of Operating Expenses [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_13905947_3431344_2_1">Disclosure of operating expenses [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_DisclosureOfOperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfOperatingExpensesExplanatory" xlink:label="mrus_DisclosureOfOperatingExpensesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3515484_3_1">The disclosure of information about operating expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3515484_1_1">Disclosure of Operating Expenses Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOperatingExpensesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3515484_2_1">Total Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOperatingExpensesExplanatory" xlink:to="mrus_DisclosureOfOperatingExpensesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfOperatingLeaseAbstract" xlink:label="mrus_DisclosureOfOperatingLeaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOperatingLeaseAbstract_lbl" xml:lang="en-US" id="id_13905947_3430079_3_1">Disclosure of operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOperatingLeaseAbstract_lbl" xml:lang="en-US" id="id_13905947_3430079_1_1">Disclosure of operating lease [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOperatingLeaseAbstract_lbl" xml:lang="en-US" id="id_13905947_3430079_2_1">Disclosure of operating lease [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOperatingLeaseAbstract" xlink:to="mrus_DisclosureOfOperatingLeaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfOperatingLeaseExplanatory" xlink:label="mrus_DisclosureOfOperatingLeaseExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfOperatingLeaseExplanatory_lbl" xml:lang="en-US" id="id_13905947_3515705_3_1">The entire disclosure of operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfOperatingLeaseExplanatory_lbl" xml:lang="en-US" id="id_13905947_3515705_1_1">Disclosure of Operating Lease Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfOperatingLeaseExplanatory_lbl" xml:lang="en-US" id="id_13905947_3515705_2_1">Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfOperatingLeaseExplanatory" xlink:to="mrus_DisclosureOfOperatingLeaseExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfRecentlyIssuedIfrsAbstract" xlink:label="mrus_DisclosureOfRecentlyIssuedIfrsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfRecentlyIssuedIfrsAbstract_lbl" xml:lang="en-US" id="id_13905947_3431953_3_1">Disclosure of recently issued ifrs [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfRecentlyIssuedIfrsAbstract_lbl" xml:lang="en-US" id="id_13905947_3431953_1_1">Disclosure of recently issued ifrs [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfRecentlyIssuedIfrsAbstract_lbl" xml:lang="en-US" id="id_13905947_3431953_2_1">Disclosure of recently issued ifrs [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfRecentlyIssuedIfrsAbstract" xlink:to="mrus_DisclosureOfRecentlyIssuedIfrsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419207_1_1">Disclosure of revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419207_2_1">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419857_1_1">Disclosure of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419857_2_1">Summary of Changes in Tarde Receivables, Contract Assets and Contract Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419461_1_1">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419461_2_1">Shareholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems_lbl" xml:lang="en-US" id="id_13905947_3429482_3_1">Disclosure Of Share Of Equity Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems_lbl" xml:lang="en-US" id="id_13905947_3429482_1_1">Disclosure Of Share Of Equity Investment [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems_lbl" xml:lang="en-US" id="id_13905947_3429482_2_1">Disclosure Of Share Of Equity Investment [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:to="mrus_DisclosureOfShareOfEquityInvestmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_13905947_3427823_3_1">Disclosure of significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_13905947_3427823_1_1">Disclosure of significant accounting policies [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_13905947_3427823_2_1">Disclosure of significant accounting policies [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="mrus_DisclosureOfSignificantAccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419471_1_1">Disclosure of significant accounting policies [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419471_2_1">Significant accounting policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" id="id_13905947_3419472_1_1">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" id="id_13905947_3419472_2_1">Disclosure of terms and conditions of share-based payment arrangement [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419640_1_1">Disclosure of terms and conditions of share-based payment arrangement [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419640_2_1">Summary of Number of Share Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" id="id_13905947_3419219_1_1">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" id="id_13905947_3419219_2_1">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" id="id_13905947_3419473_1_1">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" id="id_13905947_3419473_2_1">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory" xlink:label="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory_lbl" xml:lang="en-US" id="id_13905947_3518387_3_1">Disclosure of trade and other current receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory_lbl" xml:lang="en-US" id="id_13905947_3518387_1_1">Disclosure of trade and other current receivable [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory_lbl" xml:lang="en-US" id="id_13905947_3518387_2_1">Summary of Trade and Other Receivables Due Within 1 Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory" xlink:to="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419641_1_1">Disclosure of trade and other receivables [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US" id="id_13905947_3419641_2_1">Trade and Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_lbl" xml:lang="en-US" id="id_13905947_3419482_1_1">Disclosure of voluntary change in accounting policy [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_lbl" xml:lang="en-US" id="id_13905947_3419482_2_1">Disclosure of voluntary change in accounting policy [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DiscoveryAndPreclinicalCosts" xlink:label="mrus_DiscoveryAndPreclinicalCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DiscoveryAndPreclinicalCosts_lbl" xml:lang="en-US" id="id_13905947_3449706_3_1">Discovery and pre-clinical costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DiscoveryAndPreclinicalCosts_lbl" xml:lang="en-US" id="id_13905947_3449706_1_1">Discovery and pre-clinical costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DiscoveryAndPreclinicalCosts_lbl" xml:lang="en-US" id="id_13905947_3449706_2_1">Discovery and pre-clinicalcosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DiscoveryAndPreclinicalCosts" xlink:to="mrus_DiscoveryAndPreclinicalCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DocumentandEntityInformationAbstract" xlink:label="mrus_DocumentandEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_DocumentandEntityInformationAbstract_lbl" xml:lang="en-US" id="id_13905947_3536817_3_1">Document - Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_DocumentandEntityInformationAbstract_lbl" xml:lang="en-US" id="id_13905947_3536817_1_1">Document - Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_DocumentandEntityInformationAbstract_lbl" xml:lang="en-US" id="id_13905947_3536817_2_1">Document - Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_DocumentandEntityInformationAbstract" xlink:to="mrus_DocumentandEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_13905947_3419242_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_13905947_3419242_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_13905947_3419909_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_13905947_3419909_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_13905947_3419690_1_1">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_13905947_3419690_2_1">Effects of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_EmployeeOptionExercisedPricePerShare" xlink:label="mrus_EmployeeOptionExercisedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_EmployeeOptionExercisedPricePerShare_lbl" xml:lang="en-US" id="id_13905947_3522464_3_1">Employee option exercised price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_EmployeeOptionExercisedPricePerShare_lbl" xml:lang="en-US" id="id_13905947_3522464_1_1">Employee option exercised price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_EmployeeOptionExercisedPricePerShare_lbl" xml:lang="en-US" id="id_13905947_3522464_2_1">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_EmployeeOptionExercisedPricePerShare" xlink:to="mrus_EmployeeOptionExercisedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_13905947_3419937_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_13905947_3419937_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="id_13905947_3419279_1_1">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="id_13905947_3419279_2_1">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" id="id_13905947_3419280_1_1">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" id="id_13905947_3419280_2_1">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_13905947_3419722_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_13905947_3419722_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" id="id_13905947_3419733_1_1">Entity's total for related parties [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" id="id_13905947_3419733_2_1">Entity's total for related parties [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" id="id_13905947_3419957_1_1">Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" id="id_13905947_3419957_4_1">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" id="id_13905947_3419957_5_1">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" id="id_13905947_3419957_6_1">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" id="id_13905947_3419541_1_1">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" id="id_13905947_3419541_2_1">Shareholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" id="id_13905947_3419542_1_1">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" id="id_13905947_3419542_6_1">Total equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" id="id_13905947_3419740_1_1">Equity [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" id="id_13905947_3419740_2_1">Equity [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_EstimatedContractualTerm" xlink:label="mrus_EstimatedContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_EstimatedContractualTerm_lbl" xml:lang="en-US" id="id_13905947_3471983_3_1">Estimated contractual term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_EstimatedContractualTerm_lbl" xml:lang="en-US" id="id_13905947_3471983_1_1">Estimated contractual term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_EstimatedContractualTerm_lbl" xml:lang="en-US" id="id_13905947_3471983_2_1">Estimated contractual term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_EstimatedContractualTerm" xlink:to="mrus_EstimatedContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US" id="id_13905947_3419755_1_1">Expected dividend as percentage, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US" id="id_13905947_3419755_2_1">Expected dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" id="id_13905947_3419569_1_1">Expense from share-based payment transactions with employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" id="id_13905947_3419569_2_1">Share award expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FairValueAssumptionsGrantDateSharePrice" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice_lbl" xml:lang="en-US" id="id_13905947_3522564_3_1">Fair value assumptions grant date share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice_lbl" xml:lang="en-US" id="id_13905947_3522564_1_1">Fair Value Assumptions Grant Date Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice_lbl" xml:lang="en-US" id="id_13905947_3522564_2_1">Fair value at grant date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FairValueAssumptionsGrantDateSharePrice" xlink:to="mrus_FairValueAssumptionsGrantDateSharePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FairValueOfDerivatives" xlink:label="mrus_FairValueOfDerivatives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_FairValueOfDerivatives_lbl" xml:lang="en-US" id="id_13905947_3442401_3_1">Fair value of derivatives.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_FairValueOfDerivatives_lbl" xml:lang="en-US" id="id_13905947_3442401_1_1">Fair Value Of Derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_FairValueOfDerivatives_lbl" xml:lang="en-US" id="id_13905947_3442401_2_1">Fair value of derivatives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FairValueOfDerivatives" xlink:to="mrus_FairValueOfDerivatives_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" id="id_13905947_3419392_1_1">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" id="id_13905947_3419392_14_1">Finance cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" id="id_13905947_3419392_19_1">Finance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" id="id_13905947_3419831_1_1">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" id="id_13905947_3419831_2_1">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" id="id_13905947_3419831_6_1">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" id="id_13905947_3420286_1_1">Finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" id="id_13905947_3420286_6_1">Net finance income / (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FinanceIncomeExpenseLineItems" xlink:label="mrus_FinanceIncomeExpenseLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_FinanceIncomeExpenseLineItems_lbl" xml:lang="en-US" id="id_13905947_3431418_3_1">Finance Income Expense [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_FinanceIncomeExpenseLineItems_lbl" xml:lang="en-US" id="id_13905947_3431418_1_1">Finance Income Expense [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_FinanceIncomeExpenseLineItems_lbl" xml:lang="en-US" id="id_13905947_3431418_2_1">Finance Income Expense [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FinanceIncomeExpenseLineItems" xlink:to="mrus_FinanceIncomeExpenseLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FinanceIncomeExpenseTable" xlink:label="mrus_FinanceIncomeExpenseTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_FinanceIncomeExpenseTable_lbl" xml:lang="en-US" id="id_13905947_3475407_3_1">Finance Income Expense [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_FinanceIncomeExpenseTable_lbl" xml:lang="en-US" id="id_13905947_3475407_1_1">Finance Income Expense [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_FinanceIncomeExpenseTable_lbl" xml:lang="en-US" id="id_13905947_3475407_2_1">Finance Income Expense [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_FinanceIncomeExpenseTable" xlink:to="mrus_FinanceIncomeExpenseTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="ifrs-full_FinancialAssetsTypeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsTypeMember_lbl" xml:lang="en-US" id="id_13905947_3420716_1_1">Financial assets, type [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssetsTypeMember_lbl" xml:lang="en-US" id="id_13905947_3420716_2_1">Financial assets, type [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="ifrs-full_FinancialAssetsTypeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US" id="id_13905947_3420553_1_1">Foreign exchange gain (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US" id="id_13905947_3420553_2_1">Foreign currency translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US" id="id_13905947_3420553_12_1">Foreign exchange gain 9loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_13905947_3420155_1_1">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_13905947_3420155_2_1">Management and administration costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_13905947_3420155_14_1">Management and administration costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" id="id_13905947_3420782_1_1">Geographical areas [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" id="id_13905947_3420782_2_1">Geographical areas [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" id="id_13905947_3420376_1_1">Geographical areas [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" id="id_13905947_3420376_2_1">Geographical areas [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_GrantIncome" xlink:label="mrus_GrantIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_GrantIncome_lbl" xml:lang="en-US" id="id_13905947_3453221_3_1">Grant income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_GrantIncome_lbl" xml:lang="en-US" id="id_13905947_3453221_1_1">Grant income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_GrantIncome_lbl" xml:lang="en-US" id="id_13905947_3453221_2_1">Grant income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_GrantIncome" xlink:to="mrus_GrantIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_HealthInsurance" xlink:label="mrus_HealthInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_HealthInsurance_lbl" xml:lang="en-US" id="id_13905947_3457644_3_1">Health insurance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_HealthInsurance_lbl" xml:lang="en-US" id="id_13905947_3457644_1_1">Health insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_HealthInsurance_lbl" xml:lang="en-US" id="id_13905947_3457644_2_1">Health insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_HealthInsurance" xlink:to="mrus_HealthInsurance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_HeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_13905947_3420816_1_1">Held-to-maturity investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_HeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_13905947_3420816_2_1">Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_HeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_13905947_3420816_6_1">Total investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HeldtomaturityInvestments" xlink:to="ifrs-full_HeldtomaturityInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IFRS15RevenueFromContractsWithCustomersMember" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_13905947_3508886_3_1">IFRS 15 revenue from contracts with customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_13905947_3508886_1_1">IFRS 15 revenue from contracts with customers [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_13905947_3508886_2_1">IFRS 15 revenue from contracts with customers [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IFRS15RevenueFromContractsWithCustomersMember" xlink:to="mrus_IFRS15RevenueFromContractsWithCustomersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeMember" xlink:label="mrus_IncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncomeMember_lbl" xml:lang="en-US" id="id_13905947_3509602_3_1">Income [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncomeMember_lbl" xml:lang="en-US" id="id_13905947_3509602_1_1">Income [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncomeMember_lbl" xml:lang="en-US" id="id_13905947_3509602_2_1">Income from grants on research projects [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncomeMember" xlink:to="mrus_IncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncomeStatementLineItemLocationAxis_lbl" xml:lang="en-US" id="id_13905947_3475752_3_1">Income statement line item location.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncomeStatementLineItemLocationAxis_lbl" xml:lang="en-US" id="id_13905947_3475752_1_1">Income statement line item location [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncomeStatementLineItemLocationAxis_lbl" xml:lang="en-US" id="id_13905947_3475752_2_1">Income statement line item location [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncomeStatementLineItemLocationMember_lbl" xml:lang="en-US" id="id_13905947_3512505_3_1">Income statement line item location [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncomeStatementLineItemLocationMember_lbl" xml:lang="en-US" id="id_13905947_3512505_1_1">Income statement line item location [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncomeStatementLineItemLocationMember_lbl" xml:lang="en-US" id="id_13905947_3512505_2_1">Income statement line item location [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_IncomeStatementLineItemLocationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="id_13905947_3420215_1_1">Income taxes paid (refund), classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="id_13905947_3420215_14_1">Taxes paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" id="id_13905947_3420859_1_1">Tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" id="id_13905947_3420859_2_1">Income tax expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" id="id_13905947_3420859_14_1">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xml:lang="en-US" id="id_13905947_3420637_1_1">Increase (decrease) due to application of IFRS 15 [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xml:lang="en-US" id="id_13905947_3420637_2_1">Increase (decrease) due to application of IFRS 15 [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInCapital" xlink:label="mrus_IncreaseDecreaseInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncreaseDecreaseInCapital_lbl" xml:lang="en-US" id="id_13905947_3433500_3_1">Increase decrease in capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncreaseDecreaseInCapital_lbl" xml:lang="en-US" id="id_13905947_3433500_1_1">Increase Decrease In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncreaseDecreaseInCapital_lbl" xml:lang="en-US" id="id_13905947_3433500_2_1">Increased capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncreaseDecreaseInCapital" xlink:to="mrus_IncreaseDecreaseInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_13905947_3420226_1_1">Increase (decrease) in cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_13905947_3420226_2_1">Increase in cash, cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" id="id_13905947_3420461_1_1">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" id="id_13905947_3420461_6_1">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInDeferredRevenue1" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1_lbl" xml:lang="en-US" id="id_13905947_3439577_3_1">Increase decrease in deferred revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1_lbl" xml:lang="en-US" id="id_13905947_3439577_1_1">Increase Decrease In Deferred Revenue1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1_lbl" xml:lang="en-US" id="id_13905947_3439577_2_1">Decrease in Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncreaseDecreaseInDeferredRevenue1" xlink:to="mrus_IncreaseDecreaseInDeferredRevenue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US" id="id_13905947_3420475_1_1">Increase (decrease) in number of ordinary shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xml:lang="en-US" id="id_13905947_3420475_2_1">Common shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInSharePremium" xlink:label="mrus_IncreaseDecreaseInSharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncreaseDecreaseInSharePremium_lbl" xml:lang="en-US" id="id_13905947_3459093_3_1">Increase decrease in share premium.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncreaseDecreaseInSharePremium_lbl" xml:lang="en-US" id="id_13905947_3459093_1_1">Increase Decrease In Share Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncreaseDecreaseInSharePremium_lbl" xml:lang="en-US" id="id_13905947_3459093_2_1">Increased premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncreaseDecreaseInSharePremium" xlink:to="mrus_IncreaseDecreaseInSharePremium_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" id="id_13905947_3420273_1_1">Increase (decrease) through share-based payment transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" id="id_13905947_3420273_2_1">Equity settled shared-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity_lbl" xml:lang="en-US" id="id_13905947_3447314_3_1">Increase through contributions by and distributions to owners, equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity_lbl" xml:lang="en-US" id="id_13905947_3447314_1_1">Increase through contributions by and distributions to owners, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity_lbl" xml:lang="en-US" id="id_13905947_3447314_6_1">Total contributions by owners</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:to="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncyteCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_13905947_3486516_3_1">Incyte collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncyteCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_13905947_3486516_1_1">Incyte collaboration agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncyteCollaborationAgreementMember_lbl" xml:lang="en-US" id="id_13905947_3486516_2_1">Incyte collaboration agreement [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncyteCollaborationAgreementMember" xlink:to="mrus_IncyteCollaborationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncyteCorporationMember_lbl" xml:lang="en-US" id="id_13905947_3486468_3_1">Incyte Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncyteCorporationMember_lbl" xml:lang="en-US" id="id_13905947_3486468_1_1">Incyte Corporation [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncyteCorporationMember_lbl" xml:lang="en-US" id="id_13905947_3486468_2_1">Incyte Corporation [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncyteCorporationMember" xlink:to="mrus_IncyteCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteProprietaryTechnologyMember" xlink:label="mrus_IncyteProprietaryTechnologyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IncyteProprietaryTechnologyMember_lbl" xml:lang="en-US" id="id_13905947_3496065_3_1">Incyte proprietary technology [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IncyteProprietaryTechnologyMember_lbl" xml:lang="en-US" id="id_13905947_3496065_1_1">Incyte proprietary technology [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IncyteProprietaryTechnologyMember_lbl" xml:lang="en-US" id="id_13905947_3496065_2_1">Incyte proprietary technology [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IncyteProprietaryTechnologyMember" xlink:to="mrus_IncyteProprietaryTechnologyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US" id="id_13905947_3421839_1_1">Intangible assets and goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US" id="id_13905947_3421839_2_1">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_InterestAndRelatedIncome" xlink:label="mrus_InterestAndRelatedIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_InterestAndRelatedIncome_lbl" xml:lang="en-US" id="id_13905947_3464165_3_1">Interest and related income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_InterestAndRelatedIncome_lbl" xml:lang="en-US" id="id_13905947_3464165_1_1">Interest and related income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_InterestAndRelatedIncome_lbl" xml:lang="en-US" id="id_13905947_3464165_2_1">Interest income and similar income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_InterestAndRelatedIncome" xlink:to="mrus_InterestAndRelatedIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpense_lbl" xml:lang="en-US" id="id_13905947_3421376_1_1">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpense_lbl" xml:lang="en-US" id="id_13905947_3421376_14_1">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="id_13905947_3421854_1_1">Interest paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" id="id_13905947_3421854_14_1">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3421388_1_1">Interest received, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3421388_2_1">Interest received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="invest_InvestmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentLineItems_lbl" xml:lang="en-US" id="id_13905947_3421231_1_1">Investment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="invest_InvestmentLineItems_lbl" xml:lang="en-US" id="id_13905947_3421231_2_1">Investment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentLineItems" xlink:to="invest_InvestmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentsScheduleAbstract" xlink:label="invest_InvestmentsScheduleAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentsScheduleAbstract_lbl" xml:lang="en-US" id="id_13905947_3421884_1_1">Investments Schedule [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="invest_InvestmentsScheduleAbstract_lbl" xml:lang="en-US" id="id_13905947_3421884_2_1">Investments Schedule [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentsScheduleAbstract" xlink:to="invest_InvestmentsScheduleAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="invest_InvestmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="invest_InvestmentTable_lbl" xml:lang="en-US" id="id_13905947_3421417_1_1">Investment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="invest_InvestmentTable_lbl" xml:lang="en-US" id="id_13905947_3421417_2_1">Investment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="invest_InvestmentTable" xlink:to="invest_InvestmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IPAndLicenseCosts" xlink:label="mrus_IPAndLicenseCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_IPAndLicenseCosts_lbl" xml:lang="en-US" id="id_13905947_3530329_3_1">I p and license costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_IPAndLicenseCosts_lbl" xml:lang="en-US" id="id_13905947_3530329_1_1">I p and license costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_IPAndLicenseCosts_lbl" xml:lang="en-US" id="id_13905947_3530329_2_1">IP and license costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_IPAndLicenseCosts" xlink:to="mrus_IPAndLicenseCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" id="id_13905947_3421012_1_1">Issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" id="id_13905947_3421012_2_1">Issued and paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" id="id_13905947_3421013_1_1">Issued capital [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" id="id_13905947_3421013_2_1">Issued capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" id="id_13905947_3421895_1_1">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" id="id_13905947_3421895_2_1">Issuance of shares (net)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US" id="id_13905947_3421023_1_1">Key management personnel of entity or parent [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US" id="id_13905947_3421023_2_1">Key management personnel [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_LeasesExpirationPeriod" xlink:label="mrus_LeasesExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LeasesExpirationPeriod_lbl" xml:lang="en-US" id="id_13905947_3472053_3_1">Leases expiration period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LeasesExpirationPeriod_lbl" xml:lang="en-US" id="id_13905947_3472053_1_1">Leases Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LeasesExpirationPeriod_lbl" xml:lang="en-US" id="id_13905947_3472053_2_1">Leases expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LeasesExpirationPeriod" xlink:to="mrus_LeasesExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" id="id_13905947_3421936_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" id="id_13905947_3421936_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesMember_lbl" xml:lang="en-US" id="id_13905947_3421050_1_1">Liabilities [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesMember_lbl" xml:lang="en-US" id="id_13905947_3421050_2_1">Liabilities [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_LiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_LitigationAndOppositionExpenses" xlink:label="mrus_LitigationAndOppositionExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LitigationAndOppositionExpenses_lbl" xml:lang="en-US" id="id_13905947_3449740_3_1">Litigation and opposition expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LitigationAndOppositionExpenses_lbl" xml:lang="en-US" id="id_13905947_3449740_1_1">Litigation and opposition expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LitigationAndOppositionExpenses_lbl" xml:lang="en-US" id="id_13905947_3449740_2_1">Litigation and opposition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LitigationAndOppositionExpenses" xlink:to="mrus_LitigationAndOppositionExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_LitigationCosts" xlink:label="mrus_LitigationCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LitigationCosts_lbl" xml:lang="en-US" id="id_13905947_3463229_3_1">Litigation costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LitigationCosts_lbl" xml:lang="en-US" id="id_13905947_3463229_1_1">Litigation costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LitigationCosts_lbl" xml:lang="en-US" id="id_13905947_3463229_2_1">Litigation costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LitigationCosts" xlink:to="mrus_LitigationCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_LitigationExpenses" xlink:label="mrus_LitigationExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_LitigationExpenses_lbl" xml:lang="en-US" id="id_13905947_3467612_3_1">Litigation expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_LitigationExpenses_lbl" xml:lang="en-US" id="id_13905947_3467612_1_1">Litigation Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_LitigationExpenses_lbl" xml:lang="en-US" id="id_13905947_3467612_2_1">Litigation expenses and costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_LitigationExpenses" xlink:to="mrus_LitigationExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ManagementAndAdministrationCostsMember" xlink:label="mrus_ManagementAndAdministrationCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ManagementAndAdministrationCostsMember_lbl" xml:lang="en-US" id="id_13905947_3514214_3_1">Management and administration costs [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ManagementAndAdministrationCostsMember_lbl" xml:lang="en-US" id="id_13905947_3514214_1_1">Management and administration costs [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ManagementAndAdministrationCostsMember_lbl" xml:lang="en-US" id="id_13905947_3514214_2_1">Management and administration costs [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ManagementAndAdministrationCostsMember" xlink:to="mrus_ManagementAndAdministrationCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ManufacturingCost" xlink:label="mrus_ManufacturingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ManufacturingCost_lbl" xml:lang="en-US" id="id_13905947_3463230_3_1">Manufacturing cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ManufacturingCost_lbl" xml:lang="en-US" id="id_13905947_3463230_1_1">Manufacturing cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ManufacturingCost_lbl" xml:lang="en-US" id="id_13905947_3463230_2_1">Manufacturing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ManufacturingCost" xlink:to="mrus_ManufacturingCost_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_MilestoneRevenues" xlink:label="mrus_MilestoneRevenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_MilestoneRevenues_lbl" xml:lang="en-US" id="id_13905947_3433995_3_1">Milestone revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_MilestoneRevenues_lbl" xml:lang="en-US" id="id_13905947_3433995_1_1">Milestone revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_MilestoneRevenues_lbl" xml:lang="en-US" id="id_13905947_3433995_2_1">Milestone revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MilestoneRevenues" xlink:to="mrus_MilestoneRevenues_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_MilestoneRevenuesAndCostsReimbursements" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements_lbl" xml:lang="en-US" id="id_13905947_3434018_3_1">Milestone revenues and costs reimbursements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements_lbl" xml:lang="en-US" id="id_13905947_3434018_1_1">Milestone Revenues And Costs Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements_lbl" xml:lang="en-US" id="id_13905947_3434018_2_1">Cost reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_MilestoneRevenuesAndCostsReimbursements_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NetFinanceIncomeExpenseMember" xlink:label="mrus_NetFinanceIncomeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NetFinanceIncomeExpenseMember_lbl" xml:lang="en-US" id="id_13905947_3486700_3_1">Net finance income expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NetFinanceIncomeExpenseMember_lbl" xml:lang="en-US" id="id_13905947_3486700_1_1">Net Finance Income Expense [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NetFinanceIncomeExpenseMember_lbl" xml:lang="en-US" id="id_13905947_3486700_2_1">Finance Income Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NetFinanceIncomeExpenseMember" xlink:to="mrus_NetFinanceIncomeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US" id="id_13905947_3422463_1_1">Net foreign exchange gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US" id="id_13905947_3422463_2_1">Foreign currency exchange gains</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US" id="id_13905947_3422463_12_1">Net gain on foreign exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeGain" xlink:to="ifrs-full_NetForeignExchangeGain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xml:lang="en-US" id="id_13905947_3422464_1_1">Net foreign exchange loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xml:lang="en-US" id="id_13905947_3422464_14_1">Net loss on foreign exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeLoss" xlink:to="ifrs-full_NetForeignExchangeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NetProceedsFromIssuingShares" xlink:label="mrus_NetProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_13905947_3464160_3_1">Net proceeds from issuing shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_13905947_3464160_1_1">Net Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NetProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_13905947_3464160_2_1">Proceeds from net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NetProceedsFromIssuingShares" xlink:to="mrus_NetProceedsFromIssuingShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_NL" xlink:label="country_NL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US" id="id_13905947_3421581_1_1">NETHERLANDS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_NL_lbl" xml:lang="en-US" id="id_13905947_3421581_2_1">Netherlands [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" id="id_13905947_3421584_1_1">Non-adjusting events after reporting period [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" id="id_13905947_3421584_2_1">Non-adjusting events after reporting period [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" id="id_13905947_3421585_1_1">Non-adjusting events after reporting period [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" id="id_13905947_3421585_2_1">Non-adjusting events after reporting period [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" id="id_13905947_3421635_1_1">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" id="id_13905947_3421635_6_1">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" id="id_13905947_3422476_1_1">Non-current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" id="id_13905947_3422476_2_1">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:label="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3426637_3_1">Non current assets finance liabilities abstract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3426637_1_1">Non Current Assets Finance Liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3426637_2_1">Non Current Assets Finance Liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_13905947_3422491_1_1">Non-current held-to-maturity investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments_lbl" xml:lang="en-US" id="id_13905947_3422491_2_1">Non-current investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3422334_1_1">Non-current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3422334_2_1">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NonexecutiveCompensationProgramMember" xlink:label="mrus_NonexecutiveCompensationProgramMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NonexecutiveCompensationProgramMember_lbl" xml:lang="en-US" id="id_13905947_3514208_3_1">Non-Executive Compensation Program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NonexecutiveCompensationProgramMember_lbl" xml:lang="en-US" id="id_13905947_3514208_1_1">Non-Executive Compensation Program [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NonexecutiveCompensationProgramMember_lbl" xml:lang="en-US" id="id_13905947_3514208_2_1">Non-Executive Compensation Program [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NonexecutiveCompensationProgramMember" xlink:to="mrus_NonexecutiveCompensationProgramMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable_lbl" xml:lang="en-US" id="id_13905947_3463395_3_1">Non-refundable upfront payments receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable_lbl" xml:lang="en-US" id="id_13905947_3463395_1_1">Non Refundable Upfront Payments Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable_lbl" xml:lang="en-US" id="id_13905947_3463395_2_1">Non-refundable upfront payment receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NonRefundableUpfrontPaymentsReceivable" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NumberOfCommonShareEntitledToReceive" xlink:label="mrus_NumberOfCommonShareEntitledToReceive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfCommonShareEntitledToReceive_lbl" xml:lang="en-US" id="id_13905947_3471855_3_1">Number of common share entitled to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfCommonShareEntitledToReceive_lbl" xml:lang="en-US" id="id_13905947_3471855_1_1">Number of common share entitled to receive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfCommonShareEntitledToReceive_lbl" xml:lang="en-US" id="id_13905947_3471855_2_1">Number of common share entitled to receive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfCommonShareEntitledToReceive" xlink:to="mrus_NumberOfCommonShareEntitledToReceive_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfEmployees_lbl" xml:lang="en-US" id="id_13905947_3422055_1_1">Number of employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfEmployees_lbl" xml:lang="en-US" id="id_13905947_3422055_2_1">Number of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfEmployees" xlink:to="ifrs-full_NumberOfEmployees_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" id="id_13905947_3422508_1_1">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" id="id_13905947_3422508_2_1">Granted during the six month period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" id="id_13905947_3422508_12_1">Number of new RSUs granted during the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod_lbl" xml:lang="en-US" id="id_13905947_3472932_3_1">Number of instruments other equity instruments vesting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod_lbl" xml:lang="en-US" id="id_13905947_3472932_1_1">Number Of Instruments Other Equity Instruments vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod_lbl" xml:lang="en-US" id="id_13905947_3472932_2_1">Vesting period of Restricted Stock Units vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" xlink:to="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3421677_1_1">Number of other equity instruments exercised or vested in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3421677_14_1">Vested during the six month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3421678_1_1">Number of other equity instruments forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3421678_14_1">Forfeited during the six month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422353_1_1">Number of other equity instruments outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422353_4_1">Outstanding ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422353_5_1">Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" id="id_13905947_3421679_1_1">Number of share options outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" id="id_13905947_3421679_4_1">Outstanding at June 30</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" id="id_13905947_3421679_5_1">Outstanding at January 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" id="id_13905947_3421679_2_1">Number of outstanding share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US" id="id_13905947_3421679_12_1">Number of share options outstanding in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NumberOfReportableSegments1" xlink:label="mrus_NumberOfReportableSegments1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_NumberOfReportableSegments1_lbl" xml:lang="en-US" id="id_13905947_3471616_3_1">Number of reportable segments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_NumberOfReportableSegments1_lbl" xml:lang="en-US" id="id_13905947_3471616_1_1">Number of Reportable Segments1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_NumberOfReportableSegments1_lbl" xml:lang="en-US" id="id_13905947_3471616_2_1">Number of reportable segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_NumberOfReportableSegments1" xlink:to="mrus_NumberOfReportableSegments1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422355_1_1">Number of share options exercisable in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422355_2_1">Exercisable at June 30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422356_1_1">Number of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422356_2_1">Number of share options exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422356_14_1">Exercised during the six-month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3421681_1_1">Number of share options expired in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3421681_14_1">Expired during the six-month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3421682_1_1">Number of share options forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3421682_14_1">Forfeited during the six-month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422057_1_1">Number of share options granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422057_2_1">Granted during the six-month period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3422057_12_1">Option granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" id="id_13905947_3422510_1_1">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" id="id_13905947_3422510_2_1">Common shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US" id="id_13905947_3421685_1_1">Number of shares issued and fully paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl" xml:lang="en-US" id="id_13905947_3421685_2_1">Number of shares fully issued and paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OnoResearchAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_13905947_3513897_3_1">ONO Research And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OnoResearchAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_13905947_3513897_1_1">ONO Research And License Agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OnoResearchAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_13905947_3513897_2_1">ONO Research and License Agreement [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OnoResearchAndLicenseAgreementMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" id="id_13905947_3422069_1_1">Operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" id="id_13905947_3422069_2_1">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" id="id_13905947_3422069_19_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:label="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract_lbl" xml:lang="en-US" id="id_13905947_3429119_3_1">Disclosure of operating expenses from railroad and related business.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract_lbl" xml:lang="en-US" id="id_13905947_3429119_1_1">Operating expenses from railroad and related business [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract_lbl" xml:lang="en-US" id="id_13905947_3429119_2_1">Operating expenses from railroad and related business [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OperatingLeaseTermOfLeaseAgreement" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement_lbl" xml:lang="en-US" id="id_13905947_3472898_3_1">Operating lease term of lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement_lbl" xml:lang="en-US" id="id_13905947_3472898_1_1">Operating lease term of lease agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement_lbl" xml:lang="en-US" id="id_13905947_3472898_2_1">Operating lease term of lease agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OperatingLeaseTermOfLeaseAgreement" xlink:to="mrus_OperatingLeaseTermOfLeaseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" id="id_13905947_3422519_1_1">Ordinary shares [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" id="id_13905947_3422519_2_1">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherAccruals" xlink:label="mrus_OtherAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherAccruals_lbl" xml:lang="en-US" id="id_13905947_3436382_3_1">Other accruals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherAccruals_lbl" xml:lang="en-US" id="id_13905947_3436382_1_1">Other Accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherAccruals_lbl" xml:lang="en-US" id="id_13905947_3436382_2_1">Other accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherAccruals" xlink:to="mrus_OtherAccruals_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" id="id_13905947_3422081_1_1">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" id="id_13905947_3422081_2_1">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" id="id_13905947_3422081_12_1">Total other comprehensive income for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_13905947_3422082_1_1">Other comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="id_13905947_3422082_2_1">Other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" id="id_13905947_3422537_1_1">Other comprehensive income, net of tax, exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" id="id_13905947_3422537_2_1">Exchange differences from the translation of foreign operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US" id="id_13905947_3422548_1_1">Other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US" id="id_13905947_3422548_2_1">Other receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US" id="id_13905947_3422558_1_1">Other expenses, by nature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US" id="id_13905947_3422558_6_1">Total other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US" id="id_13905947_3422558_14_1">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherExpensesMember" xlink:label="mrus_OtherExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherExpensesMember_lbl" xml:lang="en-US" id="id_13905947_3491841_3_1">Other expenses [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherExpensesMember_lbl" xml:lang="en-US" id="id_13905947_3491841_1_1">Other expenses [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherExpensesMember_lbl" xml:lang="en-US" id="id_13905947_3491841_2_1">Other expenses [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherExpensesMember" xlink:to="mrus_OtherExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" id="id_13905947_3421733_1_1">Other non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" id="id_13905947_3421733_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherOperatingExpenses" xlink:label="mrus_OtherOperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherOperatingExpenses_lbl" xml:lang="en-US" id="id_13905947_3459137_3_1">Other operating expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherOperatingExpenses_lbl" xml:lang="en-US" id="id_13905947_3459137_1_1">Other Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherOperatingExpenses_lbl" xml:lang="en-US" id="id_13905947_3459137_2_1">Other operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherOperatingExpenses" xlink:to="mrus_OtherOperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherResearchAndDevelopmentExpenseOther" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther_lbl" xml:lang="en-US" id="id_13905947_3449705_3_1">Other research and development expense other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther_lbl" xml:lang="en-US" id="id_13905947_3449705_1_1">Other research and development expense other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther_lbl" xml:lang="en-US" id="id_13905947_3449705_2_1">Other research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherResearchAndDevelopmentExpenseOther" xlink:to="mrus_OtherResearchAndDevelopmentExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherResearchAndDevelopmentExpenses" xlink:label="mrus_OtherResearchAndDevelopmentExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" id="id_13905947_3463232_3_1">Other research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" id="id_13905947_3463232_1_1">Other research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" id="id_13905947_3463232_2_1">Other research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="mrus_OtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" id="id_13905947_3463232_6_1">Total other research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_OtherResearchAndDevelopmentExpenses" xlink:to="mrus_OtherResearchAndDevelopmentExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits_lbl" xml:lang="en-US" id="id_13905947_3422113_1_1">Other short-term employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits_lbl" xml:lang="en-US" id="id_13905947_3422113_2_1">Other personnel expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherShorttermEmployeeBenefits" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" id="id_13905947_3422421_1_1">Par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" id="id_13905947_3422421_2_1">Issue price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PensionCosts" xlink:label="mrus_PensionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PensionCosts_lbl" xml:lang="en-US" id="id_13905947_3457490_3_1">Pension costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PensionCosts_lbl" xml:lang="en-US" id="id_13905947_3457490_1_1">Pension costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PensionCosts_lbl" xml:lang="en-US" id="id_13905947_3457490_2_1">Pension costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PensionCosts" xlink:to="mrus_PensionCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PercentageOfInitialVestingOptions" xlink:label="mrus_PercentageOfInitialVestingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PercentageOfInitialVestingOptions_lbl" xml:lang="en-US" id="id_13905947_3528547_3_1">Percentage of initial vesting options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PercentageOfInitialVestingOptions_lbl" xml:lang="en-US" id="id_13905947_3528547_1_1">Percentage of initial vesting options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PercentageOfInitialVestingOptions_lbl" xml:lang="en-US" id="id_13905947_3528547_2_1">Percentage of initial vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PercentageOfInitialVestingOptions" xlink:to="mrus_PercentageOfInitialVestingOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PercentageOfRemainingVestingOptions" xlink:label="mrus_PercentageOfRemainingVestingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PercentageOfRemainingVestingOptions_lbl" xml:lang="en-US" id="id_13905947_3528546_3_1">Percentage of remaining vesting options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PercentageOfRemainingVestingOptions_lbl" xml:lang="en-US" id="id_13905947_3528546_1_1">Percentage of remaining vesting options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PercentageOfRemainingVestingOptions_lbl" xml:lang="en-US" id="id_13905947_3528546_2_1">Percentage of remaining vesting options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PercentageOfRemainingVestingOptions" xlink:to="mrus_PercentageOfRemainingVestingOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PercentageOfVestingOptions" xlink:label="mrus_PercentageOfVestingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PercentageOfVestingOptions_lbl" xml:lang="en-US" id="id_13905947_3528548_3_1">Percentage of vesting options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PercentageOfVestingOptions_lbl" xml:lang="en-US" id="id_13905947_3528548_1_1">Percentage of vesting options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PercentageOfVestingOptions_lbl" xml:lang="en-US" id="id_13905947_3528548_2_1">Percentage of vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PercentageOfVestingOptions" xlink:to="mrus_PercentageOfVestingOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PeriodOfAwardsWillBeVestedAndExercised" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised_lbl" xml:lang="en-US" id="id_13905947_3470883_3_1">Period of awards will be vested and exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised_lbl" xml:lang="en-US" id="id_13905947_3470883_1_1">Period of awards will be vested and exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised_lbl" xml:lang="en-US" id="id_13905947_3470883_2_1">Period of option will be vested and exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PeriodOfAwardsWillBeVestedAndExercised" xlink:to="mrus_PeriodOfAwardsWillBeVestedAndExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PeriodOfRemainingOptionsVestingPeriod" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod_lbl" xml:lang="en-US" id="id_13905947_3470860_3_1">Period of remaining options vesting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod_lbl" xml:lang="en-US" id="id_13905947_3470860_1_1">Period of remaining options vesting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod_lbl" xml:lang="en-US" id="id_13905947_3470860_2_1">Period of remaining option vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PeriodOfRemainingOptionsVestingPeriod" xlink:to="mrus_PeriodOfRemainingOptionsVestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards_lbl" xml:lang="en-US" id="id_13905947_3470858_3_1">Period of vesting installments of initial vesting awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards_lbl" xml:lang="en-US" id="id_13905947_3470858_1_1">Period of vesting installments of initial vesting awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards_lbl" xml:lang="en-US" id="id_13905947_3470858_2_1">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" xlink:to="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PersonnelRelatedResearchAndDevelopmentExpense" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_13905947_3463231_3_1">Personnel related research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_13905947_3463231_1_1">Personnel related research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_13905947_3463231_2_1">Personnel related R&amp;D</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PersonnelRelatedResearchAndDevelopmentExpense" xlink:to="mrus_PersonnelRelatedResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PotentialOrdinaryShareTransactionsMember" xlink:label="ifrs-full_PotentialOrdinaryShareTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PotentialOrdinaryShareTransactionsMember_lbl" xml:lang="en-US" id="id_13905947_3421771_1_1">Potential ordinary share transactions [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PotentialOrdinaryShareTransactionsMember_lbl" xml:lang="en-US" id="id_13905947_3421771_2_1">Potential ordinary share transactions [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PotentialOrdinaryShareTransactionsMember" xlink:to="ifrs-full_PotentialOrdinaryShareTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreviouslyStatedMember_lbl" xml:lang="en-US" id="id_13905947_3422609_1_1">Previously stated [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PreviouslyStatedMember_lbl" xml:lang="en-US" id="id_13905947_3422609_2_1">Previously stated [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PrivatePlacementsMember" xlink:label="mrus_PrivatePlacementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_PrivatePlacementsMember_lbl" xml:lang="en-US" id="id_13905947_3478997_3_1">Private placements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_PrivatePlacementsMember_lbl" xml:lang="en-US" id="id_13905947_3478997_1_1">Private placements [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_PrivatePlacementsMember_lbl" xml:lang="en-US" id="id_13905947_3478997_2_1">Private placements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_PrivatePlacementsMember" xlink:to="mrus_PrivatePlacementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ProceedsFromCollaborationAgreement" xlink:label="mrus_ProceedsFromCollaborationAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ProceedsFromCollaborationAgreement_lbl" xml:lang="en-US" id="id_13905947_3447310_3_1">Proceeds from collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ProceedsFromCollaborationAgreement_lbl" xml:lang="en-US" id="id_13905947_3447310_1_1">Proceeds from collaboration agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ProceedsFromCollaborationAgreement_lbl" xml:lang="en-US" id="id_13905947_3447310_2_1">Proceeds from collaboration and license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ProceedsFromCollaborationAgreement" xlink:to="mrus_ProceedsFromCollaborationAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US" id="id_13905947_3421781_1_1">Proceeds from exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US" id="id_13905947_3421781_2_1">Proceeds from stock option exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ProceedsFromIssuanceOfPrivatePlacementUnits" xlink:label="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits_lbl" xml:lang="en-US" id="id_13905947_3466494_3_1">Proceeds from issuance of private placement units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits_lbl" xml:lang="en-US" id="id_13905947_3466494_1_1">Proceeds From Issuance Of Private Placement Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits_lbl" xml:lang="en-US" id="id_13905947_3466494_2_1">Received from issuance of private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits" xlink:to="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_13905947_3422452_1_1">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_13905947_3422452_2_1">Aggregate purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" id="id_13905947_3422452_12_1">Proceeds from issuing shares, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3423106_1_1">Proceeds from sales or maturity of financial instruments, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3423106_2_1">Proceeds from investment maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" id="id_13905947_3422158_1_1">Product and Service [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" id="id_13905947_3422158_2_1">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="id_13905947_3422159_1_1">Product and Service [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="id_13905947_3422159_2_1">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" id="id_13905947_3423109_1_1">Professional fees expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" id="id_13905947_3423109_2_1">Expert fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" id="id_13905947_3423110_1_1">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" id="id_13905947_3423110_2_1">Result after taxation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" id="id_13905947_3423110_6_1">Result after taxation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" id="id_13905947_3423110_12_1">Result after taxation for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" id="id_13905947_3422161_1_1">Profit (loss) before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" id="id_13905947_3422161_6_1">Result before taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" id="id_13905947_3422167_1_1">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" id="id_13905947_3422167_2_1">Operating result</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" id="id_13905947_3422167_6_1">Operating result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_13905947_3423123_1_1">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_13905947_3423123_2_1">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3422686_1_1">Purchase of financial instruments, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3422686_2_1">Purchases of investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3422686_14_1">Purchases of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3423149_1_1">Purchase of intangible assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3423149_14_1">Purchase of intellectual property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3422688_1_1">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" id="id_13905947_3422688_14_1">Acquisition of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" id="id_13905947_3422662_1_1">Range [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" id="id_13905947_3422662_2_1">Range [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" id="id_13905947_3422700_1_1">Ranges [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" id="id_13905947_3422700_2_1">Ranges [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ReimbursementOfGrant" xlink:label="mrus_ReimbursementOfGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ReimbursementOfGrant_lbl" xml:lang="en-US" id="id_13905947_3464192_3_1">Reimbursement of grant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ReimbursementOfGrant_lbl" xml:lang="en-US" id="id_13905947_3464192_1_1">Reimbursement of grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ReimbursementOfGrant_lbl" xml:lang="en-US" id="id_13905947_3464192_2_1">Reimbursement of grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ReimbursementOfGrant" xlink:to="mrus_ReimbursementOfGrant_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RemainingPeriodOfDeferredRevenueAmortization" xlink:label="mrus_RemainingPeriodOfDeferredRevenueAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RemainingPeriodOfDeferredRevenueAmortization_lbl" xml:lang="en-US" id="id_13905947_3471985_3_1">Remaining period of deferred revenue amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RemainingPeriodOfDeferredRevenueAmortization_lbl" xml:lang="en-US" id="id_13905947_3471985_1_1">Remaining Period of Deferred Revenue Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RemainingPeriodOfDeferredRevenueAmortization_lbl" xml:lang="en-US" id="id_13905947_3471985_2_1">Remaining estimated amortization period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RemainingPeriodOfDeferredRevenueAmortization" xlink:to="mrus_RemainingPeriodOfDeferredRevenueAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RentalExpense" xlink:label="ifrs-full_RentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US" id="id_13905947_3423194_1_1">Rental expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US" id="id_13905947_3423194_2_1">Rental expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RentalExpensesOnRealEstateAbstract" xlink:label="mrus_RentalExpensesOnRealEstateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RentalExpensesOnRealEstateAbstract_lbl" xml:lang="en-US" id="id_13905947_3429062_3_1">Rental expenses on real estate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RentalExpensesOnRealEstateAbstract_lbl" xml:lang="en-US" id="id_13905947_3429062_1_1">Rental expenses on real estate [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RentalExpensesOnRealEstateAbstract_lbl" xml:lang="en-US" id="id_13905947_3429062_2_1">Rental expenses on real estate [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="mrus_RentalExpensesOnRealEstateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RentAndServiceChargesExpense" xlink:label="mrus_RentAndServiceChargesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RentAndServiceChargesExpense_lbl" xml:lang="en-US" id="id_13905947_3463381_3_1">Rent and service charges expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RentAndServiceChargesExpense_lbl" xml:lang="en-US" id="id_13905947_3463381_1_1">Rent and service charges expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RentAndServiceChargesExpense_lbl" xml:lang="en-US" id="id_13905947_3463381_2_1">Rent and service charges expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RentAndServiceChargesExpense" xlink:to="mrus_RentAndServiceChargesExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" id="id_13905947_3423198_1_1">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" id="id_13905947_3423198_14_1">Repayment of borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ResearchAndDevelopmentCostsMember" xlink:label="mrus_ResearchAndDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ResearchAndDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_13905947_3481637_3_1">Research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ResearchAndDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_13905947_3481637_1_1">Research and Development Costs [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ResearchAndDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_13905947_3481637_2_1">Research and development costs [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ResearchAndDevelopmentCostsMember" xlink:to="mrus_ResearchAndDevelopmentCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_13905947_3422758_1_1">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_13905947_3422758_2_1">Research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_13905947_3422758_6_1">Total research and development costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_13905947_3422758_14_1">Research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" id="id_13905947_3423218_1_1">Currently stated [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" id="id_13905947_3423218_2_1">Currently stated [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" id="id_13905947_3422771_1_1">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" id="id_13905947_3422771_2_1">Accumulated loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_13905947_3422911_1_1">Retained earnings [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_13905947_3422911_2_1">Accumulated loss [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US" id="id_13905947_3422913_1_1">Retrospective application and retrospective restatement [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US" id="id_13905947_3422913_2_1">Retrospective application and retrospective restatement [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" id="id_13905947_3422778_1_1">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" id="id_13905947_3422778_2_1">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" id="id_13905947_3422778_12_1">Total Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US" id="id_13905947_3422914_1_1">Revenue [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US" id="id_13905947_3422914_2_1">Revenue [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueFromContractsWithCustomersMember" xlink:label="mrus_RevenueFromContractsWithCustomersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_13905947_3496102_3_1">Revenue from contracts with customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_13905947_3496102_1_1">Revenue from contracts with customers [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueFromContractsWithCustomersMember_lbl" xml:lang="en-US" id="id_13905947_3496102_2_1">Revenue from contracts with customers [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueFromContractsWithCustomersMember" xlink:to="mrus_RevenueFromContractsWithCustomersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueLineItems" xlink:label="mrus_RevenueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueLineItems_lbl" xml:lang="en-US" id="id_13905947_3429589_3_1">Revenue [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueLineItems_lbl" xml:lang="en-US" id="id_13905947_3429589_1_1">Revenue [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueLineItems_lbl" xml:lang="en-US" id="id_13905947_3429589_2_1">Revenue [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_RevenueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRecognized" xlink:label="mrus_RevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueRecognized_lbl" xml:lang="en-US" id="id_13905947_3530760_3_1">Revenue recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueRecognized_lbl" xml:lang="en-US" id="id_13905947_3530760_1_1">Revenue recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueRecognized_lbl" xml:lang="en-US" id="id_13905947_3530760_2_1">Revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueRecognized" xlink:to="mrus_RevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRecognizedIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_13905947_3448881_3_1">Revenue recognized included in deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_13905947_3448881_1_1">Revenue recognized included in deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_13905947_3448881_2_1">Revenue recognized included in deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueRecognizedIncludedInDeferredRevenue" xlink:to="mrus_RevenueRecognizedIncludedInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRecognizedNotIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_13905947_3448882_3_1">Revenue recognized not included in deferred revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_13905947_3448882_1_1">Revenue recognized not included in deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue_lbl" xml:lang="en-US" id="id_13905947_3448882_2_1">Revenue recognized not included in deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueRecognizedNotIncludedInDeferredRevenue" xlink:to="mrus_RevenueRecognizedNotIncludedInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRemainingPerformanceObligations" xlink:label="mrus_RevenueRemainingPerformanceObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueRemainingPerformanceObligations_lbl" xml:lang="en-US" id="id_13905947_3448890_3_1">Revenue remaining performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueRemainingPerformanceObligations_lbl" xml:lang="en-US" id="id_13905947_3448890_1_1">Revenue Remaining Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueRemainingPerformanceObligations_lbl" xml:lang="en-US" id="id_13905947_3448890_2_1">Performance obligation recognized as revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueRemainingPerformanceObligations" xlink:to="mrus_RevenueRemainingPerformanceObligations_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueTable" xlink:label="mrus_RevenueTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_RevenueTable_lbl" xml:lang="en-US" id="id_13905947_3473742_3_1">Revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_RevenueTable_lbl" xml:lang="en-US" id="id_13905947_3473742_1_1">Revenue [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_RevenueTable_lbl" xml:lang="en-US" id="id_13905947_3473742_2_1">Revenue [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_RevenueTable" xlink:to="mrus_RevenueTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SecurityDeposits" xlink:label="mrus_SecurityDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SecurityDeposits_lbl" xml:lang="en-US" id="id_13905947_3439623_3_1">Security deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SecurityDeposits_lbl" xml:lang="en-US" id="id_13905947_3439623_1_1">Security Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SecurityDeposits_lbl" xml:lang="en-US" id="id_13905947_3439623_2_1">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SecurityDeposits" xlink:to="mrus_SecurityDeposits_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_13905947_3467974_3_1">Share Based Compensation Arrangements by Share Based Payment Award Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_13905947_3467974_1_1">Share Based Compensation Arrangements by Share Based Payment Award Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_13905947_3467974_2_1">Increase in authorized share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharebasedCompensationAwardVestingPeriod" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod_lbl" xml:lang="en-US" id="id_13905947_3472168_3_1">Sharebased Compensation Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod_lbl" xml:lang="en-US" id="id_13905947_3472168_1_1">Sharebased Compensation Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod_lbl" xml:lang="en-US" id="id_13905947_3472168_2_1">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SharebasedCompensationAwardVestingPeriod" xlink:to="mrus_SharebasedCompensationAwardVestingPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_13905947_3442830_3_1">Share based compensation other equity instruments grants in period weighted average grant date fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_13905947_3442830_1_1">Share Based Compensation Other Equity Instruments Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_13905947_3442830_2_1">Option grant fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" id="id_13905947_3472021_3_1">Share-based Compensation, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" id="id_13905947_3472021_1_1">Share-based Compensation, Weighted Average Remaining Contractual Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife_lbl" xml:lang="en-US" id="id_13905947_3472021_2_1">Weighted-average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" xlink:to="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" id="id_13905947_3422970_1_1">Share-based payment arrangements [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" id="id_13905947_3422970_2_1">Share-based payment arrangements [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ShareBasedPaymentExpense" xlink:label="mrus_ShareBasedPaymentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_ShareBasedPaymentExpense_lbl" xml:lang="en-US" id="id_13905947_3466922_3_1">Share Based Payment Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_ShareBasedPaymentExpense_lbl" xml:lang="en-US" id="id_13905947_3466922_1_1">Share Based Payment Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_ShareBasedPaymentExpense_lbl" xml:lang="en-US" id="id_13905947_3466922_2_1">Share based payment expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_ShareBasedPaymentExpense" xlink:to="mrus_ShareBasedPaymentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" id="id_13905947_3423692_1_1">Share premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" id="id_13905947_3423692_2_1">Share premium account</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" id="id_13905947_3422849_1_1">Share premium [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" id="id_13905947_3422849_2_1">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePrice1" xlink:label="mrus_SharePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SharePrice1_lbl" xml:lang="en-US" id="id_13905947_3433228_3_1">Share price 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SharePrice1_lbl" xml:lang="en-US" id="id_13905947_3433228_1_1">Share price 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SharePrice1_lbl" xml:lang="en-US" id="id_13905947_3433228_2_1">Weighted-average share price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SharePrice1" xlink:to="mrus_SharePrice1_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SharePurchasedPricePerShare_lbl" xml:lang="en-US" id="id_13905947_3522559_3_1">Share purchased price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SharePurchasedPricePerShare_lbl" xml:lang="en-US" id="id_13905947_3522559_1_1">Share Purchased Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="mrus_SharePurchasedPricePerShare_lbl" xml:lang="en-US" id="id_13905947_3522559_32_1">Share price at grant date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SharePurchasedPricePerShare_lbl" xml:lang="en-US" id="id_13905947_3522559_2_1">Purchase price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="mrus_SharePurchasedPricePerShare_lbl" xml:lang="en-US" id="id_13905947_3522559_12_1">Purchase price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SharePurchasedPricePerShare" xlink:to="mrus_SharePurchasedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US" id="id_13905947_3423695_1_1">Short-term employee benefits accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US" id="id_13905947_3423695_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" id="id_13905947_3423696_1_1">Short-term employee benefits expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" id="id_13905947_3423696_6_1">Total employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_lbl" xml:lang="en-US" id="id_13905947_3423697_1_1">Short-term employee benefits expense [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_lbl" xml:lang="en-US" id="id_13905947_3423697_2_1">Short-term employee benefits expense [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" id="id_13905947_3423280_1_1">Short-term investments, classified as cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" id="id_13905947_3423280_2_1">Short-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_13905947_3496111_3_1">Simcere collaboration and license agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_13905947_3496111_1_1">Simcere collaboration and license agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" id="id_13905947_3496111_2_1">Simcere collaboration and license agreement [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xml:lang="en-US" id="id_13905947_3422859_1_1">Social security contributions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xml:lang="en-US" id="id_13905947_3422859_2_1">Social security premiums</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SocialSecurityContributions" xlink:to="ifrs-full_SocialSecurityContributions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_13905947_3423004_1_1">Statement of cash flows [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_13905947_3423004_2_1">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" id="id_13905947_3422872_1_1">Statement of changes in equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" id="id_13905947_3422872_2_1">Statement of changes in equity [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" id="id_13905947_3423719_1_1">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" id="id_13905947_3423719_2_1">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" id="id_13905947_3423720_1_1">Statement of changes in equity [table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" id="id_13905947_3423720_2_1">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_StockAwardExpense" xlink:label="mrus_StockAwardExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_StockAwardExpense_lbl" xml:lang="en-US" id="id_13905947_3458121_3_1">Stock award expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_StockAwardExpense_lbl" xml:lang="en-US" id="id_13905947_3458121_1_1">Stock award expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_StockAwardExpense_lbl" xml:lang="en-US" id="id_13905947_3458121_2_1">Stock award expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_StockAwardExpense" xlink:to="mrus_StockAwardExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3423012_1_1">Subclassifications of assets, liabilities and equities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_lbl" xml:lang="en-US" id="id_13905947_3423012_2_1">Sub classifications of assets, liabilities and equities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SubsidiesIncome" xlink:label="mrus_SubsidiesIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SubsidiesIncome_lbl" xml:lang="en-US" id="id_13905947_3450701_3_1">Subsidies income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SubsidiesIncome_lbl" xml:lang="en-US" id="id_13905947_3450701_1_1">Subsidies Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SubsidiesIncome_lbl" xml:lang="en-US" id="id_13905947_3450701_2_1">Received and recognized subsidies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SubsidiesIncome" xlink:to="mrus_SubsidiesIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SubsidyAdvanceReceived" xlink:label="mrus_SubsidyAdvanceReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_SubsidyAdvanceReceived_lbl" xml:lang="en-US" id="id_13905947_3463220_3_1">Subsidy advance received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_SubsidyAdvanceReceived_lbl" xml:lang="en-US" id="id_13905947_3463220_1_1">Subsidy advance received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_SubsidyAdvanceReceived_lbl" xml:lang="en-US" id="id_13905947_3463220_2_1">Subsidy advance received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_SubsidyAdvanceReceived" xlink:to="mrus_SubsidyAdvanceReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xml:lang="en-US" id="id_13905947_3423034_1_1">Temporary difference, unused tax losses and unused tax credits [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl" xml:lang="en-US" id="id_13905947_3423034_2_1">Temporary difference, unused tax losses and unused tax credits [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xml:lang="en-US" id="id_13905947_3423035_1_1">Temporary difference, unused tax losses and unused tax credits [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl" xml:lang="en-US" id="id_13905947_3423035_2_1">Temporary difference, unused tax losses and unused tax credits [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TermsOfPaymentOfTradeReceivables" xlink:label="mrus_TermsOfPaymentOfTradeReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TermsOfPaymentOfTradeReceivables_lbl" xml:lang="en-US" id="id_13905947_3470294_3_1">Terms of payment of trade receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TermsOfPaymentOfTradeReceivables_lbl" xml:lang="en-US" id="id_13905947_3470294_1_1">Terms of payment of trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TermsOfPaymentOfTradeReceivables_lbl" xml:lang="en-US" id="id_13905947_3470294_2_1">Payment terms related to receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TermsOfPaymentOfTradeReceivables" xlink:to="mrus_TermsOfPaymentOfTradeReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TextBlockAbstract_lbl" xml:lang="en-US" id="id_13905947_3426207_3_1">Text Block [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TextBlockAbstract_lbl" xml:lang="en-US" id="id_13905947_3426207_1_1">Text block [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TextBlockAbstract_lbl" xml:lang="en-US" id="id_13905947_3426207_2_1">Text Block [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" id="id_13905947_3423353_1_1">Top of range [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" id="id_13905947_3423353_2_1">Top of range [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" id="id_13905947_3423356_1_1">Current trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" id="id_13905947_3423356_2_1">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" id="id_13905947_3423049_1_1">Trade and other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" id="id_13905947_3423049_2_1">Trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" id="id_13905947_3423049_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="ifrs-full_TradeAndOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3423053_1_1">Trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_TradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3423053_4_1">Trade and other receivables, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_TradeAndOtherReceivables_lbl" xml:lang="en-US" id="id_13905947_3423053_5_1">Trade and other receivables, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivables" xlink:to="ifrs-full_TradeAndOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivablesMember_lbl" xml:lang="en-US" id="id_13905947_3424016_1_1">Trade receivables [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeReceivablesMember_lbl" xml:lang="en-US" id="id_13905947_3424016_2_1">Trade receivables [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivablesMember" xlink:to="ifrs-full_TradeReceivablesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_13905947_3423057_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_13905947_3423057_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TransactionsWithOwnersAbstract" xlink:label="mrus_TransactionsWithOwnersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TransactionsWithOwnersAbstract_lbl" xml:lang="en-US" id="id_13905947_3430978_3_1">Transactions with owners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TransactionsWithOwnersAbstract_lbl" xml:lang="en-US" id="id_13905947_3430978_1_1">Transactions With Owners [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TransactionsWithOwnersAbstract_lbl" xml:lang="en-US" id="id_13905947_3430978_2_1">Transactions with owners of the Company:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="mrus_TransactionsWithOwnersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TwoThousandSixteenOptionPlanMember" xlink:label="mrus_TwoThousandSixteenOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_TwoThousandSixteenOptionPlanMember_lbl" xml:lang="en-US" id="id_13905947_3514207_3_1">Two thousand sixteen option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_TwoThousandSixteenOptionPlanMember_lbl" xml:lang="en-US" id="id_13905947_3514207_1_1">Two Thousand Sixteen Option Plan[member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_TwoThousandSixteenOptionPlanMember_lbl" xml:lang="en-US" id="id_13905947_3514207_2_1">2016 Plan [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_TwoThousandSixteenOptionPlanMember" xlink:to="mrus_TwoThousandSixteenOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsAxis_lbl" xml:lang="en-US" id="id_13905947_3423078_1_1">Types of contracts [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfContractsAxis_lbl" xml:lang="en-US" id="id_13905947_3423078_2_1">Types of contracts [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsMember_lbl" xml:lang="en-US" id="id_13905947_3423383_1_1">Types of contracts [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfContractsMember_lbl" xml:lang="en-US" id="id_13905947_3423383_2_1">Types of contracts [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="ifrs-full_TypesOfContractsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfFinancialAssetsAxis" xlink:label="ifrs-full_TypesOfFinancialAssetsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfFinancialAssetsAxis_lbl" xml:lang="en-US" id="id_13905947_3424453_1_1">Types of financial assets [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfFinancialAssetsAxis_lbl" xml:lang="en-US" id="id_13905947_3424453_2_1">Types of financial assets [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="ifrs-full_TypesOfFinancialAssetsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" id="id_13905947_3424457_1_1">Types of share-based payment arrangements [axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" id="id_13905947_3424457_2_1">Types of share-based payment arrangements [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UnbilledReceivablesMember" xlink:label="mrus_UnbilledReceivablesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_UnbilledReceivablesMember_lbl" xml:lang="en-US" id="id_13905947_3496068_3_1">Unbilled receivables [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_UnbilledReceivablesMember_lbl" xml:lang="en-US" id="id_13905947_3496068_1_1">Unbilled receivables [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_UnbilledReceivablesMember_lbl" xml:lang="en-US" id="id_13905947_3496068_2_1">Unbilled receivables [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UnbilledReceivablesMember" xlink:to="mrus_UnbilledReceivablesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontAndMilestonePaymentsMember" xlink:label="mrus_UpfrontAndMilestonePaymentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_UpfrontAndMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_13905947_3496110_3_1">Upfront and milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_UpfrontAndMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_13905947_3496110_1_1">Upfront and Milestone Payments [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_UpfrontAndMilestonePaymentsMember_lbl" xml:lang="en-US" id="id_13905947_3496110_2_1">Upfront and Milestone Payments [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UpfrontAndMilestonePaymentsMember" xlink:to="mrus_UpfrontAndMilestonePaymentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontPayment" xlink:label="mrus_UpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_UpfrontPayment_lbl" xml:lang="en-US" id="id_13905947_3433983_3_1">Upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_UpfrontPayment_lbl" xml:lang="en-US" id="id_13905947_3433983_1_1">Upfront payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_UpfrontPayment_lbl" xml:lang="en-US" id="id_13905947_3433983_2_1">Non-refundable upfront payment received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UpfrontPayment" xlink:to="mrus_UpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontPaymentAmortization" xlink:label="mrus_UpfrontPaymentAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_UpfrontPaymentAmortization_lbl" xml:lang="en-US" id="id_13905947_3464161_3_1">Up-front payment amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_UpfrontPaymentAmortization_lbl" xml:lang="en-US" id="id_13905947_3464161_1_1">Up-front payment amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_UpfrontPaymentAmortization_lbl" xml:lang="en-US" id="id_13905947_3464161_2_1">Up-front payment amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UpfrontPaymentAmortization" xlink:to="mrus_UpfrontPaymentAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontPaymentAmortizationMember" xlink:label="mrus_UpfrontPaymentAmortizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_UpfrontPaymentAmortizationMember_lbl" xml:lang="en-US" id="id_13905947_3514219_3_1">Up-front payment amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_UpfrontPaymentAmortizationMember_lbl" xml:lang="en-US" id="id_13905947_3514219_1_1">Up-front payment amortization [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_UpfrontPaymentAmortizationMember_lbl" xml:lang="en-US" id="id_13905947_3514219_2_1">Up-front payment amortization [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_UpfrontPaymentAmortizationMember" xlink:to="mrus_UpfrontPaymentAmortizationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" id="id_13905947_3424474_1_1">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" id="id_13905947_3424474_2_1">United States [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_USTreasurySecuritiesMember" xlink:label="mrus_USTreasurySecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="id_13905947_3535979_3_1">U.S. Treasury securities [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="id_13905947_3535979_1_1">U.S. Treasury securities [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="id_13905947_3535979_2_1">U.S. Treasury securities [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_USTreasurySecuritiesMember" xlink:to="mrus_USTreasurySecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US" id="id_13905947_3423771_1_1">Wages and salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US" id="id_13905947_3423771_2_1">Salaries and wages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WBSOSubsidy" xlink:label="mrus_WBSOSubsidy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WBSOSubsidy_lbl" xml:lang="en-US" id="id_13905947_3458295_3_1">WBSO subsidy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WBSOSubsidy_lbl" xml:lang="en-US" id="id_13905947_3458295_1_1">WBSO subsidy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="mrus_WBSOSubsidy_lbl" xml:lang="en-US" id="id_13905947_3458295_14_1">WBSO subsidy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WBSOSubsidy" xlink:to="mrus_WBSOSubsidy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3424493_1_1">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3424493_2_1">Vested during the six month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3423779_1_1">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3423779_2_1">Forfeited during the six month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3424071_1_1">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3424071_2_1">Granted during the six month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3423417_1_1">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3423417_4_1">Outstanding ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3423417_5_1">Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522918_3_1">Weighted average exercise price of share option exercisable in share based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522918_1_1">Weighted average exercise price of share option exercisable in share based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522918_2_1">Exercisable at June 30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522862_3_1">Weighted average exercise price of share option exercised in share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522862_1_1">Weighted average exercise price of share option exercised in share based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522862_2_1">Exercised during the six-month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522951_3_1">Weighted average exercise price of share options and warrants forfeited in share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522951_1_1">Weighted average exercise price of share options and warrants forfeited in share based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522951_2_1">Forfeited during the six-month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522952_3_1">Weighted average exercise price of share options and warrants granted in share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522952_1_1">Weighted average exercise price of share options and warrants granted in share based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522952_2_1">Granted during the six-month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522673_3_1">The weighted average exercise price of share options and warrants outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522673_1_1">Weighted average exercise price of share options and warrants outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522673_4_1">Outstanding at June 30</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3522673_5_1">Outstanding at January 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3423781_1_1">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3423781_2_1">Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3424496_1_1">Weighted average exercise price of share options outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" id="id_13905947_3424496_2_1">Weighted average exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePricePerShareOptionsExpired" xlink:label="mrus_WeightedAverageExercisePricePerShareOptionsExpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mrus_WeightedAverageExercisePricePerShareOptionsExpired_lbl" xml:lang="en-US" id="id_13905947_3522723_3_1">Weighted average exercise price per share options expired.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mrus_WeightedAverageExercisePricePerShareOptionsExpired_lbl" xml:lang="en-US" id="id_13905947_3522723_1_1">Weighted average exercise price per share options expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mrus_WeightedAverageExercisePricePerShareOptionsExpired_lbl" xml:lang="en-US" id="id_13905947_3522723_2_1">Expired during the six-month period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mrus_WeightedAverageExercisePricePerShareOptionsExpired" xlink:to="mrus_WeightedAverageExercisePricePerShareOptionsExpired_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" id="id_13905947_3423785_1_1">Weighted average number of ordinary shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" id="id_13905947_3423785_2_1">Weighted average shares outstanding Basic (and diluted)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>mrus-20180630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFS Xcelerate Taxonomy Presentation Linkbase - http://www.dfsco.com/financial-services/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2018-12-20T14:39:20Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DocumentandEntityInformation" roleURI="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_1_2018-03-16_role-210000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_1_2018-03-16_role-320000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_1_2018-03-16_role-610000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#ias_7_2018-03-16_role-520000" roleURI="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureGeneralInformationAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureInvestmentsSummaryOfInvestments" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureInvestmentsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureDeferredRevenueSummaryOfDeferredRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureDeferredRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquityAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs" roleURI="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRevenueSummaryOfRevenue" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRevenueAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTotalOperatingExpensesAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts" roleURI="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureEmployeeBenefitsAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureFinanceIncomeAndExpenseAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#DisclosureOperatingLeaseAdditionalInformation" roleURI="http://www.merus.nl/taxonomy/role/DisclosureOperatingLeaseAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory"/>
  <roleRef xlink:type="simple" xlink:href="mrus-20180630.xsd#Role_NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory" roleURI="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DocumentandEntityInformationAbstract" xlink:label="mrus_DocumentandEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentandEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentandEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentandEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentandEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentandEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentandEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentandEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DocumentandEntityInformationAbstract" xlink:to="dei_EntityExTransitionPeriod" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000" xlink:title="[210000] Statement of financial position, current/non-current">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:label="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Assets" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_EquityAbstract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_NonCurrentAssetsFinanceLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000" xlink:title="[320000] Statement of comprehensive income, profit or loss, by nature of expense">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:label="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_Revenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_OtherExpenseByNature" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_OperatingExpense" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_FinanceIncome" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_FinanceCosts" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_FinanceIncomeCost" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_ProfitLoss" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000" xlink:title="[610000] Statement of changes in equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" xlink:label="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TransactionsWithOwnersAbstract" xlink:label="mrus_TransactionsWithOwnersAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="mrus_TransactionsWithOwnersAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_IssueOfEquity" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TransactionsWithOwnersAbstract" xlink:to="ifrs-full_Equity" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000" xlink:title="[520000] Statement of cash flows, indirect method">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets" xlink:label="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangeInWorkingCapitalAbstract" xlink:label="mrus_ChangeInWorkingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangesInAccruedCapitalExpenditures" xlink:label="mrus_ChangesInAccruedCapitalExpenditures"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangesInRestrictedCash" xlink:label="mrus_ChangesInRestrictedCash"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ProceedsFromCollaborationAgreement" xlink:label="mrus_ProceedsFromCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromExerciseOfOptions" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" order="1.2400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" order="1.2800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="mrus_ProceedsFromCollaborationAgreement" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="1.1700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="mrus_ChangesInRestrictedCash" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_2" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets" order="1.3000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="1.3800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="1.3900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="mrus_ChangeInWorkingCapitalAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="mrus_ChangesInAccruedCapitalExpenditures" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfGeneralInformationAbstract" xlink:label="mrus_DisclosureOfGeneralInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationAbstract" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationAbstract" xlink:to="ifrs-full_ParValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationAbstract" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfGeneralInformationAbstract" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CashAndCashEquivalentsMaximumMaturityPeriod" xlink:label="mrus_CashAndCashEquivalentsMaximumMaturityPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="mrus_DisclosureOfSignificantAccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NumberOfReportableSegments1" xlink:label="mrus_NumberOfReportableSegments1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="mrus_NumberOfReportableSegments1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="mrus_CashAndCashEquivalentsMaximumMaturityPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfRecentlyIssuedIfrsAbstract" xlink:label="mrus_DisclosureOfRecentlyIssuedIfrsAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_EstimatedContractualTerm" xlink:label="mrus_EstimatedContractualTerm"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IFRS15RevenueFromContractsWithCustomersMember" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInDeferredRevenue1" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteProprietaryTechnologyMember" xlink:label="mrus_IncyteProprietaryTechnologyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="mrus_EstimatedContractualTerm" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="mrus_IncreaseDecreaseInDeferredRevenue1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfRecentlyIssuedIfrsAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_IFRS15RevenueFromContractsWithCustomersMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteProprietaryTechnologyMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureoffinancialinformationAbstract" xlink:label="mrus_DisclosureoffinancialinformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_Revenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureoffinancialinformationAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedBalanceSheetStatementTable" xlink:label="srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureoffinancialinformationAbstract" xlink:label="mrus_DisclosureoffinancialinformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_RetainedEarnings" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureoffinancialinformationAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangeInWorkingCapitalAbstract" xlink:label="mrus_ChangeInWorkingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:label="srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CondensedCashFlowStatementTable" xlink:label="srt_CondensedCashFlowStatementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureoffinancialinformationAbstract" xlink:label="mrus_DisclosureoffinancialinformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_ChangeInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="ifrs-full_ProfitLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="mrus_ChangeInWorkingCapitalAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedCashFlowStatementTable" xlink:to="srt_CondensedCashFlowStatementsCaptionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureoffinancialinformationAbstract" xlink:to="srt_CondensedCashFlowStatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AgencyBondMember" xlink:label="mrus_AgencyBondMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CommercialPaper1Member" xlink:label="mrus_CommercialPaper1Member"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CorporateFixedIncomeBondsMember" xlink:label="mrus_CorporateFixedIncomeBondsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentHeldtomaturityInvestments" xlink:label="ifrs-full_CurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinancialAssetsTypeMember" xlink:label="ifrs-full_FinancialAssetsTypeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_HeldtomaturityInvestments" xlink:label="ifrs-full_HeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="invest_InvestmentLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentsScheduleAbstract" xlink:label="invest_InvestmentsScheduleAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="invest_InvestmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NoncurrentHeldtomaturityInvestments" xlink:label="ifrs-full_NoncurrentHeldtomaturityInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfFinancialAssetsAxis" xlink:label="ifrs-full_TypesOfFinancialAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_USTreasurySecuritiesMember" xlink:label="mrus_USTreasurySecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_CommercialPaper1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_USTreasurySecuritiesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_CorporateFixedIncomeBondsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsTypeMember" xlink:to="mrus_AgencyBondMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_CurrentHeldtomaturityInvestments" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_NoncurrentHeldtomaturityInvestments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_HeldtomaturityInvestments" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentsScheduleAbstract" xlink:to="invest_InvestmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentTable" xlink:to="ifrs-full_TypesOfFinancialAssetsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentTable" xlink:to="invest_InvestmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsTypeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="invest_InvestmentLineItems"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentsScheduleAbstract" xlink:label="invest_InvestmentsScheduleAbstract"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="invest_InvestmentTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NetFinanceIncomeExpenseMember" xlink:label="mrus_NetFinanceIncomeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_NetFinanceIncomeExpenseMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentLineItems" xlink:to="ifrs-full_NetForeignExchangeGain" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentsScheduleAbstract" xlink:to="invest_InvestmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="invest_InvestmentTable" xlink:to="invest_InvestmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentInterestBank" xlink:label="mrus_CurrentInterestBank"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentPrepaidGeneralExpenses" xlink:label="mrus_CurrentPrepaidGeneralExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentPrepaidPensionCosts" xlink:label="mrus_CurrentPrepaidPensionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CurrentUnbilledReceivables" xlink:label="mrus_CurrentUnbilledReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="mrus_CurrentUnbilledReceivables" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="mrus_CurrentPrepaidGeneralExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="mrus_CurrentPrepaidPensionCosts" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="mrus_CurrentInterestBank" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedAuditorsFee" xlink:label="mrus_AccruedAuditorsFee"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedIntellectualPropertyLegalFee" xlink:label="mrus_AccruedIntellectualPropertyLegalFee"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedPersonnel" xlink:label="mrus_AccruedPersonnel"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AccruedResearchAndDevelopmentStudies" xlink:label="mrus_AccruedResearchAndDevelopmentStudies"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_Bonuses" xlink:label="mrus_Bonuses"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:label="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherAccruals" xlink:label="mrus_OtherAccruals"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SubsidyAdvanceReceived" xlink:label="mrus_SubsidyAdvanceReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_AccruedAuditorsFee" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_AccruedPersonnel" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_AccruedResearchAndDevelopmentStudies" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_AccruedIntellectualPropertyLegalFee" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_Bonuses" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_SubsidyAdvanceReceived" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="mrus_OtherAccruals" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfAccrualsAndOtherPayablesAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncome" xlink:label="ifrs-full_DeferredIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_DeferredIncomeClassifiedAsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredIncomeAbstract" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeAbstract" xlink:to="ifrs-full_DeferredIncomeClassifiedAsCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeAbstract" xlink:to="ifrs-full_DeferredIncomeClassifiedAsNoncurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeAbstract" xlink:to="ifrs-full_DeferredIncome" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AmountPaidForFullTimeEquivalentFunding" xlink:label="mrus_AmountPaidForFullTimeEquivalentFunding"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AmountPaidToCompensateForResearchServices" xlink:label="mrus_AmountPaidToCompensateForResearchServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DeferredIncome" xlink:label="ifrs-full_DeferredIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeferredRevenueMember" xlink:label="mrus_DeferredRevenueMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredIncomeAbstract" xlink:label="mrus_DisclosureOfDeferredIncomeAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredIncomeLineItems" xlink:label="mrus_DisclosureOfDeferredIncomeLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredIncomeTable" xlink:label="mrus_DisclosureOfDeferredIncomeTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FairValueOfDerivatives" xlink:label="mrus_FairValueOfDerivatives"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NonRefundableUpfrontPaymentsReceivable" xlink:label="mrus_NonRefundableUpfrontPaymentsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RemainingPeriodOfDeferredRevenueAmortization" xlink:label="mrus_RemainingPeriodOfDeferredRevenueAmortization"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRecognized" xlink:label="mrus_RevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRemainingPerformanceObligations" xlink:label="mrus_RevenueRemainingPerformanceObligations"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontAndMilestonePaymentsMember" xlink:label="mrus_UpfrontAndMilestonePaymentsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontPayment" xlink:label="mrus_UpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeAbstract" xlink:to="mrus_DisclosureOfDeferredIncomeTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_DeferredIncome" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_NonRefundableUpfrontPaymentsReceivable" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_UpfrontPayment" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_FairValueOfDerivatives" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_RemainingPeriodOfDeferredRevenueAmortization" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_RevenueRecognized" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_RevenueRemainingPerformanceObligations" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_AmountPaidForFullTimeEquivalentFunding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeLineItems" xlink:to="mrus_AmountPaidToCompensateForResearchServices" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="srt_ProductOrServiceAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfDeferredIncomeTable" xlink:to="mrus_DisclosureOfDeferredIncomeLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCorporationMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="mrus_UpfrontAndMilestonePaymentsMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="mrus_DeferredRevenueMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" xlink:label="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfGrantAward" xlink:label="mrus_DescriptionOfGrantAward"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfOptionLapse" xlink:label="mrus_DescriptionOfOptionLapse"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfOptionsGranted" xlink:label="mrus_DescriptionOfOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInCapital" xlink:label="mrus_IncreaseDecreaseInCapital"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInSharePremium" xlink:label="mrus_IncreaseDecreaseInSharePremium"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCorporationMember" xlink:label="mrus_IncyteCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NetProceedsFromIssuingShares" xlink:label="mrus_NetProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NonexecutiveCompensationProgramMember" xlink:label="mrus_NonexecutiveCompensationProgramMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NumberOfCommonShareEntitledToReceive" xlink:label="mrus_NumberOfCommonShareEntitledToReceive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" xlink:label="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfSharesIssuedAndFullyPaid" xlink:label="ifrs-full_NumberOfSharesIssuedAndFullyPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PercentageOfInitialVestingOptions" xlink:label="mrus_PercentageOfInitialVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PercentageOfRemainingVestingOptions" xlink:label="mrus_PercentageOfRemainingVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PercentageOfVestingOptions" xlink:label="mrus_PercentageOfVestingOptions"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PeriodOfAwardsWillBeVestedAndExercised" xlink:label="mrus_PeriodOfAwardsWillBeVestedAndExercised"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PeriodOfRemainingOptionsVestingPeriod" xlink:label="mrus_PeriodOfRemainingOptionsVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" xlink:label="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_PotentialOrdinaryShareTransactionsMember" xlink:label="ifrs-full_PotentialOrdinaryShareTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ProceedsFromIssuanceOfPrivatePlacementUnits" xlink:label="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharebasedCompensationAwardVestingPeriod" xlink:label="mrus_SharebasedCompensationAwardVestingPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" xlink:label="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ShareBasedPaymentExpense" xlink:label="mrus_ShareBasedPaymentExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePrice1" xlink:label="mrus_SharePrice1"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TwoThousandSixteenOptionPlanMember" xlink:label="mrus_TwoThousandSixteenOptionPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ProceedsFromIssuanceOfPrivatePlacementUnits" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NetProceedsFromIssuingShares" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_IncreaseDecreaseInCapital" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_IncreaseDecreaseInSharePremium" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfSharesIssuedAndFullyPaid" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ShareBasedPaymentExpense" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfOptionsGranted" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharebasedCompensationAwardVestingPeriod" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfInitialVestingOptions" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfRemainingVestingOptions" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfRemainingOptionsVestingPeriod" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PercentageOfVestingOptions" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfOptionLapse" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_NumberOfCommonShareEntitledToReceive" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_PeriodOfAwardsWillBeVestedAndExercised" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_DescriptionOfGrantAward" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharebasedCompensationWeightedAverageRemainingContractualLife" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharePrice1" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncyteCorporationMember" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_PotentialOrdinaryShareTransactionsMember" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="mrus_NonexecutiveCompensationProgramMember" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="mrus_TwoThousandSixteenOptionPlanMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AllOtherEmployeesMember" xlink:label="mrus_AllOtherEmployeesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ContractualLifeOfShareAwards" xlink:label="mrus_ContractualLifeOfShareAwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_EmployeeOptionExercisedPricePerShare" xlink:label="mrus_EmployeeOptionExercisedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FairValueAssumptionsGrantDateSharePrice" xlink:label="mrus_FairValueAssumptionsGrantDateSharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SharePurchasedPricePerShare" xlink:label="mrus_SharePurchasedPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_FairValueAssumptionsGrantDateSharePrice" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_SharePurchasedPricePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_EmployeeOptionExercisedPricePerShare" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="mrus_ContractualLifeOfShareAwards" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AllOtherEmployeesMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement" xlink:label="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WeightedAverageExercisePricePerShareOptionsExpired" xlink:label="mrus_WeightedAverageExercisePricePerShareOptionsExpired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="mrus_WeightedAverageExercisePricePerShareOptionsExpired" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement_2" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AllOtherEmployeesMember" xlink:label="mrus_AllOtherEmployeesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_AllOtherEmployeesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CollaborationIncomeMember" xlink:label="mrus_CollaborationIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeMember" xlink:label="mrus_IncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueFromContractsWithCustomersMember" xlink:label="mrus_RevenueFromContractsWithCustomersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueLineItems" xlink:label="mrus_RevenueLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueTable" xlink:label="mrus_RevenueTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontPaymentAmortizationMember" xlink:label="mrus_UpfrontPaymentAmortizationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_UpfrontPaymentAmortizationMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_CollaborationIncomeMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_RevenueFromContractsWithCustomersMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_IncomeMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="mrus_RevenueTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="ifrs-full_Revenue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="mrus_RevenueLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CollaborationIncomeMember" xlink:label="mrus_CollaborationIncomeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_GrantIncome" xlink:label="mrus_GrantIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IFRS15RevenueFromContractsWithCustomersMember" xlink:label="mrus_IFRS15RevenueFromContractsWithCustomersMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncreaseDecreaseInDeferredRevenue1" xlink:label="mrus_IncreaseDecreaseInDeferredRevenue1"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncyteCollaborationAgreementMember" xlink:label="mrus_IncyteCollaborationAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_MilestoneRevenues" xlink:label="mrus_MilestoneRevenues"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_MilestoneRevenuesAndCostsReimbursements" xlink:label="mrus_MilestoneRevenuesAndCostsReimbursements"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OnoResearchAndLicenseAgreementMember" xlink:label="mrus_OnoResearchAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ReimbursementOfGrant" xlink:label="mrus_ReimbursementOfGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueLineItems" xlink:label="mrus_RevenueLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRecognizedIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedIncludedInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueRecognizedNotIncludedInDeferredRevenue" xlink:label="mrus_RevenueRecognizedNotIncludedInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RevenueTable" xlink:label="mrus_RevenueTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SimcereCollaborationAndLicenseAgreementMember" xlink:label="mrus_SimcereCollaborationAndLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TermsOfPaymentOfTradeReceivables" xlink:label="mrus_TermsOfPaymentOfTradeReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UpfrontPaymentAmortization" xlink:label="mrus_UpfrontPaymentAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="mrus_CollaborationIncomeMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_GrantIncome" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_ReimbursementOfGrant" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_TermsOfPaymentOfTradeReceivables" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_IncreaseDecreaseInDeferredRevenue1" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_RevenueRecognizedIncludedInDeferredRevenue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_MilestoneRevenuesAndCostsReimbursements" xlink:to="mrus_RevenueRecognizedNotIncludedInDeferredRevenue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="mrus_IFRS15RevenueFromContractsWithCustomersMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="mrus_RevenueTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_UpfrontPaymentAmortization" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="ifrs-full_Revenue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_MilestoneRevenuesAndCostsReimbursements" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueLineItems" xlink:to="mrus_MilestoneRevenues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_TypesOfContractsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RevenueTable" xlink:to="mrus_RevenueLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_IncyteCollaborationAgreementMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_OnoResearchAndLicenseAgreementMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="mrus_SimcereCollaborationAndLicenseAgreementMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdditionsInContractAssets" xlink:label="mrus_AdditionsInContractAssets"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdditionsInContractLiabilities" xlink:label="mrus_AdditionsInContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AdditionsToTradeAndOtherReceivables" xlink:label="mrus_AdditionsToTradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ifrs-full_ContractAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractAssets" xlink:label="ifrs-full_ContractAssets_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities_2"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeductionsInContractAssets" xlink:label="mrus_DeductionsInContractAssets"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeductionsInContractLiabilities" xlink:label="mrus_DeductionsInContractLiabilities"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeductionsInTradeAndOtherReceivables" xlink:label="mrus_DeductionsInTradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DeferredRevenueMember" xlink:label="mrus_DeferredRevenueMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:label="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="ifrs-full_TradeAndOtherReceivables"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeAndOtherReceivables" xlink:label="ifrs-full_TradeAndOtherReceivables_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_TradeReceivablesMember" xlink:label="ifrs-full_TradeReceivablesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_UnbilledReceivablesMember" xlink:label="mrus_UnbilledReceivablesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_TradeReceivablesMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="mrus_UnbilledReceivablesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesAbstract" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherReceivables" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsToTradeAndOtherReceivables" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInTradeAndOtherReceivables" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_TradeAndOtherReceivables_2" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractAssets" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsInContractAssets" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInContractAssets" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractAssets_2" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractLiabilities" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_AdditionsInContractLiabilities" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="mrus_DeductionsInContractLiabilities" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" xlink:to="ifrs-full_ContractLiabilities_2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesTable" xlink:to="mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="mrus_DeferredRevenueMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfOperatingExpensesAbstract" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IPAndLicenseCosts" xlink:label="mrus_IPAndLicenseCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_LitigationCosts" xlink:label="mrus_LitigationCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ManufacturingCost" xlink:label="mrus_ManufacturingCost"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherOperatingExpenses" xlink:label="mrus_OtherOperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherResearchAndDevelopmentExpenses" xlink:label="mrus_OtherResearchAndDevelopmentExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PersonnelRelatedResearchAndDevelopmentExpense" xlink:label="mrus_PersonnelRelatedResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_ManufacturingCost" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_IPAndLicenseCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_PersonnelRelatedResearchAndDevelopmentExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_OtherResearchAndDevelopmentExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_LitigationCosts" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_OtherOperatingExpenses" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_OtherExpenseByNature" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_OperatingExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_AttorneysFees" xlink:label="mrus_AttorneysFees"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfOperatingExpensesAbstract" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_LitigationAndOppositionExpenses" xlink:label="mrus_LitigationAndOppositionExpenses"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_LitigationExpenses" xlink:label="mrus_LitigationExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_AttorneysFees" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="ifrs-full_ProfessionalFeesExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_LitigationExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_LitigationAndOppositionExpenses" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ClinicalCosts" xlink:label="mrus_ClinicalCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfOperatingExpensesAbstract" xlink:label="mrus_DisclosureOfOperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DiscoveryAndPreclinicalCosts" xlink:label="mrus_DiscoveryAndPreclinicalCosts"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherResearchAndDevelopmentExpenseOther" xlink:label="mrus_OtherResearchAndDevelopmentExpenseOther"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherResearchAndDevelopmentExpenses" xlink:label="mrus_OtherResearchAndDevelopmentExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_DiscoveryAndPreclinicalCosts" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_ClinicalCosts" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_OtherResearchAndDevelopmentExpenseOther" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingExpensesAbstract" xlink:to="mrus_OtherResearchAndDevelopmentExpenses" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_HealthInsurance" xlink:label="mrus_HealthInsurance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PensionCosts" xlink:label="mrus_PensionCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_WBSOSubsidy" xlink:label="mrus_WBSOSubsidy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_WagesAndSalaries" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="mrus_WBSOSubsidy" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_SocialSecurityContributions" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="mrus_HealthInsurance" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="mrus_PensionCosts" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfEmployeeBenefitsAbstract" xlink:label="mrus_DisclosureOfEmployeeBenefitsAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfEmployeeBenefitsTable" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:label="mrus_DisclosureOfShareOfEquityInvestmentLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ManagementAndAdministrationCostsMember" xlink:label="mrus_ManagementAndAdministrationCostsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OtherExpensesMember" xlink:label="mrus_OtherExpensesMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ResearchAndDevelopmentCostsMember" xlink:label="mrus_ResearchAndDevelopmentCostsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_StockAwardExpense" xlink:label="mrus_StockAwardExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsAbstract" xlink:to="mrus_DisclosureOfEmployeeBenefitsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_DisclosureOfShareOfEquityInvestmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfShareOfEquityInvestmentLineItems" xlink:to="mrus_StockAwardExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ResearchAndDevelopmentCostsMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ManagementAndAdministrationCostsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_OtherExpensesMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:label="mrus_DisclosureOfEmployeeBenefitsLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfEmployeeBenefitsTable" xlink:label="mrus_DisclosureOfEmployeeBenefitsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationAxis" xlink:label="mrus_IncomeStatementLineItemLocationAxis"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_IncomeStatementLineItemLocationMember" xlink:label="mrus_IncomeStatementLineItemLocationMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_ManagementAndAdministrationCostsMember" xlink:label="mrus_ManagementAndAdministrationCostsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_NL" xlink:label="country_NL"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SubsidiesIncome" xlink:label="mrus_SubsidiesIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:to="mrus_SubsidiesIncome" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsLineItems" xlink:to="ifrs-full_NumberOfEmployees" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_IncomeStatementLineItemLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfEmployeeBenefitsTable" xlink:to="mrus_DisclosureOfEmployeeBenefitsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_NL" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationAxis" xlink:to="mrus_IncomeStatementLineItemLocationMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_IncomeStatementLineItemLocationMember" xlink:to="mrus_ManagementAndAdministrationCostsMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract" xlink:to="mrus_DisclosureOfEmployeeBenefitsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_InterestAndRelatedIncome" xlink:label="mrus_InterestAndRelatedIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_InterestExpense" xlink:label="ifrs-full_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RentalExpensesOnRealEstateAbstract" xlink:label="mrus_RentalExpensesOnRealEstateAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="mrus_InterestAndRelatedIncome" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_NetForeignExchangeGain" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_FinanceIncome" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_InterestExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_NetForeignExchangeLoss" order="1.0500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="ifrs-full_FinanceCosts" order="1.0600" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency" xlink:label="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FinanceIncomeExpenseLineItems" xlink:label="mrus_FinanceIncomeExpenseLineItems"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_FinanceIncomeExpenseTable" xlink:label="mrus_FinanceIncomeExpenseTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_PrivatePlacementsMember" xlink:label="mrus_PrivatePlacementsMember"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RentalExpensesOnRealEstateAbstract" xlink:label="mrus_RentalExpensesOnRealEstateAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="mrus_PrivatePlacementsMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_FinanceIncomeExpenseLineItems" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_FinanceIncomeExpenseLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_FinanceIncomeExpenseLineItems" xlink:to="mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_FinanceIncomeExpenseTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_FinanceIncomeExpenseTable" xlink:to="mrus_FinanceIncomeExpenseLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_RentalExpensesOnRealEstateAbstract" xlink:to="mrus_FinanceIncomeExpenseTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/DisclosureOperatingLeaseAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfOperatingLeaseAbstract" xlink:label="mrus_DisclosureOfOperatingLeaseAbstract"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_LeasesExpirationPeriod" xlink:label="mrus_LeasesExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_OperatingLeaseTermOfLeaseAgreement" xlink:label="mrus_OperatingLeaseTermOfLeaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_RentalExpense" xlink:label="ifrs-full_RentalExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_RentAndServiceChargesExpense" xlink:label="mrus_RentAndServiceChargesExpense"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_SecurityDeposits" xlink:label="mrus_SecurityDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingLeaseAbstract" xlink:to="ifrs-full_RentalExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingLeaseAbstract" xlink:to="mrus_OperatingLeaseTermOfLeaseAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingLeaseAbstract" xlink:to="mrus_LeasesExpirationPeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingLeaseAbstract" xlink:to="mrus_RentAndServiceChargesExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_DisclosureOfOperatingLeaseAbstract" xlink:to="mrus_SecurityDeposits" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfAccountingPolicyForSeasonality" xlink:label="mrus_DescriptionOfAccountingPolicyForSeasonality"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory" xlink:label="mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DescriptionOfAccountingPolicyForSeasonality" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" xlink:label="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" xlink:label="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" xlink:label="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfHeldToMaturityInvestmentExplanatory" xlink:label="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfHeldToMaturityInvestmentExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory" xlink:label="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" xlink:label="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfDeferredIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredIncomeExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfDeferredIncomeExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDeferredRevenueExplanatory" xlink:label="mrus_DisclosureOfDeferredRevenueExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDeferredRevenueExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" xlink:label="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfInformationAboutRevenueExplanatory" xlink:label="mrus_DisclosureOfInformationAboutRevenueExplanatory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfInformationAboutRevenueExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfOperatingExpensesExplanatory" xlink:label="mrus_DisclosureOfOperatingExpensesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfOperatingExpensesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" xlink:label="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory">
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_DisclosureOfOperatingLeaseExplanatory" xlink:label="mrus_DisclosureOfOperatingLeaseExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="mrus_DisclosureOfOperatingLeaseExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2018-03-16/full_ifrs/full_ifrs-cor_2018-03-16.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <loc xlink:type="locator" xlink:href="mrus-20180630.xsd#mrus_TextBlockAbstract" xlink:label="mrus_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mrus_TextBlockAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g569434g02u78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g02u78.jpg
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M5;^?")UG?JJ8S]0Y5R=^-HPCSOL*Z)!M_P#C^&MQ^G545.B.FX@H7GCH[1V
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MW(]M0>[SY\?I2(;+>SS_ .W]F^/Q_P"7V^/QXZT5TO%V>G\2GUIQR_VY,_\
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M5/N[[-L2JD)NG*E6_P!;=<9J6".::E=Q>(HS2(':K[+BX_;! 6W"/+)* [J
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M+-)V]\?H^:1\KTC"-AC]\CE>[XX83HX8F>57VQ11LCC;X9&QK41$<1U3U"
M,M:V  &[*3L/J2I)_,DD_/3$WIWT0Q+'IO&[L23M&ZC<G<[*L@51]   /@ !
MJ361R&8P6:I\=C*.NS67SX; *:CJ1V"U]>(QSY/B@A9_;Y9))II'JZ6>>66>
M=\DTCWN9K%B>U-)8LRO-/*W*260\G=M@-R?L  !\      -2JE2JXZK!2HUX
MZM2M&(X*\*A8XD&YXJ!]2223N68EF)))UQ.1^+..N7L\F4Y.QF?W&>:=!9Q5
M6AKX3QQK(:.:&"P$61/E#-B@))':4+)#/].22.LBPD3,?TIWK>/E[]*Q+6FX
ME"\+E24)!*-MX9254\6!&Z@[;@'7#)XC&9JM['E:-:_6[BRB&S&LBK*@(61-
M_*. S*'0AN+,N_%B"B^,^V?@'ANX)T/&'$N+QE\6&^OFNJ>HB9:_02OCDF"B
ML)UG+'%(DAA>2./+%$0Z&%9VR+%'[5-W,Y7(QK#=OV;$2MS$<DA[?,#8,4&R
MLP!/$L"5W.VVYW0XKI;IW"3/9Q.'HT;#H8VG@A43=LD$H)&Y.J,0"RJ0&*KR
M!XC9\NFS3_J-^S[0.V/D/36VRVO">$T6HO9HR;B[/JO)MB1%!$*P@M\,L399
M_@@B8^5S/DD]B.D<]ZJY7BOG\U4ACKULE:A@B!6.-)/=122VR@@[#<GQ\O@/
M&HO>Z*Z4R=N:]?P./LV[#!IYY(?WDK!0H9RK*"W%0"VVYVW))\Z<OC3B3C/A
MNC)S7%N)S^&HS;&6W,KL^"P.$RSF@'&D.+<BNE))4848=))I'N9!!%$SVQL:
MU$5R_<R$JS7;,UJ54$:O,Y8J@)8*OR5=V)V 'DDGR=.N*PV*PE=JN)H5L?7>
M1IGBK1A%>5E53(Y\L[<45=V)(554;  :<7I)ISU&3E+LS[7N9[ FXY%X7Q]Q
M=FO=(=?5T)V5O["9W\SV-YDC:*UL9OZ24XLB1$1&^[VHB=/5'J+-8Y!'3R-B
M.)?PQ.5GB4?1(IUE1!]E4#Y_'45RW1'2><D:;)X.E/.^Y>Q&LE2Q(3\Y+%-X
M)I#]"[L1IEJ_TM^QZO*:5_P<F-<QR/C@L.0.2216JB^41PZZYL<[4_A6$I,Q
MR?A[7=.+];=2LO']HA?J4J4PQ_7V?Q_U=M,47I+T#$X?]AF0CR%ER.4=!^:F
MYLWY-R'UWU+WCCA_BSB"LEJ.+^/LC@P"/C4R/,T8%7/8OA14BEM#1X6FVL\;
M55K2+$@J9&K[4D\?CI@N9"]D'$EVW8M,-^)FE>0(#\0BL>*#[( /MJ:8S"XC
M"Q&#$XVGCXVVYBI7CA,I7P&F=5#S,!_%*SM]]=+D'CG#<K98[$\C9BJU^5L9
M1)S*2Y@6<.:< F,P.?PUT<L<PY,,<L4L,D<C516^[V/>UWBI;LT9ULU)Y*\Z
M!@LD9V8!E*L/H05)!!!&NN2QF/S%22ADZD-VG*49X)UY(S1L'1OB"&5@"&4@
MCZ[$Z86F[&.T;/V]9>U' F!$M:8\2TK2E!*(^E/!G82(2D)1DX\CH)XHY6-F
MADC]S$5S%\>.G23J;/RQO%)E+31R*R.O)1R1@58;JH(W!(.Q&H[!T!T96FBL
M0].XY)H)$FB?MNW"2-@Z,%=V4E6 (Y C<?#4K^F+4PT=&C42^6^Q?M5YOO2M
M5R%Q#2FZ@]_RGZ&CL;_(VED0OA'%6TN4M:>*X,<U$8XRVA-)5C6-67PQGM?J
M'4V<QL2P5+\BP)X2&5(IXT'\J"=)#&OS"H57?<[>3J'9GH#I#/6'MY+"P26Y
M#O)9@DL4II6_GF:G- )G/P+S!V( !/@;>_B'LJ[7^"[.&^XWXASU7HAW>\72
M6\]MK;\&7Q[5FJ[35V%T53RN:JL>^H>"KF.<Q?V.<B^,AU'FLFABN7YGA/XH
M8PD$3#Z/' L:R#Y_O WGS\AKIA>A>D^GY18Q>%K0V5\K:F::Y9C/UBFN23O"
M3\"83'N/'PWUT>5NS_MMYOU";7E/BJFUNI2M$J%N2;'0UY+Z\%\[Q!YF4UQ7
M03_ I$K8YIH7SI&K8EE6*.)C/%'J#,8R#V:C>DKP<VD[82%QS;8,09(W(WV&
MX! W\[;DZZYCHOI?/VQ>R^(@NVQ$D/?>2S&YBC+%%8031*W'DVS,"VVPWV
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MQ);SI3\F]NO!G,QP%IREQ5BMO:U@Z!@VUY2C3VHX22OF:"EG&V(]X#)I99F
MR$/$9+--*R%KYI'.X4LOD\<K)1O6:R.>31Q2,(RVP'+@=TY;  L!R( &^P&E
M>5Z9Z?SDD<N7Q%&_-$O".:Q C3+'N6$8E&TG;#,S",L4#$D+N2==,'@WARLP
M+^+*_C##B<<2F#V,^)@S=6S-DV(M@):CV!=4@_TI9T5D $>TPEDI/U08TRRJ
M^"-6^&R>0>U[<]VRUSB4%DS/W@C(T90/ON%*,R\00O%B-O)UUCP&$AQQQ$6*
FH)C#(LK4%JQ"JTJ2I,LCP\>#R"6..3FX+<T5B=U&G4Z0Z=]?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g569434g04t94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g04t94.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1S@4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  %1&5L=&$< @4 -TUI
M8W)O<V]F="!7;W)D("T@365R=7,@+2!&+3$@4V5L;&EN9R!3:&%R96AO;&1E
M<G,@+F1O8W@ .$))300E       0 N028I-(E$*<Q"1!X98HL#A"24T$.@
M   !,P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #0 ,       #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8KC8         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _0      !( -0    $ +0    8       $X0DE- _<      !P  /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      $U   !70         !                          $
M     5T   $U                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   $U     %)G:'1L;VYG   !70    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !-0    !2
M9VAT;&]N9P   5T    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     $X0DE-! P     $GX    !    H    (X   '@  $*0
M$F( &  !_]C_[0 ,061O8F5?0TT  __N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( (X
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M^UN_[CW?<W_R:2F7V+#_ -!7_F-_N2^Q8?\ H*_\QO\ <H_:W?\ <>[[F_\
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MOX+ND=0Q:\S#95=CVSLL#  8)8[Z36N^DU9XZ#T1MC+&=.NK>Q]5@+'.;+J
M68V_;=[_ $=WZ/<KV!5B]-Q6XF#A648["2VMH$ N)>_Z5A^D]VY)3:^QX?\
MH*_\QO\ <E]BP_\ 05_YC?[E'[6[_N/=]S?_ ":7VMW_ ''N^YO_ )-)3+['
MA_Z"O_,;_<E]BP_]!7_F-_N4?M;O^X]WW-_\FE]K=_W'N^YO_DTE/__0]+Z;
M_0:?A_%6E5Z;_0:?A_% ZGD=8I<3@4,O9L&T.Y]2?H..]NVNSV,]3;^@]]_Z
M79Z*2FU;>]F512 -MH>7$\^T-B/\Y'6!D9?7A9@V58-.1D$7[F6W'%@ M#';
M/2S_ *5?_"HAS_K;)CH^) X_7W:__"])3MI+$^W_ %MG_D?$B/\ N>[F./\
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M9JO5@85%@LIHKKL&Z'-: 1O=ZENH'^$L][_Y:+O=_HW?]'_R26]W^C=_T?\
MR22F:2AO=_HW?]'_ ,DEO=_HW?\ 1_\ ))*9IB X$.$@Z$'A1WN_T;O^C_Y)
M+>[_ $;O^C_Y))3&C%Q<;=]GJ93O@NV-#9@;&SM_=:$50WN_T;O^C_Y)+>[_
M $;O^C_Y))3-)0WN_P!&[_H_^22WN_T;O^C_ .224QOQ<;(#1D5,M#3+0]H<
M 8V_G*====5;:JFAE; &L8T0 !HUK0$V]W^C=_T?_));W?Z-W_1_\DDIS+_J
MMT&\6[L1@?<;2ZUL[PZ\/9>]CC]#=ZUKOY%EGJ*YB=-P,)]MF)0RE]^SU7-$
M%WIM%-.[_BZV[6H^]W^C=_T?_));W?Z-W_1_\DDI_]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
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M   !-0         & 0,  P    $ !@   1H !0    $   $R 1L !0    $
M  $Z 2@  P    $  @   @$ !     $   %" @( !     $
M $@    !    2     $X0DE- _T       @          /_A 41-30 J
M"  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    8   "PAVD
M!     $   "X    Y    \     !   #P     %!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C X.C(U(#$W.C4S.C4X $1E;'1A      .@
M 0 #     ?__  "@ @ $     0   5V@ P $     0   34         !@$#
M  ,    !  8   $:  4    !   !,@$;  4    !   !.@$H  ,    !  (
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MT1DE4F)H=8:QM>$H1F5GH[3%T_$**3,T0T1%@X62D\;2_\0 % $!
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MTR%E%)O,L)2VT64@3LE78;ET$GDBBZ(0IS"02JI$,)B"(>IV$0V/LLY!WV[
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MEGY@QW-)WS.XMGKI<7Q .6=I0EN"VGEWPP2,E*3TC)B:109":VV=G<LZX@/
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MON%!UW$-PV^O70<?VW[])(CX-(#0._U#>B_]?]GAH.P- H% H% H% H% H%
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M2XK@M:R6MUY(O&V;&A7J$)9KUJ=PJYG)(Z2;MPS18-SK.D Y8!;H[&(;B@4
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MF,_Y.YB@AMM:.I=;/4EC VJ*\BVVTQBA>24MV/<=<X/+J7"WB#,3+^EOFPI
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M0*!0>LFH6*N*)D(*=CVTI#RS19C)1SQ,%6SQHY3%-=NNF/08BA#"4VP@/3N
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g569434g08c57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g08c57.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1\:4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  %1&5L=&$< @4 -TUI
M8W)O<V]F="!7;W)D("T@365R=7,@+2!&+3$@4V5L;&EN9R!3:&%R96AO;&1E
M<G,@+F1O8W@#.$))300E       0 N028I-(E$*<Q"1!X98HL#A"24T$.@
M   !,P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #0 ,       #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8K)S         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          $Q   !A@         !                          $
M         88   $Q                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   $Q     %)G:'1L;VYG   !A@    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !,0
M  !29VAT;&]N9P   88    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M(V[_ -]4 RQGU@Q18\6/&!<TO],M)(LQ=[C=]!V__0?X+_KBUEFV?^*/'_\
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M]^14&47''<' E[1)@3[>6JBUEC/K!BML>;(P+6[BR)(LQ=[_ %?SM_\ HO\
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M2FAEX/U:S&,9=U!Y%=K+FQGV_2K.]G.044X_U9=._)99//J9;WS/_&7N6D[
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MVOT3ZGIADMDC<3])J2G_V0 X0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !0DU- "H    (
M  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #
M 0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    !@   +"':0 $
M     0   +@   #D  \/6P  )Q  #P];   G$$%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,3@Z,#@Z,C4@,3<Z-30Z,S$ 1&5L=&$      Z !
M  ,    !__\  * "  0    !   !AJ #  0    !   !,0         & 0,
M P    $ !@   1H !0    $   $R 1L !0    $   $Z 2@  P    $  @
M @$ !     $   %" @( !     $              $@    !    2     $X
M0DE- _T       @          /_A 41-30 J    "  ( 1(  P    $
M 1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X
M  !^ 3(  @   !0   "< 3L  @    8   "PAVD !     $   "X    Y
M \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R
M,#$X.C X.C(U(#$W.C4T.C,Q $1E;'1A      .@ 0 #     ?__  "@ @ $
M     0   8:@ P $     0   3$         !@$#  ,    !  8   $:  4
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M'^?3 'J M?QW[0_-.E_LAP!Z@+7\=^T/S3I?[(< >H"U_'?M#\TZ6^R' 'J
MM?QW[0_-.E_LAP!Z@+7\=^T/S3I?[(< >H"U_'?M#\TZ6^R' 'J M?QW[0_-
M.E_LAP!Z@+7\=VT/S3I?[(< >H"U_'=M#]_S3I?[(>G_ )?O]0.?4#:_CNV?
M[W]Z=+^]_BB]_P!L?XN@>C 'J!M?QW;/#_FG2_I_RZB'^+ 'J!M?QW;/_-.E
M_LBP#CU 6OX[]H?FG2_V0X ]0%K^._:'YITO]D. /4!:_COVA^:=+?9#@#U
M6OX[]H?FG2_V0X!SZ@;7\=VS_P!_S3I?[(NG\6 <>H"U_'?M#\TZ7^R' 'J
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M7'P&8^<<W]=P!ZPFN/@,Q\XYOZ[@#UA-<? 9CYQS?UW 'K":X^ S'SCF_KN
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M5F?L#6)=3KB$AY&51AF2[%J[DSL&JKD&;=S)N6;!!5?P^X11VZ00*(]3J%#
M*$6CGP%9C(JQ+:N=*U]VRUA'2 C96Q9EC>MR,7SJAP:+%)@NR=P15F"S2S6+
MSFB>),9-9G%RB(F. C.^/5[>?U8\\RTVL=R)V[7UJNESC6-*7U_-W:!O"*,N
M:9A(MQ0G#E*=D6,RHPC%WL.1%JJ[1<N(Q@X% HBJT2,'02WY=I*WY=^#HZ2Y
M2<?N1SJV,M(;4J>QWE%+!GMS6MR)'CB )91EP@3R2( 51N25&!F 9&.4"K^;
MW7<$?"-T G[ & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MQ6(I827))<DCFJM6I7J3K5IRJ5:DG.I.3S*<Y/,I2?:V]V^T[V26Q@# & ,
M8 P!@# & , 8 P!@$ <:OO?]._)[61_RQJ'4/X!P#)-*>XZ9^5O?WZ]]CX!+
M> , ^!5"'Z]PY#]T>Z;NF W='\ ]!'H/Y!]. ?/ & , 8!K(XR6.R63M%^T&
M5LE!G=?J16KN'4)$MIZ6J<LK8X2.DN3:<=;H\]3GI]!G%3R8F<L8^85CY]HF
M'<E(IBMT2P-L+UO//9X6VZ7K]33]>S? & , 8 P!@# & , ^M4@JI*) HHD*
MB9R JD(%53$Y1+XB9C%,4%"=>\03%, & !$HAZ,/W>HE/#3PGAIX?)X['AIX
M?)X:]9775<'8&NQ]E$E-E["M,=6Y",814+8G]?7BT4I6,\L64.2.K<8[5616
M_L4ZCL02)]R8JGMCAT(35:MQ5ZTU"248S<.%*4<_HP3?@\G2ZM<6T],TMTM*
MTVTJ75.K4JU[6G=1JRE1J]6HKK;NM!1<=YI4UE[IHL=F8<R, ^/?)U[O>+U]
MKIW@Z]?P=.O7 /E@# (OD]VZ=AK8E0Y?:-"C+LLY;LD:F^M<*UL2KMTHT2;-
MDX=9X1^==PJ^9)HI%0$ZAW;8I0$5DP-9E<V\)JG*M2C4;24)5(J3;QA*+><O
M*PO%=YMJ.@:Y<6;U"AI&I5K",)U)7E*RN)VRA34Y3FZ\:;IJ,8TZCD^+"4)/
ML9*&7C4C .BXDXYHH"+I^S;K&Z=U)=RBDH;K[70ASE,/7WN@>G(RES:]Y6J=
M22XHPG**YR49-+'/=+!W@$! ! >H#Z0$/2 @/M" Y)0, H9S1W\CJ::T%3$B
MT!]8=B[=IQ:Q V.YVR#LDP_K\XTDW)8F#JNKMA+O(AJR266EYE=9D$8 (E39
MOU%RIEMU:NEP^+T[Z[NJ%:I=T.II6UC3N^LIQEQ59YG?6DHRIK=14)1DL\52
M&-^PZ*:'K.ITM?OM/L57LM-T+4?C]W4KPMZ%M*ZMYT;:$ZE1<'%6J2X8Q4N-
MX;C"2SB[D!(.96$BI-VG'HN9!@U>*I1,@O*QA#.4BJ]&,DZC8=R];=#AX3A>
M*CU5"]!.U1-U(%Z?5\4NIG.=+/Y.=2"ISE#]&4J<:E6,&USBJDTOX3.1E"=.
M4H58\%2$G&<,YX9Q>)1SA9PTUG"/7RDI& , 8 P!@# & , 8 P!@# & 5_XT
M_>_Z=^3VL_HQ# ,ETI[CIGY6]_?KWV/@$MX!3OG-*[LA^/\ ;7NDH6,EY-)D
M[6LRCC84AK69BZVU;'=NG]<L$="R[CSAWT"MEFS96*DE6KA0(F1;/Q153#SY
MS@B'A#K33\C6J?L^BWB6;[%;120[6JU*Y$;4VQ1'LY*,#@X962&VE8;*8KML
MX,#I"3:,(*9!XU! TDY8D6:JB7]'9LE[\?>S9%@@8!JDY36KEQ%[\?--2+7H
M*2C!5=-!E!0QWS=6,?-7QKQ,Q21ZV\B7[V$12*J1=]8FDHUES1S2,@I=!POW
M!#]OLQ[_ #L6XX[3.R7&F[+)3"5KM$TSLNPAURGL5-*NV>QUED]=#1D9]8T;
M'D8FDD2-VYI%Q'D.1%3RE=,>X)<$E2.&]BVM9^>7.N3W%KB)U=;O6:X7-PK,
M-<65X:#%HO.3/D,B,TP:,T 6=@93Q&8I"HW\,O>.8#EP3V;?PGOCPCM[DGX<
M1M:P0, 8 P!@# & , 8!]:JJ:"2BZQRI(HIG554.(%(FFF43G.<P^@I2% 3&
M$?0  (CAM)-O9+=OP1*3DU&*RY-))<VV\)+ULI1Q;Y':KWM>-WR>MYIU,Q">
MP%JJTEE(YTSC92:I,:5E96L6Z<)D(]&-74+XADA$#I""Q.J?W6:RPO;>\J74
MJ$^.*K=6I<+2E*E%*:BW\[#?-;8W.YZ6=&=7Z/6.@T=5H0MZ\M.5Y.@JM.I6
MHV]_5=6TG6A!MT^MCG"EREF+PR[>;,X48!62K:]K;7D1L232-93+,*EKVPLF
MSB\7=W$-9>PS>R_/#I&!=V%:$(#TK%F0S8L>#1%-J@FW;I$2(4,*%&FKNM+T
M\JG1FLU*C2E.5?B:BYN*SPK;&-N1U-WJ5W/HWIE)_%5"I=ZE;3E&PL(5IT;:
MAI741E<0MHW#ZOCGB3J<<G.;E*3;;LWF:<L, JK;MM4"*Y/:RJ[ZP((3:>N-
MN0IV0HN#&+)S=LT&:,:B<J1D^\Y!,_0W>[I!#H<2B(9=6FWM2I0N84).B[._
MJJ>8X=.C5LU5EC.?0;79EYVR;BA5IKH[J\>+TEK?1Z.,/G*RZ287K>,^I-EJ
MLM&G& 5>W3K'6UIV5IB6L^O:18Y16T2#962G:G S#]5LV@72C9NJ\D(]PX.@
MW.4IT$C*"1$X%.F!1 !S"N:%&I5MY3I4IOK-W.$)-I1>%F2?)[I>[<ZS0]5U
M2TTK7*-IJ6H6U%6E*2I6]Y<T*493N(QG)0I5(Q4IQ;C)\.9)X;+/)IIHID22
M(1))(A4TTTRE(FFF0H%(0A"@!2$(4 *4I0 I2@    &9IRC;;;;;;>6WNVWS
M;?:V?/!!0OF)QDU_MJ^\8MR2ZTQ%;$TQN6I-:;-Q+E A4XZZ3+.)GF#YJY;N
M$W**J7A.FYB"BJ@\;(*"=1(IT5-;?65*XJVEQ)RC6MZR5.<6MHU'PS333SE<
MN6'OV'H'0SI5J6CZ;TJT*@J%73-=T:ZG?4*T)-NK849UK:I3G"47&49<4))\
M494YRCA-J2O)$QC:&C6,4S _DL>U1:HBJ8#JG(D0"^(L<"E ZRH@*BIP*4#*
M&,8"E >@;",5"*BN45A9Y^WQ?:<'6JRK5:E6>..I)SECDFWR66VDN23;PDMV
M>AE1;& , Z[M0R35RJ0>ADVZRA1Z=>AB)F, ]!]OT@'HR'R>.>&502E."?)R
MBGZFTF?AMV-VSO/^ V%>X&,VM$H1L)<K/$QZ(TNNJ&28QLV^9M$C'.T$QQ3;
MHIE$YA[QA#J(]1'/&+CI=KM.O6A&ZI\,*U6,5U4&U&-1Q2>W8OJ9^J&B?N:?
M@AO-&TBZK]';F=>ZTRPN*T_E.^BIU:UI2JU)85917%.4FDL)9QLC%4>VA[2%
MPU5>MMFLUV2+QK'J/$]?P"K9-\[(LHT:*+IL!3*Z=$06.W0$WBK%16\,A@3-
MTM_A?KV,JY36RRJ,,9;V7S?G/#PMLXREW9TOW-'P+1J*G/09QJ.G4K*D]8O5
M-TJ;2J55%U\]7!N*E->C%SBG++6?J=]M3VC4>\<,'^TXYD]:+*MG;-S0:^W<
MM'"!Q3717068D42625*<BJ2A"'3,40,4!#H)],-?64[F,6N:=*":\,-;-97?
MOC;NFG^YE^!FM3A4I='JU2E4BITZM/5KZ<)QFLQJ1G&X:E"4<.+64TTTWG+^
MH.VT[0T>O[K<1T#T=?416NG[_P#8G_VRE],->_RNGW_FH9?LP7/[F'X&]O\
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M@I&4.\00,UFG;?O'D&2 *-FZ@ 5)4Y1ZX&-O6W]45[O7VM]F#9S@# & , 8
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M9?\ WET;_GRT \_]2!_L?<@_H8L_X!'_ /S)6JT'_B;M>NVF/Q<:U^L>C?\
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MN49*,9.3GEO7U1/=Q3>O^ZNN_O?VW9]<Y^A^?H_ZVG_QH]DU;_!6I_[/O?\
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M8 P!@# & , 8!#NYO[7:_P#EBU=_VJ9YM=)_.7W^RM1_Y:98K_-I_P"OH_\
MR1)BS5%\8!YLG"P\TFFE,1,;+)(F,=%.38-7Z:1S%[ICID=)*E(8Q?N3&* "
M)?0(],IE&,OG1C+'+B2>/>7:5>M0;E1K5:+:PW2J3IMI;I-P:;6=]SL,V3*.
M;),H]HU8,T ,"+1FW2:MD0.<RAP200(1),#J'.H;N$#O',8P]3&$1E)16$DD
MN22PE[$43G.I)SJ3E4G+YTYR<Y2PDEF4FV\));ODDC[EB>*DJEUZ>(F<G7\'
M?*)>O\'7*D\-/N:?N*3\PMS_ *'EGK7;[5:"\CH=H2R62<GRM#4MXH9J67E'
M<B5N90)$ 4%$'/A"?H &$O>  ZY]"6GPWV]M:VUO\A5I.A;T:+DKFFN)TJ<(
M.2]#.[CG#[\/)PU7H<ZE2I-7JCQU)S2ZM[<4F\<^SO,;_I<:P?X2\./_ .R7
MOH]H?1TD_P (?DR_^/:@N6@5DO"[I^_>F_._KH_ N7^71_\ :YOVM^?$Y_I<
M:?Z=/9+P_M=/<0]#^/SF/M^_[>/Q[4/\WZO\KAS[7CJ\9\1^!;_RY8[NJ>.[
M.,\SC^EQI_I]\O#_ #(>_P 7]<_1U_( ?DP_AVH//]X*O\KAZOXO[^[D1^!;
M_P M7_M/[P/]#C6 ?]LM#?E_T$/>H_D_ME[6/QZVZ_[@K?RN&%SW2X,>/KY8
M'X%O_+E_[3^\!_0XT^'^V7A_WO42]Z>G_G+_ #]?XLE_#M;[?W@K>+^-TT]M
MU_BWV^>Z7T+D_P#ZY/Q=)Y^L#_0XU@]/3DO#>GI[=(>]/1^3SG[_ +^/Q[6_
M/Y K+&>5U3[?7#O]_M'X%O&/CR[/\4]\<OTNSL_8>M ?T.U8(6=A9@>24.N$
M3+1TF*(4MZ05@8O$70I ;SB/=$_A=P#=!Z=>H]<M5OARMZM&M26A5DZM*I3R
M[FGMQP<<[07:TWZB8=#'&49?'4^&49?FW^B\X^=VGZ>X=B,7$Q<8*GC#'1S)
MB*H!W?%%HV2;BIW?>[XI][I[W7IGSU5GUE2I42PISG/'/'%)O'LS@[J*Q%+N
M27N6#T<H)( XU?>_Z=Z?%[6?;_XM0P#)-*>XZ9^5O?WZ]]CX!+> 8C?P8FH=
MV+)J/$HTU1L@2"L<@=U()L1AGH.U&+5,2G<O"(>(9L@00.LL!$RB F < TW]
MD--5Q"1VI38<C'HUI&M;/".VD-JGR]_3)B7OL?!NK98];(IO#VY1Q#R/G.M6
MTQY:)3\G>@<X2JIL82Y9YM[X^SVCN>-L=S3SV\_9[>Q8-WV , 8 P#6%Q>H3
M&@=HKVA#9C.VJ=+8]8\/;<X5M<VI-KQ[N=E.3:ZT5#JJ(HBPK[$2%3BXLH'(
MR2$Q"J' >N"?T5ZW]439[@@8 P!@$+<>EDFW';1SAPH1%%#2VLUEU5# 4B22
M5&A#J*',/H*4A2B8QA'H  (CF/:M?%;9]GQ>B_9U<6;WI*G+I-T@C%.4I:[J
MJ26[;>H5TDN]ME;^/#<W(C<%NY932"JE.@CRVKN.+1P4?)5*HP=>#;]F-DE
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ME6KRE)[<*55K;*W@\RZRM4?'7JOG4J/F_",?FPCRC%)=Y83-(9(P!@# & ,
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M&32G#BX9I/YT>.,)X?-<48OO2+Z>4GAKP?->O&5])W<I)& , 8 P!@# & ,
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MLOT(\MVR^.<<;(8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , K_QI^]_T[\GM9_1J'^;VL R72GN.F?E;W]^O?8^ 2W@$+<BZDG>
M-&;1K2CN'CQ>4^5=H24]3&>PXN,=PZ033.36I4@L@TL2T>ZCT7C*/65*!GJ+
M=0I5#IE3,!J<[(N)IL%;-FI0TM1Y"QV33FE;C,DU[H33NGXLC>8F-DD3/9I'
M5]DL[Z8N9)%K)M9.'L"L.C$-6S)Y&17]=W;E4-]NY9[^>V=N78NS?U&\S &
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MGBPZ=&I=SA<W490IP?%;VK?)]E6OC9U.V,.4.W,ME?O.,-D, 8 P!@# & ,
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M:6.L=1\M32M).I&XNIJK7C^;BEBC0[^JB]W+L=26[[%'MN1G+&<, 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!7_ (T_>_Z=
M]_\ <]K/I_YM1P#)M*^XZ9^5K?WZ]MCX!+6 8S=2]^FVT@1[R7$]9GBA%1RY
M6TA)]Z*=!YO8N3]2-WCWKY,V7, E265(H;T%' -._9)SMF/)[;JCU:]/ZS#5
M;7SZ(2L4SM9]#:^?O9>\MGVJ/)-HQK WJNJS9@P>3TE63KPSQC+0R( D=H'?
M#M]G=CSYSS1NNP!@# & :N^*]TH]U[13M#'%&!8&T%K;B!69_P 6L3-7ZVJ'
ME.3:$V)$9J)B%)9,5Q+W9UDF\C9+_P!*SD'1 $X"?T5ZW]GGVFS:3DF4/'/9
M:27!K'QS59Z]<F(HH5!LW3,JLJ)$2**G B93&$J9#G'IT*41]&5TZ<ZM2%*G
M'BG4DH0CE+,I/"66TEE][2*6TDV]DEE^I&L_:'::4IM+U_7?'O66RMV[3V$N
MYB=>H!5)>ETQ[()IB529D)FV-8J3-5H=0Q'$O,LH96,! ATD9'R@Q"#L]7T:
MOHEMQ:A=V%"^K>C::73N:=Y?59MX4JE*TE5IT*,$^*I.M6BXI84')I&_Z+:,
M^D->M<595;/0--2K:SK56FZ=O:T5OU-!U>%W-]77H6UO2C-SE).6(J3,+TCP
M3Y"S:MSMW*3>YT;)M&7&8OL'IA-:OO)5B7H6.IDA?78N)PE2A&P T90T $2T
M4 7"ZP"NX4/F3IE]I&@T85K#3HZAK=51J76JZLE6I4JR7S;&Q6*=.G3Y4^NE
M4DL9WRRCI1K-77JU"QM4]-Z-:7&=OI.EV\FI3I-^G=W]7G6O;MI5+B<5%<J<
M4HQ2-EVL]3ZZT[7$*IK6I1%3A41[ZB$:W KAZX$3&.\DWR@G>R;U4QC&4=OE
MUUS"80[X%Z &NU#4K[5*[N;^YJW-9[*526T(_P "G!8A3@L+$81BMN1S]*C2
MH1X*4(PCX+=OOD^;?BVV2)F"71@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & 5_XT^CC_IT/][VL_HU' ,ETI[CIGY6]_?K
MWV/@$MX!&NY:XPMVI]CUN3;3#UA+4NQ-G#* F):OS3TH1CA4K.-FH$Q9B.=.
MCID;IN([ONB^(()I+";PC@:2>RBO4-3MH6K7<_2+[#6&^T&CN("P2&J>:S%D
MP>0KZ^NYG6-DL^]VMDI:,C3VOD\H-NAYFJ05K6LB+&.9O7C,J*08]7=A8[/5
MV-=K[<[]B_0!@# & , U@\7;S$WOM%.T)=1$';H-. UEP]JKQ.X4Z>IB\A(P
MDER:0=RD*VL#"/6FZZ],8IXJR1Q'$1,) 99B[7(43 &.;[W]B)LY^\HT.'O&
MBZ;N5<11',&I'1L6QEZS(VIK,3,X\2C(N+/'QMBK"B*;IZX2*X?+28(M&_BK
M&;N!*"1KU"@J\I*6H6&ETZ<)U:E[J4IQMJ481;2Q2:JU*LY)0HTJ2E.I4E&,
M8MLWG1S3):SK%GIM/2M5UF=U4X%9:/5H4;R45Z52KUMU1K6].C0IJ56M4JJ$
M(4XRE*<4BOO98S-.WYIP_+M[.GV!MG9TI)Q-DL\I6AK2U);1 M1];&JPH24J
MQB:M7U7 J-%8I5$)DKHC^1!5^*Q\HN=!NM%NW'4:].\O[BWM[F5Q'K$XT;FG
M&K3H]554:E!PRTZ<X0F]IM2C*,I;OI?T@IW=2.@:195-&Z.Z/6K6]OIRN*5R
MKRZH5:E&MJMQ=4(QA>5KK@34^*I"CPNC3<%!PCM4R@X@8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 0!QI^]_T[\GM
M9_1J& 9)I3W'3/RM[^_7OL? );P#%+VHV2H]R5>2$M$LTJI8E'4K ]_SY&MB
M1#PR\A#>&4ZGG9FD!G,=X9#G\L31[A3&Z (&D+L=:U#U*X[>C&FS5[LM,ZXU
MU?(F)CJS#P<9%5F[WG;<ZV=W1S$;KW"5WMDTXXG8BR$=$JBB<-$U]1%K*)*@
M[3$OGVKLW>6VDL]B-]&"!@# & :P>+EW6O':)]H.Z6IMTI8P6LN'U7(VNT.6
M&<S:<)*<G&Y++!I%<.?+*S,@(.(:2,9(7C</$%!(>I<$]G_[2^J/GV=V"<^>
MG'W7/)WCA;M1[,C;[(0LTXBW\<?6\1(S=G96&%>I2<(Z191\;+"=D#]LBG(%
M<-/)E&9UDU%D!."I=?J=K2O+2=&JJV.*$X.A%RJ1J4Y*=.2BE)-*264TUC)V
MGP?](]2Z+=)K/5],J:="M2IUZ-9:K5A1LYVES2E1N82J3JT<5)49RZIPJ*2J
M<+2EAH]OA5JFCZ8X^T^B4.CR>O63%!!S.U^4J3RF+EMCB+C"6!VE$OF;-=5N
ML[0!,DB;RORX43+&?.CB=3-A\=O-0_?5_7N;B[J1IQJU;J+C4;ITH4XQ46DH
MTX1BHQ45P[-KM-1TDZI:O=1MW9.TC4K?$_B-S3NJ*MJES7K4^*M3G-.M)U93
MJ1DU*+EAQ2P6PP:$8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M8"3!/9[7W=R]OO\ 8;/,$# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M+L7)%SV,5%QB?A1L:PCTA-WO"8LV[1/O#[9NXW33+WA_#TZX(._@# & , 8
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MLX P!@# & , 8 P!@# *_P#&G[W[3OR>UG]&HX!DNE/<=,_*WO[]>^Q\ EO
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M 8 P!@# & , 8!7_ (T_>_Z=^3VL_HU# ,ETI[CIGY6]_?KWV/@$MX P!@#
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M<Z]/.-Z^AC='V?X ]E%ISWI&]#_B9W1]G_HP![*+3GXQO7T,[H_C_<_]'\.
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8 P!@# & , 8 P!@# & , 8 P!@# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g569434g12d69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g12d69.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1H&4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  %1&5L=&$< @4 -TUI
M8W)O<V]F="!7;W)D("T@365R=7,@+2!&+3$@4V5L;&EN9R!3:&%R96AO;&1E
M<G,@+F1O8W@ .$))300E       0 N028I-(E$*<Q"1!X98HL#A"24T$.@
M   !,P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #0 ,       #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8K"1         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          $G   "%P         !                          $
M         A<   $G                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   $G     %)G:'1L;VYG   "%P    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !)P
M  !29VAT;&]N9P   A<    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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MZ%I"DDDBM4AW_P R_P"!1$._^9?\"DI__]/U-GT!\$#+^GC#QMC_ *%B.SZ
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %"34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    &
ML(=I  0    !    N    .0 #P\1   G$  /#Q$  "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP.#HR-2 Q-SHU-3HQ. !$96QT80
M   #H $  P    '__P  H ( !     $   (7H , !     $   $G
M  8! P #     0 &   !&@ %     0   3(!&P %     0   3H!*  #
M 0 "   " 0 $     0   4(" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!1$U- "H    (  @!$@ #
M 0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    !@   +"':0 $     0   +@
M  #D   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,#@Z,C4@,3<Z-34Z,3@ 1&5L=&$      Z !  ,    !__\
M * "  0    !   "%Z #  0    !   !)P         & 0,  P    $ !@
M 1H !0    $   $R 1L !0    $   $Z 2@  P    $  @   @$ !     $
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M 0             &!P$% @0( PG_Q !Q$0 ! @0#! 0(!P<-" T*!04! @,
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M-E7&&>'6:87(U\0TE:]O3]O7A<"6/6[5@J"/BZZ4CT&2C4Q5A=2"*I"K*J(
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MYHQT1L!5@8%1?%,H84NUE O6#R,S6,KI%-E2I+@2TGQ@JRV[ZK4>A^2JVH2
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M$VC)6?309.>WWB&P$='C+POFAA 2%JJFSJV!LFA<<\6W6';S^3CB0.#[B,J
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M;F*NF9=%0#%/P^Q]_/D.Z\239Q <-DM].%&36RK-\2953*G@D*M<N94D$9;
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MK "<H&8'6.BATWF17#'+3\FCIKU>''2K6Z"CG5KNJ9)\,>8S 0QQ[,'7E$0
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MZ=6^VV.8?)IM'* V_,7PA82) SDV[6G,.&CIZ0QTPQR)>S@BT4W4XN1M@$
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MO2[9\Y=6)'5^Y:N.20SNDTCU8;*V0KIR+'-68&QTN99TP;7*5@N/$4%%&HK
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MQ4'9]2TEN8$]G2&DM! 4@M%0NHN*2H< #>-W%8B!0I"%(1%62/KAPM]U4_\
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MM;$4MR;ZMU1BXY9O5" Z%E9Z@$F^O(\+&*LE\041K9=X1R7JG*-K./DMA*W
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MAXFL=QLF9J6WFC@RX#L/L8-W3941V^D6(;SUIV\.5M5<KTR*9-%B;D9>6EG
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MI*_*!O$.1\-$#I_UJO!C67:8Z^+928.#-T^N9D4R<]2.1J?AW1**12IF @E
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MA??GMFS&PCM]O8_#\&W[]><ZC^#JCK^$".(_ZR7^@1Z(E_[X:KCJV85&W_\
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M&HS)*K@&UO.8M#TGZ"3;(CYL@F"2#?2]>Z"*28;$321<+$3(4 V "$(4I0
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M:K@L>TKLP=TB,K<<#&S$A:60+QG+<=OVR:ZL-+),5")OV)S@(H.2$4.4%4Q
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M;^?3PAOZ-7?7T=GL^R_4>$-L-_4ZZR_NK61W]WUVW7[^_=Z/O^]9Z?G<Q/\
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MA[P!]&4CS'TCR]'=S]\?2:--KG_]NFNJ_P![GKGS6]T>>%FW@_X"[-L,X?\
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MK.?A?3OQ>[^</?\ 3&UP[_>[XT_+"G?V1N+]S4%#W''+Q$]&,Y>,<B05V#]
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M_-G#[.PCORBP]D_SC80_'4K;_O'J(/?TC^])GV-F%_M$A_\ [#UC#_WEIO\
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MB26Q;,^$AB.59<8EJO@BK3C++Q&];2Z\%)"LMQ<:Z7/OC:P6TK8*]FY$L!%
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M>4=U!!%J@BV;)$0;MTDT$$4R@5-%%$@)I))E#D4B9"E(4H<@*  %<@   !8
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M !AP#X1\HK[\7PU&VOP3I?XV/;_CBXNB<U\(''?]'>G;;#DOQ[\1Z(WT1_U
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M4.KXOI>/<?6[^;BVW\U(1^93^:')!@Y?Z4X5!^Q/+I2][OU(\72(.4V?9H8
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M>)1P$*0CXN7*#-NNZ=+)MVS9)1===4X$2212*)U%%#F$"E(0H"8QA$   H2
M"3H!J3V".*UI;2I:U!"$ J4I1LE*1J22=  -23H!&N/%RZNJ[4P\S:9%0V'\
M&^$;4Q>HJ4>S7+>#DW57!<[<# !56S(B1&C)<@&#B$YDU-A&H_+7J=25._XI
M(YF94\G'B;.NC7@D )&GOBFJ$LX^QLYBC(HX<PKOZ=05*_<Y^HN'+.SZ$D6+
M;82&FEZ@D$@ZVC9%4@BYX4A"D(U_]()]9^'>>WZ]UDCSW'N?I>BHIBO]PIOX
MSEOZT7_X/PO5\9:V_8/6_3\2>PQ?9C]1-/\ @K?^Y$J5)^2/,/=%"/?NKO\
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M10/51T?6.-5U]1%^7?=5PP<A$6XA;:+:(;M54%&R#UZ]*L<RZA#=8*CTY1
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M2Q?D3/\ S@4A#L63/;)8OR)G_G I"'8LF>V2Q?D3/_.!2$.Q9,]LEB_(F?\
MG I"'8LF>V2Q?D3/_.!2$.Q9,]LEB_(F?^<"D(=BR9[9+%^1,_\ .!2$.Q9,
M]LEB_(F?^<"D(=BR9[9+%^1,_P#.!2$.Q9,]LEB_(F?^<"D(=BR7Y[DL7Y$S
M_P"?XTA'/8\E^V.QOD5/_G_37N/MAW[Z1QV+)?MDL7Y$S_Y_T[]]8=^^D.Q9
M,]LEB_(F?^<"D(=BR9[9+%^1,_\ .!2$.Q9+\]R6+\B9\/\ _OQI".>QY*]L
M=C?(J?\ S^I"'8LE^V2QOD5/_G_2$.QY*]L=C?(J?_/ZD(=CR5[8[&^14_\
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,*=-5#CR(]7T7C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g569434g13w29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g13w29.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Y^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  %1&5L=&$< @4 -TUI
M8W)O<V]F="!7;W)D("T@365R=7,@+2!&+3$@4V5L;&EN9R!3:&%R96AO;&1E
M<G,@+F1O8W@ .$))300E       0 N028I-(E$*<Q"1!X98HL#A"24T$.@
M   !,P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #0 ,       #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8K@^         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          $R   !B          !                          $
M         8@   $R                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   $R     %)G:'1L;VYG   !B     9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !,@
M  !29VAT;&]N9P   8@    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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MVGI?7Q>Y]O5 ZMF]M ]/\U["UC[6AU;7V57N;_.>O[*?\'Z]BG^S_K!)/[6
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M '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8
M   ! #A"24T$(@     !0DU- "H    (  @!$@ #     0 !   !&@ %
M 0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M    %    )P!.P "    !@   +"':0 $     0   +@   #D  \0/0  )Q
M#Q ]   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#@Z
M,C4@,3<Z-30Z,C$ 1&5L=&$      Z !  ,    !__\  * "  0    !   !
MB* #  0    !   !,@         & 0,  P    $ !@   1H !0    $   $R
M 1L !0    $   $Z 2@  P    $  @   @$ !     $   %" @( !     $
M             $@    !    2     $X0DE- _T       @          /_A
M 41-30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @
M  8   "PAVD !     $   "X    Y    \     !   #P     %!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C X.C(U(#$W.C4T.C(Q $1E
M;'1A      .@ 0 #     ?__  "@ @ $     0   8B@ P $     0   3(
M        !@$#  ,    !  8   $:  4    !   !,@$;  4    !   !.@$H
M  ,    !  (   (!  0    !   !0@("  0    !              /
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M 0$! 0$! 0$! 0$!_\  $0@!*@%] P$1  (1 0,1 ?_$ !\  0 !! (# 0
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MB,$]J0K:O$M4$>N,8)5RLO!PTTVFWBI8V,4.N4PE/Z^02;;2WPFW[$GU_O\
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M5%F3H@<ED#X!:R'1GZ>:UVRU)"6=)UNXU2D4:SQ!8./%I,U+6[Y.3HL"\ 7
MG,PK+])-U&$(<ATU" )SJ!W8!<0]'Y01N2>PAMLH-U2V#';53L?J+&>J)-B1
M%+/KJ-MH'[3J>JS.D*'K2*O9]F$:84Q2$_[)@% )T:6H$XQQ#$EW01;JM[#I
M[AEZA1W8*UG;$R:Q;&ACE%<1\#MTV8TE+% 0.HZ'KI'2#D& 6? ]&6S@N(/7
M^\FNZK"W+IK5CK5FGH1K6H<7E0AY=<ZDUVLV\5=/)-)1'LV\:FY,<\<F"@(J
M@4_5 ,]/'?E]OMY&1COA+,^V1$;?>;7M+C9D#5W]*A[DI$Q S$?5)1\62D(-
MNKW)%8NWY"NE2&1,<5"@(' .[ (RG.CFUA9=Q,-_3UBD)/;T:^AY5K=7$'%B
M_"8KS0S" FUVA%"Q3R;@V1C-H>8>,%Y&-2'DS<I"4HE<@6VIT?<[;=A<2L]M
MG=DE>Z3OF/U- $J[JN1H+I5O6D3+=6+L+CJI \(I9IV5EF!6BA2(I+E(MS4#
MD#'G[_'VDYY>CSZB:(_@_;Q6Q%]LQVT;,SV.ZI['7[FWHQ,2667ID:[*_85U
M53F*1XYH\(5PBF9$3E4* ]?EW8((C<=&1IQU=K1L1:9D1N%S;33:R2Z48V;^
MJ 6-F$=/N"L6[M*-8R$PQ#P21DXYFTD'2 F35<F Y^L!$.SNAWT[>*] 5FOV
MYW28=GL34MVL<?"5J,9LK.RU"RD8JN1#QLT702370BI [!*62*G) F4IU72J
MI$SE$Y?UKW\_K9.E Z.35^K5:(YH-BD*V]UF[ODA29!G"QJLA#2.T&J#'8<E
MX<[5<.I&2N#1JU;S;^55?.W23=%/M2E3(!8\-_T^?I(+39=%5H&/4NQVJ@D+
ML-C+1MK;*0,>X8O6$[(A+S#5C'N'"K&!2D90 D'00#>+%1V';B/7[\DAI/'H
M*:?HE>'A2L$J!W$D,.2<5L@*>#J%FS3B\>,2M(*V<LH%D645BQ&-.FK*G0,Q
M_:HI=C]Y@GSY]Q>"/1HZ>;),T&THJW18)ZU19I(5Z*23;IZ>?N)7692%35*7
M^PZ1=N7L2(@)BN%U%' KB8<#]/T[,BOB#Z*J'V]6'L76=I-ZW-2^VI+=$_(V
M#7L)96\Y?I^#2KD_97 @\92#&9D8ELS07<1SQ!NZ29(-7;55 .0"4VO=CQVS
MGSZR1]:]&W6*%POUSA+DMK6>Y:DA8=_%O*_.5Z &.DU)B?DK5*N0:)%_:/:6
M"7?OF)&BQ%(X#HD;+%% A\>?J#>7E^<+"^@HSCHH>'YU3(B@+.'?BO!3<A8X
MULG')H224W+MRM)606L*#]*PO%)-J4&T@1[*.$7:  DLF<@ &""\W'1Q:K=/
MDI%6<<^&(.M>/454Z]$H@DZU.BY0URNFDBH1$AZDB\=$BNJF!2 NH*P+"//(
M2QXOU@]>K^C>U9I:[/-BZOL<I3KD]82D6,U&Q3(YV,9.2*,O,QT*T>.7,? ,
MI63;HOI!M"-(])TY3*HL4XAD@H:71N02FQMAW.6VU9IR'V%L.B;L>5J1@X@[
M>+WC1&!(5ALF-42%(J,HXAF$"BLGU!(9Y$%>J JJX4Y 5J[]&WJG8SB[O;I/
MR,[([&G*Y9KG*+P[!O*S-@J3)Q&UN9-*,G#9^QD8=@Z<-&CJ-<,U 064(H)P
M-CQW]2\!Y\^=BMU/H_J%1CQYZI:Y"%/%T>1ULS,WK\,IU:-+N57LK7%P<BN5
MZQDW2ZR[\7H.%W9U3BX64 PA@$:PW1/</-?K%NIT.)F=>O2\(XLC(L(S55=*
MUIRJ\K8L9!=VK)0A*\Z77<0B<&\CDXM594S(J(J'ZP$96[H9],V^X:M?O[M.
M>(&L:3M"ILJ$6.(FB^=;0G:S/3<T[FD9!.9>/7;JOF+**OWSI641=G;NSJM@
M%$0^K[>OV$WSW1DZ9LSHCR;DEWBQ*/7-; 4L#'-&PT2HNQ?UFL*,F2[9FM&P
M;T3.8XBJ!U6RISF(K]\;F!=##H_J'&/H:2C[=*M'U>V-(;<A'*4+%@K&[)E6
M81\C<&XBH(%EW;(H-UE# 9(4PY D ]^!Y\^\[5[X"Z;LYW>W]^NDQ:7FS:;%
MZ]OSB4A8I12TTJ$D'$K%5R4%,Z8*1S&1=.':!$P34*JL<14$!Y8\\_/N&7[M
MUZ_*+3<=&EJ!UMAIO%Q,.E=ILI*+FV]K&"C.V">@XU*(A["I&@KZC+V*+C44
M6C"?7CE)=L1,ADW@*% X 774> JF4);6[BG728KZ^H$[VEK-2/A8LAJ:GLY^
MZE+\2'ZYS@F%ID'KMW*=L"W:*KG%/L@$ ",>OWORO8"M3?!9#62>NMGG]A3<
MS.[&IC77=YD)&!A':EGI+)5RLTK<JDL!FZ\:W5>.5$TP1*<IUC&[3F!>4@A%
MOT3W#\TJBU+;.Y%&"5GFEF#J-3!,-IQ@S&.8OV%E]4O&..,SCQ%@V182K=LD
MS$6Q$01$28] ]/AZ2-+#T,FD+7L6 LD_:I!_1*MI./TS7]<!"-6D0QC65_G;
MZJY469/&ZTBWD'\^^+)L)([Q"3754=2!7*I@, >/I\^63A-]&9IJQ;)B=NS,
MDJ\V#"*UQQ'3OB[$-RINJ@U18U1XXB&IT8-\^K;%NW90CU]&N7,:T00;M5$T
M44B$#T=%R*PWZ.K635*(01L#L$(&7O4]$(*5Z(7093&S2/4[\_317.HF9:TD
MD7I93M2J$5!RIV9$Q$.0$;P?1'<-M<BK)"0Z'@L;;8=I 3[<T.W="]AHZ4]6
MHV/36=O5UV"$7*<GL6$<HT-'*@7P,R!  H"<M<F250NCNUSK!W39&B6N8KTE
MK]2VK5&4;13%Q*1+B]E9$N#KU1?.'3U\[L!(YB21=22[QPJ1J@0JA"IE !'V
M\_210[Z)S5<- ;#C]6W26UK-[(IEBUS,6")AF;I6,HUV>IKW:!K+)X[78UAM
M/)F<JJ(P#>.;A(G2>'2,*?5%Y]8-D^L*%&ZLUU2-:PKA9S"T*KPM0A57":22
MP0U?8(Q<4@<B %2+X-'MF[8O4  $J0"/>(X!?6 , @+A[#E!;']_G>0_R[-L
MF!^DLRI:AH=OV#Q"34_#G>2*NX(Y$RY7[U !30TIITJ9>S0733#J\Q[^J!A\
MXB. 2)Y/.J/1U3Y4D_K6 /)YU1Z.*?*DG]:P!Y/.J/1U3Y4D_K6 /)YU1Z.J
M?*DG]:P!Y/.I_1Q3Y4D_K6 /)YU1Z.J?*DG]:P!Y/.J/1Q3Y4D_K6 /)YU1Z
M.J?*DG]:P!Y/.J/1U3Y4D_K6 /)YU1Z.*?*DG]:P1A<L<O/GQ'D\ZH]'5/E2
M3^M8)'D\ZH]'5.__ *4D_P ?/]]?C# 'D\ZH]'5/E23^M8(PMMN7+^X>3SJC
MT=4^5)/ZU@D>3SJCT=4^5)/ZU@#R>=4>CJGRI)_6L Y'AZU0/^#JGRI)_6L
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M?*DG]:P!Y/.J/1U3Y4D_K6 6OPO0,96J=?8:(0%M'L]Z;P2;H"JHL)"%V99
M*':*F.H;N /[HPC@%WZL]=G$![\K3YEM.8!,N , 8 P!@# & , 8 P!@# &
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M]D11)=22H\+9XQ]9F2< X1:39W$0BN9XF6*<N$$'YC)<FRJR1%1*8Y0$";\
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M# & , 8 P!@$!\/?X"V/[_&\OG.LG+^; *OJSUV<0/ORM/F5TY@$RX P!@#
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M(Z^SSZ?5[39=@D8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8! 7#W^ MC^_SO/YSK)@?I\^WF5C5GKLX@??E:?,
MKIS )EP#TN'"#1NNZ=+)-VS9%5PX<+G*DB@@B0RBRRRAQ B:2293'4.<0*0A
M1,80 !' ,-H_I .%N3M+6L-[I9TD'TLG!,;T_P!4[5C=0OI=9SX&@Q9;FD*8
MVU8Z5=/!(T9F0MITGCI5%LU.LNH1,0\]/JY_09G (& # (" @ @(=X" ]X"
M_B$, YP!@# -:NR;H]E^E!X4J8M0;U",J?H?BZ79WV:9U]*C7@;$3A??.6]*
M>,;'(3[MQ6%&Y(^REG:[72-W[EL2+6EVQU'"8?H^WSR-E6 , 8 P!@# & ,
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MAN1;<1RN>+3;MY,&9*^,6@@<[0ZWAPJ*@0V!MOX[;],+B^\V78 P!@# & ,
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MX+AA"$(KE&,8Q2]B217?!&O[V;_ I_Z.6>*7^M+WOST17A>'GRV/!&O[V;_
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MJ*YI)_..6_&_Q/-F]/!NE1B3="BH>%J-X^X1JP^R(1A -%6$.DUV,>D&N@>
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M9<?VA'Q>W_>*/YJ']4?<<U%[E>N/Q^L>L?ZKQ\JZI_&5_P"'[<N/[0?%[?\
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MF%@A18NW!%E(:-C5)0Y@<2)WBR::A \?3A^[/+JN>_B;,L 8 P!@# & , 8
MP!@'B<Y$B'55.5--,ICJ*',!"$(0!,<YSF$"E*4H"8QC" % !$1  PDVTDLM
M[)+=MODD@8%Z33/Q);SLG$Y+-Q5UKK@T]JOAN:N0,=O(I)O@;;'VX@W6*!2J
MVV4CF\)67Y42JA58E-9!<4Y=R4_9:L_D'2*'9^G+%_?JAJ.O..%*FW#BL-,E
M*/2VIU)5;BFY-?&*K4EFG'&MM_V7<2NVOQ5+CHVJ>V5G%6MA_P"O**C&2>'"
M*:_*:,]LXTV0P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P" N
M'K\!;']_G>?SG67 *QJSUV<0/ORM/F5TY@$RX P#YY]!UG46K.DX7UG1-1\/
MM0N2.V-XV*1L<!'Z;-.&UM9* LYKL+6G*5H>[@B]@-)Z,DGUG8#7V,,6%F[8
MT'L(EI#)8)WQSVSR6<?=G"6>I]#&""/]I;,JNH*+8-A7)X9I!UYDHZ5(B4%7
MK]QU1!I%QC?F!G<G(K]1JQ:D'K+.%"$#D B( 0?KGBXINR[A5*O#5:UM6-OB
MRKQ=L>'KQH(+"E5XRVR50739S;J7++Q47+LP</"QIX1=T8[=E*.3IGY",\O3
MGZ//WF6&"359:HC1ZW2H<-MXU^-.>;.L^C>+2,VO,5^30?SCWQ2\FF&J3.R)
M(.URM#Q+/U48L4SH-SB5-P4_:&1$2!ON^BX?>^+[%YR;4\ 8 P!@# & , 8
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M$*<%B,(J,5X)+"+GS'*Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MD91FX1;;WPM=96T9RE?U825>O+CCF=3-.C_FX</%P[KYTHXQE\MC8EG$&T&
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M!2E*  4I0#D!2@'(   #D !W '<&<6;(YP!@# & , 8 P!@# & , 8 P!@#
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MY3EF4F^;9*6:\O# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MI2>3:9GG9N!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M5M/\JC7AO&I#?*4D\/=89(C%BSC&;:/CVZ31DS13;M6R! 31012*!2)ID*
M4I0#D  &7DE%*,4DELDEA)>A&KG.=6<JE24ISG)RE*3S*4GNVVSMY)26A>:!
M1]FUUW4=AU*OW:KOSH*/:_9XIG,Q#I1LJ5=N=9B^26;J'06(15(QB"9-0I3E
M$#  Y;JTJ5:#IUJ<*M.7.$XJ47CEE/*9FZ?J-_I5U3O=,O+FPO*7$J=S:5IT
M*\%-.,E&I3E&24HMII/#6S*[$0\5 1K2'A(YG%13!($&4>P03;-&J)>?)-!!
M(I4TR!S'N* !E48Q@E&,5&*V2BDDEZ$C'K5ZUS5G6KU9UJU1\4ZE23G.<GS<
MI2;;?I94LJ+1UGC)G(M'#"0:MWK)VBHW=-':*;ALY05*)%$5T%2G3534*(E.
M0Y1*8!$!#ED-)IIK*>S3Y-%4)SI3C4ISE3J0DI0G"3C.$HO*E&46G&2>Z:::
M9UHB'BH".:Q$)',HF+8I$09Q\>V2:,VJ*90*1)!N@4B::9"@!2E*4 *4 * <
M@ ,B,8P2C%*,5LDEA)>"156K5;BI*M7JU*U6;<IU*LY3G)OFY2DVVWXME2RH
MMGS![(_4[4[?M@76[I\6,5%DMMHG+$2--I9T[,Q+,2+A\#0SHNT6P.#-P7[(
M5P;( J)>OV2?6ZH><7'8!UZ]6M\JJ'>U)U.'XBY</$V\9^-K..6<+U'W3HOZ
MLJVTC1]+TM_![7KO3K"TLG77:>G355VU&%'O%3>@3X./@XN'CEPYQQ/&2ROZ
MFLL'G#C B/S?<-=\N?Y_NL_S<OQ^R/=9_6[>/^6%_0.F<X_;GV^O.YLO\-JT
MS_S;W&.O^-=/?V?@]C#Z]7MX'A_4U,_S ?+!B?9 ?[1SL>8"(?\ :P'+ERY\
M^_F(B(^?NG];Q_QO'^@/T_\ ZWP>-L8PO A_JV;5_P#X<7'_ ,54]M\[?XO>
MA=>>7GH<_P!356#N_P!V#$#RY\N>C'@=_L?XVAY\OQ=WT/UNWTU?'_\ !Z=5
M^V^OZ>@_PV;7/_-Q7]#_  JIY^CL\O#8\R_J:ZQDZW4XQ(M/KE$B@$T>]*"A
M!'F)#\MM??%$?.!N8#[)<E?!Y)<M8VQR=C__ +%UW(?ZMBSDEQ?!M6>'F/\
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M9[8.Q:.$$$V??Z_/K]2)X5AMR3Y82RL;]=LOU)8Y;XR;=B\3G%:/+GT=.ZP
M0Y_NS\*O/G^4/NV\P[OX^?=D^>93MGGGTXECZL_0>CRD>,HXB*/1U;#*F81[
M,77$)PS(J 4?[D5TTMF..S'V3E(982ASY=<>0"'GK]J-2G23=*7TG'#%;]!P
M6M^"!K4&U\F' /2621:;L->WS>18LV](A7VJITC*LO5T7(J+^&J.Y=P9ZP69
M-DF[98L@)2SGQZ?W<W[#:LVW_P!(([;MUB]']66AG"*2O92'%A0D3MQ5(4_9
M.RMJD\.FJGSZBI4B+]4X" ";ESP0_1OO]'B=@-U=(FKR%/@9U(@4>X"ON,%@
MFJ4?QG!EIJ03 GY2*G/RY_><^0""QC?*?AA/Z<KSU-;?28[XZ;J!U;2G7#5P
MX5W6\JI< 1L\OHR[H<35S<L#)(>IK)>LV+3%9;04,J[[4LA+(,Y=10!*W,I&
MIAVS@2L==O7R7K?E>GH9S:HVKTK3G6E$<7OA-X9'=R6JL*I9G4GQ4VVH2+B:
M.P1,_6?U>.X;;2Q@'BC@3G<Q+2PS#=BJ)VZ3Y<A .(AYZ->Y_>B0?NG=)=S_
M /1%X5N7_P"<N\^;_P"$[S_Q8\^=B-_%>Y_>81=(-Q?=+'P^\-]FV#0^$O1\
M9,-7T6R5LM!W)<=]3-88NW14W,L;7CG2.MDWC<A![,[]2=70C1.#IS'NT2&3
MP2EXO?U87M>7]7Z))X0^)SI5MQ<.^L]B7+@]X?T[#8H(CAZZN/$'=M1STMU%
M#II3#K79= WWQ9+(I%*LFR-9Y 3!S7(""*R:1 ?H?O6?<T]UZ=L^'CDI]T[I
M+OX(O"M_\9=Z_P#XGA@C?Q7N?WF/7%?>.F G.';;$7I7AVT#K_9CJK+A6+?1
M>)J:O]UAU4G+9:24J51M'#O3(*8L;F'3D&4*1]9(\&TBY;/D"O739%@Y$K'5
M^Q1^WB?H_<^/K+]Z(-'CK0X1FI>D"<SKK;XWNQC6SW'P/Q[+KSP2'+$$N(M$
M43&D@FBV 6II$HRIHPS,71C(>"&$/5])M)P#\V#B"Z9'I/*OOK;]1J_%OL".
MAH+9EQ@H&):P=$5(SCF%@?,X]BW[6I*KJ DBFF@F*ASJ&Y%YG.8>8Q]/J_OZ
M=?L*\1V^;+&V<-=>3W75^SP9&5@Z9;I;ZG,R5=L_%EM6 GX=VJQE(>7J]$82
M,>[1Y]HV>LW%,36;+$'J@*:I"G 1 ! ,GV9\^>J*N"..K^:I;27+&^-M_#;9
M;\\%]V'I1NFUJ5(A=E6C?6_8#7UC[#U!N<OKZJ1];EO"2B9J+&7<T9-FX!R4
MIC(B14>U .:?7#D(BG$-\9V]*?NV6=]L^C.-\+U172F]-A-T&4VI#[^WW)ZW
MA5C-Y>\,=?5-S5HY9,R8*)NYI.C&8HF(*J93@98.H)R@;ES <C?T8\^>9/#'
MTI[[96>6V%C=_7TVW<8CTVW2I\@'RR=B>QW>H>ON7G\X<J=W@/\ 'RPGG..G
MGQ^O'AMAAJ'IY9QE>SI[_'HCO!TTG2Q>III@.+S9WJ4F\)''DO%RA^!%?G1%
MR#(SGQ-%$'1FX&6*@)^T%(!.!>J'/&?1X\M\8^D<">\4VGZ5MTWVZ/'K/6RZ
M:CI7Y)ZTC(_B^V8]?OW2#)BT:5Z@KN7CMR<B+9LW1)3A4467543323( G4.8
MI2@(F#G)&$O'WXZI97S7E;^OKC!6V_3-=*_&7%"M6'BVV:PDHVR(P<[#2%=H
MC1ZQ?-)4L?*1C]LI3BKMG39=-=JY15*15)9-1,P 8H\GGH3PQ_VNO5/IF/3&
M_CG'V_I/ZFEI&?U7K2=F'1WTM-:_ILM*/52IE4>2,C7(UX]=*%2(FD4[ARLJ
MJ<J9")@8X@0A2\@ 6UR1(& 0%P]_@+8_O\[S^<ZR8!6=6>NSB ]^1I\RVG,
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M%B\35(,BZ08NFRI8ZW"FX;2C@S6,<('"N=55"0=$.V8JIB9-TN4R*!E%"B4
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M"K=L:J LLF@!R"L=,ABI=<O7$O6#F&'Z/>OO.'G23\$,>9H1_OR!9'D'1&+
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M.BP<4TC <B0.X@K@U[42AW%$W(/-@@N? ("X>OP%L?W^=Y_.=9< K&K/79Q
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MR80RB(N8=L]DW[=FX;,Q3(S:<E55#HK*8!E)@# & , 8 P!@# & , @+A[_
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M@$R8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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L$/:4O@R?1@#L$/:4O@R?1@'F4I2!U2%*4O>/(H 4.8]XCR#D'>/>/X\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g569434g34o39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g34o39.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2+64&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  %1&5L=&$< @4 -TUI
M8W)O<V]F="!7;W)D("T@365R=7,@+2!&+3$@4V5L;&EN9R!3:&%R96AO;&1E
M<G,@+F1O8W@ .$))300E       0 N028I-(E$*<Q"1!X98HL#A"24T$.@
M   !,P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #0 ,       #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8KC8         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _0      !( -0    $ +0    8       $X0DE- _<      !P  /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      $U   !70         !                          $
M     5T   $U                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   $U     %)G:'1L;VYG   !70    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !-0    !2
M9VAT;&]N9P   5T    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     $X0DE-! P     &'0    !    H    (X   '@  $*0
M&%@ &  !_]C_[0 ,061O8F5?0TT  __N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( (X
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M)K?;158]F^KZ'VFFC)]%6NM=7:US^C8+G.ZODU_HV-#IJK=+']0L<T?S./\
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MSM;[5F="^OO0.OY_[/Z>ZXW['6?I*RP;6[0[W'^NDIZ-)4?VYTD5^J[*K:V
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MZ1L^U[;=_P#X$K?V;J'_ ',_\";_ 'I*;:2J?9NH?]S/_ F_WI?9NH?]S/\
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M  %"34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (
M   &    L(=I  0    !    N    .0 #Q!4   G$  /$%0  "<0061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP.#HR-2 Q-SHU-#HP.0!$
M96QT80     #H $  P    '__P  H ( !     $   %=H , !     $   $U
M          8! P #     0 &   !&@ %     0   3(!&P %     0   3H!
M*  #     0 "   " 0 $     0   4(" @ $     0              2
M  $   !(     3A"24T#_0      "           _^$!1$U- "H    (  @!
M$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    '@   'X!,@ "    %    )P!.P "    !@   +"':0 $
M 0   +@   #D   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,3@Z,#@Z,C4@,3<Z-30Z,#D 1&5L=&$      Z !  ,
M   !__\  * "  0    !   !7: #  0    !   !-0         & 0,  P
M  $ !@   1H !0    $   $R 1L !0    $   $Z 2@  P    $  @   @$
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MM=/41%-E9W:2EO_$ !4! 0$                    !_\0 &A$!  (# 0
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M E 5"@(;%\!@,!@,!@,!@,"--3?):5^\O=/XQ7O [:I^2\I]Y.Y?Q?O.!).
MP& P& P& P-0W:7<#%IXPK3JN4A8R1=-]?U#9T(BYC[#!0RK>4V#">96DFD$
MLS<*@\@%2I2C-5 Q2G63*0W1RZL#!*O=DEM"J46QPT#7;$QO3AWJ^TT[81+_
M $P\G5]@ZU(N;X3*-!B.XDRV)=RX&59JG(4R2RA"*<QYX%_; X%>/;<&MEF>
MT=@66Q;A)M^@[9K]T+:*4E3Z>OKQLNVB(>O4$61H]NW==]Y3(N3NA7<NA.H;
MF \L"I[!X".+7B6F]-/>,%_:-L0^EUKW+0$92+]5=3N'-DM[!C#-)A>2KC-9
MR4\-"H/8Y-,@@#A.2==9B%4,4X2OPH<!TCPUUNFP4OPX*;4D-16JUR.E;3:-
MOQ2<[0*G8)U[/LJFFNW8"A*(Q#J0=$0>/$#*J)G*!B% I2X%G[+X)^*VRZHX
MC=;ZZ3L&L'?$7N0^T;#9(B_51=ZPC%T6:+RG)E*P:'6C7Y&@)/%P<(++(*J)
M" %,.!C'?>R>XGKU3:'6WT94B.JQ0YO54D8D=K0L$%'FY9&45=U>!.P5;UNZ
MH'2,4+2W55>KJ*G<+&%4>>!MRT9 \4VGFTG7WNM5;?3&]>J%<I<(^V'46;ZM
MLJS -X9R=U,(0AW,RM*JMP>G.[ !;F,**8B0.>!K<C>RFG(G6E3K+#1L2SV3
M6^(^S;Y<;E86B@L+Y+1UGLLS-/*$[FFT"21-#%8S!HDISO5.;=N011#GT $1
M0'8R;%C8W8%;D:61Y7)1K82ZY6;66G-K33WT[8?A*FZDY]5JX\^I1T@!4TVO
MDK)-RV#H<"(^.!=ANS%XPY%6RW>PS:LIN:0N>K+O6KFA(4"/AJ[):MC5(>,;
MJ5I%D+>2;O&)_P#"16<D,*P=8!X\@!7>S"XP*"YKMYU]8I"%W6RE-RFL&P'T
MIKV58RL%NZ6;S%F9LZTZCA8QDE&O4C*0SXIW!4BB":J)REY"%VL^S(WTXF3$
MM<5+6>IEW[,;V(P6N%%CYQS)6:GO*M8XQ_,,H=,BR;T[U60;KI,T!:&$$$TA
M('/ L5'LG^(J8KR50OXR5HKE(UW):KTLT;6*APZ].J,G/I3JXSKAO&J&L\HD
M5(K!)TY!N (_RADQ4P-A&DN'C=>F-B[QO[+4*TL?=-*IE/<1BFRJHT2@R5"M
M%KB;Q!1*$$7*CPA?*3D.4A4S?$*(A@8;UOLP-M0-/L]3-3I)V2R<.M_T +Q6
M\TWK9MKU;7%I5L22?FDP"Z8F7\D(UY@FJ0.\,<IA  #/W8&J]Y7K@ZD>$A32
MZS!@_P!-Q>HAMZ>T*NJ\(WBX)A"%F 8&A 1%98K$%S-Q4Z"BH) ,(!SP,2=Y
M\#_%!L6'X?":XB'.M;/I/2;[0,A.K6NE6=*U46:J3&JS)O-SR-;(QDHX18D<
MMW*2BH-S',4"F  P(J@>RTVW#5*3JIZI*/0D:UH^NB^7O-,%4A=,3*\N@Z$@
M1(E$\Z=<4G).8%; '4GU^K _>8[-3B0B+.OLW4C!U1MK$V)M.V1T](66C62#
M0KNW(:,AK)65X!U'((K*-DHXCB.E 5*LDN8 ,D) $,"<N#7@5V3P<;2A]C5C
M54E:AB^'='1BC*9V344EG;Q;9\KM*:M_E:,*8[=:3F9AV@6+1(#9JW[L$SCT
M>(1YQF<!W%;Q7[!M4LI"Q$9KF_L(-A/5&U+ZTNT_3C0ZYSJ/]4W61A&\U2GT
MDF?I<J-3J 14A%D_C^&!$6Q^RSXI+ PGH&B2<M5:I9MKU?9]CJTY9*3;(6TG
MIE785V @[2U=LVHS<<DJP))NDG)^[=N3B5=,Y0Y"%T5#LN=V,^).J[ILE5@W
ML4O<Z%L"^1(NJ84[BXTM!NU2D*T9LD1&NQ"X-&[@8MFS64;&2[MJX(4W@'I$
M)SZ"<R](])>9>?/I'D'Q>?S\O5S^?UX'; 8# 8# 8# 8$::G^2TK]Y>Z/[=Q
M7L?^&!$E'VK(PL?8HI'46VIY)EL_<B1)B#BZBM$OP]+EW.*S%5_=(UX9'F;H
MYN&3<X'*8.[Z0 PA>?IIEOL*W?\ N>A^\/ >FF6^PK=_[GH?O#P'IIEOL*W?
M^YZ)[PL!Z:9;["MW_N>B>\+ >FF6^PK=_P"YZ'[P\#CTTROV%;P_<]$]X6!S
MZ:9;["MW_N>B>\+ X]-,K]A6\/W/1/>%_']88#TU2WV%;P_<]$]X7\?T8'/I
MIEOL*W?^YZ'[P\!Z:9;["MW_ +GHGO"_LP'IIEOL*W?^YZ)[PL!Z:9;["MW_
M +GHGO"P./33*_85O#P__1Z)[PO'^K Y]-,M]A6[_P!ST3WA8#TTRWV%;O\
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M^80$0' )JI*@)DE$U2@82B9,Y3@!BCR,41*(@!@'P$/6 ^O _3 8# 8# 8#
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M@BMYK%L(S(@$P*_D_E1C * D[SH3*/(2ATC5.T9[VLC*!PW=T)[?\*_)&%L
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M=HL<BA2',!1((B0?BF' B3@Z;F:<-6I&BCE9VHWJZ21G3@P'<.!3=.2"LL8
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M>!?&!QX\_5_7@6(2[*#8S5TU<EDS)E!920.9N#(C0513\K$_>=7=\P$P^',
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MHJ:9"%\"%(4  H!X '@ !@9*8# 8# 8# P^X@MM[PUO=]<PM&CM3.*Y?YE2
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MD2II/=+:,<H)]U*]":%YM488H"4D4@ &\Q1[@HB!7 \G1DC=1 )S <#X]?\
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M.C+;A&T?6= Z+IE&K"BKEN9@G./GS@I"N'LG,D*^>+GZ.8  JK&*0O4/20
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MY4(\FS7%\;7WB\IFWF5O:/\ R,:^K4*)77*C]HJV<D<N5#KE%%LS7234Z3%
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MG^<H<_GP,F,"U+U/L*M3+38I1R1FPAH"6D'3A0 $J235BLJ8PE'P-RZ? H^
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M,".])Q2K.D-I1V7E(6AX\L;TXAR,<9)8RR(&#YNE 2  ?,&!+N P& P& P&
MP& P& P& P& P& P(TU-\EI7[R]T_C%>_P"!P.VJ?DO*?>3N7\7[S@7W)IBM
M&R")4@<&58NTRH&/W95A.@H4$C*!RZ 4$>@3\_B@;J^; TX\%O!9Q5ZEX@9S
M;-GV4QU_I*3/8>CAXAK?,[#8R;V0>F586)Q,RS5(D0X23Y\X]DY<II]70 @
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MQ/K[)-J)_>-4'A8S9:,++J+.F];O"LHY</@KY7/),7+<IG;7H,3D4O( ]'.
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M[U!JF0?BD$C0J(*"4 $3"//QP,ML!@,!@,!@<<O7Z_'G_ ?[L#GE_'\?T8#
M8# 8# 8# 8# 8# C34WR6E?O+W3^,5[_ (# [:I^2\I]Y.Y?Q@O.!><XW*\A
M)AH9-14KJ+D&QDDB HJJ"S15(R:29C$*HH?KZ"$$Y2F.(%$P (C@>:O@,K=F
MX>^,#7NI;/%;^J%=LH[0)K]GL_AYU+3J_-EC7B<F^;L-B0<X_M3PS1.126;
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M^MN=0'"RH&3,/B8HE4#YO6&!+6 P& P& P& P& P& P& P& P& P& P& P&
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M"1$;):QLM@5UJ\J6L;+MYB^B48/6TOQ)2=52@JRYB74\SEY@;)(1>O1D7D?
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M']6!V\V;;^N^N?9;9O?#@=0B=L@(F"ZZW QN748-5V4!-R\ YCZ8>8\@]7/
M[>;-M_7?7/LMLWOAP'FS;?UWUS[+;-[X<!YLVW]=]<^RVS>^' >;-M_7?7/L
MMLWOAP'FS;?UWUS[+;-[X<!YLVW]=]<^RVS>^' >;-M_7?7/LMLWOAP'FS;?
MUWUS[+;-[X<"KT:MO*I7_-,C)M9A^O.VZP/9!E&*P[-5W;;;-VMPDUC5Y2:6
6:MV:LT=FB564>**)MRK'4 R@ID#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g569434g36t94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g36t94.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[22.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  %1&5L=&$< @4 -TUI
M8W)O<V]F="!7;W)D("T@365R=7,@+2!&+3$@4V5L;&EN9R!3:&%R96AO;&1E
M<G,@+F1O8W@ .$))300E       0 N028I-(E$*<Q"1!X98HL#A"24T$.@
M   !,P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #0 ,       #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8K72         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          $?   !3P         !                          $
M         4\   $?                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   $?     %)G:'1L;VYG   !3P    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !'P
M  !29VAT;&]N9P   4\    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M       ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M       X0DE-!"@       P    "/_         X0DE-!!$       $! #A"
M24T$%       !     (X0DE-! P     &:$    !    H    (D   '@  $
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M$Z6\C+P]H:W?GX;V-:20V;L=G@WP4 @8R!8H1EARXR96,A B*KYSP_\ =/\
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MMK.RYK:ZS6&ONQLRM[^FNQF.W69&#GT5WW7^K^D_H"T^C]3R;A;TSJ8V]6P
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M%KJ+V.IO9H^JP%CVG^56_:Y66YFG*]<ZATGIG4Z_3ZABU9+1HWU&@EL_N/\
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      4)-30 J
M"  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    8   "PAVD
M!     $   "X    Y  /#]X  "<0  \/W@  )Q!!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C X.C(U(#$W.C4S.C0T $1E;'1A      .@
M 0 #     ?__  "@ @ $     0   4^@ P $     0   1\         !@$#
M  ,    !  8   $:  4    !   !,@$;  4    !   !.@$H  ,    !  (
M  (!  0    !   !0@("  0    !              !(     0   $@    !
M.$))30/]       (          #_X0%$34T *@    @ " $2  ,    !
M  $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M    ?@$R  (    4    G $[  (    &    L(=I  0    !    N    .0
M  /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q.#HP.#HR-2 Q-SHU,SHT- !$96QT80     #H $  P    '__P  H (
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M@9&A)"4S&%)7EL'6)B=#L4148W*2T?#_Q  = 0$  04! 0$
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M-J:>8>;44K;<;4 I*DJ!!!&]>UY=K%IQ2G%*<4K5'J[ZO\9=&V/H^^Y'2E9
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M6XH?XLXJ?9>U%RV9LF6[=OP;:TL;=;SC-K;MR>5M#EP^YDDJ<=6H[U/G-Q4
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M%%(@K4D&3Z#)D?F-K.I?RJQ7>!H/*2MMM#164<ZG%1',$K.!)B.F]4257^*
M6!1(MYZ.52H; %W-3R^554"_XCHLIBAH$4,'GM1.^3 W@/6#>PZ&_P"R0@$L
M:XGF^ZEVQ,'( E;=RH]1,(P),'819KCEM4>+ISB9,$MW"5P/ZH6VWZX)Z3)G
M&\V)/XBKH/OZK5E>F^3\,OUU")*'MM7).0R1C@'U?BM/=39P2*81 RKE@U
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MJ2@I4%J0CF6E*DJ2I20"D@D5T/V7Z3PSKOM!X2T?C&\^@<,ZAK-M;:O<^/\
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M%(*5)1!"HG($C(G'^UM]QI];R!5IZE7"):SM8LT:YB)N(>E$[9\P=$[%45
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MJ]KI5OK#UHM-E<$\JX\R #"5N(^TE"_NJ(@[F 03QMK4K-Z[=LFWD*N&8YD
MS)ZA)V)3]X#[/7K6YW-'6?3BE.*4XI3BE.*4XI3BE.*4XI6N?4-U9]/_ $KL
M*J_SID6+I 7>:+7JDQ<(O9"6L$N8G?\ *QD5%MGC]QV_00ZI4/1(=5,IS@)N
M)C)P*\+<0TA3CB@A"$E2UJ,)2D"223B !FLMCW^)NHRCJ_,143>*<\7(5Q%V
M2'(LB#E)--PD9:/D$A.@L1-8AR*=I%"@8P 8![@YC/V]K?,J:N&6[AE1RAU
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M\Z?%4I>0U/F(0%#[4[K()G (&*VO8.#I$! 0*H #].A$HE#R)O @8>T/L(@
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M&<UI[AYU,E2"E/V02""3\1&8,#U![5D,G8 4*(@H!0[M@(^?U N_(;T)O/\
MJ/VYG) Y0023RCF/+RXC(Q@#?OFM([< %1D"<0< 0HSG'N'OVS%86]G2B81!
M5,1 ?(B<"@(_I^@;T)AUL!V'C^;0)&2#!)C;<P.O; &P]16 NZ,D3^'E$>@&
M/PZ@]CB[JP$$!T8GD?.S![^?W]MZ$>"WU';<2"9'I._6=CO6*NY$QT[2)^/X
M>GQ$UCZ\\8=Z.4OGR&][#6@_<1_3[?IO?"6SS($3UV( [C'SS/K6.Y=)$\RI
MQ  5)D;P)[^LU6EUTXXCG,?'Y6AFGI2";I**M!VY"]CI!<H!'R*Y"E /62.G
M\HLN._4*HW*8>X@";G7M X>;6AO5[9OE>#B6;HIY86@@^&X0D8*22DJG;E[8
MX_[1+)GZ.UK-N@)="TLW80" I*O\-U<?>!3R*43F43D$U6 9Z)0-Y[A\" =P
M>QA#R'N(;T4 #]//N <Y@+3 !])S)P(,@$Q$8C ,B:XTN_4F?-(SC$@'J# F
M0<S@[]YB:UR QLJ58BQT4WB8+  C]/JDT0X%#V'>RCH V!A$=^^K#EMRG* J
M0<1F3@P?7OV,17/M=O39WX6VZMI%P@.05RDN)\J@D>OE,"))*C7Y1]J$H@58
M_J$'0@("'<7]]%T;S[AO[?UYA/,\OV/+)CH22#,=('0]?E5=/XA(4 \I*DF"
M"@C!B,A,3MB)/2)K]K2A7,IT>\40[IC*EDX5_#/F8KIG.R?.V0J,?FT]][=1
M)8S9VGZ@%/H"G#QSS;/7&GW=I=\BVRTZEU"X #B$J 44JQ/,D*0>4F9(SBNG
M\/:R]I]UI6K->,V&WF;VU60MLO-LO<K@:48*DJ*7&5Q."M!Q(KI<^!)GX<W_
M  [L5P4O).W][P ]FNGZ_)R!Q4>M)?'C@C:'354.8RBQ%*BZKRZ2YQVIZABF
MV<A^?1C+J'V6GFSS(=;0XA0V4E:0H$1Z$5^A-E=-7MI:WC"TN,W5NS<M+3!2
MMM]M+B% C!!!D$8@UQ\_&CR9(9/^)IU*G=NA=,Z-:(_&<,B?R5JQIL2S8.FB
M0#O1?QM25<&_518YM  [Y]3<!VK=IPKI82D!=PTN[<.,J?<*DD]R4<B!/:-M
MN3<4W!>UNZ!/^ 6F$#_*EL*,8_K6N1\JTBJ#4!4UX 0[?M[^? ?;V$0]OMY_
M7DE4H*)DC?,G/[VQ/OR!6M3);4!Y9Q()B !F!^_A6SU0:[ A=;#O((>=_?\
M]/?W\<PG,$^F_;;]<_Z[5Z820E(S/QF">OKF)K:6J,0[41$.T!$P^0#0Z+L?
M;?@/M[#[?UYJW""I9)$"/= ,QM\!UF:W+(Y"#'*G>8Q@&/?L/AT.)V2K;$A$
MTBAH?81T >1T&_(>1T(:W^@^V^:]P_:F(Q&?GC? @U>!E4 _;,DC:.GH, 3O
MTGJ*N%^%O0VTYFY[8W2!5"TRJ/I-MWALI7;Y9&*0,'_ZB7S9U"?<!3[OMSG_
M !K<^%IJ6D*_ZP^AM7JE(4X?GR_IO4DT%D&Z*B(\-I2]]U*5RX]T^Z1BNA?G
M*:F%.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE4@_&$A>M&5_L@/TW
M'O2E$1+-EMK?'+I9K-A:CN67X,M+"S51?*1HLO5*Q*F?Y4CD'@NBB)D1+ROV
MD,\0O*T[^5&[-D$N>,+-3B5BYYT\I>\,A1;Y" WN H+)&Q'W%_!U>^Q2T/&(
M]I@T).NK-C_)W.)&D/6)TH-7'TU%HEY*F!=>-RFX*AXBF2R&CA8,AY5FNH*L
M?"L0A,K.W:6?[Y5X7%;ETNHF:6;RV2+8%4KYGRC71#2Z$/)QY7IR"'_%E4$X
M]X'$9KPPG4TZ%8)U@J5?AM9=Y\N!'BK+"7#U6EGD!.^!.9KYA]MUWP6/:'QI
M=^S]+:>$1?*7I(:"T6Z@+5GZ4;9+GG1;*OA<_1^;_P!D4E,)*:^>NO)T;T7_
M  ^U*]7GA82:EZQ4L#T,R#=9VNUE;0T;UU>138-$7#MR$3$ED9%P#9NJN0B/
MJ%)L-\DY*4(A,G$#L-R?7>9C$&N76#7A6S#9 \K:2H#$K(YE^IE1))W./05I
M9\+7)&&,:94ZJ>C_  W;U[+B][C^)S7BA5Y&V.,*:2?UE2)RU%1R=C8,'2J;
M*S)-Y9PL4AR&4E@T83 /+4@RD'&#^GQGU(CW5F+R4DQ@P<CWS))]).YR.E0A
M\*K/D=T+]/&9QN J&I-KZ9I+K=QA'*&4.$O;:XXD\:Y3IK!80$QI&8ML!CQV
MQC$ ,<'-X*9-,?6$>>>GX_I^X_2JF.;FZDD9G G$_OTZUK$GBFS87Z2_BX42
M]KKO,C?V@_#ENN4GKDXJK/,KY2KE#R?D]PHIW'[RFOEPGRIB!A#T2I@&BZ *
M5Z29*,[8^$SL.D'M^M=I<D_2CFBKI40 "%^DOW.<?Y2@'W$1_3^O/21S&/F>
MPZFK#SH:;4L]!@=ST JK;X@5#Q5>NF_J"MMQQO0;5:X?"&2SPEDL50KTU/0I
MV]5E7#8T5+R4>YD(\6[@A%T!:N$A26(14FC@4P9:@GPX(@)!(, _'8XW/X$1
M6A3=N*N$)YR"IU @$P94,$?$SZ9CK5?$)(USIF^&55L]X:H&-*EEF+PGBTWY
MN9T2NMY.1--3U3C9,)AZQ9,Y"4*Y;OW"BA7;PX&= DX4$QT]\H $(D <T(B!
M(Z8/I^0]T5AJ7])U$VSJW/#+CH*0HC9"S@$D#*=XSMUJ9NH+J0R'0\Z]/-!K
MKV,)7LBX6ZGKQ:474<5RZ6G<75?'4K4%&;CUB&:M47UAE1>H%(<'I#HIB<@(
M['8*2I):2 (<:6HX$R@((/:!,Q[^AK0CPW+:[=7S%35U9M(S&+A5P%"!U(;3
M!W ^%5T5[J.Z[)3''19E-[ES'AGO5](0%&=5,<>HI0U#)9*C)SD=>6+Y%Z=[
M*31212DD\AG/IQWJ.R1J2GHHG7-:"'BFW5S)^OP!RX!Y2H1G)$$D;9QOC(=.
MFH?U=CP'O_5B5N<P>\SH;=2TIM2>4)2DE?*%@D@ JZ168R/5MU!XYCLN8;EK
M17[]E>$SUCC#6.\BO:VA!L19Y,B"2@3MC@6*YV2CJMID=G3;I+II/Q]!(PE'
M8CZ^L25ID%0<0A*LC"\R1M@R-@#ML9K7EBT>-K=)2ZU;+L;F\N&0X5DFV5R\
MB%J$A+A(!.>428KW]ESYG_I_M^0<6WW(4-E=W(=-F4<T8YO U)G6WT'9<?0[
M]=["34.Q<K,I"+,\^1<L%O43541%5LN(&#NYZ(>:<*20KZI;B%1RQR9@@?[]
MNM8"6K'4&[>\9;<M@G4[2QN6?$4X%MW*TI2MM2@"E<<P4"(F""!M)_3U+YCS
M#T\.[%G:XURQ/LQTF/E86O0%?2B8JEH2D(44&@.C'4<2;KYQ1!\LY.!2I.2F
M*W_NP(/+KUD;ZP?9=Y%?2F5I "8">=OE1/<H60KFWD8Q49XI;T^X;U'2+=I2
M4>%=6BEOK\0N.*"@VZ1LCPU<I3&1R@[[<YN6LUW>IS6456=X9-'N/I:291E,
MB*LM/1[A"#13,\2ME@T"<;(.G!'"8H(J",:F!3+ (]VN3LZ*S+++UNLJ7*'7
MUNAM:%E10?!; E:1OS*$+G'>N/\ #?#&G7B^'-.O]!N"=:6TS?:S>ZRUI;S3
MMS?OVK;FCZ8HER\8;0VT$**(O70M+9B"5UL>7<JW,M<HP+M8QACVKW!8T-7G
M4_+-Y.;6D4U6^D"*:9J^DV*8ZI0[/3/Z8]Q_& [IMK;VZ7G+9R[7]*6SRA:D
M#PP$^;R DP02!@9S4(_D_##W"UGK&H</ZKQ/J">,=9X>3;V5S<V]NFUT]BT6
MJZ>-LTZXAWZUP-IGD4XM',809A^-O^4I9*EP*BBM5EIE&Q.'\ZYB5#"LC6Y%
M2)6/&-'@)HF,J[3,1QLQP;F*=,=&#08EWIEI9_2KAUA;K#:F0PRI11)>0ESS
M+"22$C @9.*IK'LXX?X*_P"E'$E]I^IZEI%B]HK&@:,]=.V+A<UJU1=K-Y>)
M:YW$622MHE"94X DP)!D+IZL\NPM^6R3S]LZE#VF/]9\W1%LD\%*#8)%6%#8
ME2]5),!.0!$I3[ H^W-/Q PRY::0IEM26S;.@(4>;PY?<4I/,1F"K!ZQ.*P^
M/=9T^WT;V:.Z,W<V5E<<-WC[5K=.E]RW6K6;_P 6V6["/&;0L*"'"$E20"8-
M=$/\.#;$VN1?B*8L55*BNAE''N56$<&^TS*[P$G'O'Z._'8HO!M$U0+_ "J"
M #KQSIG#+@=T+32"5%%NEHDYRT2V1\.7W]3O7W-[(M43J_LZX5NTK#G+IJ;1
M9!!Y'+%Q=FMLQMR%F #F(FN9GXE)55/B/=:)S^1#J6RW]_<B=RDR):]P\)@3
M>A#W,7P(<^RN%I'#.B$8!TJS&TRKPD ]9ZGW8]YC/$4G7M02#YOI'-$;CPT@
M>G4?+WU#E/V"I?V!,1'?V\!Y\_M_4/TYLEQS'.3(Z?J<3M^&-ZL)R".Z<1OC
M^_KD^M;24T  6^A  ]8H;UO>QW__ '_G_7?+;GWI!$D^@@#\/>?G63;P2CI]
MCTQC'[WZ>NUU7  *CL=;,("&M:#L\Z#[:_T\?TUIU_95[X)&>IS'H%"?E6V4
M):4#C?KTG((^8&W]MCZP1,2)ZWO0C^FO(!KW_3[Z]]Z_7FK?!Y9CXG ^X"('
MXYV/415&(,2#E20 ,$R5>FVX(W[#.+T?A.@B%ER> !_>_EF(]_Y@(,KY#]="
M;6_L.@_;?-^./\"SS/\ Q#D__MB/=]Z1[OC,= $*>Q'D'O\ M=CVCU&>]6'=
M3M%ZB;;"LI# O4"A@Y6OL9=_.@OCRLWLMA!%J==JE_\ $+=<8\$3)B F;=HJ
M ;ZMZYSFI-6C'PS;!ULY\H%"ZALS=4L;:Z?)2MUBYG%S'$5)@$W_ .!R<E L
M5R6.-9)2C42.&R4@8J*@ H)10,(IF$.*J1&.H,[_ (>OY5M#UX=161\*U?$>
M/,%LX-UU ]3.6X3#&*G=H;G>5JI'=L7T]<,B3T>F8JDK'TBJ13^4+%$'_F#\
M[)!7;85P%5(GMU.3&WYGTJ+8C%_Q"L&7O%5F2Z@_^UA1;%<8: SE0K;2Z727
MU8KLT8&LC>\:R\$UC5$DJFLH,BK6I-9R:49%]$BPK)@512LXOOQ+>GN@WNTT
M]>#R_:H''UA;53)N7*3CMS8,/XUL2_RIG,7;K@21;J(+0Z;UFM/J1,7+-H1-
MR0)%=!0JJ::E:G=3'6_F^A7#K<:8_MD&%=P_5NDF=Q<O^!1,DF@3+]CKC*TO
M%'*J1QEF\K&RBQF(N3*)M05(JV[1 G%5 ]^Q_ 3_ +^E;47KXD^#\8ST]6IV
MM9EMC;'!:TRS'DB@XY4L6-L6RT[%1DH="XSB<HT>H&8,I-K(2Z<'#30Q318I
MW14]"4%4JP=D]:R+-I(,EB.63YL@\:.$A[DUVSE(JR"R9@]R*)'*<H_<!#BE
M>5Q2G%*<4IQ2G%*<4IQ2G%*<4K2#K9@9&R(=-4:@[02AO^U/B)U8F*X!_P S
M8,I-RZ:H)'$0 JK>329/2%,!@5%L"?:(F#E0.8@>H/RS^E8MXSX[/A$PA2V^
M?U2'$E0/H0(C8SFLKRKTTU;,V4L&9&N,S*N&."YB:M%=H8(,%:U+6N4C%8EE
M8)D%VQWBSJ#9KN@CD"+%:]ZYE%DCF*00O*[C82=HF1Z;=?GFK@V(/??H,YCW
MXP*\#)_1[1<EYCPOFUE+2E#M^'6MYATQJ;*(;-+C5[[$)1DK6+.55H8ZL8W<
MMVTLS%L*:R;]$!$XIF$O+143[\R1&?3'3XF:]#^GH8(D2??\8V/0S6M\K\)?
M!<[C+I+Q?+6^\.XGI-N1+)"O0&*0=9%@%;1 7&7Q_?$D6I&[RHSD[5*V[D6;
M4B)S_A*12&*"RW?YJX3,D@9F>P)[?[1Z5EV:?AIXXS2PZSF<CD6]5U3K2L6#
M+-;G<,A!'6I3_ T!7H"N!5"O&*R:J<HC7&CF3_%2NA*NJJ#7TB=H IVQM^.3
MO^7PKTU9Z?,SXVO[":MG6WG/,T#%).TG=(NL+CYI R2[EN=$BCA>OUZ/D"G9
M*"59 $G!0%8NE ,78<S6&)1SE<!72,Q.^?4&<_,XK0:E>)E3( (3]XG/-L1O
M'2.Y,^^LES)56.3L<7[&DL^=L(V^5*P5*1D6/H?.LF5@C',8Y<-2KD41%R@B
MY.=(%2&3%0A>\I@WO(\ $05&%'"HV)V,=._Q]]1A=ZI#R7$B?#4E8!GEE"@<
M[&#MO^-:L6OISI<_TN&Z4I.8G5Z82@1M!1GDU&[>PI)0@,U8F92.B0K4LDS?
MQ[.0*0$OESJH@F<@I&,4;XL4J3!<(2,2!DXWQVW/3X36L>UE3-W]+2E'B!PN
M!$RCS3S@YV*5$3)(!WV-:U1W1N]_M#J>6,G9\R%E&Y4K'^1,80RLK'5J(B$*
MKD&'CXAP4D5#QS9N249%C@>J2A0^9DW"P%?BJBS:)I7PRKQ$%2U+*&UH ,)
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M)!TW@FTX@N+GTADEEP4G>>HC&.L]/=\JRI3J2ZM.J:Y8EHN#^F[J$Z5JI%9
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M7P\S754?@HZB<G?E?\0EW(E<D+\]&_CR_P D4A4VYC()"NFILX#1RX4A3HY
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M8@^ZL5,KVRK5+I\;FM48[6?KY!N<K7K!'PE2A$V2I&Y6CQ\,,56R.7PH@V;
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M0:MYD@D$)YAL?0R,"!C[($]0-JR3,?:.?>,XP<QM/<0,]JGRO3X>F0OJ> 3
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M1#WV(>V^9Z&UYQTB,8(,G!Z8Q'>:B-Q<.%1YC"02GWD1$$S ,?EFHR>R0AW
M!NW1A$?83;\[_01 ?V\[\C]^9@;;.0,J'-B$C?MTK17%YRD$G*=L& #YICO'
M3/8S,UALE-"0WD^BAL1^X^/T#[:^WGE]-N("N4)B!,[9&(B#.-JT%UJ7F*>?
MECH.:<^[Y[XW]*KFZF,JGL,]^5F3LWX37U!%V38E*YE!#TSB?V[BM VFD(>"
MF.J8!^KFKOT^*XEI!'(B0L]%$YB/\J9.3$YQRU&;^Y-XY'-+;4\LS)<@I)^
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ME:A(BNPC)O'0\%&,8>*CVB1$&K*.C6R3-FU;HI@4B2+=NBFDFF0 *0A0*
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MEBWJ$Q]/8MS#3(>\TBQM%&LC#3#<%2E$Y#%3>,7!>US'2343>JSD&2J#MLJ
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M=_IRSX8W[GH9VCL?E]T9S$UX^DD1YE#&T$Q\(_\ F C:-JRIO;R#L07 /ZF
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M*V4XJ,TXI3BE.*4XI3BE.*5Z^0EHN)1%Q*R+&-0#_P"L_=H-$O\ ^:ZB9?\
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M(A$TR%333*4A"$*!2$(4 *4I2E  *4H        :#DQKM0      $ #  &P
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M0 "@ ;$1$?   >1$? !Q2J'>OOXR%6P:^E<:8)(PM-T:&5:2-M6$CN&CG!
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MHK?,?EJ:>'1]=_$%6_O2,W!SID/HQ *(!Q2L3QATA=+6%W17^*NGW$=#D2&
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M*C)1E<B8=S.XW/ NGSRR6,:PE%$;G.X=,%5J728O1J77U?\ )D1B])M4I_I
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M)U9@F+ZQ*%,'U!W$!FV4 - =!PLF(_5H54)_ 2?T]#UJ GD"Q4K+BLLT$VS
MT.I$H()E "(MQ:F033+YT(%)VAY'8^YNX1'5!U]^/AV_(_,1->"<B?QZ29@B
M8&WO[STPK#4HJ[IC:'>Z)+U9=S791'?UIJ1ZRB3<Y@]P35;^F9,W^+7TB(!O
M@]\R.V3GM7H3)S(QV^/<[1'[-2OXUOP)M_Y;_;8;WK7MO]@WYY4","A)['W8
MZ1\=_?Z=#7@XHG#XWZ@8=%%3T:_EUDYB91L E30+9H5 73!\5,! A57+8RZ)
MS>5%3&#>^T.*J._>.GO_ +_AO%68<56G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G
M%*<4K07J]35C<D8)LSP@E@TU[97U7AO^@VEI5BW-'D5,/TIF<@BH1,PZ[NP_
MGZ.*H?B/=WC:.M8F8Y4BF44,1,A2B<QC"!2%*&OYC"( &@ ?(^/<?U *#8=?
MS]_QW]QKR1D^Z8GKZ>L _P"NU:Z'=2R5]L-VQS!2MDK,5'I%R2O&H&4CB"D<
MB9'3(Y?#F0:$'N<$1 X^D0VQ >X>5JO0 @#H9ST@=NL2?]ZG:#GHFQQZ,G#/
M$7C5<A3@)!#N(.M"FJF(B=%4G\IB& !*;P/GVH9Z?[>O]\^ZF (,[?YHC/RQ
MTK'9)%68RU@^!C-J2Q;PG-J GL3MHJ)0%9\LMV^2)JIE%$!-HIAV'GV%/3]Q
M^_TSFB1'N]<9'6/7USBK7>5KU3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5J
M7UA6F C<<LJ?(5MO;9^^2Y(FL0ZZID/E'K9$ZZMB]=,#*H%ABG3-ZJ8 />X(
M4Q@3,?CX?O\ 9JA/]_A^P:KG4P[D=%FP%]=5+4T8BBJYJSMT\9LWR28 *C 9
M!(XK=B@ 9(%# ;O 0'M#N#BJ A4_+IUQ'QWQ[NE;WXGZC,,UVA2<-*P33%LA
M4&(GE:2JF0QGQ3B"158@XE TV+PYB@'_ %%1]0.\1#8E56<3TQG'[_>U::6B
MORF4+0[N6/H(<+0[Q518AT7+@7\Z50PF!\ZAT^QHR,J']X %#N^K0A]Q50_(
M[3TC,2/7\_E4K=,JI,69?;U^^MD['-WUNNTK&0UUU#.4%F21G"\"9LL)DVH+
MI@)RG1, JF*4H^!  IV]?U_<57U_#'[^1JU+E:K3BE.*4XI3BE.*4XI3BE.*
M4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*56OU\7BN8EL&',HWAZI'4Z(_.,2[>)MUG9DY.0CVIV""*")3
M'.Y=@10B0!H.U-0YS%(D8P9EA8W.HW";6T;\1Y:5* *@D)2@<REJ4H@!( R?
M4 22 8SQ=Q;H/!.B7'$'$E\FPTRU4VVMXMN.K6Z^2AIAIII*EN..*!P! 2DK
M4I*4\PK3E/BF8#9K&3CZ_?I-,O=IQ^'1C,JFA'9B$4E%#=N]B4!T._< \\ES
M?L_UA025/V:"8QSNJB3 D^'O@GH",]17S?=_QB>S-EQ;=OIO$UV@3]:FSLV@
MHR8*0N]*N6>J@#G:HD4^(3@JV9$:V2UUJX-X:%9)D@V:<;&N3JOCF(95Q*F*
M_*8R21MB@F7U.SM*82^X#1[@#5VTJ4A^R<*9'(''$J)&8$HY1UR2!.)VFYIW
M\87LQN;AIB[L>)=-:<6$JNG+*TN&V9B5N):O0YRI!SR)4<;':MOX+K6QY8XU
MM+0<-+/(MT4?05*=ND8 +X,0R)P Q#$'P8@^P^PB4/,&OT/Z;<N6EXPIIYHC
MG3S)5@Y!!22DA70@Y&\=/N_@'@FR]IG"FF\8\'\5:;JFAZHE2K:X3:W;1YT*
MY7F7VWDMNLO,KE+B2@<IV4H0HYU3,OUK*V6<+Q$,V?L9%G?6T@H+],@%*W09
MN%3D(HBH<1%7TQ)V]H%\@(B > QF[EMQ21YDE6,QRST$@[^F_>L[7_95Q)P]
M8OZBZNRN[2V2%O+MG5A;:)@K*'4IE() PHJZQ%7;<R:YI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*5JCUA=/S7J#Q2Z@CI)R,A7%E+'#0#Y!%Y#ST@S2[@C
MW[18HE,HNW*NV9+%$!26<"!@,10PEU3UA?'7=#UVPUS4],<T=.I-.V5HZ$V.
MJ,:BRR@IO6B.;QK1ZV9>L[AM:%M<UPT0INX6!@ZMI.D:]I5YHNN:58:OIUZ6
M2[;:A;-W+7,PLK0?#=2I!R9(*3YDH4""@33F]Z1^DBU8]G;LQQ*UC)>+BI(T
MA%M9^W181$ZP;*"Z8N(Y"=0(D*#D!*0IT2E,B"1A3UH G;?&/$;8 &HJ5  "
MG&+5Q43,<RF"K?,DS)WFN+WG\-?L5O'2ZYP4PTHS*;35=<LVQMLS:ZFTV,=D
M8)G  K*\;="73 E6*W+R.,6<K*/(IH\=.)&=M#U!19RD"YA%FO-':"0 ,!"E
M]'M$A?J 1$=^7.+^(G1RJU%21_D8MFU;0(4AI*A'OZ8@3-;/^&_V+Z>ZEYG@
MFW=4F"$7NIZU?M=/MV][J;[+FT0ILI@F9K8%OT^X4AV2:#.A0D;',4Q$B#8S
MUJS;HD#9A*DF\32(4 #N$.WP("(^1 >1FX'TMY;]RI;[SBN9QUQQ:EK,;J43
M)^?]J^D^'^*M=X4T:QX?X:O&M$T33V@Q8Z;IMAIMI9VK0,A#++=H$(S)) *B
M9DDF:ESH_P 2UR7O\_EZ'KK*'J,"@I6:2"+;TQE9#O.2;G-J=RBA$1(#-HL8
MYA,"BY=%[0$?"66D<I2D C8@;SU)W.>FPIJ7%?$>LH4QJ>LW]XP2"IEU]09)
M!D2R@(:,?=\IC<;U9ER[6AIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*
M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2L,G+.M$
M6NFP/RZ1V=G"?26='.8JC=W&-F+EFBD77:?YDBSL3 (@( @ EW]7,MFV#MK=
MO<Q"[;P"$@"%(<4M*R3N.4A,1OS58<=*'F&XE+H=D]04!)3'OE4^ZLSYB5?K
M1;J$Z8)6>=6&\8D4;,YRQ,'3:X4U<2MX>V>NDJ560;F**:;.>/W@)ES?0Z/W
M'.8JBBGK/]3[R=_B3DGK5(]/EC;;WC]Q6J]">Y,J5?;U:Y8GR 22@B"Q;N&,
M"[>H.FR)A*W #D3$H'33$J?> F(<"@;O\\H1^78G\B/WM5:ERKX:RCFMVDG:
M(N3QEC8JA#2"#X?0MED0*.Q9IH%T,>T6 =*J* )C%V4 $1UP!^&W[_#_ $Q5
M#Z;_ +_>V*L;KM>AJI"QU>K\>VC(B*;)M&3)JD1)))),H%#Z2 4!.;7<H<0[
MCG$3&$1$1Y6JUZ>L69>=F\BQ2S9-!.EW!C6FJI#&,9X@[Q_1K@9PL @ $4(Y
MM;AH!2")12:IG$>XY@#+N;=+#-@Z%%1O+1=PH$"$%-]>V@2,Y!3:I7F#*B-H
MJPR\7'+I!  MWTL@]5<UM;ODGME_E_\ AGK69<Q*OTXI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*5A=UH\?>&D4@\DIR%=0DNE-Q4M77J,?*LWR;1XQ$4W"[5XD**K9
M\NFLBHW.4_T&\&3*(9=G>.6:G5(;9>2\T676GT%;2T%2%Y2E2#(4A)20H$9Z
M$U8N+=-PE 4MQLMK#B%M*"5I4 I."4J$$*(((,UB7]DCS_Q<S#_YDA/_ &QS
M*_FB/^Z]*_\ +O\ _P!S5@62A_SM\?>ZW_\ 1I_9([_\7,P_^9(3_P!L<?S1
M'_=>E?\ EW__ +FALE'_ )V^'N=;_P#HU$B=>OHYO7QLMD_((44V.C75E)IR
M<4%F"?9SK.$=1JTF,&*!XA9M*INRM@9%63<M2""XD.<O-J7['^3#4!IMC]-_
MF'T-;9;=^C^ IE3R7 WXW,'0MHHYN>"E1E,P1A>%<_S#Z(;NY^C?13<)6%-A
MX.I=2V4%?AP4%*^;EY<$#-2Y_9([_P#%S,'_ )EA/_;'-7_-$?\ =6D_^7?_
M $N?S^%9HLE9_P"-OC/_ +UO'N^IKX_LD=_^+F8?_,D)_P"U^/YHC_NK2?\
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1*<4IQ2G%*<4IQ2G%*<4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g569434g38s90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g38s90.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1O>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &4< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  5$96QT
M81P"!0 W36EC<F]S;V9T(%=O<F0@+2!-97)U<R M($8M,2!396QL:6YG(%-H
M87)E:&]L9&5R<R N9&]C>  X0DE-!"4      !"1XU)=X#3[6?T_X7'^&2 5
M.$))300Z      $S    $     $       MP<FEN=$]U='!U=     <
M0VQR4V5N=6T     0VQR4P    !21T)#     $YM("!415A4    " !# $D
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #P     $  0/      0 !.$))300F       .             #^    X
M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             !.P   @<
M         0                         !              ('   !.P
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !.P
M  !29VAT;&]N9P   @<    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    #
M.$))300,     !#_     0   *    !A   !X   M>   !#C !@  ?_8_^T
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M=52]QR0^I]=]<L<VOTF/L?Z5KG?3]5K/T*M@?97?]UWF .S''_T4_P#\#_\
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M1N< /:?3?[_H;FO&Q/3GX-]GITY%=EG.QK@3_FI;<&QG%3V.E_YI!VGU'/\
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M+]FZC#A]O!D-VDU,D$'W?G>[>G^S=0V%IS_<1HX5,T*2D5W6WUL:YO3LRPN
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M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3
M #8    ! #A"24T$(@     !0DU- "H    (  @!$@ #     0 !   !&@ %
M     0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!
M,@ "    %    )P!.P "    !@   +"':0 $     0   +@   #D  \/00
M)Q  #P]!   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z
M,#@Z,C4@,3<Z-30Z-3< 1&5L=&$      Z !  ,    !__\  * "  0    !
M   "!Z #  0    !   !.P         & 0,  P    $ !@   1H !0    $
M  $R 1L !0    $   $Z 2@  P    $  @   @$ !     $   %" @( !
M  $              $@    !    2     $X0DE- _T       @
M /_A 41-30 J    "  ( 1(  P    $      1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    8   "PAVD !     $   "X    Y    \     !   #P     %!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X.C X.C(U(#$W.C4T.C4W
M $1E;'1A      .@ 0 #     ?__  "@ @ $     0   @>@ P $     0
M 3L         !@$#  ,    !  8   $:  4    !   !,@$;  4    !   !
M.@$H  ,    !  (   (!  0    !   !0@("  0    !              /
M     0   \     !_^%!"&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M94&O4^S$KU(NNR[#*;/GYZ8FG[2,V,I6RP[)^V;%, "BNF+<ZQ.UJ0@)@4X
M&$^7%6*I_I3=V,+5"T?:M.UG'2BN\-?4.=L$-)R+>O,JGL&K>^5JZ!64(@*,
MC&D,1NLNX.1NL8!,!2_P<*'0D>762@F=]*+LY[M&J[97E8>"IE3USU7E/56\
MJ^&CVJ0UW:&$)3YB8!HDX7=N!*H04Q:IJ"<RHIH" *\X5!N+]>/?Q^MEK!_2
MD]7&RV51"/<4[7S^B=5FMM?W9TUB7T>WO-1NM.D;2VC',1,D=NH8I09F;+<.
M2NG0J-E$SH\F3$G7SX=>6JVN!]-=U GC-CW64T'%/Z4SA;F[J2C0DO&C6Y&N
M3I8./)9Y%T10DLP>&$7+YU'M4 8E#L$#A\;"<O+3316X]'[U!=0FWNHSJ?9[
M5N5*M"D5J34EKJ=?UY-O)6BPKZTQTA(^KM470BHSD#B9NUDP*<?%.D)@ O\
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MTK?M*ZU5J=NHTAYRV$=MF:K5,J*"K031P*-E$TB^&"B)R&[![1$0PEG>USX
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MF8=-0XCO6XP/6=TN6-4$(_=E&07'@/"F)0L H41YX Y)LC Q!\A\C  AQY@
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MM5O6L.NC;UTH5:NC_H\VT9I.1J+H5(EU'"N17M[5P5BWZ;5\V$%2G J2I .
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MH\:&,0-^4A^H41+X<*I*3QQ.'(=A0AHY]W&$0X  ',H;/8T;7PZ=M^+PV/\
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M")A%$^UM4H[481;!:Y76GA&.U'97%+G%81P[%1$R/@O%$R'%9$O=WD(/  H
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M5P >Z>[=(LS"/QU66I'<PL #_P!%2QR[[D0^03E$>?/R^7EVFRK+D8/72&P
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MX&(<H& 0 BS],^Q"K_B]#?V>WP5Q;^4=<5I6Y=YZKZ?:HWNVW[A&TFKNIAK
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MK::!]7+VLTDH#W!EK1B3LV :,:!K<FZ<;2Z=#]ON14ZS%=GF3W-@8MCV\?\
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M-V5%LWDM!=5MM4@UDB+,*MMEJELFN&8"0#H-&DFLLA-MT3D$""J5T<P%X\N
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MC'8FRNS%)B@_#RW.08V:^X]U^)MEX+V[<3KZ.S*["WB)N7;T7[R/=''L[!S
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M,F3O[0-YB \!QP>USA9LDD9N#>-[F$VX&QS7N-A]OL3V#K9Z[#:+"ZZ:>'L
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MB81,(F$3")A$PB81,(F$3")A$PB815SZKAXTG+?+_GSI?Y.?]=6O>/E#Y?\
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MI3'-%A.K+5%GWCT[;5U13IQK7+'=JRM$1LN^.X38MU#.6[@Y'IVATG16;E)
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M81,(F$3")A%7/JM_B4E?QYTO^#_75KW_ !_O\LAS!\$4Z9445:E^R_J+\_\
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MR9AHFQ1,C!3L<TEH:69KQ\G&OT".6;UFZ3,DNW<(J )%$U$S"40$.0YY 0,
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M@0#P53=&[$MFG[L3IEW7)'?.$DE%=.[$?"*:=XK* <(PTBY.()#:(E(@I+I
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M!ZU96ZS4._N[1-M(A0P=R9FY8F-48M%S\$6>D5-X8<%-Y#SGUCT;X;L7)M'
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M")A%Y!N>GV][]V+*K33RR5QI']8ELM-XM$(]1834%7]::VC%M/PT$NZ27 [
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MO8U[<C9P#A<&X-CR(NNPHR9K)E25:-E4B% A$U$$E"%*4  I2D,02@4
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M&'6="X=N43+K-@5604<F2(ZZZ]ZE^XY]'.^7RX K)Z>E.H%]8=:.G,_;I+7
M[(MT:_&SPK1&=F:T-!]<3D)QYZNQ7:LXN^EEHB&33CFXNV",<LHJIP!UB97M
M]^[]._WKT.PJF$3")A$PB8143OEJW%$]3+5!DO;?>.W) F90[",3<520A5XY
M7WR/I!V5JHO[ILWPH@U3*[0$IOB@@J4!,$.776B===?-3OK578AMC;<2MDD\
MD:K[I03FBBO&(1S9I'.HA!5VR;"D=11R+=V*A%EUS@H93GDA/9E4 MS\[]>Y
M3KA5,(F$3")A$PBB+>9;U\&5C4UQ)N8NVH(MUHY9G'H23E;PW2(KMD4'"B:9
M3KH>(3Q?CBF B8"&$.,)U[\E)$$9V>$ASR'?Z^>*CS/?$#@_K9FB(N>\
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M_@.$643TM1TH96%38&!$CZ\/8AT<XG>0([&6D'-O2BUC#RDE++R\L=4#@<2
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EPB>J-/+_ "5OY" A]93\A*("40^+[0$ $!]H" "'GA%V,(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g569434g46a06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g46a06.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1CX4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  %1&5L=&$< @4 -TUI
M8W)O<V]F="!7;W)D("T@365R=7,@+2!&+3$@4V5L;&EN9R!3:&%R96AO;&1E
M<G,@+F1O8W@ .$))300E       0 N028I-(E$*<Q"1!X98HL#A"24T$.@
M   !,P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #0 ,       #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8KLT         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          #6   "7          !                          $
M         EP   #6                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   #6     %)G:'1L;VYG   "7     9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    U@
M  !29VAT;&]N9P   EP    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M7,LG@.Q2?^WG+L%ROU^Q#G=*=@-,.R\C!H!\/4R"R4['\\?,(.Q;/U+P3@=
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %"34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    &
ML(=I  0    !    N    .0 #Q"Q   G$  /$+$  "<0061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP.#HR-2 Q-SHU-3HS-@!$96QT80
M   #H $  P    '__P  H ( !     $   )<H , !     $   #6
M  8! P #     0 &   !&@ %     0   3(!&P %     0   3H!*  #
M 0 "   " 0 $     0   4(" @ $     0              2     $   !(
M     3A"24T#_0      "           _^$!1$U- "H    (  @!$@ #
M 0     !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    !@   +"':0 $     0   +@
M  #D   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3@Z,#@Z,C4@,3<Z-34Z,S8 1&5L=&$      Z !  ,    !__\
M * "  0    !   "7* #  0    !    U@         & 0,  P    $ !@
M 1H !0    $   $R 1L !0    $   $Z 2@  P    $  @   @$ !     $
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M=(31\45356-F>(.%AI341$=697.(DK+5_\0 '0$!  $% 0$!
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M;&6+;_D7(L=;\RK5N*JZV+YEQ$VV(A9-C09L;.186JJD(_3;QY70F3!RBU*
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M:(C1$:(C1$:(C1$:(C1$:(OR8Q2%,<Y@*0A1,8QA "E*4.3&,(]@   1$1[
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M(G[+(UN #RKA55V2GD35DG8BL8B7!>DDZ6&@R\LL^M5M"Q1MUVWU6:I%[Q7
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MT1'E&OW,W_S*?^[HB6O;64"*YO*!2E N<+N'!2@4H?5T>P 'L\?S#Q]X!YU
MS/6@ZNB9S4HC1$:(EC@DD5=U&1/%234XQQ3>.LA3<?5W_NZ@'W_%_ET1,IY1
MK]S-_P#,I_[NB*.<BY4Q%B)K&/LH7BD8_9S3E9E$.;=,Q,"C)NVZ9%EVS$\B
MLW*Z712.111)$3G(0Q3&  $-$ZRGX*]*7"@(UEE<UK#6$JE(H,G+&R*OH].%
M=MY$2 P6;R)C@U53>"HF#<Y%!!83E @CU!HHFTYKF9VBCR'J7R,W6W8V1DI)
M0 -WL>KZYCT@*95[&=!S>=:I@<HG7;]:9>H.3=]%*R+P6')0\)GR<.2AT(\F
M#W\E#CN''?MSHBQ^>LU)JZ:"UDFJY!).3%(W4E7L>Q(N8SQA'E*D9R=,%!%]
M*1S3@O(^8?-4OKUTP,15<M+U:!:(/YJ0A(IBZ=-6+9W(+LVC9=X^5*@S:HK+
M&(FHX=+'(D@D4PG5.8"D 1'C11-I[O566[7K'&-H12R7^SU.FP"2Q&ZDQ9)&
M-B(\BZ@\)HBZ>J(I>(<?K2=74/P!HIZXJF3R/BU:K15W2N%,/3YQTR8P]F++
M10P<F\D5O+L&K&2\;RCEP[7^I-T4E3**J>P0HF[:)UU"S<J<<8@*%39&(/N.
M!$!+[N?K@#CW#S[]$E?02CQYX29CP F'@B \ '81'@/< ^\?<&B*E3<0:KT\
M:DK%J2";9-XHQ(9J9T1HJ<R:3DR!>5004.0Y"*B7H,8I@ PB Z(J[RC7[F;_
M .93_P!W1$>4:_<S?_,I_P"[HB66Z)(I;I\&@DDFF)J/E'GPTRDY &\7[Q*
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M^6_@J3_![W]&4T1+;@B.FI;;#3(^NRA869=0DFFPDS 8Q6BPV"5X4$"D5-V
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MV=IU.BNNBG7T\U?;+Z07'T(TDE(Z@Y!L,A!/RQEB81T:14*VZ5D4V;<TZZ:
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MY+2C\T[B)=CE/.41*)<NUP0,'(" @BZ$! 0$! 0'N'P_%W[ZZ%]FW[\JV_\
MXZGQ%O%8C;4?LS!_W!Y=R?#T*F:PS=Z.[!$NX=^9E:I#N:1)D,8#+(&KSM9H
MT*L8!'J,=J5,X"81-TB'5W#6%[98+]A[08YD0VJ\5FD9'V@EQ'_E(T')76SJ
MGM,)2.H&Z<A]TD<3P6US6KJ^2T[H_P")U&^63&?]=CH>OUT[T3+:(K9,PT38
MHJ0@IV/:2T/*M56,E&OT2.6;UHN42+-W""@&(JDH4>#%, @.B)?T=GNV%N"9
M4L(X_*5-T9[TC!H'*JY.4A3*.04Z@==14TP,5SXI#=!.2CTEX(OPXV<[77:2
MJ+G!N/%TUW*CI;Q8%L<RQU$!;"FJ<P"=1J5 PI),C&%HD41!)$FB+\L-I&$D
MR7I.P59I=$\@6*#L4NE96$,*+12KQ@0U681B,+%0Z2#2OQG6S8N%R.9=9)0_
MK&3?&Z3%(F$A(2(K<1'0,#',XB%B&:$?%Q<>@FV9,&38@)H-FS=("II(I$*!
M2$*   !HBNFB(T1&B(T1&B(T1&B(T1+=NP#G"\O^,%-_VHB_OAHB@+THP"/H
M[MSG'?C$4N/OX]S0G_;_ $ZSW9B/]_;,G_Y+/GR.0D^"M<=^$K_TW3W>/7Q&
MECYEJSL:Q82SA@!\[$R^/+1&W2'06.!E3QUK369OP;_WWEF;F-9@<G!2D4>E
M$H#UFXW'[3,$*>.P6/8V&XFBZD\@$#?I01(/\1#G7U OD)QNPZDTJU+^1^\#
M(R=W :C@+Y2NUKKF"SBM\M_!4G^#WOZ,IHBA#:W]@/''X,DOZ_EM$4_Z(DSM
MVTG; $E-6"^)O!:VBSN7A8RTY*LQ*PRN5W79QCMQ78A_8"1T3.6;H;0Y$8Y-
M([A%==BR0($@\(Y=_/.WEY2H\?&T_#Y9*/KWLSP$QGL<+-KO;J,_;7%%G7NF
M_P!S=RH1QSOY0^/J7)*V0%JE$.9!4\BJT9 =L8K1NV.@+9FR2;!^D(3?H0./
MRZ*O,QB3:O4&$CC6OK0]=L_4ZDXYE83W6R,DY=6(<0:LQ)QQ9ABK-M#-I992
M4Z9A!)==THZ<NDUS"L5QY9]>*1>9^&6>@^:J:/LQV]36.,2QX2LC?(*FP\4,
M9,0=VFV];N#V.D%YAI8G;2(G%F+]T275</4GA'2SA<H%;OW;]ND4@.'77&R&
M^L7&4"_5H*JXW9KME>,[!4*^-P9P]5E*^F[KL3D>\M("HW&&3J%ECYQC'^N
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MGT@]<$=H/2/ ,Z6+X_0<2Z(OVUVQX*92#J2;8]CTW#Z!7K3Y+UG8#QSZ'<Q
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MT5/6>[,?O[9D_P#R6CS!5ICOP>(_I.7EIIJ'26*JF<2*)'(H00Y 2G()3%,
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M_14]9[LS^_=F_P!PWX%6F._!XC^DY>6B(#W$! .>/C]X"' C\'Q_V$=?33#
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M4;3_ /3B&N.^ 3 #@Z^LQ,"!)7'?M>[-=K>TV'[+4.S6+&%PF [0X7:&WO\
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MZ XJ.5U2?584]=<4[F3;!GIOB>$RG&V:O5%6*II+!<:=7H@L^M+.WX,G#5K
M6.QQ*AHX[-%<Z*BKRKO2JG$P^4*(%,!%'V)-T&6\A(SB,[1*S72.L;W.W4N0
M92\Q)R!'=7<OHM!*SM75>BV!5W[MLF]!.+%1(J)C$!,W(%*1+O6=]N<:C3&:
M-OJ=3OEM8-E&+UBO-O86[34FXCSR[:SA!0]*91;.B-P51CUWZ#,7:2'EW9BN
M5UCI:)PZTZ^BSEUO-W)Q[HAWF(\5>JVJ]Y))JH6N\J/!0QVE6'4VK'HC32IJ
M'DT[)Y:%3743 58]5=R<"K W2)UU982KOVRWD6UKT6C1%-IZ3JSUIDQN"JLJ
M_<(0$Q,JPSX#Q,]!MSDF6ARIK)+.HPD894WA$\TCTKJ$ZZZOX+:;CJ MM9JK
M.(N]Z=Y'L2*[Q5U:GL-!P"[Q)=P=5J@,976,=%I$9(&(V(=)J518I 46.=0P
MFT19SHB6&[_;48,_$7*7YB*T1:4?FGC[1NH#_C<KG;X?WEUKH7V<?ONM_9U?
MDL/MK\.P?]P7T703'MWUV\9CO'Q"U==YKYETS@-GV\Y;PF]> =UCVY%G8U!9
M3J7&.L*8*'\$IA$0;(+ "?24.DIA'7'?M-P(H[0PF,:V!B*&X\@>[O4[7_S&
MYY@:Z;)L6KO4GTR9W7;PXP>/+A:\YG3L$[HOXGT7MS_=DQIV_P#OH=<O-P;Q
MS6<3*ZE$:(OSTEYYZ2\_'P'.B+[TE]_ <]^_ ?#[_P"GX=$7SI+V]DO;N'8.
MP_&'Q:(@2E'WE*/\X!HB^B4H@ "4! /< @' ?S:(OG27_JE^#X ^#W?T?!HB
M^\!\0?T:(K$TJU983LG:&->A&=EFFS1E,6%K%L4)N59L1.9DTD91) KYXV:&
M44,V0<+J)(F.84RE$1T3KK@K]HB-$1HB-$2W;L/L+S'O_C!3?=^-$7_8?O:(
MH#]*-_)V[G?DAE_T5/\ G_U:SW9C]_;-_N&_ JUQWX3$?TW=:?$+RU/\NOI9
MH&G&_.WCQ&L23R6DKL=_,S&</H?;XI_%;UX",;FC',Y$(I+*"5N$Q7 2LT>H
M0!,!1>+EBU&"(CR8X.SI$#J/SK0?M&P7[1L2EBFM!=@\0QY<!?<J$TG#*P&\
M'D3;,Z++[&J%N*+)M48;6CW;B.><QI [^_;+?P5)_@][^C*:X2MI4(;6_L!X
MY_!DE_7\MH$67YFR0VQ+C6U7Q=$KI6%CS&CV1C= /Y9R8&T8RZN0X\R]412]
MX#[7;OJ_V9@7;1Q^&P;#!KU USOY69O=D?NM!.6BM<=BFX+"U\2ZXI,+H.1.
M@S&9@6NNN_D"N168I&:GLO1D=D&<LASGEW%C:(R:**1P.*<;#H.BJ$BHAB10
M46+5F"(%*3QES+.E5UE/H'9N"I;*P]+#8(>Q;3:!+(#WSF:SBV:CC>9DD$Q
M CD^(Q%3&5W8JLY]5[B3,N]P28%,!PW6P! ,PVQ$A=:KTC^S5/;=8H_,.'S2
M$'1IZ0*W<L(MV[;*5>:5*90@LW:"B:S9DY$@^$F57E(X 4O !R.?PU;VTLJP
M7M D;L2!8&Q _P!60B(S*OL)7%3_  *T/-W4]X-<0,X)=.\(^[(D"UQ"SK8!
MZ<7=AL]GXBO72UR^:L,&6;MI&H7>1>R\E#L .0AW%8FG*ZK]DJ@D!NEJ=4[1
M00 #I_%K6WNQFR]M!]1E%N#QI:=RM1 IL=4G*LP!P?O3G9TF9.2S^%QU?!@"
MFXOI3)I/<7,#3F:9)EAF2 /<T@6CT!=K^YS%>[;$5;S'B.=1F*[/-4CKM^L@
M/X61\,IG45*-BG,9L\;'$2F*;L<H H03%, ZX+M/9F+V3BZF#QE,LJTR8,'=
M>V;/83FTZ%;9A<53Q=(5:9Y.!S:>!3#:QZN4:(C1%9K%8(>J04M9+!(M(F$@
MX]U)RDD^6(W:,F+-$Z[ERX64$I$TTDB&.81$.P<>_536N>X,:"YSC  S)53&
M/J/93IL<^I4<UE-C&ESWO<0UK&M%W.<XAK6BY) "ZC&_[TU&3LDS-@QEM?E'
M&.\?,W2T:[R%'@JUNUI*B8R*QXEX8PG@8E<Q>INHT3))K)@)CND2'\'5.+QU
M'9Q=2PHIXO%M'^+B7D/P^'=)#F89@#F5JS'-^_6)8+@,=(*^^/L1_P!DFCC\
M)@^U?VGLQ ;5 Q&![(,+\.'TC3WZ57;=;W:^Z_>:6X#"EI,.9B*LN]D[2Q2*
MY><[Y'B:XI+2TW8;'("L_G9B0>RCM%N8X*/W[QT^6<.% 31'J4.=4A3G%$@F
M* @4/78F!Q_:G:E/#5\97J4614Q+W/<6,H@W+006T]XV:QC6,WC,1<_27VL]
ML^Q?^SE]G.-VQL;8&P]G8@DX#8>S\!@\)@AC]JU*3A28^&-JUJ5.D?;8FNXO
M<& N$#W3OHQ?MZQCBB&CX^O5QB,FT*@HK95D@-/KOTN!\\G*)]#MBL57E1 S
M%5N* @02<"4!U]!X#9.S]GX8X7#86G1H%NXZG$^V&Z&DU7$$U)(_BM>5^'7;
M3MUVJ[?;<K[?[4[<QVUL97K/JTFUJ[_V; ![I%# X4.%#"4Z;8:UE!K=YH!J
M%[R2MXNQ_-=@NL3/8UNDJXFYZF(-'\--/E!6D9.LO3G013D')Q!1Z]C722C8
MSHY3++(>$==0Y_:'E/;#8M/9F,IXC#4_9X7%[Q%,1%.JW[S1   ,R!<CQ66[
M.[3J8ZA4I5C-7#D-WR3-1AR-R2=W[I.I3]:TU;&H(VY_8_L/R[[I?UF\NZ(H
M\V,?:XPORH;COUD<M:(FZT1&B(T1&B(T1&B(T1&B)0LLUV5=9%;QD<!G"UQ0
M;JE;%+PDLUC"%0<INQ'L9!F8Q7/M_4R&=!_?', RW>;+VES8CW@8@\BH<_>:
M*3R7, M3<99!(F&DP)=G87N5/=BFT\8XQFK$\24?)T>GR$NX0;E,=1R$)%JN
MSHHD)R815%#PR  "/ AV'CG7MAZ)Q6(HT9@UJK*>\;P7. WB2=,S=>51WL:3
MGQ]QI, 9Q>/B/A"TR;&O22Y1W*2+&WV>-2CZW8KW-59*NDB'+0L4T;22K.-5
M9.E0%1XN"1$3/#B=0G*BGL)B3@.D;;[(;,P.S7OPV):_%X:BRI6=[5KFO='O
M-B;9\M)6H;-V]C<7CFMJTG-P]2JZFUI:6Q!,'>.?'A%A%@MSF0:(UOD2DT46
M*V<M_%,W543!5$Z;E,$W#9RF(")D52 7JX 1 2^X0,8!YA+@06.W7 RTC,&#
MY+=" X%IN#F)(G2#&8@Y&RM^*L9Q^,X(8QJ*!UUA("OE$"MFB"2/6"+5HB4"
M@1%,3G-R( )C&$>"AP&HDF2YV\XQO$S<W&N>HXH !89"PY#@I1U*E+'ML_?L
MX?']'*[\_P"?0_XZ<>NM,N:+SMO36?REVZ3\?WO^HH?$'_;_ #Z^C.QY/_#N
MS1D#0;T2M,VC^,K_ .LK548![<"'\P_#W#C[WO[=_C#6UTC(?O96OS^N5A;D
MK$Z1GIY'Y<+KT0OF<'+4CD7T=\+5Y+QSJ8HOMKIS1PL4X@M'NG86)L":QN2J
M%;^MSMBD*/U(B)2< '&N!_:'A1A^T-2JV(Q="G6(&CA-,@S?^ &3<S=;9L>I
MO80-)DTW.:;6O#L__+RBRVOU[[:C(GR<4W\^_P!:(LJF9T1*[N#SG4<267%,
M#<J@:>AKL\M3F0GEXCULPJ,958]@Y=2"J8-G)P=.G4I'-FX 0A.!4,HJ403
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M_6\<%IFT?QE?_65K[PICV1RSF#&.,X@@J2=[O58JK),"B?K6FIAHQ*'0'/4
M"MR8>. * B/L\ZV'$XAN$P>+Q#Y#</0?6<0((#&N,7C^7/CW BUIL-2HQ@_C
M>UO_ -C"];/&E-C<=X\I%#AVY6D73ZK!5Q@U(  5!M$1K=DFD4"@  ! 1X
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M]F3&WMF<\2T>8*M<=^$Q']-R\M'D1'W>[CGW?& AW[!\0<<_#KZ9#(;,CWA
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M$D_?N2)"(H(+M&)05*!'1VQ@.0.C8OMMLFEAW/PU1]>JYI-.D*9;#[ >U+H
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M241.J8LT_.V,"@F\JJ ' >6;:JX-VU<;AZ[:K7EIW<1194+Z6](8/:-JLI-
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MJT"\GCGQX1G;H1*SBW,(7+:R]JQB\;IWIBR*E,5&:ZXI>602Y%L57Q2_47"
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MP:(HRV2$6-MNA?!=^5$F4=QYC*"FDH0Q0W(9: 0-XH"!2\]^2B4>W'/&B@^
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M9]Q4*V'*UO.0T'!0=)]4^9290<I5V+YHY=LVZO!Q$KAXY%,#G(4IP24 0 #
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MU*=#HJO ]0@'NXYU5]H^--?;%/"@DMPM$ @Z/?!,<+1Y*K8],-PQ>/XW9\@
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MIT$91;R^GC\H;MQI+)0^+D)Z>:3\45VT(BJJS@XWJ'DB39NT%LJ[,D7@HNI
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M+1$YQ'EW65\<N"-RD^IG6754(BV:H$%1=TX4'I2;H)@ F444-P4A0#GX1X*
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MX=!3!B?T4T4+,NVNHODIV6ELRVBS)$,1%^[VN[E6S&.ZP % B8PF(U2M1/\
M6BLNN[=B3@HN!#L)/CJ%-?TZ.!ONC+_Y,FYG]D.BB1Q"/IT<"_=&7_R9=S/[
M(=%,H^G1P+]T9?\ R9=S/[(=$1].C@7[HR_^3+N9_9#HB/IT<"_=&7_R9-S/
M[(=$G35'TZ.!?NC+_P"3)N9_9#HDCBLFVO2"<QB=:=09S3)C8LM;BK)%)6"O
JSM5EU82Q[ALI3D&^=5^S1T1/1A9*(?LI%JA*1K-R9HZ06%$I%2")%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g569434g50z56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g50z56.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Q64&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  %1&5L=&$< @4 -TUI
M8W)O<V]F="!7;W)D("T@365R=7,@+2!&+3$@4V5L;&EN9R!3:&%R96AO;&1E
M<G,@+F1O8W@ .$))300E       0 N028I-(E$*<Q"1!X98HL#A"24T$.@
M   !,P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #0 ,       #W!R:6YT4')O;V93971U<$]B:F,
M   , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))
M300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R
M;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8K?,         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          #G   !P          !                          $
M         <    #G                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   #G     %)G:'1L;VYG   !P     9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    YP
M  !29VAT;&]N9P   <     #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@
M   !0DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M    !@   +"':0 $     0   +@   #D  \0+   )Q  #Q L   G$$%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#@Z,C4@,3<Z-34Z,#D
M1&5L=&$      Z !  ,    !__\  * "  0    !   !P* #  0    !
MYP         & 0,  P    $ !@   1H !0    $   $R 1L !0    $   $Z
M 2@  P    $  @   @$ !     $   %" @( !     $              $@
M   !    2     $X0DE- _T       @          /_A 41-30 J    "  (
M 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P    $
M @   3$  @   !X   !^ 3(  @   !0   "< 3L  @    8   "PAVD !
M  $   "X    Y    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$X.C X.C(U(#$W.C4U.C Y $1E;'1A      .@ 0 #
M     ?__  "@ @ $     0   <"@ P $     0   .<         !@$#  ,
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M+#808VY_T?G%^[C="EUG%-M!5Q\YJH*]LMA,FV<DO/09CB;.9?8W&HF[AA*
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M-G9<Y OEEA1/W03:-1F[/QN,BEO2X&R>U$2OC'N1$R'/)BI$DCV2[^@5:PT
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MJ!AMR=KMQ:*^EEI+CU(X^:^_B=WCLE4\],><TH'D>6>%?S))203E9%;35/\
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MX)P?A4C"<$HY5/+E)3VLX)';U4P)94ZHF-G6M1O<V=@ (L>!6I/:E"/=/)\
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MALV=4>B;6YQXSC6]U 5L#>?K(V>VM4EYZ%LSMODV[62/)[C'KK;<"P;P?#%
M#EM4V50TNYD9'< IA$E"_9[G4R$YE!//Y#7]/.,!C<DUWV3#<RDRZB<9M04E
MCV%, I27#MGFS)*0]GV,9O0(D>OB1H<-EMB+%9;C,,H3PVRRR@(;;0GGV"1P
M.2?;SY\ZN%LD, & 8?DVYO8^-[M&7ERDRI*):$A*):4I0!H$@!('@P!Y]7BI
M(22>/L.#P1P2?'\O'MQ[C[<\\\ZH7[K,/34/K9[#7\]8JCD;\F=F8[ZW8V<[
M-%2::4$]Q(*B>[GD>_\ 3\>!R?MY]O.I27_IY?HUK>-S$6=R2=.=N1+:[-O;
MI%49;"$E9422D\<_;R?J_J"3V^1X)_)XA$'>[==>3<B]N;.+6BB6MD$I[4*\
M=I_<'P4GV\C[_GV'VYU42DN+7<:V '/\OGO%";,"$L.OKI?T<M;;9XCBQM>.
M]2W" !](!))(!/ Y/L/'[_TYU=!"1U/4_(:=?SC#3ZA1)#VU<;CD3?3\M8CJ
MTNBL$E?TCQ[G[_<@_GP>>3_XZJI1H2WB/$6O;?S,8J=4@!0!!+W)W>U]QU9O
M$Q'MC<@E7"O?D\#P"D CW^W[ <GG\ZJI2[V(9KAG8[BQLVW+8",1-J'>[[ G
M3P%QZ ZV.X%H2[<J[N%DD@'CGM]OO[^/(!/L?;Q]C52D'8]ZQL&N!H]SRO;X
MM83)[@.=-W>XTML[M%N2;7P!W\_D#V'M[GP>1[<GWX]^02:P0'8^C'GS;0@<
MQ\(Q\VKR@M<ZN[@C5[;CJ+AXI#UL.#]:4]OWY_?^O/MX'G[_ +\:GR6N 4E^
M?AKU9SIX$19KK"393%@_4/N.0^&FHB-]RZB!GF$Y#BDU2%IMJYYJ.XM*"&)R
M$ER)(!5R4EM]*.5H(4$%?'A7FSQ/#)>(T%323 EITM24N'"9@]Q?,95!W%RD
MF^L8C%D#$Z"IHIA#3Y2TH)OEF,\M5WRD* \ XWC0%D+,C'KJUI+%*V)E5.E0
M93:N 4/1GU,K[OL/J22"GGP>?&O/L_#9LB=.IYB2%R5J00;D92H$%SH1=C>S
M:QY6KJM='5U-+/[DRGFS),Q)RI 4A9%QL2+..8<"[Q-N:VF^PJ[B-AE<AN-\
MS&[N"I+L=0=';SY"E(2I)*?L3S^!/3TK3$EE,Y&C;%P[$#2W36->Q6L15T,Z
M5G02 E203<$*>UN7=WM<<HUR.64CE2%.$<<@@$G@@<=ODGS]O]WCGC+"5+3<
M@>=GYDAAO<?TC3D44U8#)+ZNIPP:V_+YWUCHKD.$ ]RN2>1R3_GY/W]Q[<?Y
MZF)EI!8#TWOYV;;F\7DG#5%3$-H;"YYO9M8M*VQNGR;*=MA?39-;5C/,;JK:
MPA(;?DQJ;(K.+3V,E"'%MI68C4H2@VMQ"%%D@J2/.LCAJT3*E,@DY9W=.Y!<
M92QLQTL6.;0VCT_^ROQ=7<!^T:6:<"9+Q60:<RENF6J?*=<H$AVS(*W+$C*E
MF ,>KM7_ "9O:VTBP[&DZI<O:AS8\::PF3MS5/%<>2A#[?#J,J01W-+20>P\
M'[<:VC]UI'NSE<O<&EM;WT!\?&/J:CVTUS JP2F-K%-8L VW!IR#XAND>B[I
MWV4H^G79;;O9;'+"7;5.WV-P,?CVLYI#$NR,-I+;DU]AI;C;*Y"P5EI#BPCG
MCO5[G(RT"7+1+2Y"$A(?6T<DQ;$IN+XC5XE.0F7,JYRYRI:"2E!67R@EB0-'
M(!/*+?ZH>F_!NJ;:/(MK,XB,K9LH[CE/:*92Y)I+=+:A%GQE$=Z>U?:'DH*2
MMOD'GC@W4B:)94E:>TDS4Y)THZ+1_P#DG5)V/C%3 L;Q/AO&,/Q[!JI='B>&
M5"*BEJ$&X4E0*I:Q]Z7-2"B8DN"DZ.!'A8ZKNAC?3I.SBRQ[,L2M)N.A]]5%
MEM5"DS*2T@)<_AO)E--EMM90H>HTX4J2KGQK%5V#3I:?M%(#54A+A2 2N6=<
MDU =25#P(+/I'UG]D/[2G!'M"PZFI,6Q&CX<XKE2T(K,+Q&?+IY=5- "53\/
MGS%)ESY*SWF=*T. I(BL]"W3MF^ZV_6"3F\6L7,7Q?(*[([N7)CN18;L:IE-
MR!&3)?;0VHON-MM+"2I: LJ *AP:F$44V3.36U,M4N3)S]GVB2CM9RD*"$I!
MOW2<ZB R<NFT:E^U)[9>&<&X#Q;@[!L8HL1XEXED(H3(H:B55?N_#YDQ"JFJ
MJ5R5J3+$R6DRI2225E2F RO'M!E;F;C3$,M1[6MQR(PRAIF#55XEN---@-MM
MFPG+X=4A"4IY$)L<CV(/&KE2R227<J+YM7+ERVM_6\?*X"S.X#,Q(T 8:\KW
M,1C(J;AZ9+GC)9JI<Q]<F0J3$AO-NO+ Y66F4Q>WD^X2M()'/WYU3*DEK,P?
MS>X##?ZTB(>[_0Y>7C^D<2I>0UO*Y<2/:Q$@%4FM!:EI2/YEK@N\I6E('/:P
M^ZX?LG4.Z7V+[Z:[VM^31&*S#N6 ]27U>\'C77=5):6. I#GSC,9:%I\E*PA
M]:5MG@C[_M,FQ8G1]BSV.MM6)O8,2+Q _.Q\+_)XV&I/*4G\I!_S'.JD1C])
M"02H@ >22> /ZD^!I".C^J5G?Z?ZC ]3GCT_G(_?S^.WU.[G]N.=(1WP01R#
MR#[$>1I".BY9UK3GI.V$%IT'@MN2V$. _CL4X%<_MQI".VAQ#B0IM:'$GV4A
M04D_T*21I"/O2$4*3E.,PW%LR\CHHKK1*76I-O7L.-J'NE:'9"5((^X4 =18
M\C_72*@E35!TRYBAS"%$>H$4]>?X(WSZF:XDWQX/?D=.GC^O=,&C'D?0Q,*>
MH.DB<?"4O_\ &("ZE.I;;K:39/<7-H^<8I,M*G&[(4\"!D53*G2K>1'<CU[,
M:-&F./N.F2M!"4()\?;5I7354U'43V5_#E*4+'5BT;7P3PU4\1<58'A!IYJ9
M57B%,B>I<I:4)D"8E4TJ*D@,4 C6[F/$);VMAD-[:7]H^J38W%E-M+!YPEQQ
MV7/D.2GW%*423WN.K(YYX' YX&N8R7FK)/XBM1(N223TW/7]/JM34\JBI9%)
M(2)<FEDRY,E #)3*DI2A"0UO= 'SO%QU+?\ (I(_F\GW/V\CCW\??@\?MQK:
MZ&5[K@?BW\O70.]]XK%79RBK1@5,[#H^_KMXQ*5-&'<D\<#Z22.1YX\^1_0^
M?W_KK:9$H!*1E]]G?=O'1AI&DXC/),Q1+B['5B=6%OK3E$KTD0N.)''()!3^
MP]O/^8Y_/CDD<\YF0@)"6Z; DMUMR^0YF.?XI/(20^KJ>[#1@7.^Q;FT9+[;
M8R+:T@Q'&P&$+]60?MZ3?*B#[\%1 3QSPHGVUD9<M]O$Z[/R'FVFCZ1S;&J[
ML9<Q23<I(!>X)  WOLY\;DL!A,K:C*I74OU2[W[1MEO=/8O)L(R*JAQ5+;_M
M/B2*J1_:7#Y*6Q_'CV%>A2F67.6Q)9:5VJ/C5DI!$V<N66FRBEFLZ;A0>Q+B
MSZ;W:WGZO"UXCB55)*OM4B9+F9O=,R6QSH-@X4+C9^D9!XSN3C>]FX/6EN5B
MKB5U>1]$U3-<C$\2:RP_2,A38U,Q' 4U,K9B78DAIQ*5)6V>0GD:HS)F=<Q;
ML\H&]R-0<VSN#LWC&+FU*)LRIFI?OTR24ZERE3@@Z%+]"]XC[ICL,]O,E^'_
M &'73@GZ%TG6^$X]B'3K2JM&YF%C=>I@5C6)Y7N]6J;$20YE$=$A_$(]B5PX
M[JVN]MQ!?+E@5*.1]&"1>Q9KG?DWE8QBDS5$4PJ!_ "$B4EW25ALJY@_$1[H
M.G+5_6'>--8]B]U>AH*12T\ZP2P@!(6W B.R4MH[>$I2L-A"0D< 'QXX&I,Q
M\1XMYVW;37EH(OC4LY&SL/5Q\/D]]-+NS&(]7_4?LEBO6EC?57<8ED^<Y+89
M9C.SMK&H(>RE7MQ"RRQJ&L.NTJJG;MZVE5=8I4BZ_4DK1,='I,H3]*87;7Y/
MYZ/T\(MY4V=,2F<FI9142):@!+ "BG*3J"6()<:ZQC#G'5/N%O1NSU%IE[W]
M16T;>T&5.X1M;BFQ>T<W,L4FW-56HE3+G.+Q./6WZBW.L5HC-53;\%*((5(*
MNY0X:N'(V#;NVGJ?C%5-4N:N9_%FR^S.66F5+S!TCWE'*K,_)QRWM7*7<S.]
MW]].BO.]RZ27CV<V733OPQDL&=7O53SUG7H@Q'K#]->_BPV['TTS&V%_4T'"
MG@<<:FN%))&K&_1G)N/CJ+Q?2)JYD^C4M)2OL)V<$ 7&2[&]R+#5BX8ZP?@&
M=;OXIT>="D2GM-Y<7Z?IN);H3-Y,NZ?J&#D>Y%191,ML48>V_%D0+:77XNZ\
M_/<L9\"LE27'F(\8%E))6#6S"Q)<C4@L.7]06M:*U/,G(HZ!E5")!2OMIE,G
M--2Q_A@NE9"2K,%$)/+NAB=I_0GN9_SB;27KYWO;WXBT&<W513Y595#^/9W5
M48:A/UF-[DTC]?6?)Y?5A<A,E]J$RU,BN17>P.!9,Q]W,^I(/XN;*+6.NC@Q
ML6%S.WIRU1]HRS%)S-EF)2SI1-#!IB7[Q8!K-J^8+KQ/D$>.>1Q[\#D$<@CV
M'V/Y]_.K&H!(+@D#35K^!U'47VC/RTN?!K\GL_7Z\8QSZE]G*W?#:?),7?BL
M+O(T-^RQB:M"2]%NXC2W8R&7."MM$PI,5U(4$K#J5+Y"!K ULKM):@=0"4LU
M[6#[6#>,;EP9Q!-X9QVCKDK4*5<Q$BLEBR5TTQ02HK#L3*S9TEBQ##6/.9L]
MN'?;![U8/N# +\6VV[S*#.ELI66W)$2'+^5O*MP<)46K*L5/KGTG^9J2L>Q!
MUJ*)JJ6L3-194J:F8&M8,Z2;6(=)T=)O'K;B/!J3BSA?%L&J B93XOALZ2A2
MF4E$R;**Z:>#IFDSQ*G((L"A+]?>%C]U!R2AI,BJWT2JV^J*VZKI+9!;D0;2
M$S.B/MD>"AZ.^VXDCP4J!UU.6M,Q")B2Z5H2M)&Z5 *!\P8^3=92S:*KJJ*>
MDHGTE1/I9R#JB;3S52IB3U2M!!ZB,'-@&QEV]W5KNNMOO9F[KP=J\>FD%2G*
M#:C%:*ILHJ'/_P"!%SN;F(;0DA"7WY1([UKU=21[RM68-TU/P:,)+29F(U4X
M^[*E2:66 =%D*J)JB_X@NG#"_=\'S%2DGCP?'^T@^W_K[\Z%3LXLQ8^!=M-1
MY>$7X%F%W4' +@#Z:_SC4MO=\3_<G8*X@PLVZ"-^TTV0;BP]LL*R-K),*3 R
M[([><]"H&ZQM3JWT)NO2#L020CL0L!Q0//%)1)LV]@WT7^!^<Z$BYS;/IZM=
MOT'1XS[Z;-ZMP=Z:B^L=Q^GC/^G>PJK-N#64>X5K0V$[(89B,R'+6N_1'7$(
MAL/.JBN![A9<:5Q])&I=GO\ 76)2J[?/HQ<VZ$&UO*)]LK>,REY'KM(2TI*7
M^7D)4DN@%M"P5?PE+!2$!7;R%@I!)U,E.AT (?II?PN+Q(M02 +&P%M?JV_S
MB*+7+*51G\7%:LU9[;/ML(JOT[A!4$S@'>89*4E9$CTSP%>WD"Y2FV;=V#[#
M<Z[6MS?5HPM1-+L"6-^6Y8 W?7S%^<1K9Y'&F,&;'EL/1%H4ZU(8D-NQG$ ?
MZ1#R%*;4WV^>X+X'Y\>+E*=C<!MK$MY6Z:1@ZFHR. 6)?F=VUU<Z,8C%W*8%
MDTX_ L(DUE*UH6Y#E,2FDK02%H4XRXM"5((/<DJ!3]^-5D@>0^/@/&W5]C&%
MG3E7#$"[N_-^\=;]+CDT65,R"&XZ8R)D=R0&@_\ +H?:4]Z"U*2E_P!)*RL-
M*4"D.]O82% *Y&KD2KN6&C "Y<MZZW M=XQ,^K9-@3?*#L".9TU;D;7Y19MS
MD]=5->O8SXD%E2@T'9<IF*VI:N0AI+CZT(*U<@!()/N0G[:JY0+V%P/SLS![
MG?SVC$S*A:RR<RBVPN;ZD7LP&W7>]I6N61H\9R2[,88C)0'%ON/MML(1P/XB
MGUJ2V$<>>2KM\\ZJA!U8,[N= +I_.]_SBPF5#V!)/X4W+Z@,+NVP%_.(#WGW
M]J-HMM+K<V:P]?TU0:X*C5,R.7)0LK&-7-EB0HK8*4.R0XM7)!2A0![CSJ,P
MIE2^T+J2DC1AJ6=QM]'>%$F975LNB01+F+SW6%,G)+4MB+&X2VEMHL[".I*G
MS[<W,=L(558P+##,9P[)Y=A(?87#F1\QJV;2)&CMMI#J'8K3R6WUK44+6"4#
MMU,A:%K6@)/=2E158V4' '@;7BG629])14]>J;+7+J)U1(0E((4/L\S(I1V9
M1#I NVK;ZX^L*+'QS>*PD1N]*<BAQ+M:>>!Z\CN3*<3X'(<E-J4H_E7!^^N8
M\28:A&*SYB PJ0)I) ;,4 */@59E; @MO'CGVM5:,,XK6J6)F6OIY580#;,<
MR9BAT,Q/J>AC'7$Z#)MS\EJL"PZN?NLERB4FIJJYE1*GI<E)0@*5P0AM*>7'
M'5#L;;25*/ .L++H5J4D)3=1[K!G#6=WU<7.CF- P5>)<1XO0X-A--,JL0KY
MR9--)"F"IA+LHMW$H2,Y4V5*0>427F7P3^LW!-N,YW4S*+@M-3892S\AE5K.
M2)L[B9#A?6M#$>/'0E#WIGN"5+(Y2>>=0F8)7)0N:5("4)4K*5.HCH-BVCD,
MP:/5(]A'&&'X3/Q+$)6'231TJI\V4FI,Z:>S0"4I"4A+ZZ[AB+.--SLM+:UH
M)^I"BE0YXX4E7!Y_'!'!^_/GSK$=C-<.][I?H?Y<_.Y,<U10,^9(#'+X-T<O
M=_BPBU\GLE)H;)^.XA$F&RF?&5R/H?KG6YS2@?L0XPD@_P"7GVN:23,E5$F8
ME1=,U"C9B4N'=CMHW,#:-PX(5^[.+, JT9B9>(R$$)-SVJC).VW:.^P!!Z_T
M\.EK-E;D=-VQ6=+8<C.91M3@ULXP[_I$.OX] #G?[>5+2I?_ ,VNCC^7I:/H
M4+@'F(GK2(PTA%*N**CR&&JOOZ:JO("_*X5Q7Q+.(H_E4::R\R3^Y1SJ>7,F
M2E9I4Q<M6F:6I2%>J2#$JD)6,JTI6G5E *'H01&+&[N!TV&SJ.[QK&Z>AQU4
M-RHG-4-1!JX4&6J2J1'E26($=AE*9??Z"I"D?2IH)<7PI(U&9-FSCFG39DQ0
M]U4Q2IAWLZE$M?X1():98:6E" ;D) 2#SL V@L=O"(X3P?J!!2L!0(XXXX'G
MQ[@\\CW'GG\<VQ<L[ W=S;8VUY_E%0-MT/UZ?*/KD#Q^.!_0?8^?M_Z.I3]-
M]?SYQ&'N![C_ -?O_P"7/]--'T/B/CT^@813:+&)5UN%C]36ME42UD(G7[:?
MI:CQJMQ,I,]Q*> ''G6VXX/ ]0^"21JJ@V+CFW.[%_,ZMM$-3KHQ^8(/U8QE
MUGVZE;ARDU->P+O)'$!2:UET(9A-$'B39/@*$=L$#M9 +SG/TI '.HD@:EH>
M&OU^48TW619;DSCCE_D$XL.<\556Z[65K(/'T@1UHD/$#P5N/#N'DH'/&J96
M=K?7AT,1^/\ (_E%M"EJ^/\ [HWZG/=ZW+GS ///(D>H7@H$\]P<[N?OJ;,&
M))4Y?8?DS;D?3(J:=R,KJ6!@4:VG?*VKB7(UHJ0X[8UL5MM3LF"S*<*G>V0$
M]C2EK+C2"KM43QQ%^Z5>+#DW/QB#?EX>7+G;I%(=JJT!UY^/\P\$J=7(DK<D
MR5$ \K^9?6X\5>1RKN\>2 /L2Y(:X#E[[:>/+<7N[.3.0']XA(',EP/"YUZ1
MC9TU[JYZ_FV?1(>7V[,>-82)<"NF3';*K2AF8J,&%1):W.UDM)3]++K7!\CG
M5G33%*F3P25#,Z0[M?38#X CR$=J]IO#]#A/#_"4^EII4F::67(GS$(2A4PS
M) J%&:4@%:PM2@%*<W =K#9U@>\4:]E,4.31FZ:\=^F+(0OFJM% >T=U?!CR
M%<'_ *.Z3R?#:CX&KT$'=]/K^4<6^OIOKPC"?<OX0W2INSGV4;BY?;[VN7F6
MVDBWLXM9NQ>5M.W)DD%Q$*M9;4U%CC@=C*"4I^VKE%3,0 $Y;<T@_/ZUC;*3
MC3&:*GDTLA- )4A 0@JHI2EY1IF4;J+DW-X\Y7QM^C3:7HOG;(M[(2,ZKXN;
M0,E7D)R#,[2_7(?K9$1$4MJD>EZ1#;J^[P>X_C[Y"BFJFY^TRJ;1TC\N3_'I
M'5?9[CE9CPQ']X_9UF09(E"73RY82E05FL-= .C><:.L F2WLVQDNR9#ZC<1
M.XO/N.?]<DDGN4KW_)Y/D^/Q2QU(_=5?9(_X>9HVHZ:]>5A':N%PE&/X60A
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MDTT!'C@++UBTQ)?1SR>8463W $=PY[M2Y6U+.-'U;X;>K.YB:.>#7V\6P@9
M]9M/75:^F77QDMG]&9<2>X-*AN^H9/=_(J0^LO)Y"V0V0$ZB% :"VMBY_EMZ
M'6$9DT^[%),P65F%@##<JDJC6M:DE3S=JCA"(4<!/+OS;BD&*I*25-N)44^"
M!4^OJP?QA\^GU\/*YC$#)GKG+;F=F4F4*JZDLI;CQ8:4*KX\)E+AC0IK'A,]
M80?X\MUU#_>28[K"$IT#.'=B;D7\P#M:YT2><2*;*5:,#=G+-L+'R>_G&BCH
M$RZ7"ZM=WD6 F2$7#F9&::Z!.F_7&NWW6UF)#;E2$LMJ2 E2@YVI !6>TG75
MN+Y*/^SN'*2!_#^R@!K'-* -R [VMX'4Q\]?V:\3JIWMMX[E3%JF?;E8ZN<<
MRR29&)3!+U8G*D)"7-@&!#!MY!RV@[%%,I]YQ(Y,9JNL79?@<\?*)C*DI( \
M]S0 ]U$#DZY,4/=-N?3J2'^$?0L'8N^Q(9^@ZMS8=8R7Z>(,R14W&5R(LB#%
MO)26:R/*06WW(4(J;^9<:));]9WO[$GSV '4P# !W9_"]XC]?R^N<:!/^4OP
MRK;KIVG#GAO++^-R!]W*QQWCG_\ 3YXY]@=9+#BTR8.:1M;4N_K'7?9,?^.Q
M-/.GE_!>M^7/Q<1Y-,'449;CZN/'ZG$YX_O?Q %>/MY3R/P4\?@&YQ1+X=6!
MQ_W:807L&0P<@.S"X.Q<M>/0^"]W%L.-[5D@N[-_$ ?U.O/7ILDBJ[7![#M4
M/ /'CV)]P??QP2?///Y/$Z&RLH+&SDEW4[_-P&U'A'JA=FV=W.FB?4[Z!F?=
MHD2H7P4?5R!_,?<#[_S!/;R>?/D?D@_?=*)0&5E-=-N]8:$V'EY:-%"N_L-B
M+LS-H]GL;'?GSB6J1?(!)']WCD]WGV\@_8$G@#W/OSK8Y)(5:[I/306VMZ6C
MGF) MF4]GN; '3E?D[GGI$UXN[]0 *>#VG^@X))YX2>T\D<_?@#QY.LU+4+'
M0J[Q:^@Z$;]-U7$<UQ5">]:P<N0S,SW)UUZ@L;VC+G;6P2AI3)5QVN)6![#Z
MT^1S[<#CCN]CRH\#SK)22GO)?KSMS(%_+4<COS#&96970I.NKAKEK$6TZVW?
M,#"[5*5,'E/:.U*C^"?;R"." 3^3[CCSI-3KN;D'9AMI^=_C'/J^4Z%@ N"Y
M<$VWU\2WQTC*[%;="4,J2H$$C[$^_ )_H?ZG@?YZQDR7F!%G].?-GV(N8TVJ
MEN"#F8\K>;*L0_@?$1DCBV4)8#25KXY"!Y/(4GCC@?<GCQXX!(/GD><5-0J[
M![E^26+/;YE]=CKKM1(S$W(/@Q=K%F (WT/36)/3D4):.0H=W;[ \_5QSX !
M)3QY"O8^/)\ZH%)#]'^#[>1'C%CV"S;JW47;2_\ .+0N\D;<0L!8\>  ? !_
MKQRGQ[CD>XY]^9@D]&9V<'SW&OG>SN'R--2E)26<EC>W@;==G)\(B:XMVTA:
MBOM)Y(3[\\<_W1^/;GP$^_\ 6K+E*)(U2&N[ACM;ZW;2-BDHR@ FY9AWC?>X
M\;ZQ$-Y<#E8[D\'N3[@<$^Q]P!^?;CCGWXU?2Y6IT8[:&_RO=P-@!&6DI*B$
M@6WR\SR?31]]?2+K6WX*E(< *5 ^3W<<D=P)\<<\GGR1Y\#D$"NE)O<[L&M8
M[.?2X\7C/4LK.4NDLD-M?D-6+V#CH="\69*M?//J*[BHGP??@_@@_P#S$C[^
M/;5K4 @$$ )-KV>[ '0ANFWC&PTDH$ 7&UWU-R2 !<OI;P?3@_55$ *)';X\
MD<D^. GV*O;D\'_8.=86ILG4<@=K[:^C\M[-L%/( 8,S@@DV=B[VZ'=NKBT?
M;<XJ(^W'/OQ[GSQY/']?!\^..?.M=JIC:-YLQ#M:^Q'(/SLQR0ISD*AE+@;D
M%F;X?D;:F-!W7%E365=0^5MLN!QC'HU7C[9[APAZ#!9$UOD #D6"Y">!X2!Q
MY/G6IURR9W(-<[-H['6XZ$EFN\>E_9U0FAX8HG#*JE3JHGFF;,5V>I<?PPFQ
M9_-CZ:?A28[(Q[H8V>^:;+3UX_G&0]JN.XQ[+.LB$)P\?9V"Q&=1_P# M/'(
MX)WGAY!3A4@D-G7/6.;&<M()\DANC1X/_: K$5GM6XD[-04FE3A5&X8C/)PF
MB[5/BB:M:%.Y"DD;,)Z=RRGH^J"\P6?#?@VF?;.X]EN,S2CB#?\ _-_E&04^
M8QFU<A!LZ5K.,)<=04EV3 L4*Y]*N/&>3H0-?F/Y>(-[1Q90/E\G &[=?7S&
M0;21VA/_ .'W)/ 'X'M^>">-2&(FUMM!;5RU]AJY \M+]J8L,QU< <K24CGD
M C]R">/?DD?Y>>1$:A[1*HLDMJQL]O O<=!8"\=6 XF9&"@KGTU%!!')Y0#Q
MV\A/_:Y"3X /VU%08VWN&B1"LZ".18@!W8CH';F0#8<WB-=T(BQCKTT%03$E
MLN+]@ VZ%,*( _*W$$$GCCG[GQ<TROX@20&95_0LYO;2QT.]C&'QM %&9OX)
MLM1&CI+R@][NHI/2VKVPXM9G<3Y]N1Y^WL2 ?=/V\>?VY]]9)(8^#L[<RS_'
M[NY\(Y]4+[I)/4EW))%F/G;D;M9S&=Q/[$+'<.X@@#DCC^O!/XXY//XU>)2P
MW\+!_@YUM;SYZU53LQ*@]]R+[VZ?'GII#MM8*4IU16KM'\J03^3R1R."2///
M'/VY^^KI*?=#7^\6MIITVL1RVC7ZRH9P#UUN6#E];$]2&ZQ'%K9E/?PK@\>5
M<CN \]P)!2 5#CD@\@'Q^=5D)O8;[AW??KH1S<#SUVHJ-=DG4,2^;7QT8 7T
M=FB+[:U6KN[5?0">03]_L0G['GD@\<< <\ZNY<L['SS;;W+GD"QY^$:KB.(,
M"F6==4NQ4'YL"XV]X  '53BP+&U"0KN5_3@_?W\'S[_?E/O[<<#FOEO9P[&^
MY\6)%NO*UHUB9.*CF47+EDO<;V&HV>S\[VBSY=P5A24K*1[$DGQ^Y'CG[\CC
MCSX\:JIE7[UWN-R7N.C[G?;G%E-GY74HL+G*YNU[DC;>P&G.+7LLCBUL.7.F
M/AF)"CO29+BE\)0W&;4\L\#RHE*3P!R>X!/')\U>S !4P(3>_P"K!B&%B#TM
M<X^=B$N4E4Q64)0DJ4?PI2"27N;)!-N4:^L'ZW-]MC=U,VW)V4SAW#IF6NL0
M[1IVJH[QBQI:N0\*FOF1[NNL$!J.AQ7:81BO$N*_B<)2!K57)15S5*6ATA1"
M0%+\-BD;=T,6T;GK7#?'/%?">,8AC/#N)G#IF)*E(JI?V6DJD3Z>G"A2R9HJ
MY$XA,M*C_8J0O-;,,K&'.J7KWZEM\]P\>W%RK=&]@YUC++#&.6&&S96)#$H[
M!"RJB9IY,<U<NP>Y>GRVGA(E$EIU1CAIE&C\4UZ<*I4T%*O+45!"YG>!4E";
M@J9R,S,G8 ?B+GJW#V+\6>T#BF1QEC]=.SX+*[###2"924\B:I+3!2RY:F0I
M0*ESU9U3)BE)2I1EA*1F/M/\<#>N;M1E>PG5GC<7?_;S,<5LL6D92%Q*;<:N
M:F15LQ9DJ0&OT;)U0WO1>(FL5T^1Z94]:NNDE6HT^.3IDLR:N6)Z%I*72&F!
M]"0;%NIS:W)<1Z:P[C#$%TDS#\8E#$*>?),HSF3+J4Y@0#,MV<UB ;A*^9)O
M&D6R;AJL)RJWUOD#+D*@&2A+<@PRZI4?UFD+>;;>#13ZB4/.(2H$)61YUAE2
M"5J*;))4P*0" [L#JXN+;W;2-5%"C.2D#(5**"HN<I=G&8AVU8CSC/?X5O3#
M9=5W73M!BXJ7;3 ]J;>+NQN9)  @PH5 [ZV-0)3RDK3\W/NDLOL1R0IP12KC
MA/ V+A^A(FKJ5ATH2$()_$JY8L'L!<Z$::9>B<#8-DGSL17+2!*09,DM]]39
MR.=MP=;;./5^UB?4QDGQ*^LX]/N\.U>U;47;[IZ%^C<;9>^W75:%>$Q/E#6J
MI=VMLA4I8"7 ZEY-EZW<""UV\';8ZB&W!/@6_(QKR=.[..T&+)<W+VMJ=UJ_
MXG&X3<_<C*\)MHNV*KI%7?IEV<C"F<]B6T&LDK[BQ7_VZ?>C!02NPD%)4J!>
M^]@WT&^>NXUB 8WVON/FQ\=MMK1L'ZI,IWNONBOJ,B[H[\],>\%NB!B[F+-[
M&X/DF(,TSIR*O2IW)F;O=C<E^?'=D>CV&%^FJ;:2ZD^JM22F/)_@_P!?#\H6
M&C^9?Q.VO*(XW9A=5<+<CX?$[J?L-AKS:>-NO5.4"-DJG/Z7/8&7)Q!;E"[9
MS<KE6K$FG5%;D-SH5&8%C,DA"6W2E+:-(@'8M?5F?3=R7_(>40[U,YC@59%Z
M+9/3!>;=-].<7J+@9#!P>EJ,AK^HF#N382\AJ+N\<R?*KBVGN-HLI-@]D-',
MH*RX?C-1U2KER*PPSI\.E_K]-V@7%G(=G+D/LQ;Y6#[:MM.8A-1UNO +=DRU
MEV;-D.*DSYKQY*WIDMY2GY+RU$DK=</'@)X3P!34I7,C>Q-P?Y<_AI!O/E86
MU_5MK><=OGG[ _UY\?U\< _MYU+<N27?F03\W_E$8>_/GR.?[OCC\<G_ #X'
M (_PT# ,=#?J][@^+O9M 3J0BL[?9DG"L_JJH!PTV7J<BVL5"D_*Q9JAV0[5
MQ@CM!?<'RLA8[>\=I(<7X-5)S#:Q;D_UJ3H.@:(<]_'XC3T](OS/MI+*BDRK
MS"XBK"CD.+D3L9C(YG5CJR5NR*-'/;)B.**EN5H*'&%J[X@<25-)@I+W&MO#
M7SZV^>SZ\_KZTB'XLR-+2HLN\N-J4V\PL%EYET$\M.L+[7&G$\<*2I"2D^#J
M4H+7#W#%G8CK^3%A#I;P^?PCN%7MY/CCD']_<>_OQX'L#_MTRON]G %@_F +
M;MN8/SL.9^G]1%I27;(V_;'+IQI4R"J[5P3$39(:=-8'CSZ25^H 4^.XN!"2
M2>-1 (3>W+H'9WZ.;P<<]?RBZ'$!84D@%"NY/C[I4D]P'@^X) '(XY_'&HIO
MK<N2 "YS#0N3;3<[AM;RJ#@Z[@@%@RA<^CY6^]YF-+O0WM_.Q3JNZ@+&X85!
MC8S-OHH=>;6V%.7ELJ2PTTI7'<M4>0A:$H[BI'!23SKIG%58F;@&%(04DSTR
ME-[W]G+RD@$LS@Z[@AFCPM^SQPE5X;[9O:7454F;*3A=1B,E,Q29B4*5B-<9
MZ$A1[I49,Q*F&SL>>^#"]K[S-'6)MW'E4F)A0<6W)2N-:W: 0M+3$=7#D2O=
M^GU)#_8\ZCE++7:KU-<S"6+^5O!KM8^7Q>WNR.GN7U]]%>P&33-LMQM^=N\%
MRG&F8S,W%)]HTQ8UC3C"78R'8384XWZC*DN(!3RL*[O/).JR9,U8!3+6H'0A
M)(]6:,Y1\-8[B$A%31X955$A;Y)LN4I2%,6+'=C'G&^.YUG],?5#M7L[2;$;
ML8]N)=8SG-A87,.E^:*X=<]2S(Z9"W'F&D+:5(6VV/34L]RN>./?(4,F;+F*
M*T*2"G4C=Q;I8_EK'4_9S@.+X37ULS$:&=2RIM,E*%34Y05B8DVW]U[LP9G!
M>/-IB"7/[3T/:A9XM(?LDGV>1^ /Q]P?''(_%SB >CJV_N\YQM="@";7&@+V
M9]X[=ABLN)4)S,15R.6\R7IS+7O8/U+;(VO"AW) / XYY2?'\RO/N?'!_I_7
M7"J503.+ZZL=_(ZG??QVCU>H.S,Q (VL0^HMI?4>!M%]U+R?HX]_ ]^ 0/'O
MQ_B![<>_.MQHE)(  U&QWN=3<EW&Y,0GRQ,D$ #O)+"[.#MOYQCKU36.6M3]
ML?['WEM53XMG9W 9K)TJ(FQ%/!<F_)2VXSC8D,O):6A33R%H(/(1K9):G2DH
M.C%V_1A8^F]X\Q>V/]Z(JN'T895U5-/%153PBGFS):*@TLE4[LIJ4+ F)4E#
M92,NS,(DGJ#W2L\GV3PZHP2\LJ:WW0BM6:[.DGR(UI4XY35OZUD,AJ5#6R^T
MMMI@P75I<;[7%\$A23QDU3%F4D(LI37"F( [S @C>UM;O&I\=8JNOP'#DX;/
MF2I^.R4U/:R)F2?)I9$D5-4L*0<P(R=FIU A;.=HR;V/W[W"Q':38&HQ+;^R
MW/RW+,%;L)UGD&6#&,<A1X#'<_(O\QLH5TM,^4ZM#<.-\G(D2UE1Y 2HZR4F
M?,0B1D0J8I2 2<S)#)%U++L^UG+681J(JZP8/@DN723:ZHJ:%$U<Z;.[*2@(
M2,ZIU2M*R9BRH=FG(I:] ;/&6.(=?5)7[9Y;EV2X+;5V;X;G43;.5MY3W59D
M)N<UM.S]'K:'(FA#KID*P*A_[P>8B?+H"U.LA0*#<_;$KE**D*$Q"A+,M)!S
M*+%.5=@W+0 /O&I5&()5)GS5R%)G2:C[--D)6B8E4]0!0B7-#)4E;CO,EFN
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M02DL&V"B;<K"U_ D#K&>I\*F*91 8-<LP&_O%CY>1U$6I.LR._N5SR0>?J(
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M%-M:W='D3[+:WOT^:U=3)TZ-*EJ'9'EL32VETH#L=:5%:<;/PR2I),H%"@Y
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M!K78S$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$0;OATW[,]1>/\
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M:!^AUUCUE^SW[,L3I:__ +98Y23*.4B49>%4]0A4NHF]J!FJ3)6 I",K=GG
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MFH6$G27+DLH CM$N\>B_9[9W MB\$IMN]NJ9FFQ^F82VA*4I5+G2.!Z]A8R
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FA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g569434g75u56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g75u56.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1=^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  %1&5L=&$< @4 -TUI
M8W)O<V]F="!7;W)D("T@365R=7,@+2!&+3$@4V5L;&EN9R!3:&%R96AO;&1E
M<G,@+F1O8W@ .$))300E       0 N028I-(E$*<Q"1!X98HL#A"24T$.@
M   !,P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #0 ,       #W!R:6YT4')O;V93971U<$]B:F,
M   , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))
M300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R
M;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8KRG         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          #D   !L0         !                          $
M         ;$   #D                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   #D     %)G:'1L;VYG   !L0    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    Y
M  !29VAT;&]N9P   ;$    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M6P.'!!+W6UO:[\U^RQCUT53+&%P):6$N<(F?<XO_ ._*KG=-%UAR*G^G9$6
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M0SJ.K[[;,*YH!V.K83!D!['U^]EE;&OW,M]3W_0_FE!N!UEM3F?;][G!@#G
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M &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !# %, -@    $ .$))300B      %"34T *@    @ " $2  ,    !  $
M  $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M    ?@$R  (    4    G $[  (    &    L(=I  0    !    N    .0
M#Q#I   G$  /$.D  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q.#HP.#HR-2 Q-SHU-3HT-@!$96QT80     #H $  P    '__P  H (
M!     $   &QH , !     $   #D          8! P #     0 &   !&@ %
M     0   3(!&P %     0   3H!*  #     0 "   " 0 $     0   4("
M @ $     0              2     $   !(     3A"24T#_0      "
M        _^$!1$U- "H    (  @!$@ #     0     !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    !@   +"':0 $     0   +@   #D   #P     $   /
M 4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#@Z,C4@,3<Z
M-34Z-#8 1&5L=&$      Z !  ,    !__\  * "  0    !   !L: #  0
M   !    Y          & 0,  P    $ !@   1H !0    $   $R 1L !0
M  $   $Z 2@  P    $  @   @$ !     $   %" @( !     $
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MT1,RX?$'%$)2(V*2,U-R%21#8X+_V@ , P$  A$#$0 _ /W\: : : : : :
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MEDE))DCGP!YSGK4B=.68X=M)N[7Y)G=O.GX]06VZT%C;7!*NRM\ED+CP':?
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M'X?45ES%K7W9$$W+,5";%V.ZZHE3;L@*4" E)YY"1SH3CW')%C- - - - -
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M[@"/40L+'/@@Z^+O/_%GPQM]-7Z6SU;'B53&)@U1\SU<JZ7"4OM]38?C_?\
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M::;).;*M*';BXN>;9-KKV#:L/:*:HH=2HQJ4E\^&\WS=+NLGQ\5C=973XEK
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M4Q9_KYV)WTV^ZB=NJ?<K;BU384UF@-RXCBD)L:2T;0A4NHM6$J46)D52Q_\
MAOLJ;D,J4TZDZ_*>]=U;;N;;<78-NPJL+'PJFH:M73+2KI>M+BQ^@]W;PV;>
MFR86V;)7X\+%I37_ "I<7IJ6E2U)CU\X]X: : : : : : : U;;^=)VXV<=6
M&/3L7KH#W3MOC,VOROJ=0]*8;+.1]--O8Y#@[2:QQU+UJG=:/:4^%9,IAM3;
M5%A=>W,"FBVDN\OOH._5==(46>?"Q5G-NF;J:N^IZ?N- VEM8*4;UY_93KV@
M=VXKZ"\V_P DPI>*T-JO()E@_N-;V+K2(B+NGF2ZVD@(:6(-8Z @K$OY><^2
M2[X3<YUQT5;PX%MQ1TVV^SU%+^(Z9L"PK/Z1J52O/7.;Q]W9N59?(5#E6D*O
MR3)&Z<PYC#]Y*74V"FT1)CLAMKX50MO#&4U2\N&7Y\^+(TP7I)WIQK-\.R'<
M+I9R#=G;3%=WMZ<R;P6XD[/1IB:;<7 MNZRCF,8K43JC"T2X]Y3W:)]6RAIB
M.I3LX29CR6W'AG*[TO=].5IS4:\)@]K?H.ZIT8=6L?<LMVJ@;>=)L:_PFJM<
M8NY=S1;;[R]6F97.T<.'E#SF.W"=NJ;=/;%Z&Q?H&/VXHFX<9TEKAET_'/Z^
MYI_M\,9.=-4DXX6MFOH7RZ;]H\JV<V7PZ@RNJOL<=N>H]O*:7%LBF8NY+QNF
MN;>"6(+-;A<&%C./L293,NV-'4*FQH<BP>5\8MQU:&W?;,M6<+^;\N/WO!LX
MT-#0&F7.)QONI#J(O'U*4N'EN/8A%'G]C!QG#L?9#*.1X0N=*G22D$)]1]U?
MNL\]L[EPUA;CW;32H\=&)COG5BXV(U5SLDJ=(T.N=ZXCQ-[;;5,_IUT8*X4J
MG!HG/552X6=Y93WJZZ>4;SXHFWHT,HS3&HSJZ_A/*K2" IU=85@@AP+!<C=Q
M[$.J6D >J5)YA\.[YKW/ME%<S@8E2IQJ9A0[>+.93O\ 7B<;WSNNG>6S.E1^
MK0G5AU-:K26TU-XX971HDMJFPH["55VL1Z%/AO+8DQGVE-.MN-DI4E25<*"@
M1YY'U]OGW?LNUX&V8-.-@UJNFI-^)/)RI56<-'5.T;/B[/B5X6+2Z:J:O##I
MN\HBRLUEZ9'7'_GZ_P /KX\Z]@\'?IWIKID>/ _U_P!//_/^FA(/9M1;6A:5
M%)2>Y)!X([>2"%#@CCGP>??CSSK-5%.(G14I52:::E73S1JFJJBJFI6=+33R
M?5?;\'['OLI]WK?=CI.QM%]*=G6>"6<[#%2WUJ6\]"@!M^M2I2N>4QH4AF(C
MR?P,)Y\^3^._\B[IP]T_$^VX6"E3A[1&TTTJ(I_4S5K7:=72I=7^FO@O>&)O
M'<.RXF*W57A>+ =3SJ\#L^22A+I!LIUP4Y8- - - - ?CV^U9WUO-TNIG(\6
M7.?.+;>*_L_25P=7\,AUH%4R:&3^ /R75'U".?"!YU^JO\3;AP-BW)1O%T4_
MZG;&ZGB9M4J(2<IV7IR/S]_D3>^-M6]:]B536!LJ5"IF)=6;B;W\YT-8!X^7
MZ'D$?R_7Q['7:[<PWGESLN/K:V>IUWG:FR=[VSS\M(R\DHRK!Z![*,LQ['V!
MRY:VL*$D#R4^O(;0I7'GP$JYX^@/GCSKY>]MI_T>[]KQ\G3@M)MV\40IROTN
MXFT'O[MP%M6V8&%'RU8B343KGTOEP;5S],>,44/&,=I<?@MI9B5-;%AMMH2
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ME556ZFK_ /;R6>9>Z\Z>MD,D?,J[VLPB?)4I2U2'<?KP\M2_WE+<2PE2B?\
MO$ZX/A[VWG@KPX6W[50LH6-7$+E)RO$W=L.*YKV3 J><O#IGS<7DHO=83M["
MWARR3AN'8[CM7@Z6,+JT5%7%A]\]MI$V_ENJ9;!6_P#&2C 0M1Y2U$"!QR1K
MP[3M^V;4HVG:L;&Y8F)56K:^%N+3>W-\36#LFS;._P#H8&'AN;NBBE6SB4I>
M=E[V,J!)_3Y$?PX_X\_TUZ<)3'II+Y:?@]B^JR>:X:\_+-HZ.Q5/HYU=F>/E
M35]C3Z9C9;\&=7I/,ZN>XX+C3S/<4)4?#B4D?0U.^:Z+OC^7F/?-](R22GN^
M=C8[BF1P<MQVHR.N<#D2V@L2VR#SVEQ *T'_ +R%\I(^1&J:[[S,@)"05$\
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MU:DG\:3P1P!KZ>P;VV_=TO9-HJPZ:_W4-*K#JMK16FLLM=>9Z6T[OV3;4O\
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M"$!(2.$@  ?[H '@ #CQXX^6LM97B%;R:B?:<UP@+7KIP>3]NV>WD>Y_U_Y
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MR)VEOGT7"T:?DV@UK08KX+"5)4&(<9GN2H*2?290CD*!((_#[@\'5-'-T T
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M%4.Z-FV.WU?D])67]6Z'H%I$9F1U@@D(>0%=BN.>%H)*5#Y$:I3NM - - -
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MDMK4/U"21_70&L"@<6^K(9C_ "94_,,K?EJ7_B*?^_I[9[B"?"4-H;2/8)2
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MWZDIG7T??U_OV\\_EQ^G\#]1QSX]OD=9;B.+BV<Q,/SM?/(T1UFS1JIE)FC
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MJJRR2Z=_DL97=I[?30V+I2E"4H2 E*4A*4CP E(X 'Y #@:I3VT T T T T
MT T T T T T T T T T T T T T T T T T T T!"G4/<OTNT&8.17"W*LHL
M2B86D\*"KV?%JG"D_)09E.$<>?'\=.I'IUGT[\LRGD&,B%!A0FD!#<6+'CMI
M _" VTEL)_D.=8\*US=W>(U])77T*<H#C]/'/!]N/?\ KS[>?'\-1N5SS4J;
M3EPRC.UT^8"UI:;4XLA#;:2M:E'@)0D=RE%1\<)2"3\N/8^-6RJOK>6E;/7^
M#+\32:CI,S]N\R<>F+&%R6\CW.F-*2<E<348X'$\*1CM4ZI*I".?\EA/2Z^A
M2>.YI*2>01K95W:"V>A1H!H!H!H!H!H!H!H!H!H!H!H"&=G??<CCV_VG95Q_
M_*&C_'T)3DN^_MD3-H4: ^,B.Q+8>BR6D/1Y#2V7F7$A;;C3B2E:%I4""E22
M001H,R@FY.W%GM382+*LB2[/;R<\X]W1VUR)&+.O+*UM/H0"HU7<3V.@<,#A
M*O'M(EKEW[:$:TF)M_7"QBL:;%FQT2(4AJ2RX I#K*TN((/!'!22/G[>_P!
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M#14J(9:[4<GC0)0H,DT*- - - - - - - - - - - - - - - - - - - -
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MP2QOL9:2S27,W&_BU1_C(2$)[D1%Q8DM24KFQI"D@Z%+:    #@   #V '@
M?IH#SH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H
)!H!H!H!H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g569434g75x33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g75x33.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1S.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %T< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  %1&5L=&$< @4 -TUI
M8W)O<V]F="!7;W)D("T@365R=7,@+2!&+3$@4V5L;&EN9R!3:&%R96AO;&1E
M<G,@+F1O8W@ .$))300E       0 N028I-(E$*<Q"1!X98HL#A"24T$.@
M   !,P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M     $-L<E,     4D="0P    !.;2 @5$585     @ 0P!) $4 ( !2 $<
M0@       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O; $
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #0 ,       #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8KOS         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          $$   !F@         !                          $
M         9H   $$                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   $$     %)G:'1L;VYG   !F@    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !!
M  !29VAT;&]N9P   9H    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M?!2  "R8@6(^K]Z6R)\,8>Y.7#&^'2R;^;]%]$Z9?5E8P-E;?7K/IW@,VC>
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M^3UP.<\L;6 QKMVUL,>UWI[O;[UKN+VV.(K<\. U&V--W[[FJ#>GX;7WO;6
M[*$7&3J-9C7V;MWN]/\ KH>3CLII-C!=:X$#:+KNY#2[VO>_V_2]K$E)+&"S
MFAVO(]O_ )-8O5.@VY3G&FDZ@$26@3^[]-7*WVO98?LF2U[*W/8UU]P#G-_P
M6[]YW]7_ ,#].RQ76NJ>YHQ,RS:X@%EMI! VRXN-C6^_=^A]-UG_  OH/2[=
M*5XAP:/JEG->TVU;F3+@'-D#_."ZC'9;26 4O+:Z]G+).L_Z1-Z#',I>UMP]
M6"YK[K6N:"-T%OJ?SC41_3J'NK<7W U/%C?TUFI;QNE_T-?>S_"?0L_1I&S1
M))29&1U)-+V&VTU@5.;M>'$N+8 ']5[E+-_H=_\ Q;_^I*.@9O\ 0[_^+?\
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MS?1KVDV.!(VMB6^B_;_G*QOSO]%5_P!NN_\ 2"^7$DE/U'OSO]%5_P!NN_\
M2"6_._T-7_;KO_2"^7$DE/U'OSO]%5_VZ[_T@EOSO]%5_P!NN_\ 2"^7$DE/
MU'OSO]%5_P!NN_\ 2"6_._T57_;KO_2"^7$DE/U$Y^9!W54QWFUT?^>$SGY>
MT[JJ=L'=-KHCO/Z!?+R22GZA#\N1%5,Q[?TKN-./T"1?E:353S[?TI^EKQ^@
M^DOEY))3]1;\S3]%5Y?I7?\ I!"L>_[15ZE6-]IA_H;K??'M];TIHW_N>KL7
MS$DDI^H]^=_HJO\ MUW_ *02WYW^BJ_[==_Z07RXDDI^H]^=_HJO^W7?^D$M
M^=_HJO\ MUW_ *07RXDDI^H]^=_HJO\ MUW_ *00<MV8<6X.JK#?3=N(L<2!
M!F&^BW=_G+YB224__]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !0DU- "H    (  @!
M$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    '@   'X!,@ "    %    )P!.P "    !@   +"':0 $
M 0   +@   #D  \0S@  )Q  #Q#.   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,3@Z,#@Z,C4@,3<Z-3,Z,C, 1&5L=&$      Z !  ,
M   !__\  * "  0    !   !FJ #  0    !   !!          & 0,  P
M  $ !@   1H !0    $   $R 1L !0    $   $Z 2@  P    $  @   @$
M!     $   %" @( !     $              $@    !    2     $X0DE-
M _T       @          /_A 41-30 J    "  ( 1(  P    $      1H
M!0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^
M 3(  @   !0   "< 3L  @    8   "PAVD !     $   "X    Y    \
M   !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$X
M.C X.C(U(#$W.C4S.C(S $1E;'1A      .@ 0 #     ?__  "@ @ $
M 0   9J@ P $     0   00         !@$#  ,    !  8   $:  4    !
M   !,@$;  4    !   !.@$H  ,    !  (   (!  0    !   !0@("  0
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MJ;F-$^"]V2.R7Z>;1S-8>![0GFN1LAW3EB)Q9/1D"Y,5"U'DC&R+]P]<2"B
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MHSRQ,F@+(SI:4E)DMJ:NU1%PHYC4TX:VR*JW"J==^@@B#B#11.O*M./K#)$
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MOQV=FJ]^2M9NFS$&2H7$>1,GPMM7U.A'BTBGI'?1-^VRXM8H))^1 S*.-).
M,BQ*Z63%P<H@F [43.>ZI6)V]V0;1_=%[26/8C-EK*W/$EN,7[5<[EJU14M$
M%37&V"1<()L5'42FBJL[;I+G531(*@EX>=$EKHL)PGV13"FHS4,^P9AASW;,
M&&,UL@JWTS54;19ED)M:'&&2:/&Z"ZP*@F1VA)(F.T515*)##L(T4RI/GCP4
M=0NNS4#):OUM)CW2$ZC9*/@XS($Q=Q\NV8M'Q^)Y.Z5K82O0&B?S5PY(JW6<
MFMY,XR()D NVX@--M,O'@HIMSG*AT&ON4LZFM8UQXER9C;!.%,.OL^YJR3!7
M1=[2V&-U0]J0T#9UGE:C+S4Y<$ITC= RZSM)G%LR$,L\=CT8<)0$U,T77Q79
M%\%P-J6&]S\K):>,@7DO(LW&,;^;JGGX->(D@B7TB]7CDEVH6R=X9,65Q*&1
MCW**R9@.4P'*4BP6-[)A8\AFM#$HV:[;QRV993% WN>;CQA2-8S'BF0S7:(
M'%VK5CR="4O'Q;""_%P<J(K5X.U9X!U'R%Q1>',@QUXO;831<2:31N\;@:/<
MKK-FLJP4=-T4Y"*=.&RZ3=^T,J@H=(X ;E1%8ZB)1$HB415JSY].NF+W:;D^
M#OG/]?MTT[OBJ.$Y=LA.6S:L4T(\M-D'XOW4=27PE<N45U<"B)1$HB41?%)
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MF,!%2G'@$! **=-M,NV?.FJ[$_8Q<P2C2'B)NT#$B&KS4XM)&A[PA&<DNWU
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MI0 *(=)=N[WS5A7V&<R2NL&\]2TKAY1S WGIQ8X">6:CD**;/2)M[I?7 YF
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M[)./K*B\5DES3T1E"S[D>&AY1**6+%PCX'S@KA=9VT!1FJ9$B3E$IE3*)G$
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MIU;B$YR-"=JROT&\5^0-K^]3?^S7BO1/0<Q7Y VO[U-O[-$7B.'L4[;C85K
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MQYT6<^@1AOVM;0]YVW]FIW*5476?+V)I@Q ]R5;&FZWL@':/H]H^,DVAV,;
MM7KU!H>2E1<J$=+($Z?O$F**ZQC[ )0#<P;FXKK@WM;19(MI%FQ-<YHPO<^*
MYH+L#,(D'&52XCBM3?%X1;MLCK3"L_I&$@.]9K6PVDM&)Q)F1,Y-!/#-0UDS
M,MFXTSVTQ]*:9+5''/<S"2KF[NT[@7;I>:BI%\,@P.G'GB1B8IZR:Q+Y)=\1
M^9Q(HG2;F*4=\^R]'H%KN\VIEK_2NMB,ZF;9-:Q[6X7>MC#WM<7LDW#)CID4
M6+'OF+ MS;.;+.SB&UYC>M,XF1#-M,&%I8UAFX.G$$A*JO!C+'F%+\LZ'GPL
M+&SF0<M4S3#2#0C9-M$22A>E6B%G#8RA.M,"G*V<\]A724,3<@@-:"V6?T>T
M/AX8@:UWYLQ&N87L&40-,O5=])NXC5;FSQ1'A-?-CB0,88X.#7$3+"128G(K
M/_0(PW[6MH>\[;^S6,O=/0(PW[6MH>\[;^S1$] C#?M:VA[S-?[%1(=_/X;$
M3T",-^UK:'O,U_LU*)Z!&&_:UM#WG:_V:<YHGH$8;]K6T/>9J/\ _&HD/GKW
MYHGH$8;]K6T/>=M_9J40,$8;#_FUL_WF:C^,E1(3GJBCW(6,<>V@:P9JU[/@
M8&62RMC=LG(1;!)HZ*W>77&MG: *I 4W1.&ZJB*Q-^%1(QB& 2CM27,SP39S
MH59NI1*(JU9\^G73%[M-R>/;_%WSGZU-.[XJCLVRSKLW;05BFA'U-L)[J6I/
MX2N7*"E%8?$^\JX%%*AW/V0GV+</7]>\.O!)W#"V[(N+:1N*3914:^GRME3Q
MS$SF07;-U%EE"&,BU%4IW1D^A+\\(@0JJG8]M1>;-1MGY"N3,L3:T2M&75'M
M[70MEW&.>K1#^W8N35CI,T8]?)&?1[UTN@HLHH4ZFW(G"4IC$KSSSO6.M=-S
M$-7<E/EN)T7);>SK*RRYOL$"=<=.W&3L@1,C;QF^_!V@<6  62DQ'=)!BW8N
MB$ZVT25*49_CER10\58[4AFW&6$9#$<WDF<4B&\A><DVB4FT>\E'CUTE:TR=
M<J#-@BNY4!% QE%1(F/"3<QN] :V-WW7:[S,<65@<;/#$1^)P:T!SVL'K.(
M))U^-<2V6^R6%K'6J+U?6.PPP&N<Y[@,1 #029-!)\5'H]D4TL@8Q1NZXN]V
M 1[A;LVXA_P=^U?SP;<R[;@'/P5G?O9O;V,+_B(/_.L+]WKM]K$^XC?\GXJ#
M-1FK/3'G?$]Q8X9Y%D(5U*+Q3MJ^D\6W%<$>"D8]0? D]C'<.=)5!P*1D!4)
MP+)<72(J%.4!K8W7<UZW=;(5J=961&M#FN:RV0H;I/:02'M?,$3F1J*$56%;
M[UNVVV:)9Q'<QSBTM+[+$>V;7 U:YDB*$:&:U[-H73Y:V'%<8V#J-DH8+O>Y
M*6RTF_PU-2-G7.ME!QUIU)Q]O+1!D(J0MKO6EO*I;="F8 '<0$:Z1T:\8UN;
M:K1=;(@@>B>AN;;H;(T$6-L@QT01)O;%-8HU)!K(K0B%88=B=9X%X/;UWI/I
M+76.(8,8VHS<YL(LDUT*4H1K++2EKI#,^CN5Q-C;"1\HW8VMG&UE)V8$N>P[
MD-<$^_BK8)#6[)GDNU8N "&=G<3'51/MVS:M%1#=OO6F;9+Z;;;7;Q8X)BVJ
MT==@])@]6QKXO616!N.4X@&"<IAN(5FMJZUW6ZRV:R>E11"L\ 0\741NL?AA
MAD-Q<63]4^M*9&(-(H%FVA#+^G+$P*X7B,R2=Z77?-T+/H5.0M:;MJ,ZRWAT
M&X1L:A(H$23=+M8]1^]$5-W+X[E?AW.(UC](+'>=N/ISK"R!!LT$"(61H<9X
M!>3B>6$F0<[ T$2:T-$Y+UN6TV"S2LC+8^-$M$0N8'0HD)I(8!)N, 3(;B=6
M9>3DMMB;]LJ[!L14!6%$5>C*8#[$ P<S\.X$-S#8!'<0'<-PKC%U/?SX\[5]
MB9P4(!R@8 'P<0<(\N7@&BE=;)IIK)HMA'FLN1(B?'T8"=/A= ;D'$/ 1 W>
MEY"4Y@-WNX5(YYYR52:@#M&[;Y>:[/<=P 0'F&XB'@ >7+?\7UJA3.H&V?A)
M>5%*41-]^8<PHB410IBD-KHS'_#TO^AF'Z[5$ZFF4J[<T4UU*)1$HB41:]=4
MP_MX^V\31#_]H_C#PC6EO?\ 5'LY[UZ0OI#ME/;W'G9FLKT5Y')<%JS%D.UP
M&1M9X<[9,Q@XSQSHYCDX W$QBIG$0,8=@W'[GG<=IZR$^SFAA&;=[75H2:RJ
M):!6C"3@9"1G4:D'57?K?+Q2B)1$HBH)K]U*Y'TZX\@9'$+6T)>]IR848C&W
M),0S-1HP%ONG))L).08F=-B.! CA1,3=&'"&PB>B*5\.3F1\ZZ7;>D[Q?L+4
MO^^K5<MY25MP6SEFS.Y<KM#/XX&ZR[<AW4>7I$RI+J U57[T_$D%$40Z3L$6
M_CZ_<NW#9#E6#8Q.6+PLN=A4R =O<C!O:-A.8I\^,(\Y9E(F5=F?" K+=;>D
M.80<J;D7W7OJJPMAC41=UOWW<;UE+JV7#+BSCH*8FE$DU'HBF9?M:T< B"@$
M,) .(;[;!SVK;V2X[RML 6B!!!@N<6->^(R&'.&8&-PG+5:VT7O8+)%,"-&P
MQ0,18UCWD G,X6D"<]?@5VO_ ,H?I=\K+C_["7;^BJR/WLWM[&%_Q$'_ )UX
MF_;L&<=_W$;_ )%"VH35/I)U!8ENG%$Q?UV1,?<Z3(BS]I85V'<-^IOF[THD
M*:)$!XC( 0VX> PUG7;=%\W;;(5L99H3W0L4FFTP "'-(^OO^6BP;PO.Z;?9
M(ME?:(C6Q0 7"!%)$B"*89Z<E>&4=4>D'*L-;ULSE]W4E!0Q5S/&S:PKJ3<R
M2J<4LPAU%'01(+)DC'JH2*:0&Z)9PDF"A3%"K62Z;ZL;XL6'9H)B1"TL<;3!
MDSU\3Y#'(XFR::3 -*T5K3>=U6EC(;X\0,;/$T0(WK>J6LK@Q>J3C&E 2%'F
MD_-.D;2U;-QV_&92O6YC7$_C'*KA[C^Z&J+=M"L#1L>1)JA% EUQ5 XGDWHA
MTT@ZV77,8X;UDWS8;ZO>-#BOLD"%U;7@!MI@F9B.#G5QY _1'\D&0HL>Z[9=
M5VPGPV6J+$QEIK C"C6X6T#)8B*N.M"5L>PUJ+Q+GLL\.,[C/,K6RLV0FV;J
M.?Q3Y@9XF*K4RS.0007!-<@"*:G!PFV'81VKEK==ELN[J_2H08(LS#<U[7M=
MAH9%I(IJN@LEOLMNZST:)C,(@/!:YI:3E,. -=-LC)3>8>$HF'<0* B( &X\
M@WY!XQ]8*P%F+D.?.B)1$HB41*(E$4/9E^AUA^Z[B[^>451%,-$2B*M6?/IU
MTQ>[3<GP=\YTTGP\9^2J3(CMS[%BFA'U-L)[J6I/X2N7**RN!1%3W7A83._]
M,>16[T\UT=K,#7PDUM]FU?2DBXMILZ<HQZ"#M!TGP.#*CTRA4%5DTB',D0QP
M HD5+>PSS[*>PYD=9DQED [KX=T[<O6G5F)I!]:,(Y>1K$YHR,.LK$*G%B_,
M)%0!TF<"G#YPI1.IYK.7PV2IFM@+7U7UP>MZ7*RO]960_P!?]]$U[,N><U3O
MLBEXL+ RUHLNV59IOHZ&R!E%T\;JD%4HH%Q-<15% 3 #"<R13=(0"E$PF*&U
M=%=1+;GZ1.:7-<+/89%I(SMT$2F*B>W9HM-> #KSN5K@".NM9J)BECBZ>XZ*
MOUP]D"QZZ2/'M8.#9HE4))E,=@VV=M@%0Q6Y%#)F%14RJ:93K"!.%,3E$#!L
M%:'K8I_G8E/Z;O-;; R?ZMNAGA'#922A]]V3Z.9D=1[.S[?Z%N!%DG)(MB!C
M"H @I'&W0$RR9 $X@Y$Y3)F$AB%Y5;%:'4Q1B3D)O,YY=ZOZ.7?S!),L/YLN
M)F21*33.<C+#.=0,E$$[V2%V_8*1*T"S3(\50,Y?,&K-LX(GU=NFHV:B9L(%
M*F= 3"<^XG35X0V,0!'(AV:\8DRR':G  N/ZR@F6SJ:5#FRSD-@6; N>\+0'
MF!=L>((</K'X8!FUN(MF6D T>UXT,VND*372/.R+OSK-UXNT8U@])T).L@V8
MFV,FU.V.*:9VPD1,LL";U8Y0^;'XT3B*1AJ766WM^DV./4$7^7(M(+B9SEZM
M9UF#GJK1+EMT,'K;"]A$(1ABA&1A$8B0^4B6LJX DM,YKW7%JFB;IR'I>DCL
M4TIN+RVH[D7;%HW;JN2.+<ER**N'*:*:2I""X$%Q !*ALH4! I0WVMR.>ZSW
M\U[G$_N;.1+C+](A&N(YFLJ4EL7*7JUL.U71ZF$^GRRPTZB)/3+6LJS7Z',6
MY"BKT9E4;G!Z9=),Z@,T.C!Z1$Y$Q.W<EX2*E:*D AC$,4%1 VPB4!$>;$J[
M=-^7G\]%NB)':":SG09REORRW:J>@DVAE 3;K N81,"I$C=(9L"(@0_'P\92
M 0Q3$5 1X@/R !'<:D"?/@I) VU.S9GLIS4+UEEX]P_79$XU'+ C5SWI2F34
M3?&6;IJ(G PE/PF27!0O(Y"IF'A$!"DC7QW;.$Y<S28\>_3MS\-R[@IN+B]8
M#" <A >0  [\7A[[?F'(0V$*A2/C[J>^:\J*4HB41*(H3Q3]-&9/X>D_T*Q_
M'_737GGD(ILHB41*(E$6O75. ]O'VVW-HAXO^H/A\.X^O_LK2WS+J-M*[JF6
MH\]RM#^D)[3KI7A+<J.Z?,GAC//]OKNEQ2B+C=FM^3XCB1( >B8C953?ELFN
M!?7'<P;\JY2PVST2](&)TF10(;]GK4:3NQ2U66]N* =H)(E(T$R<LL])#X[Z
MB&*<I3D$#%.4#%,'@$I@ 0$/J" @-?15A+RHB41*(M)W9CK8CXFR;%RPY"==
M+1LFK;0M8]@@XBFC9WT3E9_+. C)-XD(E3Z%FFDF1-57<ISARHH//)[%L)T4
M/F\CI?Q&Z:,96/:FMP$V[>:; T?F11=N44W)T ;M>!%V4@.6N[=$PME4A,0!
M$:*5WFGSZ(ZA/LB+M_F?8-$4$XTC8]_KQU'=>8,GH)XPQ[P=;:(.> 1?N0'A
M%9,_#N'+O=M]QWKI;6YS>CMUX7.;^EVC(D?R=W:M#9FM=?EXDM!E9K,*B?\
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M2-)9R]64S\RLJ.[U%'*"+B#L%=%R0IB+)RL@D*1B% "M^))+<#<S;"(B&XF
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M>1/,UWK/*VB]%"6*/IIS+_#TG^AF5$4VT1*(E$2B+7KJF']O'WB_8B&V_+_
M-X-MN7VZTM]?J.P$TS&(\S5H7TQ_O'*O)W+2YF   KX0 ?"IX-_'N&P_R;_T
M5\WO44!I5HU-*C0>'S6T@9"=?6(V;3M\-130*VO8D,V]K[XOK!TJ\$&\RU/=
M5M)*&#AZ\S$B<HV1 1#OE&X]8, ;C\Q\'C':=!KRPVBU78]QPN!CP 3J,(>
M*RSGHO&VLGAB "E'2!!SS.Z>_P#E+?Q7TY:]*(E$6L[LG-VW#9V-<:REG7=<
MUD7>&0B=S\_"RL-!Q#=PC&+K+IW3*3S-_&HQ:R!3$117:*@Y="1+O?#3MT*@
MF6SM,O@K3:3+\D\F:>L97M,R,W+2LW @K(25PMHYK*/7B#E=JX<K)Q*#:.,D
MJJB8[5=H@DBX;"DN4A>DVHIYYFN-/GT1U"?9$7;_ #/L"B*$L5* 77KJ.(/S
MQ\88]$H?4!^XW'P^#P;_ (O7Z2VC_HY=1VVNT_W5H[+_ !Y>']5L_;ZSLN=%
M>F3=%:-C*F5!';<>,2 ?D'A*'$(% 3<B[F[WGSKF_@MV>9"9X<[%6G*,H_20
M$TDX?/&STBJL;&I] DT3<\T"-'X=(F4[=P40.4%!.82@80\.U#I60R R$\\\
MSNF=VJ@5&^HK7;H=^8D!3@J8MUYFX[Q;RLE((M&A3M-V" &#I(U'C!PR21(9
M)!87"_6%$5W!!6;$6^9G.8_$6,A\<]1+;VREM5A+(B=#*1R.D^_+NR6Q^T3E
M2B6#0!!1!=NT4,XX4.@,T><?0LDQ1#B3X X0.8PB;P"._#5P !*8H*<3*0WR
M'=KDO.9Q3&TC/.4B<\N:;:M0=K9&M_5%G:ZL?)6_)DN2"QZSD6D\Z79IL^U;
M1\DB=J+<A^F*)#["!A*(; (%\8\_;^D-_P!MM+KCNRR7?U-SM;$='M42(U\1
MUMF^0:T$>KAS^2UL.!$AV^V6B%)W7-@M=B__ )M($I"F=9TUKDIU,]U%;E6"
M/QR1N''TI1E) Q!,<P 4>D%$3$X1'8I2B  ([B!N05A=9TR_U:YC_P"=&TST
MYV@56:#:990OM$_#XG9)=4X=ZA1;E:&88Z.F#@R8'7DGSC8A2*\73B9(1$@=
M&LF4ZA=S'+L(#MO3K.F7^JW,:#^>C^-*9B>:C%:3I#IM) UD099>_M7N1?ZB
M")$*UA\=F0(N1,AT7[PX"9542*'W!$1 NXF%8X@ @ F-L/.G6],O]5N7[Z/Y
M=G'=51.TT($,Z SYSW[JS*[9)_J+,03&@<=D, \'?RDCN<"_X>X)#N4=Q$-]
MO'4=9TRG_![F^^C4_P#CY\5(])E.4/+:9G9IXGW576FNW)C:Z[5M#(MMV:O!
M7NK(1BG:QTZ>F 4&*CDQ5D7*0)F24*7A$!W'GXO#7@;PON';[!=]\6.[7V2\
MW1H!ZA[XA&&$7D/9$ :YK@)'-,4;$UD5L,M>2*5R$Z@\CQ4O!CRQ@@C6R%J0
M80!G'6C10,$>J"ZWX@<"3AWZ<-Q %>+C O> 8"<JZ']Q[K]%-B] LOHA?UA@
M""T0R_ZY %7?TISE2<J+WZN'A+,#<)S$J+O48.';MHQFA&,T6L,8IHILF@F1
M!@8K=9H46Z10 B8@W762#8/ H(_/;&#+;9;.QD"&R!";#LTC 8UC0V%)CH8P
M "39,<YM-"5:0,A(2&0E0*&\G6]!P,=: PL4PB^V&9L8.WO4FR;?K3DUYQIA
M55Z,H<1MSG$ 'O2B<_" <0[Q9[)9;)UOHUGA0.O>8D7JF!F-Y)<7.PRK,D[*
MFE2JAC000T"I-)9D$5W5RX:*>:R%=*(JTY]V[M=,6_MTW+]3_%WSGX]ZG0\1
M\54B9';\,Z%8KH1]39">ZEJ2^$KERH5E<"B*O&K64G(73+G24MH[A.>98SNI
M6+.U2(LN5SVL6(44TCD4*<>$Q@$HD./#OPE$VP414;[$.9,,*7NFF9MQ=V;=
M=RBVEG<F";UU;L.L[%0KJ-CA:*J+F,<Z"9%2 81$%/\ !*4#7GGW>*NPU]5]
M<'V.5E<_XRLA_K]RBE:[>RY-G[NXM'B,:_2C71<G7TL1XL(E(D5+',T=01,
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M %FT[?\ 4H^S\%K(?S#27BYB6;')!N$U09@T?K+"*ZZRBIW!V:0["LP,!AV
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MQO VB_AVS9&,;F%XF\*[>N#N%RG+L+<I.D(8FXB<1KC+\M=ULZ2='C=UDM4
MOA7E#?Z1:&1L0?9Z89,9]$S+N(EHH;9;>^T0/3+59XC6/,1@@V<PS-@(,R8C
MYS E*0E,3U4SW%B7M0UB;Q7317<OGJL,JF5-9J!SI(F.LY(D@!E2=6222,OW
M@=9W NP&W -AS4Y<*":WFRNW(4/OYX*FV6\@.+5<(]I;HEWKM(SDSI%ZW<H-
M5%S"JDNN4BQ2<+9'<O:\@EV$"FXCB!BT3;IOYH/CL5;%\HW1,72G=3=XN@\E
M!69*IMT#FC"],99+A22*8"-!6!%J82KB*@&,*Y1$"@-%'89[MW8)SELV937Z
M(^QCO))WB216DW+I98SM(PBX(Y BFYW2BIVJ:AC%31!=11+B+S4.D?<-B@%$
MU&F><YYU$B?/NDK>9\ IX.SS&( "&0[6 AC;<P%R<1$-N8;^#81#;GX*Y/I=
M_!+N_MBP?XB\;0?5;3^6V1!&5*Y\RI-3T7YTOU@_%76+(7-$2B*$\4?31F3^
M'I/]#,:<^]%-E$2B)1$HBUYZIP_;M]SWV:H#RY_X!N0^MX=ZTM\R$'CG7B*]
M@TF5>']-O%:U[&QHME?-5I6CT)E6:\VD]E>C+Q 2-CS]:<&'?EPB"94QXOGN
M(0#?P5QD.R&W6^SP)3;B:Y\LPUI#B=@RH25G8RR$3D9&IG.;CE3*9KG+*8JO
MT4L&2$:Q9Q[5,J39DV0:()D#A*1%NF5),I0#D  4H  >*OI;6AC6L;0-:&C@
M!(+7+ZZLB41*(JSY:L730-Z-,E9B1QVK=4=:DA#11;[D[>1Z2%*L1^Y3CV$\
MND114RZ"9>G1*(@(@01#BH=M>&U/@LQT^Y#LS*F)+3OC'L,2W[/ET7Q(2)23
M9I(M6T?).XX>@)'B+,$%5&IU41;B)!3.40'G1%C6GSZ(ZA/LB+M_F?8-$5<K
MRPMJ%+JCR!D7!N5+'LP+KL:W8Z;C[RL5>Z@,6)>'%!1FJC)Q_0B851X@.)M]
MM@"NCLUYW:Z[8%AO&Q6B,+/&B1(<2!:!!^F)$.!ANG+3M6CCW=> ML6VV*UP
M((CL9">R+ ,8CJYD$'K&2G/9IJLD5QWV0=02<>HC!W"4WSGH,O0*KN&P@<.Z
M<=^6^P>OS\51Z3T:!_BR\-WZ> >/ZKOWY;%7T?I!7_.%C_X+_P#U\UC$G8W9
M RNR ;-^$WIF@N'#91GAIRH)%>B*FL17BN;A34.FH ID$-Q*43;;%VJ?2.C$
MA_FV\9RR].;0UI^I06>_LA>%BW_H9.?_ )N@V]NBP]&U]>;EJXD5L^8+CU43
MF;+1KC$P\0]$()@< )<H]96Z!8RB H&'O>$@=^ T-JZ,_P"S+>!OMS>^0A 9
M<#.LAD8]'OX2'I]CF,OT)VL]D8>._MJME:Z]:,7:#.!E<Z8L;1KT7A8Z0;8;
ME$#=%TYT12.^4G%RD*OWIN($@$2J =,P@(#4FT=%S*5VW@-I-N&R7L2=NG;M
M]66>_2?XPL+2-760X::&43.E*]@R5&H3'SE.?;7)EN](JZGT1*)/'ZT1%K,(
MF6:.5.-$ADW*Z@(K(]&= 3*+<8GV @=Z4!X>QVJ">E/29MWP8L&SQH%UCJXL
M0/BM(AQ9GK&M8).) (E+(:S6XNNTWA 9;+-'BP8T2T.8(L:##ZDX1/"UDG%S
M03]-LY/&><UG63-5V/K=9&86\DZZT2#",3C!6%5BSZPN0KEPW6(7DLV12*<A
MEE#I'6Z,O1\0<^LL=QWA;2>IA8@W#BK48C($:.GL!G('2172V#HK?%Y.<VS6
M?K,#6O?)P&%CY2=.59 DG#,@-=F0J6W5J*E9>3362 '+9B[=@P=)<3)JLDLL
MJL@5RW(3YH*9US*K)B!.E!,0 2<>X=)"Z&6IT%L:+B@X6SD(9+G1,Q4^IA)D
M!6;029$!==8>@;;6_#$O*RV>U0(#XOHK7L-KBEK7.,0C$&B& !#F*,<XU)$E
MF=JZJ)V!6*Q8OD6D:BU(U6<LQ*G(.Y!1LD55\=P40*W(#CB70,5,3&X3D7 Y
M_G?"W]%;6T,BLA%CGXG.80  0X5J:N#:. H7$EOJKQMW0*VNAPXT!L)T6+C/
M50'B(T2<'#K ,6&,&!^*'(8G#$S$VJW%Z+-43"\0B+<>W.5S(KL6KXSIX9!%
MT<8M95-9 C82)F7*3I4NG$ZB@F3*=0 X4RUR-HL\:S13#C,,-WU2)>J1.;0:
MR((STHOG]OL-IL,=]GM<(P8HK@(E($-<TRG,3:X$:BH,JK9!=RXO,D84=@90
MZ"TW,F1/NF"1R]IEA+PIAN<% XN8F$2B40X?7KC[\_COHR0?^N6F>F=F?21G
MMK+<M6[]9!&QSJ$SIAE3MW>]64KJ5DI1%#^9/H;8GNN8N_GE%44'3C\"I@HI
M2B*M6?/IUTQ>[3<OP=\YU.AXCXJI)!$M^D]F\+%-"7J;83W4M2?PE<N5"LK@
M41:SNRT*1Z.CZ;5D;CMNV$T[XL\R#ZZ<?.LF1CEWTD@",:6UV::JRCMYN8&S
MX"@5H8@\1B@IO1.>=G&O!05V%*0+)88RNN,7$L%"Y*(B=Q$V1"V$C)%3MJ%*
MF\/!QBRKU(3D  )VW*D\*F!" 0$RD$24K*FZA[3EGFMB;7U7T_\ 8Y67ZWME
M9"^W_11%)5^=5"8QZ#P4P24NI5 O2E Q17<0LFBW* >'B.L<A0V]<=^7,,NS
M &#;"2 6P&EHI4]=#&1V G)>,2T=2^##ZPL])>Z%A&+\YAAOBX#ARJP.F:3
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MUW+8"F4$O5FY1XD"@<5!03(;YN!:O',+'^9Q=6UH +P XD#UG2$_I.F0,P)
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M)\^.59X+7Q&L(FZ(,)F",$SZI$C4RF095RD%LK%9&/B-A16M>Z*US#-TA")
MD\2G-V<M-P$RM>V7\C3DBRB7CA9Q'M'*"S#J*1!:E 6_&=LJ9NB?HQ7*141!
MP8O$ B(=(&P[6Z'75"M72[I/"+,<.%!NG%UKFBN&(72;FYII*1EH5W/0WH_9
M+;>=OAF&Z+9X LY?#C&&(SWC$YX8P";V/: &EKFB=75 5:V$>>470Z94Y@<
M(*;K%$YD1-Q;+B CPAN &,(CR'A$0WY5]DO^UP>B%S&T"#-T</B&,V ;0R"U
MQ8QK84%GKNC$'%#A>J7_ %A(D?'ORQ?E=OSHO:+==_1BQP836/<RQVBT1HEE
M-GM=G8YT6'9NK:6QRQKCZD4MAF42A-#*!+59$;IF531*8@@?A*7;8Q=S$,;D
M(& "EVWX>+??<=@"OSA'_+Q>[.E5MNBZX-IM%UOM<"&UT6 T18D,-99X<2#
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M/_8Y67S_ (RLA?K]JB+.<BR1F-VX>;%(4XRE[OF@B;?O2DM.><',&WCX$3
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MV[%C<O::#Y0JC97J:P)#TYB)(_LGA Q404.8@[='N(%'P@01V\6SY>%%$I4
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MM$G;@'QW*2#19@BLN)DBG(8AEKI515V,>VHNT8S/EN1[3(-I*Q62(Q!UC')
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MXVW]4XZRV9[E&F2LZ05\M;5BXFUK\24:WG RCI=[:DJW;MV;)<YW"JBAFX
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MMW":2Y?\%5,I5"^(P41=TDDD@FFBBFFBBD0J:221"IIIID "D(F0@ 4A"E
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M5T6QB^Q+>O1=!U=4-;,5'3J[9=1TBK(-6I$ES%<JG547[XNQE3**=(8!,!S
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MZMT2%:@]D&#".")#PGJH;8<P"V=<,\Z;-5SUFL5\V,1X<&TV!\*+:[7:6]9
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M](L4.%'; A6@1(T/JYQ'PRUHF"3ZK0333?FO(V*\[1:;'%M=HL?562-U^&!
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M\VC(ORLJ(G<YJH]N73_YM&1OE941<=S>JCVY=/WFSY&^5G1%SW.:J/;ET_\
MFT9&^5E1$[G-5'MRZ?\ S:,B_*RHB=SFJCVY=/\ YM&1?E941<=SFJCVY=/W
MFT9&^5E1%SW.:J/;ET_^;1D;Y65$3N<U3^W+I_\ -HR+\K*B)W.:I_;ET_\
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)^:2J#6GQ7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g569434g77h39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g569434g77h39.jpg
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MME@NGGA:])HI2ZQRQR-&5$BHZN4+*&4.%)*EE(90V,J01R-0S6MS;K$\]O/
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MY8G9>V+4BT4Z=O=5#*ZM\,5;YIJ8XXMMTKT&-KHO?$"2Z:1/]%NSE#%$H/*
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MCCSUVU9A7V"EVI5TX1;L%7"RF&%[#=VH8J;B#<&92O%3(9 6=2-W(H 2PZU
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M&X<LDL3S)Y=X U* KBZD)R1&XV,UE%4WN9?<0> V,[>2$IS)SH^R.<R1?/\
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MT%<<>+75.=KWQ3E=[6RRQO\ Y"Q^++"]\<K?P[]5[7M0_P#2)]CH=<FM=_\
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M; V]I'Q9N%=,\FS<J=RAA7<<L.61RYU/U?7JX6E*4I2E*4I2E*4I2NQ/]?\
M5_?2E?,0X6I^:U1NF/[0C,H%PV4Z_!3V3Q(^6?8,&[:8LH#)DH<W3SSO;IG)
M&4N! ]%"]\6]^LY*D%FHQ)Z\;_?+^%;BU>!XVECF:*.1%7<3&94XA/>"H&8G
MKY<LM@'R?I5S)9WL=W#*L$UO'<2PR,<!9UMY> /K+2E% ZNZ[LJFYAZTSOBE
MX23.L?='F>L'PT'&N(/N5-R1?4TCNY'.Y1M-_MZ$;KXCX""S399(,(] F;%>
M&";/[CAK]P$?8Q#(MV20LOSL-AJ*SZ,9PS26GMA;/<)A@EN+:6ULI7R>Z>4D
M2MC) 8<0+@UU]QJVCO:=)UM2J1ZE[47L-G+N4RW;7<%]J=M&0N$BM@# F[:C
M&-N!OW#.IW'%L.*;BXL]S<0VG]U1A#5N]E87V&#*E7P"4XQ]R/@S9;5$QA>+
M.RL<9Z\?QQFF[>&NK:^S91(<1B4B-K8!FRVPTN&2VT^VLKBUD-Q:\7<^T-'O
MS,>R(Y<X<S*YP%S+F0K*BC<:U&OW,5[J]]J-E>Q"UU#@;$WM'+PRMN#:30A<
MQBU:),F3%L5@5H)9"$6LHX[;Z,XD..WB#W<&W[ +ZJGVW(;G%W+%X0L?DD7>
M! Z4JD"31\+0PC#*.C 1AMCE)\61$A)7<<'#@ST:1?%Q=FE=EV6DV=JUI-V1
M%;R\0$#8D@9S&F03Q&=G4]QE0@<E@0 9ND!L-4Z0:C?QZA;]B7%Y!PB-_$EA
M,:":4!H\1+$L;C]* [RF)%C979TJN)_;7"GQ%PG@_P!T30@893"&1F2Z#WWJ
M;6K^-@MC+Z]U^J4OP^S6+O"  S!DT6 1ZA C:1#%X9Q!14%GBQQ0>-7[>EA;
MZA92ZC:Q*ICED2[M+B<.T/&EQV9'( XER64RH1@%Y&R>6*:I>Z3J<&BWTYD6
M:&*73M0L[8QQW/8UL7]KIXBT;VX"QL+:0,3)LAB[G:P9<7&; UV5X#8AI6*;
MC&P*8(>Z*/\ :D1:S62/L9%KK3I'5PJ% MA2 E%Q*Z318'(4%')AI$V6<ELN
MW<'Q$8NR7:K9R-#,NJRW4EJTT9T=;>3A(-D]RMP\KQ(KMS#H0%,C;,$(SY!J
M);FV?H_#8Q7@MYATE:[A6>1N);636J0)=2/"A X<HRXA7C9!D2':5)]"=><5
MFD-1;#8@9YQ&Z7XGM>1[4?"]IF/QBS*?X1=;66LM[$Y>7V(=V-L+7\?E*.\M
M8$2DAVI$8B!%J!$!1\?$11">WCC6/O\ 33V%U<0EH;*ZL9GN;ZY=_P!$7$\]
MJL:PK!#,\9M9P$@DD=@VY&E81;RPZ.VU:PL[I8[C4K'5;:.RTJQCBV7(A-K:
M:@\[W,ES<V\4PO[1GDNX(8UV!)%A1KGA",Z3^YLEP)_W8C59V*GY#*XP:WIN
M0O')3+<;82N2@24:V4\#GY/CBDA;&0F!ZS<B:QL@C:Q)RYM9).UN9;9:\KKT
M9N5D1(Y%M+57CCYHCB2 ,B$_T%.57Z@*TW15XY.FMG)#))-$]_>O%--RFEC:
M&Z9))1@8D=2&DY#NB>0K^M;B4TIMV?;8X@SD-831F$E/ D1U3'7\;<:NLTFN
MQ%I'M!ZE W:4V2)DA]E6DF$*6+X(1P5C@^<XYR3!9KGBVX+3+ZSM[33HYFA+
MPZ^MY*)!<[H+81VBF=>"55CF)^X/$;N1^CP>?H.6-V>4KNPUOL&-G=/E^Y.[
M)'PAS[D<SD\N6.:CUCN>&[ FIXO =IL0YIKPCICP0A31)",R-]K?749 2C*4
MKGC#R4AVD.D;3)PX(QLDQ?Y6"V)1EA*[XMQY:2[N;*:W@C6YM&=#J^Z1^SUE
MC6ZN)7BX0C18G::-L!95*Y?;*T7-EHB2*[G8X!X. #$0=J@-G+;AM(_HG/+*
MANHX)PT:*W7J@L*EFV-,R78K%GIC>$7AD4%E]4M"< <R#>;G9YG7$H&K2D>"
MG#?<*0;71J!2QY(B;.#NP<FB\F;1EJ<<%S4^IW]E=HT-I>Q6[->V$L\SK=E;
M@1V"VJ7$3")G@-FS7"7$2QJTX>&6,RF,+';#'(A!>,L!'(% ,>5W2[RA[H!M
M^$*DG"[6#;<Y;=3AVNYB+>\4>Z9V-KLGL:2[=VS('1['6=X\-D)"2QHD38Y(
MP38DMP&X&EIE=O%+-VJV9=M#Y&;EC@6?(M;R#2:D!,>,M[;7*6T5G:1B,W7$
M:-8I55@;BVAW;!#NFR1L,\<<(>-3PYX^YY<-D+EW;.S 8L"?@L>O=RQU[26P
MQRVHPW0F[VA6)&EX]/<V WW2G9>[7D-N[U'D"9:I//MH.!.QTG"2F,I6ZZG)
MQ"G8.\H<'T57KG!>*H8-<TV^X:_L629!+;AFZ,VM@LV+O>UW$+0/;$<X@%,3
M_I.$(R%!$ISSA$3Y4D,0+IY-O<8",7P_A?TARSN&?@U@&&B.(7N+U=-Y:WVN
M1GJ^LC4?;1PL[X>$8[#WSC;L<DW4XQ(AAUL:>/RXULV(J-I 2.@<F4>54<E!
MIEHP%23([/T[VZ%YV39K;BZ20R(-2,DRBSDBS+&\90*C$J#&J2!I,*K1EGCM
MX4O8_#VMNV$;28L [P<*P.<D<^9*\NL$ -,S+1NRL]-\4NH9I#)D\V'O*=[3
M=N=U19KJ,I&I\A.];AHV /IP^2/<T-<"R$'C$:U/L2+Y1U)3ME%'I*PD[FTE
M;SW+":^M>S=+O()X!;6-O:*+*4WB2P&"Y>62/C1#-RZSRRW=M+Q".$\<31#A
M&W%XB?AS1L#ND9_T@V$-N0 -M)[D%0(V7;\(,0>Z#'TJ"8%4PPA,[V/N;P%L
M,#%Q&*^ JY7%HEB0[&8.>5S@/ZW9;J6+B]U\6W1V5_?+95S,FPNYCW<,NVS?
MC?LR=N_'+=C&['+.<5EC.!GK^/'5GX\5^$OX0%_E6_\ 99.KH_@S?JO\R.H9
M?A0?KO\ *EK6C?4VX<=2C]@[;FD4UM)-BZ[@<@V.LRN+A6>S3334L1-[$2'!
MB9E-)[D=$QT69.@&:K])PQ8I/R[3%!@@]=I[&P@U*[-O:0RW45K<7$=L&W3]
MBQF\FCMBSHAV\-Y62.1@I#-M0Y8JI2-$@>1@I9%+]2[SPU+X'QY R1_>1\=7
MM0SPEFA\><KKZ%*"[;->OHRLNV@SQDVV^M(F@-\6&9*H*(L)X[EDB%B,S*70
M&GTADH9CB[6(R$8D^LV:NC2 >V"-V*JR@-.&-F(VD5& .3;K#&[\,Y18XW;:
M%C8K7]"<?R9[LD<E^'G!(_[V2!D<\D#.35A"2+@C,'LFT=?<,Y.1R@HTY]@R
M6MG9.0E9H3E"3%QFLS246*K2L]G,6;5]DHOB<D#@^/27=%G;U!61XM<2/,BZ
MFD<2'X9N56-(4BR &.%$48A)4 <.,(Q 1010& GD8B2?BV9)8MWNO<=W/XVW
M#KS4J1Z^DIZ.G,?B5]?2 ?*$[$]@CHUV&S[8$9F/6;-I!(,1/1K$TI4-8.,!
MDE7R6P-M1ZN0XBYP8Y9(XD@OK=K>2;LB-HNYMVEW_H^"P)CCWY"\)F&Z(8V%
MAN4;N=XX;;@NT[N;8QSW#&3CKR!R/QXY'E5[7U3K1ZW--RL!AAKMG<!'TL7,
MQ4 1<RXG'$VV ,O*57 [+L^5%=4;9CGY+%PX8J()9,\T.C3MC&+NZ4H4N)DX
M0=8@DLB"%9,\1(@&'#1]QW*N V3G.:KL0YRJG=C=D [MN,;L]>,#&<XQ5!?2
M.F+NG3Z^HM87>OG!IX]>7@,4ZT\=R1B]&2)TZ<=B>F<.#PTD1'FEU<\U2C%^
M]:/LET'2Z:EW9U[@+V9=;5"*!V1+@"-E>, ;\ 1NJL@')&567! --B=>Q?C_
M *(^/D?B^,$Y[^>=<S.EM.2-@F*D.IM9G1:(,9&$AIF!Q8HP2C01]<F&CR;-
MZ*7;X Q!*]R P3BG9@P?7N[:-TE_WRB7U[$V^.[NHW,CREDN)4;BR+L>3<K@
M\1U[EWSN9>1)'*J&.-N11", 8*J>0.0.8Z@>8'?K* D-B,98!A<9B\=C8Z-C
MW0J-L0(,4)9QX:^S05>#P;1DT1;"F+I5JU5<,V22+9PHV;YK)*713YL3SS2L
M[RRR2M*RO*TDCN967(5I"S$NP!(!8D@$X(S5P50    !@8 &!]7Q"OT-$HZ"
MC^47'BVU@:UR^;UBYPZ[@4<2%\]*2)Z7R=]-F5?2$H3)%#KQ_DNX+D2+YX_4
M77=+9YGFEDDXK.>(-FU@=I01JJQA,8V+&JJL87 154+@ 4  & .7/EW\\SGO
MY)))/622:Y'8E%)0)2 2:,1Z1 D' YVB%.A1I<2BZ#N$78ERD-(-G#--P+=M
MV[H<M@C91DX016;9)*)898TCFFB<R12R1R$,"\;LCD."'!92&(8$AAG# D'.
M:$ C! (Y<B 1RZN7U?%6-F-0:ED*A)8_J[71Q8R>$RHPJ8A,:)J%9.!:W8@Y
M&2S>C%\GQX,RRR9B3#JZI <URNW9N$4KWPJ5+R[C"B.ZN8PD;Q($GE4)%(=S
MQKM8;8W;NG085CS()JA1#UHIR0QRH.2.H]76/B/6/BJH(:KU@6;X-"NN($3:
MIRVT^P;$(?'GK?"=8Y99XS7!%R.43QEML\\\[2.V-C%LL\LK/.7*][T6[ND.
M4N;A"8>QR5FD4FWY?H,A@>#R'Z+X'(=S0HAY%5(W;N:@]UX75\+Z^NL$G7#;
MJ6=X6Z>+!XXN\V7#-K2EY%HW#V#R?R>"D,B06T]7?1LG>3,\G%^1WF\M8KDC
M:Z34HTQS5Y^1;ZG>6_5,\@6UFM(EEEF86\4Z[7['"RIPFQ\';W&>91JM:)&^
M(#NU<X &XJ<C=R.?_'ZZSY?5^M'+UF1<Z[@K@@/;Q]FP?KQ( J]8M(FHZ6BS
M5FZ4'Y+MF\:6?/58^@CG@D&4>.LQV+;)PK?/&%U=!2HN9PK&1F432!2TP E8
M@-@F4*HD)YN% ;.!5VU<YVKD8 .!D!3D#/U$DCO$\JN4<@\*A]\[Q*'Q>+74
M&B@ZEXY'Q(2Z@@#@Y3!BL[C&C7GC0R;QY@*8Y<K8=@Z<XLTD;+JVRMDGGF_E
MII9<,[CB2/)AY,<1^Z)[I]J[VZVP,DX%5"JOP5 Y <@!R'4.7Q#XN]5]9,&(
MU'-N.9-&#=1V_?J(,FR+5%1\5?.2A1[FDA@GAD[)$WCLB_<Y8W6>/G3EVXS4
M<+JJ91LS,<LQ8@*N6))VHH55R?B50%4=04 #  JN,=7+K/V\S]IYFJNJ4KS2
MXK5,,=H\F6>&-^P N_)EE:U^3]^^/DO?]'Q7_P#"]>(?^DZ">FN@X!_V2MO_
M %O7:^]^Q&"=#U; /\^2?%_\LTRM:.F2[ZGY>/IKS=@]X_8:^K8/>/V&G3)=
M]3\O'TTP>\?L-,'O'[#3IDN^I^7CZ:8/>/V&F#WC]AITR7?4_+Q]-,'O'[#3
M![Q^PTZ9+OJ?EX^FF#WC]AI@]X_8:=,EWU/R\?33![Q^PTP>\?L-.F2[ZGY>
M/II@]X_8:8/>/V&G3)=]3\O'TTP>\?L-,'O'[#3IDN^I^7CZ:8/>/V&F#WC]
MAJE=*I7Q1Y%$[_XTWO\ %GC^BRN/+?\ 3^JKT!RW(_ ;XOJJ2,'+<C_)R?%_
MW355TR7?4_+Q]-68/>/V&H\'O'[#3IDN^I^7CZ:8/>/V&F#WC]AITR7?4_+Q
M]-,'O'[#3![Q^PTZ9+OJ?EX^FF#WC]AI@]X_8:=,EWU/R\?33![Q^PTP>\?L
M-.F2[ZGY>/II@]X_8:8/>/V&G3)=]3\O'TTP>\?L-,'O'[#3IDN^I^7CZ:8/
M>/V&F#WC]AITR7?4_+Q]-,'O'[#3![Q^PTZ9+OJ?EX^FF#WC]AI@]X_8:IFR
MJ5L%.51/^$N;_P#OX]^S_P!M7N#E>1^ OQ?54D@.5Y'^3C^+_NBJGIDN^I^7
MCZ:LP>\?L-1X/>/V&G3)=]3\O'TTP>\?L-,'O'[#3IDN^I^7CZ:8/>/V&F#W
MC]AITR7?4_+Q]-,'O'[#3![Q^PTZ9+OJ?EX^FF#WC]AI@]X_8:=,EWU/R\?3
M3![Q^PTP>\?L-.F2[ZGY>/II@]X_8:8/>/V&G3)=]3\O'TTP>\?L-,'O'[#3
MIDN^I^7CZ:8/>/V&F#WC]AJ4=(J89;=U[;'/#*_;!:_)CE:]_P#-S_\ 5:]?
M2_8>![971+D?YQ;XO_A;BN9Z9@^Y37N1_P!1[W]?#7KG7Z25Y4K2ICQ ;?QV
M"=@#_76#YX'<S0>B_$1H^B)(%89(T94V%)%G1YPA9Y-M!GX@=CV::"[!A/WY
M$*\?/,62PQMM396W!283D*PB;#.A8+*ACW%0G5%=I*C\\F%58 $@G0KJ5]V3
M);-:[F0W"ADBEV,\$HF"!S(1FXTZ6"2,X*K<,\99MI06@1Q([*D<GU;&!3:
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M$JQ36-M=R<1P3+(UB+R6*)E1,*\F;=,;F4D=T6%7<5N'(_+*R.@ '4%E,8+
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M/UTW^$N*^B!7Q6O2U*4I2E*4I2E*4I2E*4JU$OX0%_E6_P#99.I8_@S?JO\
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M)K:W=Y$VNW!C0L44+011@J0O-,;3ECC"L@',\P%=@ <@;B1SYUCXK@]X?09
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M^+%8,]X)N&HBDZ:O8&57'/&[Q%41[Y.TDPN#@CKUIJQ^9;!TIHF-9R5Y"![
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MQ3SVS(=XC1,A:8-T\'08!LZ7RV0!6:%VN23:4R"./%GT8*.@V=K:O>,L:9C
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MH((((P3UA&C!.<Y[EB#GKY'K&:L 3@DTQ'(/(]:A'FQ!T$E4+CD),Q5*=EU
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M6O"R2F6H14\WSP\.-E1$VRG@F0/=-[(T_+2QB10Z.R)\-VZUV@N6UU(3ILD
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MTJ')A_,&J]9! '^J]\U<G2#H^"2=?T/X+C^>-.ZRC ?]I[Y%=_O>;$\7D_\
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M]O;E2KK&;:V@O8]R;E!NA!&6A0.M!%)NC+$[1LXBAVP2L<JNV<@G>[QD @?
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M=U,+*98WSQ3OEC;/+"V6.%\K8WOSKXVSSPQOE:W);+/'&]^7*UKQ8/7CE_\
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M<7"[M9A9'8^VL'MS<?Z5)P6LKO=/[9+P'D;H_=6L20Y7AQS-=3!$<F5DD).
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ML0 <]R"& 502>9!4D8R&5"!NV?K55-2E*4I2E*4I2E*4I2E*4I2E*\U>*O\
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M4JLKEN-$.[14VLPP6WH/<'7"?H?=/#Z'W'%H9!8Q/>"G6+Y@EN1MM;9\ /\
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MZH;\,D6V.UBTKAMX.Y'25[M'8$7+GBK:81,!L03_ )(B[1--@;<M1=FV.11
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M9!^.-D7"2=3-GEA2:O.L1B6.+@2=V8^Z+*H427:6>U@<$31R/NEAZT3:=Q+
M5<]A\1:4)*[%C>43,8E(5#99+FY99#)8*]81R'C98D\PRSN-073?(NC+%BRN
M69J/2D/D0_-VP33;/U*0V/%6"3B*5EDCC*CDX9Y6C*_&000A)VG"RHV#S%7W
M6J"W>ZB,+AX()Y@Y&8V6*!)PP^"#NW2(JEU+/!*N0,,:"(<1KF0[94@;T*'0
M%/C#J)B7 TQUTHTD(F3<30YVZ*],FU26&%P6@$G[1HU:(NP[XVBBJY.-'N+D
M7=+8B.VXP=BZKQ&!7"M&T=@PV\R05:\P2<A@I.%*X-D&J&6]-LR1B-G,,95]
MSK*DVK(S/D %'CTT,  #&T@&9 VY,/$\80T<IU":CQ=U,IU)(GVQ!7J(V/,&
M]MH[YA<3(F42! JX&AF<?T:4.3Z3*/<F05(@S)M!JPY5XD)D?3">ZB9L<&.3
M8XW.3V/9RRJFT*&8O=JL,>,OM92VX M"FMJIVW")GLB:'BQL$B4=F:E;P.X9
MG*QB+3GDN9BVV/<KJA0L$S22<33:+?NRD,=HMQZS=P=<=FV:R&  CJF0;,"%
MXP\;-%ATKN==1:00D8DS?-6B\E#ND>R-D7 S-]%'IYD^#*"2"$&P@EUN$@9'
M!(:/8)$E?()5'!VY# 3RZL(?AP$!"#(>(".&UG)=1R0L%*3<1HI+=,,H,J-W
M6"FZ[/-T$WK[5S=G>+0L/L$3L@DK,9(_&2^,)D(42 # $:$%8S*A80@_G3,P
M5F8)?L]9U>,0TZT<A6A?)UV"L%JH%P3Q)6A:!1$@:*0K*KLTC*\;.JPE5C<;
M,<25"&*XW2&_9FLP.% ERETYGE9)X0UN\:1PH\4J1LUPLCSQGB9X,$BF,/GA
MX>>XLA\99O<7,2?'7X9"6]D7(Q\R&#G*NOF6UW4J6;HOE7;ECUM#3T@*1=BX
M5=7+ACT3>W()IO2:@J1-.,A&) @?A[0P+$"8VXCR1@''9*+(P V,D@V\EW02
MZRD*MF%I&03[BC*BL;9;QIL!B2NX64CPJ2V^.2%MV&<I5D>+ ,+Z=%U"S&3M
MK(>UI;%N4&J,%7*Q.=#AY]@34LBW?0EYG 2#;*2I8X]6-%0P%0=D^4(]C2Z<
MS8Q*N&3>,JP8 +$61EZQ*.,OZ/XU#.&Q@&YM91<@V\FX2<(@.A7):X59%?D&
M@;L=AQ>6)'CB*[BVR@RXM@SJ1JQIB*8H+#C[T"8>J'61&R3T5L74T$=-1S-&
M[&SWK*^Q"ULW*KYGF,O&';E-B8M=1DG<--8()&8X9 ZC:5R&@N)02>>,<%>6
M"&W@97KJSVY1IC"J*"LC1NW$5\%+FRMV"J-NX$W3@DLI3A$[7^"+N%XK8\;-
M0\2C%##=&7Y!,V[YR^88=4;R.VK4AJ>;7_G5"[4CMJ/C9 'OD@J&<B)-^_O.
MI"L35CZ<Z)*QD4F+?D!3S*<<MSZ@I6W=D;F'#)R&6VR1ZQ%)) @A<"?AE6+*
M,++V(%[GK+J][&DL?(QE)<D[4XFUM:ZMQ2E*4I2E*4I2E*4I2E*ZUL,E$E4\
M%E&^:B>>&"Z-DLE4,LL;XXK)67270NHG>]L\++(K)7RQM91)3#EPN'(@XS]1
MS@_4<$'G]1![QI7G#K7:>\9UPG</$W;[9&CMOSWAUFTH,R"9!H6/AJ^S5M?H
M8@S4\8BXFAD"C,+V(5%I%FL:1"8HI?Y.,I$55+(J=+<VEC!J^HP&S9K2WU&"
M)(X7G:86HN#Q$@9YB'EFMD<H92^3W2%>L8J/(T$3;P)&A))8 *7*#!; Y!6/
M,#']]3UPJ[-DFPP>RAT\O/1FQM>;&2ATZ@^PV<"S+:^,9:[@$D1!AY9K,2%B
M&PXB=8'VL^B\S:CV9-R+F"0<Z,!E@SH$,P-6M8K:2V:W['>VN;8S6\]L9PEP
MG9%Q&7>&Y=YK>:-HS;RPLQ4/"71I$<2-)"Y8/NW!U?:RMMRAV*<!D 5E((=6
MQG#8(!! VHK4U-2E*[$_U_U?WTI7RJ8[*9-$'RY.)R(Y&23H84".2$?*O@[U
MP&.,5AAH2LZ'KMUU1I<:Y<#R;'//)L_8N%VCI)5!51/+T*\<<H"R(KJ&5@'4
M, RG<K8/])6 *GK! (YBO(<<LL+%H9)(F*NA:-V1BDBE70E2"5=25=3R9200
M0:RQGN;;X^/RN),-J;&916>"8R G$::S:2MP$Q!0IBR%PT+*1"1+$?(!,2&#
MAX^,CBS=VS L6#)J+1:H-4$\(S:VQ>.0V\)DA9WB<QIOC>4EI6C;&4:0DERI
M!<D[LYJ5;V\6.:%;NZ6*X2*.XB%Q*(YXX%58$F0/ME2%5585<,L2JJH%"@"J
M([SW,7&!0Q7:NP"(V.M@;(&V>2PVX[%L8NN@ZBX]HLJ]R73'1=RV;N(T/Z6[
M./K(IJ"$&>>-KU06EJK,RV\(9RY<A%&YI/Y1C@8W..3MUN.3$BJO?7KJB/=W
M++$(UC#3R'8L)#0JI+9"PE085SMB(_1A:R MQ/\ $H>(/BQSB#W89*DSC"3$
MR17:<X($",D%BB (9('[QV<6</#8X(5*"&!5RHJ^9C"+Y@W73:NUTE+%L+%0
M%6SME55**JP1@!"P8H %P%+*K%1R+*"1D"I7U34Y&9Y-2OW=I%F9WO+AF:5$
M:-)68R$M(L;LBN265&900"16#O=I;,)P(;JLCL.</]8ACCJ3A]=/96==045)
M'R:J3V0#8DL_S L3;M)=9)R5;,$GRZ:JB:J^6&>5KRK;6ZS&X6&)9V4(TP11
M*R#J1I,;RHP,*20,# K'-S<M;I:-<7#6D<C2QVS32&W25@0TBPEC&LC D%PH
M8@\S7'/:&RU-?I:F4V%-L]6(GLI2CK;.5',H$E)\T+-<Y&G$+OKQ_ ]DUM9M
MD7Q'V(9-[60NXNE:V%.QX!-V1P8NR"G#,^Q>+P\YV<3&_9DYVYVYYXS3LJY[
M'%GV3/V()#,+7C2=CB8C!E$.[A\3'+?MW8Y9Q67#.(_B%"CG(</O7<(L2\AL
M?UTZ&#]E3)H/7@$2?/B<5A*C- S@WO$XR0)DWL?C_1]B@SHD07&M6RCYUDK&
MUC9.P9K2V9A*\P9H8R>-*%627)7/$D55#O\ "8* 20!4RZEJ**434+U$,,=L
M46ZG53;PLS10%1(!P8F9FCBQL0LQ51N;.Y'N.M^7W2KA7O?X[WEDLO>]_P!?
M_)I-JU?2?^8M0_5Q?XB&M[T)_P!J=(_73?X2XKZ$6$5BZ<D<3%.-@<)<[$H
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MGR%"B,<LBDXQDJ"<=[)'5]5=QS5VN)*D>2.0:*D;2E]&B4F47!CNLR%_#23
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ML&0>  6P(<@'ACN,@=SR%-B#)"KDMN/<CFWA'E\+Z^NKRW#!XXPB,?CPD:!
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MG=*V72,7HM@_(V>8<K9!BQ>NW2J"#5QFG:;:<=<3CFXYC'-&"L/[0Q"XZR2
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M=J7CE9)9A^A$B1LZ+,X(X4;E0AF(98L[W 0,PLD<QH6"E\%<JOPL$@$J/Z1
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M^J_S(ZAE^%!^N_RI:@'<'"QK7>++9#>>K&7;_8$8!1<5(VK6'XR?4Z,:4($
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M7 >)&";HE4W#1,A92X,L<DB/))PY%!4)5(5C.59NKF#MP2,]T3MW X..Y(!
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M#/REOP*4V'ZOV_E3M0(?*&?E+?@4IL/U?M_*G:@0^4,_*6_ I38?J_;^5.U
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%*4I7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6723122384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DocumentandEntityInformationAbstract', window );"><strong>Document - Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">F-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRUS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merus N.V.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001651311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DocumentandEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document - Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DocumentandEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6725686160">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statement of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 1,876<span></span>
</td>
<td class="nump">&#8364; 1,168<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">381<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentHeldtomaturityInvestments', window );">Non-current investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,650<span></span>
</td>
<td class="nump">7,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">167<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,074<span></span>
</td>
<td class="nump">8,669<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,477<span></span>
</td>
<td class="nump">4,413<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Current investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,077<span></span>
</td>
<td class="nump">34,043<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,327<span></span>
</td>
<td class="nump">149,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">212,881<span></span>
</td>
<td class="nump">188,134<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">231,955<span></span>
</td>
<td class="nump">196,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued and paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">1,749<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium account</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">258,061<span></span>
</td>
<td class="nump">213,618<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(167,226)<span></span>
</td>
<td class="num">(158,775)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">92,872<span></span>
</td>
<td class="nump">56,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">105,718<span></span>
</td>
<td class="nump">112,551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,433<span></span>
</td>
<td class="nump">2,855<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax', window );">Taxes and social security liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,972<span></span>
</td>
<td class="nump">15,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Other liabilities and accruals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,860<span></span>
</td>
<td class="nump">8,627<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,365<span></span>
</td>
<td class="nump">27,660<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">139,083<span></span>
</td>
<td class="nump">140,211<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 231,955<span></span>
</td>
<td class="nump">&#8364; 196,803<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentHeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current held-to-maturity investments. [Refer: Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentHeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as non-current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of present obligations of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentHeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current held-to-maturity investments. [Refer: Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentHeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2018-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2018-03-01&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 70<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6726045808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statement of Profit or Loss and Comprehensive Loss - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract', window );"><strong>Operating expenses from railroad and related business [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 6,543<span></span>
</td>
<td colspan="2" class="nump">&#8364; 6,237<span></span>
</td>
<td class="nump">&#8364; 16,464<span></span>
</td>
<td colspan="2" class="nump">&#8364; 10,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,523)<span></span>
</td>
<td colspan="2" class="num">(8,420)<span></span>
</td>
<td class="num">(22,821)<span></span>
</td>
<td colspan="2" class="num">(15,427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">Management and administration costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,639)<span></span>
</td>
<td colspan="2" class="num">(3,492)<span></span>
</td>
<td class="num">(5,491)<span></span>
</td>
<td colspan="2" class="num">(7,694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,297)<span></span>
</td>
<td colspan="2" class="num">(2,277)<span></span>
</td>
<td class="num">(5,983)<span></span>
</td>
<td colspan="2" class="num">(4,120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(18,459)<span></span>
</td>
<td colspan="2" class="num">(14,189)<span></span>
</td>
<td class="num">(34,295)<span></span>
</td>
<td colspan="2" class="num">(27,241)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,916)<span></span>
</td>
<td colspan="2" class="num">(7,952)<span></span>
</td>
<td class="num">(17,831)<span></span>
</td>
<td colspan="2" class="num">(17,120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,411<span></span>
</td>
<td colspan="2" class="nump">420<span></span>
</td>
<td class="nump">4,945<span></span>
</td>
<td colspan="2" class="nump">610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td colspan="2" class="num">(11,962)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td colspan="2" class="num">(22,696)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net finance income / (expense)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,410<span></span>
</td>
<td colspan="2" class="num">(11,542)<span></span>
</td>
<td class="nump">4,944<span></span>
</td>
<td colspan="2" class="num">(22,086)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Result before taxation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,506)<span></span>
</td>
<td colspan="2" class="num">(19,494)<span></span>
</td>
<td class="num">(12,887)<span></span>
</td>
<td colspan="2" class="num">(39,206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(87)<span></span>
</td>
<td colspan="2" class="num">(107)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td colspan="2" class="num">(118)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,593)<span></span>
</td>
<td colspan="2" class="num">(19,601)<span></span>
</td>
<td class="num">(13,026)<span></span>
</td>
<td colspan="2" class="num">(39,324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences from the translation of foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36<span></span>
</td>
<td colspan="2" class="nump">13<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td colspan="2" class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Total other comprehensive income for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36<span></span>
</td>
<td colspan="2" class="nump">13<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td colspan="2" class="nump">18<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (4,557)<span></span>
</td>
<td colspan="2" class="num">&#8364; (19,588)<span></span>
</td>
<td class="num">&#8364; (13,005)<span></span>
</td>
<td colspan="2" class="num">&#8364; (39,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic (and diluted) loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">&#8364; (0.20)<span></span>
</td>
<td colspan="2" class="num">&#8364; (1.01)<span></span>
</td>
<td class="num">&#8364; (0.60)<span></span>
</td>
<td colspan="2" class="num">&#8364; (2.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average shares outstanding Basic (and diluted)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">22,628,611<span></span>
</td>
<td colspan="2" class="nump">19,392,495<span></span>
</td>
<td class="nump">21,809,950<span></span>
</td>
<td colspan="2" class="nump">18,976,446<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">For the periods included in these financial statements, share options were excluded from the diluted loss per share calculation as the Company was in a loss position in each period presented above. As a result, basic and diluted loss per share is equal.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2018-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=26&amp;date=2018-03-01&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2018-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2018-03-02&amp;anchor=para_39L_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=17&amp;date=2018-03-01&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=5&amp;date=2018-03-01&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2018-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=32&amp;date=2018-03-01&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=5&amp;date=2018-03-01&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2018-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=33&amp;date=2018-03-01&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of operating expenses from railroad and related business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OperatingExpensesFromRailroadAndRelatedBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6725952752">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statement of Changes in Equity - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Issued capital [member]</div></th>
<th class="th"><div>Share premium [member]</div></th>
<th class="th"><div>Accumulated loss [member]</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance (Previously stated [member]) at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 34,031<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 1,448<span></span>
</td>
<td class="nump">&#8364; 139,878<span></span>
</td>
<td class="num">&#8364; (107,295)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance (Increase (decrease) due to application of IFRS 15 [member]) at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">390<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,421<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,448<span></span>
</td>
<td class="nump">139,878<span></span>
</td>
<td class="num">(106,905)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation for the period | Previously stated [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43,132)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation for the period | Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,808<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39,324)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period | Previously stated [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43,114)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period | Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,808<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(39,306)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TransactionsWithOwnersAbstract', window );"><strong>Transactions with owners of the Company:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of shares (net)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73,961<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">298<span></span>
</td>
<td class="nump">73,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity settled shared-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,880<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity', window );">Total contributions by owners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">81,841<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">298<span></span>
</td>
<td class="nump">73,663<span></span>
</td>
<td class="nump">7,880<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">76,956<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,746<span></span>
</td>
<td class="nump">213,541<span></span>
</td>
<td class="num">(138,331)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance (Previously stated [member]) at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,887<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">213,618<span></span>
</td>
<td class="num">(167,480)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance (Increase (decrease) due to application of IFRS 15 [member]) at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,705<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,705<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">56,592<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">213,618<span></span>
</td>
<td class="num">(158,775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,026)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,026)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,005)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TransactionsWithOwnersAbstract', window );"><strong>Transactions with owners of the Company:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of shares (net)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,731<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">288<span></span>
</td>
<td class="nump">44,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity settled shared-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,554<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,554<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity', window );">Total contributions by owners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,285<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">288<span></span>
</td>
<td class="nump">44,443<span></span>
</td>
<td class="nump">4,554<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 92,872<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 2,037<span></span>
</td>
<td class="nump">&#8364; 258,061<span></span>
</td>
<td class="num">&#8364; (167,226)<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2018-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2018-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2018-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2018-03-02&amp;anchor=para_39L_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=17&amp;date=2018-03-01&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase through contributions by and distributions to owners, equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseThroughContributionsByAndDistributionsToOwnersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TransactionsWithOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TransactionsWithOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6725872368">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statement of Cash flows<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th" colspan="2">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (13,026)<span></span>
</td>
<td class="num">&#8364; (39,324)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives', window );">Changes in fair value derivative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized foreign exchange results</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,648)<span></span>
</td>
<td class="nump">12,357<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">218<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,554<span></span>
</td>
<td class="nump">7,880<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Net finance (income) expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(531)<span></span>
</td>
<td class="num">(593)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Cash flows from (used in) operations before changes in working capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,433)<span></span>
</td>
<td class="num">(8,866)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangeInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets', window );">Taxes and social security assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,024)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Trade and other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(959)<span></span>
</td>
<td class="num">(1,946)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Trade payables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,307<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals', window );">Other liabilities and accruals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,233<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,796)<span></span>
</td>
<td class="num">(6,899)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities', window );">Taxes and social security liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(143)<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,829)<span></span>
</td>
<td class="num">(15,559)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Taxes paid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(302)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(15,132)<span></span>
</td>
<td class="num">(15,576)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29,560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Proceeds from investment maturities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intellectual property</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property, plant and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(624)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities', window );">Interest received</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">602<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,751)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,731<span></span>
</td>
<td class="nump">74,431<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from stock option exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ProceedsFromCollaborationAgreement', window );">Proceeds from collaboration and license agreement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,993<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of borrowings</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(486)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangesInRestrictedCash', window );">Increase in restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash from financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,731<span></span>
</td>
<td class="nump">186,332<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,848<span></span>
</td>
<td class="nump">170,727<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effects of exchange rate changes on cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,801<span></span>
</td>
<td class="num">(11,856)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents as at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">149,678<span></span>
</td>
<td class="nump">56,917<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents as at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">170,327<span></span>
</td>
<td class="nump">&#8364; 215,788<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangesInAccruedCapitalExpenditures', window );">Changes in accrued capital expenditures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in deferred income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=sect_AStatementofcashflowsforanentityotherthanafinancialinstitution&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=sect_AStatementofcashflowsforanentityotherthanafinancialinstitution&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2018-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2018-03-02&amp;anchor=para_39L_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=17&amp;date=2018-03-01&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities and accurals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdjustmentsForIncreaseDecreaseInOtherLiabilitiesAndAccurals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in Tax and social security liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdjustmentsForIncreaseDecreaseInTaxAndSocialSecurityLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for ( increase) decrease in Taxes and social security assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdjustmentsForIncreaseDecreaseInTaxesAndSocialSecurityAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ChangeInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ChangeInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ChangesInAccruedCapitalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in accrued capital expenditures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ChangesInAccruedCapitalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ChangesInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ChangesInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ProceedsFromCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ProceedsFromCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6721684736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General information</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr style="page-break-inside:avoid">
 <td width="4%" valign="top" align="left"><b>1.</b></td>
 <td align="left" valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;" align="left"><b>General information</b></p>
 </td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Merus N.V. is a clinical-stage immuno-oncology company developing
 innovative bispecific antibody therapeutics, headquartered in
 Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned
 subsidiary of Merus N.V. located in Boston, Massachusetts, United
 States. These condensed consolidated interim financial statements
 as at and for the three- and <font style="white-space:nowrap">six-month</font> periods ended June&#xA0;30,
 2018, comprise Merus N.V. and Merus US, Inc. (collectively, the
 &#x201C;Company&#x201D;).</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 On February&#xA0;13, 2018, the Company entered into a Securities
 Purchase Agreement (the &#x201C;Purchase Agreement&#x201D;) with the
 purchasers named therein (the &#x201C;Investors&#x201D;). Pursuant to
 the Purchase Agreement, the Company agreed to sell an aggregate of
 3,099,997 of its common shares, nominal value &#x20AC;0.09 per share
 (the &#x201C;Common Shares&#x201D;), to the Investors for aggregate
 gross proceeds of approximately $55.8&#xA0;million, at a purchase
 price equal to $18.00 per share (the &#x201C;Private
 Placement&#x201D;). The Purchase Agreement contained customary
 representations and warranties from the Company and the Investors
 and customary closing conditions. On February&#xA0;15, 2018, the
 Company completed the sale under the Private Placement and received
 aggregate gross proceeds of approximately $55.8&#xA0;million.</p>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>Nature of Business</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company expects to continue to incur significant expenses and
 operating losses for the foreseeable future as its bispecific
 antibody candidates advance through discovery, preclinical
 development and clinical trials, and as it seeks regulatory
 approval and pursues commercialization of any approved bispecific
 antibody candidate.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 As a result, the Company may need additional financing to support
 its continuing operations. Until the Company can generate
 significant revenue from product sales, if ever, the Company
 expects to finance its operations through public equity, debt
 financings, or other sources, which may include collaborations with
 third parties. Adequate additional financing may not be available
 to the Company on acceptable terms, or at all. The Company&#x2019;s
 inability to raise capital as and when needed would have a negative
 impact on its financial condition and ability to pursue its
 business strategy. The Company will need to generate significant
 revenues to achieve profitability and may never do so.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Based on the Company&#x2019;s current operating plan, it expects its
 existing cash balances and investments to last through the end of
 2020. For this assessment, the Company has taken into consideration
 its existing cash and cash equivalents of
 &#x20AC;170.3&#xA0;million, which include the $55.8&#xA0;million, or
 &#x20AC;44.8&#xA0;million, in proceeds received from the Private
 Placement offering that closed in February 2018, and investments of
 &#x20AC;53.7&#xA0;million as of June&#xA0;30, 2018.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 51<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6614124912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Significant accounting policies</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>2.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Significant accounting policies</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 There have been no significant changes to the Company&#x2019;s
 accounting policies that were previously disclosed in
 its&#xA0;Annual&#xA0;Report on Form <font style="WHITE-SPACE: nowrap">20-F</font> for its fiscal year ended
 December&#xA0;31, 2017,&#xA0;or in the methodology used in
 formulating these significant judgments and estimates that affect
 the application of these policies, except for the adoption of new
 accounting standards as disclosed more fully in Note 3.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Basis of Presentation</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 These unaudited interim condensed consolidated financial statements
 (the &#x201C;interim financial statements&#x201D;) have been prepared
 in accordance with International Accounting Standard 34
 &#x201C;Interim Financial Reporting&#x201D; as issued by the
 International Accounting Standards Board (&#x201C;IASB&#x201D;).
 Certain information and disclosures normally included in financial
 statements prepared in accordance with International Financial
 Reporting Standards (&#x201C;IFRS&#x201D;) have been condensed or
 omitted. Accordingly, these interim financial statements should be
 read in conjunction with the Company&#x2019;s annual financial
 statements for the year ended December&#xA0;31, 2017. In the
 opinion of management, all adjustments (consisting of a normal
 recurring nature) considered necessary for a fair presentation have
 been included in the interim financial statements. All intercompany
 transactions and balances are eliminated in consolidation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Use of Estimates</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The preparation of financial statements in conformity with IFRS
 requires the use of certain critical accounting estimates. It also
 requires management to exercise its judgment in the process of
 applying the Company&#x2019;s accounting policies. The areas
 involving a higher degree of judgment or complexity or areas where
 assumptions and estimates are significant to these interim
 financial statements are disclosed in Note 4. The results of
 operations for the three- and <font style="WHITE-SPACE: nowrap">six-month</font> periods ended June&#xA0;30,
 2018, are not necessarily indicative of operations to be expected
 for the full fiscal year ending December&#xA0;31, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Foreign Currency Transactions</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Items recorded in each of the Company&#x2019;s entities are measured
 using the currency of the primary economic environment in which the
 entity operates (the &#x201C;functional currency&#x201D;). The
 interim financial statements are presented in euros, which is Merus
 N.V.&#x2019;s functional currency. The functional currency of Merus
 US, Inc. is the U.S. dollar.&#xA0;All amounts are rounded to the
 nearest thousand euros, except where otherwise indicated. Foreign
 currency gains and losses are reported on a net basis as either
 finance income or finance expense depending on whether foreign
 currency movements are in a net gain or net loss position.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Seasonality</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s financial results have varied substantially,
 and are expected to continue to vary, from period to period. The
 Company believes that its ordinary activities are not linked to any
 particular seasonal factors.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Segment Reporting</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company operates in one reportable segment, which comprises the
 discovery and development of innovative bispecific
 therapeutics.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Cash and Cash Equivalents</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 For the purpose of presentation in the statement of cash flows as
 well as the statement of financial position, cash and cash
 equivalents include deposits held with financial institutions with
 original maturities of less than three months. Cash and cash
 equivalents include &#x20AC;34.3&#xA0;million of short-term
 investments with a three-month or less maturity, callable on
 demand. The carrying values of short-term investments approximate
 fair value due to their short-term maturities.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Revenue Recognition</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company enters into collaboration agreements which are within
 the scope of IFRS 15&#x2014;Revenue from Contracts with Customers
 (&#x201C;IFRS 15&#x201D;), under which the Company licenses rights to
 certain of the Company&#x2019;s product candidates and performs
 research and development services. The terms of these arrangements
 typically include payment of one or more of the following:
 <font style="WHITE-SPACE: nowrap">non-refundable,</font> upfront
 fees; reimbursement of research and development costs; development,
 regulatory, and commercial milestone payments; and royalties on net
 sales of licensed products.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 IFRS 15 requires an entity to recognize the amount of revenue to
 which it expects to be entitled for the transfer of promised goods
 or services to customers. Under IFRS 15, the Company recognizes
 revenue when its customer obtains control of the goods or services,
 in an amount that reflects the consideration that the Company
 determines it expects to receive in exchange for those goods or
 services. To determine revenue recognition for arrangements that
 the Company determines are within the scope of IFRS 15, the Company
 performs the following five steps: (i)&#xA0;identify the
 contract(s) with a customer; (ii)&#xA0;identify the performance
 obligations in the contract; (iii)&#xA0;determine the transaction
 price; (iv)&#xA0;allocate the transaction price to the performance
 obligations in the contract; and (v)&#xA0;recognize revenue when
 (or as) the entity satisfies the performance obligation. The
 Company applies the five-step model to contracts only when it is
 probable that it will collect the consideration to which it is
 entitled in exchange for the goods or services it transfers to the
 customer. As part of the accounting for these arrangements, the
 Company must make significant judgments, including identifying
 performance obligations in the contract, estimating the amount of
 variable consideration to include in the transaction price and
 allocating the transaction price to each performance
 obligation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company currently generates a portion of its revenue through
 collaboration and license agreements with strategic collaborators
 for the development and commercialization of product candidates.
 The collaboration and license agreements are within the scope of
 IFRS 15.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i><font style="WHITE-SPACE: nowrap">Up-front</font> License
 Payments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 If the license to the Company&#x2019;s intellectual property is
 determined to be distinct from the other performance obligations
 identified in the agreement, the Company recognizes revenues from
 <font style="WHITE-SPACE: nowrap">non-refundable,</font>
 <font style="WHITE-SPACE: nowrap">up-front</font> fees allocated to
 the license when the license is transferred to the customer and the
 customer is able to use and benefit from the license. If not
 distinct, the license is combined with other performance
 obligations in the contract. For licenses that are combined with
 other performance obligations, the Company assesses the nature of
 the combined performance obligation to determine whether the
 combined performance obligation is satisfied over time or at a
 point in time and, if over time, the appropriate method of
 measuring progress for purpose of recognizing revenue. The Company
 evaluates the measure of progress each reporting period and, if
 necessary, adjusts the measure of performance and related revenue
 recognition.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Pursuant to the Company&#x2019;s research and license agreements
 with its collaborators, the Company has received upfront license
 payments relating to the integrated packages of deliverables under
 the contracts. Each contract contains either one single performance
 obligation or multiple performance obligations that the
 <font style="WHITE-SPACE: nowrap">up-front</font> consideration was
 allocated to. These upfront license payments are initially recorded
 in deferred revenue on the consolidated statements of financial
 position and are recognized as revenue on either: (i)&#xA0;a
 straight-line basis over the period of the related performance
 obligation or the contractual term of the arrangement; or
 (ii)&#xA0;based on another appropriate depiction of the
 Company&#x2019;s performance over the period of the related
 performance obligation or the contractual term, such as costs
 incurred relating to full-time equivalent research employees. The
 applicable period over which to recognize the upfront payment is a
 significant judgment, which is <font style="WHITE-SPACE: nowrap">re-assessed</font> at each reporting
 date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Collaboration Income</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Collaboration income, which is typically related to reimbursements
 from collaborators for the Company&#x2019;s performance of research
 and development services under the respective agreements, is
 recognized on the basis of labor hours valued at a contractually
 agreed rate. Collaboration income includes reimbursements for
 related <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">out-of-pocket</font></font> expenses. Cost
 reimbursements to which the Company is entitled under agreements
 are recognized as revenue in the same period as the cost for which
 they are intended to compensate. The Company acts as the principal
 and therefore records these reimbursements as collaboration
 income.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In determining the appropriate amount of revenue to be recognized
 as the Company fulfills its obligations under the agreements, the
 Company performs the five steps listed above. As part of the
 accounting for the arrangement, the Company must develop
 assumptions that require judgment to determine the stand-alone
 selling price for each performance obligation identified in the
 contract. The Company uses key assumptions to determine the
 stand-alone selling price, which may include market conditions,
 reimbursement rates for personnel costs, development timelines and
 probabilities of regulatory success.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company capitalizes the incremental costs of obtaining a
 contract with a customer if it expects to recover those costs. Such
 incremental costs would not have been incurred if the contract with
 a customer had not been obtained. To date, the Company has not
 capitalized any incremental costs for obtaining a contract.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s contracts often include development and
 regulatory milestone payments which are assessed under the most
 likely amount method and constrained if it is probable that a
 significant revenue reversal would occur. Milestone payments that
 are not within the Company&#x2019;s control or the licensee&#x2019;s
 control, such as regulatory approvals, are not considered probable
 of being achieved until those approvals are received. At each
 reporting date, the Company <font style="WHITE-SPACE: nowrap">re-evaluates</font> the probability of
 achievement of development milestones and any related constraint,
 and if necessary, adjusts the overall transaction price. Any such
 adjustments are recorded on a cumulative <font style="WHITE-SPACE: nowrap">catch-up</font> basis, which would affect
 collaboration revenues in the period of adjustment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For agreements that include sales-based royalties, including
 milestone payments based on the level of sales, and the license is
 deemed to be the predominant item to which the royalties relate,
 the Company recognizes revenue at the later of (i)&#xA0;when the
 related sales occur, or (ii)&#xA0;when the performance obligation
 to which some or all of the royalty has been allocated has been
 satisfied (or partially satisfied). To date, the Company has not
 recognized any consideration related to sales-based royalty revenue
 resulting from any of the Company&#x2019;s collaboration
 agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Government Grants</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company receives certain government and regional grants, which
 support its research efforts in defined projects, and include
 contributions towards the cost of research and development. When
 there is reasonable assurance that the Company will comply with the
 conditions attached to a received grant, and when there is
 reasonable assurance that the grant will be received, government
 grants are recognized as revenue on a gross basis in the
 consolidated statement of profit or loss and comprehensive loss on
 a systematic basis over the periods in which the Company recognizes
 expenses for the related costs for which the grants are intended to
 compensate. In the case of grants related to assets, the received
 grant will be deducted from the carrying amount of the asset.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Reclassifications</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Certain amounts were reclassified in the prior period condensed
 consolidated interim financial statements to conform to the current
 period presentation.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618592928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued International Financial Reporting Standards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory', window );">Recently Issued International Financial Reporting Standards</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>3.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Recently Issued International Financial Reporting
 Standards</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Except as otherwise indicated, the accounting policies adopted in
 the preparation of these interim financial statements are
 consistent with those applied in the preparation of the
 Company&#x2019;s annual financial statements for the year ended
 December&#xA0;31, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Standards implemented since December&#xA0;31, 2017</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b><i>Revenue from Contracts with Customers&#x2014;IFRS
 15</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In May 2014, the IASB issued IFRS 15, which supersedes existing
 revenue recognition guidance. Prior to the adoption of IFRS 15,
 revenue was recognized to the extent that it was probable that the
 economic benefits would flow to the Company and the revenue could
 be reliably measured. The new standard requires an entity to
 recognize the amount of revenue to which it expects to be entitled
 for the transfer of promised goods or services to customers. To
 achieve that core principle, an entity must identify the
 contract(s) with a customer, identify the performance obligations
 in the contract, determine the transaction price, allocate the
 transaction price to the performance obligations in the contract,
 and recognize revenue when (or as) the entity satisfies the
 performance obligation. IFRS 15 is effective for annual and interim
 reporting periods beginning on or after January&#xA0;1, 2018 and
 should be applied retrospectively to each prior reporting period
 presented or retrospectively with the cumulative effect of
 initially applying this update recognized at the date of initial
 application.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The adoption of IFRS 15 impacts the amortization of the
 Company&#x2019;s <font style="WHITE-SPACE: nowrap">up-front</font>
 license payments. The Company previously recognized revenue from
 <font style="WHITE-SPACE: nowrap">up-front</font> license payments
 on a straight-line basis over the contractual term or the period of
 continuing involvement which was previously estimated to be 21
 years for the collaboration and license agreement the Company
 entered into with Incyte Corporation (&#x201C;Incyte&#x201D;) on
 December&#xA0;20, 2016 (the &#x201C;Incyte collaboration and license
 agreement&#x201D;), and 4.5 years for the research and license
 agreement the Company entered into with ONO Pharmaceutical Co.,
 Ltd. (&#x201C;ONO&#x201D;) on April&#xA0;8, 2014 (the &#x201C;ONO
 research and license agreement&#x201D;). In applying IFRS 15, the
 Company has evaluated the distinct performance obligations in each
 agreement. Specifically, for Incyte, the total period for which the
 Company expects to provide access to its proprietary technology is
 currently estimated to be nine years, which is the research term
 initially agreed to in the Incyte collaboration and license
 agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company adopted the new standard effective January&#xA0;1,
 2018, using the retrospective method, with the effect of initially
 applying this standard recognized at the beginning of the earliest
 period presented. The Company had two open contracts on the
 adoption date and has assessed these contracts under the new
 revenue standard. In addition, the Company elected to apply the
 practical expedient to not apply this guidance to contracts that
 were completed before the beginning of the earliest period
 presented, or January&#xA0;1, 2016, and the practical expedients
 for contract modifications (assessing the contracts in combination
 with any modifications before January&#xA0;1, 2017). Under the
 practical expedient, the Company excluded certain option and
 exclusivity agreements that expired in 2015 and 2014, respectively.
 As a result of the adoption of IFRS 15, prior year financial
 statements have been restated. The Company has accounted for the
 impact of adopting IFRS 15 as a cumulative <font style="WHITE-SPACE: nowrap">catch-up</font> as a decrease of
 approximately &#x20AC;8.7&#xA0;million to deferred revenue with an
 offset to accumulated deficit, effective January&#xA0;1, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following financial statement line items have been shown to
 reflect the adjustments recognized for each individual line item in
 the Company&#x2019;s respective consolidated statements for the
 period noted:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Condensed Consolidated Statement of Profit or Loss and
 Comprehensive Loss</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three&#xA0;months<br />
 ended<br />
 June&#xA0;30, 2017<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS&#xA0;15</b><br />
 <b>Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three&#xA0;months<br />
 ended<br />
 June&#xA0;30, 2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">(euros in
 thousands)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,027</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,237</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Operating result</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,162</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,952</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total comprehensive loss for the period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(21,798</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,588</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic (and diluted) loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.12</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.11</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.01</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Six&#xA0;months&#xA0;ended<br />
 June&#xA0;30, 2017<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS&#xA0;15</b><br />
 <b>Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Six&#xA0;months&#xA0;ended<br />
 June&#xA0;30, 2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">(euros in
 thousands)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,313</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,808</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,121</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Operating result</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(20,928</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,808</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,120</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total comprehensive loss for the period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,114</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,808</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(39,306</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic (and diluted) loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2.27</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.20</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2.07</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Condensed Consolidated Statement of Financial Position</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,</b><br />
 <b>2017</b><br />
 <b>As originally<br />
 presented</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,</b><br />
 <b>2017</b><br />
 <b>Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">(euros in
 thousands)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(167,480</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,705</td>
 <td valign="bottom" nowrap="nowrap"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(158,775</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue, <font style="WHITE-SPACE: nowrap">non-current</font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">130,195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,644</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">112,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,996</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,939</td>
 <td valign="bottom" nowrap="nowrap"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Condensed Consolidated Statement of Cash Flows</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2017</b><br />
 <b>As originally<br />
 presented</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2017</b><br />
 <b>Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">(euros in
 thousands)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Result after taxation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,132</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,808</td>
 <td valign="bottom" nowrap="nowrap"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(39,324</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Changes in working capital:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,091</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,808</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,899</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Financial Instruments&#x2014;IFRS 9</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 IFRS <font style="WHITE-SPACE: nowrap">9-</font> Financial
 Instruments (&#x201C;IFRS 9&#x201D;) replaces the provisions of IAS
 39 that relate to the recognition, classification and measurement
 of financial assets and financial liabilities, derecognition of
 financial instruments, impairment of financial assets and hedge
 accounting. IFRS 9 also significantly amends other standards
 dealing with financial instruments such as IFRS 7 <i>Financial
 Instruments: Disclosures</i>. The Company assessed the
 classification and measurement of the financial instruments it held
 at the date of initial application of IFRS 9, or January&#xA0;1,
 2018, and has classified its financial instruments into the
 appropriate IFRS 9 categories. There were no changes to the
 carrying value of the Company&#x2019;s financial instruments
 resulting from this reclassification and accordingly there was no
 impact to the Company&#x2019;s opening accumulated deficit at
 January&#xA0;1, 2018, as a result of the adoption of
 IFRS&#xA0;9.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Standard issued but not yet effective</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The IASB has issued a new standard on leases that will require
 lessees to recognize most leases on their balance sheets as lease
 liabilities with a <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">corresponding&#xA0;right-of-use&#xA0;asset.</font></font>
 The IASB has set an effective date to apply the new standard for
 periods beginning on or after January&#xA0;1, 2019. The Company is
 assessing all effective agreements to determine whether there are
 embedded leases included under the definition in IFRS 16. Early
 adoption is permitted; however, the Company expects to adopt this
 standard in the first quarter of 2019. The Company is evaluating
 the impact that this guidance will have on the Company&#x2019;s
 financial statements, including related disclosures, and expects
 the new standard to impact its internal controls, systems, and
 processes.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for changes in accounting policies, accounting estimates and errors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Section Accounting policies<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=8&amp;date=2018-03-01&amp;anchor=sect_Accountingpolicies&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6715320496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Use of Estimates, Judgments and Assumptions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Use of Estimates, Judgments and Assumptions</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>4.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Use of Estimates, Judgments and Assumptions</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In the application of the Company&#x2019;s accounting policies,
 management is required to make judgments, estimates and assumptions
 that affect the reported amounts of assets, liabilities, income and
 expenses that are not readily apparent from other sources. The
 estimates and associated assumptions are based on historical
 experience and other factors that are considered to be relevant.
 Actual results may differ from these estimates.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Estimates and underlying assumptions are reviewed on an ongoing
 basis. Revisions to accounting estimates are recognized
 prospectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following are the critical judgments and assumptions that
 management has made in the process of applying the Company&#x2019;s
 accounting policies and that have the most significant effect on
 the amounts recognized in the interim financial statements.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Equity settled share-based payments</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Share options granted to employees, consultants and directors are
 measured at the grant date fair value of the equity instruments
 granted. The grant date fair value is determined through the use of
 an option-pricing model considering the following variables:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(a)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the exercise price of the option;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(b)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the expected life of the option;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(c)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the current value of the underlying shares;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(d)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the expected volatility of the share price;</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(e)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the dividends expected on the shares; and</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="4%">&#xA0;</td>
 <td valign="top" width="4%" align="left">(f)</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left">the risk-free interest rate for the life of the
 option.</p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The estimated fair value of each share option granted was
 determined utilizing the Hull&#xA0;&amp; White option pricing
 model, which considers the terms and conditions attached to the
 grants made and is reflective of expected exercise behavior.
 Because the Company&#x2019;s shares have been publicly traded for a
 relatively short amount of time, the expected volatility was set by
 also giving weight to the historic share price volatility of a set
 of peer companies. The continuous yield on U.S. Treasury Bills with
 a term to maturity comparable to the expected life of the options,
 as published by the U.S. Department of Treasury, was applied.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The result of the share option valuations and the related
 compensation expense that is recognized for the respective vesting
 periods during which services are received are dependent on the
 model and input parameters used. Even though management considers
 the fair values reasonable and defensible based on the
 methodologies applied and the information available, others might
 derive a different fair value for the Company&#x2019;s share
 options. These assumptions and estimates are further discussed in
 Note 9 to the financial statements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Capitalization of development costs</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The criteria for capitalization of development costs have been
 considered by management and determined not to have been met in the
 second quarter of 2018. Therefore, all development expenditures
 relating to internally generated intangible assets in 2018 were
 expensed as incurred.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Income taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 As of June&#xA0;30, 2018, deferred tax assets have not been
 recognized in respect of tax losses as the Company has no history
 of generating taxable profits. Therefore, at the balance sheet
 date, there is no convincing evidence that sufficient taxable
 profit will be available against which the tax losses can be
 utilized.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Merus US, Inc., which is incorporated in the United States in the
 State of Delaware, is subject to statutory U.S. Federal corporate
 income taxes and state income taxes for Massachusetts. Current year
 income tax expense was attributable entirely to Merus US, Inc.
 which provides general management services and strategic advisory
 services to the Company. Corporate income tax expenses were
 &#x20AC;0.1&#xA0;million for the three- and <font style="WHITE-SPACE: nowrap">six-month</font> periods ended June&#xA0;30,
 2018, as compared to &#x20AC;0.1&#xA0;million for the three- and
 <font style="WHITE-SPACE: nowrap">six-month</font> periods ended
 June&#xA0;30, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Deferred revenue</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Pursuant to the Company&#x2019;s research, collaboration and license
 agreements with ONO, Incyte, and Jiangsu Simcere Pharmaceutical Co.
 Ltd. (&#x201C;Simcere&#x201D;), the Company has received <font style="WHITE-SPACE: nowrap">upfront&#xA0;non-refundable&#xA0;payments</font>
 for certain rights granted under the respective agreements. The
 applicable period over which to recognize these upfront payments
 requires significant judgment and was impacted by the adoption of
 IFRS 15 (See Note 3 and Note 8).</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Revenue related to ONO upfront payments is deferred and amortized
 based on a measure of progress in delivering research services
 under the contract. Revenue related to Incyte and Simcere upfront
 payments is deferred and amortized on a straight-line basis over
 the estimated research term (See Note 3 and Note 8).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Research and development expenses</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Research and development expenses represent costs that primarily
 include: (i)&#xA0;payroll and related costs (including share-based
 payment expenses) associated with research and development
 personnel; (ii)&#xA0;costs related to clinical trials and
 preclinical testing of the Company&#x2019;s technologies under
 development; (iii)&#xA0;costs to develop product candidates,
 including raw materials and supplies, product testing,
 depreciation, and facility related expenses; (iv)&#xA0;expenses for
 research services provided by universities and contract
 laboratories; and (v)&#xA0;other research and development expenses.
 Research and development expenses are recognized in the
 consolidated statement of profit or loss and comprehensive loss as
 incurred when these expenditures relate to the Company&#x2019;s
 research and development services and have no alternative future
 uses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company has entered into various research and development
 contracts with research institutions and other companies. These
 agreements are generally cancelable. The Company records accruals
 for estimated ongoing research costs. When evaluating the adequacy
 of the accrued liabilities, the Company analyzes progress of the
 studies, including the phase or completion of events, invoices
 received and contracted costs. Significant judgments and estimates
 may be made in determining the accrued balances at the end of any
 reporting period. Actual results could differ from the
 Company&#x2019;s estimates. The Company&#x2019;s historical accrual
 estimates have not been materially different from the actual
 costs.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6604985264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory', window );">Investments</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>5.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Investments</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On January&#xA0;1, 2018, the Company adopted IFRS 9 and classifies
 and accounts for its investments at amortized cost. The
 Company&#x2019;s investments as of December&#xA0;31, 2017, were
 classified and accounted for as <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">held-to-maturity</font></font> under IAS 39.
 The initial adoption of IFRS 9 had no impact on previously reported
 amounts (See Note 3). IFRS 9 replaces the &#x2018;incurred
 loss&#x2019; model in IAS 39 with an &#x2018;expected credit
 loss&#x2019; (&#x201C;ECL&#x201D;) model. The new impairment model
 applies to financial assets measured at amortized cost, contract
 assets and debt investments at fair value through other
 comprehensive loss, but not to investments in equity instruments.
 Under IFRS&#xA0;9, credit losses are recognized earlier than under
 IAS 39. Under IFRS 9, loss allowances are measured on either
 <font style="WHITE-SPACE: nowrap">12-month</font> ECLs which result
 from possible default events within the 12 months after the
 reporting date or lifetime ECLs which result from all possible
 default events over the expected life of a financial
 instrument.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s financial assets recorded at amortized cost
 consist of cash and cash equivalents, investments and trade and
 other receivables. These financial assets are considered to have a
 low credit risk and, as such, there was no impact to the
 Company&#x2019;s opening accumulated deficit as a result of the
 change in impairment methodology.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s investments include investments in commercial
 paper, securities issued by several public corporations and the
 United States Treasury. Current investments include investments
 with a maturity date of greater than three months at the date of
 settlement. Investments with a maturity of 12 months or more from
 the original investment date are classified <font style="WHITE-SPACE: nowrap">as&#xA0;non-current.</font></p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Investments as of June&#xA0;30, 2018, and December&#xA0;31, 2017,
 consist of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Balance as per</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>(euros in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,715</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,527</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. Treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,177</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate fixed income bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,289</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,886</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Agency bond</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,499</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,453</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Investments, current portion</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">37,077</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,043</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate fixed income bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,060</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-current</font>
 investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,060</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53,727</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 During the <font style="WHITE-SPACE: nowrap">six-month</font>
 period ended June&#xA0;30, 2018, the Company purchased investments
 totaling &#x20AC;29.6&#xA0;million, which are held and denominated
 in U.S. dollars, and received proceeds of &#x20AC;18.9&#xA0;million
 relating to investment maturities. As a result of the fluctuation
 in foreign currency between the euro and U.S. dollar, the Company
 recorded foreign currency exchange gains of approximately
 &#x20AC;3.1&#xA0;million and &#x20AC;1.9&#xA0;million as a component
 of finance income / (expense) for the three- and <font style="WHITE-SPACE: nowrap">six-month</font> periods ended June&#xA0;30,
 2018, respectively.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments other than investments accounted for using the equity method. [Refer: Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6721703568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Receivables<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Trade and Other Receivables</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>6.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Trade and Other Receivables</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Trade and other receivables are short-term and due within 1
 year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Balance as per</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>(euros in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,069</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 VAT receivable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">622</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">582</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,640</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">427</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid pension costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">359</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">838</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest bank</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">275</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">66</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,413</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Trade and unbilled receivables relate primarily to invoicing for
 cost reimbursements relating to the Incyte collaboration and
 license agreement and the ONO research and license agreement. VAT
 receivable relates to value added tax receivable from the Dutch tax
 authorities based on the tax application for the second quarter of
 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Prepaid expenses reflected above in the form of prepaid expenses
 and prepaid pension costs consist of expenses that were paid during
 the reporting period but are related to activities taking place in
 subsequent periods. The increase in prepaid expenses at
 June&#xA0;30, 2018 relate primarily to advanced payments made to
 contract research and contract manufacturing organizations in
 support of the Company&#x2019;s upcoming clinical trial
 activities.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6604985264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities and Accruals<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory', window );">Other Liabilities and Accruals</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>7.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Other Liabilities and Accruals</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 All amounts are short-term and payable within 1 year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Balance per</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>(euros in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accrued auditor&#x2019;s fee</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 R&amp;D costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,777</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,272</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IP &#x2013; Legal fee</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">509</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Bonuses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">940</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Subsidy advance received</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">465</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">535</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,627</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The research and development costs relate to accrued expenses for
 costs of certain development activities, such as clinical trials,
 and are recorded based on an evaluation of the progress to
 completion of specific tasks using data such as patient enrollment,
 clinical site activations, and information provided the Company by
 vendors on their actual costs incurred. The increase in research
 and development costs accrued expenses reflect the timing of
 enrollment in and support of the Company&#x2019;s clinical trials,
 manufacturing of drug candidates used for clinical <font style="WHITE-SPACE: nowrap">purposes,&#xA0;pre-clinical&#xA0;research</font>
 efforts to support the Company&#x2019;s internal research programs
 and the Incyte collaboration and license agreements and other
 collaboration agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The bonuses relate to the employee bonuses for the financial year
 2018, which will be paid out in February 2019. The decrease in
 bonuses accrual compared to December&#xA0;31, 2017, related to the
 annual payment of the 2017 bonuses in the first quarter of
 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The subsidy advances received relate to active grants where the
 Company has received cash in excess of allowances which is required
 to be repaid or recognized as grant income when the relevant
 reimbursable costs are incurred as services are performed.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6721680608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDeferredIncomeExplanatory', window );">Deferred Revenue</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>8.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Deferred Revenue</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Deferred revenue as of June&#xA0;30, 2018, and December&#xA0;31,
 2017, consist of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Balance per</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017&#xA0;Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue &#x2013; current portion</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,972</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">105,718</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">112,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="2%" align="left">*</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><i>See Note 3 for details regarding the restatement as
 a result of a change in accounting policy.</i></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Of the total deferred revenue balance at June&#xA0;30, 2018,
 &#x20AC;120.6&#xA0;million related to the Incyte collaboration and
 license agreement and a share subscription agreement entered into
 by the Company with Incyte on December&#xA0;20, 2016 (together, the
 &#x201C;Incyte Agreements&#x201D;), &#x20AC;2.0 million&#xA0;related
 to the collaboration and license agreement entered into by the
 Company with Simcere on January&#xA0;8, 2018 (the &#x201C;Simcere
 collaboration and license agreement&#x201D;), and
 &#x20AC;0.1&#xA0;million related to the ONO research and license
 agreement. The total deferred revenue balance at December&#xA0;31,
 2017, related solely to the Incyte Agreements.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Under the Incyte collaboration and license agreement, Incyte agreed
 to pay the Company a <font style="WHITE-SPACE: nowrap">$120&#xA0;million&#xA0;non-refundable&#xA0;upfront</font>
 payment, and under the share subscription agreement, Incyte agreed
 to purchase 3.2&#xA0;million Common Shares at a price per share of
 $25.00, for an aggregate purchase price of $80&#xA0;million. In
 January 2017, the Company completed the sale of its Common Shares
 under the share subscription agreement and received the
 $80&#xA0;million aggregate purchase price. In February 2017, the
 Company received the $120&#xA0;million <font style="WHITE-SPACE: nowrap">non-refundable</font> upfront payment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As the contract for the share subscription agreement was
 denominated in U.S. dollars, the Company determined that the
 forward contract to sell its own shares at a future date to which
 the Company became committed on December&#xA0;20, 2016, represented
 a derivative financial instrument. The fair values of the
 derivative, or &#x20AC;31.4&#xA0;million, and the <font style="WHITE-SPACE: nowrap">non-refundable</font> upfront payment, or
 &#x20AC;112.0&#xA0;million, were recorded as deferred revenue. The
 Company identified a single performance obligation, providing
 access to its proprietary technology, relating to the Incyte
 Agreements and allocated all of the consideration received to this
 obligation. Both the upfront license payment and the derivative
 financial asset are being amortized as revenue over time by
 measuring the progress toward the complete satisfaction of a
 performance obligation or specifically, the total period for which
 the Company expects to provide access to its proprietary technology
 under the Incyte Agreements, which is currently estimated to be
 nine years in total, of which approximately 7.5 years remain.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Under the Simcere collaboration and license agreement, the Company
 agreed to grant Simcere an exclusive license to develop and
 commercialize in China three bispecific antibodies utilizing the
 Company&#x2019;s Biclonics<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;technology
 platform in the area of immuno-oncology. The Company will retain
 all rights outside of China. As part of the agreement, the Company
 has agreed to lead research and discovery activities while Simcere
 has agreed to be responsible for the Investigational New Drug
 enabling studies, clinical development, regulatory filings and
 commercialization of these product candidates in China. The Company
 received an upfront, <font style="WHITE-SPACE: nowrap">non-refundable</font> payment of
 $2.75&#xA0;million, or &#x20AC;2.3&#xA0;million, relating to three
 separate research programs. Each research program was determined to
 be a separate performance obligation and consideration was
 allocated to each separate obligation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company will amortize the upfront payment to revenue over time
 based on the estimated duration of each research program. As of
 June&#xA0;30, 2018, the first research program had commenced. For
 the three- and <font style="WHITE-SPACE: nowrap">six-month</font>
 periods ended June&#xA0;30, 2018, the Company recognized revenue of
 &#x20AC;0.3&#xA0;million relating to this program for both
 amortization of upfront payments and the achievements of
 milestones. The remaining two research programs had not commenced
 as of June&#xA0;30,&#xA0;2018. Accordingly, no revenue has been
 recognized related to the remaining two research programs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 On March&#xA0;14, 2018, the Company entered into a second contract
 research and license agreement with ONO (the &#x201C;second ONO
 research and license agreement&#x201D;). Pursuant to an exclusive
 option granted to ONO in the ONO research and license agreement,
 ONO exercised its option to enter into the second ONO research and
 license agreement. The Company granted ONO an exclusive, worldwide,
 royalty-bearing license, with the right to sublicense, research,
 test, make, use and market bispecific antibody candidates based on
 the Company&#x2019;s Biclonics<b><sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup></b> technology
 platform against two undisclosed targets directed to a particular
 undisclosed target combination.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Under the terms of the agreement, ONO identifies and selects the
 licensed bispecific antibodies for which it is responsible for
 conducting <font style="WHITE-SPACE: nowrap">further&#xA0;non-clinical&#xA0;and</font>
 clinical development activities for such licensed bispecific
 antibodies and pharmaceutical products containing such antibodies,
 including manufacture and process development. Additionally, ONO
 controls and has exclusive rights over the worldwide
 commercialization of any approved products, including worldwide
 supply, and is solely responsible for all costs and expenses
 related to commercialization. ONO has also agreed to fund the
 Company&#x2019;s research and development activities and be
 responsible for the payment of all costs and expenses for its own
 research and development activities, which are set out in a
 mutually agreed upon research plan. The Company retains all rights
 to use and commercialize any antibodies that are generated under
 the collaborative research program, excluding the up to five lead
 and/or selected antibodies against the targets ONO is pursuing,
 provided that the use and commercialization is not with respect to
 the particular target combination.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 ONO agreed to pay the Company an <font style="WHITE-SPACE: nowrap">upfront&#xA0;non-refundable&#xA0;payment</font>
 of &#x20AC;0.7&#xA0;million, &#x20AC;0.3&#xA0;million intended to
 compensate the Company for research services already completed upon
 entering into the agreement, and &#x20AC;0.2&#xA0;million to be paid
 to the Company over time for full time equivalent funding. The
 Company identified a single performance obligation of providing
 research services to ONO and recognized as revenue approximately
 &#x20AC;0.1&#xA0;million and &#x20AC;1.1&#xA0;million during the
 three and six months ended June&#xA0;30, 2018, respectively.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDeferredIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred income. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDeferredIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6613885088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Shareholders' Equity</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>9.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Shareholders&#x2019; Equity</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Private Placement of Common Shares</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On February&#xA0;13, 2018, the Company entered into the Purchase
 Agreement. Pursuant to the Purchase Agreement, the Company agreed
 to sell an aggregate of 3,099,997 of its Common Shares to the
 Investors for aggregate gross proceeds of approximately
 $55.8&#xA0;million, at a purchase price equal to $18.00 per share.
 The Purchase Agreement contains customary representations and
 warranties from the Company and the Investors and customary closing
 conditions. On February&#xA0;15, 2018, the Company completed the
 sale under the Private Placement and received gross proceeds of
 approximately $55.8&#xA0;million, or &#x20AC;44.8&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Share Subscription Agreement with Incyte</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Concurrent with the Incyte collaboration and license agreement
 discussed above under Note 8, the Company entered into a share
 subscription agreement with Incyte on December&#xA0;20, 2016. On
 January&#xA0;23, 2017, under the terms of the share subscription
 agreement, the Company issued 3,200,000 of its Common Shares to
 Incyte at the agreed price per share of $25.00, for an aggregate
 purchase price of $80.0&#xA0;million or &#x20AC;74.7&#xA0;million.
 During the six months ended June&#xA0;30, 2017, the Company
 received proceeds, net of issuance costs, of
 &#x20AC;74.4&#xA0;million. A &#x20AC;1.1&#xA0;million discount on the
 subscription share price, combined with a &#x20AC;0.4&#xA0;million
 foreign currency translation accompanying the issuance of these
 shares, increased share capital by &#x20AC;0.3&#xA0;million and
 share premium by &#x20AC;73.4&#xA0;million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Issued and <font style="WHITE-SPACE: nowrap">paid-in</font>
 share capital</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 All issued shares have been fully paid in cash.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Common shares</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 For the <font style="WHITE-SPACE: nowrap">six-month</font> period
 ended June&#xA0;30, 2018, 34,041 options were exercised at a
 weighted average exercise price of &#x20AC;1.93 per share. As a
 result, 34,041 Common Shares were issued, share capital increased
 by &#x20AC;3,064 and share premium increased by &#x20AC;62,635.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For the <font style="WHITE-SPACE: nowrap">six-month</font> period
 ended&#xA0;June 30, 2017, 110,869 options were exercised with a
 weighted average exercise price of &#x20AC;2.05&#xA0;per share. As a
 result, 110,869 Common Shares were issued, share capital increased
 by &#x20AC;9,978 and share premium increased by &#x20AC;216,830.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 At June&#xA0;30, 2018, a total of 22,632,800 Common Shares were
 issued and paid up. At June&#xA0;30, 2017, a total of 19,396,720
 Common Shares were issued and paid up.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Share Premium Reserve</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The share premium reserve relates to amounts contributed by
 shareholders at the issue of shares in excess of the nominal value
 of the shares issued.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 All share premium can be considered as free share premium as
 referred to in the Netherlands Income Tax Act.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b><i>Share-based Payment Arrangements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Share-based payment expenses included in personnel expenses were
 &#x20AC;4.6&#xA0;million and &#x20AC;7.9&#xA0;million in the
 <font style="WHITE-SPACE: nowrap">six-month</font> periods ended
 June&#xA0;30, 2018, and June&#xA0;30, 2017, respectively. For
 details on the related share-based payment expenses recognized as
 employee benefit expenses, see Note 12.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In June 2016, the Company established the 2016 Incentive Award Plan
 (the &#x201C;2016 Plan&#x201D;). Options granted under the 2016 Plan
 are exercisable once vested. The options granted under the 2016
 Plan vest in installments over a four-year period from the grant
 date. Twenty-five percent of the options vest on the first
 anniversary of the vesting commencement date, and the remaining 75%
 of the options vest in 36 monthly installments for each full month
 of continuous service provided by the option holder thereafter,
 such that 100% of the options shall become vested on the fourth
 anniversary of the vesting commencement date. Options will lapse on
 the tenth anniversary of the date of grant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Restricted Stock Units (&#x201C;RSUs&#x201D;) granted under the
 2016 Plan also vest in installments over a four-year period from
 the grant date. Each RSU represents the right to receive one Common
 Share.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As stated in the 2016 Plan, the Company has established the
 <font style="WHITE-SPACE: nowrap">Non-Executive</font> Director
 Compensation Program whereas <font style="WHITE-SPACE: nowrap">Non-Executive</font> Directors are entitled
 to cash compensation as well as equity compensation. The equity
 compensation consists of an initial option grant as well as annual
 awards. The initial awards granted under the <font style="WHITE-SPACE: nowrap">Non-Executive</font> Director Compensation
 Program vest in installments over a three-year period. Thirty-three
 percent of the options vest on the first anniversary of the vesting
 commencement date, and the remaining 67% of the options in 24
 substantially equal monthly installments thereafter, such that the
 award shall be fully vested on the third anniversary of the vesting
 commencement date. Each subsequent award shall vest and become
 exercisable in 12 substantially equal monthly installments
 following the vesting commencement date, such that the subsequent
 award shall be fully vested on the first anniversary of the date of
 grant.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Share-based payment expenses are recognized for each subsequent
 award that a <font style="WHITE-SPACE: nowrap">Non-Executive</font>
 Director is entitled to over their remaining term. Since subsequent
 awards are not subject to shareholder approval, the grant date is
 established and expenses are based on grant date fair value. The
 grant date fair value is not updated in each future reporting
 period and therefore the estimated fair value is not revised and
 expense recognized is based on the actual grant date fair value of
 the awards granted.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 During the six months ended June&#xA0;30, 2018, the Company granted
 options to purchase 469,068 Common Shares with a grant date fair
 value of &#x20AC;4.4&#xA0;million to employees under the 2016
 Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Pursuant to the &#x201C;evergreen&#x201D; provisions of the 2016
 Plan, the number of Common Shares authorized for issuance under the
 plan automatically increased by 777,194 Common Shares to 1,090,368
 Common Shares effective January&#xA0;1, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Measurement of fair values of the equity-settled share-based
 payment arrangements</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The fair value of the employee share options has been measured
 using a binomial option pricing model, including members of the
 Board of Directors. Service and <font style="WHITE-SPACE: nowrap">non-market</font> performance conditions
 attached to the transactions were not taken into account in
 measuring fair value. Key management personnel include the
 Company&#x2019;s executive management and the Board of
 Directors.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The inputs used in the measurement of the fair values and the
 related fair values at the grant dates were as follows for the
 options granted during the <font style="WHITE-SPACE: nowrap">six-month</font> period ended June&#xA0;30,
 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>Key&#xA0;Management<br />
 Personnel<br />
 (&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>All&#xA0;Other&#xA0;Personnel<br />
 (&#x20AC;)</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value at grant date</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">9.34-9.45</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">9.30-10.37</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Share price at grant date</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">14.57-14.87</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">14.57-18.24</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise price</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">14.57-14.87</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">14.57-18.24</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility (weighted-average)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>95.1%</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><b>94.6%</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contractual life</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>10 years</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><b>10 years</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividends</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>0%</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><b>0%</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate (based on government bonds)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b><font style="WHITE-SPACE: nowrap">2.79%-2.94%</font></b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><b><font style="WHITE-SPACE: nowrap">2.84%-2.94%</font></b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Reconciliation of outstanding share options</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The number of share options and the weighted average exercise
 prices of share options granted were as follows for the
 <font style="WHITE-SPACE: nowrap">six-month</font> period ended
 June&#xA0;30, 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br />
 exercise price<br />
 (&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br />
 options</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>13.99</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,213,985</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>19.67</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(12,044</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expired during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.02</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(5,146</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1.93</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(34,041</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.68</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>469,068</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.24</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,631,822</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercisable at June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>12.18</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,105,059</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The options outstanding at June&#xA0;30, 2018, had an exercise
 price in the range of &#x20AC;1.93 to &#x20AC;27.47 and a
 weighted-average remaining contractual life of 8.2 years. The
 weighted-average share price at the date of exercise for share
 options exercised during the six months ended June&#xA0;30, 2018
 was &#x20AC;17.12.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 There were 2,631,822 outstanding share options at June&#xA0;30,
 2018, with a weighted average exercise price of &#x20AC;14.24.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The number of options outstanding as of June&#xA0;30, 2018, was as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom"><b>Group of employees entitled</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Key management personnel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,153,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 All other employees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">478,012</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,631,822</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 During the six months ended June&#xA0;30, 2018, the Company did not
 grant any new RSUs. The number of RSUs outstanding is summarized as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br />
 grant price<br />
 (&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of<br />
 RSU&#x2019;s</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>194,546</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(76,245</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>118,301</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6603612960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>10.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Revenue</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Revenue is recognized at the amount to which the Company expects to
 be entitled for the transfer of promised goods or services to
 customers.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Disaggregation of Revenue</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s revenues are generated entirely in the
 Netherlands. In the following table, revenue is disaggregated by
 primary source of revenue as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="54%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">Three months
 ended</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">Six months
 ended</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30,<br />
 2017&#xA0;Restated*</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30<br />
 2017&#xA0;Restated*</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Upfront payment amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,250</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,973</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>9,087</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,898</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Collaboration income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,179</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,195</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,391</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue from contracts with customers</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>6,429</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,444</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>16,282</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,289</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Income from grants on research projects</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>114</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">793</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>182</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">832</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><b>6,543</b></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,237</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><b>16,464</b></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,121</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="2%" align="left"><i>*</i></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><i>See Note 3 for details regarding the restatement as
 a result of a change in accounting policy.</i></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For the three- and <font style="WHITE-SPACE: nowrap">six-month</font> periods ended June&#xA0;30,
 2018, the Company recognized amortization of
 &#x20AC;4.0&#xA0;million and &#x20AC;7.9&#xA0;million on upfront
 payments related to the Incyte collaboration and license agreement,
 respectively, amortization of &#x20AC;0.2&#xA0;million and
 &#x20AC;1.1&#xA0;million on upfront payments related to the ONO
 research and license agreement, respectively, and
 &#x20AC;0.1&#xA0;million and &#x20AC;0.1&#xA0;million on upfront
 payments related to the Simcere collaboration and license
 agreement, respectively. For the three- and <font style="WHITE-SPACE: nowrap">six-month</font> periods ended June&#xA0;30,
 2017, the Company recognized &#x20AC;4.0&#xA0;million and
 &#x20AC;6.9&#xA0;million of amortization of the upfront payment
 related to the Incyte collaboration and license agreement,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Collaboration income for the three and six months ended
 June&#xA0;30, 2018, was &#x20AC;2.2&#xA0;million and
 &#x20AC;7.2&#xA0;million, respectively, and consisted of cost
 reimbursements and research milestones achieved in support of the
 Company&#x2019;s research and license agreements with Incyte, ONO
 and Simcere. During the three and six months ended June&#xA0;30,
 2018, the Company recognized &#x20AC;2.0&#xA0;million and
 &#x20AC;4.3&#xA0;million of cost reimbursements in support of the
 Company&#x2019;s research and license agreements with Incyte,
 respectively, and &#x20AC;0.1&#xA0;million and
 &#x20AC;0.2&#xA0;million of cost reimbursements in support of the
 Company&#x2019;s research and license agreements with ONO,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company recognized an aggregate of &#x20AC;2.5&#xA0;million in
 research milestones under its ONO agreements for the six months
 ended June&#xA0;30, 2018 and &#x20AC;0.1&#xA0;million in research
 milestones under its Simcere agreements for the three and six
 months ended June&#xA0;30, 2018. During the three and six months
 ended June&#xA0;30, 2017, the Company recognized
 &#x20AC;1.5&#xA0;million and &#x20AC;2.4&#xA0;million of cost
 reimbursements in support of the Company&#x2019;s research and
 license agreements with Incyte and ONO, respectively.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The Company has been awarded grants consisting of cash allowances
 for specific research and development projects. The unconditional
 receipt of the grant allowances is dependent on the final review of
 the reporting provided by the Company at the end of the contract
 term. For the three and six months ended June&#xA0;30, 2018, the
 Company recognized &#x20AC;0.1&#xA0;million and
 &#x20AC;0.2&#xA0;million in grant income, respectively, compared to
 &#x20AC;0.8&#xA0;million in grant income for the three and six
 months ended June&#xA0;30, 2017. On June&#xA0;12, 2017, the
 European Commission approved for reimbursement the final
 installment of the <font style="WHITE-SPACE: nowrap">FP-7</font>
 grant for &#x20AC;0.7&#xA0;million. Revenue for this final
 installment was recorded in income from grants on research projects
 during the three and six months ended June&#xA0;30, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b><i>Contract Balances</i></b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 A trade receivable is recorded when the Company satisfies a
 performance obligation by transferring a promised good or service
 and has earned the unconditional right to consideration from its
 customer. Trade receivables relate to invoicing for cost
 reimbursements and research milestones achieved in support of the
 Company&#x2019;s research and license agreements with Incyte, ONO
 and Simcere. Payment terms relating to these receivables are 30
 days.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 A contract asset is recorded when the Company satisfies a
 performance obligation by transferring a promised good or service
 and has earned the right to consideration from its customer. These
 assets represent a conditional right to consideration. Contract
 assets relate to unbilled amounts for cost reimbursements and
 research milestones achieved in support of the Company&#x2019;s
 research and license agreements with Incyte and ONO.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 A contract liability is recorded when consideration is received, or
 such consideration is unconditionally due, from a customer prior to
 transferring goods or services under the terms of the contract.
 Contract liabilities are recognized as revenue as control of the
 products or services is transferred to the customer and all revenue
 recognition criteria have been met. Contract liabilities relate to
 upfront payments received related to the Incyte Agreements, ONO
 research and license agreement, and the Simcere research and
 license agreement (See Note 8).</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table presents changes in the Company&#x2019;s trade
 receivables, contract assets and contract liabilities during the
 six months ended June&#xA0;30, 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="38%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Balance&#xA0;at&#xA0;December&#xA0;31,<br />
 2017 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Additions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Deductions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Balance&#xA0;at&#xA0;June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade&#xA0;&amp; other receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(11,628</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,069</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total trade&#xA0;&amp; other receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(11,628</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,069</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">693</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(957</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">693</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(957</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,430</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,226</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,430</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,226</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As a result of the adoption of IFRS 15, total deferred revenue was
 reduced by &#x20AC;8.7&#xA0;million as of December&#xA0;31, 2017.
 See Note 3 for details regarding the restatement as a result of a
 change in accounting policy.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Deductions from deferred revenue are comprised of revenue
 recognized that was included in deferred revenue at the beginning
 of the period totaling &#x20AC;7.9&#xA0;million and revenue
 recognized that was not included in deferred revenue at the
 beginning of the period totaling &#x20AC;1.3&#xA0;million for the
 six months ended June&#xA0;30, 2018.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6594774448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingExpensesExplanatory', window );">Total Operating Expenses</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>11.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Total Operating Expenses</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Research and development costs are comprised of allocated employee
 costs, the costs of materials and laboratory consumables,
 intellectual property and license costs and allocated other
 costs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 A breakdown of total operating expenses is presented as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;period&#xA0;ended</font></b></p>
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="center"><b>June&#xA0;30,</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;period&#xA0;ended</font></b></p>
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="center"><b>June&#xA0;30,</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center">
 <b>(euros&#xA0;in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Manufacturing costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,580</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,236</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>9,858</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,611</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IP and license costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>492</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>844</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">968</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel related R&amp;D</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,107</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,771</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>3,808</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,303</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other research and development costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,344</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>8,311</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Total research and development costs</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>12,523</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,420</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>22,821</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,427</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Management and administration costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,639</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,492</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,491</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,694</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Litigation costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>552</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">104</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>849</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">394</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,745</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,173</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,134</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,726</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Total other expenses</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>3,297</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,277</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,983</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,120</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Total operating expenses</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,459</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,189</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>34,295</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,241</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Research and development costs were &#x20AC;12.5&#xA0;million and
 &#x20AC;22.8&#xA0;million for the three and six months ended
 June&#xA0;30, 2018, respectively, as compared to
 &#x20AC;8.4&#xA0;million and &#x20AC;15.4&#xA0;million for the three-
 and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2017, respectively. The increase in research
 and development costs is primarily attributable to the increase in
 manufacturing costs, higher research and development headcount and
 related costs, as well as additional spending in support of the
 Company&#x2019;s clinical development programs
 for&#xA0;<font style="WHITE-SPACE: nowrap">MCLA-128,</font>&#xA0;<font style="WHITE-SPACE: nowrap">MCLA-117,</font>&#xA0;<font style="WHITE-SPACE: nowrap">MCLA-158</font>&#xA0;and&#xA0;<font style="WHITE-SPACE: nowrap">MCLA-145.The</font>&#xA0;significant
 increase in manufacturing costs and other research and development
 costs during 2018 relate primarily to the expansion of the
 Company&#x2019;s Phase 1 and Phase 1/2 clinical programs.
 Specifically, the Company incurred higher costs relating to
 outsourced contract manufacturing for process development and drug
 delivery in support of the
 Company&#x2019;s&#xA0;<font style="WHITE-SPACE: nowrap">MCLA-128</font>&#xA0;and&#xA0;<font style="WHITE-SPACE: nowrap">MCLA-158</font>&#xA0;clinical
 development programs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 A breakdown of other research and development costs is presented as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;period&#xA0;ended</font></b></p>
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="center"><b>June&#xA0;30,</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;period&#xA0;ended</font></b></p>
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="center"><b>June&#xA0;30,</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"><b>(euros in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Discovery and&#xA0;<font style="WHITE-SPACE: nowrap">pre-clinical</font>&#xA0;costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,078</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,698</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,763</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,076</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Clinical costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,850</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,292</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,248</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,002</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other research and development costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,416</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">820</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,300</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,467</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Total other research and development costs</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,344</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>8,311</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Other research and development costs consist mainly of laboratory
 supplies and depreciation expense related to research and
 development activities, which cannot be specifically allocated to a
 research project.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Litigation costs</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On March&#xA0;11, 2014, Regeneron Pharmaceuticals, Inc.
 (&#x201C;Regeneron&#x201D;) filed a complaint in the United States
 District Court for the Southern District of New York (the
 &#x201C;Court&#x201D;), alleging that the Company was infringing on
 one or more claims in Regeneron&#x2019;s U.S. Patent
 No.&#xA0;8,502,018, entitled &#x201C;Methods of Modifying Eukaryotic
 Cells&#x201D; (the &#x201C;018 Patent&#x201D;). On July&#xA0;3, 2014,
 the Company filed a response to the complaint, denying
 Regeneron&#x2019;s allegations of infringement and raising
 affirmative defenses, and filed counterclaims seeking, among other
 things, a declaratory judgment that the Company did not infringe
 the patent and that the patent was invalid. The Company
 subsequently filed amended counterclaims during the period from
 August to December 2014, seeking a declaratory judgment of
 unenforceability of the patent due to Regeneron&#x2019;s commission
 of inequitable conduct.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On November&#xA0;21, 2014, the Court found that there was clear and
 convincing evidence that a claim term present in each of the patent
 claims was indefinite and granted the Company&#x2019;s proposed
 claim constructions. On February&#xA0;24, 2015, the Court entered
 partial judgment in the proceeding, on the grounds that the Company
 did not infringe each of the patent claims, and that each of the
 patent claims were invalid due to indefiniteness. On
 November&#xA0;2, 2015, the Court found Regeneron had withheld
 material information from the United States Patent and Trademark
 Office during prosecution of the patent, and Regeneron had engaged
 in inequitable conduct and affirmative egregious misconduct in
 connection with the prosecution of the patent. On December&#xA0;18,
 2015, Regeneron filed an appeal of the Court&#x2019;s decision. On
 July&#xA0;27, 2017, the U.S. Court of Appeals for the Federal
 Circuit affirmed the trial court&#x2019;s conclusion that Regeneron
 had engaged in inequitable conduct before the United States Patent
 and Trademark Office and affirmed that the &#x2018;018 patent is
 unenforceable. Regeneron petitioned for a panel rehearing and
 rehearing en banc of this decision by the Federal Circuit on
 September&#xA0;12, 2017, which the Company responded to and opposed
 on November&#xA0;2, 2017. On December&#xA0;26, 2017, the full
 Federal Circuit denied Regeneron&#x2019;s request to rehear the
 matter.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The case returned to the District Court to adjudicate the
 Company&#x2019;s motion requesting that Regeneron pay the
 Company&#x2019;s attorneys&#x2019; fees and costs incurred as a
 result of Regeneron filing suit. On March&#xA0;26, 2018, the trial
 court granted the Company&#x2019;s motion for attorneys&#x2019; fees,
 expert fees, and costs and ordered the parties to address the
 amount of award. The Company provided a detailed explanation of its
 attorneys&#x2019; fees, expert fees, and costs of such award, which
 Regeneron responded to seeking a reduction of the amount. The
 matter was fully briefed as of May&#xA0;18, 2018, and the Court
 issued an Order on June&#xA0;25, 2018, which published on
 July&#xA0;10, 2018, granting the Company&#x2019;s motion for
 $8,332,453.46 in attorneys&#x2019; fees, $465,390.34 in expert fees,
 and $1,717,100.69 in litigation expenses and costs, along with
 interest. Regeneron has appealed the decision awarding
 attorneys&#x2019; fees to the Company to the Federal Circuit. On
 May&#xA0;25, 2018, Regeneron filed a petition for writ of
 certiorari seeking review by the Supreme Court of the United States
 of the decision affirmed by the Federal Circuit. The
 Company&#x2019;s brief in opposition was filed on August&#xA0;8,
 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On March&#xA0;11, 2014, Regeneron served a writ in the Netherlands
 alleging that the Company was infringing one or more claims of the
 European patent EP 1 360 287 B1. The Company opposed the patent in
 June 2014. On September&#xA0;17, 2014, Regeneron&#x2019;s patent EP
 1 360 287 B1 was revoked in its entirety by the European Opposition
 Division of the European Patent Office (the &#x201C;EPO&#x201D;). In
 Europe, an appeal hearing occurred in October and November 2015 at
 the Technical Board of Appeal for the EPO at which time the patent
 was reinstated to Regeneron with amended claims. On May&#xA0;25,
 2018, at Regeneron&#x2019;s request, a hearing before the Technical
 Board of Appeals for the EPO was scheduled for September&#xA0;13,
 2018, to address whether the description of EP 1 360 287 B1 patent
 having claims amended during the course of opposition complies with
 Art. 84 EPC, Art. 123(2) EPC and Rule 80 EPC. The Company believes
 that its current business operations do not infringe the patent
 reinstated to Regeneron with amended claims because it believes it
 has not used the technology or methods claimed under the amended
 claims.&#xA0;The Dutch litigation procedure is stayed.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The costs incurred in the above litigation and opposition were
 &#x20AC;0.6&#xA0;million and &#x20AC;0.8&#xA0;million for the three-
 and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018, respectively, as compared to
 &#x20AC;0.1&#xA0;million and &#x20AC;0.4&#xA0;million for the three-
 and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2017, respectively, and are included in the
 statement of profit or loss and comprehensive loss for the
 period.</p>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On July&#xA0;15, 2014, Regeneron filed a notice of opposition
 against the Company&#x2019;s EP 2314629 patent (the &#x201C;EP
 &#x2019;629 patent&#x201D;), entitled &#x201C;Recombinant Production
 of Mixtures of Antibodies,&#x201D; in the EPO. The notice asserted,
 as applicable, added subject matter, lack of novelty, lack of
 inventive step, and insufficiency. The Company responded on
 February&#xA0;24, 2015. Following an oral hearing before the
 Opposition Division of the EPO on June&#xA0;22, 2016, the
 Opposition Division upheld the EP &#x2019;629 Patent with
 amendments. Both Regeneron and the Company filed a notice of appeal
 followed by grounds of appeal on December&#xA0;1 and 4, 2017,
 respectively, with further proceedings to follow.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On August&#xA0;11, 2014, Regeneron filed a notice of opposition
 against the Company&#x2019;s EP 2147594 (the &#x201C;EP &#x2019;594
 patent&#x201D;), entitled &#x201C;Antibody
 Producing&#xA0;<font style="WHITE-SPACE: nowrap">Non-Human</font>&#xA0;Mammals,&#x201D;
 in the EPO. The notice asserted, as applicable, lack of novelty,
 lack of inventive step, and insufficiency. The Company&#x2019;s
 response to the oppositions was filed on April&#xA0;2, 2015.
 Following an oral hearing before the Opposition Division of the EPO
 on October&#xA0;28, 2016, the Opposition Division upheld the EP
 &#x2019;594 Patent without amendments. Regeneron filed grounds of
 appeal on July&#xA0;19, 2017, and the Company responded on
 November&#xA0;30, 2017.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On April&#xA0;5, 2018, Regeneron and an unnamed third party filed
 notices of opposition against the Company&#x2019;s EP 2604625 patent
 (the &#x201C;EP &#x2018;625 patent&#x201D;), entitled
 &#x201C;Generation of Binding Molecules,&#x201D; in the EPO. The
 notices asserted, as applicable, added subject matter, lack of
 novelty, lack of inventive step, and insufficiency. The Company
 intends to timely respond to these submissions with proceedings to
 be ongoing.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 As each of these proceedings continues, the Company is not able to
 predict the outcome of, or estimate a possible gain or a range of
 possible loss, if any, related to the above actions. Based on the
 current facts and circumstances, no provision has been recognized
 under IAS 37 related to contingent liabilities.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6605880304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Employee Benefits</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>12.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Employee Benefits</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Details of the employee benefits are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;period&#xA0;ended</font><br />

 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;period&#xA0;ended</font><br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Salaries and wages</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,876</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,451</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,505</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,182</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 WBSO subsidy</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(733</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(953</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,900</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,005</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Social security premiums</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">198</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">293</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Health insurance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">188</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">62</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Pension costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">188</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">181</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">390</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Share award expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,109</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,554</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,880</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other personnel expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">148</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">433</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">264</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total employee benefits expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,931</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,263</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,619</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,998</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Share-based payment expenses (see Note 9) were recognized as
 employee benefit expenses as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;period&#xA0;ended</font><br />

 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;period&#xA0;ended</font><br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">714</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">673</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,525</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,798</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Management and administrative costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,343</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,852</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,782</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">205</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">177</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,109</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,554</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,880</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Subsidies earned under the WBSO relating to eligible research and
 development costs are deferred and recognized in the
 Company&#x2019;s income statement as a reduction to labor costs over
 the period labor costs are expected to be incurred. The Company has
 received and recognized subsidies of &#x20AC;0.7&#xA0;million and
 &#x20AC;1.9&#xA0;million for the three-
 and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>periods ended June&#xA0;30,
 2018, respectively, as compared to &#x20AC;1.0&#xA0;million and
 &#x20AC;2.0&#xA0;million for the three-
 and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2017, respectively. The decrease in subsidies
 is primarily attributable to the decrease in eligible payroll tax
 withholdings during the same period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company&#x2019;s headcount at&#xA0;June&#xA0;30, 2018 was
 approximately 85&#xA0;full-time equivalents and consisted of 70
 employees in the Netherlands and&#xA0;15 employees in the United
 States. A total of 18&#xA0;employees who are devoted to activities
 other than research and development and overall management of the
 Company were included under management and administration costs for
 the three- and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company&#x2019;s headcount at June&#xA0;30, 2017 was
 approximately 64 full-time equivalents and consisted of 55
 employees in the Netherlands and&#xA0;nine employees in the United
 States. A total of 13&#xA0;employees who were devoted to activities
 other than research and development and overall management of the
 Company were included under management and administration costs for
 the three- and&#xA0;<font style="WHITE-SPACE: nowrap">six-month</font>&#xA0;periods
 ended June&#xA0;30, 2017.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2018-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2018-03-01&amp;anchor=sect_Scope&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6605447104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income and Expense<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory', window );">Finance Income and Expense</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>13.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Finance Income and Expense</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;period&#xA0;ended</font><br />

 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;period&#xA0;ended</font><br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2018&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 &#xA0;&#xA0;&#xA0;&#xA0;2017<b>&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2018&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 &#xA0;&#xA0;&#xA0;&#xA0;2017<b>&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Finance income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest income and similar income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>494</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">420</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>834</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">610</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net gain on foreign exchange</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>6,917</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,111</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,411</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">420</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,945</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">610</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Finance costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(1</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(1</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,667</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss on foreign exchange</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(11,962</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,029</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(1</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(11,962</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(1</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(22,696</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Interest income primarily results from interest earned on cash held
 on account and accretion of investment earnings. The
 Company&#x2019;s current year increase in cash, cash equivalents and
 investments was due primarily to the $55.8&#xA0;million of funds
 received as part of the Private Placement during the first quarter
 of 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company experienced gains on its U.S. dollar denominated cash,
 cash equivalents and investments of approximately &#x20AC;6.9
 million and &#x20AC;4.1 million for the three and six months ended
 June 30, 2018, respectively, as compared to losses of &#x20AC;12.0
 million for the three and six months ended June 30, 2017. The
 Company presents foreign currency gains and losses on a net basis
 as either finance income or finance expense depending on whether
 foreign currency movements are in a net gain or net loss position.
 The Company experienced foreign exchange losses on its U.S. dollar
 denominated cash, cash equivalents and investments of approximately
 &#x20AC;2.8 million during the three months ended March 31, 2018,
 which are reclassified to net gain on foreign exchange for the six
 months ended June 30, 2018. As of June 30, 2018, the Company held
 approximately $40.9 million and $92.6 million in U.S. dollar
 denominated cash and cash equivalent accounts and investment
 accounts, respectively, subject to the fluctuation in foreign
 currency between the euro and U.S. dollar.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 On December&#xA0;20, 2016, the Company entered into the Incyte
 Agreements. As these contracts are denominated in U.S. dollars, the
 Company determined that the subscription agreement to sell its own
 shares to which the Company became committed on December&#xA0;20,
 2016, should be accounted for as a forward contract or a derivative
 financial instrument. Interest expense for the three and six months
 ended June&#xA0;30, 2017, related entirely to the effective
 settlement of the forward contract on January&#xA0;23, 2017.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of interest income and expense. [Refer: Interest income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInterestIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6721684048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingLeaseExplanatory', window );">Operating Leases</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr style="page-break-inside:avoid">
 <td width="4%" valign="top" align="left"><b>14.</b></td>
 <td align="left" valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;" align="left"><b>Operating Leases</b></p>
 </td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company leases its corporate headquarters under an agreement
 term of five years which expires in the fourth quarter of 2021. If
 the lease is not terminated by Merus N.V. it will be automatically
 renewed for a period of two years. The agreed rental price is
 &#x20AC;0.4&#xA0;million per year. On May&#xA0;1, 2018, the Company
 leased additional space to expand its corporate headquarters under
 a separate agreement. Under the terms of the new agreement, the
 term began on May&#xA0;1, 2018, and expires in the fourth quarter
 of 2021. The agreed upon rental price is &#x20AC;0.5&#xA0;million
 per year.</p>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 For leases that contain fixed increases in the minimum annual lease
 payment during the original term of the lease, the Company
 recognizes rental expense on a straight-line basis over the lease
 term and records the difference between rent expense and the amount
 currently payable as deferred rent as a component of other
 liabilities and accruals. For the three and six months ended
 June&#xA0;30, 2018, the Company recognized &#x20AC;0.3&#xA0;million
 and &#x20AC;0.5&#xA0;million, respectively, compared to
 &#x20AC;0.2&#xA0;million and &#x20AC;0.3&#xA0;million for the three
 and six months ended June&#xA0;30, 2017, respectively, for rent and
 service charges related to the office space. In addition, the
 Company has provided a deposit of &#x20AC;0.1&#xA0;million included
 in other assets as of June&#xA0;30, 2018, and December&#xA0;31,
 2017.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingLeaseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingLeaseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6645676784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>15.</b></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><b>Subsequent Events</b></p>
 </td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company has evaluated subsequent events through August&#xA0;10,
 2018, the date of issuance of the unaudited consolidated financial
 statements for the three months ended June&#xA0;30, 2018.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Except for the items described in Note 11 under litigation, there
 were no additional events requiring disclosure in the notes to
 these financial statements.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2018-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=10&amp;date=2018-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6722799936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory', window );">Basis of Presentation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Basis of Presentation</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 These unaudited interim condensed consolidated financial statements
 (the &#x201C;interim financial statements&#x201D;) have been prepared
 in accordance with International Accounting Standard 34
 &#x201C;Interim Financial Reporting&#x201D; as issued by the
 International Accounting Standards Board (&#x201C;IASB&#x201D;).
 Certain information and disclosures normally included in financial
 statements prepared in accordance with International Financial
 Reporting Standards (&#x201C;IFRS&#x201D;) have been condensed or
 omitted. Accordingly, these interim financial statements should be
 read in conjunction with the Company&#x2019;s annual financial
 statements for the year ended December&#xA0;31, 2017. In the
 opinion of management, all adjustments (consisting of a normal
 recurring nature) considered necessary for a fair presentation have
 been included in the interim financial statements. All intercompany
 transactions and balances are eliminated in consolidation.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory', window );">Use of Estimates</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Use of Estimates</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The preparation of financial statements in conformity with IFRS
 requires the use of certain critical accounting estimates. It also
 requires management to exercise its judgment in the process of
 applying the Company&#x2019;s accounting policies. The areas
 involving a higher degree of judgment or complexity or areas where
 assumptions and estimates are significant to these interim
 financial statements are disclosed in Note 4. The results of
 operations for the three- and <font style="WHITE-SPACE: nowrap">six-month</font> periods ended June&#xA0;30,
 2018, are not necessarily indicative of operations to be expected
 for the full fiscal year ending December&#xA0;31, 2018.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign Currency Transactions</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Foreign Currency Transactions</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Items recorded in each of the Company&#x2019;s entities are measured
 using the currency of the primary economic environment in which the
 entity operates (the &#x201C;functional currency&#x201D;). The
 interim financial statements are presented in euros, which is Merus
 N.V.&#x2019;s functional currency. The functional currency of Merus
 US, Inc. is the U.S. dollar.&#xA0;All amounts are rounded to the
 nearest thousand euros, except where otherwise indicated. Foreign
 currency gains and losses are reported on a net basis as either
 finance income or finance expense depending on whether foreign
 currency movements are in a net gain or net loss position.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfAccountingPolicyForSeasonality', window );">Seasonality</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Seasonality</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s financial results have varied substantially,
 and are expected to continue to vary, from period to period. The
 Company believes that its ordinary activities are not linked to any
 particular seasonal factors.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment Reporting</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Segment Reporting</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company operates in one reportable segment, which comprises the
 discovery and development of innovative bispecific
 therapeutics.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Cash and Cash Equivalents</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 For the purpose of presentation in the statement of cash flows as
 well as the statement of financial position, cash and cash
 equivalents include deposits held with financial institutions with
 original maturities of less than three months. Cash and cash
 equivalents include &#x20AC;34.3&#xA0;million of short-term
 investments with a three-month or less maturity, callable on
 demand. The carrying values of short-term investments approximate
 fair value due to their short-term maturities.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue Recognition</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Revenue Recognition</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company enters into collaboration agreements which are within
 the scope of IFRS 15&#x2014;Revenue from Contracts with Customers
 (&#x201C;IFRS 15&#x201D;), under which the Company licenses rights to
 certain of the Company&#x2019;s product candidates and performs
 research and development services. The terms of these arrangements
 typically include payment of one or more of the following:
 <font style="WHITE-SPACE: nowrap">non-refundable,</font> upfront
 fees; reimbursement of research and development costs; development,
 regulatory, and commercial milestone payments; and royalties on net
 sales of licensed products.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 IFRS 15 requires an entity to recognize the amount of revenue to
 which it expects to be entitled for the transfer of promised goods
 or services to customers. Under IFRS 15, the Company recognizes
 revenue when its customer obtains control of the goods or services,
 in an amount that reflects the consideration that the Company
 determines it expects to receive in exchange for those goods or
 services. To determine revenue recognition for arrangements that
 the Company determines are within the scope of IFRS 15, the Company
 performs the following five steps: (i)&#xA0;identify the
 contract(s) with a customer; (ii)&#xA0;identify the performance
 obligations in the contract; (iii)&#xA0;determine the transaction
 price; (iv)&#xA0;allocate the transaction price to the performance
 obligations in the contract; and (v)&#xA0;recognize revenue when
 (or as) the entity satisfies the performance obligation. The
 Company applies the five-step model to contracts only when it is
 probable that it will collect the consideration to which it is
 entitled in exchange for the goods or services it transfers to the
 customer. As part of the accounting for these arrangements, the
 Company must make significant judgments, including identifying
 performance obligations in the contract, estimating the amount of
 variable consideration to include in the transaction price and
 allocating the transaction price to each performance
 obligation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company currently generates a portion of its revenue through
 collaboration and license agreements with strategic collaborators
 for the development and commercialization of product candidates.
 The collaboration and license agreements are within the scope of
 IFRS 15.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i><font style="WHITE-SPACE: nowrap">Up-front</font> License
 Payments</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 If the license to the Company&#x2019;s intellectual property is
 determined to be distinct from the other performance obligations
 identified in the agreement, the Company recognizes revenues from
 <font style="WHITE-SPACE: nowrap">non-refundable,</font>
 <font style="WHITE-SPACE: nowrap">up-front</font> fees allocated to
 the license when the license is transferred to the customer and the
 customer is able to use and benefit from the license. If not
 distinct, the license is combined with other performance
 obligations in the contract. For licenses that are combined with
 other performance obligations, the Company assesses the nature of
 the combined performance obligation to determine whether the
 combined performance obligation is satisfied over time or at a
 point in time and, if over time, the appropriate method of
 measuring progress for purpose of recognizing revenue. The Company
 evaluates the measure of progress each reporting period and, if
 necessary, adjusts the measure of performance and related revenue
 recognition.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Pursuant to the Company&#x2019;s research and license agreements
 with its collaborators, the Company has received upfront license
 payments relating to the integrated packages of deliverables under
 the contracts. Each contract contains either one single performance
 obligation or multiple performance obligations that the
 <font style="WHITE-SPACE: nowrap">up-front</font> consideration was
 allocated to. These upfront license payments are initially recorded
 in deferred revenue on the consolidated statements of financial
 position and are recognized as revenue on either: (i)&#xA0;a
 straight-line basis over the period of the related performance
 obligation or the contractual term of the arrangement; or
 (ii)&#xA0;based on another appropriate depiction of the
 Company&#x2019;s performance over the period of the related
 performance obligation or the contractual term, such as costs
 incurred relating to full-time equivalent research employees. The
 applicable period over which to recognize the upfront payment is a
 significant judgment, which is <font style="WHITE-SPACE: nowrap">re-assessed</font> at each reporting
 date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Collaboration Income</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Collaboration income, which is typically related to reimbursements
 from collaborators for the Company&#x2019;s performance of research
 and development services under the respective agreements, is
 recognized on the basis of labor hours valued at a contractually
 agreed rate. Collaboration income includes reimbursements for
 related <font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">out-of-pocket</font></font> expenses. Cost
 reimbursements to which the Company is entitled under agreements
 are recognized as revenue in the same period as the cost for which
 they are intended to compensate. The Company acts as the principal
 and therefore records these reimbursements as collaboration
 income.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In determining the appropriate amount of revenue to be recognized
 as the Company fulfills its obligations under the agreements, the
 Company performs the five steps listed above. As part of the
 accounting for the arrangement, the Company must develop
 assumptions that require judgment to determine the stand-alone
 selling price for each performance obligation identified in the
 contract. The Company uses key assumptions to determine the
 stand-alone selling price, which may include market conditions,
 reimbursement rates for personnel costs, development timelines and
 probabilities of regulatory success.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company capitalizes the incremental costs of obtaining a
 contract with a customer if it expects to recover those costs. Such
 incremental costs would not have been incurred if the contract with
 a customer had not been obtained. To date, the Company has not
 capitalized any incremental costs for obtaining a contract.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s contracts often include development and
 regulatory milestone payments which are assessed under the most
 likely amount method and constrained if it is probable that a
 significant revenue reversal would occur. Milestone payments that
 are not within the Company&#x2019;s control or the licensee&#x2019;s
 control, such as regulatory approvals, are not considered probable
 of being achieved until those approvals are received. At each
 reporting date, the Company <font style="WHITE-SPACE: nowrap">re-evaluates</font> the probability of
 achievement of development milestones and any related constraint,
 and if necessary, adjusts the overall transaction price. Any such
 adjustments are recorded on a cumulative <font style="WHITE-SPACE: nowrap">catch-up</font> basis, which would affect
 collaboration revenues in the period of adjustment.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For agreements that include sales-based royalties, including
 milestone payments based on the level of sales, and the license is
 deemed to be the predominant item to which the royalties relate,
 the Company recognizes revenue at the later of (i)&#xA0;when the
 related sales occur, or (ii)&#xA0;when the performance obligation
 to which some or all of the royalty has been allocated has been
 satisfied (or partially satisfied). To date, the Company has not
 recognized any consideration related to sales-based royalty revenue
 resulting from any of the Company&#x2019;s collaboration
 agreements.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Government Grants</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company receives certain government and regional grants, which
 support its research efforts in defined projects, and include
 contributions towards the cost of research and development. When
 there is reasonable assurance that the Company will comply with the
 conditions attached to a received grant, and when there is
 reasonable assurance that the grant will be received, government
 grants are recognized as revenue on a gross basis in the
 consolidated statement of profit or loss and comprehensive loss on
 a systematic basis over the periods in which the Company recognizes
 expenses for the related costs for which the grants are intended to
 compensate. In the case of grants related to assets, the received
 grant will be deducted from the carrying amount of the asset.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory', window );">Reclassifications</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Reclassifications</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Certain amounts were reclassified in the prior period condensed
 consolidated interim financial statements to conform to the current
 period presentation.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of entity's accounting policy on basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfAccountingPolicyForBasisOfPresentationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfAccountingPolicyForCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for reclassification of prior years information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfAccountingPolicyForReclassificationOfPriorYearsInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfAccountingPolicyForSeasonality">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for seasonality</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfAccountingPolicyForSeasonality</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for use of judgements and estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfAccountingPolicyForUseOfJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6624760336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued International Financial Reporting Standards (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory', window );">Condensed Consolidated Statements of Financial Information</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following financial statement line items have been shown to
 reflect the adjustments recognized for each individual line item in
 the Company&#x2019;s respective consolidated statements for the
 period noted:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Condensed Consolidated Statement of Profit or Loss and
 Comprehensive Loss</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three&#xA0;months<br />
 ended<br />
 June&#xA0;30, 2017<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS&#xA0;15</b><br />
 <b>Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three&#xA0;months<br />
 ended<br />
 June&#xA0;30, 2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">(euros in
 thousands)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,027</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,237</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Operating result</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,162</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,952</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total comprehensive loss for the period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(21,798</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,210</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19,588</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic (and diluted) loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.12</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.11</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.01</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Six&#xA0;months&#xA0;ended<br />
 June&#xA0;30, 2017<br />
 (As originally<br />
 presented)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS&#xA0;15</b><br />
 <b>Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Six&#xA0;months&#xA0;ended<br />
 June&#xA0;30, 2017<br />
 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">(euros in
 thousands)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,313</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,808</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,121</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Operating result</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(20,928</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,808</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,120</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total comprehensive loss for the period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,114</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,808</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(39,306</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Basic (and diluted) loss per share</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2.27</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.20</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2.07</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Condensed Consolidated Statement of Financial Position</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,</b><br />
 <b>2017</b><br />
 <b>As originally<br />
 presented</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,</b><br />
 <b>2017</b><br />
 <b>Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">(euros in
 thousands)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accumulated loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(167,480</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,705</td>
 <td valign="bottom" nowrap="nowrap"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(158,775</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue, <font style="WHITE-SPACE: nowrap">non-current</font></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">130,195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,644</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">112,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,996</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,939</td>
 <td valign="bottom" nowrap="nowrap"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Condensed Consolidated Statement of Cash Flows</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2017</b><br />
 <b>As originally<br />
 presented</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>IFRS 15<br />
 Adoption</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,&#xA0;2017</b><br />
 <b>Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center">(euros in
 thousands)</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Result after taxation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,132</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,808</td>
 <td valign="bottom" nowrap="nowrap"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(39,324</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Changes in working capital:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,091</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,808</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,899</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of adoption of new international financial information regulations amendments and interpretations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfAdoptionOfNewInternationalFinancialInformationRegulationsAmendmentsAndInterpretationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6624554688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfHeldToMaturityInvestmentExplanatory', window );">Summary of Investments</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Investments as of June&#xA0;30, 2018, and December&#xA0;31, 2017,
 consist of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Balance as per</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>(euros in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Commercial paper</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,715</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,527</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S. Treasury securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,574</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,177</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate fixed income bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,289</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,886</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Agency bond</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,499</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,453</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Investments, current portion</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">37,077</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,043</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Corporate fixed income bonds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,060</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <font style="WHITE-SPACE: nowrap">Non-current</font>
 investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,060</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total investments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">53,727</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">41,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfHeldToMaturityInvestmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of held to maturity investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfHeldToMaturityInvestmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6715401152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and Other Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory', window );">Summary of Trade and Other Receivables Due Within 1 Year</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Trade and other receivables are short-term and due within 1
 year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Balance as per</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>(euros in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,069</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 VAT receivable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">622</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">582</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,640</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">427</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid pension costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">359</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">838</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest bank</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">275</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">170</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">66</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">92</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,477</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,413</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of trade and other current receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfTradeAndOtherCurrentReceivableExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6718875408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities and Accruals (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock', window );">Summary of Short-term and Payable Within 1 Year</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 All amounts are short-term and payable within 1 year.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Balance per</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>(euros in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accrued auditor&#x2019;s fee</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">90</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">315</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 R&amp;D costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,777</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,272</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IP &#x2013; Legal fee</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">509</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Bonuses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">940</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Subsidy advance received</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other accruals</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">465</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">535</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,627</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accruals other liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfAccrualsOtherLiabilitiesExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6715521488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredRevenueExplanatory', window );">Summary of Deferred Revenue</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Deferred revenue as of June&#xA0;30, 2018, and December&#xA0;31,
 2017, consist of the following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="68%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Balance per</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2017&#xA0;Restated*</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue &#x2013; current portion</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">16,972</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,935</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">105,718</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">112,551</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="2%" align="left">*</td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><i>See Note 3 for details regarding the restatement as
 a result of a change in accounting policy.</i></p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDeferredRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDeferredRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6715357792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 The inputs used in the measurement of the fair values and the
 related fair values at the grant dates were as follows for the
 options granted during the <font style="WHITE-SPACE: nowrap">six-month</font> period ended June&#xA0;30,
 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>Key&#xA0;Management<br />
 Personnel<br />
 (&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>All&#xA0;Other&#xA0;Personnel<br />
 (&#x20AC;)</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Fair value at grant date</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">9.34-9.45</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">9.30-10.37</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Share price at grant date</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">14.57-14.87</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">14.57-18.24</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercise price</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">14.57-14.87</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">14.57-18.24</font></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility (weighted-average)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>95.1%</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><b>94.6%</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contractual life</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>10 years</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><b>10 years</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividends</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b>0%</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><b>0%</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate (based on government bonds)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><b><font style="WHITE-SPACE: nowrap">2.79%-2.94%</font></b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center"><b><font style="WHITE-SPACE: nowrap">2.84%-2.94%</font></b></td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Summary of Reconciliation of Outstanding Share Options</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The number of share options and the weighted average exercise
 prices of share options granted were as follows for the
 <font style="WHITE-SPACE: nowrap">six-month</font> period ended
 June&#xA0;30, 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br />
 exercise price<br />
 (&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number of<br />
 options</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>13.99</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,213,985</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>19.67</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(12,044</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expired during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.02</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(5,146</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1.93</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(34,041</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.68</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>469,068</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>14.24</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,631,822</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercisable at June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>12.18</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,105,059</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory', window );">Summary of Number of Share Options Outstanding</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The number of options outstanding as of June&#xA0;30, 2018, was as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom"><b>Group of employees entitled</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Key management personnel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,153,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 All other employees</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">478,012</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,631,822</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory', window );">Summary of Reconciliation of RSU's</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 During the six months ended June&#xA0;30, 2018, the Company did not
 grant any new RSUs. The number of RSUs outstanding is summarized as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="63%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;average<br />
 grant price<br />
 (&#x20AC;)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of<br />
 RSU&#x2019;s</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at January&#xA0;1, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>194,546</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Forfeited during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(76,245</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted during the <font style="WHITE-SPACE: nowrap">six-month</font> period</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at June&#xA0;30, 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>20.03</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>118,301</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOtherThanOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6624148512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfInformationAboutRevenueExplanatory', window );">Summary of Revenue</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s revenues are generated entirely in the
 Netherlands. In the following table, revenue is disaggregated by
 primary source of revenue as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="54%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">Three months
 ended</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">Six months
 ended</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June&#xA0;30,<br />
 2017&#xA0;Restated*</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">June 30<br />
 2017&#xA0;Restated*</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Upfront payment amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,250</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,973</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>9,087</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,898</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Collaboration income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,179</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,195</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,391</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Revenue from contracts with customers</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>6,429</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,444</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>16,282</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,289</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Income from grants on research projects</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>114</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">793</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>182</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">832</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><b>6,543</b></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,237</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right"><b>16,464</b></td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,121</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="2%" align="left"><i>*</i></td>
 <td valign="top" align="left">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="left"><i>See Note 3 for details regarding the restatement as
 a result of a change in accounting policy.</i></p>
 </td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Summary of Changes in Tarde Receivables, Contract Assets and Contract Liabilities</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table presents changes in the Company&#x2019;s trade
 receivables, contract assets and contract liabilities during the
 six months ended June&#xA0;30, 2018:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="38%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Balance&#xA0;at&#xA0;December&#xA0;31,<br />
 2017 Restated</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Additions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Deductions</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>Balance&#xA0;at&#xA0;June&#xA0;30,<br />
 2018</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade&#xA0;&amp; other receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Trade receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(11,628</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,069</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total trade&#xA0;&amp; other receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,594</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12,103</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(11,628</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,069</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unbilled receivables</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">693</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(957</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">710</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">693</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(957</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">446</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred revenue</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,430</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,226</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total contract liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">128,486</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,430</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,226</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">122,690</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=sect_Presentation&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfInformationAboutRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfInformationAboutRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6701724608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory', window );">Summary of Total Operating Expenses</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 A breakdown of total operating expenses is presented as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="62%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;period&#xA0;ended</font></b></p>
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>June&#xA0;30,</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;period&#xA0;ended</font></b></p>
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>June&#xA0;30,</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center">
 <b>(euros&#xA0;in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Manufacturing costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,580</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,236</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>9,858</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,611</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IP and license costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>492</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">603</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>844</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">968</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Personnel related R&amp;D</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,107</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,771</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>3,808</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,303</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other research and development costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,344</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>8,311</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Total research and development costs</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>12,523</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,420</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>22,821</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,427</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Management and administration costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,639</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,492</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,491</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,694</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Litigation costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>552</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">104</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>849</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">394</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other operating expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,745</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,173</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,134</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,726</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Total other expenses</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>3,297</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,277</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>5,983</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,120</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Total operating expenses</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>18,459</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,189</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>34,295</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">27,241</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory', window );">Breakdown of Other Research and Development Costs</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 A breakdown of other research and development costs is presented as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;period&#xA0;ended</font></b></p>
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>June&#xA0;30,</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;period&#xA0;ended</font></b></p>
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt" align="center"><b>June&#xA0;30,</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>(euros in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Discovery and <font style="WHITE-SPACE: nowrap">pre-clinical</font>
 costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,078</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,698</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,763</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,076</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Clinical costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,850</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,292</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,248</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,002</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other research and development costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>1,416</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">820</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>2,300</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,467</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <i>Total other research and development costs</i></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,344</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,810</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>8,311</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,545</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information of research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailedInformationOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information related to operating expenses explanatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailedInformationRelatedToOperatingExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6715506576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory', window );">Disclosure of Detailed Information About Employee Benefits</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Details of the employee benefits are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;period&#xA0;ended</font><br />

 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;period&#xA0;ended</font><br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Salaries and wages</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,876</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,451</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,505</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,182</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 WBSO subsidy</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(733</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(953</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,900</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,005</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Social security premiums</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">198</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">449</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">293</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Health insurance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">36</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">188</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">62</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Pension costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">188</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">181</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">390</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">322</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Share award expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,109</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,554</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,880</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other personnel expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">224</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">148</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">433</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">264</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total employee benefits expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,931</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,263</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9,619</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,998</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory', window );">Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 Share-based payment expenses (see Note 9) were recognized as
 employee benefit expenses as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="58%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;period&#xA0;ended</font><br />

 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;period&#xA0;ended</font><br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2018</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2017</td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">714</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">673</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,525</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,798</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Management and administrative costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,343</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,376</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,852</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,782</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">205</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">177</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">300</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,109</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,254</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,554</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,880</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailedInformationAboutEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDetailedInformationAboutShareBasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6715447200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income and Expense (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TextBlockAbstract', window );"><strong>Text block [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Summary of Finance Income and Expense</a></td>
<td class="text"><div>
 <p><br class="Apple-interchange-newline" /></p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="55%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Three-month&#xA0;period&#xA0;ended</font><br />

 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b><font style="WHITE-SPACE: nowrap">Six-month&#xA0;period&#xA0;ended</font><br />
 June&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2018&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 &#xA0;&#xA0;&#xA0;&#xA0;2017<b>&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 <b>&#xA0;&#xA0;&#xA0;&#xA0;2018&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 &#xA0;&#xA0;&#xA0;&#xA0;2017<b>&#xA0;&#xA0;&#xA0;&#xA0;</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(euros in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Finance income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest income and similar income</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>494</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">420</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>834</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">610</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net gain on foreign exchange</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>6,917</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,111</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>7,411</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">420</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>4,945</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">610</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Finance costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Interest expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(1</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(1</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,667</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss on foreign exchange</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(11,962</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap" align="right">
 <b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,029</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(1</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(11,962</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"><b>&#xA0;</b></td>
 <td valign="bottom" align="right"><b>(1</b></td>
 <td valign="bottom" nowrap="nowrap"><b>)&#xA0;</b></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(22,696</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Text Block [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6725634256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information - Additional Information (Detail)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 13, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Feb. 13, 2018 </div>
<div>&#8364; / shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfGeneralInformationAbstract', window );"><strong>Disclosure of general information [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Common shares issued | shares</a></td>
<td class="nump">3,099,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Issue price per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="nump">$ 55.8<span></span>
</td>
<td class="nump">&#8364; 44,800<span></span>
</td>
<td class="nump">$ 55.8<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="nump">&#8364; 44,731<span></span>
</td>
<td colspan="2" class="nump">&#8364; 74,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,327<span></span>
</td>
<td colspan="2" class="nump">&#8364; 215,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 149,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td colspan="2" class="nump">&#8364; 56,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_HeldtomaturityInvestments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 53,727<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 41,103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="13"></td></tr>
<tr><td colspan="13"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets with fixed or determinable payments and fixed maturity that an entity has the positive intention and ability to hold to maturity other than: (a) those that the entity upon initial recognition designates as at fair value through profit or loss; (b) those that the entity designates as available for sale; and (c) those that meet the definition of loans and receivables. An entity shall not classify any financial assets as held to maturity if the entity has, during the current financial year or during the two preceding financial years, sold or reclassified more than an insignificant amount of held-to-maturity investments before maturity (more than insignificant in relation to the total amount of held-to-maturity investments) other than sales or reclassifications that: (i) are so close to maturity or the financial asset&#8217;s call date (for example, less than three months before maturity) that changes in the market rate of interest would not have a significant effect on the financial asset&#8217;s fair value; (ii) occur after the entity has collected substantially all of the financial asset&#8217;s original principal through scheduled payments or prepayments; or (iii) are attributable to an isolated event that is beyond the entity&#8217;s control, is non-recurring and could not have been reasonably anticipated by the entity. [Refer: Derivative financial assets; Held-to-maturity investments; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfGeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of general information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfGeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharePurchasedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share purchased price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharePurchasedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6721617936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;) </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfSignificantAccountingPoliciesAbstract', window );"><strong>Disclosure of significant accounting policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfReportableSegments1', window );">Number of reportable segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CashAndCashEquivalentsMaximumMaturityPeriod', window );">Cash and cash equivalents, maximum original maturities</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents', window );">Short-term investments | &#8364;</a></td>
<td class="nump">&#8364; 34.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CashAndCashEquivalentsMaximumMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents Maximum Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CashAndCashEquivalentsMaximumMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfReportableSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reportable segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfReportableSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6725511824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued International Financial Reporting Standards - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2014</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_IFRS15RevenueFromContractsWithCustomersMember', window );">IFRS 15 revenue from contracts with customers [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInDeferredRevenue1', window );">Decrease in Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8.7<span></span>
</td>
<td class="nump">&#8364; 8.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember', window );">Incyte collaboration agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EstimatedContractualTerm', window );">Estimated contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember', window );">ONO Research and License Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EstimatedContractualTerm', window );">Estimated contractual term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteProprietaryTechnologyMember', window );">Incyte proprietary technology [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EstimatedContractualTerm', window );">Estimated contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_EstimatedContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated contractual term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_EstimatedContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseDecreaseInDeferredRevenue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseDecreaseInDeferredRevenue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_IFRS15RevenueFromContractsWithCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_IFRS15RevenueFromContractsWithCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteProprietaryTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_IncyteProprietaryTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6726111664">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Profit or Loss and Comprehensive Loss (Detail) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 6,543<span></span>
</td>
<td class="nump">&#8364; 6,237<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 16,464<span></span>
</td>
<td class="nump">&#8364; 10,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(11,916)<span></span>
</td>
<td class="num">(7,952)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(17,831)<span></span>
</td>
<td class="num">(17,120)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (4,557)<span></span>
</td>
<td class="num">&#8364; (19,588)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (13,005)<span></span>
</td>
<td class="num">&#8364; (39,306)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic (and diluted) loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">&#8364; (0.20)<span></span>
</td>
<td class="num">&#8364; (1.01)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (0.60)<span></span>
</td>
<td class="num">&#8364; (2.07)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Previously stated [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,027<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,313<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,162)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,928)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (21,798)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (43,114)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic (and diluted) loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1.12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (2.27)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member', window );">Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,808<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating result</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,210<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,808<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic (and diluted) loss per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">For the periods included in these financial statements, share options were excluded from the diluted loss per share calculation as the Company was in a loss position in each period presented above. As a result, basic and diluted loss per share is equal.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2018-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=32&amp;date=2018-03-01&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=5&amp;date=2018-03-01&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6718933184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Financial Positions (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated loss</a></td>
<td class="num">&#8364; (167,226)<span></span>
</td>
<td class="num">&#8364; (158,775)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">105,718<span></span>
</td>
<td class="nump">112,551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsCurrent', window );">Deferred revenue</a></td>
<td class="nump">&#8364; 16,972<span></span>
</td>
<td class="nump">15,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(167,480)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,195<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member', window );">Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,705<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,644)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 8,939<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as non-current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6725567504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Cash Flows (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation</a></td>
<td class="num">&#8364; (4,593)<span></span>
</td>
<td colspan="2" class="num">&#8364; (19,601)<span></span>
</td>
<td class="num">&#8364; (13,026)<span></span>
</td>
<td class="num">&#8364; (39,324)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangeInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (5,796)<span></span>
</td>
<td class="num">(6,899)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember', window );">Previously stated [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,132)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangeInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,091)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member', window );">Increase (decrease) due to application of IFRS 15 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedCashFlowStatementsCaptionsLineItems', window );"><strong>Condensed Cash Flow Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Result after taxation</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangeInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (3,808)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in deferred income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2018-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2018-03-02&amp;anchor=para_39L_e&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2018-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=17&amp;date=2018-03-01&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ChangeInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ChangeInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedCashFlowStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedCashFlowStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_PreviouslyStatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6726708464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Use of Estimates, Judgments and Assumptions - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expenses</a></td>
<td class="nump">&#8364; 87<span></span>
</td>
<td class="nump">&#8364; 107<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 139<span></span>
</td>
<td class="nump">&#8364; 118<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expenses</a></td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2018-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=26&amp;date=2018-03-01&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6725578288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Investments, current portion</a></td>
<td class="nump">&#8364; 37,077<span></span>
</td>
<td class="nump">&#8364; 34,043<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentHeldtomaturityInvestments', window );">Non-current investments</a></td>
<td class="nump">16,650<span></span>
</td>
<td class="nump">7,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_HeldtomaturityInvestments', window );">Total investments</a></td>
<td class="nump">53,727<span></span>
</td>
<td class="nump">41,103<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_CommercialPaper1Member', window );">Commercial paper [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Investments, current portion</a></td>
<td class="nump">17,715<span></span>
</td>
<td class="nump">15,527<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_USTreasurySecuritiesMember', window );">U.S. Treasury securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Investments, current portion</a></td>
<td class="nump">2,574<span></span>
</td>
<td class="nump">9,177<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_CorporateFixedIncomeBondsMember', window );">Corporate fixed income bonds [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Investments, current portion</a></td>
<td class="nump">15,289<span></span>
</td>
<td class="nump">7,886<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentHeldtomaturityInvestments', window );">Non-current investments</a></td>
<td class="nump">16,650<span></span>
</td>
<td class="nump">7,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_AgencyBondMember', window );">Agency bond [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentHeldtomaturityInvestments', window );">Investments, current portion</a></td>
<td class="nump">&#8364; 1,499<span></span>
</td>
<td class="nump">&#8364; 1,453<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentHeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current held-to-maturity investments. [Refer: Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentHeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets with fixed or determinable payments and fixed maturity that an entity has the positive intention and ability to hold to maturity other than: (a) those that the entity upon initial recognition designates as at fair value through profit or loss; (b) those that the entity designates as available for sale; and (c) those that meet the definition of loans and receivables. An entity shall not classify any financial assets as held to maturity if the entity has, during the current financial year or during the two preceding financial years, sold or reclassified more than an insignificant amount of held-to-maturity investments before maturity (more than insignificant in relation to the total amount of held-to-maturity investments) other than sales or reclassifications that: (i) are so close to maturity or the financial asset&#8217;s call date (for example, less than three months before maturity) that changes in the market rate of interest would not have a significant effect on the financial asset&#8217;s fair value; (ii) occur after the entity has collected substantially all of the financial asset&#8217;s original principal through scheduled payments or prepayments; or (iii) are attributable to an isolated event that is beyond the entity&#8217;s control, is non-recurring and could not have been reasonably anticipated by the entity. [Refer: Derivative financial assets; Held-to-maturity investments; Prepayments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentHeldtomaturityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current held-to-maturity investments. [Refer: Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 8<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_8_b&amp;doctype=Standard&amp;book=b<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentHeldtomaturityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_CommercialPaper1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=mrus_CommercialPaper1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=mrus_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_CorporateFixedIncomeBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=mrus_CorporateFixedIncomeBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfFinancialAssetsAxis=mrus_AgencyBondMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfFinancialAssetsAxis=mrus_AgencyBondMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6701609616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Purchases of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 29,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Proceeds from investment maturities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign currency exchange gains</a></td>
<td class="nump">&#8364; 6,917<span></span>
</td>
<td class="nump">4,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncomeStatementLineItemLocationAxis=mrus_NetFinanceIncomeExpenseMember', window );">Finance Income Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign currency exchange gains</a></td>
<td class="nump">&#8364; 3,100<span></span>
</td>
<td class="nump">&#8364; 1,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2018-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2018-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeStatementLineItemLocationAxis=mrus_NetFinanceIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeStatementLineItemLocationAxis=mrus_NetFinanceIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6719562064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Trade and Other Receivables - Summary of Trade and Other Receivables Due Within 1 Year (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 2,069<span></span>
</td>
<td class="nump">&#8364; 1,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CurrentUnbilledReceivables', window );">Unbilled receivables</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">VAT receivable</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CurrentPrepaidGeneralExpenses', window );">Prepaid expenses</a></td>
<td class="nump">1,640<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CurrentPrepaidPensionCosts', window );">Prepaid pension costs</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CurrentInterestBank', window );">Interest bank</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Total</a></td>
<td class="nump">&#8364; 5,477<span></span>
</td>
<td class="nump">&#8364; 4,413<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CurrentInterestBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current interest bank.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CurrentInterestBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CurrentPrepaidGeneralExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current prepaid general expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CurrentPrepaidGeneralExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CurrentPrepaidPensionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current prepaid pension costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CurrentPrepaidPensionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CurrentUnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current unbilled Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CurrentUnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6719221664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities ans Accruals - Summary of Short-term and Payable Within 1 Year (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfAccrualsAndOtherPayablesAbstract', window );"><strong>Disclosure of accruals and other payables [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccruedAuditorsFee', window );">Accrued auditor's fee</a></td>
<td class="nump">&#8364; 90<span></span>
</td>
<td class="nump">&#8364; 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccruedPersonnel', window );">Personnel</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccruedResearchAndDevelopmentStudies', window );">R&amp;D costs</a></td>
<td class="nump">8,777<span></span>
</td>
<td class="nump">5,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AccruedIntellectualPropertyLegalFee', window );">IP - Legal fee</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_Bonuses', window );">Bonuses</a></td>
<td class="nump">940<span></span>
</td>
<td class="nump">1,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SubsidyAdvanceReceived', window );">Subsidy advance received</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherAccruals', window );">Other accruals</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Total</a></td>
<td class="nump">&#8364; 10,860<span></span>
</td>
<td class="nump">&#8364; 8,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccruedAuditorsFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>accrued auditors fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccruedAuditorsFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccruedIntellectualPropertyLegalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued intellectual property legal fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccruedIntellectualPropertyLegalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccruedPersonnel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccruedPersonnel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AccruedResearchAndDevelopmentStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development studies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AccruedResearchAndDevelopmentStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_Bonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_Bonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfAccrualsAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accruals and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfAccrualsAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SubsidyAdvanceReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidy advance received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SubsidyAdvanceReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6725403968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deferred Revenue - Summary of Deferred Revenue (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeAbstract', window );"><strong>Disclosure of deferred income [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsCurrent', window );">Deferred revenue - current portion</a></td>
<td class="nump">&#8364; 16,972<span></span>
</td>
<td class="nump">&#8364; 15,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">105,718<span></span>
</td>
<td class="nump">112,551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncome', window );">Total deferred revenue</a></td>
<td class="nump">&#8364; 122,690<span></span>
</td>
<td class="nump">&#8364; 128,486<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability representing income that has been received but is not yet earned. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncomeClassifiedAsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred income classified as non-current. [Refer: Deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncomeClassifiedAsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDeferredIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deferred income [abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDeferredIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6728828640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Revenue - Additional Information (Detail)<br> $ / shares in Units, &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 13, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><sup>[1]</sup></th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncome', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 122,690<span></span>
</td>
<td class="nump">&#8364; 122,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 128,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="nump">$ 55,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 44,800<span></span>
</td>
<td class="nump">$ 55,800<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="nump">&#8364; 74,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayment', window );">Non-refundable upfront payment received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrus_UpfrontAndMilestonePaymentsMember', window );">Upfront and Milestone Payments [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember', window );">Incyte Corporation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NonRefundableUpfrontPaymentsReceivable', window );">Non-refundable upfront payment receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 74,700<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RemainingPeriodOfDeferredRevenueAmortization', window );">Remaining estimated amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember', window );">Incyte Corporation [member] | Deferred revenue [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayment', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FairValueOfDerivatives', window );">Fair value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31,400<span></span>
</td>
<td class="nump">31,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember', window );">Incyte collaboration agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncome', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,600<span></span>
</td>
<td class="nump">120,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember', window );">Simcere collaboration and license agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncome', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayment', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember', window );">ONO Research and License Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredIncome', window );">Total deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueRemainingPerformanceObligations', window );">Performance obligation recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AmountPaidForFullTimeEquivalentFunding', window );">Paid for full time equivalent funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AmountPaidToCompensateForResearchServices', window );">Compensate for research service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember', window );">ONO Research and License Agreement [member] | Deferred revenue [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfDeferredIncomeLineItems', window );"><strong>Disclosure of deferred income [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPayment', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="15"></td></tr>
<tr><td colspan="15"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability representing income that has been received but is not yet earned. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AmountPaidForFullTimeEquivalentFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid for full time equivalent funding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AmountPaidForFullTimeEquivalentFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AmountPaidToCompensateForResearchServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid to compensate for research services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AmountPaidToCompensateForResearchServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfDeferredIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfDeferredIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_FairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_FairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NonRefundableUpfrontPaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NonRefundableUpfrontPaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RemainingPeriodOfDeferredRevenueAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining period of deferred revenue amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RemainingPeriodOfDeferredRevenueAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue remaining performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharePurchasedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share purchased price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharePurchasedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrus_UpfrontAndMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrus_UpfrontAndMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=mrus_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=mrus_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6733700720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Additional Information (Detail)<br> &#8364; / shares in Units, $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 15, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 13, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th" colspan="2">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 13, 2018 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 44,800,000<span></span>
</td>
<td class="nump">$ 55.8<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 44,731,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 74,431,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Issue price per share | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,900,000<span></span>
</td>
<td class="num">&#8364; (2,800,000)<span></span>
</td>
<td class="num">&#8364; (12,000,000)<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInCapital', window );">Increased capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,978<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInSharePremium', window );">Increased premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 62,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 216,830<span></span>
</td>
<td class="nump">&#8364; 62,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 216,830<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of share options exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,041<span></span>
</td>
<td class="nump">34,041<span></span>
</td>
<td class="nump">110,869<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares fully issued and paid | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,869<span></span>
</td>
<td class="nump">34,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,869<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ShareBasedPaymentExpense', window );">Share based payment expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,900,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Option granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,068<span></span>
</td>
<td class="nump">469,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharebasedCompensationWeightedAverageRemainingContractualLife', window );">Weighted-average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePrice1', window );">Weighted-average share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of share options outstanding in share-based payment arrangement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,631,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,631,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,213,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of new RSUs granted during the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 27.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 27.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember', window );">Incyte Corporation [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 74,700,000<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NetProceedsFromIssuingShares', window );">Proceeds from net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements', window );">Change in fair value asset and discount on share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInCapital', window );">Increased capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInSharePremium', window );">Increased premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 73,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 73,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_NonexecutiveCompensationProgramMember', window );">Non-Executive Compensation Program [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfInitialVestingOptions', window );">Percentage of initial vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfRemainingVestingOptions', window );">Percentage of remaining vesting options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PeriodOfRemainingOptionsVestingPeriod', window );">Period of remaining option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 substantially equal monthly installments<span></span>
</td>
<td class="text">24 substantially equal monthly installments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Three-year period<span></span>
</td>
<td class="text">Three-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PeriodOfAwardsWillBeVestedAndExercised', window );">Period of option will be vested and exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12  substantially equal monthly installments<span></span>
</td>
<td class="text">12  substantially equal monthly installments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfGrantAward', window );">Description of grant award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Following the vesting commencement  date, such that the subsequent award shall be fully vested on the first  anniversary of the date of grant.<span></span>
</td>
<td class="text">Following the vesting commencement  date, such that the subsequent award shall be fully vested on the first  anniversary of the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_TwoThousandSixteenOptionPlanMember', window );">2016 Plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfOptionsGranted', window );">Description of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Options granted under the 2016 Plan are exercisable once vested.<span></span>
</td>
<td class="text">Options granted under the 2016 Plan are exercisable once vested.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharebasedCompensationAwardVestingPeriod', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfInitialVestingOptions', window );">Percentage of initial vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfRemainingVestingOptions', window );">Percentage of remaining vesting options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PeriodOfRemainingOptionsVestingPeriod', window );">Period of remaining option vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 monthly installments<span></span>
</td>
<td class="text">36 monthly installments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PercentageOfVestingOptions', window );">Percentage of vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DescriptionOfOptionLapse', window );">Description of option lapse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Options will lapse on the tenth anniversary of the date of grant.<span></span>
</td>
<td class="text">Options will lapse on the tenth anniversary of the date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod', window );">Vesting period of Restricted Stock Units vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_NumberOfCommonShareEntitledToReceive', window );">Number of common share entitled to receive | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Option granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,068<span></span>
</td>
<td class="nump">469,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Option grant fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Increase in authorized share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,090,368<span></span>
</td>
<td class="nump">777,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid', window );">Number of shares fully issued and paid | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,632,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,396,720<span></span>
</td>
<td class="nump">22,632,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,396,720<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_PotentialOrdinaryShareTransactionsMember', window );">Potential ordinary share transactions [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Common shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,099,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Purchase price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_PotentialOrdinaryShareTransactionsMember', window );">Potential ordinary share transactions [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ProceedsFromIssuanceOfPrivatePlacementUnits', window );">Received from issuance of private placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_PotentialOrdinaryShareTransactionsMember', window );">Potential ordinary share transactions [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ProceedsFromIssuanceOfPrivatePlacementUnits', window );">Received from issuance of private placement</a></td>
<td class="nump">&#8364; 44,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="19"></td></tr>
<tr><td colspan="19"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=sect_AStatementofcashflowsforanentityotherthanafinancialinstitution&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2018-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2018-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssuedAndFullyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity, for which full payment has been received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_79_a_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssuedAndFullyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of financial assets and liabilities and exchange movements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ChangesInFairValueOfFinancialAssetsAndLiabilitiesAndExchangeMovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfGrantAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of grant award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfGrantAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfOptionLapse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of option lapse.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfOptionLapse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DescriptionOfOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DescriptionOfOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseDecreaseInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseDecreaseInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseDecreaseInSharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in share premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseDecreaseInSharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NetProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NetProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfCommonShareEntitledToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common share entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfCommonShareEntitledToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of instruments other equity instruments vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_NumberOfInstrumentsOtherEquityInstrumentsVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PercentageOfInitialVestingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of initial vesting options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PercentageOfInitialVestingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PercentageOfRemainingVestingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining vesting options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PercentageOfRemainingVestingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PercentageOfVestingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PercentageOfVestingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PeriodOfAwardsWillBeVestedAndExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of awards will be vested and exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PeriodOfAwardsWillBeVestedAndExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PeriodOfRemainingOptionsVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of remaining options vesting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PeriodOfRemainingOptionsVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of vesting installments of initial vesting awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PeriodOfVestingInstallmentsOfInitialVestingAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ProceedsFromIssuanceOfPrivatePlacementUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of private placement units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ProceedsFromIssuanceOfPrivatePlacementUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangements by Share Based Payment Award Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation other equity instruments grants in period weighted average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ShareBasedCompensationOtherEquityInstrumentsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ShareBasedPaymentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Payment Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ShareBasedPaymentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price 1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharePurchasedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share purchased price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharePurchasedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharebasedCompensationAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Award Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharebasedCompensationAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharebasedCompensationWeightedAverageRemainingContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Weighted Average Remaining Contractual Life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharebasedCompensationWeightedAverageRemainingContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_NonexecutiveCompensationProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_NonexecutiveCompensationProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_TwoThousandSixteenOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=mrus_TwoThousandSixteenOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_PotentialOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_PotentialOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6729427008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 13, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Share price at grant date | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (weighted-average)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ContractualLifeOfShareAwards', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FairValueAssumptionsGrantDateSharePrice', window );">Fair value at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Share price at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EmployeeOptionExercisedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (based on government bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.79%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FairValueAssumptionsGrantDateSharePrice', window );">Fair value at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Share price at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EmployeeOptionExercisedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (based on government bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.94%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember', window );">All other employees [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility (weighted-average)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ContractualLifeOfShareAwards', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember', window );">All other employees [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FairValueAssumptionsGrantDateSharePrice', window );">Fair value at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Share price at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EmployeeOptionExercisedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (based on government bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.84%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember', window );">All other employees [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FairValueAssumptionsGrantDateSharePrice', window );">Fair value at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SharePurchasedPricePerShare', window );">Share price at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_EmployeeOptionExercisedPricePerShare', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate (based on government bonds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.94%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ContractualLifeOfShareAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual life of share awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ContractualLifeOfShareAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_EmployeeOptionExercisedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee option exercised price per share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_EmployeeOptionExercisedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_FairValueAssumptionsGrantDateSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assumptions grant date share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_FairValueAssumptionsGrantDateSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SharePurchasedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share purchased price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SharePurchasedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6719589232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Reconciliation of Outstanding Share Options (Detail)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>shares </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at January 1 | shares</a></td>
<td class="nump">2,213,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the six-month period | shares</a></td>
<td class="num">(12,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the six-month period | shares</a></td>
<td class="num">(5,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the six-month period | shares</a></td>
<td class="num">(34,041)<span></span>
</td>
<td class="num">(110,869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the six-month period | shares</a></td>
<td class="nump">469,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at June 30 | shares</a></td>
<td class="nump">2,631,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable at June 30 | shares</a></td>
<td class="nump">1,105,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement', window );">Outstanding at January 1 | &#8364; / shares</a></td>
<td class="nump">&#8364; 13.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement', window );">Forfeited during the six-month period | &#8364; / shares</a></td>
<td class="nump">19.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePricePerShareOptionsExpired', window );">Expired during the six-month period | &#8364; / shares</a></td>
<td class="nump">14.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement', window );">Exercised during the six-month period | &#8364; / shares</a></td>
<td class="nump">1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement', window );">Granted during the six-month period | &#8364; / shares</a></td>
<td class="nump">14.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement', window );">Outstanding at June 30 | &#8364; / shares</a></td>
<td class="nump">14.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement', window );">Exercisable at June 30 | &#8364; / shares</a></td>
<td class="nump">&#8364; 12.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of share option exercisable in share based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WeightedAverageExercisePriceOfShareOptionExercisableInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of share option exercised in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WeightedAverageExercisePriceOfShareOptionExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of share options and warrants forfeited in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsForfeitedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of share options and warrants granted in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options and warrants outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WeightedAverageExercisePriceOfShareOptionsAndWarrantsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WeightedAverageExercisePricePerShareOptionsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share options expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WeightedAverageExercisePricePerShareOptionsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6726044400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Number of Share Options Outstanding (Detail) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of outstanding share options</a></td>
<td class="nump">2,631,822<span></span>
</td>
<td class="nump">2,213,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of outstanding share options</a></td>
<td class="nump">2,153,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember', window );">All other employees [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of outstanding share options</a></td>
<td class="nump">478,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_AllOtherEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6719388096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity - Summary of Reconciliation of RSU's (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding beginning balance | &#8364;</a></td>
<td class="nump">&#8364; 20.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the six month period | &#8364;</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the six month period | &#8364;</a></td>
<td class="nump">20.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement', window );">Granted during the six month period | &#8364;</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding ending balance | &#8364;</a></td>
<td class="nump">&#8364; 20.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding beginning balance | shares</a></td>
<td class="nump">194,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the six month period | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested during the six month period | shares</a></td>
<td class="num">(76,245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the six month period | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding ending balance | shares</a></td>
<td class="nump">118,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6718709616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Summary of Revenue (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">&#8364; 6,543<span></span>
</td>
<td class="nump">&#8364; 6,237<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 16,464<span></span>
</td>
<td class="nump">&#8364; 10,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_UpfrontPaymentAmortizationMember', window );">Up-front payment amortization [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">4,250<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,087<span></span>
</td>
<td class="nump">6,898<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CollaborationIncomeMember', window );">Collaboration income [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">2,179<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,195<span></span>
</td>
<td class="nump">2,391<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RevenueFromContractsWithCustomersMember', window );">Revenue from contracts with customers [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">6,429<span></span>
</td>
<td class="nump">5,444<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,282<span></span>
</td>
<td class="nump">9,289<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncomeMember', window );">Income from grants on research projects [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total Revenue</a></td>
<td class="nump">&#8364; 114<span></span>
</td>
<td class="nump">&#8364; 793<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 182<span></span>
</td>
<td class="nump">&#8364; 832<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=5&amp;date=2018-03-01&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue [line items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_UpfrontPaymentAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_UpfrontPaymentAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CollaborationIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CollaborationIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RevenueFromContractsWithCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_RevenueFromContractsWithCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_IncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6732520496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 12, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 6,543<span></span>
</td>
<td class="nump">&#8364; 6,237<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 16,464<span></span>
</td>
<td class="nump">&#8364; 10,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_GrantIncome', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ReimbursementOfGrant', window );">Reimbursement of grant</a></td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_TermsOfPaymentOfTradeReceivables', window );">Payment terms related to receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueRecognizedIncludedInDeferredRevenue', window );">Revenue recognized included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 7,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueRecognizedNotIncludedInDeferredRevenue', window );">Revenue recognized not included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CollaborationIncomeMember', window );">Collaboration income [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,195<span></span>
</td>
<td class="nump">2,391<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember', window );">Incyte collaboration agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPaymentAmortization', window );">Up-front payment amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestoneRevenuesAndCostsReimbursements', window );">Cost reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember', window );">ONO Research and License Agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPaymentAmortization', window );">Up-front payment amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestoneRevenuesAndCostsReimbursements', window );">Cost reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">200<span></span>
</td>
<td class="nump">&#8364; 2,400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestoneRevenues', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember', window );">Simcere collaboration and license agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_UpfrontPaymentAmortization', window );">Up-front payment amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_MilestoneRevenues', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_IFRS15RevenueFromContractsWithCustomersMember', window );">IFRS 15 revenue from contracts with customers [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RevenueLineItems', window );"><strong>Revenue [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncreaseDecreaseInDeferredRevenue1', window );">Decrease in Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 8,700<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2018-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=5&amp;date=2018-03-01&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_GrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_GrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncreaseDecreaseInDeferredRevenue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncreaseDecreaseInDeferredRevenue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_MilestoneRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_MilestoneRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_MilestoneRevenuesAndCostsReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone revenues and costs reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_MilestoneRevenuesAndCostsReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ReimbursementOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ReimbursementOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue [line items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueRecognizedIncludedInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized included in deferred revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueRecognizedIncludedInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RevenueRecognizedNotIncludedInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized not included in deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RevenueRecognizedNotIncludedInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_TermsOfPaymentOfTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terms of payment of trade receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_TermsOfPaymentOfTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_UpfrontPaymentAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Up-front payment amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_UpfrontPaymentAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CollaborationIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=mrus_CollaborationIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_IncyteCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_OnoResearchAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=mrus_SimcereCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_IFRS15RevenueFromContractsWithCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=mrus_IFRS15RevenueFromContractsWithCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6733052768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Disclosure Of Changes In Trade Receivables Contract Assets And Contract Liabilities Explanatory (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems', window );"><strong>Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables, beginning balance</a></td>
<td class="nump">&#8364; 1,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsToTradeAndOtherReceivables', window );">Trade and other receivables, additions</a></td>
<td class="nump">12,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInTradeAndOtherReceivables', window );">Trade and other receivables, deductions</a></td>
<td class="num">(11,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables, ending balance</a></td>
<td class="nump">2,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Contract assets, beginning balance</a></td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsInContractAssets', window );">Contract assets, additions</a></td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInContractAssets', window );">Contract assets, deductions</a></td>
<td class="num">(957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Contract assets, ending balance</a></td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities, beginning balance</a></td>
<td class="nump">128,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsInContractLiabilities', window );">Contract liabilities, additions</a></td>
<td class="nump">3,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInContractLiabilities', window );">Contract liabilities, deductions</a></td>
<td class="num">(9,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities, ending balance</a></td>
<td class="nump">122,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=mrus_DeferredRevenueMember', window );">Deferred revenue [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems', window );"><strong>Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities, beginning balance</a></td>
<td class="nump">128,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsInContractLiabilities', window );">Contract liabilities, additions</a></td>
<td class="nump">3,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInContractLiabilities', window );">Contract liabilities, deductions</a></td>
<td class="num">(9,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities, ending balance</a></td>
<td class="nump">122,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradeReceivablesMember', window );">Trade receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems', window );"><strong>Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables, beginning balance</a></td>
<td class="nump">1,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsToTradeAndOtherReceivables', window );">Trade and other receivables, additions</a></td>
<td class="nump">12,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInTradeAndOtherReceivables', window );">Trade and other receivables, deductions</a></td>
<td class="num">(11,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivables', window );">Trade and other receivables, ending balance</a></td>
<td class="nump">2,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=mrus_UnbilledReceivablesMember', window );">Unbilled receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems', window );"><strong>Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Contract assets, beginning balance</a></td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AdditionsInContractAssets', window );">Contract assets, additions</a></td>
<td class="nump">693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DeductionsInContractAssets', window );">Contract assets, deductions</a></td>
<td class="num">(957)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractAssets', window );">Contract assets, ending balance</a></td>
<td class="nump">&#8364; 446<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity&#8217;s future performance).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2018-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=15&amp;date=2018-03-01&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdditionsInContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions in contract assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdditionsInContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdditionsInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions in contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdditionsInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AdditionsToTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions to trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AdditionsToTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DeductionsInContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deductions in contract assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DeductionsInContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DeductionsInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deductions in contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DeductionsInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DeductionsInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deductions in trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DeductionsInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of changes in trade receivables, contract assets and contract liabilities [line items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=mrus_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=mrus_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradeReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_TradeReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=mrus_UnbilledReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=mrus_UnbilledReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6725495824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses - Summary of Total Operating Expenses (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingExpensesAbstract', window );"><strong>Disclosure Of Operating Expenses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ManufacturingCost', window );">Manufacturing costs</a></td>
<td class="nump">&#8364; 5,580<span></span>
</td>
<td class="nump">&#8364; 2,236<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 9,858<span></span>
</td>
<td class="nump">&#8364; 5,611<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IPAndLicenseCosts', window );">IP and license costs</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">844<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PersonnelRelatedResearchAndDevelopmentExpense', window );">Personnel related R&amp;D</a></td>
<td class="nump">2,107<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,808<span></span>
</td>
<td class="nump">3,303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherResearchAndDevelopmentExpenses', window );">Other research and development costs</a></td>
<td class="nump">4,344<span></span>
</td>
<td class="nump">3,810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,311<span></span>
</td>
<td class="nump">5,545<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Total research and development costs</a></td>
<td class="nump">12,523<span></span>
</td>
<td class="nump">8,420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">22,821<span></span>
</td>
<td class="nump">15,427<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">Management and administration costs</a></td>
<td class="nump">2,639<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,491<span></span>
</td>
<td class="nump">7,694<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LitigationCosts', window );">Litigation costs</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">849<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherOperatingExpenses', window );">Other operating expenses</a></td>
<td class="nump">2,745<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,134<span></span>
</td>
<td class="nump">3,726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Total other expenses</a></td>
<td class="nump">3,297<span></span>
</td>
<td class="nump">2,277<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,983<span></span>
</td>
<td class="nump">4,120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">&#8364; 18,459<span></span>
</td>
<td class="nump">&#8364; 14,189<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 34,295<span></span>
</td>
<td class="nump">&#8364; 27,241<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses [abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IPAndLicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>I p and license costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IPAndLicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LitigationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LitigationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ManufacturingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Manufacturing cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ManufacturingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other research and development expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PersonnelRelatedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Personnel related research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PersonnelRelatedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720667168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses - Additional Information (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th" colspan="2">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingExpensesAbstract', window );"><strong>Disclosure Of Operating Expenses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development costs | &#8364;</a></td>
<td class="nump">&#8364; 12,523<span></span>
</td>
<td class="nump">&#8364; 8,420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">&#8364; 22,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,427<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_AttorneysFees', window );">Attorneys' fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,332,453.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Expert fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,390.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LitigationExpenses', window );">Litigation expenses and costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,717,100.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LitigationAndOppositionExpenses', window );">Litigation and opposition | &#8364;</a></td>
<td class="nump">&#8364; 600<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 400<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2018-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2018-03-01&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_AttorneysFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Attorneys fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_AttorneysFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses [abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LitigationAndOppositionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation and opposition expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LitigationAndOppositionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LitigationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Litigation expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LitigationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6725609600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Total Operating Expenses - Breakdown of Other Research and Development Costs (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingExpensesAbstract', window );"><strong>Disclosure Of Operating Expenses [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DiscoveryAndPreclinicalCosts', window );">Discovery and pre-clinicalcosts</a></td>
<td class="nump">&#8364; 1,078<span></span>
</td>
<td class="nump">&#8364; 1,698<span></span>
</td>
<td class="nump">&#8364; 1,763<span></span>
</td>
<td class="nump">&#8364; 2,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_ClinicalCosts', window );">Clinical costs</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">4,248<span></span>
</td>
<td class="nump">2,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherResearchAndDevelopmentExpenseOther', window );">Other research and development costs</a></td>
<td class="nump">1,416<span></span>
</td>
<td class="nump">820<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">1,467<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OtherResearchAndDevelopmentExpenses', window );">Total other research and development costs</a></td>
<td class="nump">&#8364; 4,344<span></span>
</td>
<td class="nump">&#8364; 3,810<span></span>
</td>
<td class="nump">&#8364; 8,311<span></span>
</td>
<td class="nump">&#8364; 5,545<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_ClinicalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_ClinicalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Operating Expenses [abstract].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DiscoveryAndPreclinicalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discovery and pre-clinical costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DiscoveryAndPreclinicalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherResearchAndDevelopmentExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other research and development expense other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherResearchAndDevelopmentExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other research and development expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6719538112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Disclosure of Detailed Information About Employee Benefits (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract', window );"><strong>Short-term employee benefits expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Salaries and wages</a></td>
<td class="nump">&#8364; 2,876<span></span>
</td>
<td class="nump">&#8364; 2,451<span></span>
</td>
<td class="nump">&#8364; 5,505<span></span>
</td>
<td class="nump">&#8364; 4,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_WBSOSubsidy', window );">WBSO subsidy</a></td>
<td class="num">(733)<span></span>
</td>
<td class="num">(953)<span></span>
</td>
<td class="num">(1,900)<span></span>
</td>
<td class="num">(2,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security premiums</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_HealthInsurance', window );">Health insurance</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_PensionCosts', window );">Pension costs</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share award expense</a></td>
<td class="nump">2,109<span></span>
</td>
<td class="nump">3,254<span></span>
</td>
<td class="nump">4,554<span></span>
</td>
<td class="nump">7,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherShorttermEmployeeBenefits', window );">Other personnel expense</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Total employee benefits expense</a></td>
<td class="nump">&#8364; 4,931<span></span>
</td>
<td class="nump">&#8364; 5,263<span></span>
</td>
<td class="nump">&#8364; 9,619<span></span>
</td>
<td class="nump">&#8364; 10,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2018-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2018-03-01&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2018-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2018-03-01&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2018-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2018-03-01&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_HealthInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health insurance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_HealthInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_PensionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pension costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_PensionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_WBSOSubsidy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>WBSO subsidy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_WBSOSubsidy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720829056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfShareOfEquityInvestmentLineItems', window );"><strong>Disclosure Of Share Of Equity Investment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockAwardExpense', window );">Stock award expense</a></td>
<td class="nump">&#8364; 2,109<span></span>
</td>
<td class="nump">&#8364; 3,254<span></span>
</td>
<td class="nump">&#8364; 4,554<span></span>
</td>
<td class="nump">&#8364; 7,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ResearchAndDevelopmentCostsMember', window );">Research and development costs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfShareOfEquityInvestmentLineItems', window );"><strong>Disclosure Of Share Of Equity Investment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockAwardExpense', window );">Stock award expense</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">673<span></span>
</td>
<td class="nump">1,525<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember', window );">Management and administration costs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfShareOfEquityInvestmentLineItems', window );"><strong>Disclosure Of Share Of Equity Investment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockAwardExpense', window );">Stock award expense</a></td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">5,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncomeStatementLineItemLocationAxis=mrus_OtherExpensesMember', window );">Other expenses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfShareOfEquityInvestmentLineItems', window );"><strong>Disclosure Of Share Of Equity Investment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_StockAwardExpense', window );">Stock award expense</a></td>
<td class="nump">&#8364; 52<span></span>
</td>
<td class="nump">&#8364; 205<span></span>
</td>
<td class="nump">&#8364; 177<span></span>
</td>
<td class="nump">&#8364; 300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfShareOfEquityInvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share Of Equity Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfShareOfEquityInvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_StockAwardExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock award expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_StockAwardExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ResearchAndDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeStatementLineItemLocationAxis=mrus_ResearchAndDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeStatementLineItemLocationAxis=mrus_OtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeStatementLineItemLocationAxis=mrus_OtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6731089344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;) </div>
<div>Employees</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;) </div>
<div>Employees</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;) </div>
<div>Employees</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;) </div>
<div>Employees</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfEmployeeBenefitsLineItems', window );"><strong>Disclosure of employee benefits [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SubsidiesIncome', window );">Received and recognized subsidies | &#8364;</a></td>
<td class="nump">&#8364; 0.7<span></span>
</td>
<td class="nump">&#8364; 1.0<span></span>
</td>
<td class="nump">&#8364; 1.9<span></span>
</td>
<td class="nump">&#8364; 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NL', window );">Netherlands [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfEmployeeBenefitsLineItems', window );"><strong>Disclosure of employee benefits [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">United States [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfEmployeeBenefitsLineItems', window );"><strong>Disclosure of employee benefits [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember', window );">Management and administration costs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfEmployeeBenefitsLineItems', window );"><strong>Disclosure of employee benefits [line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Number of employees</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfEmployeeBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. Disclosure of employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfEmployeeBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SubsidiesIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidies income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SubsidiesIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_IncomeStatementLineItemLocationAxis=mrus_ManagementAndAdministrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720393296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income and Expense - Summary of Finance Income and Expense (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RentalExpensesOnRealEstateAbstract', window );"><strong>Rental expenses on real estate [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_InterestAndRelatedIncome', window );">Interest income and similar income</a></td>
<td class="nump">&#8364; 494<span></span>
</td>
<td class="nump">&#8364; 420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">&#8364; 834<span></span>
</td>
<td class="nump">&#8364; 610<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Net gain on foreign exchange</a></td>
<td class="nump">6,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">7,411<span></span>
</td>
<td class="nump">420<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,945<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(10,667)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeLoss', window );">Net loss on foreign exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,962)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,029)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance cost</a></td>
<td class="num">&#8364; (1)<span></span>
</td>
<td class="num">&#8364; (11,962)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">&#8364; (1)<span></span>
</td>
<td class="num">&#8364; (22,696)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 3 for details regarding the restatement as a result of a change in accounting policy.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 23<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2018-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2018-03-01&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2018-03-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2018-01-01<br> -Paragraph B13<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2018-03-01&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2018-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2018-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net loss arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2018-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2018-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_InterestAndRelatedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and related income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_InterestAndRelatedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RentalExpensesOnRealEstateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expenses on real estate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RentalExpensesOnRealEstateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6719234944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income and Expense - Additional Information (Detail)<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FinanceIncomeExpenseLineItems', window );"><strong>Finance Income Expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gain 9loss) | &#8364;</a></td>
<td class="nump">&#8364; 6.9<span></span>
</td>
<td class="num">&#8364; (2.8)<span></span>
</td>
<td class="num">&#8364; (12.0)<span></span>
</td>
<td class="nump">&#8364; 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (12.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency', window );">Foreign currency denominated cash and cash equivalent accounts and investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=mrus_PrivatePlacementsMember', window );">Private placements [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_FinanceIncomeExpenseLineItems', window );"><strong>Finance Income Expense [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Increase in cash, cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=sect_AStatementofcashflowsforanentityotherthanafinancialinstitution&amp;doctype=Illustrative%20Examples<br> -URIDate 2018-03-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2018-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2018-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2018-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2018-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent accounts and investment in foreign currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_CashAndCashEquivalentAccountsAndInvestmentInForeignCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_FinanceIncomeExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Income Expense [line items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_FinanceIncomeExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=mrus_PrivatePlacementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=mrus_PrivatePlacementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6701719744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2018</div></th>
<th class="th"><div>Nov. 01, 2016</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_DisclosureOfOperatingLeaseAbstract', window );"><strong>Disclosure of operating lease [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Rental expense</a></td>
<td class="nump">&#8364; 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_OperatingLeaseTermOfLeaseAgreement', window );">Operating lease term of lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_LeasesExpirationPeriod', window );">Leases expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Fourth quarter of 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_RentAndServiceChargesExpense', window );">Rent and service charges expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.3<span></span>
</td>
<td class="nump">&#8364; 0.2<span></span>
</td>
<td class="nump">&#8364; 0.5<span></span>
</td>
<td class="nump">&#8364; 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mrus_SecurityDeposits', window );">Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised on rental activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2018-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2018-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2018-03-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_DisclosureOfOperatingLeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_DisclosureOfOperatingLeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_LeasesExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_LeasesExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_OperatingLeaseTermOfLeaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease term of lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_OperatingLeaseTermOfLeaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_RentAndServiceChargesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent and service charges expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_RentAndServiceChargesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrus_SecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrus_SecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrus_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>84
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W$_:]=0?WCXVO@JJ!7W>AO@!02P,$%     @ 4X.;39E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    " !3@YM-@4OH-!P"  "&!@  &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'55VXZ;,!#]%<0'K+GG(H*TV:IJI5:*MFK[[) AH+4QM9VP
M_?OZPE*$G1?L&9\S9\:7H1P9?Q,M@ S>*>G%(6RE'/8(B;H%BL43&Z!7*PWC
M%$ME\BL2 P=\,21*4!)%!:*XZ\.J-+X3KTIVDZ3KX<0#<:,4\[]'(&P\A''X
MX7CMKJW4#E25 [["#Y _AQ-7%IJC7#H*O>A8'W!H#N%SO#_&AF 0OSH8Q6(>
MZ%+.C+UIX^OE$$8Z(R!02QT"J^$.+T"(CJ3R^#,%#6=-35S./Z)_-L6K8LY8
MP LCO[N+; _A-@PNT. ;D:]L_ )307D83-5_@SL0!=>9*(V:$6&^07T3DM$I
MBDJ%XG<[=KT91[N29Q/-3T@F0C(3XL+48H5,YI^PQ%7)V1APN_D#UF<<[Q.U
M-[5VFJTP:RIYH;SW*BK178>9$$>+2!:(>$8@%7L62'P"Q\2A)WYZZLTO-?1T
M04_]],Q+SPP]6]"S57D6D2\0N5\@]PKDCD"Q$G 1&[] X14H'/IV)> B=GZ!
MC5=@X]#C]17P0![<@:U78NORDY6$!_+@H'=>B9W+7Y^TA10&TEM(D<?IHU+B
MR/]@(E<I7S\9#Z9XH/+@6<9NA,U:Q<6L;Q9:M $*_&H:H AJ=NM-]UUXYR;[
MG)@V\A]N._1WS*]=+X(SDZH9F9;1,"9!91(]J3O>JI_";!!HI)YNU)S;SF@-
MR8:IZZ/YUU/] U!+ P04    " !3@YM-@+57(EP$   -%0  &    'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;(U8V8[C-A#\%<'O69'-0Y)A&]BQ%"1  @PV
M2/998],'5H=7THPW?Q]=XWBZFPN_6!)=S:Z6R"J2JVO=?&M/SG7!C[*HVO7B
MU'6791BVNY,K\_93?7%5_\^A;LJ\ZQ^;8]A>&I?OQZ"R"$$(&Y;YN5IL5F/;
M<[-9U:]=<:[<<Q.TKV69-_\^N:*^KA=R\=[PY7P\=4-#N%E=\J/[RW5_7YZ;
M_BF\];(_EZYJSW45-.ZP7GR6RTR)(6!$_'-VU_;N/AA*>:GK;\/#[_OU0@R,
M7.%VW=!%WE_>W-85Q=!3S^/[W.GBEG,(O+]_[_W7L?B^F)>\==NZ^'K>=Z?U
M(EX$>W?(7XON2WW]S<T%F44P5_^'>W-%#Q^8]#EV==&.O\'NM>WJ<NZEIU+F
M/Z;KN1JOU[G_]S ^ .8 >#1 S0'J%B#U3P/T'* ?#3!S@+D%C/AP*GU\EVG>
MY9M54U^#9AH.EWP8=7)I^J^U&QK'CS/^U[_.MF]]V\AX%;X-_<R0[02!.PA\
M1*04(9,;).SSWT@ 2P+&>'6?0?#QBHU78[R^CY>HB D2C9!JKC.RJ X&)"UZ
M'1F3#'BRFB6K:;Q"9">(O>.A8E10RF D^BX9D\I#U;!4#8W7B*HA-*2U1B"R
M%!4)BT 9D\W#UK)L+8TWB*UEV$:(*X.!!%%E4GFH1BS5B,:CM[&-*(U$1.CU
MIQ056XO9,MD\;&.6;4RGI^7C$S8^H?G12]\FI ZC(_QE*$AKB>9.QB3S%"L%
MKXB"]D D4=#9%PE"F(-IH3%E+J./LT?%)>TAP9PE'5&14/A3I!Q.)S;".LCE
M]+'F95\"[<%BUD#8@(28R"&#DSU*:<R:R>ECS9N-I :@\.2=,1]8*YD8@UE3
MG$QL+,@(>=QT).\Z4I-)K*2G!]X,)-5G!;AN*O0@%!EAC&E$&JL6D\];,V\(
MDLJTPE8KJ=R#B84EXXO!267Q8BEC<GI9\]X@J5SC4;R55/=_Z9T,\/1)6:")
MH\A@WH^;A.1=0L:4-\KRQ&" C*&84$X@CLB:D\*,-8F/,^],,J&SPF-MP+L%
M4.W&XWT+U :D,!$>.RF'DV ,&HL9D]/WK8#W"Y"T[MC3@V?)3G548<<!JLE&
MXQF8,BB(L5)F3#YOS;QN ]50C74;&#T6>#'+@(!X.I/-RY=7;*"K=SJRZ"Y
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M$YR>1I'3*#P-H+-0.($F,/0DFIQ$XTG@MM>8BX@$!SMJB3W!>L<//?4"-F3
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M!GS9U/_:V@ H97.#(]3B!YL-!76(QUL\NW',1B/8;OI!;/[&Q1]02P,$%
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M[\+9CF,V&AZ[Z0>Q^1L7?P!02P,$%     @ 4X.;353O_M&S 0  T@,  !D
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MY]\U=K]&=.!3V=WX 6K]]UH,!;4+QP_^;*8AFPR'_?Q_V/*)BS]02P,$%
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M'\+9CF,V&AZ[Z0>Q^1L7OP%02P,$%     @ 4X.;3<3Z4L<6 @  G 8  !D
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M0>7"\<Z?S3AFH^&PFWX0F[]Q_@=02P,$%     @ 4X.;32,6@2*V 0  T@,
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M4[*#LR%VT%J8/R=0..8TI6^.9]FT+CA8D?6B@>_@?O1GXRVVL%120V<E=L1
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M^;.9QFPR'/;S#V++-R[^ E!+ P04    " !3@YM-;Y ;&+8!  #2 P  &0
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MO"P$U-9/']Q<3V]Y6EC5SVU*EG]%\0E02P,$%     @ 4X.;35(FS[3" 0
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MRJQ>5B3R%]ZE)FHQZP9#^I@A8C-%0-)!/".@4T%0%<3:!P,5@!,$*$%@">B
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MD'II#)K":;I!D^25ETDHPEE%810*HE  A7HH@R:_BD)I[I&$F@(G,$@&@F0
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M+%0WDWTV71730-!AO@;!<A=7_P!02P,$%     @ 4X.;3=RJ1\(S @  4@8
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MK*F!+((((Q3Q$CA%"4W>QZG8W><X-76+1 &G4<8>@@/%>D+'06HV%AD#1L?
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MR([^*GO-5C6\\:2V<9^ORO;_T?U+6>5KJZ5V99W^[OXN-^W?-ZM_)X8+<"O
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M2+B92$B5@S#7(X)O.,(2D29T$"S!]0=FAJ  [E, AUO0"XYTD1RI69>AP%D
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M[D>3.EV>L_1A_V65/5;-1U-_+KJW1;LO5;X]Z=Z$G>Y?QSW]'U!+ P04
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M!*4 B'B@= ;Z@ E*$IB3@9P,X%"/D\TY*4XR&).#F!S )!XFGV-H@A)O>W>
M#&-49 L'H0#C*8!X4B^>8@9*LA)E!<PI04X)<#*/4\[/2T9Q00@,P@C^1!&
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M_^BWTJS0K')H.72J%5T@X5B%'^+UIK!X!_C9PJ 6\\ FV0GQ:A=?#E4864/
M8*^M C7#!3; F!4R-GY/FN&\I24NYU?U3RZ[R;*C"C:"_6H/NJG"/ P.<*1G
MIE_$\!FF/&D83.&_P@68@5LG9H^]8,H]@_U9:<$G%6.%T[=Q;#LW#I/^E>8G
MX(F 9T*<_)= )@*Y(:#1F8OZD6I:EU(,@1P_5D_M/Q&OB3G,O2VZLW/O3%IE
MJI<ZP6F)+E9HPCR/&+S X/>(S3TB+F8(,@9F%]CK CL^6? )_H< \0H0)Y"\
MBY'=Q!@QF<-T8XR,Q#F^#>/!X9@4>>HWE'@-)7>&2+[R"Z1>@?3Q(\F\ MD#
M1Y+=1XU3DL>1?Z.5=Z/5_481]@OD7H'\\:B%5Z!X(&IQ%S59Y5%\:Q0M+HYM
M9-^H/+6="G9"FSOH;LI1" U&,GHRWZ@QO7->,#AJ.UV9N1P[R+C0HI^:(YH[
M=/T74$L#!!0    ( %.#FTT[HJ^/2@(  '8'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;)65VXZ;,!"&7P5QWX#-,1%!2K:J6JF55EMM>^T0)Z U
MF-I.V+Y];4,HA8F4WN #,_\W8\LS6<?%FRPI5<Y[S1JY=4NEVHWGR:*D-9$K
MWM)&_SEQ41.EE^+LR590<K1.-?.P[\=>3:K&S3.[]RSRC%\4JQKZ+!QYJ6LB
M?N\IX]W61>YMXZ4ZE\IL>'G6DC/]3M5K^RSTRAM5CE5-&UGQQA'TM'5W:+-'
M@7&P%C\JVLG)W#&I'#A_,XLOQZWKFX@HHX4R$D0/5_I$&3-*.HY?@Z@[,HWC
M='Y3_V23U\D<B*1/G/VLCJK<NJGK'.F)7)AZX=UG.B04N<Z0_5=ZI4R;FT@T
MH^!,VJ]37*3B]:"B0ZG)>S]6C1V[0?_F!CO@P0&/#CBQN?0@&_E'HDB>"=XY
MHC_\EI@[1ANLSZ8PF_8H[#\=O-2[USS$2>9=C=!@L^]M\,0&C1:>5A\1&$+L
M\<(=KU-8( !C#*Q ,(T1^;! " J$5B#\)\ETEF1ODUJ;IH_27_D!C(E 3 1@
MUC-,;Q-/,'<RB4%$O$0$_@S1VR#\6"H)R$D #IIQDD=324%$"B#P#)'^SZ6L
M0<P:P 0SS'J1"5J'41C#'.3#+\D'2.'\*?F/'AJZ\UX10(GF%+2@?$AB'$9W
M4."[W2$,H.(Y"C^<$/RX40!0%A4H6-X02@-_7H>\2=FKJ3C;@B^=@E\:VVTF
MNV-3V6%;-O^:]QWI&Q'GJI'.@2M=?&V)/'&NJ ['7^E77.HF."X8/2DS3?1<
M])V@7RC>#EW.&UMM_@=02P,$%     @ 4X.;35%),D,> P  E P  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3 N>&ULE5?;<ILP$/T5A@\(Z,+-8WO&U[0S
M[4PFG;;/Q)9M)H HR';Z]Y6 $) 6UWD):'7V:/>LO%FF5UZ^5B?&A/66I7DU
MLT]"%!/'J78GEL75 R]8+G<.O,QB(9?ET:F*DL7[VBE+'>RZOI/%26[/I[7M
MJ9Q/^5FD2<Z>2JLZ9UE<_EVRE%]G-K+?#<_)\224P9E/B_C(?C#QLW@JY<KI
M6/9)QO(JX;E5LL/,7J#)(PJ50XWXE;!KU7NW5"HOG+^JQ=?]S'951"QE.Z$H
M8OFXL!5+4\4DX_C3DMK=F<JQ__[.OJV3E\F\Q!5;\?1WLA>GF1W:UIX=XG,J
MGOGU"VL3\FRKS?X;N[!4PE4D\HP=3ZOZK[4[5X)G+8L,)8O?FF>2U\]KL^.3
MU@UVP*T#[AQ"]Z8#:1U(YX#H30?:.M#.X3;>:_'>QP'>30>_=?#OC2AH'8)A
M1$ZC;5VL=2SB^;3D5ZML[EL1JVN-)H&\#CMEK*M?[\EZ5=)ZF5,23IV+(FHQ
MRP:#^QA_"-F8$-0A'!E %P6&HEABPQT/#UB9"!IH,?R79'N39! F <4BM3\9
MB!7!!!0DH#4![1-05U.[P00U)J\QOD>))@< PD039&V>AC5%-B8/\JE/-=T
ME(LP&J(>;QXW$,<#Q?$ <49ND0\2^/>7)P )@CO*TV#\GA84>QIH98)(%&@U
MW)B@R VU&FY-D!]&(9Q4""85 DF-U"4"":+[944NW&3<.X1M0?U4,0HB35D
MA6B ]'9DH@(4>9JVT(DD&KER:*1_(B U,D(!-K\%PI\0&&Y,B-PC,#'O$L6&
MP";*HY3J ILHY.-0;[@ +,+A6&YPST10TZ0C%'!G0=XG%(9["_+O4=@W&R6B
MNL F*(CTW@ QF>J:H)",_+21WO&&NW#K0&;OT/^#+ &,41VG-XUDK#S6HV=E
M[?@Y%RK^GK4;;Q=833.:?8DF:P38-VH<!NPK/%E#/%L\>83L"Q1(H@ \.7R?
MN)V/%)IY_7M<'I.\LEZXD&-:/4T=.!=,RN,^R*MWDI\(W2)E!Z%> _E>-G-R
MLQ"\:+\!G.Y#9/X/4$L#!!0    ( %.#FTU4?E+.R ,  -\1   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;)58[6Z;,!1]%<0##&S,5Y1$6MO11MJD
M:M.VWS1Q$C3 &3C-]O8SX++@>YVD?Q(PYY[[X>N#\?PDFE_MGG/I_*G*NEVX
M>RD/,\]KUWM>Y>T'<>"U>K(5395+==OLO/;0\'S3&U6E1WT_\JJ\J-WEO!][
M;I9S<91E4?/GQFF/594W?^]X*4X+E[AO U^+W5YV ]YR?LAW_!N7WP_/C;KS
M1I9-4?&Z+43M-'R[<#^2V8JFG4&/^%'P4WMV[72IO CQJ[M9;1:NWT7$2[Z6
M'46N_E[Y/2_+CDG%\5N3NJ//SO#\^HT]ZY-7R;SD+;\7Y<]B(_<+-W&=#=_F
MQU)^%:<GKA,*74=G_YF_\E+!NTB4C[4HV_[761];*2K-HD*I\C_#?U'W_Z?A
M211K,]R :@,Z&B3^18- &P2C 6$7#9@V8+<:A-H@' TNXR.-CVYU$&N#^%:#
M1!LD-T:4:GQJ./"&V>O;X2&7^7+>B)/3#!U]R+N%0V:I:KAU-]CW5_],=42K
M1E^7C(5S[[4CTIB[ 4,GF&B*N8<8.D4\("SQ%))=)7F\3K*"$)*.$$\58ZP(
M12M">_O@W$5@(0A0@J G8.<$J5&M 1+WD+J'1"$+C((A(!H8V7Z"SJA1LPSR
MD(A%S*@L@O())5/4TT5WD]HPM#8,UL:<P/L!$TTB\8W:0$QB8C(&,J(FYO$R
MSR2A$$TH1!)*C/43@D!BFY,(=1(A3HR6RA!,:'$2HTYBA,"8_BR&F:2V5!+4
M2X)X,1LV@0T0V+RDJ)<4*9BE3XF/ZZ)_NPP0B[22ZT*@,>>Y4A*GIG1"%&&Q
M.3D(*B9I:"HHXC%(B24S7"()A3+ ;!2X2)+@'?7%M80@8A(&9H'A"F<^D).;
M4!F"FK2_+C!$1=9%0G!5(8BLA,Q,+80SB:0&U8>$,#7(Q:QKCN J1: $4<8L
M%+@&D?@=78$+#,$4!G0%E!CP;L@0$"'6FN!"1! E@A.97G_C90@(OLXT:/+.
M8[:0*:Y\U$="-E0DTZ!)-*'5$:Z/%.IC0 (+A66O]H[-&L6%B"+;-= O&G1Y
MAJZ IL'@DD8Q20O-8.#&!@GF\BYJ&@PN0A2*$ T2"P4N"31ZQ_S@DD#AOD2U
MM)DMW)@DL5F3U374-!Q37J9/\>5.X7(WM^-W" :HI'?V^5;Q9M>?!K3.6AQK
MV9F>C0XG#@]D]JD_'S#&'\GL"1O_2)/92J4(GZCXW@XOO/^NAZ./+WFS*^K6
M>1%2?9#VGXU;(217:?D?5+?L>;X9;TJ^E=UEK*Z;X<AAN)'BH(]3O/%,9_D/
M4$L#!!0    ( %.#FTW8*N@B/P,  -$.   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;)57VV[;, S]%</OJRW*\:5( C0=A@W8@&+#MF<W41*CMI79
M2M/]_>1+O50Z*I*76%)('M'FX65^DLU3NQ=">2]56;<+?Z_4X38(VO5>5'E[
M(P^BUO]L95/E2F^;7= >&I%O>J6J#"@,XZ#*B]I?SONSAV8YET=5%K5X:+SV
M6%5Y\W<E2GE:^,Q_/?A>[/:J.PB6\T.^$S^$^GEX:/0NF*QLBDK4;2%KKQ';
MA7_';E><=PJ]Q*]"G-JSM=>Y\BCE4[?YLEGX87<C48JUZDSD^O$L[D59=I;T
M/?Z,1OT)LU,\7[]:_]0[KYUYS%MQ+\O?Q4;M%W[J>QNQS8^E^BY/G\7HT,SW
M1N^_BF=1:O'N)AIC+<NV__76QU;):K2BKU+E+\.SJ/OG:;3_JH85:%2@28$&
M7P:@_N8?<Y4OYXT\><WP\@]Y]XW9+>EWL^X.^U?1_Z<OW^K3YV4TB^?!<V=H
ME%D-,G0FPR:)0%N?( A!K,A2SPCK<WA%WNOS-U=,L($(&HAZ ]$; ZGAXR"3
M]#+UX.,LBS#*#*+, $IFH PR\3D*L9!CF!C"Q#9,'!HPL07S@;&84HR30)P$
MX# #)[%P*(PSC))"E!2@D(&26B@)"S%(!D$R ,(-D,P"B3/'=V$A9E((8"*3
M2J']:3)7-#,'91D FIE S **HMB! WE[QPC@6+F!0$BG4>J"PA1G'$ E)A2W
MH'C$'9' <"I@(!?$9BX8A=Y^)"*72S@=,) /8C,?,)00*,Y<3N&4P$!.2%PF
M,-M9<GF299C*#''9"A>;S.^&"R8T0XRVPL6FM#M<"'.:$*?-<"'$:6>X$"8U
M(5*;X4(VJ=\+%\*\)L#KQ%71,5_IBII,F(ET254FFXGNLDR8B'1)8::K*C-A
M'M(EM9FN*\Z$^4J7E&>ZICX39C4!5B>.]HTP6RF[/%@XYB%'/#3[!&[ST-DH
M<,Q"CEAHM@K<9J&S5^"8@AR55K-7X'9I=?<*W-$[H\)J]@JCT'GS:_<*P=E$
M48EFU\]2K;>6Q[H?Y,Y.IWGMCOJ)Y+_X,.Q]RYM=4;?>HU1ZKNFGCZV42NB[
MA#>:B'L]7TZ;4FQ5MTSTNAF&K&&CY&$<((-IBEW^ U!+ P04    " !3@YM-
ML.%?-*L#  "'#P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6R-5]N.
MHT80_17$!RST#1K+MC3XEDB)--HHR3-CMR]:H!W X\W?I[D,:ZIJG'TQT#YU
M.:>*IFM^M]6W^FQ,XWTO\K)>^.>FN<Z"H-Z?39'57^S5E.Z?HZV*K'&/U2FH
MKY7)#IU1D0<\#*.@R"ZEOYQW:Z_5<FYO37XIS6OEU;>BR*I_4Y/;^\)G_L?"
MU\OIW+0+P7)^S4[F#]/\>7VMW%,P>CE<"E/6%UMZE3DN_!<VVS'5&G2(OR[F
M7C_<>RV5-VN_M0^_'A9^V&9D<K-O6A>9N[R;E<GSUI/+XY_!J3_&; T?[S^\
M;SORCLQ;5IN5S?^^')KSPM>^=S#'[)8W7^W]%S,04KXWL/_-O)O<P=M,7(R]
MS>ONU]O?ZL86@Q>72I%][Z^7LKO>!_\?9K0!'PSXSQJ(P4",!DP^-9"#@1P-
MGN/5@%<_ JBG!M%@$/UL1O%@$$\S"GIMNV*MLR9;SBM[]ZJ^WZY9V]9L%KMV
MV+>+7?6[_UR]:K?ZOI2QF ?OK:,!D_88_HB)II -AK 1$;@$QBPXE47*D3F?
M!EAAA(Q!#O_K9/O4R21-08HE.GLQL9>T TDZD)T#.7&@@-H])NXP98=12H=
M#@SB7,"B8%"BE0::$.$B]DGQ%$E*$:1 *FF/B1ZBR 26&&.B$+3B!F.TE( 1
MQB21I@E%)*&(( 2:+8U0$,Y" %IA$(MC!BAAD- AK!(!$@_B3$C%)*F8( 6B
MI#&NDH#RKC!(: ;Z<X-!6C# ?(M!2DE%D](D*4V02@ IC8O %0>-M<(H+3E@
MM<;A.&CB#?;#N>:0.9&3DARTS^YIN(DZ":E.@NP52"1-<+J1  JN,$B@MW>-
M@R%ML!\E$R@-!L51 GIP]S381!D6TI^]$'<.W&33 31M4+AK$2 6@GPW!$A+
M(/.6 (GDD\\+^^1KS@A:L.8#:%+T6"K(BT Q>#38$"C%!-R1"92(>?0)-?*(
M\,(X08U#:AP'X@G<E@D4YW"'7Q,!44<3GE2B!:2/49+!S67W/-Y4(OIXP@1^
MX=%93J#O/=-2P5>>@DFF$Z@1CH@UPJZ$Y(F"(F$8C[ED4*6G$:<JP3/8]%_Z
M,,/P:08R2@F,A.]I\'  +TQUZJ:MVMO;6]FT+!]6QXGNA;<'>+">LMF:$>N;
M=@(DUE=\MJ;\;/EL1ZV_,.D<23*R^A@R@Q\4^A'U]ZPZ7<K:>[.-FTRZ >)H
M;6.</.$7)\_93<7C0VZ.37L;N_NJ'PW[A\9>A[$W&&?OY7]02P,$%     @
M4X.;39$D*7;* @  C0D  !D   !X;"]W;W)K<VAE971S+W-H965T-30N>&UL
MC59_;YLP$/TJB \0P!@P41*I^=5,VJ2JT[:_W<1)4 $SVTFZ;S_;N R,EU:1
M@GU^[][=^<">W2A[Y6="A/=6E36?^V<AFFD0\/V95)A/:$-JN7*DK,)"3MDI
MX TC^*!)51F ,$R#"A>UOYAIVQ-;S.A%E$5-GIC'+U6%V9\E*>EM[D?^N^&Y
M.)V%,@2+68-/Y#L1/YHG)F=!Y^505*3F!:T]1HYS_R&:[J)0$33B9T%NO#?V
M5"HOE+ZJR9?#W ]51*0D>Z%<8/FXDA4I2^5)QO';./4[347LC]^];W7R,ID7
MS,F*EK^*@SC/?>1[!W+$EU(\T]N.F(02WS/9?R574DJXBD1J[&G)];^WOW!!
M*^-%AE+AM_99U/IY:U<R:&AN C $T!%0>)<0&T+<$4!TEP - 7:$^Q$E!I]\
M5B UA/2SA,P0LL\2D"&@80I!NQEZ=]=8X,6,T9O'V@9ML'H/HBF2_;-71MTN
M>DUN,)?6ZP*B>!9<E2.#6;88T,>D0\AF#(DZ1" #Z*( KBB68$3/P5!AY8!8
M<6X^]K(=0R""0\SC7:5!,K&SI+'FQWV-#+H=0*<#J!W 09")M2<M)M.8NBTX
M2(!5D=48A2 (AZ#U6 Y89=N,_0" 0&05SA%3 D$V1.WNR@VJDSBKDSBJ8[7C
MML5$<3_Q. 8PB2>]UAV(I4ZQU"%F);1M,1'HB<$TB?-P$O]GVS.G5N;00I96
M-DXLRN0O#"=I[A9#3C'D$,NM'D.C_4Q#JWE68TQD8S9C#+(QCV,,[&$&">56
M0H-%>8HZ/W/AATV^=&"@O8%![[M:$7;2IR[W]O12"Q5^S]J=[ ] ?9<M^S*:
MKB.'?:-N @[["DS7+C^/8+ISV1_RZ2YWZH;O5XW@7P+M1>4;9J>BYMX+%?*X
MT:?"D5)!9''"B7RESO)NU$U*<A1JF,DQ:R\([430QEQ^@NX&MO@+4$L#!!0
M   ( %.#FTT%*4;P?@(   X(   9    >&PO=V]R:W-H965T<R]S:&5E=#4U
M+GAM;(U686^;,!#]*X@?4(,QD$8D4DDR;=(F59VZ?7:($U !,]L)W;^?;0@E
MMI?M2["/=^_NG0]?LIZR-UX2(KSWIF[YRB^%Z)8 \*(D#>8/M".M?'.DK,%"
M;MD)\(X1?-!.30U@$"2@P57KKS-M>V;KC)Y%7;7DF7G\W#28_<Y)3?N5'_I7
MPTMU*H4R@'76X1/Y3L1K]\SD#DPLAZHA+:]HZS%R7/E/X7*7*KP&_*A(SV=K
M3RG94_JF-E\.*S]0"9&:%$(Q8/FXD VI:T4DT_@U<OI32.4X7U_9/VGM4LL>
M<[*A]<_J(,J5O_"] SGB<RU>:/^9C'IBWQO%?R474DNXRD3&*&C-]:]7G+F@
MS<@B4VGP^_"L6OWL1_ZKF]L!C@YP<I"Q[SE$HT/TX8#N.J#1 ?UOA'ATB(T(
M8-"NB[G% J\S1GN/#>W08=5UX3*6QU4HHSX=_4[6DTOK98T>@PQ<%-&(R0<,
MG&.26\C6AH03 L@$IBR@*XL<6N[P-L#&1J#4R.&?)+N[)#=I1LYB1=H_NO%'
M;@+D)$": -U4.S2J/6!2C6F'4@;IPBB' Y0\&J"M Y0FD5$3&P2#-'&+BIVB
M8H<HH_+Y@$GFJ2QBH\\V#A TF;8V"$%D*-_9('ES0K>HQ"DJL469AY G=KXH
M-+Z,C0U:0$/XUL; *#! .U>TY"_MFSHUI8Z#,MHA3ZUV0!%"AB8;%"U"4Y0-
M6D2AT>P[&Q3'*#9$@=EEUA!VTI.%>P4]MT)]CC/K-+R>H+H,#7L>+C>AP[Z5
MPVZ831_TPZ3\AMFI:KFWIT)>P?JB/%(JB,P]>)!=5LKA/&UJ<A1JF<HU&T;4
ML!&T&Z<OF/X"K/\ 4$L#!!0    ( %.#FTTI#MHU^@(  & +   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;(V676^;,!2&_PKB?@6#S4>41"HDTR9M
M4M5IVS5-G 05< 9.TOW[V892<GS2[B;8SG,^7ML<SOPBVN?NP+ET7NJJZ1;N
M0<KCS/.ZS8'717<GCKQ1_^Q$6Q=23=N]UQU;7FR-45UY@>]'7EV4C;N<F[6'
M=CD7)UF5#7]HG>Y4UT7[-^.5N"Q<XKXN/);[@]0+WG)^+/;\!Y<_CP^MFGFC
MEVU9\Z8K1>.T?+=P[\EL38R!(7Z5_-)-QHZ6\B3$LYY\W2Y<7V?$*[Z1VD6A
M'F>>\ZK2GE0>?P:G[AA3&T['K]X_&_%*S%/1\5Q4O\NM/"S<Q'6V?%><*ODH
M+E_X((BYSJ#^&S_S2N$Z$Q5C(ZK._#J;4R=%/7A1J=3%2_\L&_.\#/Y?S7"#
M8# (1@,5^SV#<# (WPSHNP9T,*#_&X$-!@Q$\'KM9C-7A2R6\U9<G+:_#\="
M7SLR8^JX-GK1G([Y3^UGIU;/2YK2N7?6C@8FZYE@RD37R,I&R$AX*H$QBP#+
M(@LL\^ Z0&X3- 8Y?.AD_:Z3JS1#=+-"8Q]>;1;#'5#4 34.Z)4#L)59S\2&
M:7H920R@'($H(V!#;(@QGX$]L2%*D@ 7Q5!1#!$%SB;KF6@2Y5,<AD 4 J4,
M0"L$(JGO U4(I8KGC;.*4%D1(BL!LB(K#(%,CC#6ZV,SE*9 DLT$:8@+BE%!
M,2((!,EB*T@$D-Q&0BC'1D@"MF6-1+IQZQ)436*I8? 69,G'>>08 U\DFPE3
M>.,0)K@A*$4%I8@@D$B6VG> ^/" ;"@,&*CI*QNB#$)K&XJ3Q,=%$1__OOB(
M+%"7LP&ZTA6 9'($(A2<Y@J!**PS:RQ<1&_(NO'9)(BL$,HB=FU-0P)UV10+
M(ECV$"J-"*P1"*7NQZ0D]=J\27=0\W9O6K7.V8A3(_7W;;(ZMH/W@>XNP'I&
M9CE!UE>Z?33=R)O[OO?\7K3[LNF<)R%53V,ZCYT0DJOL_3M5M0^JW1TG%=])
M/8S5N.U[OGXBQ7'H9[VQJ5[^ U!+ P04    " !3@YM-^S)L.J,"  "?"0
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M1 C'POO$$Q6[B![>3@I\XG*8B#%M.EDSX:3631JT_Q06_P!02P,$%     @
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M;YG^XNPI%2 -94=\KY07[S AL!=JF,DQZZ^??B)H:VY6-%SOQ5]02P,$%
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M_G"6#-/AH)],T^%H9IH%N9*+03\=3(?)"WGL8I8N)O"G.;<(RL5PD,X6<S?
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M9C0=:LE1IR3(A>)7.U-[I7$Y5A*,"G5S,"Q@+6PFHT4O3[_DKK?QY*";)_^
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M-SPQ<-F\&# @7#*^$QPL'[U=AQ?;EY)LL0%$IR!3VC-[K\YEV@:#R6T+]AX
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M$S8EU$=[)YUO&==H]9BLSE(K<\UY[[A.1\FEN&G:9YR@:9ZA346JE A+-DQ
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M^EQJ-\=SJBZT]7XY5G7!)IF9P(MHC_6L*@O#=E=DE,#&ZS:G1;?FK%Q'@;4
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M];!Y1SS4EJ1I9"DU3X("-[3\2Z.,.CYOC0N:A2)%.['J-="G)0SP4%3E5K'
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M9?#&3I7X\/3M!-81$%<MSDW$/1Y<1E*)5Y2'BY8W;O<4#2=M^#MK_78T/>M
MPYMT'-\'_7[;3*V02M;9KHL1U8RN](0>Y#['R)IGGV-XCSA-I=X#!67;=[G\
MS&)GQ[DY'K#T(@U<.I57R;R+ _B\U2.IG7XI=+<>]O<E9R4IB>\86_MWB(#0
M25A+!!\2TS)XPZ_2?,P\W1[_T*9</F\F&.$L!OE1]7'NHNXU\=M)G_&=[3/^
M:RSJ7(;\C'6=J4S] S.EK89V5%,XT[AS*H:F.R?YF/C2F:38&11P5H9R\RU,
M6([)5C-U.:9V[40XSF=N/M%*)4_N]1EXV94O?O:IQ'LZIJA\1:)VQ+DP;_MK
M0'(6_6C- 6]+;^V,S!CWIO&1'1OA&:=%>>K/'/NL;9^F,<](?N\D%P$=X'M\
MBAH$]HZ_J]6@T_'0E<?;R6M/9,.?T ./)L>??/=HLOR)MX\FSY]XMSUO^-1"
M&_GT9X_N'<$I!#KW,$Z-<]ZQG![EO ,Z-<YY1W5JE,Y#.W,;\?&=Q=R/TIDS
M*B3X_L=3!AG?PA/8?GX-"DC5"3JIG;_BF_RNV)(Y0'JH=H>3=B%LTGZX;6K,
MU[[;CE5GONQO5YHJGMSK*1 ][THW%]K^]ED >LZM.^_=H^!I?Z75&?^K^.!U
MD&.F<O:>=Y1JT)XS[84)ND.>6@H3G'*#?EV \KEU"4[-_O<)H"*I9C!DJ:85
MRP0Z\;+\AA)JRXBT6#D4EH6"1BV=H3I OMNL[+$S6HN-KZ0<^='@BI;7L0/
M<X8XBFHQAJ%&$?1D:3[B//$GUGR9>)+E3ZXZQ+NM1)[Y\6;-XA!7'<4A,/H-
M;CWW1FA+T3@S;L:O&]$,)7M&C8BC!*"[ZF0:4^MGO9UI78EGO;6R-2B>]5I(
M;;MT=QO,=W)GT1N=NXF>[-Y!].B9J_8.\SE+#UX[O?[@\3,V$3Q_?"=GQQ3$
M]4(Z0W';*GMT#MM5)R,,->VLIO$KA<(!?6D9O5LI;2EG$;' EBH6+3;[]B(6
MD?AR1JY^.VB?]TZSU$3[.N):$.USAP4FGG'TS\BI.\[D&Z$7,:\YFC[=*3A?
M[8&!;/,G4%5N\U9E-:_VK3]Y ':9XMO5R=,@XKK3#M+=*SL"U&?7X/CEMZN]
M\D6[-SNH>G$,GYZ'T7%EBD"P>&8-BE\8QNYBK+MK(W03G;C,1/,)O[I$]'9'
M,8GF<\U:$C'-.A*OWE),HIV$1#4DVD^\$TSG'//?I7K$K\ERQ,1RJ_8./\/F
MB&3(WM"C0#Y!V+JX\3E5BKK>;=2&Z'3\M!S4WS6%6B<\;ML^[Y60<,3(R:?6
MGA=E79 9M9^RR,;7%:]U)U%W]K2\:V5>!<9N9U-WX8U VCI6H..7F3VH&Z!%
M$;((X!>4"7J$\)VNL-$"CLX"&YVC=]RE8T4RG@7BKT#S$T&V 0IWE8WH2/\Z
M(TPSR"M+%@B$%T<MIV%PYRK?4DL]2OWNJ!F@&>NU-%)3 AAQG::;_JCMR09H
MX&QI5*<@(EU67/J!7OR[E 5XGSW9$-T(Q<H'&[\[/4YTG.R]IK5VWYKPNG7O
MF<<AJ03&Y[]L:'WSM4E'/%/[UP1.XME%=2QEX6UYJ$#F^(]#5DG#Q&%_V%+B
M5OB21-.C%::ZRSME@M<YR<O>JGY7U_O?_S]02P,$%     @ 4X.;35\B=V!P
M @  (PX   T   !X;"]S='EL97,N>&ULU9?=:MLP%,=?1:AEM#!J.VG<=K4-
M6Z$PV$:AN=A=46+9%NC#D^7,Z>6>9T^U)YED^2LN2TGH(+F)C\[1^9V_E)-P
M'!1J3?%CAK$"%:.\"&&F5/[!<8IEAADJ+D2.N8XD0C*D]%*F3I%+C.+")#'J
M3%S7=Q@B'$8!+]D]4P58BI*K$/J="]C\.Q'C$#Z=O?M1"G7[Y]=O8*V3]R<G
M[M/Y[<O(61TZA\!R/L<A]/Q+Z.P"OG"WL75TA)^]@C_=A _8IR/R".SO OXG
M=@2]VO4RMM[%"'Z]VU5LNXLQ^L:@G:9CHB 1O&^<*;0.71LQ#%:(AO .4;*0
MQ&0EB!&ZMNZ)<2P%%1(HW;%:FV<\Q;,->W9EFKGA,,*%K&O;"O9ST6P?!=J5
M$4@H[01.H'5$08Z4PI+?ZT6]N7:^"('&GJ]SK3"5:.U-9K!/J!^ZR$+(&,NN
MC =;5Q10G!@YDJ29>2J1.R:HE&#:B E*!4>UAC:C,31VB2E]-+_T[\D&NTJ
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M<R\N<F5L<U!+ 0(4 Q0    ( %.#FTTGZ(<.@@   +$    0
M  "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 4X.;3;HJ?T_O
M    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ 4X.;39E<G",0!@  G"<  !,              ( !MP(  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !3@YM-@4OH-!P"  "&!@
M&               @ 'X"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 4X.;38"U5R)<!   #14  !@              ( !2@L  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %.#FTU-=WY.8 4
M *(9   8              "  =P/  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " !3@YM-Q(]G3(P$   -%@  &               @ %R
M%0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 4X.;31!&
MS$YE!0  ,AP  !@              ( !-!H  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( %.#FTV$XCJ M $  -(#   8
M  "  <\?  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !3
M@YM-LGP*&;,!  #2 P  &               @ &Y(0  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ 4X.;30M.J<NS 0  T@,  !@
M         ( !HB,  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( %.#FTV@YM.3M $  -(#   8              "  8LE  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !3@YM-CQ]WK;0!  #2 P
M&0              @ %U)P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( %.#FTU4[_[1LP$  -(#   9              "  6 I  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 4X.;3?>!Q\VR
M 0  T@,  !D              ( !2BL  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " !3@YM-#*-[NK,!  #2 P  &0
M@ $S+0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %.#
MFTT%4]D0LP$  -(#   9              "  1TO  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ 4X.;3=\_!Q.U 0  T ,  !D
M         ( !!S$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " !3@YM-* T=R;,!  #2 P  &0              @ 'S,@  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( %.#FTWV@DU'M0$  -(#
M   9              "  =TT  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ 4X.;31RO-8JT 0  T@,  !D              ( !R38
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !3@YM-*7IB
MB[,!  #2 P  &0              @ &T.   >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( %.#FTUU+R#AM $  -(#   9
M  "  9XZ  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M4X.;3<3Z4L<6 @  G 8  !D              ( !B3P  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " !3@YM-4S7A]K<!  #2 P  &0
M            @ '6/@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( %.#FTTC%H$BM@$  -(#   9              "  <1   !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 4X.;3<8AKHRV 0
MT@,  !D              ( !L4(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " !3@YM-;Y ;&+8!  #2 P  &0              @ &>
M1   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %.#FTT5
MITC7M0$  -(#   9              "  8M&  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ 4X.;3:"2IV#; 0   04  !D
M     ( !=T@  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %.#FTWF3]!Q20,  *4,   9              "
M 6-2  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 4X.;
M38YS> W< 0  G@0  !D              ( !XU4  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " !3@YM-]OSH4B("  !$!P  &0
M        @ 'V5P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( %.#FTU3SL'1T ,  -,0   9              "  4]:  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 4X.;39P!>1#! @  ^@D
M !D              ( !5EX  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " !3@YM-L5Z 33,#  "+#   &0              @ %.80
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( %.#FTU01U_W
M< (  &0(   9              "  ;AD  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ 4X.;3<_)P$+D @  ,@L  !D
M ( !7V<  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !3
M@YM-'ZLGDR<"  !)!@  &0              @ %Z:@  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( %.#FTT?35-]E0(  -T(   9
M          "  =AL  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#
M%     @ 4X.;3?B!WBU. @  EP<  !D              ( !I&\  'AL+W=O
M<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " !3@YM-W*I'PC,"  !2
M!@  &0              @ $I<@  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM
M;%!+ 0(4 Q0    ( %.#FTVN2"H\( 4  -<:   9              "  9-T
M  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 4X.;3> Z
M6'XW!P  FBL  !D              ( !ZGD  'AL+W=O<FMS:&5E=',O<VAE
M970T-2YX;6Q02P$"% ,4    " !3@YM-L2Z?$D@#  #H#P  &0
M    @ %8@0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M %.#FTUC.71JQ (  ,P)   9              "  =>$  !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ 4X.;30,7J*KW 0  K04  !D
M             ( !TH<  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " !3@YM-.Z*OCTH"  !V!P  &0              @ $ B@  >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( %.#FTU123)#'@,
M )0,   9              "  8&,  !X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ 4X.;351^4L[( P  WQ$  !D              ( !
MUH\  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !3@YM-
MV"KH(C\#  #1#@  &0              @ '5DP  >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( %.#FTVPX5\TJP,  (</   9
M      "  4N7  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ 4X.;39$D*7;* @  C0D  !D              ( !+9L  'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !3@YM-!2E&\'X"   ."
M&0              @ $NG@  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( %.#FTTI#MHU^@(  & +   9              "  >.@  !X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 4X.;3?LR;#JC
M @  GPD  !D              ( !%*0  'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " !3@YM-9G DPJP"  !;"@  &0
M@ 'NI@  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( %.#
MFTTL\VUNX (  ,\*   9              "  =&I  !X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ 4X.;39^\PEIR @  -0@  !D
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M='EL97,N>&UL4$L! A0#%     @ 4X.;3<<<JQ;1!   FR@   \
M     ( !GA@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %.#FTVQ!/BZ
M& (  .PD   :              "  9P= 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( %.#FTV7BHMLZ $  &LD   3
M  "  >P? 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !& $8 '!,   4B
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>156</ContextCount>
  <ElementCount>259</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Unaudited Condensed Consolidated Statement of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/StatementOfFinancialPositionCurrentNonCurrent-210000</Role>
      <ShortName>Unaudited Condensed Consolidated Statement of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Unaudited Condensed Consolidated Statement of Profit or Loss and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/StatementOfComprehensiveIncomeProfitOrLossByNatureOfExpense-320000</Role>
      <ShortName>Unaudited Condensed Consolidated Statement of Profit or Loss and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Unaudited Condensed Consolidated Statement of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/StatementOfChangesInEquity-610000</Role>
      <ShortName>Unaudited Condensed Consolidated Statement of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Unaudited Condensed Consolidated Statement of Cash flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/StatementOfCashFlowsIndirectMethod-520000</Role>
      <ShortName>Unaudited Condensed Consolidated Statement of Cash flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Disclosure - General information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</Role>
      <ShortName>General information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</Role>
      <ShortName>Significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Recently Issued International Financial Reporting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory</Role>
      <ShortName>Recently Issued International Financial Reporting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Use of Estimates, Judgments and Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccountingJudgementsAndEstimatesExplanatory</Role>
      <ShortName>Use of Estimates, Judgments and Assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Trade and Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory</Role>
      <ShortName>Trade and Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Other Liabilities and Accruals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</Role>
      <ShortName>Other Liabilities and Accruals</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory</Role>
      <ShortName>Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Total Operating Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory</Role>
      <ShortName>Total Operating Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Finance Income and Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory</Role>
      <ShortName>Finance Income and Expense</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingLeaseExplanatory</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEventsAfterReportingPeriodExplanatory</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatoryPolicies</Role>
      <ShortName>Significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Recently Issued International Financial Reporting Standards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatoryTables</Role>
      <ShortName>Recently Issued International Financial Reporting Standards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfChangesInAccountingPoliciesAccountingEstimatesAndErrorsExplanatory</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatoryTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Trade and Other Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatoryTables</Role>
      <ShortName>Trade and Other Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfTradeAndOtherReceivablesExplanatory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Other Liabilities and Accruals (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatoryTables</Role>
      <ShortName>Other Liabilities and Accruals (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Deferred Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatoryTables</Role>
      <ShortName>Deferred Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfDeferredIncomeExplanatory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatoryTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfSharebasedPaymentArrangementsExplanatory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatoryTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfRevenueExplanatory</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Total Operating Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatoryTables</Role>
      <ShortName>Total Operating Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfOperatingExpensesExplanatory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Employee Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatoryTables</Role>
      <ShortName>Employee Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfEmployeeBenefitsExplanatory</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Finance Income and Expense (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatoryTables</Role>
      <ShortName>Finance Income and Expense (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merus.nl/taxonomy/role/NotesToFinancialStatementsDisclosureOfInterestIncomeExpenseExplanatory</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - General Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureGeneralInformationAdditionalInformation</Role>
      <ShortName>General Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Recently Issued International Financial Reporting Standards - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsAdditionalInformation</Role>
      <ShortName>Recently Issued International Financial Reporting Standards - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Profit or Loss and Comprehensive Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfProfitOrLossAndComprehensiveLoss</Role>
      <ShortName>Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Profit or Loss and Comprehensive Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Financial Positions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfFinancialPositions</Role>
      <ShortName>Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Financial Positions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Cash Flows (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRecentlyIssuedInternationalFinancialReportingStandardsCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Recently Issued International Financial Reporting Standards - Condensed Consolidated Statements of Cash Flows (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Use of Estimates, Judgments and Assumptions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureUseOfEstimatesJudgmentsAndAssumptionsAdditionalInformation</Role>
      <ShortName>Use of Estimates, Judgments and Assumptions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Investments - Summary of Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureInvestmentsSummaryOfInvestments</Role>
      <ShortName>Investments - Summary of Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureInvestmentsAdditionalInformation</Role>
      <ShortName>Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Trade and Other Receivables - Summary of Trade and Other Receivables Due Within 1 Year (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureTradeAndOtherReceivablesSummaryOfTradeAndOtherReceivablesDueWithin1Year</Role>
      <ShortName>Trade and Other Receivables - Summary of Trade and Other Receivables Due Within 1 Year (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Other Liabilities ans Accruals - Summary of Short-term and Payable Within 1 Year (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureOtherLiabilitiesAnsAccrualsSummaryOfShorttermAndPayableWithin1Year</Role>
      <ShortName>Other Liabilities ans Accruals - Summary of Short-term and Payable Within 1 Year (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Deferred Revenue - Summary of Deferred Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueSummaryOfDeferredRevenue</Role>
      <ShortName>Deferred Revenue - Summary of Deferred Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Deferred Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureDeferredRevenueAdditionalInformation</Role>
      <ShortName>Deferred Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Shareholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation</Role>
      <ShortName>Shareholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Shareholders' Equity - Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfInputsUsedInTheMeasurementOfTheFairValuesAndTheRelatedFairValuesAtTheGrantDates</Role>
      <ShortName>Shareholders' Equity - Summary of Inputs Used in the Measurement of the Fair Values and the Related Fair Values at the Grant Dates (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Shareholders' Equity - Summary of Reconciliation of Outstanding Share Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfOutstandingShareOptions</Role>
      <ShortName>Shareholders' Equity - Summary of Reconciliation of Outstanding Share Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Shareholders' Equity - Summary of Number of Share Options Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfNumberOfShareOptionsOutstanding</Role>
      <ShortName>Shareholders' Equity - Summary of Number of Share Options Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Shareholders' Equity - Summary of Reconciliation of RSU's (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureShareholdersEquitySummaryOfReconciliationOfRSUs</Role>
      <ShortName>Shareholders' Equity - Summary of Reconciliation of RSU's (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Revenue - Summary of Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRevenueSummaryOfRevenue</Role>
      <ShortName>Revenue - Summary of Revenue (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRevenueAdditionalInformation</Role>
      <ShortName>Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - Revenue - Disclosure Of Changes In Trade Receivables Contract Assets And Contract Liabilities Explanatory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureRevenueDisclosureOfChangesInTradeReceivablesContractAssetsAndContractLiabilitiesExplanatory</Role>
      <ShortName>Revenue - Disclosure Of Changes In Trade Receivables Contract Assets And Contract Liabilities Explanatory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - Total Operating Expenses - Summary of Total Operating Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesSummaryOfTotalOperatingExpenses</Role>
      <ShortName>Total Operating Expenses - Summary of Total Operating Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Total Operating Expenses - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesAdditionalInformation</Role>
      <ShortName>Total Operating Expenses - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Total Operating Expenses - Breakdown of Other Research and Development Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureTotalOperatingExpensesBreakdownOfOtherResearchAndDevelopmentCosts</Role>
      <ShortName>Total Operating Expenses - Breakdown of Other Research and Development Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>157 - Disclosure - Employee Benefits - Disclosure of Detailed Information About Employee Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsDisclosureOfDetailedInformationAboutEmployeeBenefits</Role>
      <ShortName>Employee Benefits - Disclosure of Detailed Information About Employee Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>158 - Disclosure - Employee Benefits - Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsScheduleOfSharebasedCompensationExpensesRecognizedAsEmployeeBenefitExpenses</Role>
      <ShortName>Employee Benefits - Schedule of Share-based Compensation Expenses Recognized as Employee Benefit Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>159 - Disclosure - Employee Benefits - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation</Role>
      <ShortName>Employee Benefits - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>160 - Disclosure - Finance Income and Expense - Summary of Finance Income and Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseSummaryOfFinanceIncomeAndExpense</Role>
      <ShortName>Finance Income and Expense - Summary of Finance Income and Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>161 - Disclosure - Finance Income and Expense - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureFinanceIncomeAndExpenseAdditionalInformation</Role>
      <ShortName>Finance Income and Expense - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrus-20180630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>162 - Disclosure - Operating Lease - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merus.nl/taxonomy/role/DisclosureOperatingLeaseAdditionalInformation</Role>
      <ShortName>Operating Lease - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mrus-20180630.xml</File>
    <File>mrus-20180630.xsd</File>
    <File>mrus-20180630_cal.xml</File>
    <File>mrus-20180630_def.xml</File>
    <File>mrus-20180630_lab.xml</File>
    <File>mrus-20180630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001193125-18-359219-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-18-359219-xbrl.zip
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M 6?KC$1[K,C6T+#&DZ&=1^U:PI+K8&CD)L?1THO3A_>!"\(LG*'"6.Y%9!^
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M J5,@0MM@KD12WON()A'7]6^;1^Q">8!4JB.V$1+SDI==DRIVF\LZXA-M'+
M=X]M[2/;Z(A-M#*(M\T^>DJ*PA'+"VVJ,]!:[[[W6"^R!K CUH_(K.F,<@)(
M#UQA:!.%K@L1'1ZT(Q^B0H=X"E@/6V1HT[6!MNY6Z/"P';%&#66I2BDW8(Z>
M%M(C4*Q*%(M=WJBTN0.P!ZHJV,\)=[K?)(?>LM6ZI#VC(H.C8H-J34U#JUM-
MNQ0=/)$5CLGDVG9,OI]K^Z,>K-0*WF-W^$=@\-T%6R?(J9N28=N;RZ7.AL$/
MC@UJ?"#)C5KR4S+X$72;1KI-,RVK6^/9_7/XP4]66J>['V/RPQ1.';>#'"\M
MTM>5NYZJ*U8#&<?HF$9&#9!Z(^)S\@9R)T*'OJ^DQ(-3QQ'ZQ[$V/_"Z<^>4
M(_2/(X/7ELW=I :[9LDGT@RC!=[9NAAR+@62D\%#<VK-5S>>5=M&.*OT/HK]
M_]WU;HDCSN1#*<K69#,,WS+L<J3K^G#L6*)MJH RU93%@6X:HF*/G8$R'"BV
MY>2].DW3E.UL&-7^,7!.Z+4D63HB>IDBDVQ)-:QCX/=FZ<6P7GCW"PXJ_>3%
MBYLY_=.YB[TM;X5DUG*'\-42QK8D9S)T!F"K:9H(N#3$@0T8<)0QF#!#1U5E
MYS-EI+[7_SM+.WIT=R50JC-QMMRV*2F*U6G^W\YS?2BMI3;4I[KG9AU,?8YL
M7FL0S_S0C1]V:Y\C,\)69/61<HF68[3&@^'$&$@BP&9BSP*<<S%R1,,"+%C6
M6-4G#K-&5<F&_ZDT3M\.H)9TXZGGS9))'"WP%UF=U!:J9@WD6\QZ[ @_YHGH
MEE2W.=:"4!=Y[U?Q])[X&:\SM^\-]3B@V_2"Z@@T-23M%QD(ZP$Y\-%^9O,B
M-+K  5VUVU'KCF')FJV(JC(<H2D!,EL&B6588]EV]+%I*5K>^/)L3KL;[-N<
M?G<\*%L2 /VJCB5,5[F9OZ>97M[[P)V2H/\]W"J]-,>(WL3(]C,DGD(=&LN*
ML\IB?PN0SP11ZV8_[)&-2/<7;+0;HLIACS#-\RBWQH<N[9Z7W,70(3M/;TB,
MRJ9+1S].4GACBB8@N\U?N0&:0UO"I4F:9'UN&6M0AT&RL?11&\ A&8:H&4,'
M?*>)(PX531H-!ZHV=.R\D^I[[;^-7_F!K=MH"98/GK^X7<4)'=W-_&?,R]G:
M6C-D9=?S&9GF:&AKDC@9CN!\I+$I.@88;ZILF99AJI8RLEC>N%DFQ;9M'TJ-
M=6_JV&7\1)?VAG(6-M+,;=78*<'O('ZZ@D_:R\K-\QW =V;_L^(!@DD4_^SZ
M8?)+E"38&V9XC\[:N_"I,SEE*Z/_)\QI[]2"/6LD;-1C(SM#N1E=3==@UU9\
M^\"1/IP,P2F?B,:$W'7'$9TQBD-I.!AKMJ/9(".H S%(R,8HANT@VQ8OE0RV
MK%KO+$F(FI6 1-T2/:T UK$T<!-_BMGV?K!*B\L-),4=[.<...F>T3H$E3]0
M!R-Q-,1P "@;T9Y,)J*N#!3)&>@CS5$_LT[=2E^J.,@=H&KK+#L)HJ\DGWZG
M&>0L4@D/.E/@O"US58]('XJ)*&@,,ND$4 <T\.C15IU@CLD=)B51Z7H'!!2@
M;)86!1.U,M-..;S'1 GEG]B-0;"[ KD961,_1'^"7WE'R396Z/%P@F-0[,TB
MM '(9KA_#P%M@0^$!7]X_ETX_C8ES<WT.*GTLT0%=112]<T621?H.@@/AM/S
MEZ$J(L4R5+71CZ\33-W%Z-EC0F&M2G2S<>_=":;'!.LRADVRJY=PYBRB./79
M3<SV(8;CX82:-VWFE\<AVXR91A'->5*'02D1==_N,5"VLC(&WAPD#G."DG?A
M'U'\)U#8UKT$CX@4"SC&LHSN#/,8E,TJF@50UST6HW_Q3N'(=;3%T9%30<LV
MBZ0:^Z^#R)7OEFT"]@&;.1F9 P<['ABZ)&H#;8B5<RK\J8[EB3F4K,GHL\8*
M0XU&!F1YWXW,/L;X>/P-G@!;*TS<*='"'WYZO\/,O'T ;P^DR= R)7$PMDQ1
MDU1'M+0Q_,MP=&NB&:.Q9#/@6]A^)_@:2)K/O6EZ,\_LBP]NFK'%3?C4>1_'
MM" ,U)NRI3=&NV\/X!KF. 7G=^0.3 ]NU,Q5MEV'B7=H0%TY6_BAGZ0Q!;A.
M8@<HMCJ2;7DD*AJ60SKF0 28;=%QC*&D&HHQ,63.!D:C%O(12%K2$5@':R]Y
M[_HSV.H*"*"4*GPIEJ)L\TR,6F["UM ]EK#QZ3Z.5G?W&V7,D3'4)6/:PC?:
MK9)S%P@W"H7C^]V*IIKJ&&NE#6< + /JP[''P#>#H>W(EF(.-&09M(T416ID
MT3[J;#<#FNVRDAE2&X3L6?*.RIKSF(U,Z[V!W9"WY2N&[/<C'Q:(/3@(^)"(
M+2#S](,WC>Y"GVS6]W$T]].;&)\]("Y;[IR&JC-2M8DI6@8PF#8>6:)E3N E
MFJE--&?BC"9#(#%R6%L&V^\%XK72FTMWO*#U0[S-.E6<M",CT@"*1A%M%W!:
M^DI3 ZF3:.J.]@A>F;3<NM6VO@ZRK,U+66]=S&T V*%:PTW9$K)-5])9AY";
M^=8-XH\I8*E)?/W\-\*QCAK0CKE(^\QBN3%M=- !IM:9#J!JMBQ7.ZZY!2";
MJFW4NZQ7]M[HD9W!?LZNAXVC^!2M#EA][^W]OT\=/NJJHB@(7X=P#02MD*YM
M'GJ64160U(I1]R8WP]$BF.%C-%280;C5Z*<C'JU-D4&E$1ELV?]Z$%%JGU[X
M=@N%LA8 S"QM!W@--!M'_')-E:FNV;XZD:U%3,?<9FULJY,1( 78%X28AK,?
M-,44%=V0!A,55!)8ZJSUF R^H+UV[N]V !XB<^Z(EAK&!C2M,>"Z<Z;<;U[:
M<CE[EO8XW3E+C225=@BZ*C%X^F9.OLMFW^XL)2)E=755=ETA;<4<-PT&#[]A
M">9YFC<6#AQK",NV[3=XGA=&8#[[FBD$%^G&Z=@BMVZ^/QW89GY_6\?=<[:$
M6;?9AFNW$9 FU%^\<'5D^!QU-!D:IB4.AF/P8@QK)-K*<"BJ _B!/I84TS8Y
M?)*LU+4"WW*C\7]E7":5"_BWJQ/XY1UM7NSFULC#V@#$>FOP+%.9)78#KM2M
M^F+;35)<\BR)F_D@BN/H*Z:JEKGX8G*HL#=,(]"_$WR=QUN<1%!U)'632M#M
MYAB/S; T)L2X=Q[VWOWH!FY\]+/O"*N$^KLQS+:^]>V&WYS&X^D^\J:CTX-C
MC_M2953EWN%^!+%[<X(ZU;9W-8"1/RP;V^09&Y#3*/5MNR$[<&Y8"Y =#Q^,
M?-LVLQX4:[>^ICQU& 6!>QNQ>YA=6DD<4?C39##9YKJ](R@MQ\JOPBM&P."!
MBCF2XI-/T<W7T(N3\XY&XYV;)5L\:OMD,,M3!QXK_L$$#)2\U6GJ6W;A/N9E
M!8T%*T]>> J(Y7$&@1_Z4S<X06:A,G",L>SH(LA!1]3,(<B(,<Y$DW1P X83
M4)]H\*."D*32,)3*ENOCKC;Z.?2+LP02>QIH1FE>3T=@2N #9TPC4 K()>]C
M;WKV!TLD;9;F;FR"H 3H+V #WV69Y#=+&K!5Y)$?.0D#Z-)0AB8 IPW \1G:
MI@CB#UXS,J61.IR,3-/B!B#/P.@"PQ:BC,B@-%X!\^RFP.Q;C7P[IB2C_OK6
M%I)L X3;B?R&--QIS,8Q<87U!+*]E=#?!&19[F>I]2!C0*%.L9F"F]R?)1I4
M5N%;T@#MFV\,5/+Q-P>^SVWK_> ,5,V8V"#_; UDPG B.BI.'=(=:V*-56,P
M<3+Y5Q8*M4V7P*$^$"<!I4L;"P*ETE&EM-^R[;[3K,,CNND@FE2E9&FLF6_X
M#\\-TOMW80(R*)R>9W0%6,8H05+;<IE3TFCZ)S7R.TFP:*P.AIII&^)(E751
MPYX9ECJ6X5\C@-,$E\E1&#AYGG#[MLL#K 8?;_A@LK,\&V;1E@;"E39<MV?K
M&2S'-N6Z73J8P#BF8M3,U\;>6XVX4QBHW: "[:O:6IO15I<(O[KA:HY]B&*L
M4CM^LGDW>+ 9%';.S %J;+LBK/DXS0]>@*V6+N\F#'PJ597* 9=M0-K*L3Q/
M^J6&@5I]P/)F0"HMM.CJ]*,7?_&GF#<?@\UU^ /?=0BSQMJ!EG3$)@ JH366
M] D_Y81QQI5D4E%)MG'SK=V->63\)&=H:2!Y)IHJZO;  /4^E$1[HH"-/%)D
M,/3E(5C\K&&=:5>,XC6[+Q_@>X#^%SABRM _5VV"3<"-TBCMQJ[/JB3EN%WA
M5*P=S (D!RE1.<S=R+&Q9-0D7)<;D]Q9+C5,XW?*;L#BP42(Y?A*ANM?HR_>
MD[HM'!M!&J50EC"T%^A+V/S-2_>>1GEL)*F46%G&TB:H]IP<5 (6"Q&4 R8+
M45]<L )MQ:IG5JY)%]H;;+ID&P>%3<$=X#BQ1DN>@X,F R [3IGM!)K*VQDK
MJMTQRVN_L.TX#J1;_AKN &TXJY'XL@:VO=05'7&(KH5-3BU,8VL44S:KC$YV
MM7ULA-#]K6TU-??N%]T'))$##^FUL TPE:(91CW7\5R)Y!@H02(I<+)W,MEC
MG=L11P%;W.[=M7/2,;ME'!LMA^N>L>_"R&-C1G]"J>33<ZB/#:W6,:WZ/"3I
M$1!"DK1R7[17?7O )A<X-4$R+<*4IIE=IA:V!=MD?6+8]EAT5%T7-76DBY9J
MCD1X?J!,1A-Y9-K,/:)!8"T29.NV%\=IM+Z?<<:=JA44UJ_/DNIRY&F-UP_8
M4KP;<O;<8IQZ^$M]I8*B73J,[U79[&.N=S?H\9:I22-;J9D]%VX?%7RY%?RM
MR[B?[L$?#V2I%>0U[OM>C(GCB;QVV-:79QU?ZN\^XKH3"F0F]:5&Z.DBI/YZ
MY.Q9ZLM\L(3RY,$2AQ'[3YCVW@U\I!)-E>6ZR7TN@O_@", .'HID*^<D^@\.
M-$9N5;D>LSJ*Z#^XW),813?N$UJ=R.I(6=;._7^?U$VB&!>G688N&[LY/@ZX
M.K)D:Z*J388XDUL&QT?5X5@E61D8$UDS![GC8U02#=:#5$[T\@,O2:/0XV>.
MUX5T>5\9W/:D Z_.S-L%"<;(&D@3QQ2'EFG@(%7P V79$@W3<,:VI4ZTB<1N
M64"(*Y6+P([P'2)_%& W=5-'S]>2=[9S.N63YIZO60[);THI/024-I:^'1!*
MA5]_5C(&C@PD7:AU"6+L"F1V6:B;EO(HE$>S6ZV#5T6  M9!8.MFHY?E)<R%
M.PI^4+B!,-T2/2>;"[<1)]W-]T[EY2J5%HE2WWARV.8P@^&.02 T&$Z63+WN
MZIW#;+BC< @A  3K9<R&.PI*T*VQ&\/RSG4TW#%0@J/A&DWXSF\TW#%00?=L
MAK;Y0J#[:+B9Y[]QX+$9/CH)W+O=@6[TW[# L;.T(;*W*FK2"/S9L6*)EN,H
MVLB6'&,X84[\')#B_>UU8R]'FEYWC&/#Z76:9C:(^*R&UQU%X['A=4T??S_#
MZ^I2D:3ACDTUCB+L^07?=K*^!-71I_D= RLXR:N1.W%VT_R.@0D<%:#K]0CO
M&4_S.P92+!HGHJGU(.AYC?-[$B:ZNE#H@&,PN-Z&M,,=P,A+IK%/3<QNYLYT
M&JTPP^+N?13XTP<D*^\.B>F#MT36H@K:P W=-(JWS\%9:R3H,I8&J$,1'K9%
MS8+_Y\!7V,5D,+9M4U45A06&_SU(W\[\+_]^E[X%0/"OI9"D#X'WT\M?G0\_
MO_M-'-Q\^G3SZQM!6J9OA<G-;Y_$C^_^W_B-(!<?3)Q?W_WRWV^$3_X"].-O
MWE?A0[1PP[<"7^+3S7OXO;5,7Y;>X^._.3:$'!WXS6OZBOZU/,+&C&)?G^X]
M <_8#1^$B&@<'O-#(0H](:8MHO$O)&S7/>'KO3_%SAI %3[6BH("@55F6;<;
MP0UG0)%Y*:80S6&U,/I"8]*$6S]9 KG._2D\A+K'77JKU)\F_0;LK_D9E8GQ
M"92V+=%R>W>XBK$\ZZ%4FW40\AW(AF--!A-Q8DTFHC8Q)-$Q]0E:NX8QL1UC
MH)X'^7*\"!EBA'+FY6E)^5WJ+1(@VFD4S[P9$K'G JT"!:8%D?^[NUB^_;=O
M<!;VVT0 8F$6+@:Y%F 3K6)O!DNM$J %>FR:P<F7 ;)?N'#R\)8P6OA36.*+
M'T<A$3N\DO$'XPI:O<16KW"!8@/#M_-52(A#]<C?4WP]>OMC']D3%O*Q,-9?
M"/.LV N0"2LR:P.W#B(Z@3\XU*LX2C).]1/A5R]>);#*;_U_]JO@M[R?7MGV
M!2(@6^GWCST!=$$?5T>8?N]_[ LS;/L79V]PI+=.$ CN AF+;3*&?^+!I!''
M3^AA##"%OZ)5@H*#[]S[-O66*0#@P5,1BHFO(&L M)D_Q:K@OL"I$-;(MW='
MGC:N$I!OREY)D@#>&86""^]+!3!O8-,N'+V/"\,*#*FX/&GG*,X_\;AE._/@
MOS.DB @/V*/.:_/F%A9YA2&^V\]>B3O#9?'?N#<AZY"U'Z'725)M*_YX 2K[
M?M=;[;72SE GFF9)CCC1%5/4!@-3Q)5H^-L82-.4!OI92+L,\A(ZSD==(\/'
MJ*R!H:;EGIN"FS7=3+@40'K\"@3OATSO"J"NEQZR]+O)AX^"K!=R0<N!GH/Q
M*U!R,8CWA)X'L9^DP"4Q2H%795'66 ?$5T] AH\+F9AO/6"EXB"ML0$L")$(
M^<@#8P-998/ 7L;1;#5-A2DPNC\CJ8HL#Q(6^'&!NXIY2XB&)9*PU@D)DW#8
ME3GAKP(6=XL&N[A(^K#$;GW! TJ%8#4#"<L\(GP"32-@9W 4O6RO<T _=;M^
MPTEA'N$;&37\\8]WG\;BQ_?.$,X^C+Z"T4/'&4:A&-/05#2Q>D1.^!Q^)ZS8
M#3[*)\]+W@)8I3MK?.U:.*=XQ?VV_%&/T'*W"D@4].@)D'4+[#<,$GZ1W9-G
M0,+3^),X>G #THY 4B"\8)7$Q6 WO)T?X"P[D!8#[F",JI14/J,Z@.Y?*S\F
M8LBT+C!%S+CV?STZ(Z:*&.H8@1/5<369DK2?$BT*MQY;)0  @:[H\13EZARH
M&18 H!<8%!7NHFB&] *_R<@+GY]F7-(7?B<.X/OL59@@WQXC6[8G4"^A0%.L
M^!I"=)OF0>0X"C*2HU>77]PC0P$QP"%-[]T4UIT'#*Q[$N")/^..+/N^M"&T
MXSWD"S]$'Z""D9@-$R3S@H> .6:BI-@+4DC!95&Q7 Y>7 A2>K[,=[0A+I\R
M')4V5,BP5@G6JX&2B80J?X)N!RB2U%LF;X17_H^%M0)X@2.?/W#;9,KEWJOD
M1R;YW/Q$WL*#ZY[,7HOV ]+%;<"[+)%3Q<^ %J95RLL4R,K)C9G5" RV"\<G
MOI0> /D4H3U4_SW[-3>SMMD0,OVK\AL*!BJ3)XI^/#K ##[/^0U#9LG<9RYA
M^:VE=V;V;':Z[G(99$_@P8AX,"!89UY ;)3KGB@$4<Q9 XQ.PDAT2YXI43%\
M^M4/ E*#0+)MQ!X5G$X+Y S>).D6YL+',@F0%!9L1A)]P0'=Y,9IQIUN;E)E
M:]:43(^OD*%B 2L)"_=/($XPYM!#=H&%_V<UN^,_9XH(%\SH#?Y=T'D-TXW3
M!:LZ2<%U23/')A>'L,87-_8)F0V<9>J/K]:D,J 96("38K9V*S&2,[:.&D^C
M/LK6%+/B4Z"S.QKR3J:%0(&$B&P2%,JYYF"55R0G*H87NA],-5:,,!0@-"O>
MNP.7L7@F(D,JH[JR%J_JZ"P?D>F>F@74YY!TVLH:*5KHTB.>1)O%W=5X^GTI
MDH%4M9IX"R)8,(M@GS@DP:1!=@Y<)+=:MNCCD_!:@4FVY".?F*C*-<.,&R<S
M'_,W@ C(1,<ER4M>)PO0,& RPV?RCO@_HXEU1DE&[ F]94]V[1;+K%I/&*WA
M3-P0/KC!D*&8E$3Y PQ1<,$=Y\&'PKI"-JG*<GR":99(6"4DX0#G-+>EP#=?
MO8\G'$8I"X'2F?3J;P<NOJ6S(RG0.*C-2IE"'86[1,J.)625%L4E-IU_]81=
MC([PT*T0LCEQ) #8>_FZ[4LA3@H[)0N%9!;3YD<!%9F-,!,P6"R /B)/"F%"
M31;Y+(9&GP/:0>G-BU\R*,!D -X =95BP [,SQG;/ O>H0*"[X&TDX3$ZG(5
M+]%"):N?43;^AI-VOZP!T";XX@8KDOSX*AX/Y$*7K4E*+,[BRPBJ#SO@>Z60
M%A@+B4M>%MVM-9<J88>\+-;I+ML2N0*YC7P:M?@>_,P5FA^;Y%7%_VPJ&O2L
MD-[90-Z2OJL2X[V;9+[%+/-YL]60)+(K5<(2F1=L2R@M[V)"W-*=_HG#AQ"Y
M8#CZ.$N&<K(H^)#3-3<E^\+8G=[G?],_R+UB\4!R[C'X&ZRWG,GY7X%GO S6
M&;I)[EP]6>!53;*O;E*86R3.B(8!]37D%:ACL4@@)XIG9.%QYBS.>/YL;MA$
MN?A)HH#,BUDYU@PHSF/0Q+$LD$DTP.*M7'O,!#<I+\JP6W.YD.G1*L(8D!B@
M1&'16<;RS(OPB<'IKXQ3-IU+^:Q1D:*HRFWRPOQ^RYS5JA]'-]\4*0Z9."W+
MFIFW]*>9#58QW6L!JC(];(1CK>V^#HZ>D*R0WQ(6XJ$3)*MU5F$/C.^*)$(Q
M* (2#<W)G%L]/HDLR7PQ\L&FI/"R;7XI8G;U($I&95DX#'4EGF*+SU*Z@>C*
M ;$G<NTTJS(!\%)5\J+"!22>V%BM3#H2V.WX:0W.ZH[8E4;I((JX9L9,=,+E
M<ACT1]#*J0CMW$5YG.:+R"02UYH8+ \,,V[ *V&Z'2ZT1X\9OB5QP@43%Q!S
M@?8FW$>P;P&U-DJ<%(,T!=,$J-)I36 0))96[&0N;E+# X),6V!XZDK"77\7
MK5(QFHO+:/JG5Y7X5<KG=U );CY):4.57>9QC;)6]9,BO,$P75',ZR5UYA6Z
MBUP:N%GH,$F)"NAM3*L^<-V2>MF]'N8%P'8)V67GFH(X?"40J* _EJ1 N/4=
M4TH-UTT)CY;4 '63JH/+Q!\<X(DBSV%N".<1E9*Z: LVH^=6H!VA3RJG!H)[
M[@=!0C93V98HF*7,(=7X437<F0<YP1Q(D'P!;5^\>I0*M]"(4Y759-56HQ 5
MYV;:?;):+$O6#@_"YPJ@ZBP07:5PX*(;@)%%H>(@8 8[1HCP]?404<5]J'NP
MI2!ME=A6Z-S\Z3U4=UC;"YD>^6ZJ>\D$YL(M[G\6;@R,BF^<^<RIJO.BP&)&
MY'5DS=F9INY59""JYH!%M"EVQB*9V>@>HICLJ@85/OH39Q =8^EM%!=@]O<T
M)JA=#B-=C-%-!:+1+1U./7R.3EWC<H&;2E'") V(NX\K$C/-%WV-5L$,G6YP
M'C"ER//"PA#RYQ73*7./2V^_=]G#]!S;,684X&T%G%_3.V'>?0$_>GL/+=O"
M<R\AH*#-4Y]=55>78NKSE&&.Z+L6>ZS<&+;<$);NE3.+K22F%DQ5!?Z?'I@:
M7!9R;YT%-D.R^T-V8A22KT7TZU9E<8$$E)( UAD91#@\JR_\VMP@OTS"'>)Q
MEV*>Z_&"MVMQ.7[C57Z4$744%*9X"4LD_\$6 7[/WIHY;^RBE,!#EV4.U$=4
M,KWW/?)\0;0%G/[S93(]3<XQR&YF ]/)9/&')LEN86KGT8ZJQ<%T=":3'EAX
MA>\TNWPN4TM.'.PJG@41F=&4GS-=0>.W<-IK0B0H <!F:]X= .0A24)BY")A
M.3=C*-N+$GRFJP4>!FJ_KG@ -WIZ+ZZ651R0F9FI 49I[GP.\JH1\<^#I)RX
M"E>OV.II1  &#DN!?W9/QKF=[O%%YO#FU_RE.R8,J#59*G>0B4.0!!!.6JN7
MF7*ER"=%KN'M6=2:$98WBQ880L!+.V]1M5^+C -&0;W:;7 S."WP*VS\-5W-
M5P(,63"X9,?S# 84&SUD]FH(((\>MQLAN)ULOPE/%D.:S1Q[VCY3&Z1>BCA-
M]A'E4&1!4+Q%17.,16;RSW]\5!N5C??PH18B*GEVS6-^J,09$XQBH>F'#A]E
M &](O:E;WP5MG=@+_QE%!TO I%EM)[[S^50E6)3>29[;=%?LE05_[UB6Y1UM
MO)=[5\EJB3*>7SIFL9LYT&2:\, =B[7'T?^@&<7XC[-WIJ>R#I! "M@^H.3(
M;<@?Z@M_L#M^\LM0,6.M$&P253-:U&Q.7#UY)+M_7RSQIAXMOMQ$YP8SL&H*
M:H11IEM$?0ETMO^,_6(O\_\WO9D>9.^]+11EKX1C6((A=G-PTH5?85XF"RZ4
MO8N6("B_#L#;(+R9P>?X76U1)\$^9EPB) _@@>'%^[0]O)E4TH;;LX.R*$#N
MI!4:-K,]BQ5*()=\<W9#DWOG[WB@UV67(_R9DNQPJ2JLQ]_&<)OA,T<Z++W"
MB97%Q=@4W,<'LFUR#YB<2EQM/_FN;:FIC?16/YG"&:QB[V9>[1%QD.S]L354
M',ET1%5395%S1F-Q8*NZ:%G#\42SAD-'E];EL_+Z"B:5MI1 @YL/H_$'<7CS
MRR_.^X_P$,GH9>*]!($3!,G2Q?)/&FJ/?R_=V2S[^ZL_2^]_>BE+TE]?"K=H
M0\7X>7EC<;:K]\[/ -"'L?.?XKO?/KX;P8O<+Y$_J_QZAF$X,-A_>IE&RWQ]
M#5;G'P?>/,U#9+?X#XL1Q&TNJ=/9AA7KRQQ8HL//-VP](RJ!$V -D J-5Z!Z
MG<:5O_#TCZN?1O4['Y><]_]8A5YA"*E23T"*9W)Y!/R_N/7BTO<RVF;8):?'
MS(\D9_4B%W9W[:O@!_73R!;*-]%8?QTO6<=@)=,H:'U*N=EK&:M*Y?QYP_KK
MRT<YX39*TVA1O'/](_OZ_&2OKG)*(8VV.]<M91<'DG94I;-'T%)[8O.S'!).
M<QD7_!OUMI($>0E>*QH>+QNX!Z($2H0/C#JI5:33P W(5 (#HZ.$[0CW]4PV
MG(FR\4P:\I6^B877?!LH;?=[6&>.D%:ETD2*67R/$]+1//T_5Z+N>(8[RH]7
M5(@G\&HA5IR7_'ATK'<Q<M:B7;B] V@C4+[_-AR.QY/)!FOUL ;8+^/))WC
M6S1,FK?"I_%_?8*-C\:_P4]$^,U:*ZT(QJAOLV3E+#WY$9MSOT2T/<EFI$;%
M7O2\;/1L4^GT+(O5_O2R?,=^-(;9"ZQZ#WS!0\!Z:!:Z:(:Y/)Z0])[);8#O
MGREDI:?K\JFX8OFM@UH^ AJ[\! WP(@%"NOK&[.^=O&2+V9CQR?KLP#[;#=V
M:GVTK4EW$8)047J&+3T3J:]8/<TRKE)_-V96@9EGT>HV\,Y-S.QW9Y<C]Z\G
MLM=;#6._8?_OXPI-:;E"^S\;R>>LKLMXTSM/^"U*/4&EN^J9E[I^0,ES;CS+
M\J=CK[AD9V5./$6%LJD$7J*/+2Z*I.4EW0JS>\3VC(^SN'XKYV7=L&NR-,+<
MT48!UBT/W;OINANY@A<4R1F"3I7Z1O&SA1\$M2P@?-N[</J0MI2(O_BA6;O'
MTO@$ZM O)*O;_#J^]!,*&E(J-F46W#[4<D'2^^R5\%@STJLP8 SA51K=41%I
MEL]>Z2G$5G#R1*-:=Z$R&I2^)'#8R_TKLDJKK.SW\1+Y"F@<L!<_5$'[Z"^F
MU)LL%/[##5=N_%"\TV+'U&SVQA]ZT:EG0 U2=E)E>*6^_.BAW_QVTUJF^:*4
MO,6[(3U*C)NO@//LNBC C-\JT3D[)8I]JS(<_EWCJ&\=5,,AQ1U_S>]YVO,Z
M)FL>;R_[+2M/8@2Z=*M<Y!($79)8_P)"H$$-Q0?5@OSB<U[,1T@K%>CS?$]V
M]5\D=6^2!^WPK(#N,+]([2M-6@4H%_ ?ZCF<L-HM5@BRA/>Q=U'F\5\4O2^!
MN*!N0?C*.]0:\*I\>?88Z(B_6$TL8*83K,+9E)-K&<N4LN81U]RSQ-BLV4=E
MA[!&-U3PO#Z>W,:$1]O&UD)"N5D3[S:N;K@D@\JK"ZUGWYER:J11IH1ZK>=I
MLIB=O',5*^C($N V'@&KDIYY(:4:\[:8I2:5M2+T<G^-HFP;WH19D\6K,:$6
M3$!6GO4U9%O@I#M?41^%&;5CBLI%<OE;;KVI2]V?%PL_Y3TIUVM&E*EY5T^R
MA8#X?-Y&M^@#ZF."_:H0Y'/7CUD]9%(4>15/4LIS68VH<E]K4$^1S'T ,NJQ
MTNN*"2.#]F[9Q5>OG.'O)@T%5>\G5:H1<UNJ^$N9W#W,X?SB\UQWEZJLJ-]1
M2H4HP(A@H@+[I=[T/HR"Z.ZAU^A!P$0>TFBIO0Z:3GG6=RDWO)ZCG7$P+D6Y
MKN4N68.(Y<^N*^K/SZ<XV1<_E*B"LBTI 937F; !@+7$U[P%QRT6RA8--'@!
M"&MXP5*'L]X@)"EYIKJ;E\-3\XZUI>Q9QV=,<N^53%]>*5&K*2VZ6Q;U8>RH
MO$['5)'3#0.D5 I=]'OBC;&R.@58(<0BP0>PFU@V,&ZWAX#RHB<LT/E&C\#3
M9E_G/XV]A>N?J&5'881DMFDG*Z2$\!=YK31@@67Y9DNYU"$M6+'4YJ*7$<\:
MY]9IN5L5N6G#>R!(> 4L6FK\#;]._=MHAE4>J]0/6$.6#1T5!OXTB$)_2FG]
MR6K9EIZA__6M\,_QAT_OALXOHO/+NY]_>R/D46 N6,;,.H05JM&,"NTL@<61
MCO,N2;'GDCVP6*S"2(S"*?VR6G!*V= Q^K24\8U_L+:FT2I%IL<%"!G--G'K
MC@)K/8KC"#QW5DO8+QJN%V-:@#R#G  :B]RR6GN40Q@NR10IGP;&^!78$HEM
M%*]0+'J8>H^GDZ2K&14(3>%/Y.1*=]%R#=S<QP>2%I+(&YBQZNZ61JX9R=2[
M\N3"$NB0"\3>7C13T=.5[,R^J;<HH9K"5/IJRX^JJ@$P_@++F^&DT1[(#XZ$
MJKO(>M#4/T>SI=KK"SUK#U59MM0:*9O55&[J$\.*J_.5SJGU'O%/IJ-:VXQ0
MD7!-;2%RR@5IA1B?K>*<VKPV3!,?TJFORWIF5?1QDC9/"0N(B;#A$%@K<JZY
MZ.!%.HRNU)GXWT3P,=+[A@_&2T-8]<:F73;J14K-?.:-H$&3>&NTRPIQ"5"4
M$+<1JY\N#T4&K-;.)\D-DE*=*,=P41[*^)II27K?UZC)&WE]=H[B%S^LRU O
M6\VR!8<Z15,1S3XP-,*"9$K%=Q4L58(EC^SK-%QR$PJ_XC8*2&6M[? K,2N4
M%UAVE7LN+VI=L9LQ+XIJ8;BH$;7B2\%WCZY2B5GU*UW$RA8$VKK,82,K@YT
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M?S:/&)932G:')^"Y*L=U2=).\B1M9-$L"YNA HX4\[.;2=CP,LP![>$Y(G(
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M!?HM($^JP?-*H(<Y<.^<CX)J][E[P>]F&&JY-<W1>^_.X$4E(P5L^R]^M$K
M;0./%=#(?+T%P_>KCUDC7Q7\7[X&_ Z50R)4/6CK;99& @N@7U)&O+"(9AX&
M._E667P$3-KR\WE6RA06\=.V95Z5/?;Q\)=JT(5>PBRF$"@4H?1C4F+T#7,_
M M\KV;V$)U#V .S"<U'HSYH4U2/Y'0/**&I'OV;W,;=IG1;G\$H>-<D,#;*.
MD8PPV.;=XW!PL,D0MAX8?"E9M>3V%0MA]@2I$O@7F((K^A3/]W=VWG 2!;W:
M/8ZQS!UTJQV7/3<&H/F%$A$,+,1)IK2@ .O@ F@H1U^Y#04KY7@!<O%\#DM7
M4@;5U!*>A)-+N''#?"AT*<A[@?=3RLC,F[OP.3HOB \D%W[?)BL"K0B;FZ<L
M>,'"+7AB8*;,*,85"X$_]^@*L/$R]BJ\.,M>1VYMY87H^C(+,2-*7(_\TH)R
MR&G(CF>OE]0;Q2R:X8_>GC;(&PDBGK61-Y$F78LB?&O-UEZ5U#%>%;M@EO*8
M!+F S*1$=9/'QAL;09K*#&?FR3 OBOC]:T;*L9_\B4M3"E:RFM[W6-P4KWQ+
M(HRY?^ND/;@.(=($2.S5 H,0'C(MN$I^GD-'!)'?FDZ!1>XH>:DL/,B<H]N,
M,SODJLA@7D)-C!2Q%0R*NDN,!21YM%OP$W ^9\+M WQ(M\F9PP_$LLS]=1Z<
M)/F#%R#\^D/X%)-L "]UR)VU1W;$T[\ \YENX_PZ%^Y@K3234G01DO-YRE++
M\N U7L8$9,?WA9)YU%@:;^!S:0$B :B>14EX%#V*_3N*<A<[9&\A$BV4?E=A
MYR:%4 XQ5X(AI=_4W]THJ"4YO)Y<?=B\Y$?-5OZ:=PVKJMVC8V[B!HNK*HI8
M2!.U$3#Q4\<!;%\$<%I_R32>UJO=E+;OU7["KN4'?_5.[4H;Y[JE@WK*7K'_
M)M'_[*$[]H"%U)"U07]T]*0/V47VN1S+YI[%K8W$2XW&+Z2G\?X0TJI8FD@Q
MKQ1\)H(E;Y!\9NV1NY_.\5O4K;/)=FI'-\R] ^8;/!)7/+_^!& SFO*I>[4=
M"U:]IRL':<UV:"ZY*)[XO?^QGWNV)5_YXGA#Z>GF,VE38O<.U+3PJC\>T1\L
M2H1AOF]T+TR5JK<1:/*+XQ>0KXKU3#HX85^?@S2#OJJ2$GLX=UXX?2!VN#QN
MZ&GV,V$& %4_2!/X[[G)5>$%GEG#Q(-L[/A$?19@G^W&3JV&+MQN*UW8]/)$
M2[I!YV5HEZ2I5+,G/9N6Y5I/.LS DJOA]MWZ-4;/T _2Q//\8 518%S[E9Z#
MAC[;C5U-N?/:V*D5TX6;<KB7+LE)OQ4)2835+!_IQ0_E!*VK<CMC6*_*[0DR
MZ_RZU1YF9Y>CWJXG<O6\&NKL$_7.NF2-I*L]\S#7].<'JR;W9.D:.C\+,7.^
M.[NJI'/;V7;<=[0"TG+1RZCH#-S5Q6EOA@5K\3;8FWJ,5JM2LT9"LUKQ"G5V
MQ&WE=3C8X=GN&\6"M>)]+"7!>DY>,,CZ*K$J2S]DN48S+ V(>>>4O"B_W%^G
M_#;9:NF<_>*'2E/R4CT++X9A#38:)4_"/%A-TU7>OX Z4WM L_Q2 "^OO?2K
MY[':.TS7I%V6]EUO+9+7F356\K[Q\JH[UP^;?8,*"B8XU;[< )-U1BLCHZV+
M.%5V8;%E%'K4$@/>E'<Y88'<U\(KWE/GQR[-U[8CN,[=URI]MYL\^TBS@SWU
M)MC4_@#6B%<>_IK:#SGAC-[TB\]:B0!1':3)@3EQAMIDHHIC['2@J:.QZ*B*
M)%IC8V*.%&5DZLJUR4&C4X!YN4T.V%CL$ET1&Q+YN<$E]3UPL-L>KYY'T9_<
M1S$V7XX7K..5^T#TR>N99>'!<^,G%)5>*]L><SOX,];I*ML._NIK <J3*]NN
M96WG4\5U+6N[EK6=^X%=R]K..HC,_1;!7<U\<$URCY%U1O&\G2(W)ZUO>28W
MG/:U)N'0O/'>BY,H#+W@XIA ?2Z%GIIVD6QPX4KC ^$._V_$9N!<'(-8/?.Y
MY$'K/<54+I%)+HHEWKTO-6A4WPJ_>'?8D_L"#2A9L9X)8T@'*=J[ZHZ-C#*(
MPE5R@2T";.V9.!9R3]<.8CU>]46)#=C@[(=\F$AVF7UQ?"$?AEC.#U!%.4B'
MD*NZV,@G[+K3+5]O7A)W:,8SX0Y=/9G.N/3<QFOMTO4\SN\\3FNM78+(DZ6>
M=9@BH_.#U>H9I^NG=^D"_IHJ?3V1\SR1,TA>QXD-.(K3C:?W//.[F)I)EPLL
M7]MC4_K8;74^Y7,>L7$Q"<U1$Z9>C -FJY,W,6V8,B5[-!T#DY[KDSA?\.E)
M?!H,)67?9F/WW%#PX(17^;Q-3(%>QM%=C.,':= PGQ?+O\^G=*=N\F<BK!(^
M;,7-W[^$M7!O7AA'04##\W"5;%>)CY,5<-]LJD0V,RZ?U8:O_^+/^'S:+!7_
M%A/#OWCA#*<%LWF!/OI.Z8JF*B9LT 0-'NKS\4=3;-Y)4SRR,^"H:)Y" _>Q
M-\=)URPCW%_08$Z<.5$ A>OB8GR09X:[]AF&S2,!NEG-<?LQ6UN8Q:N[\B36
M5<(G2^4/(]5V24=?KN)E!$#T"NY8QIZ8K5-\FJ&%^*-4)^'-X;UL5&(&W5K0
M:+@Y#L_(Z9RHQUUD4[O8-./I0UH;_TE?!OX4\<T&51<398I1294'\A^=;O[*
M+8OPEMB6"B* 0Z('K_@ZG\2;3[W!#-\76<8_JPFA,9ZWP&ZN#R"OTOHX19L1
M\LS+"1D6R-[ HP;$G2X?H+-IAAG;\*R8E..&X8KZ/3_P^8ZT8?QQ_@X^:FGN
MQTDJ_ NVA8-9^)S,MKF,QSJ$I!I?+(VP+$M3+*@0[G#2-LY]PIE!U3G8.,0S
M?Y"F'.&XK6]3%'Q8E%*,O^+S-_'G_UKY;+09O.(6!2H[O+@\: O6I==F528T
M+S8E51" L.7C6?W%[2I.* .;RZ#8RT4833ORXB]^-GUKZ<4H($&X-?7B(P4B
M6U5O;"H#&5+93O(NY#4E(+C>@\<VA16*3\9)2H4\^)YQ'(.T/DAMB*Q(AJ,[
MDBB/Y8FHR1-'="SXESY1+%T:6::L2=?:D$:!A7JYM2$?/,RQ#!Z$=VQ6U3NF
M>/B Z'RVJ_ A&P&'%Q$I:!,WGEU2Z<CX&\ZMIOE)R*9??9+\,]#<(+Y9E9V;
M<YNPY R8#] D)<&,.)!-<=FNHX4 :?ZBI)>2?!8NRID7^> EU DT2"N]CU!!
MT\3$6:82FHN_6#-[C:N9UA=F6A)U(ZN2@U76*[$C*AQK6:%XHIR<F' H')L[
M!@@!^W?J;=CT!LH[ C'EF\=_^(R-2E/BAWR>)9^9-EPEX.)Y<6G8IO869T+"
M2CSISL\A.1E,[T+A5Y<,)(VQPSOGXR";8$<3+&4],[' ? 5PO)E7#.1^D<]&
MSW0V4?'="NQN.,H^3K]&NF2676-X*JQ=6N$KLR$RS9^9@]^(?6A2MI_2C\ H
MOF6SZ._9'#LTLX'5H@6X4K=>Z,UQH"V;)C_'^8>U@?:9)9V]>(J_1'.0K I0
MY2 8LPF=Q>C3A)-L9K@DY.^!Y*"9\R]^*/;.@*6*-00U>PWL@AL_Q;1U9OG0
M*@%Q;%XY"T9/,B<3$>%=^.C!W$58 @N_R,T9')B>$1IL%;>1#:AGL\5Q/-\2
MW**I#VS6*VUY 8^!)8!_S1^R48V<A%\E/V:#_[+5>Y7?9B84W4A'MZ!FF/_Y
MXH=,J&5+]<#DQE(]/_0*N-">)-\48.B1<3@E2Y,VT?A%=GQKWMEX(_>5BN/(
M"0QMQU<T7_A'/JJ>4)' 0LG<9^-W7_RPYD7]C&;1> 6OCE49LWG%3"XSWYN4
MPHOR^-2L=OG6N_-#&IZ)/!#S8:OK9CKS(:#)/='Q;:$V8B^-HZ+*&='CN>0K
M^F0[5U^+\* [20*6OJ\^S?42X(^-\T28&'3,.^&3C^&7^/X'UC\ ,+!:TEC'
MLJE>F2F9/?B"3PB>,B2>S,]I$3Y\X&F2\2O.;^VBAKO&#E9+$31#LS=<YJAS
M=Y&-=2WZ))3'1^?(C4NJAF-NYRTT-@ +8D@ %HM=C.2+ ;+KK0NV2S&U-^,O
MI'0JON62BC>"(&+!W_CA"HG$#[]$P1?2[)F+3J([!\[CSLV,"T%%A@70>BEL
MF0XQCEJG!*H<(M,*I2V2-@^7#(O9J]6)U^S[XA,<>DV-&YIFB,+Z6AC"J^J8
M[FR1]?M%)LAV7'D5"]AI?;T&>270V;)(19\U@;[Y[49X?^^"#)MZJY0"7L.H
MCY+QEQ146@4!\-LZ]((#LJ04V[((;JT)-SQ+DJZYV37PXG#90I#D!D8SF, #
MJ3QP.2-S T32!AV ,K",HK[PD8=747KU"+7LG)BE0WU',NK%+QF55K=2TM,\
MDHH. POG"FAEP*> *R_%,%/J3>]#FFD,*@*Y@;6&;*'U$/F+3KQ7!$0JYXX<
M5I6^"->,=2+I% >LX.)D8C>WN;A+E=:MJ4*3MBC"/,C'0N,,0R7]Q>=(]PHM
MEJNN G5< Q6JJV3)U957246S&!X;]$X#O3FIY-JT*K;O70#N:T3SL7-9F477
M<0N9_F'3D.&<D,QQ?G>2,+PD7NDYFBF?8:MD)&=[9XPTFY'!76VTXP5LNCH&
M[A#NS*K!A4D4(%'/Z%H!?A)&:?XSP$UFNI-EF>\&;4E8XJM'<\;I"@,O/CSL
M1[,9;RU62 \UQQJKQ^CEUGG+?A-N(&<;$Q;1C!B<"8%7#)L9I13;9S.[;_TP
M:\K#C%O 574!#M":O9D@O7[/CJ4=H;6#^$;#NF?Y;1.G &;8T;<)WC@]E$/V
M9+;#@CZ3Z/ABG7#"?+1*?QM8I:7_4)N;Q8U#"@[DX0.T+HL  DV,O\6V1+ <
M?MP@\"0+EO#+%(8&/C4>H[STXD*N\ZY!A5W9U6J!\YC>BZMEU6JAU?( /MD;
ME69'E2Y&5M\LSB_K8@0T/?/ J8I+!A4G!32!YO/$2_GM87VV?6^SH#IQ$#^?
MZ-T6&Q+(FO/AC_(A@U_Q-<P<U^)^SIW]SRH;.UX2CWC<Y&1@] S4(!J!^;)%
MG*S57"Y(EN)AF)=$F&T&KPHA"U+)FSUA//D^8E3#")@]1.$\+&_[8XY7(/GW
M<30'=QZV_TN4))RS$0NQ!\YF@C#C%_L(\EQD7QI+>UI?&MV^J(GKQG78^_-L
M7K&YV\@G;(-74D?8WHYD0JG;"(7L:Y^UME4T:S]ZY6!(T ?["XW=VI>YT;7G
M9AEGCG T0$KJ6:\"7\)/_H3#C:9GA::#TN4';D7N%Z/?L11:>XBRU':*>4<<
MLKTJ/7$.C^/G7&G$;_T>N?P^O]1LK2<]EQ[J2D^1GTG"O=%3U(L<TWU1/'\#
M?BEK!<UB+1?'_*]DJ2<;.[?W^/&RF.(9\?\KLV?KASG7JQW08:S*M!+L"3 *
M-*_<C%Z>J%#DGFGOW-OE*BK.%=17LMW3K<,<[-5:*+>N<1-_*KRB\A@_6&'X
MA4D&D A"<N_&E^<\O)+[\G.Q'J2^+#\7B="7=@9U"WFP>^[W\[SUV*$;O[SA
MF7U]ON[=&RYI#OWJPX/]'4<<#QU?_NA_:T27\[^O%Q[7"X_O@R"O-QW7FX[O
M,L)QJ3<=1D^5#S)!]?Q 57N6]$S:\&($6SF(8W8-7GQ75QV*U+-W[TU]8<&*
M9R0 7LDF2("=@[77NX[K74>#I#2U)\L[]^N]RHIS!?65:O=4:>>9+]>[CN=\
MUZ'T=T^4NC"1(/5W5ZB7!2F<JG284]WYKN-;E5/Q[UI52M'0=/U=QR%;")5>
M0X&M+C4Q1?N@]U'BM\08=]F\L=][H Z1LS.X!MHPYGC=?<@)*U#T[_C5WW$P
M]F2C=C??3S3[/;7>8G2Y"JJ)G^_[BH/7WM9P\2QO>PY*>==+G^NESW<9ZG%*
MQ>]!5KM\4>Z;;)@]S3I,G/#\P+5ZIK3[2)T+ /"5K.,4UIUAO,9RNK+^J-8<
MHT>[Z]*Q(XQ"D;<[(JQF33LN3GC(JM23[6<RBPLO5 SMN42_95GIZ?I%7B!?
MN$E1ERL7)Q6,GFT?9'[\^8%J]6QU]W''%P"@K .$1YA!>+PA.;LV+QKBG(9)
M$'W=1W^B/0=H+R11_]J>Z%Q>_1U'3@X=)VLD.1=_7*.PURCLJ:GK&FF]1EJ_
M2[?H VO;RL8 I.XW-Y<-E^0;40J=^EQJ@Y^60G<! %+BG'*8F- UV%KB?CX!
M#GL\?XWB/S'A?NHN_=0-FGUO#TXTI_K==<][_MU5Y7[?D<A7:D^R#].RX2R!
M?8*VO31@C9YE[QQY/4HSCGT$)O$?-/BN2!-]%R9IO*).\!R*?%B>P!!R#I/R
M<#?XKB[7H;9(6\Q'%TQ*(Q=*T-8F$3%X\T]P%D_L+0-WRB:3L0DT"4VJP-$.
M#HX25&TV,:(Z0[DTC*\G3 ,W2?(I%S1+@D^WPTV\P,$'I;$!.$.#3XXN/@R*
M^;8XT*T\ZX_F,!2_] OH>C0:PH^S<'/K.^Z]V1V-1\G'</(Y:S9P2!()"1 ^
M[9WFZ+BPUHP/\\Q'H>!4D)D'+ (6%$US:-U-/E*=5C>%)AU6S^:-4(SK30HB
MK,[$*(]O>?'#(YC.YG.T;\]/ 1<TAK!]CEIYBEH^V<->-TOE138X)QLTDVT-
MAXK@P(7V/83%1.LEFVR$F^#G@3/Z[J(8:("0$'ML'DP8"5-NRN9/3]TXIGD[
M(+E6WL9Q[JT[>?$#+SZED18X79.&TP#=-3&,E!-C8)]-NHG9(,D0!UOPT235
M\8_5U^.X'GQ)R\@/@6;>K!OVT6/S2-:.7N$BHWC./I.1J]ETS]M52L-_'KRT
MF&UR6AG[*1M BA3+M^E6QT4!;@.<_\('Y=#8=SZ0$Q8(D!L9(1;C'Q=1DF8/
ML7%,?BS<N@&-.4KN/1)%"?L%KE'(NFP(9E>QW_5W0+ X%"4*D6P+"B%;0(SF
MXBHI14Q)6/8K^J3R1QUO.,,&QWSFXVIFV13W;!A4%:/S*'[QPVXS*NVJ-*2A
M9\4,)A>.IMA%><115!H*^O7>(VG.6)>-3<:LW1D.3N*GYH=\D%(Q%0MYE&L@
M<*!9N-WH"V,W9@._,D;TJ1!MX:? V&^%^^@KV/UQ?4Q3/N.-'B-9\^*' D-\
MX-K<CX&0_@6(2-E<UC8,9(/KV'!<?"P30FQ6;7G$%A$O3>1A9-DJH2K:M1B9
MT^-(877Z7&X5"HL)?@X9WTCEU'&.'-N8SP0_SO\.V,RL*(#GDX<$)P;U^$P;
MT 8X]@YD?]-EXA/A__;Z4*/N_PYO$O[6OOH[8"+@]?370M'>S"=@=OP35<_-
M_&><F7L3?^03<W'R.9#C["-6)MX0C20_QRY>4(U6,6Z-&*'T<L*)]RW]X,U_
M>NE%P>?W8]LT=5L71=F:B+(H29+V^>.GT6?9DC^C:I ,5?HLO13\V4\O_=EG
M6;4EW=;,SY.!8XUM317!SI=$;3@:B?9@X, "(T>=3)01//Q9AB?_CFCE6#VP
M])6JTM</ERN</I<4X\G;+!A +U/M23:NC30V(\/*M\R6N4,,DR!*F-'@)GQF
M57GV$V/9A/T:Z9D.A!;H*ED3_YM(?9VJ]C>?*D4=GIH]G;BQ](1Q4Q?9I= T
MGIC\L*'J:ET:@"QOGP>P=JVM6_]]QW=^.]_B;KBY_4^OI/%_!7%XQP:Z!I5[
M6A"8212&7E#[O/!MG>';_7?C.P3 3E :>GN#%DGQY]/!O(9F-X9F)[G:0*U1
M:(RCAFC74$>GF$]?U42[K^E-4_U@T</=MBF)LM3G0T/6[_-Z65<B3C(7<8CJ
M]$*I4];ZNBG"_[<>._<3TR??J-7G=]"G(] +EZ?C;UX\]1-.M5<Z_6[I]%&<
MG!UA+MF \B\1SH4.< #VJZ\>!K^\F>A^\6(P-'\\!X(E0\[6^_)?]VZ^;K,!
MK6]LW,"Y",+S);DA'P7/QE;/ST(:TF'*$LUDKQ=@')6^NNSA*L/6R#":AHZ7
MDF=#4M))A=7FMU\EU:,YP7[RISB//8_%Y+TD%6*\OWEUZV),-@J%NP@T9$CA
MV-LHS]0^!\KK:CHI?=/^JZCT;>VO3=/I1'3;?>^6MNW>'TF_>>S^Y. W')NO
M5Q@5O@NGT<)#L1<FWD%N1W19-4;F<"R.!J8M:MK$$!U%&8AC?3(<6Z9F#6Q]
MW>W(%H%T(IE_K:+T;8UOBR_>"G_<?!C1X;_[[6?>J&]MO)TS\Z</SF\?)S<?
M?D5R">'3FP_O_P$?O1$46._=Z.8/]L]?QI\^P3KYXF$4+]R@)A'HC>)7[_9/
M/Q41O6*2QM&?GDBA;_X]?3[SIE%,R1 B@?\FRQ=I?D^2,?^^\S6!+$E_77LQ
MD.'\-O;</T4_3$ 9/A[@R98N55\&WCRMF25JOZ- H"7KZSQ=KG>BE/JESWIX
M6)Z1)S!.HGLSSDXU,->+\KT.U=J!*ZHRD=%M"ZNT\P.][X_QNY__ 02N2=);
M 7CIYL,;(;Z[?27UX']_S';YZ;]_*;UA#2,U=.JY<-9; 96"^,6-?9"Z(M"#
MF^*=?+&CRO=3$"+95_N],[R*NBU%G:T<_T;TVK#S>WOU3K?,G7BUNY8]Y:5S
M(<\[50\;>['+/]V#S\13/_)-\Z$$^=_YA*^*V5ZZS'W1,O'KT%[)I6+\8YYJ
MLSN^#XSL*R=N11>M=?S\';=KM]/R+W3SNO[V^V.OM6CLCCUS:Y0_(S1>J?&9
M4>/S$>/K.W=H&W7VAA8>QSR%77W0MF,X?O;%-O&>W3+<> 3(IPC0([&>2RP^
MO^[YNN?]-B;8LQ0_I;!0MQ,6V<4+EQ84+T[\A1^X\2D%2-T,V$K%-(O>\R4U
M6]MRK37]=9ZTP2=C:*?[R (=VL4,XSH@*5CJE132MX9\$%*X6G%/%<R_>:EP
MY_HAYF+,H]B#_0O>-U8"_UV)9*-GU]LS7APG/EU2UE=H(JQPIJEMR>FV>L[$
MI/5D6;X2T[D24Q>U4!I&>5)?I8N.X#$S$N>5@-DW%C#;I5KWDO9V?.%Q+I"?
M\]ZNIW*.>[N>RCGN[<P<F<UNRZ5;9V9/NWCK;!].]S7^0J:ZS8O8GS<QG# "
M\QV8VBHH@UFTN@V\,]14^]W<11D0UW.YGLOU7*[G<OXF]R7<'>R8 3*-DO0$
M@[5/];OKGJ][/B^'_12R8M<$$*]4)?B]W"V^VF>TH3[[X'H9])S"%9=/2CN0
M3@,=KV2I9QCFK@@XP-BN[]KNVR%G)(B2Y.0Y(P<)U'439+6W;)9HSSOR^$J6
M>[9Q"2,5K_1T&?2D]"3E&+.EOMMP]O7>]7HJUU.YGLKU5,Y^;X^=RED$HDX0
MWKLZX%>;_4H/1Z,'1>D9MG&UN7?7"M>KU^NY7,_E>B[7<[F8S6UG>^]S$GDG
M^_Q\.YBRGJSGTC%S#RU,Z_T+EK&_@)\'#WQD<L+F.N==SCTW#EF#\ZF;W&>S
ML''&,YL1FLUZCKUL K8??H$'J1$Z/NR'=VPP]8L?VD<]3U=QC#_&80>XJQB'
MR^*42WQAC[T6)PD#?]&86C;XM'A+0H.E9ZLR+'RT]%]TO5_J,;7P@X!O<KX*
M9VR<->O*C9,OEVZ<C])\'\/[4O@OCGDG6$I3+RL39U_\P&?.6GL=)'WEF_/B
MFT^UR<2Q[X53H!LL.:?[0YS7^WO_8Q^D=H#-0&9>&"W\D$:O$B6_^*&5EBN4
M#)1$$]Z_T=!=(.2<59SA6Z-OPQH9$>.CY6^UOIQ_QV>WPO_AQ +6HN2;0%TA
M$S9M]05K\BBH4C8V'2=?LYG0P0,-49\BM+%',XGQDM2C[95?*2M]J;2CQ]]:
M>:=9DPK OEY"6,BN8IEDF#YP)..*V49"&D">"K=NPL=;"YY/ ZOGE6Y.."L[
M^X0G[,#)P']G?)8VGW,-2S3>NHB^\,G8.&3.SU[)F@S$]&^Z/%Y&"4V\[F\@
MD_KM<@F0&N' (@W2V9YP"O. 3DKI6_DQE009.ZG*"?WJQM-[094Y6< Z7^]]
M^ 11 ,(R<)/$G_N,*L(-+1=R:@ :0!I91P567W!H^S5R+$\"YTJGRAE_T:2^
M7>&&O]A*W\@_@6UMQBH]4T-LIM7J",:W\V_JG)*L;O_'PT'B3.7,@Q7.,\HF
MH'.T(.]G9'7KI5\]CPUQQOYP]*K25J]JY#M6(S>A, *38W%;GF&K,*HWJE1/
M_01IWC<GK7= /2D*3.<.V);XGI@'ODL\-B+>G7)I52;V*B<D/3[6.WO/S(/W
MP&^1I^_Y8' @ZF0:^S2E1'"SUR&-)UX0D,B*OB)5)SC-),$OF)@H W#K3=T%
M;FRQ\-.4&9&MP+_X@8.?W$>K8 8/9MS&)"=*=Q?_\=6-9SF@*(-=V#U9:L",
M*,))TL-) <QP^BO<=+^1L;E14<$J:\:1D\[JY>/486D_]@I;TYO/F5! K'AI
M&E1'LS<V'PK_X89@0I9F.2LJ5XQ-?^[1632;Q\%L&B4S_H*4Y,QAA0_>,HK3
MMEDT>YPG,]%'JJ':HCT82J(F#V315A1-'(U46;8<1QXJ^Y@G<X#![)TFKNPP
M5[?;V!7]Q&-7UHW3ZC!BY2-($]"QR Z,V&J0''ZRRI;@&$60I6S0W:.5"6A>
MD0!(_G_VOK3);>18\/M$]'] :.T(S09 XR()C.R)X#G6VQE)H=:\"7]2H,EB
M-SP@0.-HJ?WK-S.K"A=!-MD7C\9;>]TBB4)F5MZ5E5E@Q0@KU"=1=GVC#++K
M+$D+N3:DBA-^#0XHID@Y23+R3(62R$(OF_ODGT0AG;O2BW*MAIHEA8^6TDO>
MY,0UZJZGC4^WT@_-MB3@Y/N,K=(<6D!O"=$Z0_-RQ8W3APC(81B /@B6$H"I
MO2;K2\2*49]^@_\!0ZJ@3.(WH. %R6/TW<B?G><J#=?$5X6P+IJFBQ^$B2S,
M0T'&_77M3OIRF\+]D*$%'(3S/\1PU0&?K2HG W_"P<#)QT5Y4MBSJ&+7F3@3
M<^AJCC6>:K8[T36WU[>T[LB9V,[0&H[<R295_$*B%Q*M4$#(TU B3@XRVKC'
M<CZM(N;3@HWG1(3G:<!RLO[L-9^ZQKG*0T$*@NA;+E "P5UF+23YK 7D&SE,
M0>'S%BJ!]KHT_O1P:22G>/^D\&&M9[_WN"$^/6O_(3Z&?KAY-L__[@?U7W_"
MV:_/>-#3W&+__^CT?P_OKY][)%+S%F (_4&_* :AL+5A[:4OWY8S+$_<U?W(
MZ?=!JN4:282*?5I:M--I[[O'\C%+P:/A.4V(X-<"2Y'->] 9YK&6,QE6QW7W
M7.TH+Q$\(XU,U30LU75>OFU0.YB\UF$@BA>,0KM2^OU)W,SS$FJWTSOUWL;/
M32.Z-60_92_V'8LY6SM\GY1#E.['K8S?(^-V1S=;&=\NXUW5L'OG)^*G)] \
M_FM%>KM(=URKE>CM$FW98+4/< 6CM=KW"?DO(A_<BOAVJ]US6AG?WJ&WYZKZ
M :AT2O>.#O:[%[QC4.19C^QJ[[, UL"GK4^Y1[*V\73PW&R'>1:SXYZ11J;:
MLPS5,5\^,FX=Q!VC0#H^?R42:W:,UMN[AT:JH7=5O?ORAU#W5,7=5\#TR/JC
M;:5- UZV"Z;M?[+Y-:^P@A=-DI3*]I^GC&D\<49.S^UK_>ETK-GN0-><GC[4
M)KWNI&OH@Y'9'[45I6M5F?;I%I3^GE#-9,Y6JH+LMLQOQ@R2)%LVEB(<<ZGI
M>UZVZ*U6@3_SY'7*4D5]]=ZDE\N:L@)??N8#'6 5>(/')4_Q97TDOZZS]/YD
MRK\EH52%2?+Q.YP%S2Y^X#<!/"II)PABJG3$.KLEOQ^#%XZ2A.$Z@>]=^5BV
MB1M1C,6^^$$6W"=B.2KB3&$M;XZ7- %1CVY^THW3B&YO)5$6@_*15\/60(QF
M/M7$EJ"E=:^\A%\PN/$3T"Y OT"\G]_ HN?Y*Q;>#'Y1@@F+;?TY$U2Z0F0#
M=NN%*5[H&N!MGB"_'+OT[I2Y#W2).=2\L#0'\T EMA4J41EM<$?A18U*,;OU
MV3=.* ^O;5U'\#-8@:[1=93/\'U"OP9"E/BKM W\&EAT'?K_I>+&51P5MZ$.
M@_X7NE^!-9R$<\R(8V<Q<"2P0<'Q=38G#JA*#%9X+[UY7D(,V $WRNMUG*B;
M!/+BAR:1%)6J'JY]RR%;1DFJ)*#:_ 4 B.7C7,ZBD 2/Y3)6$%K"0]>R_>6.
ME<R;B?^]2GS\=X6Z3BE=M#D3\)S*O_0:TMX3T&/IG;A9,^<5O1J7^I5WM[SG
M5L$+:._+QAICD".V7 71'4/EB)H&U(@GF7$.JIDK(X_JW)?,0S]JKHAK6+0*
MORZP\/P8+7*6WQ9@G"+%32?D0/%>TI\;'O>3ZI4O?F>![A^0644^#@4B&M8]
M(CLOHSD+<DV97X3/I8[NO('%3!Y>UMP[Q:KFI_3@"J?MOI3:'N[>6^_'TW#N
MB*4KY;:2T3DKOI#_UG+ALW#AU4EQ(3HTH!L#?]$RX1DQX>R$F%!VQ:F8_))K
MSR]>M_QXROPX/R%^S)7B;11X*8;[=Y(K^>TZ,MDM/YXR/[(3XL>Y?PN12#A/
M"LZ,PH(=DW<88+7<>,+<N#@A;HS]Y$]M@??P\\9Y,87=XM9[R9.\D+?D&FZ>
M'T-"NIY9D[F_>2T%P;S93>5B=7&OVL-,1"G'D*&]^*],&OPS"X+:F1[^5_GC
MQD_SM43> 7,BF'E017L9F8!(>.<#> %/I,#GO#, _#-- 3*>>N'D)KA$7H_:
M.F%F;1'PI"6A(C5('G]>L1OOUH]BS  /V<S#S,C&1+SH@4/YO2OL[+3*K@)_
MAJUA8F\N6]A<_,!;QU"B%#O=Q*E(]!%CP);PYA!-AA8;'";8[0S[>GE!$BG7
MH/Z GOSZNVQ!(W/?98M<L]<>KG-!+0M7C,6\R5OHBXP[G<GY819EB7+GLX!T
M*O4.^A)3:NI.&?J@7D!NTQL$A;: GRVD68SOX%WC2+7)QCB;PRDZL,#.BTBP
M!#?MZHZ^IG>.&79DE%UT) 0J48,.2=C\< EG?B!0=8$$[_(.(94V!:)I$#R+
M]&%APH]W9$,BR@_[E82OU!Q%LS$%FY%QF>#UI8FL6.6RD;#XEAH>B!R]Z&L9
MRX9W1,=0R 3/Y_$F9ZLLQ=Z7WA(E-L$LX+Q#C5K@MY0;+"7(<P$4J>I")R#T
M7A*%O$H"DYML <CY^,_\=$:\G,'"\RB(KBE!SK<RIY4?+K!E%F\]=>OY :ZH
M\L,;D&)D>%(O,=+$$Z<Q=(Q4Z"=)O<WRFJMASOD)JQZ6 "S50X]%%M/I$;89
MR9*$4O*P!O4N<?/F;X],RS^219V&O/G(6_DIF*S_Y@>*<P8:*%J)[4P.G3?_
M(LYJ8#^IQY<RNQ_B0M>21.7'=Z ]2KS*F3"W0GCT"/M4J&E@0W&N<H$MN]"&
MR*:N>4M7! ^,110#!WI!4 &%I!?,#K: R[4[&KF(>P$A/'"G7+.0Q:(/6^J%
MUR00_.@4WXYOH4XDQ7$I-:/U0\H O*2&:V(?WE!,2;WO[,!\4G2)7*^]4DG9
MQ'2"ZWV7U*6=QET7C%(]3A.*E30X/"/Z<7I)M?,D_#N,A&&]XW93;"CMM/>=
MU-TJCA9^FE2YA1_A7'D!M7@"ZT:&%T]C1&,CU/BP./ =V'(Z96$4T\R$04BR
MQ0+/$+'Q'G\1/V^%5X$!!F;$/GE202H>-4E-2WWX2FC-O!!^#8]S5^Q0AO,W
M%H-G\?NEBKT,.]*I\XG;HW@523GA/D!(]Z4O4]+!N:#2OW$?QB!OWSPD-2Q0
MZL*)JC>C"B/R(J8,=(.'9U?B!1<_R"(%XFK>_X\6K7R,JN@WX"1P)C,\=83=
M'94Z55=6R0TYN29I&OM7&0_ORET"J]A?R,ZJL*.X[8E@K*"LP@J;3D B^-?@
MWWGS6S_A#)G_0I@@P;D K,2W <Y$:IQR!Q.]8ZRWRJXT&=-XT^'@">[&;.Q4
M=B$;I=4Z$#\ 4L'83P7KQ89.3@WM&E]418^EZHNQ)UK&#JNF/V4Q-K5+:_Q8
M]<"PT3/V&59YWN)*M%OE'9Z!FT/JWY7W'>7QAO+QPT=5-$%5Z:?_XX,]33+E
MTE_.4)]^ L=NZ<U8Q@L_1A$*V:\I>+-%JQYC]$[\O/AH_.Y'=4WMYQ[TKCR4
MK18Q,D[.'V$4:F -LG!.H7O^>:5>0?+:Q0_<^6%QBAV5J=ZT*"/@K?%J\8!7
M:@/+RZ5$Z1B9)-Z#++J%YX1)B H+*.J6!,AY!04922H82RH%*K*$AJB..LX'
M.E%,)^(U;RYB'RH?>#_]?*D87>7M)6/<0[;H2?K3^?$I"U7,8RE4^<R%+V\/
M"]0&?EVC,*^^$ )+]4A+["#(:ZGR,,F3E2 4I\<1;'1")A""-MAY"OJD#.46
M *U[SB:RSVRG"3 N0_1Z*3H"3G0P[H640XC6")E4"\"[Y@5DQ&TB,"S21CF@
ME"MX IYX!AWZ6<+(8X::CY\<VO>]%SRLS^3=\T6 1 YD/@^#.RM!AM,/W_H_
M5E11#!J8UI4,PA=XRQ_(CQIYK57!'_FK?RR799*>CC= RQ,7212&+'@'+R@#
MPE]:XM$9L!5I<7"FO$!._5AA"WKY!4^';*V13=GL)I2)!I(.2AWD(!$8ZW#
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MGA:XDW(@VGUI]Z7=EW9?CM_E/H6S@P=6@!2M?-H"D!;FUP'S407LA] 5#RT
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MGU97WEH_W]KF37ZA^7H;AO 0G.6V[31^0$ZLRGOU?V#8^SW _E\=Y3T?SK4
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M9_&J)6%AD#UP&[P$J(C-EK +'C(&\AV2R5_XLZKFF(-U":(5Q2:RWJE#[\S
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M)(+(X"7.TBA.#K[GW+H70=.Q['RA)E%:0BF[/+W(H98Z#?V2V$^X*P:KH->
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M5"@"L#+T7#"J^\[/L@1ET"!+6)!#"BF+BN5R].)"D?*D94GN"""AG_*+U 5
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M10LK@1['O@H("Z^]:]H+('V#<J)'RB:$7<=@V*,L499X/XG_B+JUP3]"1LQ
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M%<\?_.9_)ZJ01PP/7T5S+'.L%%$(.PD.,O<>!:9> F$?>'N4T*'42P ^]E6
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MCLIGD>2 LN[XCZ006&1&HHA,J^S;+V+3-*&B"3K]3<"ZJ F&(P%!,W0'(,/
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MF(JVHOH>:&-)K8:Q@[>0L0R&&WN3T7N>@>?Y2Q9^22P#M0BCF$UN[)Y1 !_
MM7@/X@=0R62.]F%*N2J>C6H!>W!V1^PKO?40B]]Z@!//E/7YL7>?N*2I^M75
MH]WCB&/5\>4[[\=>='G]^W#A,5QX]$,@AYN.X::CEQ&.KMYTR&,$T'5X\&BL
MBDUWT*H)51;!AHV-3+R:X$7WKSJ@.-;@M<0OK\@ O <*M0!G!VN'NX[AKF-/
MI# : X '6]$[6X&T,1+/;APYW'5<\UT'_'!^HE3'3(+XH?'F8_5Q5:R&JV??
M=?S8UE3V^TY5RJ9>_OA=1Y4C+3.OX8&M/#4QZP*NT6T8>P=BC.< 7_)HU!R1
MLQ9< YTQFZO!"I0^CP7K<3"VZIC[P>F,VQ;AT/W$>IS&Z5N,/%=!.^:GWU<<
M["9HE%P 96AQE;<]E4K><.DS7/KT,M2C3R;+9U9M3_TZ?U6[W*GC&Y"5,5:K
MB1.V#UUUK(CG-_3J (+O@41Q5,[&<8CEY![=1&8DBJC>1\G%[YA#EV=\4Q &
MPF1)GPV2^Z*MP9!=,AX B6.@5=(@KWW(L@L5&5]+]!L .):D3EX@=]REV+4K
MG;,*\EC3*AE"U3Y4U;&&M#Z[$T"B&-;0 ?7\G/>ZFA>9;OPT<OSP>QG]B4H.
MT'8D47]H3]265_<X<E)UG&Q_5OKZER$*.T1AFY:N(=(Z1%I[>2SZRO-K1^Z,
M<F*T<'^X:]O0I;,13Z%#UU(;?%D*70<0Y(ESL)J8T!!LS<Y;?G*#1\+L[NA[
M&/W!$NXG[MQ;N/Y^W]O*A::I[PTPE_R]8<OM=R3R/1J+6C4M&UJ)[ 6[;=>0
ME<>J=G;D]9($U1-#+JINTW]L.L!D$BU=/^8CL;]X[H/G\V$&F2?OR8^%X8>3
M/\KK] ^A*$%=M 51D64!2PX0#--R!-O&N@TDK.E6[4,Q,A,H=-\?N<]LU$(R
MU"%^"J.%0"G[S(=*S-U7'DO][BV>J$\!1J_$C?8G.?2[\XHB7Q;05<[HO'(B
M2[>LSQM[=8^C))?'O>23<2_#I:9JPBOC^/N'R%4;8Y'^5LR1[0[E,JOE!#F:
M(KM-%&60X)98E76P=C=46R=SKOD$R5U3>H!TEU./^J$I)5>SP$CW3I3:E=3_
M59/ ,X0T,[IQ2Z(X# +B=TX)$+B2E$^,.ZD&'=\TOG+:L?]9=*./%]TKJF 9
M^%<R/$0:0^7LZ\QAK\BI$I]O1QO?"?T\^D(>V0#2#CI0X/Q>4QU3#/'\Q.!A
M[SB[P4H8+&/2O1U#PU=RL !C"=>03W[E^\7=\B'VIJ\C=_K"PZH1F1#OA72O
MY1BH1EC:AR@\/XMHV"[.;]_)KDQ';GJ!VCGMP/*5:(=41PW28>W(=)4ZCEX-
M),RC.6D@G0O^)HK^(XFBGW,_W1G ZA?I5J#=6L":WI=.[T)=,'E '*ORE1P*
MU+%<S;#=:S#PB.KM-%P^^*1M%J5<R+ICX@>.'-*^0IF4!5(:CV1%6F3A>CZ9
M;F5<\D9-]^&Z:S]=C]5]9]<M+T,2.$#&CNP(DBA; C9,2]!-1Q1TU<(*,I'A
M8%!WAB1+5%Q?SH\>(N+^,0V_!ZS ?<&[EH?K@08DI<W(BS=UJ2,WID_.0I\5
MPN^77O0[7U*#E^5+RK!XOB1J+E^RP5<WV!VU<JQ[G,]5+$VKH,W(091=@W(J
M-XS]D*=9U_U31(C QY]ML$\'.*Q_7T]#V^[EM4DSRV,D0;4('TSG/ )BC8F<
MURQ;=]Z/0;*&;-BW)/QT5G+KTK"+X;%.F.Z0R1D8<MV:>GG>.L G=BTN-TGN
M^@80+]C\W/=L]H*1CAHO#/_A!LN9.UDL(]Z"H)GLQ+6;L?UH;C'8#\"NEY3&
M4MH+.O]J1WIW7 3BQ32Z]#I^#%'3/2Q;*B+:6)4*[F^]%!%I+(-.]L?MFLW]
M?,M+MGUOPN*1/32Z6(.#/OTLBTU/H6ZI>*AIT_'K%@]-KB1Q?'!Y<]>IC:+D
M_BQ;H-,K.PS'0"Q8O-U+50-C1:G$L^F^+=[T6+IN$4%C5,UV/3B_AS*4V?6[
M&TV>N",\)2_$#^>\,7T/G>$Q&OR=Q-* IM/_6BHBZABE)^_K%A&IR5JJKJ=-
M#GG8 S\ZS8^!1^WG49?0;BU@31\9NA_"8;!X[.=[GN.;XS3AK;?OOIPKV#Q#
MB :OD7K/& X'B\,!0#A6X7"RX&/_<',56=<4W_F'&[B/R9!!9HW=Z;,7>/$B
MX@4K/0SOP+&<3LR\;@U#X]6M[V"%]W*0L#88X<7/REC6>MT4I+U6^8NW\![[
M:H(E:4@W8?7UE>A6]\VOBH?]F>[/W32]73.TR?7F?M%QKPPN'"OI/<UUZQ0<
M V7(\3OB\P(TW'JS8Y$"&^NY/5QI=@&P$HU!E]!N+6#M,,ZM($5K 1MTIEV
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MN"1NC]0/$'?!'M5)%[!-E[;;HSI)0^T1$#\@Y3*#5-Z!B-("'#K2EW4@0NQ
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M3@!;=(G*@3TE!D67J!S84Y&.HDM< JSA*#I=7T2F(F -T3?9IB&(CN-@K!M
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MN43L2?P@<RIF\#ZB\;$O%W&$SJ]$L_0);@6+S4MP0^(?14@8<CV4"?966O(
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M4^W0%.]WKHC[T@)Q;W.@KL>#VG*)GW &=NS7,2%,F3V *T"Z:QWYT=OD:$C
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M!RN9WF9-%RHV*:72JYV;XOW.%7E?(#CN;0[H>MRH+5?AA/?>G/TZP)@ILQN
M HR[ABB/WB9'2P(V*9O"^=;OK!!TXI;'WD9:VM4F^5UQ,_4[NLKNH/#=VX@;
M=+I)&2R[3OH=>E5O0+CN;>#U?6[6*D\1IC9NI7^PN=@W>*'I$A+_/<(-1AT[
MV0>YGVI#F_]*7QM=_R\<VAFGS&HO;H+<(QSVC=^9]5M(PL.^J3 D=Z;+V]CL
MLO0[+B,OBHZ/BH:;G%6UPC@]#<+I:5'FE%7HD1[:%;OPE<0G 1I[692VHVZU
M^F9H3:9>&'<F-:_=)Z6\AY,I8B&G+<E<J-HCC1/:!/:S)W122:8=I:(&"GJ#
M*E_$+:5L@6;TFJ(X0$%)-6MJ[6O]>:^GB]WV1DJGJ_O.2.QZ/=\=P>(K^+QK
MVGF4^ L]1BRU18*%JX#/W7","9_ 58_U-?S3<19%WUB)^O]._ 0W;NKGU_?9
M=UZ"B3.)\QN)Q1V-UY"4O4?>$XH^'&N+GP+B9FER*%E9+@N%CURT4M*+GV%1
M^Z4X'90T?VF> UM(^;=S,+33*8N9SGN%BG\S-$H&LUD4^L4UB9OKA^'9.PUW
M+9N!ROUH@I/L>;*"=(ZP%Q//+^X@&<K J+%VDE@U+]B7JN>B1WZ;('S*> \?
MYRP,.R3UEU%R]SVNKL<LL;-^>V#&EE^TO_1F8>I%NNDK* N*C_*<5'-0E8)"
M._<@MCE.I16@<'2/T4N89"2:<^4LT$PL27$XW#"=-T_"(N6@*@*%Z@=$3&2_
M5 P.]2FU95'PR<-Q&#\3+1?"XH"XP0F9(7J<O:#&@4\/B86?BL'@;D.5:="U
M/2CRX*<]7?73,)MJ1E90% P74L.3VK;HAOXF'T&3NO#YY(!W!Q[S>E:TNJ:>
MR+)JY%K6X(GPJZ(BO4U3HZ*JABH&>)$^#_MEPP6BU07N+%H8XV1J8/:7!"12
M0^\HP0'"/%,KSPPXPV&"Z<\?CL^/CS)":4QF^266#?!8H*QV6:06(0 F%P%:
M,8<B8W>1+Z'B73/WEZUF3K2_U[S]O-6\R323BK\SR!-3K!4N<BC3WNL1_''+
M.6R+Y]2<_P1[9UU3T5R>Z40R_HYF./> BAEOH8LM;54ZY:;D^NW;@N_<&_:>
M.891\.$XQ2Q[2?DQB5/TFGZ*>),?C@GB.?K +I;.8BN!EGI.G '>$SJSV33]
M:U;/=Y%5.0I5,WZQBXQK>/YA=W@V,IAJSM^YX5P87="6_P7+='6\1=:'\^.M
M;\8[*P>%9,XAVEPM0 "! 59[#&KU'=Y!UIW'3IZ[6A3P#KJ6HK#@^*NE87;Z
M.8E[43_GL%FZVK_.X(J^#B\LN"+5YF,(0&!E30:&*I6 'DQOWQ(4:-V4<C70
MWJX5*[![V6:5E#'SHA'"4Q'@+BUK)ZR#(S7%9:QK>DB4O?"CX3(C*57HL=B!
MV*$!JZ$HY;E\$R]EHSY3!9PH:MFB;IZBRR2BG2<XW[>?,>)GC4*,^EH6J:.&
M.3V)4>KA^0CYDSB)DF=Q<)EA)2@[PE>Z6P?_1R<=6[C2*P=*[W"+)N!RK7$+
M2ROL'$>MPR EZ^8N3AHI1V]#GV?HTZ]KHWI0I#ZBG;+W7LH=7+E.A(6A<J*9
M/9+BFP?B.VMUBY9K2\5HIT'ZM42JT=:V []?7P(F&I=S@+\% -C)<%A<8N*]
M<IM04 M":*-NN8=!36.(VBN1.JF \0&;>L+[$L'VQ"#I--!Z;VQG0;MWC1E.
M 94RJ-X*X<QVDX%6JXK-(U!KUF^'J]>083.+Q[F_T_X8*\&1ME%<6P-VK_]H
M+1#3[Z-'0I^[I:(LK0,-&8GTU.+..ZD=:%(7BHGK[@;QV"-/G ^"4\["*8I2
MPOXZR:D].[DXX]323]^JB97W6T^I2R]_"TSFH6A9V34_(B>#OCR4V;3?=W1W
M]<8=4T>KO$,#%I["DZPJ&-/5A,+CUM_/.]QH6Y!'\8RAE+_FPX3] [+=SBVF
M1QJ<$#N(MG:7EV .0 95;3!JL#T[QU)[%L'6!4K;8-K(,'$.#VD!9&,=V&[X
M+' 4R<[-,,@82K\WPUS=B=O&FV&[@RFM9/%; T7J:,5_]"+V^.)P@E#:$9LP
M;6+C"(60,"U.H:@%Q5Y8?$/B,O(("<<A>\^U2/XH#_;4UH3/X]<D]CNSV:@,
MA=,#]K0[V-/6XS(+V0E4@,MB04 <P$*6-HG4M#S+5_ :U7FYZZA-!]FIULW6
M@#AK\6UV1F\-FM.3+"Y7!>$(X6D';NC5YP/$T1KB@)P0H%^(PQ6X<X X7$(<
MU>5B*/$Q Q[5R*F[3K \LEL34M*R&2N7</(HY9OXMP3_3@>A2/^FRE:HJ;%Q
M1*:<#1V1)I/J[GG2(DR2&E!LJ ,>L3MXQ"'[])90#^B]BAW'4'3Y8<Q.V45]
MKZU2X5PK5@-)+8[I%1!)=ASN.H#44F;B+7IK8*.6W!HM+.<X43MX1*WW':"1
MUM (O+"G34$C[J_"J6^$@L)&=A$AZG(OU %&]$A8SL/R8O3?LX"?RNPZU("0
M;)H? (>T88>T86NF#>N/]\\H><;>;$*7;C1@N[32<A&7!LN+QN"4E8?"3VX<
MC;S7XD%8=ETUC#,ZF8H@<<W+@/K*W3DER'_SG+R<\NF-.9\_E7\P=/"G!CI8
M?/[V.%RBMO'#(;7.UEI]UD5J-N^=FX:;3:TBV:BW1EE4'C0:5N%HQB:K0',,
M,5Z;.V);*]^!FGL3OZ "S1MFTZF'Y]1TJ[^UTV4EOKS!,XK]^<<D%L/$XC)V
MO(C)E$J 1YU[=$6?R?N7E+1$!9ZQ/"+H.GPM<5'&J2+5JJX*%#VFB/?Y;T3/
M-+J THS-[^;\D>DPVHI0.*P" JC9AU+"THMH=$]YC1WD"9 OI_TDM#G[R++Z
M'/+F&$<7Q?^SK>&BH3SG7[_5_4HM<7E!-X0*S65Q(2BSHX[2;#]/3.I"X;/(
M?[2T8$W2NXJJ6#G_'H<CIBME>#Y$/A-<B!1'GZ*T2]5/NV?6OA^)TN'<JK',
MIVI8G?NWK(^I1H7;#M>..<.K.KMS%\XJX*,]/[GQ*3F\=A&N,1-("^W=>?"&
M16Z-- #WU]3M,6S$IJ-W6O4(FU+G%&8E%>H\[H$E4\^S7G-;Y%JQF4-BVB3S
M[/H\;XE7N;$(+?B.Y0^_-#.UE+O$;5+X\%=M >-JMAZF476D?)S&H.+!=G=C
MNTM&^RM*\U5;9'\J/#_R4597@&)G,RH3C,+G^-.KS_T^GQO[W"J$("X.A9M[
MG/@(!3Q-V="+Z)Z,OQ1Z0V-WOHD)U8KS$,C&I<]\VABGG;3;$1@)9IB.*PL:
MLBJNM5IU<KBW/8*:*;E-C@7WNHTFJ+[5\59QK]DF#];WSEG?:^X8H.'$MJ*P
M?OR !B#; A<25<,YYFC!B#<_+;; NAMA+T"#.+A+)^P!'1^%+XS?.K)"5N J
M0^P%F3 ^^R?RL+.WDSE9MZ'W%$9\&0UB,O!]G'E1S<)PDN T17A*V;CWYHQ\
M"*0O/5)6D;OT'0I]_1G_@RD+0+KWPH#N&==T^QC1I<F>:'^A^VJ<7F=Q0+=*
M80B.64TK1F'=URAA&8+IYL&<*PDNWZ$9(OP2^BN:<<O*4(R#2TK?,]VN&-;U
M@")V&>+>PWR)J1RSFFI0N#-,(]%'FHBE924'%<0%[=#0B !=Y%&&"1E7ZYD^
M$11D5 7*S/L4IU0%(*,D]2*^_IMK1!/29%)W3_BT]7+RM1?B7[THX[,&TW.#
M71$33GY)25OP,OA7V<MX AW<+2QJ!Y9-X@<TIF<Z6]"/,ZJOLR-USJVK6C,5
MXK-F-:&LG:\9$QI37#V,2)[R20[3B@I;D?=>O"K>M..9\%CZ+"Y)(SQXL<:F
MDAM1"H+,3^]PH34*-#)IL0W3R&Z?EKKMU0+TNDJHH.Q646OK3'I K+7J'=L5
MBY :$_0D_",WP 3KKU5]2Q3SANE6FCS'X1\KNY6DD-V^:Z:Y>1K[Z.XI"I^%
M-Q/;U+1")=\A2O@TN,=TUDC>>]06MT-/./417E(>VFSR[1J LMN/T)1I)GA^
M%8[IFD!TJ!_CC(IXY+VR'"\,0 JJ+Y=TS82Z2.3.+6ZU3#0:_#IM'N0B;!/0
MM94B!$KX^+8L5'^Q,%1.=,,G+KY3W-C28@HSB\[G+V&$2)K$J#2Y%#<IM)5L
MTE8TK2"D+.$ZT-(,C5WTP1DA,.Y#$PS#+GN20)<@S/X#%=J"M)5;4@N<[F 0
M0Q=AR3T!D&,4.D\+4^0,<@C">L,LAM2<AR/T,=A*4]-Y4%9O(ZP \B!?">H\
MS,LZ#.1K0)V9E+EGG%\&ZH/9=KA?+8*_[)((5H#$FL^?=Y!/#6A9,7\&-'*X
M"_.F\3XU\SNDBK4((ZKYAYIQN4VPAO#^XQ*$Y-P2ZY%CG0%;\'Z^B[RO ;L7
M8KG8';'(/;@%KS] O"?2*;*G&2XM#B&I]SB86;9U[O:E 14YD)UO:FJ(;6T.
M04!HFI<1M/[]9;-*!5O7<]:5I65\/W]==Z>%;7SKD&8X0H.^LJSZ2FL,6QP@
M7:\Z]T]5&F7%$+I'U5KP]JV5-5G=HAFN]*VN*#JJ2-YZ)L-#G5LSW#*0J.8=
M'G#7FG>S -F:93.@SL%5+PZ43Y*($DH8$)/.03\3\C%)TV1*S6AVL503Y" J
M"R5> \(=*^5CMN0F;B#PRRF/V)1O7+P,RJN^7Y(7),I.:K%A,"/(+G6S<> K
MJ'PS33EXTAJ@>=*L,E4=2[?FB(]#OE'>C3]CCUIHWSTLC#.6%;5/QQW_]]:;
M$?&5-%G9OB@AG%MQ]+6J.)29UP311@A/V=IG#_KQDZB<7$_<JYV;Y .,V;Z@
M3&9EN?5=D)7YTU'=6H8BHWVY:\ER:Y#<S+ZK$F[4ECC].*(C1"*NQ!6^5<+P
MZ?QQTSNL?(':3NNV;B(N/=U;'#6B'4]>N"=:\L ;C*9A-C4C:*'&;MW51*GI
MS3I]>2CK["NUA_A3TNR5I!>>$7.<LJPH,Q:84<9M*-6_%DW Y5JS=4HKV+H%
MC%Z1G[%(H,J!3F<OG3[/V)LJDC0:5;1#8Q%MR/+J)_DJY^=)A()1D@=<BN\I
MF]0#,R\*8ALYKG@VGAQ :'P5:Z5K-&1UC+2]_IJGZLI7IFK46K8$;1SOLI2D
M'H^]X3.O,!*TPR:K!XV_)G&?7MES%UQ+4:FS6MZ[M E9+L4*LR@5LQ9!RF0#
MF1<VRPDUY%BXW9Q%G[7B:J$B% [O,-UR/#S/"=7H),+"4#BA5B5'0B4WPA4%
MK9R$M#6?+D+O&;$SC)KY7E2<5.(CP+"2==JJ:-EVU,FJ6:>O'5D]4<,#QSG@
M27X+H^@C8OWP%5R=3Q+*3&I:I;(:F$(&6D7+K*)5&HNFF1+G15&NVRW-]UQD
M*GK-&P&S(R4II9*2M[!O<IS'\[G,-?NM<0-V1FL).N!Q].-[?F$$W4>>S[6,
M1RIQ\3BUJ YFA$#D+;++$_?1*N&3N@0HFG6K8:'0UE)N*S, GW4?F270A&$:
MY@#Y.*_+E-8"VR 7==-!EDX2+$LWU$,O]KA_6J&+=:P] (WK]CA."FB&W,1Y
M_[^A\'G"=(<7A*FRPW^\8M=<2I^_^8#9Z:['D5OJO-)-RN"AS(MNP[&<X\X-
M0ME'5(:];GLQJ;LG?-K?78NNBF<YU$MNJ:S%G&?L_OF9M//BY^W.L=9C1I]D
M9A;FME+0BD1'WY/1),F(%P?#\#5%*,XM+JH3*QR+!K7 R#</]%0N3Y/L5OH&
MH'"\=+J4ICV?_G8Q<OL];9\,&[Z1WJ5HWM=NIG*"<)/ 5 *ZL-&EJ\.JB$SW
M3)M$U!L$E2[R+$;W*V8O'"6]6'U3K)_HQ:4D5>L'^^U@XJ^-B%Z7. I>:HH>
MQ=(>;(6<4:QO01DFXH)\":S'A664KPM>DK+-R&;%(0PYA5G?ZT@=2PHY[UG?
MDK%T2PMR-K6-K#=+ ?204[+U/145H?F0,[AM7BR+MP0@)WC;O'[=%GF"G"%N
M(]+K <USGG7.M4SUD9/;D<"A1Z-&Z%YRG\K+G524EW'=9ZYQ/%V,HAW<9]5R
M"*GH(W"W(W%*_^*1!@&W3;.R8P(RB:BM1;1_BK@J4+N2R_E>*>&:A!:U5/9*
MN5[K<F ML[U2GEM<>JTEM'^Z<X=+!;6X]D^I-KW-4LMH__1K:5ZD6BA[I4Y;
MN=Y:RV[_=.U>@[YKP>Z?CM['K8=:GGNET/<<B5<'&>V?.;#F'8=:=/MG,RR$
MN]>"V"M#8/7XE685J26T5X; JH3,\^?4(G-D#&C?0K$:LB@46HL47,XC8]V+
M2Q%H#/^]H=ZE8W[[ _XK1/U/);/WJ]P]7N1>1(W[ZX4TWL&.RC>Z5;$:T:)Y
MRNG"E=5L>/NB?1I'W1FT77<Q= D=EV)1C5.!U!, ^@LM*XDF!.L8T* :SNL6
M7&W/NRNB+!5+I_C*'=EZ(D+&/O6<"=^YJ)C[ ?*PM;@LWWREWB2S:SVZD$&O
M+@(PN6Y=#[\KA*7E,UC&=ZL7Y[Z1_-QO8>W>R>I/%ETV=! /#0VSZ90J%0P&
MF64I>>01JJ,)W>X\5H&Q2'7T2>U%8+HZ_;O051N?4_JU<CJ0=F\52?(?#*(H
MAV2FLRB9(TFV)&51*'?6#V\F]?]FTB(:7BQW>7I 97DH\EYP,+-87Y^*[M>$
M786)V/)=]:Y*QZ!#4R"E\!"2WZ\Q0C>41(Q(^D!G4V<YF#8&1A*'-WKV\(T>
MR8Y7'G;Y7*U"<K2IEXSJ01G%%B#95K\B5.[(5^%+&% ];T#JF-DVVUO;=JS,
MQ$H/'!"231L=7)7[*9]<HLEH6A7*./T/FG_Q8B]?S%2T)(EC%-$3E<^U.TQG
M%ZI?'Y4,4JM&H'"^ G =\L,><N&UR85WR'=UR(9TR(;4+;S)^(3=YU0EABE_
M(+LE^A&,F:6P]XE(NJ M^YQU1 VY[6GBD35,NKU/1](-Z'.>A\1][)-A>-@^
M!V.NAH>Y"[[L(SRL*T2Q':D0N\3*2?V'[C,<VH\I K#&-Q)W SKEZUKA4H8Y
M6F'%#;!T?+%/U>/\HJ+TP@E TD575!OD'T(8X+G^83H+#X[5;76L'MR6!W<8
MV(?;#^Z2@[ODX"[9R"5H5Z:O>U0$/' $$RJ!;(3V!)7L@G7Z,'QT9XH^H!<4
M9ZA!'/^[G9VYV_:=-+0[HOT6%UYO8C^9BH-0-(6A:(ZP; .)S'5B!BG9<DG)
MI%?^;D5"16/L4932$4I^"]/)9492*AJLP'I,J]JD4X92B,O8[%ED\Z_^;J7'
MQQD]#>E)7JA 4W:E_(^%>_*K5&CK'"RR;5-G]--@=U4YQ6&Y'<_!=6':>"]V
M;O+UF1E$.-2.7)PK:(OR+%H>R-U%/K1B$&@SSF,ZM3B%]+CO%VUP9\4-@AQY
M\:*;>)S@*=]M#Z;<P90#:,KQ0+E<?"(I-W^V8SI>/PS/WJUA'K5KP):YN_12
MW!4:(XQ14)!Q)C&"=;5L4<>S?C66P^ 9(W[0*4UT72TKU'T)(T2')"[W1J&%
MN5JHG[XY+$Y2\H#"Z5.&2?G*I@%%DJI0]IKVB=-6?8_F3<#E6K.M2BM8F6]W
M<?* "***T82_[>JSU]<,UJ)1/4N@2V/V%J\2B,$703DHH^X"R','D!5OVO[!
MDN_X41:P?Y<.$@5-)K7[H?9KDJY'L+*!+84@A^'41WCIV&VS5;1KP K-W*%\
M-R[PLKOQ"'L!RA\-8H(1K@AM'2A[29']J](AE2>DL#!43G0WL<7%>P;:VT'L
M!W!]ZX!&$X 9X.O%7<R%BN<%$]HY'-<7EV+5$?+%Z;78U9]ZD&]$K\6Z"=P!
M^6;SFM/<7.N&?(G9KA#4RKS[J\F']/+6TLMW06GK">#(<7IP*'9T*&KU=<BQ
M$.NY2X%JH=K1,M[4(8<S=&050.R"+7?W;CV79<BT&&YQGG)APR$,[MZJ:ID4
M7PB+J4=TNQ0B-6BV\K"2RL7J/-&,38;-/%DURY!?0#=DN24T7_-NAO.XBT9J
M7@Z[G/ D%#?Q,IQ12F= "$J+ZV/\PVWH/;$$9W0/^_0ZB[R8H<!S._D/BC I
M2LYB]R*46%[8"F0M:+[!N2%!S1IVJ1HE?,#HN/";6!KOBTDU*&Z+ZAG,8N8I
M8] $98'RH?&^B$OO$"_?SN%QTUB>9M-LN0(8CE2[I;08-.KE^ZNZK)6=]0H%
MF6]\^"A*]T:-YOC15;%.5YL#R*B>)0H7L&AYX(2XH!T:;"E8*T#( @/V>X'%
MO30,QW(/4/;!!F&:$W:UY [P $A#,-S:#"J XJA!F"X82%S<3C!03,<]8ANO
MFAI-X?X!,?63F0H[90D#%"O/[O$PTZ"GM1C=GM>+E4;.$L8I64V0?4DM&-4M
M4_=^I-:+5&+J+0ZKX/!R/W7;KM)NG()8IF*G?7_:=#77;:NLNQHXT.]0F.A?
MSKV];D5D#@*##SO=Q+(V0BO 1ZQN:M4MPU[@0SHWN=9644'PP9X;7F%2^0!\
MG\;)NEH <,%??G"SN"0R AJOYFB%280$.OZM'U18"4!L5:C<1N6S8B,Z#[@S
M BZDX')CM0B]/VUCEAW$YO!+=7=TIG@\_O-UQH*,2)7^5?RSL^RT8G(4:8[
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M3W@#//MD^6:@CXP!W8"E3B<.M<=*UP,I^5"]6;#-'  >B?(F?J4U@Y:ZE%K
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MDYD#'K&G6P(4X7+Z<)G@NB)LA."7=3CO@9=;-\?V/BJ5%.^,Q%2\OO:]1S]
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MPR>9'N[<Z>.WGQ=@9YL]'G^]S::XA6$;I7-'?>ZE,2]P;XN^0YKM+C,6TGE
M&[6:NT-H;6>SK2XDK&;[K?)<NMGN"Z/%O+\YPM@;WFRS7C?-<X9/4CGHNH_?
M45Z G<WV>/SL9EL4ME$Z=]3G7AKS O>VZ#NDV>XR8R&=!QRP-U_VCJ"QZK>=
MS;:ZD+BLD+Q5HDNWVWUQM)_X4<>A9]UO64+K2.[(KGGOF%E4V+6O298'NRS
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MH((=2=8KAIDRH..UF6VXC+&G7SD>H_M&2"34S>2%PS)2W7JO>-%D<A/>1_B
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M+'>D^^/SU9+/'L/C#6K0<1EDQ4A#3[7K89'JW:%D52ES_4CKS[H'X2ME"U>
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MSU[H/9&] [?H&T9A" /D:I@B5V_B6Q1ESLZ@@4:T4D?&,QEE=FE[@^R#0U$
M..8E$+*1,D 4HYPF-K>U1DLPW,Y@V-%@#:GJ=1I+!U#)J,0UWC68?/YV]+,=
M JA@/VH>0]3UI.[Q";8;XO>0N;-S>L1)9@DOL:&F<*5"MC2/4R@!Y%0 E:9
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MH1-*)L'L6(&Y6Q@F >ZJ *Y%.^3(6^B)1-14:<QI[VW34^R'3[@$SJ=L/&1
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MJUI$QV:QTR,'"899-9*S#G)5JM?66E17;P%A6>@;6-RC(UQ$"2K&>W)=_0G
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M9A#0^#5ATP 5H)ZI_7,J89*]<P^X3/[E;Q. E<O:%%;?Q;#/JC-)$[SL329
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MG9S T[7UK_60]K'BI@?"M>5\[13G"V CP"/G1$$SF_Q&PG X,$P,V8Z$XDI
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M-4W6_4,,O>04O](;_/S.H6'^T]J;*:XKPIHV/]^L\@;JA_L?0&XPOY+1-S=
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M_WQ!?LU*Q_XO,6GE(7().!($GC%+X+_.BV+G^!,&^,/EV]?8>_,?N,,_PR@
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M<J/>">Y#I$BDQ/W6=;II[\@@!(\P4< LA6AKP[-,ZR#W:M4\;- >@39]_SD
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MQ$R\1-EJI/86,F'PL&46:6_ ..KB_BS0 UE3<W\9^@O?Q3%YKANE(?9GS*+
M=[$EWM^P8N5#I,KH)^?57Z?K(O9U1D*M:<J(2G7MIA,?,DDK2JX1+;07:LTC
MV$0PP=$%<[ D\GU)HY)7W!1E>KY"I*'IM:Y,UNH1CJRUK=J.$<N;DOSM]E*N
M%)R,;ML-.Z75ZF247V4L>\S?_6G'!]J'<0!BF 3;S-HD9_RADQ&VNP"235UL
M,R1.Z#G0T[%!#[=(5V6EZKK.)>4V3GQ$,(@?FB]*MY9I]99,V:AD*:\]S]N9
M_ZP5[0I/0S87[7<V65H.IZ86*@O./?(T*FHV=8(GM*S0Z&*6U4+)_=WC_/*'
M1_ "PA1D.1NR7LCKI-=IC P,M Q] G@7II&GUH >FIF1?SD95/U0HI8NZK8)
MH*>^X, HKJ61.GRG"?H@<>#V";BK, JBY59$'*^2*>O69[2GD/ *O+R\X#UX
MLDAPF'R^ V7*3O:N.F/14FC"7*ZI8RE108N,3</H$2D=2#7#VN>#[^(T;1)S
M0*J>*9@_H4YCM*T5JQU7IJB%3>5$(#N,XH>-1^BLL^UL)?:6;*N1J1,]F2W9
M5@.SI]9<MS#IRTH!W;NW[[K$HIX(=BJ;?X'HY8@H!]$."\-.5*V3U0[V93<T
M\P$IUTN[<.RCK8LF?*&[G")V=;VMW)K5+'Q;CZ?E-'?^9GPZTL6W":IJG]#7
M86N B#)8<F:QK=$.'66+ZZFR/LJAV^D*0M;#LH5-V3@*? ^;M;N(_9BD-%KX
MR122RT8A*K9&?*Q0%?^%/%9@RDG,E1/[+B+PQ@]2Q,*M T.< A>3* RHE:EK
MB@>F-@#%[74&7[2RW?E8./$SX2.&"6'A @1)C/\ZSZB]//]P2:A%G[[M!"OK
MMQ2I:R?+C\TZ$E.L?&A^:*=:XO*:SZ^BQ:*8XK[J;0=!75/DONDUNDG!4S39
M; +?)01/%YGR*O!(*C9C"O<S"%[\*(V#+1$D3\ EH[@YW!375[&-H?(<J+BF
M*3SB=.$2(]4H9@[U"8SB#<"X@LKT0)MD[:><?+RP<0\UNK9G#A[$).;PE_U^
M"&VYVV[;?#\@Y\_6 PP=($DL6[:>6^B CZJYVFKQZP!,RJ2QU0<GK7,W%[*.
M&Y>UQV9*0*J*[<F<X,A96"((3^:TAJ[]-K=3NDUCOU=3!AU5>]?^/"(];9+F
M/A$SA&[H*6F7>WA7=Q;%)$R_AT.XHT/NR@GP YOS%0!)1S>C;!-[=S92"1.Z
M'#FU3#&HZ_E7:_=B4HC7 O9% 6%-\WG\'(5N9S8KE4<W\NA&/ETW\M&[6!VT
ML>S,>I[OM%[0( [,<A(?RJI6U$!:'HN&')R$#[879G([:R]GK-'/6.\#R>LV
MC!:[:,6*]NAGU YG-S$>?8Y\GR,/^]'S*.=YM.LL95^>1WO]M:/GT3C/XRZ7
MM"D1J*I/#C&L(,5FM+B Y)[&J&4GX]?8NZ.TD(:.#F"9ZH?G2>CX9=08W82C
MF_!TW835UUB9'.R*F$+UT3LW3]8UN/\W"RU3O+MN[*?W"',?I!1?2;(XGI6O
M9XU^/ZU0JHOLZ._C^_M8F(^^/CE?GUVG&OOR]=GK(1U]?=U]?5]B,%WLDM/\
M-?6R]-OXK?(X3M?9VCYF]!TS^O;,Z+L?WG^+ D2K [>%FMS( ;YE^+SZMF8*
M%A]!M(3.9H66P&""]P>NC4XO;2PO L<*J[PI_.R>^"9/8\8 ITCQ0_S:4O5E
M>;9?4ERY.Z<Q<-\NHY<+(MZ0\/E3\0?V+/]4\7CGG[]]F3>HK?QP'+GQ!/X(
MN0&SU5/1<W.I0\E8EZPUL;6"-^9I%"*KO.^/N1NYV'+U",'4/IT\>@(-!>-4
MW2SWYYH]D"U9>3=GGJ[7:#I.%]6'ZW0<:D^6('2W5U%(/V>CE]$3<A&M$0+D
MYIR#]O]+=O^,DIJH@!N<C!'<^:_%P1+FE/.(AZB**0IR'K^L_DZVL*(I'.ZB
MIR9Q#)(8YTH4&#7L&J;P=-AGS>.F!>.3YC!''_)_XTGTH6*_9%^_E?TR'4/L
M@H<A-)Z[*^"E 6!Y,<05#D,XU>U$+V2*6)?74M0%7*:N*7SF^5H;ZXS,>R>T
M*EJVN"_S)ZQ,I7 [!RX&S@><W8U3^K#:H7"Q+\_T&9J%_:X%>8QX0F%KS$,W
M61+HA_8?H\J#U38FK#TN%2H]C=1OPKVO5RR;T7<U5;&24A6LS?:C")841#]U
M@"A*G.!((&+J\00JAO)LK3N-:RQ0G^R@*JOVGB6( >+,P5,X"1#;,'4QXB@(
MUL?[5%8A#5$]['=HJTD4"W%\B/+(K+9U*5U-USNYO(ZX;^5*5!S=6*,;2X>8
M?@9)ME3ER9?S. 2V>/(KF.)RPE1&$/C+\/;5):>M'QT_9'O3Z,5-X68&(Q<
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M#EAM6XVNMJ%!$^J<IY/45]TMR9F]]OHC):T4@7#9[E"3MG\P3E55U%:'3R=
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M#0 1              "  0    !M<G5S+3(P,3@P-C,P+GAM;%!+ 0(4 Q0
M   ( %.#FTW-V^H5@!D  (0P 0 1              "  6L6 0!M<G5S+3(P
M,3@P-C,P+GAS9%!+ 0(4 Q0    ( %.#FTT<W<,5'Q4  ,<S 0 5
M      "  1HP 0!M<G5S+3(P,3@P-C,P7V-A;"YX;6Q02P$"% ,4    " !3
M@YM-,QD\R#\C   D4 ( %0              @ %L10$ ;7)U<RTR,#$X,#8S
M,%]D968N>&UL4$L! A0#%     @ 4X.;387SXIAK:@  3"4& !4
M     ( !WF@! &UR=7,M,C Q.# V,S!?;&%B+GAM;%!+ 0(4 Q0    ( %.#
MFTW6PHR(Z3L  %6&!  5              "  7S3 0!M<G5S+3(P,3@P-C,P
>7W!R92YX;6Q02P4&      8 !@"* 0  F \"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
